{"question_id": "55031181e9bde69634000014", "question": "Is Hirschsprung disease a mendelian or a multifactorial disorder?", "retrieved_chunks": [{"doc_id": "15829955", "chunk_id": "15829955_1", "score": 9.81470012664795, "text": "Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes."}, {"doc_id": "15829955", "chunk_id": "15829955_0", "score": 9.639654159545898, "text": "Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes"}, {"doc_id": "15617541", "chunk_id": "15617541_0", "score": 5.455429553985596, "text": "In this study, we review the identification of genes and loci involved in the non-syndromic common form and syndromic Mendelian forms of Hirschsprung's disease. The majority of the identified genes are related to Mendelian syndromic forms of Hirschsprung's disease. The non-Mendelian inheritance of sporadic non-syndromic Hirschsprung's disease proved to be complex; involvement of multiple loci was demonstrated in a multiplicative model"}], "context": "[15829955:15829955_1] Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes.\n[15829955:15829955_0] Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes\n[15617541:15617541_0] In this study, we review the identification of genes and loci involved in the non-syndromic common form and syndromic Mendelian forms of Hirschsprung's disease. The majority of the identified genes are related to Mendelian syndromic forms of Hirschsprung's disease. The non-Mendelian inheritance of sporadic non-syndromic Hirschsprung's disease proved to be complex; involvement of multiple loci was demonstrated in a multiplicative model", "answer": "<think> Okay, let's tackle this question about Hirschsprung disease being Mendelian or multifactorial. The user provided three evidence chunks. First, looking at the evidence from [15829955:15829955_1] and [15829955:15617541_0], both mention that Hirschsprung disease is a multifactorial, non-mendelian disorder. They talk about mutations in the RET gene contributing to risk along with other genes, which suggests multiple factors are involved. The term \"multifactorial\" points towards a combination of genetic and environmental factors, rather than a single gene mutation. Then there's [1561754", "citations": [{"doc_id": "15829955", "chunk_id": "15829955_1"}, {"doc_id": "15829955", "chunk_id": "15617541_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question about Hirschsprung disease being Mendelian or multifactorial. The user provided three evidence chunks. First, looking at the evidence from [15829955:15829955_1] and [15829955:15617541_0], both mention that Hirschsprung disease is a multifactorial, non-mendelian disorder. They talk about mutations in the RET gene contributing to risk along with other genes, which suggests multiple factors are involved. The term \"multifactorial\" points towards a combination of genetic and environmental factors, rather than a single gene mutation. Then there's [1561754", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let me tackle this question. The user is asking whether Hirschsprung disease is a Mendelian or multifactorial disorder. I need to look at the evidence provided. First, evidence document [15829955:15829955_1] and [15829955:15829955_0] both state that HSCR is a multifactorial, non-mendelian disorder. They mention rare mutations in the RET gene contributing to risk along with other genes. So that's clear evidence for multifactorial. Then there's [15617541:15617541_0], which talks about Mendelian synd", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question about Hirschsprung disease being Mendelian or multifactorial. The user provided three evidence snippets. First, looking at the first two pieces of evidence (both from [15829955:15829955_1 and 15829955:15829955_0]), they both state that Hirschsprung disease is a multifactorial, non-mendelian disorder. The key terms here are \"multifactorial\" and \"non-mendelian\". That seems pretty clear. They mention mutations in the RET gene contributing to risk along with other genes, which supports the multifactorial aspect. The third evidence (from [1", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question about Hirschsprung disease being Mendelian or multifactorial. The user provided three evidence snippets. First, looking at the first two pieces of evidence (both from [15829955:15829955_1 and 15829955:15829955_0]), they both state that HSCR is a multifactorial, non-mendelian disorder. The key terms here are \"multifactorial\" and \"non-mendelian.\" So that's a clear indication that the answer should be multifactorial. The third evidence (from [15617541:15617541", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question about Hirschsprung disease being mendelian or multifactorial. The user wants a strict JSON answer with the answer and base_confidence. First, I need to look at the evidence provided. There are three chunks here. Let me read through them carefully. The first two chunks (15829955:15829955_1 and 0) both say that Hirschsprung disease is a multifactorial, non-mendelian disorder. They mention rare mutations in the RET gene contributing to risk along with other genes. So that's clear evidence pointing towards multifactorial. The third chunk (15617541:15617541_", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking whether Hirschsprung disease is a Mendelian or multifactorial disorder. Let me look at the evidence provided. First, there are two entries from document 15829955. Both mention that HSCR is a multifactorial, non-mendelian disorder. They talk about rare high-penetrance mutations in RET gene and other genes contributing to risk. So that's clear evidence pointing towards multifactorial. Then there's another entry from document 15617541. It says that the majority of identified genes are related to Mendelian syndromic forms, but non-Mendelian inheritance of sporadic non-syndromic HSCR is complex with multiple loci. So", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about Hirschsprung disease being mendelian or multifactorial. The user wants a strict JSON answer with the answer and base confidence. First, I need to look at the evidence provided. There are three documents here. Let me read through them carefully. The first two documents (15829955:15829955_1 and 15829955:15829955_0) both state that Hirschsprung disease is a multifactorial, non-mendelian disorder. They mention that rare mutations in the RET gene contribute to risk, but in combination with other genes. So that's clear evidence for multifactorial. The third", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking whether Hirschsprung disease is a Mendelian or multifactorial disorder. Let me look at the evidence provided. The first two documents (15829955:15829955_1 and 15829955:15829955_0) both state that Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder. They mention that rare high-penetrance mutations in the RET gene contribute to risk, along with other genetic mutations. That suggests it's not strictly Mendelian because it involves multiple factors. The third document (15617541:15617", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["12239580", "15617541", "15829955", "15858239", "20598273", "21995290", "23001136", "6650562", "8896569"], "ideal_answer": "Coding sequence mutations in RET, GDNF, EDNRB, EDN3, and SOX10 are involved in the development of Hirschsprung disease. The majority of these genes was shown to be related to Mendelian syndromic forms of Hirschsprung's disease, whereas the non-Mendelian inheritance of sporadic non-syndromic Hirschsprung disease proved to be complex; involvement of multiple loci was demonstrated in a multiplicative model."}
{"question_id": "55046d5ff8aee20f27000007", "question": "List signaling molecules (ligands) that interact with the receptor EGFR?", "retrieved_chunks": [{"doc_id": "23399900", "chunk_id": "23399900_0", "score": 6.7815752029418945, "text": "the 7 known EGFR ligands (EGF, betacellulin, epiregulin, heparin-binding EGF, transforming growth factor-α [TGF-α], amphiregulin, and epigen)"}, {"doc_id": "24323361", "chunk_id": "24323361_0", "score": 6.202628135681152, "text": "the epidermal growth factor receptor (EGFR) ligands, such as epidermal growth factor (EGF) and amphiregulin (AREG)"}, {"doc_id": "32533590", "chunk_id": "32533590_0", "score": 6.164878845214844, "text": "Gene ontology data showed the upregulation of genes related to EGFR signaling, and we identified that FGFR4 overexpression secretes EGFR ligands such as amphiregulin (AREG) with consequent activation of EGFR and ErbB3."}], "context": "[23399900:23399900_0] the 7 known EGFR ligands (EGF, betacellulin, epiregulin, heparin-binding EGF, transforming growth factor-α [TGF-α], amphiregulin, and epigen)\n[24323361:24323361_0] the epidermal growth factor receptor (EGFR) ligands, such as epidermal growth factor (EGF) and amphiregulin (AREG)\n[32533590:32533590_0] Gene ontology data showed the upregulation of genes related to EGFR signaling, and we identified that FGFR4 overexpression secretes EGFR ligands such as amphiregulin (AREG) with consequent activation of EGFR and ErbB3.", "answer": "<think> Okay, let's tackle this question. The user wants a list of signaling molecules, or ligands, that interact with the EGFR receptor. The evidence provided has three chunks. First chunk [23399900:23399900_0] lists seven known EGFR ligands: EGF, betacellulin, epiregulin, heparin-binding EGF, TGF-α, amphiregulin, and epigen. That's a comprehensive list. The second chunk [24323361:24323361_0] mentions EGF and amphiregulin (AREG) as examples. The third chunk [3253359", "citations": [{"doc_id": "23399900", "chunk_id": "23399900_0"}, {"doc_id": "24323361", "chunk_id": "24323361_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants a list of signaling molecules, or ligands, that interact with the EGFR receptor. The evidence provided has three chunks. First chunk [23399900:23399900_0] lists seven known EGFR ligands: EGF, betacellulin, epiregulin, heparin-binding EGF, TGF-α, amphiregulin, and epigen. That's a comprehensive list. The second chunk [24323361:24323361_0] mentions EGF and amphiregulin (AREG) as examples. The third chunk [3253359", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer about the signaling molecules (ligands) that interact with the EGFR receptor. Let me start by looking at the evidence provided. The first piece of evidence [23399900:2339990So] lists seven known EGFR ligands: EGF, betacellulin, epiregulin, heparin-binding EGF, TGF-α, amphiregulin, and epigen. That's a comprehensive list. The second evidence [24323361:24323361_0] mentions EGF and amphiregulin (AREG) as examples. The third one [325335", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a JSON answer based on the provided evidence. The question is asking for signaling molecules (ligands) that interact with the EGFR receptor. Looking at the evidence, there are three documents mentioned. Let me check each one. Document 23399900:23399900_0 lists seven known EGFR ligands: EGF, betacellulin, epiregulin, heparin-binding EGF, TGF-α, amphiregulin, and epigen. That's a comprehensive list. Document 24323361:24323367_0 mentions EGF and amphiregulin (AREG) as examples of EG", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants a list of signaling molecules, or ligands, that interact with the EGFR receptor. The evidence provided has three chunks. First chunk [23399900:23399900_0] lists seven known EGFR ligands: EGF, betacellulin, epiregulin, heparin-binding EGF, TGF-α, amphiregulin, and epigen. That seems comprehensive. The second chunk [24323361:24323361_0] mentions EGF and amphiregulin again, which are already in the first list. The third chunk [325335", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, so I need to generate a JSON answer based on the given evidence. The question is asking for signaling molecules, or ligands, that interact with the EGFR receptor. Let me look at the evidence provided. The first piece of evidence (23399900:23399906_0) lists seven known EGFR ligands: EGF, betacellulin, epiregulin, heparin-binding EGF, TGF-α, amphiregulin, and epigen. Wait, \"epigen\" might be a typo here, maybe it's \"epididymis\" or another term, but according to the context, it's likely a correct term in this case. The second evidence", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants a list of signaling molecules (ligands) that interact with the EGFR receptor. The evidence provided has three chunks. First chunk [23399900:23399900_0] lists seven known EGFR ligands: EGF, betacellulin, epiregulin, heparin-binding EGF, TGF-α, amphiregulin, and epigen. That's a comprehensive list. Second chunk [24323361:24323361_0] mentions EGF and amphiregulin (AREG) as examples. So it's repeating some of the ones from the first chunk.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking for signaling molecules, specifically ligands, that interact with the EGFR receptor. I need to look at the provided evidence to find the answer. First, I'll check each of the evidence chunks. The first chunk [23399900:23399900_0] lists seven known EGFR ligands: EGF, betacellulin, epiregulin, heparin-binding EGF, TGF-α, amphiregulin, and epigen. That's a comprehensive list. The second chunk [24323361:24323361_0] mentions EGFR ligands like E", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user wants a list of signaling molecules, or ligands, that interact with the EGFR receptor. The evidence provided has three chunks. First chunk [23399900:23399900_0] mentions seven known EGFR ligands: EGF, betacellulin, epiregulin, heparin-binding EGF, TGF-α, amphiregulin, and epigen. That's a comprehensive list. Second chunk [24323361:24323361_0] lists EGF and amphiregulin (AREG) as examples. So this is a subset of the first list. Third", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["21514161", "22247333", "22260327", "23089711", "23099994", "23212918", "23382875", "23399900", "23729230", "23787814", "23821377", "23888072", "23959273", "24124521", "24204699", "24323361"], "ideal_answer": "The 7 known EGFR ligands are: epidermal growth factor (EGF), betacellulin (BTC), epiregulin (EPR), heparin-binding EGF (HB-EGF), transforming growth factor-α [TGF-α], amphiregulin (AREG) and epigen (EPG)."}
{"question_id": "54e25eaaae9738404b000017", "question": "Is the protein Papilin secreted?", "retrieved_chunks": [{"doc_id": "7515725", "chunk_id": "7515725_0", "score": 5.666638374328613, "text": "Collagen IV, laminin, glutactin, papilin, and other extracellular matrix proteins were made primarily by hemocytes and were secreted into the medium."}, {"doc_id": "21784067", "chunk_id": "21784067_0", "score": 3.164663791656494, "text": "Using expression analysis, we identify three genes that are transcriptionally regulated by HLH-2: the protocadherin cdh-3, and two genes encoding secreted extracellular matrix proteins, mig-6/papilin and him-4/hemicentin."}, {"doc_id": "11076767", "chunk_id": "11076767_0", "score": -0.5660957098007202, "text": "Papilin is an extracellular matrix glycoprotein"}], "context": "[7515725:7515725_0] Collagen IV, laminin, glutactin, papilin, and other extracellular matrix proteins were made primarily by hemocytes and were secreted into the medium.\n[21784067:21784067_0] Using expression analysis, we identify three genes that are transcriptionally regulated by HLH-2: the protocadherin cdh-3, and two genes encoding secreted extracellular matrix proteins, mig-6/papilin and him-4/hemicentin.\n[11076767:11076767_0] Papilin is an extracellular matrix glycoprotein", "answer": "<think> Okay, let's tackle this question. The user wants to know if the protein Papilin is secreted. I need to look at the evidence provided. First, evidence document [7515725:7515725_0] says that collagen IV, laminin, glutactin, papilin, and other ECM proteins are made by hemocytes and secreted into the medium. That directly mentions papilin is secreted. So that's a strong point. Then, document [21784067:21784067_0] talks about genes regulated by HLH-2, including mig-6/papilin and him-4/hemicentin. It specifies that", "citations": [{"doc_id": "7515725", "chunk_id": "7515725_0"}, {"doc_id": "21784067", "chunk_id": "21784067_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants to know if the protein Papilin is secreted. I need to look at the evidence provided. First, evidence document [7515725:7515725_0] says that collagen IV, laminin, glutactin, papilin, and other ECM proteins are made by hemocytes and secreted into the medium. That directly mentions papilin is secreted. So that's a strong point. Then, document [21784067:21784067_0] talks about genes regulated by HLH-2, including mig-6/papilin and him-4/hemicentin. It specifies that", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the protein Papilin is secreted. I need to check the evidence provided. First, looking at the evidence documents. The first one, 7515725:7515725_0, mentions that collagen IV, laminin, glutactin, papilin, and other ECM proteins are made by hemocytes and secreted into the medium. So that's a direct statement about papilin being secreted. The second document, 21784067:21784067_0, says that mig-6/papilin is a secreted extracellular matrix protein. That also supports the answer. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if the protein Papilin is secreted. I need to look at the provided evidence to find answers. First, looking at the evidence documents. The first one says that collagen IV, laminin, glutactin, papilin, and other ECM proteins are made by hemocytes and secreted into the medium. That directly mentions papilin is secreted. So that's a clear yes. The second document talks about genes regulated by HLH-2, including mig-6/papilin and him-4/hemicentin. It specifies that these are secreted extracellular matrix proteins. So this also supports that papilin is secreted. Third document states that papilin is an", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the protein Papilin is secreted. I need to look at the evidence provided to find out. First, looking at the evidence documents. The first one, 7515725:7515725_0, mentions that collagen IV, laminin, glutactin, papilin, and other ECM proteins are made by hemocytes and secreted into the medium. So that directly states that papilin is secreted. The second document, 21784067:21784067_0, talks about genes regulated by HLH-2, including mig-6/papilin, which are secreted", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if the protein Papilin is secreted. The evidence provided has three documents. First, looking at document [7515725:7515725_0], it mentions that collagen IV, laminin, glutactin, papilin, and other extracellular matrix proteins are made by hemocytes and secreted into the medium. So that directly states that papilin is secreted. Then document [21784067:21784067_0] says that mig-6/papilin and him-4/hemicentin are secreted extracellular matrix proteins. This also supports the idea that papilin", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, so the user is asking if the protein Papilin is secreted. Let me look at the evidence provided. First, document [7515725:7515725_0] says that collagen IV, laminin, glutactin, papilin, and other extracellular matrix proteins are made by hemocytes and secreted into the medium. That directly mentions papilin being secreted. Then, document [21784067:21784067_0] talks about genes encoding secreted extracellular matrix proteins, including mig-6/papilin. So this also supports that papilin is secreted. The third document [1107", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, so the user is asking if the protein Papilin is secreted. Let me look at the evidence provided. First, document [7515725:7515725_0] mentions that collagen IV, laminin, glutactin, papilin, and other extracellular matrix proteins are made by hemocytes and secreted into the medium. That directly states that papilin is secreted. Then, document [21784067:21784067_0] talks about genes encoding secreted extracellular matrix proteins, including mig-6/papilin. So this also supports that papilin is secreted. The third document [11076", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, the user is asking if the protein Papilin is secreted. Let me look at the evidence provided. First, document [7515725:7515725_0] says that collagen IV, laminin, glutactin, papilin, and other extracellular matrix proteins are made by hemocytes and secreted into the medium. So that's a direct statement about papilin being secreted. Then, document [21784067:21784067_0] mentions that mig-6/papilin is a secreted extracellular matrix protein. This also supports the idea that papilin is secreted. The third document [1107", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["11076767", "12666201", "15094110", "15094122", "19297413", "19724244", "20805556", "21784067", "3320045", "7515725"], "ideal_answer": "Yes, papilin is a secreted protein"}
{"question_id": "535d292a9a4572de6f000003", "question": "Are long non coding RNAs spliced?", "retrieved_chunks": [{"doc_id": "26649774", "chunk_id": "26649774_0", "score": 5.515077114105225, "text": "Circular RNAs (circRNAs) are long, non-coding RNAs that result from the non-canonical splicing of linear pre-mRNAs."}, {"doc_id": "25994219", "chunk_id": "25994219_0", "score": 4.214262962341309, "text": "Long non-coding RNAs (lncRNAs) are emerging as key molecules in cancers, yet their potential molecular mechanisms are not well understood."}, {"doc_id": "25404134", "chunk_id": "25404134_0", "score": 3.977782726287842, "text": "Recent studies have disclosed the function of enhancer RNAs (eRNAs), which are long non-coding RNAs transcribed from gene enhancer regions, in transcriptional regulation."}], "context": "[26649774:26649774_0] Circular RNAs (circRNAs) are long, non-coding RNAs that result from the non-canonical splicing of linear pre-mRNAs.\n[25994219:25994219_0] Long non-coding RNAs (lncRNAs) are emerging as key molecules in cancers, yet their potential molecular mechanisms are not well understood.\n[25404134:25404134_0] Recent studies have disclosed the function of enhancer RNAs (eRNAs), which are long non-coding RNAs transcribed from gene enhancer regions, in transcriptional regulation.", "answer": "<think> Okay, let's tackle this question. The user is asking if long non-coding RNAs (lncRNAs) are spliced. The evidence provided includes three documents. First, looking at document [26649774:26649774_0], it mentions circular RNAs (circRNAs) which are long non-coding RNAs resulting from non-canonical splicing of pre-mRNAs. So circRNAs are a type of lncRNA that are spliced. But the question is about all lncRNAs, not just circRNAs. Next, document [25994219:25994219_0] talks about lncRNAs in", "citations": [{"doc_id": "26649774", "chunk_id": "26649774_0"}, {"doc_id": "25994219", "chunk_id": "25994219_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if long non-coding RNAs (lncRNAs) are spliced. The evidence provided includes three references. First, looking at the evidence: the first document mentions circular RNAs (circRNAs) which are long non-coding RNAs resulting from non-canonical splicing of pre-mRNAs. So circRNAs are a type of lncRNA that are spliced. But the question is about all lncRNAs, not just circRNAs. The second document states that lncRNAs are emerging in cancers but their mechanisms aren't well understood. This doesn't directly address splicing. The third document talks about enhancer RNAs (eRNAs), which are lncRN", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if long non-coding RNAs (lncRNAs) are spliced. The evidence provided includes three documents. First, looking at document [26649774:26649774_0], it mentions circular RNAs (circRNAs) which are long non-coding RNAs resulting from non-canonical splicing of pre-mRNAs. So circRNAs are a type of lncRNA that are spliced. But the question is about all lncRNAs, not just circRNAs. Next, document [25994219:25994219_0] talks about lncRNAs in", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if long non-coding RNAs (lncRNAs) are spliced. The evidence provided has three chunks. First, looking at the first chunk: it mentions circular RNAs (circRNAs) are long non-coding RNAs resulting from non-canonical splicing of pre-mRNAs. So circRNAs are a type of lncRNA that undergoes splicing. But the question is about lncRNAs in general. The second chunk talks about lncRNAs being key molecules in cancers but their mechanisms aren't well understood. No mention of splicing here. Third chunk discusses enhancer RNAs (eRNAs), which are lncRNAs, and their role in transcription", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if long non coding RNAs (lncRNAs) are spliced. The evidence provided has three chunks. First, looking at the evidence: the first chunk mentions circular RNAs (circRNAs) which are long non-coding RNAs resulting from non-canonical splicing of pre-mRNAs. So circRNAs are a type of lncRNA that are spliced. But the question is about lncRNAs in general. The second and third chunks talk about lncRNAs in cancers and enhancer RNAs (eRNAs), which are also lncRNAs. However, they don't mention splicing directly. The key here is to determine if lncRNAs are generally", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if long non-coding RNAs (lncRNAs) are spliced. The evidence provided includes three references. First, looking at the first evidence: [26649774:26649774_0] mentions circular RNAs (circRNAs) which are long non-coding RNAs resulting from non-canonical splicing of linear pre-mRNAs. So circRNAs are a type of lncRNA that are spliced. But the question is about all lncRNAs, not just circRNAs. The second evidence: [25994219:25994219_0] states that l", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if long non coding RNAs (lncRNAs) are spliced. The evidence provided has three documents. First, looking at the first evidence: [26649774:26649774_0] mentions circular RNAs (circRNAs) which are long non-coding RNAs resulting from non-canonical splicing of pre-mRNAs. So this suggests that some long non-coding RNAs, specifically circRNAs, are indeed spliced. The second evidence [25994219:25994219_0] talks about lncRNAs in cancers but doesn't mention splicing. It's", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if long non-coding RNAs (lncRNAs) are spliced. The evidence provided has three documents. First, looking at document [26649774:26649774_0], it mentions circular RNAs (circRNAs) which are long non-coding RNAs resulting from non-canonical splicing of pre-mRNAs. So this suggests that some long non-coding RNAs, specifically circRNAs, are indeed spliced. But the question is about lncRNAs in general. Next, document [25994219:25994219_0] talks about lncRNAs", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if long non-coding RNAs (lncRNAs) are spliced. The evidence provided has three chunks. First, looking at the first chunk: it mentions circular RNAs (circRNAs) are long non-coding RNAs resulting from non-canonical splicing of pre-mRNAs. So circRNAs are a type of lncRNA that are spliced. But the question is about lncRNAs in general. However, the answer needs to be based on the given evidence. The second chunk talks about lncRNAs in cancers but doesn't mention splicing. The third chunk discusses enhancer RNAs (eRNAs), which are lncRNAs, and their role in", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["21622663", "22707570", "22955974", "22955988", "24106460", "24285305"], "ideal_answer": "Long non coding RNAs appear to be spliced through the same pathway as the mRNAs"}
{"question_id": "55262a9787ecba3764000009", "question": "Is RANKL secreted from the cells?", "retrieved_chunks": [{"doc_id": "23698708", "chunk_id": "23698708_0", "score": 7.07332181930542, "text": "Activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL."}, {"doc_id": "22901753", "chunk_id": "22901753_0", "score": 5.878667831420898, "text": "Although B. abortus-activated T cells actively secreted the pro-osteoclastogenic cytokines RANKL and IL-17, osteoclastogenesis depended on IL-17, because osteoclast generation induced by Brucella-activated T cells was completely abrogated when these cells were cultured with BMMs from IL-17 receptor knockout mice."}, {"doc_id": "23632157", "chunk_id": "23632157_0", "score": 5.340981483459473, "text": "OPG, on the other hand, is secreted by osteoblast as a decoy receptor for RANKL, prevents RANKL from binding to RANK and thus prevents bone resorption"}], "context": "[23698708:23698708_0] Activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL.\n[22901753:22901753_0] Although B. abortus-activated T cells actively secreted the pro-osteoclastogenic cytokines RANKL and IL-17, osteoclastogenesis depended on IL-17, because osteoclast generation induced by Brucella-activated T cells was completely abrogated when these cells were cultured with BMMs from IL-17 receptor knockout mice.\n[23632157:23632157_0] OPG, on the other hand, is secreted by osteoblast as a decoy receptor for RANKL, prevents RANKL from binding to RANK and thus prevents bone resorption", "answer": "<think> Okay, I need to answer whether RANKL is secreted from cells based on the given evidence. Let me look at the evidence provided. First, the first piece of evidence [23698708:23698708_0] says that activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL. So this directly mentions that RANKL is secreted by T cells. That's a clear citation. The second evidence [22901753:22901753_0] talks about B. abortus-activated T cells secreting RANKL and IL-17. Again, this confirms that RANKL is secreted by these T", "citations": [{"doc_id": "23698708", "chunk_id": "23698708_0"}, {"doc_id": "22901753", "chunk_id": "22901753_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants to know if RANKL is secreted from cells, based on the provided evidence. First, I'll look at the evidence documents. The first one, 23698708:23698708_0, says that activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL. So that directly mentions that RANKL is secreted by these cells. That's a strong point. The second document, 22901753:22901753_0, talks about B. abortus-activated T cells secreting RANKL and IL-17. It also mentions that osteoc", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to answer whether RANKL is secreted from cells based on the provided evidence. Let me look at the evidence again. The first piece of evidence says that activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL. So that directly mentions that RANKL is secreted by T cells. The second evidence talks about B. abortus-activated T cells secreting RANKL and IL-17, which also supports that RANKL is secreted. The third evidence mentions OPG being secreted by osteoblasts as a decoy for RANKL, which implies that RANKL is secreted but maybe not by osteoblasts. So the answer should be yes, RANKL is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to answer whether RANKL is secreted from cells based on the given evidence. Let me look at the evidence provided. First, the first piece of evidence [23698708:23698708_0] says that activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL. So this directly mentions that RANKL is secreted by T cells. That's a clear citation. The second evidence [22901753:22901753_0] talks about B. abortus-activated T cells secreting RANKL and IL-17. Again, this confirms that RANKL is secreted by these T", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if RANKL is secreted from cells. Looking at the evidence provided, there are three references. First, reference [23698708:23698708_0] says that activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL. That directly mentions secretion. So that's a strong point for the answer being yes. Then, reference [22901753:22901753_0] talks about B. abortus-activated T cells secreting RANKL and IL-17. Again, this supports that RANKL is secreted. However, the focus here", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if RANKL is secreted from cells. I need to check the provided evidence to find answers. Looking at the first piece of evidence: [23698708:23698708_0] says activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL. So this directly mentions that RANKL is secreted by these cells. That's a strong point. The second evidence, [22901753:22901753_0], talks about B. abortus-activated T cells secreting RANKL and IL-17. Again, this confirms that RANKL is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if RANKL is secreted from cells. I need to look at the evidence provided. First, evidence document [23698708:23698708_0] says activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL. So that directly mentions that RANKL is secreted by T cells. That's a strong point. Then, document [22901753:22901753_0] talks about B. abortus-activated T cells secreting RANKL and IL-17. Again, this supports that RANKL is secreted by T cells.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if RANKL is secreted from cells. I need to look at the evidence provided. First, the evidence has three chunks. Let me check each one. The first chunk [23698708:23698708_0] says that activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL. So this directly mentions that RANKL is secreted by T cells. That's a strong point. The second chunk [22901753:22901753_0] talks about B. abortus-activated T cells secreting RANKL and IL-17. Again", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if RANKL is secreted from cells. I need to look at the evidence provided. First, evidence document [23698708:23698708_0] says that activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL. So this directly mentions that RANKL is secreted by T cells. That's a clear citation. Another piece of evidence, [22901753:22901753_0], talks about B. abortus-activated T cells secreting RANKL and IL-17. Again, this supports that RANKL is secreted by T", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["21618594", "22867712", "22901753", "22948539", "23632157", "23698708", "23827649", "23835909", "24265865", "24267510"], "ideal_answer": "Receptor activator of nuclear factor κB ligand (RANKL) is a cytokine predominantly secreted by osteoblasts."}
{"question_id": "51406e6223fec90375000009", "question": "Does metformin interfere thyroxine absorption?", "retrieved_chunks": [{"doc_id": "26191653", "chunk_id": "26191653_0", "score": 6.750408172607422, "text": "It has been hypothesized that metformin may suppress serum thyrotropin (TSH) concentrations by enhancing LT4 absorption or by directly affecting the hypothalamic-pituitary axis."}, {"doc_id": "8835050", "chunk_id": "8835050_0", "score": 3.851344585418701, "text": "Metformin decreases absorption of vitamin B12 and folic acid, although reported cases of megaloblastic anemia are rare."}, {"doc_id": "26191653", "chunk_id": "26191653_1", "score": 2.08963680267334, "text": "LT4 absorption is unchanged by concomitant metformin ingestion."}], "context": "[26191653:26191653_0] It has been hypothesized that metformin may suppress serum thyrotropin (TSH) concentrations by enhancing LT4 absorption or by directly affecting the hypothalamic-pituitary axis.\n[8835050:8835050_0] Metformin decreases absorption of vitamin B12 and folic acid, although reported cases of megaloblastic anemia are rare.\n[26191653:26191653_1] LT4 absorption is unchanged by concomitant metformin ingestion.", "answer": "<think> Okay, let's tackle this question. The user is asking if metformin interferes with thyroxine (T4) absorption. I need to look at the provided evidence to find the answer. First, evidence document [26191653:26191653_0] says that metformin might suppress TSH by enhancing LT4 absorption or affecting the hypothalamic-pituitary axis. But then, in [26191653:26191653_1], it states that LT4 absorption isn't changed by metformin. So there's a contradiction here. The first part suggests metformin could enhance absorption, but the second says it doesn't affect", "citations": [{"doc_id": "26191653", "chunk_id": "26191653_0"}, {"doc_id": "26191653", "chunk_id": "26191653_1"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if metformin interferes with thyroxine (T4) absorption. First, I need to look at the evidence provided. There are three chunks here. The first chunk (26191653:26191653_0) says that metformin might suppress TSH by enhancing LT4 absorption or affecting the hypothalamic-pituitary axis. Wait, that's a bit confusing. It mentions \"enhancing LT4 absorption,\" which would mean it's helping the absorption, not interfering with it. But the question is about interference, so maybe this is a conflicting point. The second chunk (8835050:883", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if metformin interferes with thyroxine (T4) absorption. First, I need to look at the evidence provided. There are three chunks here. Let me go through each one. The first chunk says that metformin might suppress TSH by enhancing LT4 absorption or affecting the hypothalamic-pituitary axis. Wait, that's interesting because it mentions enhancing LT4 absorption. But then the third chunk says that LT4 absorption is unchanged when taken with metformin. So there's a contradiction here. The first chunk suggests that metformin might increase T4 absorption, but the third chunk says it doesn't change it. The second chunk talks about metformin decreasing B1", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if metformin interferes with thyroxine (T4) absorption. Looking at the evidence provided, there are three chunks. The first one says that metformin might suppress TSH by enhancing LT4 absorption or affecting the hypothalamic-pituitary axis. Wait, that's a bit confusing. If it's enhancing absorption, that would mean it's helping the body absorb T4 better, not interfering. But the second chunk mentions that metformin decreases absorption of B12 and folic acid, but that's different. The third chunk clarifies that LT4 absorption isn't changed by metformin. So, the first chunk is a hypothesis, but the third chunk directly states that", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if metformin interferes with thyroxine (T4) absorption. First, I need to look at the evidence provided. There are three documents here. The first one, 26191653:26191653_0, says that metformin might suppress TSH by either enhancing LT4 absorption or affecting the hypothalamic-pituitary axis. Wait, so this suggests that metformin could enhance absorption, but the conclusion is about TSH levels. But the question is about interference with absorption. So maybe there's a contradiction here. Then there's 8835050:8835050_", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if metformin interferes with thyroxine (T4) absorption. First, I need to look at the evidence provided. There are three chunks here. Let me go through each one. The first chunk (26191653:26191653_0) says that metformin might suppress TSH by enhancing LT4 absorption or affecting the hypothalamic-pituitary axis. Wait, that's interesting. It mentions \"enhancing LT4 absorption,\" which would mean it's actually helping with absorption, not interfering. But the question is about interference, so this might be a point against metformin causing interference. The second chunk (883", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if metformin interferes with thyroxine (T4) absorption. I need to look at the provided evidence to find the answer. First, evidence document [26191653:26191653_0] says that metformin might suppress TSH by enhancing LT4 absorption or affecting the hypothalamic-pituitary axis. But then, in [26191653:26191653_1], it states that LT4 absorption isn't changed by metformin. So there's a contradiction here. The first part suggests metformin could enhance absorption, but the second says it doesn't affect", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if metformin interferes with thyroxine (T4) absorption. I need to look at the provided evidence to find the answer. First, looking at the evidence documents. The first one, 26191653:26191653_0, says that metformin might suppress TSH by enhancing LT4 absorption or affecting the hypothalamic-pituitary axis. Wait, that's a bit confusing. It mentions \"enhancing\" LT4 absorption, which would mean it's helping the absorption, not interfering. But the question is about interference, so maybe this document is saying that metformin could actually increase absorption, not interfere with it.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if metformin interferes with thyroxine (T4) absorption. I need to look at the provided evidence to find the answer. First, evidence document [26191653:26191653_0] says that metformin might suppress TSH by enhancing LT4 absorption or affecting the hypothalamic-pituitary axis. Wait, that's a bit confusing. It mentions \"enhancing\" LT4 absorption, which would mean it's helping the absorption, not interfering with it. But then in [26191653:26191653_1], it states that LT4 absorption is unchanged when", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["26191653"], "ideal_answer": "No. There are not reported data indicating that metformin reduce with thyroxine absorption."}
{"question_id": "553fa78b1d53b76422000007", "question": "Which miRNAs could be used as potential biomarkers for epithelial ovarian cancer?", "retrieved_chunks": [{"doc_id": "23542579", "chunk_id": "23542579_2", "score": 8.470380783081055, "text": "Serum miR-132, miR-26a, let-7b, and miR-145 could be considered as potential candidates as novel biomarkers in serous ovarian cancer."}, {"doc_id": "23542579", "chunk_id": "23542579_1", "score": 8.27552604675293, "text": "Serum miR-132, miR-26a, let-7b, and miR-145 could be considered as potential candidates as novel biomarkers in serous ovarian cancer"}, {"doc_id": "21971665", "chunk_id": "21971665_0", "score": 5.796660423278809, "text": "Taken together, miR-152 and miR-148a may be involved in the carcinogenesis of ovarian cancer through deregulation of cell proliferation. They may be novel biomarkers for early detection or therapeutic targets of ovarian cancer"}], "context": "[23542579:23542579_2] Serum miR-132, miR-26a, let-7b, and miR-145 could be considered as potential candidates as novel biomarkers in serous ovarian cancer.\n[23542579:23542579_1] Serum miR-132, miR-26a, let-7b, and miR-145 could be considered as potential candidates as novel biomarkers in serous ovarian cancer\n[21971665:21971665_0] Taken together, miR-152 and miR-148a may be involved in the carcinogenesis of ovarian cancer through deregulation of cell proliferation. They may be novel biomarkers for early detection or therapeutic targets of ovarian cancer", "answer": "<think> Okay, so the user is asking which miRNAs could be potential biomarkers for epithelial ovarian cancer. Let me look at the evidence provided. First, there are two entries from 23542579: they mention miR-132, miR-26a, let-7b, and miR-145 as potential biomarkers in serous ovarian cancer. Then there's another entry from 21971665 that talks about miR-152 and miR-ight a being involved in carcinogenesis and possibly novel biomarkers. Wait, the question is about epithelial ovarian cancer, but the evidence mentions \"serous ovarian cancer\" specifically. Serous is a type of ovarian cancer", "citations": [], "candidates": [{"answer": "<think> Okay, so the user is asking which miRNAs could be potential biomarkers for epithelial ovarian cancer. Let me look at the evidence provided. First, there are two entries from 23542579: they mention miR-132, miR-26a, let-7b, and miR-145 as potential biomarkers in serous ovarian cancer. Then there's another entry from 21971665 that talks about miR-152 and miR-ight a being involved in carcinogenesis and possibly novel biomarkers. Wait, the question is about epithelial ovarian cancer, but the evidence mentions \"serous ovarian cancer\" specifically. Serous is a type of ovarian cancer", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which miRNAs could be potential biomarkers for epithelial ovarian cancer. The evidence provided has three chunks. First, I need to look at each chunk and see what miRNAs are mentioned. The first two chunks both mention miR-132, miR-26a, let-7b, and miR-145 in the context of serous ovarian cancer. The third chunk talks about miR-152 and miR-148a being involved in carcinogenesis and possibly as biomarkers. Now, the question is about epithelial ovarian cancer. The evidence mentions \"serous ovarian cancer\" in the first two chunks. I need to check if serous is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking which miRNAs could be potential biomarkers for epithelial ovarian cancer. The evidence provided has three chunks. First, I need to check each chunk for relevant information. The first two chunks are the same, mentioning miR-132, miR-26a, let-7b, and miR-145 as potential biomarkers in serous ovarian cancer. The third chunk talks about miR-152 and miR-148a being involved in carcinogenesis and possibly novel biomarkers. Now, the question is about epithelial ovarian cancer. The evidence mentions \"serous ovarian cancer\" in the first two chunks. I need to confirm if serous is a subtype", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking which miRNAs could be potential biomarkers for epithelial ovarian cancer. The evidence provided has three chunks. First, I need to check each chunk for relevant information. The first two chunks (23542579:23542579_1 and _2) both mention miR-132, miR-26a, let-7b, and miR-145 as potential biomarkers in serous ovarian cancer. The third chunk (21971665:21971665_0) talks about miR-152 and miR-148a being involved in carcinogenesis", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking which miRNAs could be potential biomarkers for epithelial ovarian cancer. The evidence provided has three chunks. First, I need to check each chunk for relevant information. The first two chunks (both from 23542579) mention serum miR-132, miR-26a, let-7b, and miR-145 as potential biomarkers in serous ovarian cancer. The third chunk (from 21971665) talks about miR-152 and miR-148a being involved in carcinogenesis and possibly novel biomarkers. Now, the question is about epithelial ovarian cancer. The first two", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which miRNAs could be potential biomarkers for epithelial ovarian cancer. The evidence provided has three chunks. First, I need to look at each chunk. The first two chunks are the same, mentioning miR-132, miR-26a, let-7b, and miR-145 as potential biomarkers in serous ovarian cancer. The third chunk talks about miR-152 and miR-148a being involved in carcinogenesis and possibly novel biomarkers. Now, the question is about epithelial ovarian cancer. The evidence mentions \"serous ovarian cancer\" in the first two chunks. I need to check if serous is a subtype of epith", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which miRNAs could be potential biomarkers for epithelial ovarian cancer. The evidence provided has three chunks. First, I need to look at each chunk and see what miRNAs are mentioned. The first two chunks both mention miR-132, miR-26a, let-7b, and miR-145 in the context of serous ovarian cancer. The third chunk talks about miR-152 and miR-148a being involved in carcinogenesis and possibly as biomarkers. Now, the question is about epithelial ovarian cancer. The evidence mentions \"serous ovarian cancer\" in the first two chunks. I need to check if serous is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking which miRNAs could be potential biomarkers for epithelial ovarian cancer. The evidence provided has three chunks. First, I need to check each chunk for relevant information. The first two chunks (both from 23542579) mention miR-132, miR-26a, let-7b, and miR-145 as potential biomarkers in serous ovarian cancer. The third chunk (from 21971665) talks about miR-152 and miR-8a being involved in carcinogenesis and possibly as novel biomarkers. Wait, the user is asking for epithelial ovarian cancer, but the first two", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["18954897", "19074899", "20035894", "21345725", "21571355", "21971665", "22246341", "23272653", "23542579", "23621186", "23836287", "23888941", "23918241", "23978303"], "ideal_answer": "miR-200a, miR-100, miR-141, miR-200b, miR-200c, miR-203, miR-510, miR-509-5p, miR-132, miR-26a, let-7b, miR-145, miR-182, miR-152, miR-148a, let-7a, let-7i, miR-21, miR-92 and miR-93 could be used as potential biomarkers for epithelial ovarian cancer."}
{"question_id": "5149199dd24251bc05000040", "question": "Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis?", "retrieved_chunks": [{"doc_id": "20663605", "chunk_id": "20663605_0", "score": 9.341995239257812, "text": "For more than 50 years the acetylcholinesterase inhibitor pyridostigmine bromide has been the drug of choice in the symptomatic therapy for myasthenia gravis."}, {"doc_id": "15610702", "chunk_id": "15610702_0", "score": 8.536487579345703, "text": "Acetylcholinesterase inhibitors provide temporary, symptomatic treatment for all forms of myasthenia gravis."}, {"doc_id": "29655452", "chunk_id": "29655452_0", "score": 8.516647338867188, "text": "The 2 exceptions are acetylcholinesterase inhibitors and complement inhibition with eculizumab, which was recently approved by the US Food and Drug Administration for myasthenia gravis."}], "context": "[20663605:20663605_0] For more than 50 years the acetylcholinesterase inhibitor pyridostigmine bromide has been the drug of choice in the symptomatic therapy for myasthenia gravis.\n[15610702:15610702_0] Acetylcholinesterase inhibitors provide temporary, symptomatic treatment for all forms of myasthenia gravis.\n[29655452:29655452_0] The 2 exceptions are acetylcholinesterase inhibitors and complement inhibition with eculizumab, which was recently approved by the US Food and Drug Administration for myasthenia gravis.", "answer": "<think> Okay, let's tackle this question. The user is asking which acetylcholinesterase inhibitors are used for treating myasthenia gravis. The evidence provided has three chunks. First chunk says pyridostigmine bromide has been the drug of choice for over 50 years. That's a direct mention of an inhibitor. The second chunk states that acetylcholinesterase inhibitors in general provide temporary symptomatic treatment, but that's a broader statement. The third chunk mentions two exceptions: acetylcholinesterase inhibitors and eculizumab. Wait, but the question is about which inhibitors are used, so maybe the third chunk is saying that despite being exceptions, they are still used? Or perhaps it's indicating that even though they are", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which acetylcholinesterase inhibitors are used for treating myasthenia gravis. The evidence provided has three chunks. First chunk says pyridostigmine bromide has been the drug of choice for over 50 years. That's a direct mention of an inhibitor. The second chunk states that acetylcholinesterase inhibitors in general provide temporary symptomatic treatment, but that's a broader statement. The third chunk mentions two exceptions: acetylcholinesterase inhibitors and eculizumab. Wait, but the question is about which inhibitors are used, so maybe the third chunk is saying that despite being exceptions, they are still used? Or perhaps it's indicating that even though they are", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which acetylcholinesterase inhibitors are used for treating myasthenia gravis. The evidence provided has three chunks. First, chunk 20663605 says that pyridostigmine bromide has been the drug of choice for over 50 years. That's a direct mention of an acetylcholinesterase inhibitor used in treatment. Then chunk 15610702 states that these inhibitors provide temporary, symptomatic treatment for all forms of myasthenia gravis. But chunk 29655452 mentions two exceptions: acetylcholinesterase inhibitors and complement inhibition with eculizumab. Wait, that", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which acetylcholinesterase inhibitors are used for treating myasthenia gravis. The evidence provided has three chunks. First chunk says pyridostigmine bromide has been the drug of choice for over 50 years. That's a direct mention of an inhibitor. Second chunk states that all forms of myasthenia gravis are treated with acetylcholinesterase inhibitors, but that's general. The third chunk mentions two exceptions: acetylcholinesterase inhibitors and eculizumab. Wait, that seems contradictory because the question is about which inhibitors are used, but the third chunk says they are exceptions. Hmm. Wait, maybe the third chunk is saying that ecul", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which acetylcholinesterase inhibitors are used for treating myasthenia gravis. The evidence provided has three chunks. First chunk says pyridostigmine bromide has been the drug of choice for over 50 years. That's a direct mention of an inhibitor. Second chunk states that acetylcholinesterase inhibitors in general provide temporary treatment, but that's more of a general statement. The third chunk mentions two exceptions: acetylcholinesterase inhibitors and eculizumab. Wait, but the question is about inhibitors, so maybe the third chunk is saying that despite being an exception, they are still used? Or perhaps it's pointing out that even though they are inhibitors,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking which acetylcholinesterase inhibitors are used for treating myasthenia gravis. Let me look at the evidence provided. The first piece of evidence (20663605:20663605_0) mentions that pyridostigmine bromide has been the drug of choice for over 50 years. That's a clear mention of a specific inhibitor. The second evidence (15610702:15610702_0) states that acetylcholinesterase inhibitors provide temporary symptomatic treatment, but it doesn't name any specific drugs. The third evidence (29655452:2965", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which acetylcholinesterase inhibitors are used for treating myasthenia gravis. The evidence provided has three chunks. First chunk: Pyridostigmine bromide has been the drug of choice for over 50 years. So that's one inhibitor. Second chunk says acetylcholinesterase inhibitors in general provide temporary symptomatic treatment. But that's a general statement, not specific to any particular drug. Third chunk mentions two exceptions: acetylcholinesterase inhibitors and eculizumab. Wait, but the question is about which inhibitors are used, so maybe this chunk is pointing out that despite being exceptions, they are still used? Or perhaps it's saying that except", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which acetylcholinesterase inhibitors are used for treating myasthenia gravis. The evidence provided has three chunks. First chunk (20663605:20663605_0) says that pyridostigmine bromide has been the drug of choice for over 50 years. That's a direct mention of an acetylcholinesterase inhibitor used in treatment. Second chunk (15610702:15610702_0) states that acetylcholinesterase inhibitors provide temporary, symptomatic treatment for all forms of myasthenia gravis. This supports the use of these", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which acetylcholinesterase inhibitors are used for treating myasthenia gravis. The evidence provided has three chunks. First chunk (20663605:20663605_0) says that pyridostigmine bromide has been the drug of choice for over 50 years. So that's one inhibitor mentioned. The second chunk (15610702:15610702_0) states that acetylcholinesterase inhibitors provide temporary, symptomatic treatment for all forms of MG. But it doesn't specify which ones. However, the first chunk does mention pyridostigmine brom", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["15610702", "20663605", "21133188", "21328290", "21815707", "21845054"], "ideal_answer": "Pyridostigmine and neostygmine are acetylcholinesterase inhibitors that are used as first-line therapy for symptomatic treatment of myasthenia gravis. Pyridostigmine is the most widely used acetylcholinesterase inhibitor. Extended release pyridotsygmine and novel acetylcholinesterase inhibitors inhibitors with oral antisense oligonucleotides are being studied."}
{"question_id": "52bf1db603868f1b06000011", "question": "Has Denosumab (Prolia) been approved by FDA?", "retrieved_chunks": [{"doc_id": "21170699", "chunk_id": "21170699_0", "score": 10.686975479125977, "text": "The fully human monoclonal antibody denosumab (Prolia(®)) has been recently approved by the European Medical Agency (EMEA) and the Food and Drug Administration (FDA) for the treatment of postmenopausal osteoporosis."}, {"doc_id": "24126422", "chunk_id": "24126422_0", "score": 9.701005935668945, "text": "Denosumab (Prolia®) is a fully human monoclonal antibody for RANKL, which selectively inhibits osteoclastogenesis, being recently approved for the treatment of postmenopausal osteoporosis in women at a high or increased risk of fracture by the FDA in the United Sates and by the European Medicines Agency in Europe since June 2010."}, {"doc_id": "24316116", "chunk_id": "24316116_0", "score": 8.695709228515625, "text": "Denosumab is a RANK-ligand antibody that was approved by the FDA in 2010 for the prevention of skeletal fractures in patients with bone metastases from solid tumors."}], "context": "[21170699:21170699_0] The fully human monoclonal antibody denosumab (Prolia(®)) has been recently approved by the European Medical Agency (EMEA) and the Food and Drug Administration (FDA) for the treatment of postmenopausal osteoporosis.\n[24126422:24126422_0] Denosumab (Prolia®) is a fully human monoclonal antibody for RANKL, which selectively inhibits osteoclastogenesis, being recently approved for the treatment of postmenopausal osteoporosis in women at a high or increased risk of fracture by the FDA in the United Sates and by the European Medicines Agency in Europe since June 2010.\n[24316116:24316116_0] Denosumab is a RANK-ligand antibody that was approved by the FDA in 2010 for the prevention of skeletal fractures in patients with bone metastases from solid tumors.", "answer": "<think> Okay, let's tackle this question. The user wants to know if Denosumab (Prolia) has been approved by the FDA. I need to check the provided evidence. Looking at the first evidence snippet [21170699:21170699_0], it mentions that Denosumab was approved by both EMEA and FDA for postmenopausal osteoporosis. That's a direct mention of FDA approval. The second snippet [24126422:24316116_0] also states that the FDA approved it in the US for postmenopausal osteoporosis. The third snippet [24316116:24", "citations": [{"doc_id": "21170699", "chunk_id": "21170699_0"}, {"doc_id": "24126422", "chunk_id": "24316116_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants to know if Denosumab (Prolia) has been approved by the FDA. I need to check the provided evidence. Looking at the first evidence snippet [21170699:21170699_0], it mentions that Denosumab was approved by both EMEA and FDA for postmenopausal osteoporosis. That's a direct mention of FDA approval. The second snippet [24126422:24316116_0] also states that the FDA approved it in the US for postmenopausal osteoporosis. The third snippet [24316116:24", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if Denosumab (Prolia) has been approved by the FDA. I need to check the evidence provided. Looking at the first evidence snippet [21170699:21170699_0], it mentions that denosumab was approved by both EMEA and FDA for postmenopausal osteoporosis. That's a direct mention of FDA approval. The second snippet [24126422:24126422_0] also states that the FDA approved it for postmenopausal osteoporosis in the US. The third one [24316116:24", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if Denosumab (Prolia) has been approved by the FDA. I need to check the evidence provided. Looking at the first evidence snippet: It mentions that denosumab was approved by both EMEA and FDA for postmenopausal osteoporosis. So that's a direct mention of FDA approval. The second snippet also states that the FDA approved it in the US for postmenopausal osteoporosis. The third snippet says the FDA approved it in 2010 for preventing fractures in bone metastases. All three sources confirm FDA approval, but the question is specifically about the FDA. The first two snippets mention the FDA approving it for osteoporosis, and the third for", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if Denosumab (Prolia) has been approved by the FDA. I need to check the evidence provided. Looking at the evidence, there are three documents. The first one says it was approved by both EMEA and FDA for postmenopausal osteoporosis. The second mentions FDA approval in the US for high-risk women since June 2010. The third states it was approved by the FDA in 2010 for preventing fractures in bone metastases. So, all three documents confirm FDA approval. The dates vary slightly, but all agree on FDA approval. The answer should state that it has been approved, citing the relevant documents. The confidence is high since all sources mention FDA", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if Denosumab (Prolia) has been approved by the FDA. I need to check the provided evidence. Looking at the first evidence snippet [21170699:21170699_0], it mentions that denosumab was approved by both EMEA and FDA for postmenopausal osteoporosis. That's a direct answer. The second snippet [24126422:24126422_0] also states it was approved by the FDA for postmenopausal osteoporosis. The third one [24316116:24316116", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if Denosumab (Prolia) has been approved by the FDA. I need to check the evidence provided. Looking at the first evidence snippet [21170699:21170699_0], it mentions that denosumab was approved by both EMEA and FDA for postmenopausal osteoporosis. That's a direct mention of FDA approval. The second snippet [24126422:24316116_0] also states that the FDA approved it for postmenopausal osteoporosis in the US and Europe since June 2010. The third snippet [24", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if Denosumab (Prolia) has been approved by the FDA. I need to look at the provided evidence to find the answer. First, I'll check each of the three evidence chunks. Looking at the first one: [21170699:21170699_0] mentions that denosumab was approved by both EMEA and FDA for postmenopausal osteoporosis. So that's a direct mention of FDA approval. The second chunk [24126422:24126422_0] also states that the FDA approved it for postmenopausal osteoporosis in the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if Denosumab (Prolia) has been approved by the FDA. I need to check the evidence provided. Looking at the first evidence snippet [21170699:21170699_0], it says that Denosumab was approved by both EMEA and FDA for postmenopausal osteoporosis. That's a direct mention of FDA approval. The second snippet [24126422:24316116_0] also states that the FDA approved it in the US for postmenopausal osteoporosis, and the third one [24316116:2", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["20811384", "21113693", "21129866", "21170699", "21208140", "21470540", "21785279", "21942303", "22074657", "22540167", "22716221", "22826702", "23367751", "23652187", "23757624", "23759273", "23956508", "24114694", "24126422", "24308016", "24316116"], "ideal_answer": "Yes, Denosumab was approved by the FDA in 2010."}
{"question_id": "5709e4b2cf1c32585100001c", "question": "List the human genes encoding for the dishevelled proteins?", "retrieved_chunks": [{"doc_id": "19618470", "chunk_id": "19618470_0", "score": 5.572644233703613, "text": "Dishevelled (Dvl) proteins are key transducers of Wnt signaling encoded by members of a multi-gene family in vertebrates. We report here the divergent, tissue-specific expression patterns for all three Dvl genes in Xenopus embryos, which contrast dramatically with their expression patterns in mice."}, {"doc_id": "8856345", "chunk_id": "8856345_0", "score": 5.32364559173584, "text": "We report here that the mouse Dishevelled-1 (Dvl-1) and Dishevelled-2 genes encode proteins that are differentially localized in Wnt-overexpressing PC12 cell lines (PC12/Wnt)."}, {"doc_id": "7958461", "chunk_id": "7958461_0", "score": 2.8897006511688232, "text": "In the Drosophila embryo dishevelled (dsh) function is required by target cells in order to respond to wingless (wg, the homolog of Wnt-1), demonstrating a role for dsh in Wnt signal transduction. We have isolated a mouse homolog of the Drosophila dsh segment polarity gene. The 695-amino-acid protein encoded by the mouse dishevelled gene (Dvl-1) shares 50% identity (65% similarity) with dsh."}], "context": "[19618470:19618470_0] Dishevelled (Dvl) proteins are key transducers of Wnt signaling encoded by members of a multi-gene family in vertebrates. We report here the divergent, tissue-specific expression patterns for all three Dvl genes in Xenopus embryos, which contrast dramatically with their expression patterns in mice.\n[8856345:8856345_0] We report here that the mouse Dishevelled-1 (Dvl-1) and Dishevelled-2 genes encode proteins that are differentially localized in Wnt-overexpressing PC12 cell lines (PC12/Wnt).\n[7958461:7958461_0] In the Drosophila embryo dishevelled (dsh) function is required by target cells in order to respond to wingless (wg, the homolog of Wnt-1), demonstrating a role for dsh in Wnt signal transduction. We have isolated a mouse homolog of the Drosophila dsh segment polarity gene. The 695-amino-acid protein encoded by the mouse dishevelled gene (Dvl-1) shares 50% identity (65% similarity) with dsh.", "answer": "<think> Okay, let's tackle this question. The user is asking for the human genes that encode the dishevelled proteins. I need to look at the provided evidence to find the answer. First, looking at evidence [19618470:19618470_0], it mentions that Dishevelled (Dvl) proteins are encoded by members of a multi-gene family in vertebrates. It specifically talks about three Dvl genes in Xenopus embryos. But the question is about humans, so maybe this refers to the general structure but not the exact human genes. Next, evidence [8856345:8856345_0] mentions mouse Dishevelled-1 (D", "citations": [{"doc_id": "19618470", "chunk_id": "19618470_0"}, {"doc_id": "8856345", "chunk_id": "8856345_0"}], "candidates": [{"answer": "<think> Okay, so the user is asking for the human genes that encode the dishevelled proteins. Let me look through the provided evidence to find the answer. The first document mentions that Dishevelled (Dvl) proteins are encoded by members of a multi-gene family in vertebrates, and they talk about three Dvl genes in Xenopus embryos. But the question is about humans, so maybe this is a starting point. However, it doesn't explicitly list human gene names. The second document refers to mouse Dishevelled-1 (Dvl-1) and Dishevelled-2 genes. Since mice are vertebrates, and humans are also vertebrates, it's possible that the same genes exist in humans. But the document is about mice,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the human genes that encode the dishevelled proteins. I need to look at the provided evidence to find the answer. First, looking at evidence [19618470:19618470_0], it mentions that Dishevelled (Dvl) proteins are encoded by members of a multi-gene family in vertebrates. It specifically talks about three Dvl genes in Xenopus embryos. But the question is about humans, so maybe this refers to the general structure but not the exact human genes. Next, evidence [8856345:8856345_0] mentions mouse Dishevelled-1 (D", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the human genes that encode the dishevelled proteins. I need to look at the provided evidence to find the answer. First, looking at the evidence documents: Document 19618470 mentions that Dishevelled (Dvl) proteins are encoded by members of a multi-gene family in vertebrates, and there are three Dvl genes in Xenopus. But this is about Xenopus, not humans. However, it's possible that the same applies to humans. Document 8856345 talks about mouse Dishevelled-1 (Dvl-1) and Dishevelled-2 genes. Since mice are mammals, and humans are also mammals", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the human genes that encode the dishevelled proteins. Looking at the evidence provided, there are three references. First, reference [19618470:19618470_0] mentions that Dishevelled (Dvl) proteins are encoded by members of a multi-gene family in vertebrates, and specifically talks about three Dvl genes in Xenopus embryos. But the question is about humans, so I need to check if this reference mentions human genes. Wait, the reference says \"vertebrates\" but doesn't specify human genes. However, it's part of the evidence, so maybe there's more. Next, [885634", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the human genes that encode the dishevelled proteins. I need to look at the provided evidence to find the relevant information. First, looking at evidence [19618470:19618470_0], it mentions that Dishevelled (Dvl) proteins are encoded by members of a multi-gene family in vertebrates. It specifically talks about three Dvl genes in Xenopus embryos. But the question is about human genes, so maybe this is a starting point. However, the document doesn't explicitly name the human genes here. Next, evidence [8856345:8856345_0] refers to", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the human genes that encode the dishevelled proteins. Looking at the evidence provided, there are three references. First, reference [19618470:19618470_0] mentions that Dishevelled (Dvl) proteins are encoded by members of a multi-gene family in vertebrates, and specifically talks about three Dvl genes in Xenopus embryos. But the question is about humans, so I need to check if this reference mentions human genes. Wait, the reference says \"all three Dvl genes in Xenopus embryos,\" but that's Xenopus, not humans. However, it does state that they are part of a multi-gene family", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the human genes that encode the dishevelled proteins. Looking at the evidence provided, there are three references. First, reference [19618470:19618470_0] mentions that Dishevelled (Dvl) proteins are encoded by members of a multi-gene family in vertebrates, and specifically talks about three Dvl genes in Xenopus embryos. But the question is about humans, so I need to check if this reference mentions human genes. It doesn't explicitly state that, but it's part of vertebrates, which include humans. Next, [8856345:8856345_0]", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the human genes that encode the dishevelled proteins. Looking at the evidence provided, there are three references. First, reference [19618470:19618470_0] mentions that Dvl proteins are encoded by members of a multi-gene family in vertebrates, and specifically talks about three Dvl genes in Xenopus embryos. But the question is about human genes, so I need to check if this reference provides info on humans. However, the text doesn't explicitly mention human genes, just Xenopus and mice. Next, [8856345:8856345_0] refers to mouse Dishevel", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["12883684", "16457155", "19618470", "23836490", "24040443", "7958461", "8149913", "8817329", "8856345"], "ideal_answer": "DVL-1 DVL-2 DVL-3"}
{"question_id": "56bc751eac7ad10019000013", "question": "Name synonym of Acrokeratosis paraneoplastica.", "retrieved_chunks": [{"doc_id": "8949310", "chunk_id": "8949310_0", "score": 6.799607276916504, "text": "Acrokeratosis paraneoplastica: Bazex syndrome."}, {"doc_id": "6225397", "chunk_id": "6225397_0", "score": 6.467101097106934, "text": "Acrokeratosis paraneoplastica (Bazex&apos; syndrome) is a rare but clinically distinctive dermatosis that has been associated in all reported cases, to our knowledge, with either a primary malignant neoplasm of the upper aerodigestive tract or metastatic cancer to the lymph nodes of the neck. Acrokeratosis paraneoplastica was found in a 53-year-old black man with squamous cell carcinoma of the tonsil."}, {"doc_id": "17097409", "chunk_id": "17097409_0", "score": 6.454122543334961, "text": "Acrokeratosis paraneoplastica (Bazex's syndrome): association with liposarcoma."}], "context": "[8949310:8949310_0] Acrokeratosis paraneoplastica: Bazex syndrome.\n[6225397:6225397_0] Acrokeratosis paraneoplastica (Bazex&apos; syndrome) is a rare but clinically distinctive dermatosis that has been associated in all reported cases, to our knowledge, with either a primary malignant neoplasm of the upper aerodigestive tract or metastatic cancer to the lymph nodes of the neck. Acrokeratosis paraneoplastica was found in a 53-year-old black man with squamous cell carcinoma of the tonsil.\n[17097409:17097409_0] Acrokeratosis paraneoplastica (Bazex's syndrome): association with liposarcoma.", "answer": "<think> Okay, let's tackle this question. The user is asking for a synonym of \"Acrokeratosis paraneoplastica.\" Looking at the evidence provided, there are three chunks. The first chunk [8949310:8949310_0] directly mentions \"Bazex syndrome\" in relation to Acrokeratosis paraneoplastica. That seems like a synonym. The second chunk [6225397:6225397_0] also refers to it as Bazex's syndrome, reinforcing that. The third chunk [17097409:17097409_0] again uses \"Bazex's syndrome\" as the alternative name", "citations": [{"doc_id": "8949310", "chunk_id": "8949310_0"}, {"doc_id": "6225397", "chunk_id": "6225397_0"}, {"doc_id": "17097409", "chunk_id": "17097409_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking for a synonym of \"Acrokeratosis paraneoplastica.\" Looking at the evidence provided, there are three chunks. The first chunk [8949310:8949310_0] directly mentions \"Bazex syndrome\" in relation to Acrokeratosis paraneoplastica. That seems like a synonym. The second chunk [6225397:6225397_0] also refers to it as Bazex's syndrome, reinforcing that. The third chunk [17097409:17097409_0] again uses \"Bazex's syndrome\" as the alternative name", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking for a synonym of \"Acrokeratosis paraneoplastica.\" Looking at the evidence provided, the first document mentions that Acrokeratosis paraneoplastica is called Bazex syndrome. So that's a direct synonym. The other documents talk about the association with certain cancers but don't provide alternative names. The key citation here is [8949310:8949310_0], which explicitly states that Acrokeratosis paraneoplastica is Bazex syndrome. That seems like the most straightforward answer. I need to make sure there's no other possible synonym mentioned. The other documents don't mention another term, so Bazex syndrome is the correct synonym. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let me tackle this question. The user is asking for a synonym of \"Acrokeratosis paraneoplastica.\" Looking at the evidence provided, there are three references. First, reference [8949310:8949310_0] mentions \"Bazex syndrome\" in relation to Acrokeratosis paraneoplastica. That seems like a direct synonym. The other references also mention \"Acokeratosis paraneoplastica (Bazex's syndrome)\" so that reinforces the same point. I need to check if there's any other possible synonym, but the evidence doesn't mention anything else. The key here is that Bazex syndrome is listed as a synonym in the first reference. The confidence level should", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking for a synonym of \"Acrokeratosis paraneoplastica.\" Looking at the evidence provided, the first document mentions that Acrokeratosis paraneoplastica is also known as Bazex syndrome. That seems like a direct synonym. The second document reinforces that by using the same term, \"Acrokeratosis paraneoplastica (Bazex's syndrome)\" and explains it's associated with certain cancers. The third document again refers to it as Bazex's syndrome in relation to liposarcoma. So, the answer should be Bazex syndrome. Now, checking the confidence. The first document explicitly states that, while the others provide context. Since the first one directly uses the synonym, I'll", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking for a synonym of \"Acrokeratosis paraneoplastica.\" Let me look at the evidence provided. First, in the evidence, there's a mention of \"Bazex syndrome\" in the first document. Then, another document refers to \"Acrokeratosis paraneoplastica (Bazex' syndrome)\" which suggests that Bazex syndrome is another name for the same condition. The third document also uses \"Bazex's syndrome\" in parentheses, reinforcing that it's an alternative term. So, putting that together, the synonym would be Bazex syndrome. Now, I need to check if there are any other possible synonyms, but the evidence doesn't mention any others. All the references tie Acrokeratosis parane", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking for a synonym of \"Acrokeratosis paraneoplastica.\" Looking at the evidence provided, the first document mentions that Acrokeratosis paraneoplastica is known as Bazex syndrome. So that's a direct synonym. The other documents talk about the association with certain cancers but don't provide alternative names. The second document explicitly states \"Bazex syndrome\" as the alternate name. The third one also refers to it as \"Bazex's syndrome.\" So the primary synonym here is Bazex syndrome. I need to make sure there are no other possible synonyms in the evidence, but the other documents don't mention any. The answer should be concise, so I'll just state that Acrokerat", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking for a synonym for \"Acrokeratosis paraneoplastica.\" Let me look at the evidence provided. The first piece of evidence [8949310:8949310_0] mentions \"Bazex syndrome\" in relation to Acrokeratosis paraneoplastica. That seems like a direct synonym. The other documents also refer to it as Bazex's syndrome, so that's consistent. I need to check if there are any other possible synonyms, but the evidence doesn't mention anything else. The term \"Bazex syndrome\" is used in multiple entries, so that's the main alternative name. The answer should be concise and include the citation. The confidence level is high", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking for a synonym of \"Acrokeratosis paraneoplastica.\" Looking at the evidence provided, the first document mentions that Acrokeratosis paraneoplastica is also known as Bazex syndrome. So that's a direct synonym. The other documents elaborate on the condition, mentioning it's associated with certain cancers, but they don't provide alternative names. The key point here is that the first citation explicitly states the synonym. I need to make sure the answer is concise and includes the correct citation. The confidence level should be high since the evidence directly states this. So the answer should be \"Bazex syndrome\" with the citation from document 8949310:894931", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["1433123", "1521479", "16435144", "17097409", "17374318", "18672707", "18775590", "22146896", "22252191", "22470801", "3819049", "6225397", "7640201", "7796616", "8949310"], "ideal_answer": "Acrokeratosis paraneoplastic (Bazex syndrome) is a rare, but distinctive paraneoplastic dermatosis characterized by erythematosquamous lesions located at the acral sites and is most commonly associated with carcinomas of the upper aerodigestive tract."}
{"question_id": "54d4e03a3706e89528000001", "question": "Which are the classes of anti-arrhythmic drugs according to Vaughan-Williams classification?", "retrieved_chunks": [{"doc_id": "9803978", "chunk_id": "9803978_0", "score": 9.344623565673828, "text": "Antiarrhythmic agents are traditionally classified according to Vaughan Williams into four classes of action. Class I antiarrhythmic agents include most of the drugs traditionally thought of as antiarrhythmics, and have as a common action, blockade of the fast-inward sodium channel on myocardium."}, {"doc_id": "11564050", "chunk_id": "11564050_0", "score": 9.344623565673828, "text": "Antiarrhythmic agents are traditionally classified according to Vaughan Williams into four classes of action. Class I antiarrhythmic agents include most of the drugs traditionally thought of as antiarrhythmics, and have as a common action, blockade of the fast-inward sodium channel on myocardium."}, {"doc_id": "10810787", "chunk_id": "10810787_1", "score": 9.307180404663086, "text": "Antiarrhythmic drugs can be divided into four Vaughan Williams classes (I-IV) according to defined electrophysiological effects on the myocardium."}], "context": "[9803978:9803978_0] Antiarrhythmic agents are traditionally classified according to Vaughan Williams into four classes of action. Class I antiarrhythmic agents include most of the drugs traditionally thought of as antiarrhythmics, and have as a common action, blockade of the fast-inward sodium channel on myocardium.\n[11564050:11564050_0] Antiarrhythmic agents are traditionally classified according to Vaughan Williams into four classes of action. Class I antiarrhythmic agents include most of the drugs traditionally thought of as antiarrhythmics, and have as a common action, blockade of the fast-inward sodium channel on myocardium.\n[10810787:10810787_1] Antiarrhythmic drugs can be divided into four Vaughan Williams classes (I-IV) according to defined electrophysiological effects on the myocardium.", "answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is about the classes of anti-arrhythmic drugs according to Vaughan-Williams classification. Looking at the evidence provided, there are three documents. All of them mention that Vaughan Williams classified antiarrhythmic agents into four classes. The first two documents (9803978 and 11564050) specifically mention Class I agents blocking sodium channels, but they don't list all four classes. The third document (10810787) says they are divided into four classes (I-IV) based on electrophysiological effects. However, the exact names of the classes aren't detailed here. The user wants the answer to", "citations": [], "candidates": [{"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is about the classes of anti-arrhythmic drugs according to Vaughan-Williams classification. Looking at the evidence provided, there are three documents. All of them mention that Vaughan Williams classified antiarrhythmic agents into four classes. The first two documents (9803978 and 11564050) specifically mention Class I agents blocking sodium channels, but they don't list all four classes. The third document (10810787) says they are divided into four classes (I-IV) based on electrophysiological effects. However, the exact names of the classes aren't detailed here. The user wants the answer to", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the classes of anti-arrhythmic drugs according to the Vaughan-Williams classification. First, I need to look at the evidence provided. There are three documents here. Let me check each one. Document 9803978: It mentions four classes, with Class I agents blocking sodium channels. But it doesn't list all the classes. Similarly, document 11564050 is the same as the first one. Then document 10810787 says they are divided into four classes (I-IV) based on electrophysiological effects. However, it doesn't specify what each class is. Wait, the question is about the classes themselves", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking about the classes of anti-arrhythmic drugs according to the Vaughan-Williams classification. Let me look at the evidence provided. The first two documents both mention that Vaughan Williams classification divides them into four classes, with Class I agents blocking sodium channels. The third document also states they are divided into four classes (I-IV) based on electrophysiological effects. Wait, but the user wants the answer to list the classes. However, the evidence doesn't explicitly name all four classes beyond Class I. The first two documents only mention Class I, but the third says four classes (I-IV). But the actual answer should include all four classes as per standard knowledge. However, the evidence here doesn't detail all four classes.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the classes of anti-arrhythmic drugs according to the Vaughan-Williams classification. I need to generate a concise answer with citations and a confidence level. First, looking at the evidence provided. There are three documents here. Documents 9803978 and 11564050 both mention four classes, with Class I agents blocking sodium channels. Document 10810787 also mentions four classes (I-IV) based on electrophysiological effects. So the answer should state that there are four classes. The first three documents all agree on this. The exact classes aren't detailed here, but the question is about the classification, not the specific drugs", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the classes of anti-arrhythmic drugs according to the Vaughan-Williams classification. I need to generate a concise answer with citations and a confidence level. First, I'll look at the evidence provided. There are three documents mentioned. Documents 9803978 and 11564050 both mention four classes, with Class I involving sodium channel blockade. Document 10810787 also states four classes (I-IV) based on electrophysiological effects. So the answer should list the four classes as per Vaughan Williams. The evidence doesn't specify all four class names, but it's common knowledge that they are Class I to IV. However,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the classes of anti-arrhythmic drugs according to the Vaughan-Williams classification. I need to generate a concise answer with citations and a confidence score. First, I'll look at the evidence provided. There are three documents here. Documents 9803978 and 11564050 both mention four classes, with Class I involving sodium channel blockade. Document 10810787 also states four classes (I-IV) based on electrophysiological effects. So the answer should state that there are four classes (I-IV), as mentioned in all three sources. The first two documents specifically mention Class I, but the third one generalizes to", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the classes of anti-arrhythmic drugs according to the Vaughan-Williams classification. I need to generate a concise answer with citations and a confidence score. First, looking at the evidence provided. There are three documents mentioned. Documents 9803978 and 11564050 both mention four classes, with Class I involving sodium channel blockade. Document 10810787 also states four classes (I-IV) based on electrophysiological effects. Wait, the answer should list the four classes. But the evidence doesn't explicitly name all four classes. It mentions Class I and refers to Classes II-IV indirectly. However, the user's question", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is about the classes of anti-arrhythmic drugs according to Vaughan-Williams classification. Looking at the evidence provided, there are three documents. All of them mention that the drugs are classified into four classes. The first two documents specifically mention Class I agents blocking sodium channels. The third document mentions four classes (I-IV) based on electrophysiological effects. So the answer should state that there are four classes (I-IV) as per Vaughan-Williams. The citations would be from the three documents, but since the question is about the classes, the main point is the four classes. However, the user wants the answer to include citations in [doc_id:chunk_id] format", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["10810787", "11564050", "1290288", "7875632", "9803978"], "ideal_answer": "Antiarrhythmic drugs can be divided into four Vaughan Williams classes (I-IV). Class I antiarrhythmic agents have as a common action, blockade of the sodium channels. Class II agents are antisympathetic drugs, particularly the beta-adrenoceptor blockers. Class-III antiarrhythmics have as a common action the potassium-channel blockade. Class IV antiarrhythmic drugs are calcium channel blockers."}
{"question_id": "55072c803b8a5dc045000001", "question": "Which are the different isoforms of the mammalian Notch receptor?", "retrieved_chunks": [{"doc_id": "22842086", "chunk_id": "22842086_0", "score": 3.7455735206604004, "text": "There are four different mammalian Notch receptors that can be activated by five cell surface ligands"}, {"doc_id": "11532344", "chunk_id": "11532344_0", "score": 3.0279664993286133, "text": "There are four mammalian Notch receptors that have only partially overlapping functions despite sharing similar structures and ligands."}, {"doc_id": "23028706", "chunk_id": "23028706_0", "score": 2.4647395610809326, "text": "Here, we investigate protein interactions between NOTCH3 and other vascular Notch isoforms and characterize the effects of elevated NOTCH3 on smooth muscle gene regulation. We demonstrate that NOTCH3 forms heterodimers with NOTCH1, NOTCH3, and NOTCH4."}], "context": "[22842086:22842086_0] There are four different mammalian Notch receptors that can be activated by five cell surface ligands\n[11532344:11532344_0] There are four mammalian Notch receptors that have only partially overlapping functions despite sharing similar structures and ligands.\n[23028706:23028706_0] Here, we investigate protein interactions between NOTCH3 and other vascular Notch isoforms and characterize the effects of elevated NOTCH3 on smooth muscle gene regulation. We demonstrate that NOTCH3 forms heterodimers with NOTCH1, NOTCH3, and NOTCH4.", "answer": "<think> Okay, let's tackle this question about the different isoforms of the mammalian Notch receptor. The user provided three evidence snippets, so I need to parse those carefully. First, looking at the evidence: The first snippet [22842086:22842086_0] says there are four different mammalian Notch receptors activated by five ligands. Wait, but the question is about isoforms, not the number of receptors. Hmm, maybe that's a point of confusion. The term \"receptors\" here might refer to the different forms (isoforms) of the Notch receptor. The second snippet [11532344:11532344_0] also mentions", "citations": [{"doc_id": "22842086", "chunk_id": "22842086_0"}, {"doc_id": "11532344", "chunk_id": "11532344_0"}], "candidates": [{"answer": "<think> Okay, so the user is asking about the different isoforms of the mammalian Notch receptor. Let me look at the evidence provided. First, the evidence has three references. The first one says there are four different mammalian Notch receptors activated by five ligands. The second mentions four Notch receptors with partially overlapping functions. The third talks about NOTCH3 forming heterodimers with NOTCH1, NOTCH3, and NOTCH4. Wait, the question is about isoforms, not just the number of receptors. But the answer might be that there are four isoforms. However, the third reference mentions NOTCH3 interacting with itself and others. But I need to check if the evidence directly states the isoforms. The first two references mention four Not", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about the different isoforms of the mammalian Notch receptor. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. The first document says there are four different mammalian Notch receptors activated by five ligands. The second mentions four Notch receptors with partially overlapping functions. The third talks about NOTCH3 forming heterodimers with NOTCH1, NOTCH3, and NOTCH4. Wait, the question is about isoforms, not just the number of receptors. But the evidence might be referring to different forms. However, the documents mention four Notch receptors. But the third document specifically mentions NOTCH3 interacting with itself and others. Hmm. But the answer", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about the different isoforms of the mammalian Notch receptor. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three references here. Let me read through them carefully. The first one says there are four different mammalian Notch receptors that can be activated by five ligands. Wait, but the question is about isoforms, not the number of receptors. Hmm, maybe that's a point to consider. But the second evidence states there are four Notch receptors with partially overlapping functions. The third reference mentions NOTCH3 forming heterodimers with NOTCH1, NOTCH3, and NOTCH4. Wait, that seems a bit confusing. If NOTCH", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about the different isoforms of the mammalian Notch receptor. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three documents here. Let me read through them carefully. The first document says there are four different mammalian Notch receptors that can be activated by five ligands. Wait, but the question is about isoforms, not just the number of receptors. Hmm, maybe \"isoforms\" here refer to the different receptors. But I need to check if the documents mention isoforms or just the different receptors. The second document states there are four Notch receptors with partially overlapping functions. Again, this seems to be talking about the four main receptors, not their", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about the different isoforms of the mammalian Notch receptor. The user provided three evidence snippets, so I need to parse those carefully. First, looking at the evidence: The first snippet [22842086:22842086_0] says there are four different mammalian Notch receptors activated by five ligands. Wait, but the question is about isoforms, not the number of receptors. Hmm, maybe that's a point of confusion. The term \"receptors\" here might refer to the different forms (isoforms) of the Notch receptor. The second snippet [11532344:11532344_0] also mentions", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question about the different isoforms of the mammalian Notch receptor. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three references here. Let me read through them carefully. The first one says there are four different mammalian Notch receptors that can be activated by five ligands. Wait, but the question is about isoforms, not the number of receptors. Hmm. Maybe \"receptors\" here refer to isoforms? Or maybe they're talking about the different forms of Notch. The second evidence states there are four Notch receptors with partially overlapping functions but similar structures and ligands. This seems to align with the first point, reinforcing that there are four.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about the different isoforms of the mammalian Notch receptor. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. The first document says there are four different mammalian Notch receptors activated by five ligands. The second mentions four Notch receptors with partially overlapping functions. The third talks about NOTCH3 interacting with NOTCH1, NOTCH3, and NOTCH4, forming heterodimers. Wait, the question is about isoforms, not just the number of receptors. But in the evidence, the documents refer to \"four different mammalian Notch receptors\" and \"NOTCH3 forms heterodimers with NOTCH1, NOTCH3, and NOTCH", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about the different isoforms of the mammalian Notch receptor. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three references here. Let me go through each one. The first evidence (22842086:22842086_0) says there are four different mammalian Notch receptors that can be activated by five ligands. Wait, but the question is about isoforms, not the number of receptors. Hmm, maybe this is talking about different receptors, but the answer needs to be about isoforms. So maybe this isn't directly relevant. The second evidence (11532344:", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["11532344", "11732008", "16307184", "21356309", "21639801", "22842086", "23028706"], "ideal_answer": "Notch signaling is an evolutionarily conserved mechanism, used to regulate cell fate decisions. Four Notch receptors have been identified in man: Notch-1, Notch-2, Notch-3 and Notch-4."}
{"question_id": "53061af558348c0f52000002", "question": "Which are the major characteristics of cellular senescence?", "retrieved_chunks": [{"doc_id": "18976161", "chunk_id": "18976161_0", "score": 7.492673873901367, "text": "Cellular senescence is recognized as a critical cellular response to prolonged rounds of replication and environmental stresses. Its defining characteristics are arrested cell-cycle progression and the development of aberrant gene expression with proinflammatory behavior."}, {"doc_id": "23422284", "chunk_id": "23422284_0", "score": 2.602902412414551, "text": "utophagy and senescence share a number of characteristics, which suggests that both responses could serve to collaterally protect the cell from the toxicity of external stress such as radiation and chemotherapy and internal forms of stress such as telomere shortening and oncogene activation"}, {"doc_id": "17664422", "chunk_id": "17664422_0", "score": 2.471251964569092, "text": "Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation"}], "context": "[18976161:18976161_0] Cellular senescence is recognized as a critical cellular response to prolonged rounds of replication and environmental stresses. Its defining characteristics are arrested cell-cycle progression and the development of aberrant gene expression with proinflammatory behavior.\n[23422284:23422284_0] utophagy and senescence share a number of characteristics, which suggests that both responses could serve to collaterally protect the cell from the toxicity of external stress such as radiation and chemotherapy and internal forms of stress such as telomere shortening and oncogene activation\n[17664422:17664422_0] Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation", "answer": "<think> Okay, let's tackle this question. The user wants the major characteristics of cellular senescence. Looking at the evidence provided, the first document [18976161:18976161_0] says that the defining characteristics are arrested cell-cycle progression and aberrant gene expression with proinflammatory behavior. That seems like the key points here. The other documents mention things like autophagy sharing characteristics with senescence, and tumor regression upon c-Myc inactivation. But those might be related to mechanisms or consequences rather than the major characteristics themselves. The question is about the major characteristics, so the first source is more directly relevant. So the answer should focus on arrested cell-cycle progression and the proinflammatory gene expression. The", "citations": [{"doc_id": "18976161", "chunk_id": "18976161_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants the major characteristics of cellular senescence, and they provided some evidence documents. First, I need to look at the evidence. The first document says that cellular senescence is a response to replication and stress, with arrested cell-cycle progression and aberrant gene expression leading to proinflammatory behavior. That seems like key points. The second document mentions autophagy and senescence sharing characteristics, but that's more about their similarities rather than the defining features of senescence itself. The third document talks about tumor regression when c-Myc is inactive, which might be a consequence rather than a characteristic. So the main characteristics from the first evidence are arrested cell-cycle progression and proinflammatory gene expression. The other points are", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know the major characteristics of cellular senescence based on the provided evidence. First, I need to look at the evidence given. There are three documents here. Let me go through each one. The first document says that cellular senescence is a response to replication and stress, with arrested cell-cycle progression and aberrant gene expression leading to proinflammatory behavior. That seems like a key point. The second document mentions autophagy and senescence sharing characteristics, but the question is about the major characteristics, so maybe this is more about related processes rather than the defining features. The third document talks about tumor regression when c-Myc is inactivated, which might be a consequence or a function of senescence,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants the major characteristics of cellular senescence based on the provided evidence. First, I need to look at the evidence given. There are three documents here. Let me go through each one. The first document says that cellular senescence is a response to replication and stress, with defining features being arrested cell-cycle progression and aberrant gene expression with proinflammatory behavior. That seems like a key point. The second document mentions autophagy and senescence sharing characteristics, but the question is about the major characteristics of senescence, so maybe this is more about shared traits rather than the main ones. The third document talks about tumor regression when c-Myc is inactive, which might be a consequence or a result, not", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants the major characteristics of cellular senescence. Looking at the evidence provided, the first document [18976161:18976161_0] says that the defining characteristics are arrested cell-cycle progression and aberrant gene expression with proinflammatory behavior. That seems like the key points here. The other documents mention things like autophagy sharing characteristics with senescence, and tumor regression upon c-Myc inactivation. But those might be related to mechanisms or consequences rather than the major characteristics themselves. The question is about the major characteristics, so the first source is more directly relevant. So the answer should focus on arrested cell-cycle progression and the proinflammatory gene expression. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, so the user wants me to generate a biomedical answer about the major characteristics of cellular senescence using the provided evidence. Let me start by reading through the question and the evidence carefully. The question asks for the major characteristics of cellular senescence. The evidence given has three chunks. Let me parse each one. First chunk [18976161:18976161_0] says that cellular senescence is a response to replication and stress, with arrested cell-cycle progression and aberrant gene expression leading to proinflammatory behavior. That seems like key points. The second chunk [23422284:23422284_0] talks about autophagy and senesc", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is about the major characteristics of cellular senescence. Looking at the evidence provided, the first document [18976161:18976161_0] mentions that cellular senescence has two defining characteristics: arrested cell-cycle progression and aberrant gene expression with proinflammatory behavior. That seems like the key points here. The other documents talk about shared characteristics with autophagy and tumor regression, but those might not be the major characteristics themselves. The answer should be concise, so I'll list the two main points from the first evidence. The citation would be [18976161:189761", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the major characteristics of cellular senescence. I need to look at the evidence provided and pick out the key points. First, looking at evidence [18976161:18976161_0], it mentions that cellular senescence is a response to replication and stress. The defining characteristics are arrested cell-cycle progression and aberrant gene expression with proinflammatory behavior. That seems like a direct answer. Then there's [23422284:23422284_0], which talks about shared characteristics with autophagy, but the question is about senescence specifically. Maybe that's not as relevant here.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer based on the given evidence. The question is about the major characteristics of cellular senescence. First, I'll look at the evidence provided. The first document [18976161:18976161_0] says that cellular senescence has two defining characteristics: arrested cell-cycle progression and aberrant gene expression with proinflammatory behavior. That seems like a direct answer to the question. The second document [23422284:23422284_0] talks about shared characteristics between autophagy and senescence, but it's more about their similarities in protecting cells from stress. However, this might not be a major", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["18976161", "8824885", "9624027"], "ideal_answer": "The defining characteristics of cellular senescence are altered morphology, arrested cell-cycle progression, development of aberrant gene expression with proinflammatory behavior, and telomere shortening."}
{"question_id": "56c1f01def6e394741000045", "question": "Orteronel was developed for treatment of which cancer?", "retrieved_chunks": [{"doc_id": "25264242", "chunk_id": "25264242_1", "score": 7.942438125610352, "text": "Orteronel is a nonsteroidal, selective inhibitor of 17,20-lyase that was recently in phase 3 clinical development as a treatment for castration-resistant prostate cancer."}, {"doc_id": "24799061", "chunk_id": "24799061_2", "score": 7.376224517822266, "text": "Orteronel for the treatment of prostate cancer."}, {"doc_id": "21978946", "chunk_id": "21978946_0", "score": 7.288248538970947, "text": "Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer."}], "context": "[25264242:25264242_1] Orteronel is a nonsteroidal, selective inhibitor of 17,20-lyase that was recently in phase 3 clinical development as a treatment for castration-resistant prostate cancer.\n[24799061:24799061_2] Orteronel for the treatment of prostate cancer.\n[21978946:21978946_0] Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.", "answer": "<think> Okay, so I need to figure out which cancer Orteronel was developed for based on the given evidence. Let me look at the evidence provided. First evidence: [25264242:25264242_1] says it's a nonsteroidal, selective inhibitor of 17,20-lyase and was in phase 3 clinical development as a treatment for castration-resistant prostate cancer. That seems pretty direct. The term \"castration-resistant prostate cancer\" is specific. Second evidence: [24799061:24799061_2] mentions Orteronel for the treatment of prostate cancer. That's more general, just prostate cancer. Third evidence", "citations": [{"doc_id": "25264242", "chunk_id": "25264242_1"}, {"doc_id": "24799061", "chunk_id": "24799061_2"}], "candidates": [{"answer": "<think> Okay, so I need to figure out which cancer Orteronel was developed for based on the given evidence. Let me look at the evidence provided. First evidence: [25264242:25264242_1] says it's a nonsteroidal, selective inhibitor of 17,20-lyase and was in phase 3 clinical development as a treatment for castration-resistant prostate cancer. That seems pretty direct. The term \"castration-resistant prostate cancer\" is specific. Second evidence: [24799061:24799061_2] mentions Orteronel for the treatment of prostate cancer. That's more general, just prostate cancer. Third evidence", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which cancer Orteronel was developed for treatment. The evidence provided has three chunks. First chunk (25264242:25264242_1) says it's a inhibitor of 17,20-lyase for castration-resistant prostate cancer. Second chunk (24799061:24799061_2) directly states Orteronel for prostate cancer. Third chunk (21978946:21978946_0) mentions it's a selective 17,20-lyase inhibitor with potential in prostate cancer treatment. So the answer should", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which cancer Orteronel was developed for treatment. The evidence provided has three documents. First, looking at document [25264242:25264242_1], it says Orteronel is a selective inhibitor of 17,20-lyase for castration-resistant prostate cancer. That's a direct mention of prostate cancer. Then, document [24799061:24799061_2] states that Orteronel is for the treatment of prostate cancer. That's another confirmation. The third document [21978946:21978946", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, so the user is asking which cancer Orteronel was developed for. Let me look at the evidence provided. First, there's the document [25264242:25264242_1] that says it's a inhibitor of 17,20-lyase for castration-resistant prostate cancer. Then [24799061:24799061_2] mentions prostate cancer directly. The third one [21978946:21978946_0] talks about it being a 17,20-lyase inhibitor with potential for prostate cancer. So the answer should be prostate cancer. All three", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which cancer Orteronel was developed for treatment. The evidence provided has three documents. First, looking at document [25264242:25264242_1], it says Orteronel is a inhibitor of 17,20-lyase for castration-resistant prostate cancer. That's a direct mention of prostate cancer. Then, document [24799061:24799061_2] states that Orteronel is for the treatment of prostate cancer. That's another confirmation. The third document [21978946:21978946_", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which cancer Orteronel was developed for treatment. The evidence provided has three chunks. First chunk (25264242:25264242_1) says it's a selective inhibitor of 17,20-lyase for castration-resistant prostate cancer. Second chunk (24799061:24799063_2) mentions Orteronel for prostate cancer. Third chunk (21978946:21978946_0) talks about discovery as a 17,20-lyase inhibitor with potential in prostate cancer. So the answer should be", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's see. The user is asking which cancer Orteronel was developed for. The evidence provided has three chunks. First chunk says it's a inhibitor of 17,20-lyase for castration-resistant prostate cancer. Second mentions prostate cancer. Third talks about discovery as a 17,20-lyase inhibitor for prostate cancer. So all the evidence points to prostate cancer. The first chunk specifically mentions castration-resistant prostate cancer, but the others are more general. The answer should be concise. The confidence is high because all three sources agree. So answer is prostate cancer, and base_confidence would be 1.0 since all evidence supports that. </think> { \"answer\": \"Prostate cancer [252", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which cancer Orteronel was developed for treatment. The evidence provided has three chunks. First chunk (25264242:25264242_1) says it's a inhibitor of 17,20-lyase for castration-resistant prostate cancer. Second chunk (24799061:24799061_2) directly states Orteronel for prostate cancer. Third chunk (21978946:21978946_0) mentions it's a 17,20-lyase inhibitor with potential in prostate cancer treatment. So the answer should be", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["21978946", "24100689", "24418642", "24799061", "25264242", "25537627", "25624429", "25701170", "26150028"], "ideal_answer": "Orteronel was developed for treatment of castration-resistant prostate cancer."}
{"question_id": "5313b049e3eabad021000013", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "retrieved_chunks": [{"doc_id": "12422054", "chunk_id": "12422054_0", "score": 6.673473834991455, "text": "Herceptin (trastuzumab), an anti-HER2 monoclonal antibody, is the first oncogene-targeted therapy to be developed for the treatment of metastatic breast cancer."}, {"doc_id": "19593441", "chunk_id": "19593441_1", "score": 6.55655574798584, "text": "Herceptin (trastuzumab) is a humanized monoclonal antibody that is approved for the treatment of metastatic breast cancer patients whose tumors overexpress Her2 (erbB2/neu)."}, {"doc_id": "25377592", "chunk_id": "25377592_0", "score": 6.241744041442871, "text": "BACKGROUND Trastuzumab (Herceptin(®)) is a humanized monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2) and is used in the treatment of HER2-overexpressing breast and gastric cancer."}], "context": "[12422054:12422054_0] Herceptin (trastuzumab), an anti-HER2 monoclonal antibody, is the first oncogene-targeted therapy to be developed for the treatment of metastatic breast cancer.\n[19593441:19593441_1] Herceptin (trastuzumab) is a humanized monoclonal antibody that is approved for the treatment of metastatic breast cancer patients whose tumors overexpress Her2 (erbB2/neu).\n[25377592:25377592_0] BACKGROUND Trastuzumab (Herceptin(®)) is a humanized monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2) and is used in the treatment of HER2-overexpressing breast and gastric cancer.", "answer": "<think> Okay, let's tackle this question. The user is asking if Trastuzumab (Herceptin) is potentially useful in treating prostate cancer. The evidence provided mentions that Herceptin is used for breast cancer and gastric cancer, specifically targeting HER2. First, I need to check if there's any direct mention of prostate cancer in the evidence. Looking at the three references: none of them talk about prostate cancer. All references are about breast cancer and gastric cancer. So, the answer should be based on the fact that the evidence doesn't support its use in prostate cancer. The confidence here is low because the evidence doesn't address prostate cancer at all. The model can't infer anything beyond what's given. Therefore, the answer would state that there's no evidence", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if Trastuzumab (Herceptin) is potentially useful in treating prostate cancer. The evidence provided mentions that Herceptin is used for breast cancer and gastric cancer, specifically targeting HER2. First, I need to check if there's any direct mention of prostate cancer in the evidence. Looking at the three references: none of them talk about prostate cancer. All references are about breast cancer and gastric cancer. So, the answer should be based on the fact that the evidence doesn't support its use in prostate cancer. The confidence here is low because the evidence doesn't address prostate cancer at all. The model can't infer anything beyond what's given. Therefore, the answer would state that there's no evidence", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.0, "sup_label": "No", "sup_prob": 1.0, "use_score": 5, "use_prob": 1.0, "notes": "Evidence only mentions breast and gastric cancer, not prostate cancer; answer correctly states lack of relevance"}, "score": 4.75, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if Trastuzumab (Herceptin) has potential use in treating prostate cancer. The evidence provided mentions that Herceptin is used for metastatic breast cancer and HER2-overexpressing cancers. First, I need to check if there's any mention of prostate cancer in the evidence. Looking at the three references: all of them talk about breast cancer, gastric cancer, and HER2 overexpression in those contexts. There's no mention of prostate cancer here. So, the answer would be that based on the given evidence, there's no information indicating that Herceptin is used for prostate cancer. The confidence level should be low because the evidence doesn't address prostate cancer at all. Maybe 0.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if Trastuzumab (Herceptin) is potentially useful in treating prostate cancer. The evidence provided mentions that Herceptin is used for breast and gastric cancers, targeting HER2. First, I need to check if there's any direct mention of prostate cancer in the evidence. Looking at the three documents: all of them talk about breast cancer and gastric cancer. There's no reference to prostate cancer here. So, the answer should be based on the fact that the evidence doesn't support its use in prostate cancer. The confidence level would be low because the information given is about other cancers. But since the user wants a strict JSON with answer and base_confidence, I need to make sure the answer is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to answer whether Trastuzumab (Herceptin) is potentially useful in treating prostate cancer based on the given evidence. Let me look at the evidence provided. The first document says that Herceptin is used for metastatic breast cancer. The second mentions it's approved for metastatic breast cancer with HER2-overexpressing tumors. The third one also talks about HER2-targeted treatment for breast and gastric cancers. Wait, the question is about prostate cancer. None of the documents mention prostate cancer. They all focus on breast and gastric cancers. So the evidence doesn't say anything about prostate cancer. Therefore, there's no citation supporting its use in prostate cancer. The answer should state that there's no evidence provided for prostate cancer treatment. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to answer whether Trastuzumab (Herceptin) is potentially useful in treating prostate cancer based on the given evidence. Let me look at the evidence provided. The first document says Herceptin is an anti-HER2 monoclonal antibody used for metastatic breast cancer. The second mentions it's approved for metastatic breast cancer with HER2 overexpression. The third talks about it targeting HER2 in breast and gastric cancers. Wait, all these sources mention breast cancer and gastric cancer, not prostate cancer. There's no information here about prostate cancer. The question is about prostate cancer, but the evidence only discusses breast and gastric cancers. So the answer would be that there's no evidence provided supporting its use in prostate cancer. The confidence would", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.0, "sup_label": "No", "sup_prob": 1.0, "use_score": 1, "use_prob": 1.0, "notes": "Evidence only mentions breast and gastric cancer, not prostate cancer. No relevance to question."}, "score": 4.75, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if Trastuzumab (Herceptin) is useful in treating prostate cancer. The evidence provided mentions that Herceptin targets HER2 and is used for breast and gastric cancers. First, I need to check if there's any mention of prostate cancer in the evidence. Looking at the three references: all of them talk about breast cancer and gastric cancer. There's no reference to prostate cancer. So the answer would be that based on the given evidence, there's no indication that Herceptin is used for prostate cancer. The confidence here is low because the evidence doesn't address prostate cancer at all. The model can't infer anything beyond what's stated. Therefore, the base_confidence should be 0", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if Trastuzumab (Herceptin) is potentially useful in treating prostate cancer. The evidence provided mentions that Herceptin is used for breast and gastric cancers, specifically those overexpressing HER2. First, I need to check if there's any direct mention of prostate cancer in the evidence. Looking at the three references: none of them talk about prostate cancer. All references are about breast cancer and gastric cancer. TheHER2 target is involved in both, but the question is about prostate cancer. So, the answer should be based on the fact that the evidence doesn't support its use in prostate cancer. The confidence level would be low because there's no direct evidence provided for prostate cancer. The model", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.0, "sup_label": "No", "sup_prob": 0.0, "use_score": 1, "use_prob": 0.2, "notes": "Evidence only mentions breast and gastric cancer, not prostate cancer. No direct relevance to question."}, "score": 0.18999999999999995, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if Trastuzumab (Herceptin) is potentially useful in treating prostate cancer. The evidence provided mentions that Herceptin is used for breast and gastric cancers, specifically targeting HER2. First, I need to check if there's any mention of prostate cancer in the given evidence. Looking at the three documents: 1. Document 12422054 talks about metastatic breast cancer. 2. Document 19593441 also mentions metastatic breast cancer with Her2 overexpression. 3. Document 25377592 states it's used for HER2-overexpressing breast and gastric cancer. None of these references mention prostate cancer. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 4.75, "gold_docs": ["10473102", "10519379", "11236029", "11331475", "11502465", "11685722", "11685733", "11786427", "11920466", "12173324", "12677892", "15036648", "15046685", "15139054", "15264245", "15571968", "15919200", "16163160", "17142577", "17210707", "17211467", "18038879", "18071949", "19373278", "20716957", "21254978", "21326934", "21364123", "21844010", "22137850", "22322558", "22505344", "22977535", "23255921", "23294030"], "ideal_answer": "Although is still controversial, Trastuzumab (Herceptin) can be of potential use in the treatment of prostate cancer overexpressing HER2, either alone or in combination with other drugs."}
{"question_id": "53137541e3eabad021000010", "question": "Which are the Yamanaka factors?", "retrieved_chunks": [{"doc_id": "21761058", "chunk_id": "21761058_1", "score": 8.523773193359375, "text": "Yamanaka factors, namely Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc"}, {"doc_id": "22357549", "chunk_id": "22357549_0", "score": 8.07437801361084, "text": "Yamanaka factors (Pou5f1, Myc, Klf4, and Sox2)"}, {"doc_id": "21761058", "chunk_id": "21761058_0", "score": 7.866320610046387, "text": "These protein sets have been called the Yamanaka factors, namely Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc, and the Thomson factors, namely Sox2, Oct3, Lin28, and Nanog"}], "context": "[21761058:21761058_1] Yamanaka factors, namely Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc\n[22357549:22357549_0] Yamanaka factors (Pou5f1, Myc, Klf4, and Sox2)\n[21761058:21761058_0] These protein sets have been called the Yamanaka factors, namely Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc, and the Thomson factors, namely Sox2, Oct3, Lin28, and Nanog", "answer": "<think> Okay, let's tackle this question. The user is asking about the Yamanaka factors. From the evidence provided, there are a few documents mentioning this. First, document [21761058:21761058_1] lists Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc as the Yamanaka factors. Then, [22357549:22357549_0] also mentions Pou5f1, Myc, Klf4, and Sox2, which seems similar but uses different abbreviations. The third document [21761058:21761058", "citations": [{"doc_id": "21761058", "chunk_id": "21761058_1"}, {"doc_id": "22357549", "chunk_id": "22357549_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the Yamanaka factors. From the evidence provided, there are a few documents mentioning this. First, document [21761058:21761058_1] lists Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc as the Yamanaka factors. Then, [22357549:22357549_0] also mentions Pou5f1, Myc, Klf4, and Sox2, which seems similar but uses different abbreviations. The third document [21761058:21761058", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the Yamanaka factors. From the evidence provided, there are a few documents mentioning this. First, document [21761058:21761058_1] lists Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc as the Yamanaka factors. Another document [22357549:22357549_0] also mentions Pou5f1, Myc, Klf4, and Sox2. Wait, but in the first one, it's Oct3/4 which is Pou5f1, and in the second, they just say Pou", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's see. The user is asking about the Yamanaka factors. I need to generate a concise answer with citations from the provided evidence. Looking at the evidence, there are three chunks. The first one mentions Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc. The second chunk lists Pou5f1, Myc, Klf4, and Sox2. The third chunk also refers to the same factors but also mentions Thomson factors. Wait, the Yamanaka factors are usually known as the four proteins: OCT3/4 (Pou5f1), SOX2, KLF4, and c-MYC. Different sources might use slightly different names, like Myc instead of c", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the Yamanaka factors. From the evidence provided, there are a few documents mentioning this. First, document [21761058:21761058_1] lists Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc as the Yamanaka factors. Another document [22357549:22357549_0] also mentions Pou5f1, Myc, Klf4, and Sox2. Wait, that's the same set but with different names for Oct3/4 (Pou5f1 vs Pou5f1). Then there", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the Yamanaka factors. I remember that Yamanaka factors are a set of transcription factors involved in inducing pluripotency in cells. Looking at the evidence provided, there are three documents mentioned. The first one [21761058:21761058_1] lists Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc. The second document [22357549:22357549_0] mentions Pou5f1, Myc, Klf4, and Sox2. The third one [21761058:2", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the Yamanaka factors. From the evidence provided, there are a few documents mentioning this. First, document [21761058:21761058_1] lists Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc as the Yamanaka factors. Another document [22357549:22357549_0] also mentions Pou5f1, Myc, Klf4, and Sox2. Wait, the names here are slightly different. In the first one, it's c-Myc, while the second uses Myc. But I think", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to figure out the answer to the question \"Which are the Yamanaka factors?\" using the provided evidence. Let me look at the evidence given. The first document [21761058:21761058_1] mentions Yamanaka factors as Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc. The second document [22357549:22357549_0] lists them as Pou5f1, Myc, Klf4, and Sox2. The third document [21761058:21761058_0] also refers to", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the Yamanaka factors. From the evidence provided, there are a couple of references. First, document [21761058:21761058_1] lists Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc as the Yamanaka factors. Then, [22357549:22357549_0] mentions Pou5f1, Myc, Klf4, and Sox2. Wait, that's the same set but with different names for Oct3/4 (Pou5f1 vs Pou5f1). Also, another document", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["19030024", "20144262", "21249204", "21640101", "21761058", "21839145", "22075965", "22357549", "22449255", "23166588", "23527808", "23612755", "23658991", "23704989", "23939864", "24150221"], "ideal_answer": "The Yamanaka factors are the OCT4, SOX2, MYC, and KLF4 transcription factors"}
{"question_id": "515aa0abd24251bc050000a8", "question": "What is the aim of the Human Chromosome-centric Proteome Project (C-HPP)?", "retrieved_chunks": [{"doc_id": "22443261", "chunk_id": "22443261_0", "score": 10.71954345703125, "text": "The objective of the international Chromosome-Centric Human Proteome Project (C-HPP) is to map and annotate all proteins encoded by the genes on each human chromosome. The C-HPP consortium was established to organize a collaborative network among the research teams responsible for protein mapping of individual chromosomes and to identify compelling biological and genetic mechanisms influencing colocated genes and their protein products. The C-HPP aims to foster the development of proteome analysis and integration of the findings from related molecular -omics technology platforms through collaborations among universities, industries, and private research groups."}, {"doc_id": "23253012", "chunk_id": "23253012_0", "score": 10.111676216125488, "text": "The Chromosome-centric Human Proteome Project (C-HPP) aims to systematically map the entire human proteome with the intent to enhance our understanding of human biology at the cellular level."}, {"doc_id": "23153008", "chunk_id": "23153008_1", "score": 9.85740852355957, "text": "The Chromosome-centric Human Proteome Project (C-HPP) aims to define all proteins encoded in each chromosome and especially to identify proteins that currently lack evidence by mass spectrometry."}], "context": "[22443261:22443261_0] The objective of the international Chromosome-Centric Human Proteome Project (C-HPP) is to map and annotate all proteins encoded by the genes on each human chromosome. The C-HPP consortium was established to organize a collaborative network among the research teams responsible for protein mapping of individual chromosomes and to identify compelling biological and genetic mechanisms influencing colocated genes and their protein products. The C-HPP aims to foster the development of proteome analysis and integration of the findings from related molecular -omics technology platforms through collaborations among universities, industries, and private research groups.\n[23253012:23253012_0] The Chromosome-centric Human Proteome Project (C-HPP) aims to systematically map the entire human proteome with the intent to enhance our understanding of human biology at the cellular level.\n[23153008:23153008_1] The Chromosome-centric Human Proteome Project (C-HPP) aims to define all proteins encoded in each chromosome and especially to identify proteins that currently lack evidence by mass spectrometry.", "answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. Let me start by understanding the question: What is the aim of the Human Chromosome-centric Proteome Project (C-HPP)? Looking at the evidence provided, there are three documents. Let me go through each one. First document [22443261:22443261_0] says the objective is to map and annotate all proteins encoded by genes on each human chromosome. It also mentions organizing a collaborative network and identifying biological mechanisms influencing colocated genes. Also, fostering proteome analysis and collaborations. Second document [23253012:23253012_0] states the aim is to systematically map the entire", "citations": [{"doc_id": "22443261", "chunk_id": "22443261_0"}, {"doc_id": "23253012", "chunk_id": "23253012_0"}], "candidates": [{"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. Let me start by understanding the question: What is the aim of the Human Chromosome-centric Proteome Project (C-HPP)? Looking at the evidence provided, there are three documents. Let me go through each one. First document [22443261:22443261_0] says the objective is to map and annotate all proteins encoded by genes on each human chromosome. It also mentions organizing a collaborative network and identifying biological mechanisms influencing colocated genes. Also, fostering proteome analysis and collaborations. Second document [23253012:23253012_0] states the aim is to systematically map the entire", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a JSON answer based on the provided evidence. Let me start by understanding the question: What is the aim of the Human Chromosome-centric Proteome Project (C-HPP)? Looking at the evidence, there are three documents. The first one says the objective is to map and annotate all proteins encoded by genes on each human chromosome. It also mentions organizing a collaborative network and identifying biological mechanisms influencing colocated genes. The second document states the aim is to systematically map the entire human proteome to enhance understanding of human biology at the cellular level. The third document adds that it's to define all proteins in each chromosome, especially those lacking evidence from mass spectrometry. I need to combine these points into a concise answer. The main aims are mapping proteins on", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking about the aim of the Human Chromosome-centric Proteome Project (C-HPP). I need to generate a concise answer from the provided evidence and return it in strict JSON with the answer and base confidence. First, I'll look at the evidence given. There are three documents. Let me read through each one to extract the main points. Document 22443261: It says the C-HPP's objective is to map and annotate all proteins encoded by genes on each human chromosome. It also mentions organizing a collaborative network and identifying biological mechanisms affecting colocated genes. Additionally, it talks about fostering proteome analysis and collaborations among different groups. Document 23253012: This", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer for the question about the aim of the Human Chromosome-centric Proteome Project (C-HPP). Let me start by looking at the provided evidence. First, the user gave three documents. The first one [22443261:22443261_0] says the C-HPP's objective is to map and annotate all proteins encoded by genes on each human chromosome. It also mentions organizing a collaborative network and identifying biological mechanisms affecting colocated genes. Then there's [23253012:23253012_0], which states the aim is to systematically map the entire human proteome to enhance understanding of human biology at the cellular level", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer for the question about the aim of the Human Chromosome-centric Proteome Project (C-HPP). Let me start by looking at the provided evidence. The user gave three documents. Let me read through each one carefully. First document [22443261:22443261_0] says the objective is to map and annotate all proteins encoded by genes on each human chromosome. It also mentions organizing a collaborative network and identifying biological mechanisms influencing colocated genes. Additionally, it talks about fostering proteome analysis and integrating findings from molecular-omics platforms through collaborations. Second document [23253012:23253012_0] states the aim", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this query. The user is asking about the aim of the Human Chromosome-centric Proteome Project (C-HPP). I need to generate a concise answer from the provided evidence and return it in strict JSON format. First, I'll look at the evidence documents. There are three chunks here. Let me read through each one carefully. The first chunk [22443261:22443261_0] says the objective is to map and annotate all proteins encoded by genes on each human chromosome. It also mentions organizing a collaborative network and identifying biological mechanisms influencing colocated genes. Also, fostering proteome analysis and collaborations. The second chunk [23253012:23253", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a JSON answer based on the provided evidence. Let me start by understanding the question: What is the aim of the Human Chromosome-centric Proteome Project (C-HPP)? Looking at the evidence, there are three documents. The first one mentions that the C-HPP's objective is to map and annotate all proteins encoded by genes on each human chromosome. It also talks about organizing a collaborative network and identifying biological mechanisms influencing colocated genes. The second document states that the aim is to systematically map the entire human proteome to enhance understanding of human biology at the cellular level. The third document says the goal is to define all proteins in each chromosome, especially those lacking evidence from mass spectrometry. I need to combine these points into a concise answer with", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. Let me start by understanding the question: What is the aim of the Human Chromosome-centric Proteome Project (C-HPP)? Looking at the evidence provided, there are three documents. Let me read each one carefully. First document [22443261:22443261_0] says the objective is to map and annotate all proteins encoded by genes on each human chromosome. It also mentions organizing a collaborative network and identifying biological mechanisms influencing colocated genes. Additionally, it talks about fostering proteome analysis and collaborations. Second document [23253012:23253012_0] states the aim is to systematically", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["21742803", "22443261", "22966780", "23153008", "23205526", "23214983", "23227862", "23234512", "23249167", "23252913", "23253012", "23259496", "23276153", "23308364", "23312004"], "ideal_answer": "The chromosome-centric human proteome project aims to systematically map all human proteins, chromosome by chromosome, in a gene-centric manner through dedicated efforts from national and international teams The Chromosome-Centric Human Proteome Project (C-HPP) is an international effort for creating an annotated proteomic catalog for each chromosome. (PMID: 23312004) The chromosome-centric human proteome project aims to systematically map all human proteins, chromosome by chromosome, in a gene-centric manner through dedicated efforts from national and international teams. (PMID: 23308364) The Chromosome-centric Human Proteome Project (C-HPP) aims to systematically map the entire human proteome with the intent to enhance our understanding of human biology at the cellular level. (PMID: 23253012)"}
{"question_id": "56af9f130a360a5e45000015", "question": "Where is the protein Pannexin1 located?", "retrieved_chunks": [{"doc_id": "24194896", "chunk_id": "24194896_0", "score": 4.8776750564575195, "text": "In mammals, a single pannexin1 gene (Panx1) is widely expressed in the CNS including the inner and outer retinae, forming large-pore voltage-gated membrane channels, which are involved in calcium and ATP signaling."}, {"doc_id": "17064878", "chunk_id": "17064878_0", "score": 4.2120819091796875, "text": "pannexin1, a vertebrate homolog of invertebrate gap junction proteins."}, {"doc_id": "25007779", "chunk_id": "25007779_1", "score": 2.516667127609253, "text": "Pannexin1 (Panx1) is a newly discovered extracellular ATP release channel with a wide tissue distribution and diverse biological functions in mammals."}], "context": "[24194896:24194896_0] In mammals, a single pannexin1 gene (Panx1) is widely expressed in the CNS including the inner and outer retinae, forming large-pore voltage-gated membrane channels, which are involved in calcium and ATP signaling.\n[17064878:17064878_0] pannexin1, a vertebrate homolog of invertebrate gap junction proteins.\n[25007779:25007779_1] Pannexin1 (Panx1) is a newly discovered extracellular ATP release channel with a wide tissue distribution and diverse biological functions in mammals.", "answer": "<think> Okay, the user is asking where the protein Pannexin1 is located. Let me look at the evidence provided. First evidence: [24194896:24194896_0] says that Panx1 is widely expressed in the CNS, including inner and outer retinae. So that's a specific location. Another piece: [25007779:25007779_1] mentions wide tissue distribution, so it's not just the CNS. But the first evidence specifically lists CNS and retinae. The third evidence is about vertebrate homologs, which doesn't specify location. So the answer should include both the CNS and retinae, as per the first", "citations": [{"doc_id": "24194896", "chunk_id": "24194896_0"}, {"doc_id": "25007779", "chunk_id": "25007779_1"}], "candidates": [{"answer": "<think> Okay, the user is asking where the protein Pannexin1 is located. Let me look at the evidence provided. First, document 24194896:24194896_0 says that Panx1 is widely expressed in the CNS, including inner and outer retinae. That's a specific location. Then, document 25007779_1 mentions it's found in various tissues, but doesn't specify locations. The third document is about it being a vertebrate homolog, which isn't directly about location. So the most specific answer comes from the first evidence, mentioning CNS and retinae. The other documents support its presence in multiple tissues but don't give exact locations. The answer should", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking where the protein Pannexin1 is located. Let me look at the evidence provided. First, document 24194896:24194896_0 mentions that Panx1 is widely expressed in the CNS, including the inner and outer retinae. That's a specific location. Then, document 25007779:25007779_1 says it's found in a wide tissue distribution, so that's more general. The other document just gives a general description without specific locations. So the answer should include both the CNS and retinae from the first document, and mention wide tissue distribution from the third. But the question is about where it", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking where the protein Pannexin1 is located. Let me look at the evidence provided. First evidence: [24194896:24194896_0] says that Panx1 is widely expressed in the CNS, including inner and outer retinae. So that's a specific location. Another piece: [25007779:25007779_1] mentions wide tissue distribution, so it's not just the CNS. But the first evidence specifically lists CNS and retinae. The third evidence is about vertebrate homologs, which doesn't specify location. So the answer should include both the CNS and retinae, as per the first", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user wants to know where the protein Pannexin1 is located. Looking at the evidence provided, there are three references. First, reference [24194896:24194896_0] mentions that Panx1 is widely expressed in the CNS, specifically in the inner and outer retinae of mammals. That's a key point. Then, reference [25007779:25007779_1] says it's found in a wide tissue distribution, so that's another part. The third reference is about it being a vertebrate homolog, but that doesn't specify location. So the answer should combine the CNS and retina", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user wants to know where the protein Pannexin1 is located. Looking at the evidence provided, there are three references. First, reference [24194896:24194896_0] mentions that Panx1 is widely expressed in the CNS, specifically in the inner and outer retinae of mammals. That's a direct answer about its location. The second reference [17064878:17064878_0] talks about Pannexin1 being a vertebrate homolog of gap junction proteins, but that's more about its evolutionary relationship rather than localization. The third reference [250077", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking where the protein Pannexin1 is located. The evidence provided has three chunks. First chunk (24194896) says that Panx1 is widely expressed in the CNS, including inner and outer retinae. That's a specific location. The second chunk (17064878) mentions it's a vertebrate homolog of gap junction proteins, but that's more about its classification than location. The third chunk (25007779) talks about wide tissue distribution and diverse functions, so that supports the idea of being in many tissues. So, combining these, the answer should mention CNS, inner and outer retinae, and maybe other tissues", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know where the protein Pannexin1 is located. The evidence provided has three chunks. First chunk (24194896) says that Panx1 is widely expressed in the CNS, including inner and outer retinae. That's a specific location. The second chunk (17064878) mentions it's a vertebrate homolog of gap junction proteins, but that's more about its classification than location. The third chunk (25007779) talks about wide tissue distribution and diverse functions, which supports the first chunk's info. So the answer should focus on the CNS and retinae from the first chunk. The confidence is high because that's", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know where the protein Pannexin1 is located. Looking at the evidence provided, there are three references. First, document 24194896 says that Panx1 is widely expressed in the CNS, including inner and outer retinae. That's a specific location. Then, document 25007779 mentions a wide tissue distribution, so it's not just the CNS. The third document is about its function as an ATP release channel but doesn't specify location. So, combining the info from 24194896 and 25007779, Panx1 is in the CNS and retinae, plus many tissues.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["17064878", "19409451", "24194896", "24642372", "24694658", "24782784", "25007779", "25056878", "25698922", "26100513"], "ideal_answer": "The protein Pannexin1 is localized to the plasma membranes."}
{"question_id": "5718bbb37de986d80d00000b", "question": "Which currently known mitochondrial diseases have been attributed to POLG mutations?", "retrieved_chunks": [{"doc_id": "20927567", "chunk_id": "20927567_0", "score": 7.503829002380371, "text": "About 150 mutations in the human POLG have been identified in patients with mitochondrial diseases such as Alpers syndrome, progressive external ophthalmoplegia, and ataxia-neuropathy syndromes."}, {"doc_id": "15351195", "chunk_id": "15351195_0", "score": 6.311924934387207, "text": "Mutations in the gene encoding mitochondrial DNA polymerase gamma (POLG), the enzyme that synthesises mitochondrial DNA (mtDNA), have been associated with a mitochondrial disease-autosomal dominant or recessive progressive external ophthalmoplegia-and multiple deletions of mtDNA."}, {"doc_id": "18546365", "chunk_id": "18546365_0", "score": 5.579039096832275, "text": "Mutations in the POLG gene have emerged as one of the most common causes of inherited mitochondrial disease in children and adults. They are responsible for a heterogeneous group of at least 6 major phenotypes of neurodegenerative disease that include: 1) childhood Myocerebrohepatopathy Spectrum disorders (MCHS), 2) Alpers syndrome, 3) Ataxia Neuropathy Spectrum (ANS) disorders, 4) Myoclonus Epilepsy Myopathy Sensory Ataxia (MEMSA), 5) autosomal recessive Progressive External Ophthalmoplegia (arPEO), and 6) autosomal dominant Progressive External Ophthalmoplegia (adPEO)"}], "context": "[20927567:20927567_0] About 150 mutations in the human POLG have been identified in patients with mitochondrial diseases such as Alpers syndrome, progressive external ophthalmoplegia, and ataxia-neuropathy syndromes.\n[15351195:15351195_0] Mutations in the gene encoding mitochondrial DNA polymerase gamma (POLG), the enzyme that synthesises mitochondrial DNA (mtDNA), have been associated with a mitochondrial disease-autosomal dominant or recessive progressive external ophthalmoplegia-and multiple deletions of mtDNA.\n[18546365:18546365_0] Mutations in the POLG gene have emerged as one of the most common causes of inherited mitochondrial disease in children and adults. They are responsible for a heterogeneous group of at least 6 major phenotypes of neurodegenerative disease that include: 1) childhood Myocerebrohepatopathy Spectrum disorders (MCHS), 2) Alpers syndrome, 3) Ataxia Neuropathy Spectrum (ANS) disorders, 4) Myoclonus Epilepsy Myopathy Sensory Ataxia (MEMSA), 5) autosomal recessive Progressive External Ophthalmoplegia (arPEO), and 6) autosomal dominant Progressive External Ophthalmoplegia (adPEO)", "answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The question is asking which known mitochondrial diseases are associated with POLG mutations. Looking at the evidence, there are three references. Let me check each one. First, [20927567:20927567_0] mentions Alpers syndrome, progressive external ophthalmoplegia, and ataxia-neuropathy syndromes. Second, [15351195:15351195_0] talks about progressive external ophthalmoplegia (both dominant and recessive) and multiple mtDNA deletions. Third, [18546365:185463", "citations": [{"doc_id": "20927567", "chunk_id": "20927567_0"}, {"doc_id": "15351195", "chunk_id": "15351195_0"}], "candidates": [{"answer": "<think> Okay, I need to generate a JSON answer based on the provided evidence. The question is asking which mitochondrial diseases are associated with POLG mutations. Let me look at the evidence again. First, the first document says that about 150 mutations in POLG are found in patients with Alpers syndrome, progressive external ophthalmoplegia, and ataxia-neuropathy syndromes. The second document mentions mutations in POLG linked to mitochondrial disease, specifically autosomal dominant or recessive progressive external ophthalmoplegia and multiple mtDNA deletions. The third document lists six major phenotypes, including Alpers syndrome, MCHS, ANS, MEMSA, arPEO, and adPEO. So the answer should include all these syndromes", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which known mitochondrial diseases are associated with POLG mutations. Looking at the evidence provided, there are three documents. Let me check each one. First document: It mentions 150 mutations in POLG linked to Alpers syndrome, progressive external ophthalmoplegia, and ataxia-neuropathy syndromes. So those three are mentioned here. Second document: Talks about mutations in POLG associated with mitochondrial disease, specifically autosomal dominant or recessive progressive external ophthalmoplegia, and multiple mtDNA deletions. So PEO is mentioned again here. Third document lists six major phenotypes. These include Alpers syndrome, MCHS, ANS, MEMSA, arPEO,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The question is asking which known mitochondrial diseases are associated with POLG mutations. Looking at the evidence, there are three references. Let me check each one. First, [20927567:20927567_0] mentions Alpers syndrome, progressive external ophthalmoplegia, and ataxia-neuropathy syndromes. Second, [15351195:15351195_0] talks about progressive external ophthalmoplegia (both dominant and recessive) and multiple mtDNA deletions. Third, [18546365:185463", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which currently known mitochondrial diseases are attributed to POLG mutations. The evidence provided has three chunks. First chunk says about 150 mutations in POLG are linked to diseases like Alpers syndrome, progressive external ophthalmoplegia, and ataxia-neuropathy syndromes. The second chunk mentions mutations in POLG associated with mitochondrial disease, specifically autosome dominant or recessive progressive external ophthalmoplegia and multiple mtDNA deletions. The third chunk lists six major phenotypes, including Alpers syndrome, MCHS, ANS, MEMSA, arPEO, and adPEO. I need to compile these into a concise answer. The key diseases mentioned are Alpers syndrome,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is asking which known mitochondrial diseases are attributed to POLG mutations. Looking at the evidence, there are three chunks provided. Let me go through each one. The first chunk says that about 150 mutations in POLG are identified in patients with mitochondrial diseases like Alpers syndrome, progressive external ophthalmoplegia, and ataxia-neuropathy syndromes. So those are three diseases mentioned here. The second chunk mentions mutations in POLG associated with mitochondrial disease, specifically autosomal dominant or recessive progressive external ophthalmoplegia, and multiple mtDNA deletions. So progressive external ophthalmoplegia (PEO) is another one here, but it's split into dominant", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking which known mitochondrial diseases are caused by POLG mutations. Let me look at the evidence provided. First, document 20927567 mentions Alpers syndrome, progressive external ophthalmoplegia, and ataxia-neuropathy syndromes. Then, document 15351195 talks about progressive external ophthalmoplegia (both dominant and recessive) and multiple mtDNA deletions. Document 18546365 lists six major phenotypes, including Alpers syndrome, MCHS, ANS, MEMSA, arPEO, and adPEO. I need to compile these into a concise answer. The key diseases here are Alpers syndrome, progressive external o", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The question is asking which known mitochondrial diseases are attributed to POLG mutations. Looking at the evidence, there are three chunks. Let me break them down: First chunk: Mentions 150 mutations in POLG linked to Alpers syndrome, progressive external ophthalmoplegia, and ataxia-neuropathy syndromes. Second chunk: Talks about mutations in POLG associated with mitochondrial disease, specifically autosomal dominant or recessive progressive external ophthalmoplegia, and multiple mtDNA deletions. Third chunk: Lists six major phenotypes, including Alpers syndrome, MCHS, ANS, MEMSA, arPEO, and adPEO. It also mentions that these", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to answer the question about which mitochondrial diseases are caused by POLG mutations. Let me look at the evidence provided. The first document says that about 150 mutations in POLG are linked to diseases like Alpers syndrome, progressive external ophthalmoplegia, and ataxia-neuropathy syndromes. The second mentions mutations in POLG associated with mitochondrial disease, specifically autosomal dominant or recessive progressive external ophthalmoplegia and multiple mtDNA deletions. The third document lists six major phenotypes, including Alpers syndrome, MCHS, ANS, MEMSA, arPEO, and adPEO. So combining these, the answer should include the diseases mentioned. Alpers syndrome is mentioned in all three. Progressive external", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["12825077", "15351195", "18546365", "20927567", "22647225"], "ideal_answer": "Mutations in the POLG gene have emerged as one of the most common causes of inherited mitochondrial disease in children and adults. They are responsible for a heterogeneous group of at least 6 major phenotypes of neurodegenerative disease that include: 1) childhood Myocerebrohepatopathy Spectrum disorders (MCHS), 2) Alpers syndrome, 3) Ataxia Neuropathy Spectrum (ANS) disorders, 4) Myoclonus Epilepsy Myopathy Sensory Ataxia (MEMSA), 5) autosomal recessive Progressive External Ophthalmoplegia (arPEO), and 6) autosomal dominant Progressive External Ophthalmoplegia (adPEO). Mutations in the POLG gene have emerged as one of the most common causes of inherited mitochondrial disease in children and adults. They are responsible for a heterogeneous group of at least 6 major phenotypes of neurodegenerative disease that include: 1) childhood Myocerebrohepatopathy Spectrum disorders (MCHS), 2) Alpers syndrome, 3) Ataxia Neuropathy Spectrum (ANS) disorders, 4) Myoclonus Epilepsy Myopathy Sensory Ataxia (MEMSA), 5) autosomal recessive Progressive External Ophthalmoplegia (arPEO), and 6) autosomal dominant Progressive External Ophthalmoplegia (adPEO)"}
{"question_id": "532f062ad6d3ac6a34000027", "question": "What is the effect of ivabradine in heart failure after myocardial infarction?", "retrieved_chunks": [{"doc_id": "21878041", "chunk_id": "21878041_0", "score": 7.201775550842285, "text": "Indeed, heart rate reduction with ivabradine, a selective and specific I(f) inhibitor, reduces myocardial oxygen demand, increases diastolic perfusion time and improves energetics in ischemic myocardium. Ivabradine protects the myocardium during ischemia, improves left ventricular function in heart failure and reduces remodeling following myocardial infarction. It improves prognosis in patients with coronary artery disease, left ventricular dysfunction and heart rate ≥70 beats per minute, as well as in patients with heart failure and left ventricular dysfunction."}, {"doc_id": "23096376", "chunk_id": "23096376_0", "score": 5.771203517913818, "text": "The most significant results were obtained in the subgroup of patients with life-limiting exertional angina. In this group, ivabradine significantly reduced the primary endpoint, a composite of cardiovascular death, hospitalization for fatal and nonfatal acute myocardial infarction (AMI) or heart failure, by 24%, and hospitalizations for AMI by 42%. In the subgroup of patients with baseline heart rate >70 bpm, hospitalizations for AMI and revascularization were reduced by 73% and 59%, respectively"}, {"doc_id": "19514618", "chunk_id": "19514618_0", "score": 5.532497882843018, "text": "Ivabradine did not significantly affect the combined primary endpoint. Significant reduction by 36% (p = 0.001) in myocardial infarction and by 30% (p = 0.016) in coronary revascularization was observed in the pre-defined subgroup of patients with heart rate > or = 70/min."}], "context": "[21878041:21878041_0] Indeed, heart rate reduction with ivabradine, a selective and specific I(f) inhibitor, reduces myocardial oxygen demand, increases diastolic perfusion time and improves energetics in ischemic myocardium. Ivabradine protects the myocardium during ischemia, improves left ventricular function in heart failure and reduces remodeling following myocardial infarction. It improves prognosis in patients with coronary artery disease, left ventricular dysfunction and heart rate ≥70 beats per minute, as well as in patients with heart failure and left ventricular dysfunction.\n[23096376:23096376_0] The most significant results were obtained in the subgroup of patients with life-limiting exertional angina. In this group, ivabradine significantly reduced the primary endpoint, a composite of cardiovascular death, hospitalization for fatal and nonfatal acute myocardial infarction (AMI) or heart failure, by 24%, and hospitalizations for AMI by 42%. In the subgroup of patients with baseline heart rate >70 bpm, hospitalizations for AMI and revascularization were reduced by 73% and 59%, respectively\n[19514618:19514618_0] Ivabradine did not significantly affect the combined primary endpoint. Significant reduction by 36% (p = 0.001) in myocardial infarction and by 30% (p = 0.016) in coronary revascularization was observed in the pre-defined subgroup of patients with heart rate > or = 70/min.", "answer": "<think> Okay, let's tackle this question about ivabradine's effect in heart failure after myocardial infarction. The user provided three evidence snippets, and I need to extract the relevant information to form a concise answer with citations. First, looking at the first evidence (21878041:21878041_0), it mentions that ivabradine reduces heart rate, which lowers myocardial oxygen demand, improves diastolic perfusion, and enhances energetics in ischemic myocardium. It also states that it protects the myocardium during ischemia, improves left ventricular function in heart failure, and reduces remodeling after MI. This seems directly relevant to the question. The second evidence (230963", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question about ivabradine's effect in heart failure after myocardial infarction. The user provided three evidence snippets, and I need to extract the relevant information to form a concise answer with citations. First, looking at the first evidence (21878041:21878041_0), it mentions that ivabradine reduces heart rate, which lowers myocardial oxygen demand, improves diastolic perfusion, and enhances energetics in ischemic myocardium. It also states that it protects the myocardium during ischemia, improves left ventricular function in heart failure, and reduces remodeling after MI. This seems directly relevant to the question. The second evidence (230963", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about ivabradine's effect on heart failure after myocardial infarction. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three documents. Let me parse each one. Document 21878041: This says that ivabradine reduces heart rate, which lowers myocardial oxygen demand, improves diastolic perfusion, and enhances energetics in ischemic myocardium. It protects the myocardium during ischemia, improves left ventricular function in heart failure, reduces remodeling after MI, and improves prognosis in patients with CAD, LV dysfunction, and HR ≥70 bpm, as well as those with HF and LV dysfunction.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about ivabradine's effect on heart failure after myocardial infarction. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three documents. Let me go through each one. Document 21878041: This talks about ivabradine reducing heart rate, which lowers myocardial oxygen demand. It mentions improving diastolic perfusion, energetics, and protecting the myocardium during ischemia. Also, it improves left ventricular function and reduces remodeling after MI. The answer should include these points, citing this document. Document 23096376: This says that in patients with life-limiting exert", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about ivabradine's effect on heart failure after myocardial infarction. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three documents here. Let me go through each one. Document 21878041: This talks about ivabradine reducing heart rate, which lowers myocardial oxygen demand. It mentions improving diastolic perfusion, energetics, and protecting the myocardium during ischemia. Also, it improves left ventricular function and reduces remodeling after MI. So this seems to support that ivabradine is beneficial in heart failure post-MI. Document 23096376: This", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about ivabradine's effect on heart failure after myocardial infarction. The user provided three evidence snippets, and I need to generate a concise answer with citations and a confidence level. First, I'll read through each of the evidence points. The first one says that ivabradine reduces heart rate, which lowers myocardial oxygen demand, improves diastolic perfusion, and enhances energetics in ischemic hearts. It also protects the myocardium during ischemia, improves left ventricular function, and reduces remodeling after MI. This seems to directly address heart failure post-MI. The second evidence mentions that in patients with life-limiting exertional angina, ivabradine reduced the primary endpoint (a composite of cardiovascular", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about ivabradine's effect in heart failure after myocardial infarction. The user provided three evidence snippets, so I need to parse each one carefully. First, the first evidence (21878041) says that ivabradine reduces heart rate, which lowers myocardial oxygen demand and improves diastolic perfusion. It also mentions protecting the myocardium during ischemia, improving left ventricular function in heart failure, and reducing remodeling after MI. That's a strong point about its benefits in heart failure. The second evidence (23096376) talks about a subgroup with life-limiting exertional angina. Ivabradine reduced the primary endpoint (cardiovascular death,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a biomedical answer about the effect of ivabradine in heart failure after myocardial infarction based on the provided evidence. Let me start by reading through the evidence carefully. First, the first document (21878041) says that ivabradine reduces heart rate, which lowers myocardial oxygen demand and improves diastolic perfusion. It also mentions protecting the myocardium during ischemia, improving left ventricular function in heart failure, and reducing remodeling after MI. This seems to directly address the question about heart failure post-MI. The second document (23096376) talks about a study where ivabradine reduced the primary endpoint (a composite of cardiovascular death, hospitalization for", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about ivabradine's effect in heart failure after myocardial infarction. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three documents here. Let me go through each one. Document 21878041: This mentions that ivabradine reduces heart rate, which lowers myocardial oxygen demand. It also improves diastolic perfusion and energetics in ischemic hearts. Plus, it protects the myocardium during ischemia, improves left ventricular function in heart failure, and reduces remodeling after MI. Also, it's beneficial for patients with CAD, LV dysfunction, and heart rate ≥70 bpm, as well as", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["14981003", "18310678", "18621770", "18757088", "19074674", "19129742", "19411283", "19514618", "19664404", "20000882", "20028694", "21838751", "21878041", "22416440", "23067195", "23096376", "23394554", "23536611"], "ideal_answer": "Ιvabradine decreases heart rate and reduces myocardial oxygen demand, increases diastolic perfusion time and improves energetics in ischemic myocardium. Ivabradine protects the myocardium during ischemia, improves left ventricular function in heart failure and reduces remodeling following myocardial infarction. It improves prognosis in patients with coronary artery disease, left ventricular dysfunction and heart rate ≥70 beats per minute, as well as in patients with heart failure and left ventricular dysfunction. The beneficial effects of ivabradine may be due to the reversal of electrophysiological cardiac remodelling in post-MI rats by reduction of functional overexpression of HCN channels. Furthermore, the improvement of cardiac function is related not only to the HR reduction per se but also to modifications in the extracellular matrix."}
{"question_id": "52bf1b0a03868f1b06000009", "question": "What is the mode of inheritance of Wilson's disease?", "retrieved_chunks": [{"doc_id": "22610954", "chunk_id": "22610954_0", "score": 5.54994010925293, "text": "Wilson's disease (WD), or hepatolenticular degeneration, is an autosomal recessive inheritance disorder of copper metabolism caused by ATP7B gene mutation."}, {"doc_id": "2724779", "chunk_id": "2724779_0", "score": 4.603377819061279, "text": "Wilson's disease is a rare genetic disorder of copper metabolism with autosomal recessive inheritance."}, {"doc_id": "30271060", "chunk_id": "30271060_0", "score": 3.657937526702881, "text": "Wilson's disease is an autosomal recessive disease of abnormal copper metabolism."}], "context": "[22610954:22610954_0] Wilson's disease (WD), or hepatolenticular degeneration, is an autosomal recessive inheritance disorder of copper metabolism caused by ATP7B gene mutation.\n[2724779:2724779_0] Wilson's disease is a rare genetic disorder of copper metabolism with autosomal recessive inheritance.\n[30271060:30271060_0] Wilson's disease is an autosomal recessive disease of abnormal copper metabolism.", "answer": "<think> Okay, I need to figure out the mode of inheritance for Wilson's disease based on the given evidence. Let me look at the references provided. The first document says it's an autosomal recessive disorder caused by a mutation in the ATP7B gene. The second one also mentions autosomal recessive inheritance. The third reference confirms it's an autosomal recessive disease related to copper metabolism. All three sources consistently state that the inheritance pattern is autosomal recessive. So, the answer should be that Wilson's disease is inherited in an autosomal recessive manner. The confidence here is high since all three evidence snippets agree. I'll set the base_confidence to 1.0 because there's no conflicting information. </think> { \"answer\": \"Wilson's", "citations": [], "candidates": [{"answer": "<think> Okay, I need to figure out the mode of inheritance for Wilson's disease based on the given evidence. Let me look at the references provided. The first document says it's an autosomal recessive disorder caused by a mutation in the ATP7B gene. The second one also mentions autosomal recessive inheritance. The third reference confirms it's an autosomal recessive disease related to copper metabolism. All three sources consistently state that the inheritance pattern is autosomal recessive. So, the answer should be that Wilson's disease is inherited in an autosomal recessive manner. The confidence here is high since all three evidence snippets agree. I'll set the base_confidence to 1.0 because there's no conflicting information. </think> { \"answer\": \"Wilson's", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let me tackle this question. The user is asking about the mode of inheritance of Wilson's disease. I need to look at the provided evidence to find the answer. Looking at the evidence, there are three chunks. The first one says it's an autosomal recessive disorder caused by a mutation in the ATP7B gene. The second chunk also mentions it's a rare genetic disorder with autosomal recessive inheritance. The third chunk states it's an autosomal recessive disease of abnormal copper metabolism. All three sources consistently state that Wilson's disease is inherited in an autosomal recessive manner. There's no conflicting information here. The confidence level should be high since all three documents agree. So the answer should be autosomal recessive, and the citations can be", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the mode of inheritance for Wilson's disease. I need to look at the provided evidence to find the answer. Looking at the evidence, there are three chunks. The first one says it's an autosomal recessive disorder caused by a mutation in the ATP7B gene. The second chunk also mentions it's a rare genetic disorder with autosomal recessive inheritance. The third chunk repeats that it's an autosomal recessive disease of abnormal copper metabolism. All three sources consistently state that Wilson's disease is inherited in an autosomal recessive manner. The confidence here is high because all three pieces of evidence agree. So the answer should be autosomal recessive, and the citation can be from any of the chunks", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking about the mode of inheritance of Wilson's disease. Let me check the evidence provided. Looking at the evidence, there are three chunks. The first one says it's an autosomal recessive disorder caused by ATP7B gene mutation. The second mentions it's a rare genetic disorder with autosomal recessive inheritance. The third also states it's an autosomal recessive disease of abnormal copper metabolism. All three sources consistently mention autosomal recessive inheritance. The confidence here is high since all three documents agree. The model can be pretty confident about this answer. So the answer should be autosomal recessive, citing all three sources. But the user wants a concise answer with citations in the format [doc_id:chunk_id]. Wait, the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking about the mode of inheritance of Wilson's disease. Let me look at the evidence provided. The first document says it's an autosomal recessive disorder caused by a mutation in the ATP7B gene. The second one also mentions it's a rare genetic disorder with autosomal recessive inheritance. The third one confirms it's an autosomal recessive disease of abnormal copper metabolism. All three sources agree on the same thing: autosomal recessive. I need to make sure there's no conflicting information here. All three chunks point to the same mode of inheritance. So the answer should be clear. The confidence level should be high since all evidence is consistent. Maybe set it to 1.0 because there's no contradiction. The answer", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the mode of inheritance of Wilson's disease. I need to look at the provided evidence to find the answer. Looking at the evidence, there are three chunks. The first one says it's an autosomal recessive disorder caused by a mutation in the ATP7B gene. The second chunk also mentions autosomal recessive inheritance. The third chunk confirms it's autosomal recessive. All three sources agree on the same point. So the answer should be that Wilson's disease is inherited in an autosomal recessive manner. Each of the citations supports this. The confidence level is high since all three documents cite the same information. I'll set the base_confidence to 1.0 because there's no conflicting", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking about the mode of inheritance of Wilson's disease. Let me look at the evidence provided. The first document says it's an autosomal recessive disorder caused by a mutation in the ATP7B gene. The second one mentions it's a rare genetic disorder with autosomal recessive inheritance. The third also states it's an autosomal recessive disease of abnormal copper metabolism. All three sources consistently point to autosomal recessive inheritance. I need to make sure there's no conflicting information. All the chunks here agree, so the answer is clear. The confidence level should be high since all three sources are in agreement. Let me check if the citations are correctly formatted. Each chunk has a doc_id and chunk_id, but the user just needs the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to figure out the mode of inheritance for Wilson's disease based on the provided evidence. Let me look at the evidence again. The first document says it's an autosomal recessive disorder caused by a mutation in the ATP7B gene. The second one mentions it's a rare genetic disorder with autosomal recessive inheritance. The third one also states it's an autosomal recessive disease of abnormal copper metabolism. All three sources consistently point to autosomal recessive inheritance. So the answer should be that Wilson's disease is inherited in an autosomal recessive manner. Each of the cited documents supports this, so the confidence level should be high. The base_confidence can be 1.0 since all evidence agrees. I need to structure the JSON with", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["12152840", "1248830", "14580665", "16932613", "1940586", "20662462", "22610954", "2724779", "6109943", "6620327", "759736", "8186659", "838566", "8615372"], "ideal_answer": "Wilson's disease (WD) is an autosomal recessive disorder."}
{"question_id": "517395b98ed59a060a00001a", "question": "Are transcription and splicing connected?", "retrieved_chunks": [{"doc_id": "19823040", "chunk_id": "19823040_1", "score": 7.05962610244751, "text": "transcription and splicing are functionally intertwined, and that modified nucleosomes with trimethylation of lysine 36 in histone subunit 3 (H3K36me3) are enriched at internal exons and the downstream flanking intronic regions of highly expressed genes"}, {"doc_id": "23074139", "chunk_id": "23074139_2", "score": 5.875174522399902, "text": "Moreover, splicing was found to be necessary for the proper 'writing' of particular chromatin signatures, giving further mechanistic support to functional interconnections between splicing, transcription and chromatin structure."}, {"doc_id": "22955974", "chunk_id": "22955974_3", "score": 4.883185386657715, "text": "We show that in the human genome, splicing occurs predominantly during transcription."}], "context": "[19823040:19823040_1] transcription and splicing are functionally intertwined, and that modified nucleosomes with trimethylation of lysine 36 in histone subunit 3 (H3K36me3) are enriched at internal exons and the downstream flanking intronic regions of highly expressed genes\n[23074139:23074139_2] Moreover, splicing was found to be necessary for the proper 'writing' of particular chromatin signatures, giving further mechanistic support to functional interconnections between splicing, transcription and chromatin structure.\n[22955974:22955974_3] We show that in the human genome, splicing occurs predominantly during transcription.", "answer": "<think> Okay, I need to answer whether transcription and splicing are connected based on the given evidence. Let me look at the evidence provided. First, the first document says that transcription and splicing are functionally intertwined. It also mentions something about nucleosomes and H3K36me3 being enriched in certain regions of genes. That seems to link transcription and splicing. The second document states that splicing is necessary for the proper 'writing' of chromatin signatures, which supports the functional connections between splicing, transcription, and chromatin structure. So this reinforces the idea that they are connected. The third document says that splicing occurs predominantly during transcription in the human genome. This directly links the timing of splicing with transcription, suggesting they are connected processes. Putting this together", "citations": [], "candidates": [{"answer": "<think> Okay, I need to answer whether transcription and splicing are connected based on the given evidence. Let me look at the evidence provided. First, the first document says that transcription and splicing are functionally intertwined. It also mentions something about nucleosomes and H3K36me3 being enriched in certain regions of genes. That seems to link transcription and splicing. The second document states that splicing is necessary for the proper 'writing' of chromatin signatures, which supports the functional connections between splicing, transcription, and chromatin structure. So this reinforces the idea that they are connected. The third document says that splicing occurs predominantly during transcription in the human genome. This directly links the timing of splicing with transcription, suggesting they are connected processes. Putting this together", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to answer whether transcription and splicing are connected based on the given evidence. Let me look at the evidence provided. First, the first document says that transcription and splicing are functionally intertwined. It also mentions something about H3K36me3 being enriched in certain regions of genes. That seems to indicate a connection between the two processes. The second document states that splicing is necessary for the proper 'writing' of chromatin signatures, which further supports the functional interconnections between splicing, transcription, and chromatin structure. So this reinforces the idea that they're connected. The third document mentions that splicing occurs predominantly during transcription in the human genome. This directly links the timing of splicing with transcription, suggesting a close relationship. Putting this all", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking if transcription and splicing are connected. Let me look at the evidence provided. First, the first piece of evidence says that transcription and splicing are functionally intertwined. It mentions modified nucleosomes with H3K36me3 being enriched in certain regions of genes. That suggests a link between the two processes. The second evidence states that splicing is necessary for proper chromatin signatures, which further supports the functional connection between splicing, transcription, and chromatin structure. So this strengthens the idea that they're connected. The third piece says splicing occurs predominantly during transcription. This directly links the timing of splicing to the transcription process, indicating they happen simultaneously or in a coordinated manner. Putting this together, all three pieces of evidence point", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to answer whether transcription and splicing are connected based on the given evidence. Let me look at the three references provided. First, reference 19823040:19823040_1 mentions that transcription and splicing are functionally intertwined. It also talks about modified nucleosomes and H3K36me3 being enriched in certain regions, which might relate to their connection. So this seems like a direct statement supporting the link between transcription and splicing. Then reference 23074139:23074139_2 says that splicing is necessary for proper chromatin signatures, further supporting the functional interconnections between splicing, transcription, and chromatin structure.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking if transcription and splicing are connected. Let me look at the evidence provided. First, the first document says that transcription and splicing are functionally intertwined. It also mentions something about H3K36me3 being enriched in certain regions of genes. That seems to link transcription and splicing because it's talking about their interaction. The second document states that splicing is necessary for the proper 'writing' of chromatin signatures, which further supports the idea that these processes are connected. So that's another point linking them. The third document says that splicing occurs predominantly during transcription. That's a direct statement about their timing and relationship. Putting this together, all three pieces of evidence indicate that transcription and splicing are indeed connected.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking if transcription and splicing are connected. Let me look at the evidence provided. First, the first evidence snippet says that transcription and splicing are functionally intertwined. It mentions modified nucleosomes with H3K36me3 being enriched in certain regions of genes. That seems to link transcription and splicing somehow. The second snippet talks about splicing being necessary for proper chromatin signatures, which further supports the connection between these processes. The third snippet states that splicing occurs predominantly during transcription, which directly connects the two processes temporally. Putting this together, all three pieces of evidence indicate a functional and temporal link between transcription and splicing. The model's confidence should be high here since multiple sources back this up. I need to make sure", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if transcription and splicing are connected. I need to look at the evidence provided. First, the first evidence chunk says that transcription and splicing are functionally intertwined. It mentions H3K36me3 being enriched in certain regions, which suggests a link between the two processes. The second chunk adds that splicing is necessary for proper chromatin signatures, further supporting their connection. The third chunk states that splicing occurs predominantly during transcription, which directly links the timing of these processes. So all three pieces of evidence point to a connection between transcription and splicing. The answer should mention this functional interconnection, citing the relevant chunks. The confidence level should be high since multiple sources support this. I'll make sure", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if transcription and splicing are connected. I need to look at the provided evidence to form an answer. First, looking at the evidence: The first document says that transcription and splicing are functionally intertwined. It also mentions something about H3K36me3 being enriched in certain regions, but maybe that's more about chromatin structure. The second document states that splicing is necessary for proper chromatin signatures, which supports the connection between splicing, transcription, and chromatin. The third document says splicing occurs predominantly during transcription. So, all three pieces of evidence point to a connection. The first two mention functional interconnections, and the third explains the timing of splicing during transcription. The answer", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["15383674", "15870275", "15905409", "16172632", "16769980", "16921380", "17189193", "20808788", "21095588", "21964334", "22156210", "22479188", "22975042", "23074139", "23097425", "23209445"], "ideal_answer": "Yes. There is strong evidence that splicing and transcription are intimately coupled in metazoans, with genome wide surveys show that most splicing occurs during transcription. Chromatin structure, RNA polymerase dynamics, and recruitment of splicing factors through the transcriptional machinery are factors that explain a role for transcription in the regulation of splicing."}
{"question_id": "52bf19c503868f1b06000001", "question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "retrieved_chunks": [{"doc_id": "22551571", "chunk_id": "22551571_0", "score": 8.945333480834961, "text": "Facioscapulohumeral muscular dystrophy (FSHD) is a neuromuscular disease, characterized by an autosomal dominant mode of inheritance, facial involvement, and selectivity and asymmetry of muscle involvement."}, {"doc_id": "15307599", "chunk_id": "15307599_0", "score": 7.493689060211182, "text": "Facioscapulohumeral muscular dystrophy (FSHD) is a primary muscle disorder with autosomal dominant inheritance."}, {"doc_id": "10969520", "chunk_id": "10969520_0", "score": 7.443556308746338, "text": "Facioscapulohumeral muscular dystrophy (FSHD) is a slowly progressive myopathy with autosomal dominant inheritance remarkable for its early involvement of facial musculature."}], "context": "[22551571:22551571_0] Facioscapulohumeral muscular dystrophy (FSHD) is a neuromuscular disease, characterized by an autosomal dominant mode of inheritance, facial involvement, and selectivity and asymmetry of muscle involvement.\n[15307599:15307599_0] Facioscapulohumeral muscular dystrophy (FSHD) is a primary muscle disorder with autosomal dominant inheritance.\n[10969520:10969520_0] Facioscapulohumeral muscular dystrophy (FSHD) is a slowly progressive myopathy with autosomal dominant inheritance remarkable for its early involvement of facial musculature.", "answer": "<think> Okay, let's tackle this question about the mode of inheritance of FSHD. The user wants a concise answer from the provided evidence, in JSON format with citations and a confidence score. First, I need to look at the evidence given. There are three chunks: 1. [22551571:22551571_0] says FSHD has an autosomal dominant inheritance, with facial involvement and asymmetric muscle issues. 2. [15307599:15307599_0] also mentions autosomal dominant inheritance. 3. [10969520:10969520_0] again states autosomal dominant, with early", "citations": [{"doc_id": "22551571", "chunk_id": "22551571_0"}, {"doc_id": "15307599", "chunk_id": "15307599_0"}, {"doc_id": "10969520", "chunk_id": "10969520_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question about the mode of inheritance of FSHD. The user wants a concise answer from the provided evidence, in JSON format with citations and a confidence score. First, I need to look at the evidence given. There are three chunks: 1. [22551571:22551571_0] says FSHD has an autosomal dominant inheritance, with facial involvement and asymmetric muscle issues. 2. [15307599:15307599_0] also mentions autosomal dominant inheritance. 3. [10969520:10969520_0] again states autosomal dominant, with early", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the mode of inheritance of FSHD. I need to look at the provided evidence to find the answer. Looking at the first evidence snippet: it says FSHD has an autosomal dominant mode of inheritance. The second one also mentions autosomal dominant. The third one too. All three sources point to autosomal dominant. So the answer should be autosomal dominant. Now, checking the confidence. Since all three documents agree, the model can be confident. But I need to assign a base_confidence between 0 and 1. Since all three are consistent, maybe 1.0 is appropriate here. But wait, sometimes even if multiple sources say the same thing, there might be variations. However", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to figure out the mode of inheritance for Facioscapulohumeral muscular dystrophy (FSHD) based on the given evidence. Let me look at the references provided. The first document says FSHD has an autosomal dominant mode of inheritance. The second one also mentions autosomal dominant inheritance. The third reference again states autosomal dominant. All three sources consistently point to autosomal dominant. I should check if there's any conflicting information, but all three are in agreement. So the answer is clear. The confidence level should be high since multiple sources confirm this. Let me make sure to cite the first document as it's the first mention. But actually, all three are valid. Maybe use the first one for citation. Wait, the user", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking about the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD). Let me look at the evidence provided. The first document says FSHD has an autosomal dominant mode of inheritance. The second one also mentions autosomal dominant inheritance. The third evidence chunk confirms it again, stating autosomal dominant with early facial muscle involvement. All three sources consistently point to autosomal dominant. I need to make sure there's no conflicting information. All the chunks agree, so the answer is clear. The confidence level should be high since all three sources are in agreement. Let me structure the JSON with the answer and base_confidence. The answer should include citations from the chunks. So, the answer would list the mode as autos", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking about the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD). Let me look at the evidence provided. First, I see three documents. The first one says FSHD has an autosomal dominant mode of inheritance. The second also mentions autosomal dominant inheritance. The third one too states autosomal dominant inheritance. All three sources consistently point to autosomal dominant. I need to make sure there's no conflicting information. All the chunks here agree, so the answer should be clear. The confidence level should be high since all three pieces of evidence support the same conclusion. The answer needs to be concise and include citations. So I'll list one of the documents with the chunk ID. Maybe use the first one", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to figure out the mode of inheritance for FSHD based on the provided evidence. Let me look at the three documents. The first document says FSHD has an autosomal dominant inheritance. The second one also mentions autosomal dominant. The third one too. All three citations point to autosomal dominant. The answer should be straightforward. The confidence is high since all three sources agree. So the answer is autosomal dominant, and the confidence is 1.0. </think> { \"answer\": \"Facioscapulohumeral muscular dystrophy (FSHD) exhibits an autosomal dominant mode of inheritance [22551571:22551571_0][1530759", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD). I need to look at the provided evidence to find the answer. Looking at the evidence, there are three documents. The first one says FSHD has an autosomal dominant mode of inheritance. The second also mentions autosomal dominant inheritance. The third one too states autosomal dominant. All three citations point to autosomal dominant. I should check if there's any conflicting information, but all three sources agree. So the answer is clear. The confidence level should be high since all evidence supports the same conclusion. Maybe 1.0 since it's consistent across multiple sources. </think> { \"answer\": \"Fac", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking about the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD). Let me look at the evidence provided. First, I see three documents cited. The first one says FSHD has an autosomal dominant mode of inheritance. The second also mentions autosomal dominant inheritance. The third document confirms it again with the same point. All three sources consistently state that the inheritance pattern is autosomal dominant. I need to make sure there's no conflicting information here. All three chunks support the same answer, so the confidence level should be high. The model can be confident because all evidence points to the same conclusion. The answer should be concise, mentioning autosomal dominant and citing the documents. Since all three sources are reliable", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["10487912", "10864616", "10969520", "15307599", "19248726", "21795275", "22525183", "22551571", "23143600", "23573591", "7739631"], "ideal_answer": "Facioscapulohumeral muscular dystrophy has an autosomal dominant inheritance pattern."}
{"question_id": "54db1d580f63c58e6e000005", "question": "Is Alu hypomethylation associated with breast cancer?", "retrieved_chunks": [{"doc_id": "24971511", "chunk_id": "24971511_0", "score": 9.603660583496094, "text": "Alu and LINE-1 hypomethylation is associated with HER2 enriched subtype of breast cancer"}, {"doc_id": "24971511", "chunk_id": "24971511_1", "score": 8.644245147705078, "text": "Alu hypomethylation is probably a late event during breast cancer progression"}, {"doc_id": "31383000", "chunk_id": "31383000_1", "score": 3.7526326179504395, "text": "In addition, hypomethylation of TBC1D16 was observed in multiple tumours, including a breast cancer primary/metastasis pair, and to a lesser degree in melanoma, although again not all tumours or cancer primary/metastasis pairs exhibited altered patterns of methylation."}], "context": "[24971511:24971511_0] Alu and LINE-1 hypomethylation is associated with HER2 enriched subtype of breast cancer\n[24971511:24971511_1] Alu hypomethylation is probably a late event during breast cancer progression\n[31383000:31383000_1] In addition, hypomethylation of TBC1D16 was observed in multiple tumours, including a breast cancer primary/metastasis pair, and to a lesser degree in melanoma, although again not all tumours or cancer primary/metastasis pairs exhibited altered patterns of methylation.", "answer": "<think> Okay, let's tackle this question. The user is asking if Alu hypomethylation is associated with breast cancer. The evidence provided has three chunks. First chunk: [24971511:24971511_0] says that Alu and LINE-1 hypomethylation is linked to the HER2 enriched subtype of breast cancer. So that directly connects Alu hypomethylation to a specific type of breast cancer. That's a strong point. Second chunk: [24971511:24971511_1] mentions that Alu hypomethylation is probably a late event during breast cancer progression. This suggests it's involved in the development process, which", "citations": [{"doc_id": "24971511", "chunk_id": "24971511_0"}, {"doc_id": "24971511", "chunk_id": "24971511_1"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if Alu hypomethylation is associated with breast cancer. The evidence provided has three chunks. First chunk: 24971511_0 says that Alu and LINE-1 hypomethylation is associated with the HER2 enriched subtype of breast cancer. That directly links Alu hypomethylation to a specific type of breast cancer. So that's a strong point. Second chunk: 24971511_1 mentions that Alu hypomethylation is probably a late event during breast cancer progression. This suggests it's involved in the progression but not sure if it's a primary driver. However, it still indicates an association. Third chunk: 3", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if Alu hypomethylation is associated with breast cancer. The evidence provided has three chunks. First chunk: 24971511_0 says that Alu and LINE-1 hypomethylation is linked to the HER2 enriched subtype of breast cancer. So that directly connects Alu hypomethylation to a specific type of breast cancer. That's a strong point. Second chunk: 24971511_1 mentions that Alu hypomethylation is probably a late event during breast cancer progression. This suggests it's involved in the development process, so it's associated with the disease. Third chunk: 31383000_", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if Alu hypomethylation is associated with breast cancer. The evidence provided has three documents. Let me look at each one. First document: 24971511_0 says that Alu and LINE-1 hypomethylation is associated with the HER2 enriched subtype of breast cancer. That directly links Alu hypomethylation to a specific type of breast cancer. So that's a strong point. Second document: 24971511_1 mentions that Alu hypomethylation is probably a late event during breast cancer progression. This suggests it's related to the development of breast cancer, even if it's later in the process. So this also", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking if Alu hypomethylation is associated with breast cancer. Let me look at the evidence provided. First, there's a document (24971511) that mentions Alu and LINE-1 hypomethylation being linked to the HER2 enriched subtype of breast cancer. That seems direct. Another chunk from the same doc says Alu hypomethylation is probably a late event during breast cancer progression. So that supports the association. Then there's another document (31383000) talking about TBC1D16 hypomethylation in multiple tumors, including a breast cancer primary/metastasis pair. But it also notes that not all tumors show this. However, the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if Alu hypomethylation is associated with breast cancer. The evidence provided has three entries. First, I need to look at each piece of evidence. The first one says that Alu and LINE-1 hypomethylation is linked to the HER2 enriched subtype of breast cancer. That directly connects Alu hypomethylation to a specific type of breast cancer. So that's a strong point. The second entry states that Alu hypomethylation is probably a late event during breast cancer progression. This suggests that it occurs later in the disease process, which still indicates an association. But the wording is \"probably,\" so maybe the confidence here isn't 100%. The third evidence mentions hyp", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if Alu hypomethylation is associated with breast cancer. I need to look at the provided evidence to form an answer. First, checking the evidence documents. The first one, 24971511:24971511_0, says that Alu and LINE-1 hypomethylation is linked to the HER2 enriched subtype of breast cancer. That directly connects Alu hypomethylation to a specific type of breast cancer. So that's a strong point. The second document, 24971511:24971511_1, mentions that Alu hypomethylation is probably a late event during", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking if Alu hypomethylation is associated with breast cancer. Let me look at the evidence provided. First, there's a document (24971511) that says Alu and LINE-1 hypomethylation is linked to the HER2 enriched subtype of breast cancer. That directly connects Alu hypomethylation to a specific type of breast cancer. Then another chunk from the same doc mentions that Alu hypomethylation is probably a late event during progression, which suggests it's involved in the development process. The third evidence is about TBC1D16 hypomethylation in multiple tumors, including breast cancer, but it's not all cases. So, combining these, the answer should state", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if Alu hypomethylation is associated with breast cancer. The evidence provided has three chunks. First chunk: [24971511:24971511_0] says that Alu and LINE-1 hypomethylation is linked to the HER2 enriched subtype of breast cancer. So that directly connects Alu hypomethylation to a specific type of breast cancer. That's a strong point. Second chunk: [24971511:24971511_1] mentions that Alu hypomethylation is probably a late event during breast cancer progression. This suggests it's involved in the development process, which", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["20682973", "24971511"], "ideal_answer": "Yes, Alu elements were found to be hypomethylated in breast cancer, especially in the HER2-enriched subtype. Furthermore, Alu hypomethylation was identified as a late event during breast cancer progression, and in invasive breast cancer, tended to be associated with negative estrogen receptor status and poor disease-free survival of the patients. Alu and LINE-1 hypomethylation is associated with HER2 enriched subtype of breast cancer"}
{"question_id": "54f9d3eedd3fc62544000004", "question": "Which proteins participate in the formation of the ryanodine receptor quaternary macromolecular complex?", "retrieved_chunks": [{"doc_id": "18206802", "chunk_id": "18206802_2", "score": 7.118478775024414, "text": "Junctin (JCN), a 26-kd sarcoplasmic reticulum (SR) transmembrane protein, forms a quaternary protein complex with the ryanodine receptor, calsequestrin, and triadin in the SR lumen of cardiac muscle. Within this complex, calsequestrin, triadin, and JCN appear to be critical for normal regulation of ryanodine receptor-mediated calcium (Ca) release."}, {"doc_id": "14638677", "chunk_id": "14638677_0", "score": 6.793920516967773, "text": "In mammalian striated muscles, ryanodine receptor (RyR), triadin, junctin, and calsequestrin form a quaternary complex in the lumen of sarcoplasmic reticulum. Such intermolecular interactions contribute not only to the passive buffering of sarcoplasmic reticulum luminal Ca2+, but also to the active Ca2+ release process during excitation-contraction coupling."}, {"doc_id": "22025663", "chunk_id": "22025663_1", "score": 6.719632148742676, "text": "Junctin, a 26 kDa intra-sarcoplasmic reticulum (SR) protein, forms a quaternary complex with triadin, calsequestrin and the ryanodine receptor (RyR) at the junctional SR membrane."}], "context": "[18206802:18206802_2] Junctin (JCN), a 26-kd sarcoplasmic reticulum (SR) transmembrane protein, forms a quaternary protein complex with the ryanodine receptor, calsequestrin, and triadin in the SR lumen of cardiac muscle. Within this complex, calsequestrin, triadin, and JCN appear to be critical for normal regulation of ryanodine receptor-mediated calcium (Ca) release.\n[14638677:14638677_0] In mammalian striated muscles, ryanodine receptor (RyR), triadin, junctin, and calsequestrin form a quaternary complex in the lumen of sarcoplasmic reticulum. Such intermolecular interactions contribute not only to the passive buffering of sarcoplasmic reticulum luminal Ca2+, but also to the active Ca2+ release process during excitation-contraction coupling.\n[22025663:22025663_1] Junctin, a 26 kDa intra-sarcoplasmic reticulum (SR) protein, forms a quaternary complex with triadin, calsequestrin and the ryanodine receptor (RyR) at the junctional SR membrane.", "answer": "<think> Okay, let's tackle this question. The user is asking which proteins participate in forming the ryanodine receptor quaternary macromolecular complex. The evidence provided has three documents. Looking at document [18206802:18206802_2], it mentions Junctin (JCN), ryanodine receptor, calsequestrin, and triadin as part of the complex. Then document [14638677:14638677_0] also lists RyR, triadin, junctin, and calsequestrin forming the quaternary complex. The third document [22025663:2202", "citations": [{"doc_id": "18206802", "chunk_id": "18206802_2"}, {"doc_id": "14638677", "chunk_id": "14638677_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which proteins participate in forming the ryanodine receptor quaternary macromolecular complex. The evidence provided has three documents. Looking at document [18206802:18206802_2], it mentions Junctin (JCN), ryanodine receptor, calsequestrin, and triadin as part of the complex. Then document [14638677:14638677_0] also lists RyR, triadin, junctin, and calsequestrin forming the quaternary complex. The third document [22025663:2202", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which proteins are part of the ryanodine receptor quaternary macromolecular complex. First, I need to look at the evidence provided. There are three references here. Let me go through each one. The first piece of evidence (18206802:18206802_2) mentions Junctin (JCN), ryanodine receptor, calsequestrin, and triadin forming a quaternary complex in the SR lumen of cardiac muscle. So that's four proteins. The second one (14638677:14638677_0) says RyR, triadin, jun", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which proteins are part of the ryanodine receptor quaternary complex. Looking at the evidence provided, there are three references. Let me check each one. First, reference 18206802 mentions Junctin (JCN), ryanodine receptor, calsequestrin, and triadin forming a quaternary complex. So that's four proteins: JCN, RyR, calstsestrin, triadin. Then reference 14638677 says RyR, triadin, junctin, and calsequestrin form the same complex. Same four proteins again. Third, reference 2202566", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which proteins are part of the ryanodine receptor quaternary macromolecular complex. Looking at the evidence provided, there are three documents that mention the components. Document 18206802:18206802_2 mentions Junctin (JCN), ryanodine receptor, calsequestrin, and triadin. It says they form a quaternary complex in the SR lumen of cardiac muscle. Document 14638677:14638677_0 also lists RyR, triadin, junctin, and calsequestrin as part of the quaternary complex", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which proteins are part of the ryanodine receptor quaternary complex. I need to look at the evidence provided. First, evidence document [18206802:18206802_2] mentions Junctin (JCN), ryanodine receptor, calsequestrin, and triadin. It says they form a quaternary complex in the SR lumen of cardiac muscle. Then, [14638677:14638677_0] states that RyR, triadin, junctin, and calsequestrin form the complex in mammalian striated muscles. The third", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which proteins are part of the ryanodine receptor quaternary macromolecular complex. Looking at the evidence provided, there are three documents. Let me go through each one to identify the proteins mentioned. First document [18206802:18206802_2] mentions Junctin (JCN), ryanodine receptor, calsequestrin, and triadin. It says they form a quaternary complex in the SR lumen of cardiac muscle. Second document [14638677:14638677_0] lists Ryanodine receptor (RyR), triadin, junct", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, so I need to figure out which proteins are part of the ryanodine receptor quaternary complex based on the evidence provided. Let me look through each of the three references. First, reference 18206802:18206802_2 mentions Junctin (JCN), ryanodine receptor, calsequestrin, and triadin forming a quaternary complex in cardiac muscle SR. So that's four proteins: JCN, RyR, calsequestrin, triadin. Then reference 14638677:14638677_0 says RyR, triadin, junctin, and calsequestrin form", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which proteins are part of the ryanodine receptor quaternary complex. Looking at the evidence provided, there are three references. First, reference 18206802 mentions Junctin (JCN), ryanodine receptor, calsequestrin, and triadin. It says they form a quaternary complex in the SR lumen of cardiac muscle. Then, reference 14638677 also lists RyR, triadin, junctin, and calsequestrin as part of the complex in mammalian striated muscles. The third reference, 22025663, again mentions Junctin, triadin", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["11069905", "12909320", "14638677", "15205169", "15731387", "16289269", "18206802", "18620751", "22025663", "22298808", "22427521", "9287354"], "ideal_answer": "Junctin is a major transmembrane protein in cardiac junctional sarcoplasmic reticulum, which forms a quaternary complex with the ryanodine receptor (Ca(2+) release channel), triadin, and calsequestrin. Calsequestrin (CSQ) is a Ca(2+) storage protein that interacts with triadin (TRN), the ryanodine receptor (RyR), and junctin (JUN) to form a macromolecular tetrameric Ca(2+) signaling complex in the cardiac junctional sarcoplasmic reticulum (SR). Junctin, calsequestrin, triadin, and the ryanodine receptor form a quaternary complex that may be required for normal operation of Ca2+ release."}
{"question_id": "5505edac8e1671127b000005", "question": "What kind of chromatography is HILIC?", "retrieved_chunks": [{"doc_id": "23073287", "chunk_id": "23073287_0", "score": 7.970343589782715, "text": "Hydrophilic-interaction liquid chromatography (HILIC) is a widely used technique for small polar molecule analysis"}, {"doc_id": "21316059", "chunk_id": "21316059_0", "score": 7.010393142700195, "text": "Hydrophilic Interaction Chromatography (HILIC)"}, {"doc_id": "21737084", "chunk_id": "21737084_0", "score": 5.63319206237793, "text": "A hydrophilic interaction liquid chromatography-tandem mass spectrometry (HILIC LC-MS/MS) method"}], "context": "[23073287:23073287_0] Hydrophilic-interaction liquid chromatography (HILIC) is a widely used technique for small polar molecule analysis\n[21316059:21316059_0] Hydrophilic Interaction Chromatography (HILIC)\n[21737084:21737084_0] A hydrophilic interaction liquid chromatography-tandem mass spectrometry (HILIC LC-MS/MS) method", "answer": "<think> Okay, the user is asking what kind of chromatography HILIC is. Let me look at the evidence provided. First, the evidence has three chunks. The first one says HILIC is a technique for small polar molecule analysis. The second mentions Hydrophilic Interaction Chromatography (HILIC) without additional details. The third talks about HILIC LC-MS/MS, which seems like an application method. So, the answer needs to be concise and cite the relevant document. The first chunk [23073287:23073287_0] defines HILIC as a chromatography technique. The second chunk [21316059:21316059_", "citations": [{"doc_id": "23073287", "chunk_id": "23073287_0"}], "candidates": [{"answer": "<think> Okay, the user is asking what kind of chromatography HILIC is. Let me look at the evidence provided. The first document says HILIC is a technique for small polar molecules. The second mentions Hydrophilic Interaction Chromatography (HILIC), and the third talks about HILIC LC-MS/MS. So, all these references point to HILIC being a type of liquid chromatography. Specifically, the term \"hydrophilic-interaction\" suggests it's related to polarity. I need to make sure the answer is concise and cites the correct document. The first evidence directly defines HILIC as a technique, so that's a good source. The other documents support that it's a type of liquid chromatography. The answer should mention", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking what kind of chromatography HILIC is. Let me look at the evidence provided. The first document says HILIC is a technique for small polar molecules. The second mentions Hydrophilic Interaction Chromatography (HILIC) directly. The third talks about HILIC LC-MS/MS, which is a method using HILIC. So, putting this together, HILIC stands for Hydrophilic Interaction Liquid Chromatography. The first document confirms it's a type of chromatography used for polar molecules. The other documents support that definition. The answer should be concise, citing the first document since it directly defines HILIC. The confidence is high because all sources agree on the term and its application. </think>", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking what kind of chromatography HILIC is. Let me look at the evidence provided. First, the evidence has three chunks. The first one says HILIC is a technique for small polar molecule analysis. The second mentions Hydrophilic Interaction Chromatography (HILIC) again, maybe just repeating the name. The third talks about HILIC LC-MS/MS, which seems like an application method. So, the answer needs to be concise. The first chunk defines it as hydrophilic-interaction liquid chromatography. The second chunk also mentions the same thing. The third is an example of its use. The key here is to identify that HILIC is a type of liquid chromatography, specifically hydrophilic interaction.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking what kind of chromatography HILIC is. Let me look at the evidence provided. The first document says HILIC is a technique for small polar molecule analysis. The second mentions Hydrophilic Interaction Chromatography (HILIC) without additional details. The third talks about HILIC LC-MS/MS, which seems like an application of HILIC. So, the answer should define HILIC as a type of chromatography. The first evidence directly states it's a technique, so I can use that. The second document confirms the name. The third is more about its use with MS, but the main definition comes from the first source. I need to make sure the answer is concise and cites the correct document", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking what kind of chromatography HILIC is. Let me look at the evidence provided. First, the evidence has three chunks. The first one says HILIC is a technique for small polar molecule analysis. The second mentions Hydrophilic Interaction Chromatography (HILIC) without any additional details. The third talks about HILIC LC-MS/MS, which is a method combining HILIC with tandem mass spectrometry. So, the answer needs to be concise and cite the relevant document. The first chunk directly defines HILIC as a chromatography technique. The second chunk just restates the name. The third is about an application of HILIC. The key here is to identify that HILIC is a", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to figure out what kind of chromatography HILIC is based on the given evidence. Let me look at the evidence provided. The first document says HILIC is a technique for small polar molecule analysis. The second mentions Hydrophilic Interaction Chromatography (HILIC) without specifying the type. The third talks about HILIC LC-MS/MS, which combines HILIC with mass spectrometry. So, putting this together, HILIC is a type of liquid chromatography. The term \"hydrophilic-interaction\" suggests it's related to polarity. The documents mention it's used for polar molecules and combined with other techniques like MS. The answer should state that HILIC is a form of liquid chromatography, specifically", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking what kind of chromatography HILIC is. Let me look at the evidence provided. First, the evidence has three chunks. The first one says HILIC is a technique for small polar molecule analysis. The second mentions Hydrophilic Interaction Chromatography (HILIC) without additional details. The third talks about HILIC LC-MS/MS, which seems like an application method. So, the answer needs to be concise and cite the relevant document. The first chunk [23073287:23073287_0] defines HILIC as a chromatography technique. The second chunk [21316059:21316059_", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, so the user is asking what kind of chromatography HILIC is. Let me look at the evidence provided. The first document says HILIC is a technique for small polar molecules. The second one just mentions Hydrophilic Interaction Chromatography (HILIC) again. The third one talks about HILIC LC-MS/MS, which seems like an application of HILIC. I need to define HILIC. From the first evidence, it's called hydrophilic-interaction liquid chromatography. The second document uses the full name, Hydrophilic Interaction Chromatography. So combining those, HILIC is a type of liquid chromatography that's used for polar molecules. The third evidence supports that it's a method used in", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["21238772", "21316059", "21737084", "22946920", "23073287", "23217321"], "ideal_answer": "Hydrophilic Interaction Chromatography (HILIC)"}
{"question_id": "5160193d298dcd4e51000039", "question": "What is the effect of TRH on myocardial contractility?", "retrieved_chunks": [{"doc_id": "1611701", "chunk_id": "1611701_1", "score": 6.403558731079102, "text": "Thus, TRH improves cardiac contractility, cardiac output, and hemodynamics during hemorrhagic shock."}, {"doc_id": "9088928", "chunk_id": "9088928_0", "score": 6.24492073059082, "text": "TRH in the range of 0.1-10 mumol/l was found to exert a positive inotropic effect on cardiac contractility"}, {"doc_id": "1611701", "chunk_id": "1611701_0", "score": 5.802417755126953, "text": "TRH improves cardiac contractility, cardiac output, and hemodynamics"}], "context": "[1611701:1611701_1] Thus, TRH improves cardiac contractility, cardiac output, and hemodynamics during hemorrhagic shock.\n[9088928:9088928_0] TRH in the range of 0.1-10 mumol/l was found to exert a positive inotropic effect on cardiac contractility\n[1611701:1611701_0] TRH improves cardiac contractility, cardiac output, and hemodynamics", "answer": "<think> Okay, let's tackle this question. The user is asking about the effect of TRH on myocardial contractility. I need to look at the provided evidence to form an answer. First, I'll check each piece of evidence. The first document [1611701:1611701_1] says TRH improves cardiac contractility, cardiac output, and hemodynamics during hemorrhagic shock. That's a direct mention of myocardial contractility. The second evidence [9088928:9088928_0] states that TRH in the range 0.1-10 μmol/l has a positive inotropic effect on cardiac contractility. The third document [1611", "citations": [{"doc_id": "1611701", "chunk_id": "1611701_1"}, {"doc_id": "9088928", "chunk_id": "9088928_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the effect of TRH on myocardial contractility. I need to look at the provided evidence to form an answer. First, I'll check each piece of evidence. The first document [1611701:1611701_1] says TRH improves cardiac contractility, cardiac output, and hemodynamics during hemorrhagic shock. That's a direct mention of myocardial contractility. The second evidence [9088928:9088928_0] states that TRH in the range 0.1-10 μmol/l has a positive inotropic effect on cardiac contractility. The third document [1611", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the effect of TRH on myocardial contractility. I need to look at the provided evidence to form a concise answer with citations. First, I'll review each piece of evidence. The first document [1611701:1611701_1] states that TRH improves cardiac contractility, cardiac output, and hemodynamics during hemorrhagic shock. The second evidence [9088928:9088928_0] mentions that TRH in the range of 0.1-10 μmol/l has a positive inotropic effect on cardiac contractility. The third evidence [1611701:16", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the effect of TRH on myocardial contractility. I need to look at the provided evidence to form an answer. First, looking at the evidence documents. Document [1611701:1611701_1] says TRH improves cardiac contractility, cardiac output, and hemodynamics during hemorrhagic shock. Another document [9088928:9088928_0] mentions that TRH in the range of 0.1-10 μmol/l has a positive inotropic effect on cardiac contractility. The third evidence [1611701:1611701_0] repeats", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, so the user is asking about the effect of TRH on myocardial contractility. Let me look at the evidence provided. First, there are three pieces of evidence. The first one from 1611701:1611701_1 says that TRH improves cardiac contractility, cardiac output, and hemodynamics during hemorrhagic shock. The second piece, 9088928:9088928_0, mentions that TRH in the range of 0.1-10 μmol/l has a positive inotropic effect on cardiac contractility. The third one is similar to the first, stating TRH improves cardiac contractility and cardiac output. So all three sources agree that TR", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The question is about the effect of TRH on myocardial contractility. First, let me look at the evidence. There are three chunks: 1. [1611701:1611701_1] says TRH improves cardiac contractility, cardiac output, and hemodynamics during hemorrhagic shock. 2. [9088928:9088928_0] mentions that TRH in 0.1-10 μmol/l has a positive inotropic effect on cardiac contractility. 3. [1611701:1611701_0] states TRH improves cardiac", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the effect of TRH on myocardial contractility. I need to look at the provided evidence to form a concise answer with citations and a confidence level. First, I'll check each piece of evidence. The first document [1611701:1611701_1] says TRH improves cardiac contractility, cardiac output, and hemodynamics during hemorrhagic shock. The second one [9088928:9088928_0] mentions that TRH in the range of 0.1-10 μmol/l has a positive inotropic effect on cardiac contractility. The third document [1611701", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question about the effect of TRH on myocardial contractility. The user wants a strict JSON answer with the answer and base confidence. First, I need to look at the evidence provided. There are three chunks here. Let me check each one. The first chunk (1611701:1611701_1) says TRH improves cardiac contractility, cardiac output, and hemodynamics during hemorrhagic shock. The second chunk (9088928:9088928_0) mentions that TRH in the range of 0.1-10 μmol/l has a positive inotropic effect on cardiac contractility. The third chunk (16117", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the effect of TRH on myocardial contractility. I need to look at the provided evidence to form a correct answer. First, I'll check each of the three evidence points. The first evidence [1611701:1611701_1] says TRH improves cardiac contractility, cardiac output, and hemodynamics during hemorrhagic shock. That's directly about myocardial contractility. The second piece [9088928:9088928_0] mentions that TRH in a certain range has a positive inotropic effect on cardiac contractility. The third evidence [1611701:161", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["15096458", "1611701", "1979356", "2848686", "9088928", "9225129"], "ideal_answer": "TRH improves myocardial contractility"}
{"question_id": "51593dc8d24251bc05000099", "question": "Proteomic analyses need prior knowledge of the organism complete genome. Is the complete genome of the bacteria of the genus Arthrobacter available?", "retrieved_chunks": [{"doc_id": "21677849", "chunk_id": "21677849_0", "score": 0.8053627610206604, "text": "Complete genome sequence of Arthrobacter phenanthrenivorans type strain (Sphe3)."}, {"doc_id": "15246528", "chunk_id": "15246528_0", "score": 0.24066407978534698, "text": "Comparative genomic analysis of the malaria causative agent, Plasmodium falciparum, with other eukaryotes for which the complete genome is available, revealed that the genome from P. falciparum was more similar to the genome of a plant, Arabidopsis thaliana, than to other non-apicomplexan taxa."}, {"doc_id": "23039946", "chunk_id": "23039946_0", "score": -0.14639154076576233, "text": "Complete genome sequence and metabolic potential of the quinaldine-degrading bacterium Arthrobacter sp. Rue61a."}], "context": "[21677849:21677849_0] Complete genome sequence of Arthrobacter phenanthrenivorans type strain (Sphe3).\n[15246528:15246528_0] Comparative genomic analysis of the malaria causative agent, Plasmodium falciparum, with other eukaryotes for which the complete genome is available, revealed that the genome from P. falciparum was more similar to the genome of a plant, Arabidopsis thaliana, than to other non-apicomplexan taxa.\n[23039946:23039946_0] Complete genome sequence and metabolic potential of the quinaldine-degrading bacterium Arthrobacter sp. Rue61a.", "answer": "<think> Okay, let's tackle this question. The user is asking if the complete genome of bacteria in the genus Arthrobacter is available. The evidence given has three references. First, I need to check each document to see if they mention the complete genome of any Arthrobacter species. Looking at the first evidence: [21677849:21677849_0] mentions the complete genome sequence of Arthrobacter phenanthrenivorans type strain (Sphe3). So that's a specific strain within the genus, so that's a yes for that particular species. The second evidence is about Plasmodium falciparum, which is a malaria parasite, not a bacterium. The third", "citations": [{"doc_id": "21677849", "chunk_id": "21677849_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if the complete genome of bacteria in the genus Arthrobacter is available. The evidence provided has three documents. First, looking at the evidence: document 21677849 mentions the complete genome sequence of Arthrobacter phenanthrenivorans, which is a specific strain. Then there's another document, 23039946, about another strain, Arthrobacter sp. Rue61a. The third document is about Plasmodium falciparum, which isn't relevant here but maybe used as a comparison. So the question is about whether the complete genome of the genus Arthrobacter is available. The answer depends on whether these", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the complete genome of bacteria in the genus Arthrobacter is available. The evidence given has three references. First, I need to check each document to see if they mention the complete genome of any Arthrobacter species. Looking at the first evidence: [21677849:21677849_0] mentions the complete genome sequence of Arthrobacter phenanthrenivorans type strain (Sphe3). So that's a specific strain within the genus, so that's a yes for that particular species. The second evidence is about Plasmodium falciparum, which is a malaria parasite, not a bacterium. The third", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the complete genome of bacteria in the genus Arthrobacter is available. The evidence provided has three documents. First, I need to check each document to see if they mention the complete genome of any Arthrobacter species. Looking at the first evidence: [21677849:21677849_0] talks about the complete genome sequence of Arthrobacter phenanthrenivorans type strain (Sphe3). So that's a specific species within the genus, and their genome is available. That's one example. The second evidence is about Plasmodium falciparum, which is a malaria parasite, not part of Arth", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, so the user is asking if the complete genome of bacteria in the genus Arthrobacter is available. The evidence provided has three documents. Let me check each one. First document: [21677849:21677849_0] talks about the complete genome sequence of Arthrobacter phenanthrenivorans type strain (Sphe3). That's a specific species within the genus, so that's a yes for that particular organism. Second document: [15246528:15246528_0] is about Plasmodium falciparum, which is a eukaryote, not a bacterium. So this might not be relevant", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the complete genome of bacteria in the genus Arthrobacter is available. The evidence provided has three documents. First, I need to check each document to see if they mention the complete genome of any Arthrobacter species. Looking at the first evidence: [21677849:21677849_0] talks about the complete genome sequence of Arthrobacter phenanthrenivorans type strain (Sphe3). So that's a specific species within the genus, and their genome is available. The second evidence is about Plasmodium falciparum, which isn't related to Arthrobacter, so that's probably not", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the complete genome of bacteria in the genus Arthrobacter is available. The evidence given has three documents. First, I need to check each document to see if they mention the complete genome of any Arthrobacter species. The first document [21677849:21677849_0] talks about the complete genome sequence of Arthrobacter phenanthrenivorans type strain (Sphe3). That's a specific strain, so that's a yes for that particular bacterium. The second document [15246528:15246528_0] is about Plasmodium falcipar", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the complete genome of bacteria in the genus Arthrobacter is available. The evidence given has three documents. First, I need to check each document to see if they mention the complete genome of any Arthrobacter species. Looking at the first evidence: [21677849:21677849_0] talks about the complete genome sequence of Arthrobacter phenanthrenivorans type strain (Sphe3). So that's a specific species within the genus, and their genome is available. The second evidence is about Plasmodium falciparum, which is a malaria parasite, not related to Arthrobacter. So", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the complete genome of bacteria in the genus Arthrobacter is available. The evidence provided has three documents. First, I need to check each document to see if they mention the complete genome of any Arthrobacter species. Looking at the first evidence: [21677849:21677849_0] talks about the complete genome sequence of Arthrobacter phenanthrenivorans type strain (Sphe3). So that's a specific species within the genus, and their genome is available. That's a direct hit. The second evidence is about Plasmodium falciparum, which is a malaria parasite, not related to Ar", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["21677849", "23039946", "28138355", "28315371", "28450506", "28642378", "28904741"], "ideal_answer": "Yes, the complete genome sequence of Arthrobacter (two strains) is deposited in GenBank."}
{"question_id": "56e2cec751531f7e33000015", "question": "What is the structural fold of bromodomain proteins?", "retrieved_chunks": [{"doc_id": "17694091", "chunk_id": "17694091_0", "score": 6.534749984741211, "text": "These new studies also support the notion that functional diversity of a conserved bromodomain structural fold is achieved by evolutionary changes of structurally flexible amino-acid sequences in the ligand binding site such as the ZA and BC loops."}, {"doc_id": "17274598", "chunk_id": "17274598_0", "score": 2.550708293914795, "text": "The Brg1 bromodomain conserves the left-handed, four-helix bundle topology found in other bromodomain structures. However, the alphaZ helix of Brg1 bromodomain is about 4 residues shorter relative to previously published bromodomain structures."}, {"doc_id": "17148447", "chunk_id": "17148447_0", "score": 1.9005732536315918, "text": "Here, we report the crystal structure of the N-terminal bromodomain (BD1, residues 74-194) of human BRD2."}], "context": "[17694091:17694091_0] These new studies also support the notion that functional diversity of a conserved bromodomain structural fold is achieved by evolutionary changes of structurally flexible amino-acid sequences in the ligand binding site such as the ZA and BC loops.\n[17274598:17274598_0] The Brg1 bromodomain conserves the left-handed, four-helix bundle topology found in other bromodomain structures. However, the alphaZ helix of Brg1 bromodomain is about 4 residues shorter relative to previously published bromodomain structures.\n[17148447:17148447_0] Here, we report the crystal structure of the N-terminal bromodomain (BD1, residues 74-194) of human BRD2.", "answer": "<think> Okay, let's tackle this question about the structural fold of bromodomain proteins. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three references here. Let me go through each one. The first piece [17694091:17694091_0] talks about the structural fold being conserved but with variations in flexible regions like the ZA and BC loops. So that's about the overall structure being similar but with some changes in specific areas. The second one [17274598:17274598_0] mentions Brg1 bromodomain having a left-handed, four-helix bundle", "citations": [{"doc_id": "17694091", "chunk_id": "17694091_0"}, {"doc_id": "17274598", "chunk_id": "17274598_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question about the structural fold of bromodomain proteins. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three references here. Let me go through each one. The first piece [17694091:17694091_0] talks about the structural fold being conserved but with variations in flexible regions like the ZA and BC loops. So that's about the overall structure being similar but with some changes in specific areas. The second one [17274598:17274598_0] mentions Brg1 bromodomain having a left-handed, four-helix bundle", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to answer the question about the structural fold of bromodomain proteins based on the given evidence. Let me start by reading through the evidence provided. First, the user provided three documents. Let me go through each one. The first document (17694091:17694091_0) talks about the structural fold of bromodomain proteins being conserved but with variations in flexible regions like the ZA and BC loops. It mentions that functional diversity is achieved through evolutionary changes in these areas. So this suggests that the overall structure is conserved, but there are some flexible parts that can vary. The second document (17274598:17274598_", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the structural fold of bromodomain proteins. I need to look at the evidence provided to form an answer. First, evidence [17274598:17274598_0] mentions that Brg1 bromodomain has a left-handed, four-helix bundle topology, which is conserved in other bromodomain structures. That seems like a key point about the structural fold. But it also notes that the alphaZ helix is 4 residues shorter compared to previous structures. So the main fold is the four-helix bundle, but there's some variation in specific helices. Another piece of evidence [17694091:17", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the structural fold of bromodomain proteins. I need to look at the provided evidence to form an answer. First, looking at the evidence documents: Document [17274598:17274598_0] mentions that Brg1's bromodomain has a left-handed, four-helix bundle topology, which is conserved in other bromodomain structures. However, the alphaZ helix is 4 residues shorter. This suggests that the basic structure is a four-helix bundle but with some variations. Another document [17694091:17694091_0] talks about the structural fold being conserved", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question about the structural fold of bromodomain proteins. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three references here. Let me go through each one. The first evidence [17694091:17694091_0] talks about the structural fold being conserved but with variations in flexible regions like the ZA and BC loops. So that's about the general structure being similar but with some flexibility. The second piece [17274598:17274598_0] mentions Brg1 bromodomain having a left-handed, four-helix bundle topology, which", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, so I need to figure out the structural fold of bromodomain proteins based on the given evidence. Let me start by reading through the provided documents carefully. The first document [17694091:17694091_0] mentions that bromodomain proteins have a conserved structural fold, and their functional diversity comes from evolutionary changes in flexible regions like the ZA and BC loops. This suggests that the overall structure is preserved but can vary in certain areas. The second document [17274598:17274598_0] talks about Brg1's bromodomain maintaining a left-handed, four-helix bundle topology, which is common in other bromodomains.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question about the structural fold of bromodomain proteins. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three references. Let me go through each one. The first one (17694091) talks about the structural fold being conserved but with variations in flexible regions like the ZA and BC loops. The second (17274598) mentions that Brg1's bromodomain has a left-handed, four-helix bundle topology, which is common, but the alphaZ helix is shorter. The third (17148447) reports the crystal structure of BRD2's BD1,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about the structural fold of bromodomain proteins. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three references here. Let me parse each one. The first reference [17694091:17694091_0] talks about the structural fold being conserved but with variations in ligand-binding sites like the ZA and BC loops. So it mentions that the basic structure is conserved but there are flexible regions that can change. The second reference [17274598:17274598_0] says that Brg1's bromodomain has a left-handed", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["10365964", "10827952", "11090279", "17148447", "17274598", "17498659", "17582821", "17694091", "17848202"], "ideal_answer": "The structure fold of the bromodomains is an all-alpha-helical fold, which includes a left-handed four-helix bundle topology, with two short additional helices in a long connecting loop."}
{"question_id": "515deafd298dcd4e51000025", "question": "List the endoscopic diagnoses that have been reported in children with autism", "retrieved_chunks": [{"doc_id": "11007230", "chunk_id": "11007230_5", "score": 5.366944313049316, "text": "This study describes some of the endoscopic and pathological characteristics in a group of children with developmental disorders (affected children) that are associated with behavioral regression and bowel symptoms, and compares them with pediatric controls. METHODS: Ileocolonoscopy and biopsy were performed on 60 affected children (median age 6 yr, range 3-16; 53 male). Developmental diagnoses were autism (50 patients), Asperger's syndrome (five), disintegrative disorder (two), attention deficit hyperactivity disorder (ADHD) (one), schizophrenia (one), and dyslexia (one)."}, {"doc_id": "12846385", "chunk_id": "12846385_0", "score": 0.0751354768872261, "text": "In a sample of 137 children, age 24-96 months, classified as having autism or ASD by the Autism Diagnostic Observation Schedule-Generic, 24 percent had a history of at least one chronic gastrointestinal symptom. The most common symptom was diarrhea, which occurred in 17 percent."}, {"doc_id": "16003132", "chunk_id": "16003132_2", "score": 0.0657196119427681, "text": "Intestinal mucosal pathology, characterized by ileo-colonic lymphoid nodular hyperplasia (LNH) and mild acute and chronic inflammation of the colorectum, small bowel and stomach, has been reported in children with autistic spectrum disorder (ASD)"}], "context": "[11007230:11007230_5] This study describes some of the endoscopic and pathological characteristics in a group of children with developmental disorders (affected children) that are associated with behavioral regression and bowel symptoms, and compares them with pediatric controls. METHODS: Ileocolonoscopy and biopsy were performed on 60 affected children (median age 6 yr, range 3-16; 53 male). Developmental diagnoses were autism (50 patients), Asperger's syndrome (five), disintegrative disorder (two), attention deficit hyperactivity disorder (ADHD) (one), schizophrenia (one), and dyslexia (one).\n[12846385:12846385_0] In a sample of 137 children, age 24-96 months, classified as having autism or ASD by the Autism Diagnostic Observation Schedule-Generic, 24 percent had a history of at least one chronic gastrointestinal symptom. The most common symptom was diarrhea, which occurred in 17 percent.\n[16003132:16003132_2] Intestinal mucosal pathology, characterized by ileo-colonic lymphoid nodular hyperplasia (LNH) and mild acute and chronic inflammation of the colorectum, small bowel and stomach, has been reported in children with autistic spectrum disorder (ASD)", "answer": "<think> Okay, let's tackle this query. The user wants a JSON answer listing endoscopic diagnoses in children with autism, based on the provided evidence. First, I need to look through the evidence documents. Document [11007230:11007230_5] mentions ileocolonoscopy and biopsy in affected children, including those with autism. They found ileo-colonic lymphoid nodular hyperplasia (LNH) and mild inflammation. That's a key point. Then, document [16003132:16003132_2] specifically states that intestinal mucosal pathology with LNH and mild acute/chronic inflammation in the colorectum, small bowel, and", "citations": [{"doc_id": "11007230", "chunk_id": "11007230_5"}, {"doc_id": "16003132", "chunk_id": "16003132_2"}], "candidates": [{"answer": "<think> Okay, let's tackle this query. The user wants a JSON answer listing endoscopic diagnoses in children with autism, based on the provided evidence. First, I need to look through the evidence documents. Document [11007230:11007230_5] mentions ileocolonoscopy and biopsy in affected children, including those with autism. They found ileo-colonic lymphoid nodular hyperplasia (LNH) and mild inflammation. That's a key point. Then, document [16003132:16003132_2] specifically states that intestinal mucosal pathology with LNH and mild acute/chronic inflammation in the colorectum, small bowel, and", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this query. The user is asking for endoscopic diagnoses reported in children with autism. I need to look through the provided evidence to find relevant information. First, document [11007230:11007230_5] mentions ileocolonoscopy and biopsy in affected children, including those with autism. They found ileo-colonic lymphoid nodular hyperplasia (LNH) and mild inflammation in the colorectum, small bowel, and stomach. That's an endoscopic finding. Then, document [16003132:16003132_2] specifically states that intestinal mucosal pathology with ileo-colonic LNH and mild acute/", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this query. The user is asking for endoscopic diagnoses reported in children with autism. I need to look through the provided evidence to find relevant information. First, evidence document [11007230:11007230_5] mentions that 60 affected children (including those with autism) underwent ileocolonoscopy and biopsy. The study found endoscopic and pathological characteristics, like ileo-colonic lymphoid nodular hyperplasia (LNH) and mild inflammation in the colorectum, small bowel, and stomach. That's a key point. Then, document [16003132:16003132_2] specifically states that intestinal muc", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this query. The user is asking for endoscopic diagnoses reported in children with autism. I need to look through the provided evidence to find relevant information. First, looking at evidence [11007230:11007230_5], it mentions ileocolonoscopy and biopsy in affected children, including those with autism. The study found characteristics like lymphoid nodular hyperplasia and inflammation. That seems like an endoscopic finding. Then, evidence [16003132:16003132_2] directly states that intestinal mucosal pathology with ileo-colonic lymphoid nodular hyperplasia and mild inflammation was reported in children with ASD. This is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking for endoscopic diagnoses reported in children with autism. I need to look through the provided evidence to find relevant information. First, looking at the first study (11007230:11007230_5), they did ileocolonoscopy and biopsy on kids with developmental disorders, including autism. They mention endoscopic and pathological characteristics. So maybe they found some endoscopic findings here. The study notes that there were bowel symptoms and compared them to controls. But the specific diagnoses? It says \"some of the endoscopic and pathological characteristics\" but doesn't specify what exactly. Maybe things like ileo-colonic lymphoid nodular hyperplasia? Then, the third study", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking for endoscopic diagnoses reported in children with autism. I need to look at the evidence provided. First, document [11007230:11007230_5] mentions ileocolonoscopy and biopsy in children with developmental disorders, including autism. They found ileo-colonic lymphoid nodular hyperplasia (LNH) and mild inflammation. So that's an endoscopic finding. Then [16003132:16003132_2] also talks about intestinal mucosal pathology with LNH and mild acute/chronic inflammation in the colorectum, small bowel, and stomach. That's another point.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this query. The user is asking for endoscopic diagnoses reported in children with autism. I need to look through the provided evidence to find relevant information. First, evidence [11007230:11007230_5] mentions that 60 affected children (including those with autism) underwent ileocolonoscopy and biopsy. The study found ileo-colonic lymphoid nodular hyperplasia (LNH) and mild inflammation in the colorectum, small bowel, and stomach. That's a direct endoscopic finding linked to autism. Then there's [12846385:12846385_0], which talks about gastrointestinal symptoms like diarrhea,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this query. The user wants a JSON answer with the endoscopic diagnoses in kids with autism, citing the evidence. First, I need to look at the evidence provided. There are three documents here. Document 11007230 mentions ileocolonoscopy and biopsy in children with developmental disorders, including autism. They found ileo-colonic lymphoid nodular hyperplasia (LNH) and inflammation. So that's an endoscopic finding. Document 12846385 talks about gastrointestinal symptoms like diarrhea, but that's a symptom, not a diagnosis. The third document, 16003132, specifically states intestinal mucosal pathology with LNH and mild inflammation in the colore", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["10547242", "11007230", "12907332", "16003132", "22607127", "9585670"], "ideal_answer": "Endoscopic examinations in autistic children have been reported to show : I or II reflux esophagitis, Achalasia, chronic gastritis and chronic duodenitis, mild acute and chronic inflammation of the small bowel and colorectum and Ileo-colonic lymphoid nodular hyperplasia (LNH). The number of Paneth's cells in the duodenal crypts was found to be significantly elevated in autistic children compared with non-autistic control subjects. Low intestinal carbohydrate digestive enzyme activity was reported although there was no abnormality found in pancreatic function. Autistic children have ben reported to have an increased pancreatico-biliary fluid output after intravenous secretin administration."}
{"question_id": "532624ae600967d132000005", "question": "What are the outcomes of Renal sympathetic denervation?", "retrieved_chunks": [{"doc_id": "23890950", "chunk_id": "23890950_0", "score": 8.073639869689941, "text": "Renal sympathetic denervation delivers not only a decrease in blood pressure levels but also renal as well as systemic sympathetic nerve activity. The reduction in blood pressure appears to be sustained over 3 years after the procedure, which implies no counterregulatory mechanism or re-innervation of afferent renal sympathetic nerve so far."}, {"doc_id": "23819768", "chunk_id": "23819768_0", "score": 7.7841081619262695, "text": "Renal sympathetic denervation not only reduces blood pressure but also renal as well as systemic sympathetic nerve activity in such patients. The reduction in blood pressure appears to be sustained over 3 years after the procedure, which suggests absence of re-innervation of renal sympathetic nerves. Safety appears to be adequate."}, {"doc_id": "23774592", "chunk_id": "23774592_0", "score": 7.633447647094727, "text": "Clinical trials of renal sympathetic denervation have shown significant reductions in blood pressure in these patients. Renal sympathetic denervation also reduces heart rate, which is a surrogate marker of cardiovascular risk."}], "context": "[23890950:23890950_0] Renal sympathetic denervation delivers not only a decrease in blood pressure levels but also renal as well as systemic sympathetic nerve activity. The reduction in blood pressure appears to be sustained over 3 years after the procedure, which implies no counterregulatory mechanism or re-innervation of afferent renal sympathetic nerve so far.\n[23819768:23819768_0] Renal sympathetic denervation not only reduces blood pressure but also renal as well as systemic sympathetic nerve activity in such patients. The reduction in blood pressure appears to be sustained over 3 years after the procedure, which suggests absence of re-innervation of renal sympathetic nerves. Safety appears to be adequate.\n[23774592:23774592_0] Clinical trials of renal sympathetic denervation have shown significant reductions in blood pressure in these patients. Renal sympathetic denervation also reduces heart rate, which is a surrogate marker of cardiovascular risk.", "answer": "<think> Okay, let's tackle this query. The user wants a JSON answer with the answer and base_confidence based on the provided evidence. First, I need to understand the question: What are the outcomes of Renal sympathetic denervation? The evidence has three chunks. Let me read through them carefully. Looking at chunk 23890950_0: It mentions decreased blood pressure, reduced renal and systemic sympathetic activity. The reduction is sustained for 3 years, implying no re-innervation. So that's a key point. Chunk 23819768_0 repeats similar info: blood pressure reduction, sustained over 3 years, absence of re-innervation. Also mentions safety is adequate. This reinforces the previous points. Chunk", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this query. The user wants a JSON answer with the answer and base_confidence based on the provided evidence. First, I need to understand the question: What are the outcomes of Renal sympathetic denervation? The evidence has three chunks. Let me read through them carefully. Looking at chunk 23890950_0: It mentions decreased blood pressure, reduced renal and systemic sympathetic activity. The reduction is sustained for 3 years, implying no re-innervation. So that's a key point. Chunk 23819768_0 repeats similar info: blood pressure reduction, sustained over 3 years, absence of re-innervation. Also mentions safety is adequate. This reinforces the previous points. Chunk", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user wants a JSON answer with the outcome of Renal sympathetic denervation, citing the evidence. First, I need to look at the evidence provided. There are three documents here. All of them mention that the procedure reduces blood pressure and systemic/renal sympathetic nerve activity. The first two documents also note that the blood pressure reduction is sustained for 3 years, suggesting no re-innervation. The third mentions a reduction in heart rate as a surrogate for cardiovascular risk. So the main outcomes are decreased blood pressure, reduced sympathetic nerve activity (both renal and systemic), and sustained effects over three years. Also, the third document adds that heart rate is reduced, which is a cardiovascular marker. I need to condense this into a concise answer", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking about the outcomes of Renal sympathetic denervation. Let me look at the evidence provided. First, there are three documents. All of them mention that the procedure reduces blood pressure. The first two documents also talk about reducing renal and systemic sympathetic nerve activity. The third one adds that it reduces heart rate, which is a cardiovascular risk marker. The key points from the evidence are sustained blood pressure reduction over 3 years, reduced sympathetic nerve activity, and decreased heart rate. The confidence here is high because multiple sources agree on these outcomes. The first two documents specifically mention the 3-year sustainability and absence of re-innervation, which strengthens the answer. The third document supports the blood pressure reduction and adds the heart rate part. So the answer should include", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a biomedical answer about the outcomes of renal sympathetic denervation based on the provided evidence. Let me start by reading through the evidence carefully. The user provided three documents. Each seems to mention that renal sympathetic denervation leads to reduced blood pressure, and also reduces renal and systemic sympathetic nerve activity. The first two documents mention that the reduction in blood pressure is sustained for 3 years, suggesting no re-innervation. The third one adds that it also reduces heart rate, which is a cardiovascular risk marker. So the main outcomes are decreased blood pressure, reduced sympathetic nerve activity (both renal and systemic), and sustained effects over 3 years. Also, heart rate reduction is mentioned as a surrogate for cardiovascular risk. Now, I need to condense this", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer based on the evidence provided. Let me start by understanding the question: \"What are the outcomes of Renal sympathetic denervation?\" The user wants a concise answer with citations and a confidence score. First, I'll look at the evidence. There are three documents here. Each mentions that renal sympathetic denervation leads to reduced blood pressure, decreased renal and systemic sympathetic nerve activity, and sustained effects over 3 years. Also, there's mention of reduced heart rate as a cardiovascular risk marker. Document 23890950 talks about no re-innervation, while the others mention safety and long-term effectiveness. The answer should be concise, so I need to combine the key points: blood pressure reduction, decreased sympathetic", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer based on the provided evidence. The user wants a strict JSON with keys \"answer\" and \"base_confidence\". The answer should be concise and include citations in the format [doc_id:chunk_id]. The base confidence is a float between 0 and 1. First, let me read through the evidence carefully. There are three documents here. Each talks about renal sympathetic denervation (RDN) and its outcomes. All three mention reduced blood pressure, decreased renal and systemic sympathetic nerve activity, and sustained effects over 3 years. Also, one mentions a reduction in heart rate as a surrogate for cardiovascular risk. The question is asking for the outcomes of RDN. So I need to combine the key points from all the evidence", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about the outcomes of renal sympathetic denervation. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three documents here. All of them mention that renal sympathetic denervation reduces blood pressure. Document 23890950 says it also affects renal and systemic sympathetic nerve activity, and the blood pressure reduction is sustained for 3 years. Similarly, document 23819768 repeats the same points, noting no re-innervation. Document 23774592 adds that it reduces heart rate, which is a cardiovascular risk marker. So the main outcomes are decreased blood pressure, reduced renal and systemic sympathetic activity, and", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user wants a JSON answer with the answer and base_confidence based on the provided evidence. First, I need to read the question: What are the outcomes of Renal sympathetic denervation? The evidence has three chunks. Each chunk talks about blood pressure reduction, sustained over 3 years, reduced renal and systemic sympathetic activity, and also mentions heart rate reduction as a cardiovascular risk marker. Looking at the answer part, it needs to be concise with citations. The main points from the evidence are the decrease in blood pressure lasting 3 years, reduction in renal and systemic sympathetic activity, and lower heart rate. The confidence should be high since all three sources agree on the blood pressure reduction and its sustainability. They also mention safety, but the question", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["21247927", "22573363", "23176687", "23514712", "23541665", "23774592", "23819768", "23890950", "24029963"], "ideal_answer": "Significant decreases and progressively higher reductions of systolic and diastolic blood pressure were observed after RSD. The complication rate was minimal. Renal sympathetic denervation also reduces heart rate, which is a surrogate marker of cardiovascular risk."}
{"question_id": "5518e7da622b194345000004", "question": "Which MAP kinase phosphorylates the transcription factor c-jun?", "retrieved_chunks": [{"doc_id": "8607977", "chunk_id": "8607977_1", "score": 9.816341400146484, "text": "A candidate for this extended family of MAP kinases is the c-Jun NH2-terminal kinase (Jnk), which binds to and phosphorylates the transcription factor c-Jun at the activating sites Ser-63 and Ser-73."}, {"doc_id": "8607977", "chunk_id": "8607977_0", "score": 9.730976104736328, "text": "A candidate for this extended family of MAP kinases is the c-Jun NH2-terminal kinase (Jnk), which binds to and phosphorylates the transcription factor c-Jun at the activating sites Ser-63 and Ser-73"}, {"doc_id": "23028407", "chunk_id": "23028407_0", "score": 5.489477634429932, "text": "JNK phosphorylates and regulates the activity of transcription factors other than c-Jun, including ATF2, Elk-1, p53 and c-Myc and non-transcription factors, such as members of the Bcl-2 family."}], "context": "[8607977:8607977_1] A candidate for this extended family of MAP kinases is the c-Jun NH2-terminal kinase (Jnk), which binds to and phosphorylates the transcription factor c-Jun at the activating sites Ser-63 and Ser-73.\n[8607977:8607977_0] A candidate for this extended family of MAP kinases is the c-Jun NH2-terminal kinase (Jnk), which binds to and phosphorylates the transcription factor c-Jun at the activating sites Ser-63 and Ser-73\n[23028407:23028407_0] JNK phosphorylates and regulates the activity of transcription factors other than c-Jun, including ATF2, Elk-1, p53 and c-Myc and non-transcription factors, such as members of the Bcl-2 family.", "answer": "<think> Okay, let's tackle this question. The user is asking which MAP kinase phosphorylates the transcription factor c-jun. Looking at the evidence provided, there are three references. First, references 8607977_1 and 8607977_0 both mention Jnk (c-Jun NH2-terminal kinase) phosphorylating c-Jun at Ser-63 and Ser-73. That seems direct. The third reference talks about JNK phosphorylating other factors like ATF2, Elk-1, p53, and c-Myc, but also mentions non-transcription factors. However, the question specifically asks about c-jun, which is a transcription factor. The key here is that the first two references explicitly state", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which MAP kinase phosphorylates the transcription factor c-jun. Looking at the evidence provided, there are three references. First, references 8607977_1 and 8607977_0 both mention Jnk (c-Jun NH2-terminal kinase) phosphorylating c-Jun at Ser-63 and Ser-73. That seems direct. The third reference talks about JNK phosphorylating other factors like ATF2, Elk-1, p53, and c-Myc, but also mentions non-transcription factors. However, the question specifically asks about c-jun, which is a transcription factor. The key here is that the first two references explicitly state", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which MAP kinase phosphorylates the transcription factor c-jun. Looking at the evidence provided, there are three chunks. First, chunk 8607977_1 and 便会7977_0 both mention Jnk (c-Jun NH2-terminal kinase) phosphorylating c-Jun at Ser-63 and Ser-73. The other chunk, 23028407_0, says JNK also acts on other factors like ATF2, Elk-1, p53, c-Myc, and Bcl-2 family members. So the answer should be Jnk, as it's directly mentioned in the first two chunks. The confidence is high", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's see. The question is asking which MAP kinase phosphorylates the transcription factor c-jun. The evidence provided has three chunks. First, chunk 8607977_1 and 8607977_0 both mention that Jnk binds to and phosphorylates c-Jun at Ser-63 and Ser-73. So that's a direct statement linking Jnk to c-jun. The other chunk, 23028407_0, talks about JNK phosphorylating other factors like ATF2, Elk-1, p53, c-Myc, etc., but not specifically c-jun. So the answer should be Jnk (c-Jun NH2-terminal kinase). The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which MAP kinase phosphorylates the transcription factor c-jun. Looking at the evidence provided, there are a few documents mentioned. First, document 8607977 has two chunks. Both mention that Jnk (c-Jun NH2-terminal kinase) binds to and phosphorylates c-Jun at Ser-63 and Ser-73. That's pretty direct. Then there's another document, 23028407, which says JNK phosphorylates other transcription factors like ATF2, Elk-1, p53, and c-Myc, but the question is specifically about c-jun. So the answer should be Jnk, based on the first two chunks. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which MAP kinase phosphorylates the transcription factor c-jun. Looking at the evidence provided, there are three chunks. The first two chunks (8607977:8607977_1 and 8607977:8607977_0) both mention that Jnk binds to and phosphorylates c-Jun at Ser-63 and Ser-73. The third chunk (23028407:2302840ity_0) says JNK phosphorylates other factors like ATF2, Elk-1, p53, and c-Myc, but also mentions non-transcription factors. However", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which MAP kinase phosphorylates the transcription factor c-jun. Looking at the evidence provided, there are three chunks. The first two chunks (both from 8607977) mention that Jnk binds to and phosphorylates c-Jun at Ser-63 and Ser-73. The third chunk (from 23028407) says JNK phosphorylates other factors like ATF2, Elk-1, p53, c-Myc, etc., but also mentions non-transcription factors. However, the question specifically asks about c-jun, which is a transcription factor. So the direct answer is Jnk (c-Jun NH2-terminal kinase). The first two chunks", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which MAP kinase phosphorylates the transcription factor c-jun. Looking at the evidence provided, there are a few documents mentioned. First, documents 8607977:8607977_1 and 8607977:8607977_0 both mention that Jnk (c-Jun NH2-terminal kinase) phosphorylates c-Jun at Ser-63 and Ser-73. The other document, 23028407:23028407_0, talks about JNK phosphorylating other factors like ATF2, Elk-1, p53, and c-Myc, but", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which MAP kinase phosphorylates the transcription factor c-jun. Looking at the evidence provided, there are a few documents here. First, document 8607977 has two chunks. Both mention that Jnk binds to and phosphorylates c-Jun at Ser-63 and Ser-73. So that's pretty direct. Then there's another document, 23028407, which says JNK phosphorylates other factors like ATF2, Elk-1, p53, and c-Myc, but the question is specifically about c-jun. So the answer should be Jnk, also known as c-Jun NH2-terminal kinase. The confidence here is high because", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["15228586", "15637069", "15708845", "23028407", "23147205", "23385061", "24113186", "24139673", "24144051", "24252081", "24270002", "24272171", "24285252", "24291243", "24300195", "24321066", "24321566", "8607977"], "ideal_answer": "c-Jun is phosphorylated by c-Jun NH2-terminal kinase (JNK). An in vitro kinase assay revealed that c-Jun phosphorylation is primarily mediated via activated c-Jun N-terminal protein kinase (JNK)."}
{"question_id": "530a5117970c65fa6b000007", "question": "What is the meaning of the acronym \"TAILS\" used in protein N-terminomics?", "retrieved_chunks": [{"doc_id": "23667905", "chunk_id": "23667905_0", "score": 4.396615028381348, "text": "analysis of N- terminomics data generated by terminal amine isotopic labeling of substrates (TAILS) enables high confidence peptide to protein assignment, protein N-terminal characterization and annotation, and for protease analysis readily allows protease substrate discovery with high confidence."}, {"doc_id": "21604129", "chunk_id": "21604129_1", "score": 2.994138717651367, "text": "Identification of proteolytic products and natural protein N-termini by Terminal Amine Isotopic Labeling of Substrates (TAILS)."}, {"doc_id": "21604129", "chunk_id": "21604129_0", "score": 2.482731342315674, "text": "Here we present in detail the steps required to perform our recently described approach we call Terminal Amine Isotopic Labeling of Substrates (TAILS), a combined N-terminomics and protease substrate discovery degradomics platform for the simultaneous quantitative and global analysis of the N-terminome and proteolysis in one MS/MS experiment."}], "context": "[23667905:23667905_0] analysis of N- terminomics data generated by terminal amine isotopic labeling of substrates (TAILS) enables high confidence peptide to protein assignment, protein N-terminal characterization and annotation, and for protease analysis readily allows protease substrate discovery with high confidence.\n[21604129:21604129_1] Identification of proteolytic products and natural protein N-termini by Terminal Amine Isotopic Labeling of Substrates (TAILS).\n[21604129:21604129_0] Here we present in detail the steps required to perform our recently described approach we call Terminal Amine Isotopic Labeling of Substrates (TAILS), a combined N-terminomics and protease substrate discovery degradomics platform for the simultaneous quantitative and global analysis of the N-terminome and proteolysis in one MS/MS experiment.", "answer": "<think> Okay, let's tackle this question about the acronym TAILS in protein N-terminomics. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three chunks here. Let me read through them. The first chunk [23667905:23667905_0] mentions that TAILS is used for N-terminomics data analysis, enabling peptide-to-protein assignment, protein N-terminal characterization, and protease substrate discovery. The second chunk [21604129:21604129_1] says TAILS is used to identify proteolytic products and natural N-termini. The third chunk [", "citations": [{"doc_id": "23667905", "chunk_id": "23667905_0"}, {"doc_id": "21604129", "chunk_id": "21604129_1"}], "candidates": [{"answer": "<think> Okay, let's tackle this question about the acronym TAILS in protein N-terminomics. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three chunks here. Let me read through them. The first chunk [23667905:23667905_0] mentions that TAILS is used for N-terminomics data analysis, enabling peptide-to-protein assignment, protein N-terminal characterization, and protease substrate discovery. The second chunk [21604129:21604129_1] says TAILS is used to identify proteolytic products and natural N-termini. The third chunk [", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to figure out what TAILS stands for in the context of protein N-terminomics. Let me look at the evidence provided. The first evidence snippet mentions \"terminal amine isotopic labeling of substrates (TAILS)\" and explains that it's used for N-terminomics data analysis. The second snippet also refers to \"Terminal Amine Isotopic Labeling of Substrates (TAILS)\" in the context of identifying proteolytic products and N-terminal regions. The third one talks about the steps for TAILS as a method combining N-terminomics and protease substrate discovery. So putting this together, TAILS is an acronym that stands for Terminal Amine Isotopic Labeling of Substrates. The key here is to make sure", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to figure out what TAILS stands for in the context of protein N-terminomics. Let me look at the evidence provided. The first document mentions \"terminal amine isotopic labeling of substrates (TAILS)\" and explains that it's used for N-terminomics data analysis. The second document also refers to \"Terminal Amine Isotopic Labeling of Substrates (TAILS)\" in the context of identifying proteolytic products and natural N-termini. The third one talks about the steps for TAILS as a method combining N-terminomics and protease substrate discovery. So, putting that together, TAILS is an acronym for Terminal Amine Isotopic Labeling of Substrates. The key here is to make sure", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about the acronym TAILS in protein N-terminomics. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three chunks here. Let me read through them carefully. The first chunk [23667905:23667905_0] mentions that TAILS is used for N-terminomics data analysis, enabling peptide-to-protein assignment, protein N-terminal characterization, and protease substrate discovery. The second chunk [21604129:21604129_1] refers to TAILS as a method for identifying proteolytic products and natural N-termini. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question about the acronym TAILS in protein N-terminomics. The user wants a concise answer with citations and a confidence level. First, I need to look at the evidence provided. There are three references here. Let me read through them carefully. The first one (23667905:23667905_0) mentions that TAILS is used for analyzing N-terminomics data, enabling peptide-to-protein assignment, protein N-terminal characterization, and protease substrate discovery. The second reference (21604129:21604129_1) says TAILS is used to identify proteolytic products and natural N-termini. The third one", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to figure out what TAILS means in the context of protein N-terminomics. Let's look at the evidence provided. The first evidence snippet says that TAILS is used in N-terminomics data analysis for things like peptide-to-protein assignment and N-terminal characterization. The second one mentions identifying proteolytic products and natural N-termini using TAILS. The third one explains that TAILS is a method combining N-terminomics and protease substrate discovery, allowing quantitative analysis of the N-terminome and proteolysis in one MS/MS experiment. So putting this together, TAILS stands for Terminal Amine Isotopic Labeling of Substrates. It's a technique used in N-terminomics to study protein N-terminal regions", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to figure out what TAILS stands for in the context of protein N-terminomics. Let me look at the evidence provided. The first evidence snippet mentions \"terminal amine isotopic labeling of substrates (TAILS)\" and explains that it's used for N-terminomics data analysis. The second one directly states \"Terminal Amine Isotopic Labeling of Substrates (TAILS)\" as the method. The third one also refers to TAILS as a method for N-terminomics and protease substrate discovery. So, putting this together, TAILS stands for Terminal Amine Isotopic Labeling of Substrates. The answer should be concise and include citations from the documents provided. The confidence level is pretty high since all three snippets", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking about the meaning of the acronym \"TAILS\" in the context of protein N-terminomics. Let me look at the evidence provided. First, the evidence has three chunks. The first one (23667905:23667905_0) mentions that TAILS is used for analyzing N-terminomics data, enabling peptide to protein assignment, protein N-terminal characterization, and protease substrate discovery. The second chunk (21604129:21604129_1) refers to identifying proteolytic products and natural N-termini using TAILS. The third chunk (21604129:21604", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["20305284", "21604127", "21604129", "22367194", "22577022", "23667905"], "ideal_answer": "TAILS stands for \"Terminal Amine Isotopic Labeling of Substrates\""}
{"question_id": "56bf365eef6e39474100000e", "question": "Do mutations of AKT1 occur in meningiomas?", "retrieved_chunks": [{"doc_id": "24096618", "chunk_id": "24096618_1", "score": 9.515704154968262, "text": "AKT1E17K mutations were exclusively seen in meningiomas and occurred in 65 of 958 of these tumors. A strong preponderance was seen in the variant of meningothelial meningioma WHO grade I of basal and spinal localization. In contrast, AKT1E17K mutations were rare in WHO grade II and absent in WHO grade III meningiomas."}, {"doc_id": "23475883", "chunk_id": "23475883_3", "score": 9.238105773925781, "text": "SMO and AKT1 mutations occur in non-NF2 meningiomas."}, {"doc_id": "23475883", "chunk_id": "23475883_2", "score": 9.040596008300781, "text": "SMO and AKT1 mutations occur in non-NF2 meningiomas"}], "context": "[24096618:24096618_1] AKT1E17K mutations were exclusively seen in meningiomas and occurred in 65 of 958 of these tumors. A strong preponderance was seen in the variant of meningothelial meningioma WHO grade I of basal and spinal localization. In contrast, AKT1E17K mutations were rare in WHO grade II and absent in WHO grade III meningiomas.\n[23475883:23475883_3] SMO and AKT1 mutations occur in non-NF2 meningiomas.\n[23475883:23475883_2] SMO and AKT1 mutations occur in non-NF2 meningiomas", "answer": "<think> Okay, let's tackle this question. The user is asking if mutations of AKT1 occur in meningiomas. I need to check the provided evidence. Looking at the first piece of evidence, [24096618:24096618_1], it clearly states that AKT1E17K mutations were found exclusively in meningiomas, specifically 65 out of 958 tumors. That's a direct confirmation. The other two references, [23475883:23475883_3] and [23475883:23475883_2], both mention SMO and AKT1 mutations in", "citations": [{"doc_id": "24096618", "chunk_id": "24096618_1"}, {"doc_id": "23475883", "chunk_id": "23475883_3"}, {"doc_id": "23475883", "chunk_id": "23475883_2"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if mutations of AKT1 occur in meningiomas. Looking at the evidence provided, there are three references. First, the document 24096618:24096618_1 clearly states that AKT1E17K mutations were exclusively seen in meningiomas, specifically mentioning 65 out of 958 tumors. This gives a direct answer that AKT1 mutations do occur in meningiomas. The confidence here is high because it's a specific study with numbers. Then, the other two documents (23475883:23475883_3 and 2347588", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if mutations of AKT1 occur in meningiomas. I need to look at the provided evidence to find answers. First, evidence document 24096618:24096618_1 mentions that AKT1E17K mutations are exclusively found in meningiomas, specifically in 65 out of 958 tumors. It also specifies that these mutations are more common in WHO grade I meningothelial meningiomas located in the basal and spinal areas. So this directly supports that AKT1 mutations do occur in meningiomas. Another document, 23475883:23475883_3", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking if mutations of AKT1 occur in meningiomas. Let me look at the evidence provided. First, there's the document 24096618 which mentions AKT1E17K mutations are exclusively seen in meningiomas, specifically 65 out of 958 tumors. It also says these mutations are more common in WHO grade I meningothelial meningiomas located in the base and spinal areas. So that's a clear indication that AKT1 mutations do occur in meningiomas. Then there are two entries from 23475883, both stating that SMO and AKT1 mutations occur in non-NF2 meningiomas. Non-NF2 meningi", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if mutations of AKT1 occur in meningiomas. I need to check the provided evidence. Looking at the first piece of evidence, [24096618:24096618_1], it clearly states that AKT1E17K mutations were found exclusively in meningiomas, specifically 65 out of 958 tumors. That's a direct confirmation. The other two references, [23475883:23475883_3] and [23475883:23475883_2], both mention SMO and AKT1 mutations in", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if mutations of AKT1 occur in meningiomas. I need to check the provided evidence to find answers. First, looking at the evidence documents. The first one, 24096618:24096618_1, says that AKT1E17K mutations were exclusively seen in meningiomas, occurring in 65 out of 958 tumors. It also mentions a strong preponderance in certain types of meningothelial meningiomas. So this directly states that AKT1 mutations do occur in meningiomas. The other two documents, 23475883:23475883", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking if mutations of AKT1 occur in meningiomas. Let me look at the evidence provided. First, there's the document 24096618 which mentions AKT1E17K mutations exclusively in meningiomas, specifically 65 out of 958 tumors. It also says these mutations are more common in WHO grade I meningothelial meningiomas located in the base and spinal areas. So that's a clear indication that AKT1 mutations do occur in meningiomas. Then there are two entries from 23475883 stating that SMO and AKT1 mutations occur in non-NF2 meningiomas. Non-NF2 meningiomas are a type", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if mutations of AKT1 occur in meningiomas. I need to look at the provided evidence to find answers. First, looking at the first piece of evidence: [24096618:24096618_1] says that AKT1E17K mutations were exclusively seen in meningiomas, occurring in 65 out of 958 tumors. It also mentions a strong preponderance in certain types of meningothelial meningiomas. So this directly states that AKT1 mutations are present in meningiomas. The other two pieces of evidence, [23475883:2347588", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if mutations of AKT1 occur in meningiomas. I need to check the provided evidence to find answers. First, looking at the evidence documents. The first one, 24096618:24096618_1, says that AKT1E17K mutations were exclusively seen in meningiomas, occurring in 65 out of 958 tumors. It also mentions a strong preponderance in certain grades and locations. So this directly states that AKT1 mutations are present in meningiomas. The other two documents, 23475883:23475883_3 and 2", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["23334667", "23348505", "23475883", "24096618", "25146167", "25857641"], "ideal_answer": "Yes, AKT1 mutation occurs in meningiomas."}
{"question_id": "52bf202003868f1b06000018", "question": "What are the main indications of lacosamide?", "retrieved_chunks": [{"doc_id": "17433624", "chunk_id": "17433624_2", "score": 5.424102306365967, "text": "These results suggest that lacosamide may have the potential to be clinically useful for at least the treatment of generalized tonic-clonic and partial-onset epilepsies, and support ongoing clinical trials in these indications."}, {"doc_id": "17433624", "chunk_id": "17433624_0", "score": 2.210594415664673, "text": "Lacosamide was effective against sound-induced seizures in the genetically susceptible Frings mouse, against maximal electroshock test (MES)-induced seizures in rats and mice, in the rat hippocampal kindling model of partial seizures, and in the 6Hz model of psychomotor seizures in mice."}, {"doc_id": "20677583", "chunk_id": "20677583_2", "score": 1.9226142168045044, "text": "Lacosamide (LCM) is a newer antiepileptic drug with a dual mode of action."}], "context": "[17433624:17433624_2] These results suggest that lacosamide may have the potential to be clinically useful for at least the treatment of generalized tonic-clonic and partial-onset epilepsies, and support ongoing clinical trials in these indications.\n[17433624:17433624_0] Lacosamide was effective against sound-induced seizures in the genetically susceptible Frings mouse, against maximal electroshock test (MES)-induced seizures in rats and mice, in the rat hippocampal kindling model of partial seizures, and in the 6Hz model of psychomotor seizures in mice.\n[20677583:20677583_2] Lacosamide (LCM) is a newer antiepileptic drug with a dual mode of action.", "answer": "<think> Okay, so the user is asking about the main indications of lacosamide. Let me look at the evidence provided. First, there's document [17433624:1743362ity_2] which mentions that lacosamide might be useful for generalized tonic-clonic and partial-onset epilepsies, supporting clinical trials in these areas. That seems like a direct indication. Then, another entry [17433624:17433624_0] talks about effectiveness in various animal models, but those are experimental results, not human indications. The third document [20677583:20677583_2] states it's a", "citations": [{"doc_id": "17433624", "chunk_id": "1743362ity_2"}, {"doc_id": "17433624", "chunk_id": "17433624_0"}, {"doc_id": "20677583", "chunk_id": "20677583_2"}], "candidates": [{"answer": "<think> Okay, so the user is asking about the main indications of lacosamide. Let me look at the evidence provided. First, there's document [17433624:1743362ity_2] which mentions that lacosamide might be useful for generalized tonic-clonic and partial-onset epilepsies, supporting clinical trials in these areas. That seems like a direct indication. Then, another entry [17433624:17433624_0] talks about effectiveness in various animal models, but those are experimental results, not human indications. The third document [20677583:20677583_2] states it's a", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this query. The user wants the main indications of lacosamide based on the provided evidence. First, I need to look at the evidence snippets. The first one says that lacosamide may be useful for generalized tonic-clonic and partial-onset epilepsies, supporting clinical trials. That's a direct mention of indications. The second snippet talks about effectiveness in various animal models, but those are preclinical studies. The third snippet mentions it's a newer drug with dual action, but that's more about its mechanism than indications. So the main indications from the evidence are generalized tonic-clonic and partial-onset epilepsies. The citation here is [17433624:17433627_2].", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The question is about the main indications of lacosamide. Let me look at the evidence. First, document [17433624:17433624_2] says that lacosamide may be useful for generalized tonic-clonic and partial-onset epilepsies, supporting clinical trials in these areas. That seems like a direct indication. Then, [17433624:17433624_0] mentions effectiveness in various seizure models, but those are animal studies. The third document [20677583:20677583_2] states it's a", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question about the main indications of lacosamide. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three chunks here. Let me go through each one. The first chunk [17433624:17433628_2] mentions that lacosamide might be useful for generalized tonic-clonic and partial-onset epilepsies, supporting clinical trials. That's a direct mention of indications. The second chunk [17433624:17433624_0] talks about effectiveness in various animal models, but those are preclinical studies, not human indications. The third chunk [", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question about the main indications of lacosamide. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. The first document says that lacosamide may be useful for generalized tonic-clonic and partial-onset epilepsies, supporting clinical trials. The second mention mentions effectiveness in various models like sound-induced seizures, MES test, hippocampal kindling, and 6Hz model. The third document states it's a newer antiepileptic drug with dual action. The question is about main indications, so I should focus on the clinical uses mentioned. The first evidence directly talks about generalized tonic-clonic and partial-onset epilepsies. The other documents talk about animal models, but", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about the main indications of lacosamide. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. The first document says that lacosamide may be useful for generalized tonic-clonic and partial-onset epilepsies, supporting clinical trials. The second mentions effectiveness in various models like sound-induced seizures, MES test, hippocampal kindling, and 6Hz model. The third document states it's a newer antiepileptic drug with dual action. The question is about main indications, so I should focus on the clinical uses mentioned. The first evidence directly mentions generalized tonic-clonic and partial-onset epilepsies. The other documents talk about models and mechanisms but not specific", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user wants the main indications of lacosamide based on the provided evidence. First, I need to look at the evidence snippets. The first one mentions that lacosamide may be useful for generalized tonic-clonic and partial-onset epilepsies, with ongoing trials. The second snippet says it's effective in various animal models for different seizure types. The third note states it's a newer antiepileptic drug with dual action. The question is about main indications, so I should focus on the clinical uses mentioned. The first evidence directly mentions generalized tonic-clonic and partial-onset epilepsies. The second snippet talks about different models but those are animal studies. The third is just a general statement about being an antiepileptic", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user wants me to generate a candidate biomedical answer about the main indications of lacosamide based on the provided evidence. Let me start by carefully reading through the evidence given. First, looking at the evidence snippets. The first one [17433624:17433624_2] says that lacosamide may be useful for generalized tonic-clonic and partial-onset epilepsies, supporting ongoing clinical trials in these areas. That seems like a direct mention of indications. The second snippet [17433624:17433624_0] lists various animal models where lacosamide was effective, but those are preclinical studies. The third snippet [206", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["17433624", "17461888", "20677583", "21271304", "21301338", "21861814", "23288091", "23648276"], "ideal_answer": "Lacosamide is an anti-epileptic drug, licensed for refractory partial-onset seizures. In addition to this, it has demonstrated analgesic activity in various animal models. Apart from this, LCM has demonstrated potent effects in animal models for a variety of CNS disorders like schizophrenia and stress induced anxiety."}
{"question_id": "552fac4fbc4f83e828000006", "question": "Which fusion protein is involved in the development of Ewing sarcoma?", "retrieved_chunks": [{"doc_id": "16697960", "chunk_id": "16697960_2", "score": 9.145721435546875, "text": "Our understanding of Ewing's sarcoma development mediated by the EWS/FLI fusion protein has been limited by a lack of knowledge regarding the tumor cell of origin"}, {"doc_id": "25432018", "chunk_id": "25432018_0", "score": 8.639945030212402, "text": "EWS-FLI1 is an oncogenic fusion protein implicated in the development of Ewing's sarcoma family tumors (ESFT)"}, {"doc_id": "16697960", "chunk_id": "16697960_3", "score": 8.251150131225586, "text": "Thus, we developed a highly validated transcriptional profile for the EWS/FLI fusion protein and identified a critical target gene in Ewing's sarcoma development."}], "context": "[16697960:16697960_2] Our understanding of Ewing's sarcoma development mediated by the EWS/FLI fusion protein has been limited by a lack of knowledge regarding the tumor cell of origin\n[25432018:25432018_0] EWS-FLI1 is an oncogenic fusion protein implicated in the development of Ewing's sarcoma family tumors (ESFT)\n[16697960:16697960_3] Thus, we developed a highly validated transcriptional profile for the EWS/FLI fusion protein and identified a critical target gene in Ewing's sarcoma development.", "answer": "<think> Okay, let's tackle this question. The user is asking which fusion protein is involved in the development of Ewing sarcoma. The evidence provided has three entries. First, looking at the evidence, the first one [16697960:16697960_2] mentions EWS/FLI fusion protein but states that understanding is limited. The second entry [25432018:25432018_0] explicitly says EWS-FLI1 is an oncogenic fusion protein implicated in Ewing's sarcoma. The third entry [16697960:16697960_3] again refers to EWS/FLI", "citations": [{"doc_id": "16697960", "chunk_id": "16697960_2"}, {"doc_id": "25432018", "chunk_id": "25432018_0"}, {"doc_id": "16697960", "chunk_id": "16697960_3"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which fusion protein is involved in the development of Ewing sarcoma. The evidence provided has three entries. First, looking at the evidence, the first one [16697960:16697960_2] mentions EWS/FLI fusion protein but states that understanding is limited. The second entry [25432018:25432018_0] explicitly says EWS-FLI1 is an oncogenic fusion protein implicated in Ewing's sarcoma. The third entry [16697960:16697960_3] again refers to EWS/FLI", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which fusion protein is involved in the development of Ewing sarcoma. Looking at the evidence provided, there are three references. First, reference [16697960:16697960_2] mentions the EWS/FLI fusion protein but states that our understanding is limited. Then, [25432018:25432018_0] clearly states that EWS-FLI1 is an oncogenic fusion protein implicated in Ewing's sarcoma. The third reference again talks about EWS/FLI but doesn质 mention the specific name. So, the key here is to identify the correct fusion protein. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which fusion protein is involved in the development of Ewing sarcoma. Looking at the evidence provided, there are three references. First, reference [16697960:16697960_2] mentions the EWS/FLI fusion protein but states that our understanding is limited. Then, reference [25432018:25432018_0] clearly states that EWS-FLI1 is an oncogenic fusion protein implicated in Ewing's sarcoma. The third reference again talks about EWS/FLI but doesn't specify the exact name. So, the key here is to identify the correct fusion protein.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which fusion protein is involved in the development of Ewing sarcoma. Looking at the evidence provided, there are three references. First, reference [16697960:16697960_2] mentions the EWS/FLI fusion protein but states that our understanding is limited. Then, [25432018:25432018_0] explicitly says EWS-FLI1 is an oncogenic fusion protein implicated in Ewing's sarcoma. The third reference again talks about EWS/FLI, but it's more about the transcriptional profile. So, the key here is to identify the correct fusion protein", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which fusion protein is involved in the development of Ewing sarcoma. The evidence provided has three entries. First, looking at the evidence: the first one [16697960:16697960_2] mentions EWS/FLI fusion protein but says our understanding is limited. The second entry [25432018:25432018_0] explicitly states that EWS-FLI1 is an oncogenic fusion protein implicated in Ewing's sarcoma. The third entry [16697960:16697960_3] again refers to EWS/FL", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which fusion protein is involved in the development of Ewing sarcoma. The evidence provided has three entries. First, looking at the evidence: The first entry [16697960:16697960_2] mentions EWS/FLI fusion protein but states that understanding is limited. The second entry [25432018:25432018_0] explicitly says EWS-FLI1 is an oncogenic fusion protein implicated in Ewing's sarcoma. The third entry [16697960:16697960_3] again refers to EWS/FL", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which fusion protein is involved in the development of Ewing sarcoma. The evidence provided has three entries. First, looking at the evidence, the first document [16697960:16697960_2] mentions EWS/FLI fusion protein but states that understanding is limited. The second document [25432018:25432018_0] explicitly says EWS-FLI1 is an oncogenic fusion protein implicated in Ewing's sarcoma. The third document [16697960:16697960_3] again refers to EWS/FLI", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which fusion protein is involved in the development of Ewing sarcoma. Looking at the evidence provided, there are three references. First, reference [16697960:16697960_2] mentions EWS/FLI fusion protein but states that understanding is limited. Then, [25432018:25432018_0] clearly states EWS-FLI1 is the oncogenic fusion protein linked to Ewing's sarcoma. The third reference again talks about EWS/FLI fusion protein. So, the key here is that both references 25432018:0 and", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["16206264", "16697960", "17250957", "17453169", "18256529", "18485618", "19718047", "20691659", "21680731", "21979944", "22241085", "22723308", "23750284", "23894528", "24481407", "25162919", "25401475", "25432018", "25483190"], "ideal_answer": "Ewing sarcoma is the second most common bone malignancy in children and young adults. In almost 95% of the cases, it is driven by oncogenic fusion protein EWS/FLI1, which acts as an aberrant transcription factor, that upregulates or downregulates target genes, leading to cellular transformation."}
{"question_id": "56be0da3ef6e394741000007", "question": "List Hemolytic Uremic Syndrome Triad.", "retrieved_chunks": [{"doc_id": "24161037", "chunk_id": "24161037_0", "score": 8.726425170898438, "text": "Hemolytic uremic syndrome (HUS) is a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure."}, {"doc_id": "17705684", "chunk_id": "17705684_0", "score": 8.694110870361328, "text": "Hemolytic uremic syndrome is a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure"}, {"doc_id": "16387683", "chunk_id": "16387683_0", "score": 8.663264274597168, "text": "Hemolytic uremic syndrome (HUS) is a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure"}], "context": "[24161037:24161037_0] Hemolytic uremic syndrome (HUS) is a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure.\n[17705684:17705684_0] Hemolytic uremic syndrome is a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure\n[16387683:16387683_0] Hemolytic uremic syndrome (HUS) is a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure", "answer": "<think> Okay, the user is asking for the triad of Hemolytic Uremic Syndrome (HUS). Let me check the evidence provided. Looking at the evidence documents, each of them mentions the same three components: microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. All three sources [24161037:24161037_0], [17705684:17705684_0], and [16387683:16387683_0] confirm this triad. The answer is consistent across all the references, so the confidence level should be high. Since all three", "citations": [{"doc_id": "24161037", "chunk_id": "24161037_0"}, {"doc_id": "17705684", "chunk_id": "17705684_0"}, {"doc_id": "16387683", "chunk_id": "16387683_0"}], "candidates": [{"answer": "<think> Okay, so the user wants me to generate a candidate biomedical answer for the question \"List Hemolytic Uremic Syndrome Triad.\" The evidence provided has three chunks, all from different document IDs but all stating the same triad: microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. First, I need to make sure that the answer is concise and includes citations in the format [doc_id:chunk_id]. The user specified strict JSON with keys \"answer\" and \"base_confidence\". The answer should list the three components of the triad. Looking at the evidence, all three chunks are identical in their content. So I can use any of them, but since they're all the same, maybe pick the first", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user wants me to generate a candidate biomedical answer for the question \"List Hemolytic Uremic Syndrome Triad.\" The evidence provided has three chunks, all from different documents but all stating the same triad: microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. First, I need to make sure I understand what's being asked. The question is asking for the three components that make up the triad of HUS. The evidence clearly lists those three elements in each chunk. The answer should be concise, so I'll list them as a single sentence or short phrase. Next, the user wants the answer to include citations in the format [doc_id:chunk_id]. Each of the three chunks is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking for the triad of Hemolytic Uremic Syndrome (HUS). Let me check the evidence provided. Looking at the evidence, there are three documents mentioned. Each of them states that HUS is a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. The document IDs are 24161037, 17705684, and 16387683. All three chunks seem to confirm the same triad. The answer needs to be concise and include citations in the format [doc_id:chunk_id]. Since all three sources agree, I can pick one of them. Maybe the first one,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking for the triad of Hemolytic Uremic Syndrome (HUS). Let me check the evidence provided. Looking at the three documents, each one mentions the same three components: microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. All three sources are consistent here. The answer seems straightforward. I need to make sure the answer is concise and includes citations. The documents are labeled with [doc_id:chunk_id], so each chunk is 24161037_0, 17705684_0, and 16387683_0. Since all three cite the same triad, I can pick one of", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user wants me to generate a candidate biomedical answer about the triad of Hemolytic Uremic Syndrome (HUS) using the provided evidence. First, I need to make sure I understand what they're asking for. The question is straightforward: list the triad. Looking at the evidence, there are three documents cited. Each of them mentions the same triad: microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. All three sources agree on this, so that's good. I need to present this information concisely in the answer, including citations. Now, the user specified that the answer should be in strict JSON with keys \"answer\" and \"base_confidence\".", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking for the triad of Hemolytic Uremic Syndrome (HUS). Let me check the evidence provided. Looking at the evidence documents, each of them mentions the same three components: microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. All three sources [24161037:24161037_0], [17705684:17705684_0], and [16387683:16387683_0] confirm this triad. The answer is consistent across all the references, so the confidence level should be high. Since all three", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, the user is asking for the triad of Hemolytic Uremic Syndrome (HUS). Let me check the evidence provided. Looking at the three documents, they all mention the same three components: microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. The document IDs are different, but the content is consistent. I need to make sure that each part of the triad is correctly cited. Each of the three evidence snippets supports the same answer. The model's confidence should be high since all sources agree. The answer should be concise, listing the three elements with their citations. The base_confidence can be 1.0 because all provided evidence confirms the same triad. I'll structure the JSON accordingly", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user wants me to generate a candidate biomedical answer for the question \"List Hemolytic Uremic Syndrome Triad.\" The evidence provided has three chunks, all from different document IDs but they all seem to say the same thing. Let me check each one. The first chunk [24161037:24161037_0] states that HUS is a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. The second and third chunks are similar, just with different document IDs but same content. So all three sources agree on the same triad. The answer needs to be concise and include citations in the format [doc_id:chunk_id].", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["16006690", "16387683", "17705684", "19227723", "19625716", "20209841", "20499172", "20865638", "22956028", "23380391", "24161037", "24516709", "24548192", "25011592", "25280590", "25345382", "25765799", "26265890", "2831711", "7487540", "8589282"], "ideal_answer": "Hemolytic uremic syndrome (HUS) is a clinical syndrome characterized by the triad of anaemia, thrombocytopenia, renal failure."}
{"question_id": "5158644cd24251bc0500008e", "question": "Does physical activity influence gut hormones?", "retrieved_chunks": [{"doc_id": "21554896", "chunk_id": "21554896_0", "score": 6.420056343078613, "text": "ur data suggest that the control of spontaneous physical activity by gut hormones or their neuropeptide targets may represent an important mechanistic component of energy balance regulation"}, {"doc_id": "11321513", "chunk_id": "11321513_0", "score": 3.98300838470459, "text": "We conclude that strenuous physical exercise; 1) fails to affect plasma leptin level but when performed after meal but not after blood withdrawal it results in an increase and fall in plasma leptin, and 2) the release of gut hormones (gastrin, CCK and PP) and stress hormones (norepinephrine, cortisol, GH) increase immediately after exercise independently of feeding or blood donation"}, {"doc_id": "36369926", "chunk_id": "36369926_0", "score": 1.4696956872940063, "text": "Physical activity is associated with reduced risks of colorectal cancer (CRC) incidence, recurrence and mortality. While these findings are consistent, the mechanism/s underlying this association remain unclear. Growing evidence supports the many ways in which differing characteristics of the gut microbiota can be tumourigenic or protective against CRC. CRC is characterised by significant dysbiosis including reduced short chain fatty acid-producing bacteria. Recent findings suggest that exercise can modify the gut microbiota, and these changes are inverse to the changes seen with CRC; however, this exercise-microbiota interaction is currently understudied in CRC. This review summarises parallel areas of research that are rapidly developing: The exercise-gut microbiota research and cancer-gut microbiota research and highlights the salient similarities. Preliminary evidence suggests that these areas are linked, with exercise mediating changes that promote the antitumorigenic characteristics of the gut microbiota."}], "context": "[21554896:21554896_0] ur data suggest that the control of spontaneous physical activity by gut hormones or their neuropeptide targets may represent an important mechanistic component of energy balance regulation\n[11321513:11321513_0] We conclude that strenuous physical exercise; 1) fails to affect plasma leptin level but when performed after meal but not after blood withdrawal it results in an increase and fall in plasma leptin, and 2) the release of gut hormones (gastrin, CCK and PP) and stress hormones (norepinephrine, cortisol, GH) increase immediately after exercise independently of feeding or blood donation\n[36369926:36369926_0] Physical activity is associated with reduced risks of colorectal cancer (CRC) incidence, recurrence and mortality. While these findings are consistent, the mechanism/s underlying this association remain unclear. Growing evidence supports the many ways in which differing characteristics of the gut microbiota can be tumourigenic or protective against CRC. CRC is characterised by significant dysbiosis including reduced short chain fatty acid-producing bacteria. Recent findings suggest that exercise can modify the gut microbiota, and these changes are inverse to the changes seen with CRC; however, this exercise-microbiota interaction is currently understudied in CRC. This review summarises parallel areas of research that are rapidly developing: The exercise-gut microbiota research and cancer-gut microbiota research and highlights the salient similarities. Preliminary evidence suggests that these areas are linked, with exercise mediating changes that promote the antitumorigenic characteristics of the gut microbiota.", "answer": "<think> Okay, let's tackle this question: \"Does physical activity influence gut hormones?\" The user provided three pieces of evidence from different studies. First, I need to check each document to see if they mention physical activity affecting gut hormones. Looking at the first evidence [21554896:21554896_0], it says that control of spontaneous physical activity by gut hormones or their neuropeptide targets is important for energy balance. This seems to suggest a bidirectional relationship, but does it directly state that physical activity influences gut hormones? The wording is a bit unclear, but maybe it's implying that gut hormones affect activity, not the other way around. Not sure yet. Next, [11321513:", "citations": [{"doc_id": "21554896", "chunk_id": "21554896_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if physical activity influences gut hormones. I need to look at the provided evidence and see which parts support that. First, looking at the first evidence snippet: It mentions that control of spontaneous physical activity by gut hormones or their neuropeptide targets is a component of energy balance regulation. That suggests a two-way relationship, so maybe physical activity does influence gut hormones. Second snippet: Strenuous exercise doesn't affect plasma leptin levels immediately, but after a meal, there's a change. Also, gut hormones like gastrin, CCK, and PP increase after exercise, regardless of feeding or blood donation. This directly shows that physical activity leads to changes in gut hormone release. So this is strong evidence. Third snippet:", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question: \"Does physical activity influence gut hormones?\" The user provided three pieces of evidence from different studies. First, I need to check each document to see if they mention physical activity affecting gut hormones. Looking at the first evidence [21554896:21554896_0], it says that control of spontaneous physical activity by gut hormones or their neuropeptide targets is important for energy balance. This seems to suggest a bidirectional relationship, but does it directly state that physical activity influences gut hormones? The wording is a bit unclear, but maybe it's implying that gut hormones affect activity, not the other way around. Not sure yet. Next, [11321513:", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question: \"Does physical activity influence gut hormones?\" The user wants a JSON answer with an answer and base_confidence. I need to look at the evidence provided. First, check each evidence chunk. The first one [21554896:21554896_0] says that control of spontaneous physical activity by gut hormones or their neuropeptide targets is a component of energy balance. So this suggests that gut hormones do influence physical activity, but the question is about whether physical activity influences gut hormones. Hmm, maybe this is a bit indirect. It's talking about gut hormones controlling activity, not the other way around. But it's related. The second chunk [1132151", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if physical activity influences gut hormones. I need to look at the provided evidence and see which parts support that. First, looking at the first evidence snippet: it mentions that gut hormones or their neuropeptide targets control spontaneous physical activity, which suggests a bidirectional relationship. So that's a point for yes, but it's more about how gut hormones control activity rather than activity affecting hormones. Next, the second snippet says that strenuous exercise doesn't affect plasma leptin levels but when done after a meal, there's a change. Also, gut hormones like gastrin, CCK, PP increase immediately after exercise, regardless of feeding or blood donation. This directly shows that physical activity does influence gut hormone release. So this", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if physical activity influences gut hormones. I need to look at the provided evidence and find relevant information. First, checking the first evidence snippet: It mentions that gut hormones or their neuropeptide targets control spontaneous physical activity, which suggests a bidirectional relationship. So that's a point for yes, but it's about controlling activity by hormones, not sure if it's about activity affecting hormones. Second snippet: Strenuous exercise doesn't affect plasma leptin levels but when done after a meal, there's a change. Also, gut hormones like gastrin, CCK, PP increase immediately after exercise, regardless of feeding or blood donation. This directly shows that physical activity does influence gut hormone release. So this is strong", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if physical activity influences gut hormones. I need to look at the provided evidence and see which parts support that. First, looking at the first evidence chunk: [21554896:21554896_0] mentions that gut hormones or their neuropeptide targets control spontaneous physical activity, suggesting a two-way relationship. But the question is about physical activity influencing gut hormones. This might be a bit one-sided, but it's relevant. Next, [11321513:11321513_0] says that strenuous exercise affects plasma leptin levels, and also increases gut hormones like gastrin, CCK, PP,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if physical activity influences gut hormones. I need to look at the provided evidence and see which parts support that. First, looking at the first evidence: [21554896:21554896_0] mentions that control of spontaneous physical activity by gut hormones or their neuropeptide targets is important for energy balance. So this suggests a two-way relationship, but does it say that physical activity affects gut hormones? It says gut hormones control activity, but maybe not the other way around. Not sure yet. Next, [11321513:11321513_0] talks about strenuous exercise and its effects on plasma lept", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is whether physical activity influences gut hormones. First, I'll look at the evidence provided. Let's check each document: Document 21554896: This says that control of spontaneous physical activity by gut hormones or their neuropeptide targets is important for energy balance regulation. So this suggests a bidirectional relationship between physical activity and gut hormones. Document 11321513: It mentions that strenuous exercise doesn't affect plasma leptin levels but when done after a meal, there's an increase and fall in leptin. Also, gut hormones like gastrin, CCK, PP, and stress hormones like norepinephrine, cortisol, GH", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["11321513", "15795476", "16942616", "17470516", "18987287", "19158129", "19737911", "20061436", "20690071", "21554896", "21615652", "21927572", "22619704", "23111564", "23402716", "2888163"], "ideal_answer": "Yes."}
{"question_id": "515a7ffdd24251bc050000a5", "question": "What are the effects of depleting protein km23-1 (DYNLRB1) in a cell?", "retrieved_chunks": [{"doc_id": "23079622", "chunk_id": "23079622_0", "score": 6.48902702331543, "text": "Finally, our results demonstrated for the first time that depletion of km23-1 inhibited cell migration of human colon carcinoma cells (HCCCs) in wound-healing assays. Overall, our findings demonstrate that km23-1 regulates RhoA and motility-associated actin modulating proteins, suggesting that km23-1 may represent a novel target for anti-metastatic therapy."}, {"doc_id": "17420258", "chunk_id": "17420258_0", "score": 1.4518711566925049, "text": "Blockade of km23-1 using a small interfering RNA approach resulted in a reduction in both total intracellular Smad2 levels and in nuclear levels of phosphorylated Smad2 after TGFbeta treatment."}, {"doc_id": "15925487", "chunk_id": "15925487_0", "score": 0.9520411491394043, "text": "Blockade of km23 using small interfering RNAs significantly decreased key TGFbeta responses, including induction of fibronectin expression and inhibition of cell growth."}], "context": "[23079622:23079622_0] Finally, our results demonstrated for the first time that depletion of km23-1 inhibited cell migration of human colon carcinoma cells (HCCCs) in wound-healing assays. Overall, our findings demonstrate that km23-1 regulates RhoA and motility-associated actin modulating proteins, suggesting that km23-1 may represent a novel target for anti-metastatic therapy.\n[17420258:17420258_0] Blockade of km23-1 using a small interfering RNA approach resulted in a reduction in both total intracellular Smad2 levels and in nuclear levels of phosphorylated Smad2 after TGFbeta treatment.\n[15925487:15925487_0] Blockade of km23 using small interfering RNAs significantly decreased key TGFbeta responses, including induction of fibronectin expression and inhibition of cell growth.", "answer": "<think> Okay, let's tackle this question. The user is asking about the effects of depleting protein km23-1 (DYNLRB1) in a cell. I need to look at the provided evidence to find relevant information. First, I'll go through each evidence chunk. The first one says that depletion of km23-1 inhibited cell migration in HCCCs using wound-healing assays. It also mentions that km23-1 regulates RhoA and motility-associated actin modulating proteins, suggesting it's a target for anti-metastatic therapy. So this points to reduced cell migration and effects on motility. The second evidence chunk talks about using siRNA to block km23-1 leading to reduced Smad2 levels", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the effects of depleting protein km23-1 (DYNLRB1) in a cell. I need to look at the provided evidence to find relevant information. First, I'll go through each evidence chunk. The first one says that depletion of km23-1 inhibited cell migration in HCCCs using wound-healing assays. It also mentions that km23-1 regulates RhoA and motility-associated actin modulating proteins, suggesting it's a target for anti-metastatic therapy. So this points to reduced cell migration and effects on motility. The second evidence chunk talks about using siRNA to block km23-1 leading to reduced Smad2 levels", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the effects of depleting protein km23-1 (DYNLRB1) in a cell. I need to look at the provided evidence to find relevant information. First, looking at the evidence: The first document says that depletion of km23-1 inhibited cell migration in HCCCs using wound-healing assays. It also mentions that km23-1 regulates RhoA and motility-associated actin modulating proteins, suggesting it's a target for anti-metastatic therapy. So, this points to effects on cell migration and maybe metastasis. The second document states that blocking km23-1 with siRNA reduced total intracellular Smad2 levels and nuclear phosphorylated", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the effects of depleting protein km23-1 (DYNLRB1) in a cell. I need to look at the provided evidence to find relevant information. First, looking at the evidence documents: The first one (23079622:23079622_0) says that depletion of km23-1 inhibited cell migration in HCCCs using wound-healing assays. It also mentions that km23-1 regulates RhoA and motility-associated actin modulating proteins, suggesting it's a target for anti-metastatic therapy. So this points to effects on cell migration and possibly metastasis. The second document (1", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the effects of depleting protein km23-1 (DYNLRB1) in a cell. I need to look at the provided evidence to find relevant information. First, looking at the evidence documents. The first one says that depletion of km23-1 inhibited cell migration in HCCCs using wound-healing assays. It also mentions that km23-1 regulates RhoA and motility-associated actin modulating proteins, suggesting it's a target for anti-metastatic therapy. So that's one effect: inhibition of cell migration. The second document states that blocking km23-1 with siRNA reduced total intracellular Smad2 levels and nuclear phosphorylated Smad", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the effects of depleting protein km23-1 (DYNLRB1) in a cell. I need to look at the evidence provided to form a concise answer with citations and a confidence level. First, I'll go through each of the evidence snippets. The first one (23079622:23079622_0) says that depletion of km23-1 inhibited cell migration in colon carcinoma cells using wound-healing assays. It also mentions that km23-1 regulates RhoA and motility-associated actin modulating proteins, suggesting it's a target for anti-metastatic therapy. So this points to effects on", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking about the effects of depleting protein km23-1 (DYNLRB1) in a cell. The evidence provided has three chunks. First, I need to parse each chunk to extract relevant information. The first chunk says that depletion of km23-1 inhibited cell migration in HCCCs using wound-healing assays. It also mentions that km23-1 regulates RhoA and motility-associated actin modulating proteins, suggesting it's a target for anti-metastatic therapy. The second chunk talks about using siRNA to block km23-1 leading to reduced Smad2 levels both total intracellular and phosphorylated in the nucleus after TGFbeta treatment. So this", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the effects of depleting protein km23-1 (DYNLRB1) in a cell. I need to look at the provided evidence to find relevant information. First, looking at the evidence snippets: The first one says that depletion of km23-1 inhibited cell migration in colon carcinoma cells. It also mentions that km23-1 regulates RhoA and motility-associated actin modulating proteins, suggesting it's a target for anti-metastatic therapy. So this points to effects on cell migration and possibly metastasis. The second snippet talks about using siRNA to block km23-1 leading to reduced Smad2 levels, both total intracellular and phosphorylated in", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the effects of depleting protein km23-1 (DYNLRB1) in a cell. I need to look at the provided evidence to find relevant information. First, looking at the evidence documents: Document 23079622: It says that depletion of km23-1 inhibited cell migration in HCCCs using wound-healing assays. Also, it mentions that km23-1 regulates RhoA and motility-associated actin modulating proteins, suggesting it's a target for anti-metastatic therapy. Document 17420258: Blockade of km23-1 with siRNA reduced total intracellular Smad2", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["15925487", "16778097", "17420258", "19571232", "19711352", "22637579", "23079622"], "ideal_answer": "The knockdown of km23-1 results in numerous effects at the cellular level, such as decreased cell migration. Additionaly, km23-1 is involved in signalling pathways and its knockdown results in decreased RhoA activation, inhibition of TGFβ-mediated activation of ERK and JNK, phosphorylation of c-Jun, transactivation of the c-Jun promoter and decreased TGFbeta responses."}
{"question_id": "54cf7051f693c3b16b000013", "question": "Treatment of which disease was investigated in the MR CLEAN study?", "retrieved_chunks": [{"doc_id": "25179366", "chunk_id": "25179366_0", "score": 5.3612213134765625, "text": "MR CLEAN, a multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke in the Netherlands: study protocol for a randomized controlled trial."}, {"doc_id": "25432979", "chunk_id": "25432979_0", "score": 4.060359954833984, "text": "INTRODUCTION: A recent randomized controlled trial (RCT), the Multicenter Randomized CLinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands (MR CLEAN), demonstrated better outcomes with endovascular treatment compared with medical therapy for acute ischemic stroke (AIS)."}, {"doc_id": "25517348", "chunk_id": "25517348_0", "score": 0.9853619337081909, "text": "CONCLUSIONS: In patients with acute ischemic stroke caused by a proximal intracranial occlusion of the anterior circulation, intraarterial treatment administered within 6 hours after stroke onset was effective and safe. (Funded by the Dutch Heart Foundation and others; MR CLEAN Netherlands Trial Registry number, NTR1804, and Current Controlled Trials number, ISRCTN10888758.)."}], "context": "[25179366:25179366_0] MR CLEAN, a multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke in the Netherlands: study protocol for a randomized controlled trial.\n[25432979:25432979_0] INTRODUCTION: A recent randomized controlled trial (RCT), the Multicenter Randomized CLinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands (MR CLEAN), demonstrated better outcomes with endovascular treatment compared with medical therapy for acute ischemic stroke (AIS).\n[25517348:25517348_0] CONCLUSIONS: In patients with acute ischemic stroke caused by a proximal intracranial occlusion of the anterior circulation, intraarterial treatment administered within 6 hours after stroke onset was effective and safe. (Funded by the Dutch Heart Foundation and others; MR CLEAN Netherlands Trial Registry number, NTR1804, and Current Controlled Trials number, ISRCTN10888758.).", "answer": "<think> Okay, let's tackle this question. The user is asking which disease was investigated in the MR CLEAN study. The evidence provided has three documents. First, looking at document [25179366:25179366_0], the title mentions \"MR CLEAN, a multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke...\" So that's a direct mention of acute ischemic stroke. Then document [25432979:25432979_0] says the study demonstrated better outcomes with endovascular treatment compared to medical therapy for acute ischemic stroke (AIS). That reinforces the same answer. The third document [25517348", "citations": [{"doc_id": "25179366", "chunk_id": "25179366_0"}, {"doc_id": "25432979", "chunk_id": "25432979_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which disease was investigated in the MR CLEAN study. The evidence provided has three documents. First, looking at document [25179366:25179366_0], the title mentions \"MR CLEAN, a multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke...\" So that's a direct mention of acute ischemic stroke. Then document [25432979:25432979_0] says the study demonstrated better outcomes with endovascular treatment compared to medical therapy for acute ischemic stroke (AIS). That reinforces the same answer. The third document [25517348", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which disease's treatment was investigated in the MR CLEAN study. The evidence provided has three documents. First, I need to look at each document to find the answer. The first document's title mentions \"endovascular treatment for acute ischemic stroke,\" which seems relevant. The second document's introduction says the trial demonstrated better outcomes with endovascular treatment compared to medical therapy for acute ischemic stroke (AIS). The third document's conclusion talks about patients with acute ischemic stroke caused by a proximal intracranial occlusion of the anterior circulation. So, all three documents point to acute ischemic stroke as the disease under investigation. The key term here is \"acute ischemic stroke\" (AIS),", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to figure out the answer to the question: \"Treatment of which disease was investigated in the MR CLEAN study?\" using the provided evidence. First, let me look at the evidence given. There are three documents referenced. The first one is [25179366:25179366_0], which mentions MR CLEAN as a study on endovascular treatment for acute ischemic stroke in the Netherlands. The title itself says it's a trial for endovascular treatment of acute ischemic stroke. The second document, [25432979:25432979_0], refers to MR CLEAN as an RCT demonstrating better outcomes with endovascular treatment compared to medical", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, so the user is asking which disease's treatment was investigated in the MR CLEAN study. Let me look at the evidence provided. First, the title of the first document says \"MR CLEAN, a multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke in the Netherlands: study protocol for a randomized controlled trial.\" That seems directly relevant. The study is about endovascular treatment for acute ischemic stroke. The second evidence snippet mentions \"Multicenter Randomized CLinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands (MR CLEAN), demonstrated better outcomes with endovascular treatment compared with medical therapy for acute ischemic stroke (AIS).\" So here it clearly states that the study was on acute ischemic stroke (", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to figure out which disease was investigated in the MR CLEAN study based on the given evidence. Let me look at the evidence provided. The first document mentions \"MR CLEAN, a multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke in the Netherlands: study protocol for a randomized controlled trial.\" So that's a direct mention of acute ischemic stroke. The second document says \"a recent RCT... demonstrated better outcomes with endovascular treatment compared with medical therapy for acute ischemic stroke (AIS).\" Again, acute ischemic stroke is highlighted here. The third document's conclusion states that the study was about patients with acute ischemic stroke caused by a proximal intracranial occlusion of the anterior circulation. So all three", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which disease was investigated in the MR CLEAN study. The evidence provided has three documents. First, looking at document [25179366:25179366_0], the title mentions \"MR CLEAN, a multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke...\" So that's a direct mention of acute ischemic stroke. Then, document [25432979:25432979_0] says the study compared endovascular treatment with medical therapy for acute ischemic stroke (AIS). The introduction here also states the same thing. The third document [2551734", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to figure out which disease was investigated in the MR CLEAN study based on the provided evidence. Let me look at the evidence again. The first document mentions MR CLEAN as a multicenter trial for endovascular treatment of acute ischemic stroke. The second one says it compared endovascular treatment with medical therapy for acute ischemic stroke (AIS). The third concludes that intraarterial treatment was effective and safe for patients with acute ischemic stroke caused by proximal intracranial occlusion. So the key term here is \"acute ischemic stroke.\" The question is asking which disease was treated in the study. All the documents point to acute ischemic stroke as the condition. The study compared endovascular treatment versus medical therapy for this condition. The answer", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which disease was investigated in the MR CLEAN study. The evidence provided has three documents. Looking at the first document: \"MR CLEAN, a multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke in the Netherlands: study protocol for a randomized controlled trial.\" So that's a direct mention of acute ischemic stroke. The second document says: \"demonstrated better outcomes with endovascular treatment compared with medical therapy for acute ischemic stroke (AIS).\" Again, acute ischemic stroke is mentioned here. The third document's conclusion talks about patients with acute ischemic stroke caused by a proximal intracranial occlusion of the anterior circulation. So all three documents point to acute ischem", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["24330796", "25179366", "25432979", "25517348"], "ideal_answer": "Multicenter Randomized CLinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands (MR CLEAN) study investigated endovascular treatment for acute ischemic stroke."}
{"question_id": "56a92be0a17756b72f000009", "question": "Which factors activate zygotic gene expression during the maternal-to-zygotic transition in zebrafish?", "retrieved_chunks": [{"doc_id": "24056933", "chunk_id": "24056933_1", "score": 8.03262996673584, "text": "Here we show that Nanog, Pou5f1 (also called Oct4) and SoxB1 regulate zygotic gene activation in zebrafish. We identified several hundred genes directly activated by maternal factors, constituting the first wave of zygotic transcription."}, {"doc_id": "24056933", "chunk_id": "24056933_2", "score": 5.883466720581055, "text": "Nanog, Pou5f1 and SoxB1 activate zygotic gene expression during the maternal-to-zygotic transition."}, {"doc_id": "23891688", "chunk_id": "23891688_0", "score": 5.523184776306152, "text": "The transcription factor Zelda plays a pivotal role in promoting the maternal to zygotic transition during embryogenesis in Drosophila melanogaster."}], "context": "[24056933:24056933_1] Here we show that Nanog, Pou5f1 (also called Oct4) and SoxB1 regulate zygotic gene activation in zebrafish. We identified several hundred genes directly activated by maternal factors, constituting the first wave of zygotic transcription.\n[24056933:24056933_2] Nanog, Pou5f1 and SoxB1 activate zygotic gene expression during the maternal-to-zygotic transition.\n[23891688:23891688_0] The transcription factor Zelda plays a pivotal role in promoting the maternal to zygotic transition during embryogenesis in Drosophila melanogaster.", "answer": "<think> Okay, let's tackle this question. The user is asking about the factors that activate zygotic gene expression during the maternal-to-zygotic transition in zebrafish. First, I need to look at the evidence provided. There are three references here. The first two are from the same study (24056933) and the third is a different one (23891688). Looking at the first evidence snippet [24056933:24056937_1], it mentions that Nanog, Pou5f1 (Oct4), and SoxB1 regulate zygotic gene activation in zebrafish. It also states that these factors are involved in the", "citations": [{"doc_id": "24056933", "chunk_id": "24056937_1"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which factors activate zygotic gene expression during the maternal-to-zygotic transition in zebrafish. Looking at the evidence provided, there are three references. The first two, 24056933:24056933_1 and 24056933:24056933_2, both mention Nanog, Pou5f1 (Oct4), and SoxB1 as regulators of zygotic gene activation in zebrafish. The third reference, 23891688:23891688_0, talks about Zelda in Drosophila,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking about the factors that activate zygotic gene expression during the maternal-to-zygotic transition in zebrafish. Let me look at the evidence provided. First, there's a document (24056933) with two chunks. The first chunk says that Nanog, Pou5f1 (Oct4), and SoxB1 regulate zygotic gene activation in zebrafish. The second chunk repeats that these three genes activate zygotic gene expression during the transition. Then there's another document (23891688) mentioning Zelda's role in Drosophila, but the question is about zebrafish. So the key here is to focus on the zeb", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which factors activate zygotic gene expression during the maternal-to-zygotic transition in zebrafish. First, I need to look at the evidence provided. There are three documents here. Let me check each one. Document 24056933 has two chunks. The first chunk says that Nanog, Pou5f1 (Oct4), and SoxB1 regulate zygotic gene activation in zebrafish. The second chunk repeats that these same three factors activate zygotic gene expression during the transition. So that's a direct mention of the factors involved in zebrafish. Then there's document 23891688, which talks about Zelda", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which factors activate zygotic gene expression during the maternal-to-zygotic transition in zebrafish. The evidence provided has three documents. First, I need to look at the relevant parts. Document 24056933 has two chunks. Chunk 1 says that Nanog, Pou5f1 (Oct4), and SoxB1 regulate zygotic gene activation in zebrafish. Chunk 2 repeats that these three factors activate zygotic gene expression during the transition. Then there's another document, 23891688, which talks about Zelda in Drosophila, but the question is about zebrafish. So Zelda isn't", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which factors activate zygotic gene expression during the maternal-to-zygotic transition in zebrafish. First, I need to look at the evidence provided. There are three documents here. Let me check each one. The first document, 24056933:2405693where it says that Nanog, Pou5f1 (Oct4), and SoxB1 regulate zygotic gene activation in zebrafish. Also, they mention that these factors activate zygotic gene expression during the transition. The second chunk from the same document repeats that point. The third document is about Zelda in Drosophila, which isn't zebrafish", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the factors that activate zygotic gene expression during the maternal-to-zygotic transition in zebrafish. The evidence provided has three chunks. First, I need to focus on the zebrafish-specific information because the question is about zebrafish. The first two chunks from 24056933 mention Nanog, Pou5f1 (Oct4), and SoxB1 as regulators of zygotic gene activation in zebrafish. The third chunk talks about Zelda in Drosophila, which is a different organism, so that's probably not relevant here. So the answer should include those three factors: Nanog, Pou5f1, and So", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the factors that activate zygotic gene expression during the maternal-to-zygotic transition in zebrafish. First, I need to look at the evidence provided. There are three references here. The first two are from the same study (24056933) and the third is a different one (23891688). Looking at the first evidence snippet [24056933:24056937_1], it mentions that Nanog, Pou5f1 (Oct4), and SoxB1 regulate zygotic gene activation in zebrafish. It also states that these factors are involved in the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which factors activate zygotic gene expression during the maternal-to-zygotic transition in zebrafish. The evidence provided has three entries. First, looking at the evidence from 24056933:24056933_1 and 24056933:24056933_2, both mention Nanog, Pou5f1 (Oct4), and SoxB1 as regulators of zygotic gene activation in zebrafish. These are specifically cited in the context of the maternal-to-zygotic transition. The first chunk talks about them regulating zygotic gene activation, and the second chunk directly", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["24056933"], "ideal_answer": "Nanog, Pou5f1 and SoxB1 activate zygotic gene expression during the maternal-to-zygotic transition. Maternal Nanog, Pou5f1 and SoxB1 are required to initiate the zygotic developmental program and induce clearance of the maternal program by activating miR-430 expression."}
{"question_id": "54f08d4a94afd61504000016", "question": "Is irritable bowel syndrome more common in women with endometriosis?", "retrieved_chunks": [{"doc_id": "21527837", "chunk_id": "21527837_2", "score": 8.362399101257324, "text": "Similarly, women with a history of irritable bowel syndrome were twice as likely to develop endometriosis [AOR=1.9, 95% CI (1.03-3.87)]."}, {"doc_id": "21527837", "chunk_id": "21527837_1", "score": 7.711513519287109, "text": "Similarly, women with a history of irritable bowel syndrome were twice as likely to develop endometriosis [AOR=1."}, {"doc_id": "19694698", "chunk_id": "19694698_0", "score": 6.986379623413086, "text": "Seventy-six women (21.4%) had previously been diagnosed with irritable bowel syndrome and 79% of them had endometriosis confirmed."}], "context": "[21527837:21527837_2] Similarly, women with a history of irritable bowel syndrome were twice as likely to develop endometriosis [AOR=1.9, 95% CI (1.03-3.87)].\n[21527837:21527837_1] Similarly, women with a history of irritable bowel syndrome were twice as likely to develop endometriosis [AOR=1.\n[19694698:19694698_0] Seventy-six women (21.4%) had previously been diagnosed with irritable bowel syndrome and 79% of them had endometriosis confirmed.", "answer": "<think> Okay, let's tackle this question. The user is asking if irritable bowel syndrome (IBS) is more common in women with endometriosis. The evidence provided has three chunks. First, chunk [21527837:21527837_2] says that women with a history of IBS are twice as likely to develop endometriosis, with an AOR of 1.9. That suggests a link between IBS and endometriosis, but it's about the likelihood of developing endometriosis if you have IBS, not the prevalence of IBS in women with endometriosis. Then chunk [21527837:2152783", "citations": [{"doc_id": "21527837", "chunk_id": "21527837_2"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if irritable bowel syndrome (IBS) is more common in women with endometriosis. The evidence provided has three chunks. First, chunk [21527837:21527837_2] says that women with a history of IBS are twice as likely to develop endometriosis, with an AOR of 1.9. That suggests a link between IBS and endometriosis, but it's about the likelihood of developing endometriosis if you have IBS, not the prevalence of IBS in women with endometriosis. Then chunk [21527837:2152783", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if IBS is more common in women with endometriosis. The evidence provided has three chunks. First, chunk 21527837_2 says that women with a history of IBS are twice as likely to develop endometriosis, with an AOR of 1.9. That suggests a link between IBS and endometriosis, but it's about the likelihood of developing endometriosis if you have IBS, not the prevalence of IBS in women with endometriosis. Then chunk 21527837_1 is similar to the first one, so probably reinforcing the same point. Chunk 19694", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if IBS is more common in women with endometriosis. The evidence given has three chunks. First, chunk 21527837_2 says that women with a history of IBS are twice as likely to develop endometriosis, with an AOR of 1.9. That suggests a link between IBS and endometriosis, but it's about the likelihood of developing endometriosis if you have IBS, not the prevalence of IBS in women with endometriosis. Then chunk 21527837_1 is similar to the first one, so probably the same point. The third chunk, 1969", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if irritable bowel syndrome (IBS) is more common in women with endometriosis. The evidence provided has three chunks. First, chunk [21527837:21527837_2] says that women with a history of IBS are twice as likely to develop endometriosis, with an AOR of 1.9. That suggests a link between IBS and endometriosis, but it's about the likelihood of developing endometriosis after having IBS, not the prevalence of IBS in women with endometriosis. Then there's chunk [21527837:215278", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if irritable bowel syndrome (IBS) is more common in women with endometriosis. The evidence provided has three chunks. First, chunk [21527837:21527837_2] says that women with a history of IBS are twice as likely to develop endometriosis, with an adjusted odds ratio (AOR) of 1.9. That suggests a link between IBS and endometriosis, but it's about the likelihood of developing endometriosis if you have IBS, not the prevalence of IBS in women with endometriosis. Then there's chunk [21527837:", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if irritable bowel syndrome (IBS) is more common in women with endometriosis. The evidence provided has three chunks. First, chunk [21527837:21527837_2] says that women with a history of IBS are twice as likely to develop endometriosis, with an AOR of 1.9. That suggests a link between IBS and endometriosis, but it's about the likelihood of developing endometriosis if you have IBS, not the prevalence of IBS in women with endometriosis. Next, chunk [21527837:215278", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if IBS is more common in women with endometriosis. The evidence provided has three chunks. First chunk: A study found that women with a history of IBS were twice as likely to develop endometriosis, with an adjusted odds ratio of 1.9. That suggests a link between IBS and endometriosis, but it's about the likelihood of developing endometriosis after having IBS, not the prevalence in women with endometriosis. Second chunk is the same as the first, so probably redundant. The third chunk says that 21.4% of 76 women had IBS, and 79% of those had endometriosis confirmed.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if irritable bowel syndrome (IBS) is more common in women with endometriosis. The evidence provided has three chunks. First, chunk [21527837:21527837_2] says that women with a history of IBS are twice as likely to develop endometriosis, with an adjusted odds ratio (AOR) of 1.9. That suggests a link between IBS and endometriosis, but it's about the likelihood of developing endometriosis if you have IBS, not the prevalence of IBS in those with endometriosis. Then there's chunk [21527837:", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["14501624", "15341718", "15605531", "15894210", "17493437", "17635599", "17701798", "18478547", "18646315", "18715239", "18715240", "19694698", "19832874", "21527837", "21868492", "22096721", "22134016", "23507008"], "ideal_answer": "Yes, irritable bowel syndrome (IBS) is more common in women with endometriosis. It has been shown that 15% of the patients with endometriosis also had IBS. Women with endometriosis are more likely to have received a diagnosis of IBS. Endometriosis may coexist with or be misdiagnosed as IBS."}
{"question_id": "54f49995d0d681a040000002", "question": "What is evaluated using the EORTC QLQ – INFO25 questionnaire?", "retrieved_chunks": [{"doc_id": "22638756", "chunk_id": "22638756_1", "score": 7.85402774810791, "text": "The EORTC QLQ-INFO25 was used to evaluate the perceived level of and satisfaction with information."}, {"doc_id": "22638756", "chunk_id": "22638756_0", "score": 7.789133071899414, "text": "The EORTC QLQ-INFO25 was used to evaluate the perceived level of and satisfaction with information"}, {"doc_id": "21680301", "chunk_id": "21680301_1", "score": 7.475852966308594, "text": "The EORTC QLQ-INFO25 evaluates the information received by cancer patients"}], "context": "[22638756:22638756_1] The EORTC QLQ-INFO25 was used to evaluate the perceived level of and satisfaction with information.\n[22638756:22638756_0] The EORTC QLQ-INFO25 was used to evaluate the perceived level of and satisfaction with information\n[21680301:21680301_1] The EORTC QLQ-INFO25 evaluates the information received by cancer patients", "answer": "<think> Okay, let's tackle this question. The user is asking what the EORTC QLQ – INFO25 questionnaire evaluates. I need to look at the provided evidence to find the answer. Looking at the evidence, there are three chunks. The first two chunks from [22638756:22638756_1] and [22638756:22638756_0] both say that the EORTC QLQ-INFO25 is used to evaluate the perceived level of and satisfaction with information. The third chunk from [21680301:21680301_1] states that it evaluates the information received", "citations": [{"doc_id": "22638756", "chunk_id": "22638756_1"}, {"doc_id": "22638756", "chunk_id": "22638756_0"}, {"doc_id": "21680301", "chunk_id": "21680301_1"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking what the EORTC QLQ – INFO25 questionnaire evaluates. I need to look at the provided evidence to find the answer. Looking at the evidence, there are three chunks. The first two chunks from [22638756:22638756_1] and [22638756:22638756_0] both say that the EORTC QLQ-INFO25 is used to evaluate the perceived level of and satisfaction with information. The third chunk from [21680301:21680301_1] states that it evaluates the information received", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's see. The user is asking what the EORTC QLQ – INFO25 questionnaire evaluates. The evidence provided has three chunks. First, chunk 22638756_1 says it's used to evaluate the perceived level of and satisfaction with information. Then chunk 22638756_0 repeats the same thing. Chunk 21680301_1 mentions that it evaluates the information received by cancer patients. So, I need to combine these pieces. The main points are about perceived level and satisfaction with information, and specifically that it's for cancer patients. The answer should be concise, citing the relevant chunks. The confidence is high because all three chunks support the same general idea,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking what the EORTC QLQ – INFO25 questionnaire evaluates. I need to look at the provided evidence to find the answer. Looking at the evidence snippets, there are three entries. The first one says the EORTC QLQ-INFO25 was used to evaluate the perceived level of and satisfaction with information. The second is a duplicate of the first. The third mentions that it evaluates the information received by cancer patients. So, combining these, the main points are about evaluating perceived level and satisfaction with information, and specifically mentioning cancer patients. The answer should be concise and include citations. The user wants the answer in JSON with keys 'answer' and 'base_confidence'. The confidence here", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking what the EORTC QLQ – INFO25 questionnaire evaluates. The evidence provided has three chunks. First, I need to parse each chunk. The first two chunks from 22638756 mention that the questionnaire is used to evaluate the perceived level of and satisfaction with information. The third chunk from 21680301 says it evaluates the information received by cancer patients. So, the main points are about evaluating perceived level and satisfaction with information, and specifically mentioning cancer patients. The answer needs to be concise and include citations. The confidence is based on the evidence provided. All three chunks support the idea that it's about information related to cancer patients. Since all evidence points", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking what the EORTC QLQ – INFO25 questionnaire evaluates. The evidence provided has three chunks. First, I need to look at each chunk. The first two chunks from 22638756:22638756_1 and _0 both say that the questionnaire is used to evaluate the perceived level of and satisfaction with information. The third chunk from 21680301:21680301_1 states that it evaluates the information received by cancer patients. So, the answer needs to be concise. The main points are \"perceived level of and satisfaction with information\" and \"information received by cancer patients.\" However", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The question is asking what the EORTC QLQ – INFO25 questionnaire evaluates. Let me look at the evidence. First, there are three chunks. The first two chunks from 22638756:22638756_1 and 22638756:22638756_0 both say that the EORTC QLQ-INFO25 was used to evaluate the perceived level of and satisfaction with information. The third chunk from 21680301:21680301_1 states that it evaluates the information received by cancer patients. So", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is asking what the EORTC QLQ – INFO25 questionnaire evaluates. Let me look at the evidence provided. First, there are three chunks from different documents. The first two chunks (22638756:22638757_1 and 0) both say that the EORTC QLQ-INFO25 is used to evaluate the perceived level of and satisfaction with information. The third chunk (21680301:21680301_1) states that it evaluates the information received by cancer patients. So, the main points here are about evaluating perceived information and patient satisfaction.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking what the EORTC QLQ – INFO25 questionnaire evaluates. The evidence provided has three chunks. First, I need to look at each chunk. The first two chunks from 22638756 say that the questionnaire is used to evaluate the perceived level of and satisfaction with information. The third chunk from 21680301 states that it evaluates the information received by cancer patients. So, combining these, the main focus seems to be on assessing how much information patients perceive they have received and their satisfaction with it. The third chunk adds that it's specifically for cancer patients. But the question is about what is evaluated, so the answer should be about the perceived level and", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["20674333", "21671697", "21680301", "22052786", "22638756", "24834120", "25475735"], "ideal_answer": "The European Organisation for Research and Treatment of Cancer Quality of Life Group information questionnaire (EORTC QLQ-INFO 25) evaluates the level of information patients have received in different areas of their disease, treatment and care, and evaluates qualitative aspects together with satisfaction with information."}
{"question_id": "531d2aa5267d7dd053000003", "question": "Does BNP increase after intensive exercise in athletes?", "retrieved_chunks": [{"doc_id": "16338248", "chunk_id": "16338248_0", "score": 8.8280029296875, "text": "Increases in NT-proBNP can be found in a major part of obviously healthy athletes after prolonged strenuous exercise. The release of BNP during and after exercise may not result from myocardial damage but may have cytoprotective and growth-regulating effects. The different nature of exercise-induced increases in BNP and cardiac troponins has to be elucidated in the future."}, {"doc_id": "11320362", "chunk_id": "11320362_0", "score": 4.886676788330078, "text": "Such exercise significantly increased ANP and BNP levels in healthy men, and the increases could be partially attributed to myocardial damage during the race."}, {"doc_id": "14523304", "chunk_id": "14523304_0", "score": 4.443329811096191, "text": "The rise in BNP in older athletes may reflect a reversible, mainly diastolic left ventricular dysfunction."}], "context": "[16338248:16338248_0] Increases in NT-proBNP can be found in a major part of obviously healthy athletes after prolonged strenuous exercise. The release of BNP during and after exercise may not result from myocardial damage but may have cytoprotective and growth-regulating effects. The different nature of exercise-induced increases in BNP and cardiac troponins has to be elucidated in the future.\n[11320362:11320362_0] Such exercise significantly increased ANP and BNP levels in healthy men, and the increases could be partially attributed to myocardial damage during the race.\n[14523304:14523304_0] The rise in BNP in older athletes may reflect a reversible, mainly diastolic left ventricular dysfunction.", "answer": "<think> Okay, let's tackle this question. The user is asking if BNP increases after intensive exercise in athletes. I need to look at the provided evidence to form an answer. First, evidence document [16338248:16338248_0] says that NT-proBNP increases in healthy athletes after prolonged strenuous exercise. It mentions that BNP release might not be from myocardial damage but could have cytoprotective effects. So this suggests BNP does increase, but the reason is different from damage. Then [11320362:11320362_0] states that exercise significantly raises ANP and BNP in healthy men, with some attribution to myocardial damage", "citations": [{"doc_id": "16338248", "chunk_id": "16338248_0"}, {"doc_id": "11320362", "chunk_id": "11320362_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if BNP increases after intensive exercise in athletes. I need to look at the provided evidence to form an answer. First, evidence document [16338248:16338248_0] says that NT-proBNP increases in healthy athletes after prolonged strenuous exercise. It mentions that BNP release might not be from myocardial damage but could have cytoprotective effects. So this suggests BNP does increase, but the reason is different from damage. Then [11320362:11320362_0] states that exercise significantly raises ANP and BNP in healthy men, with some attribution to myocardial damage", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if BNP increases after intensive exercise in athletes. I need to look at the evidence provided. First, evidence document 16338248 mentions that NT-proBNP increases in healthy athletes after prolonged strenuous exercise. It also says that BNP release during exercise might not be from myocardial damage but could have cytoprotective effects. So this suggests BNP does increase, but the reason isn't just heart damage. Then there's 11320362 which states that intense exercise increases ANP and BNP in healthy men, with some of the increase due to myocardial damage. This directly supports that BNP rises during exercise, though part of it is from damage", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if BNP increases after intensive exercise in athletes. I need to look at the provided evidence to form an answer. First, evidence document [16338248:16338248_0] says that NT-proBNP increases in healthy athletes after prolonged strenuous exercise. It mentions that BNP release might not be from myocardial damage but could have cytoprotective effects. So this suggests BNP does increase, but the reason might not be damage. Then there's [11320362:11320362_0], which states that exercise significantly raises ANP and BNP in healthy men, with some credit to", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if BNP increases after intensive exercise in athletes. I need to look at the provided evidence to form an answer. First, evidence document [16338248:16338248_0] says that NT-proBNP rises in healthy athletes after strenuous exercise. It mentions that BNP release might not be from myocardial damage but could have cytoprotective effects. So this suggests that BNP does increase, but the reason is different from damage. Then there's [11320362:11320362_0], which states that exercise significantly increases ANP and BNP in healthy men, with some attribution to", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if BNP increases after intensive exercise in athletes. I need to look at the evidence provided. First, evidence document 16338248:16338248_0 says that NT-proBNP increases in healthy athletes after strenuous exercise. It mentions that BNP release might not be from myocardial damage but could have cytoprotective effects. So this suggests BNP does increase, but the reason isn't just damage. Then, document 11320362:11320362_0 states that exercise increased ANP and BNP in healthy men, with partial attribution to myocardial damage. This directly supports that B", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if BNP increases after intensive exercise in athletes. I need to look at the evidence provided. First, evidence document 16338248 says that NT-proBNP increases in healthy athletes after prolonged strenuous exercise. It mentions that BNP release might not be from myocardial damage but could have cytoprotective effects. So that's a positive point for BNP increasing. Then there's 11320362, which states that exercise significantly increased ANP and BNP in healthy men, with some attributed to myocardial damage. This supports the idea that BNP does rise during intense exercise. The third document, 14523304, talks", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if BNP increases after intensive exercise in athletes. I need to look at the provided evidence to form an answer. First, evidence document [16338248:16338248_0] says that NT-proBNP increases in healthy athletes after prolonged strenuous exercise. It mentions that BNP release might not be from myocardial damage but could have cytoprotective effects. So this suggests BNP does increase, but the reason isn't just damage. Then there's [11320362:11320362_0], which states that exercise significantly raises ANP and BNP in healthy men, with some credit to", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if BNP increases after intensive exercise in athletes. I need to look at the provided evidence to form an answer. First, I'll check each of the three documents. Document 16338248 says that NT-proBNP increases in healthy athletes after prolonged strenuous exercise. It mentions that BNP release might not be from myocardial damage but could have cytoprotective effects. So this suggests BNP does increase, but the reason is different from heart damage. Document 11320362 states that intense exercise raises ANP and BNP levels in healthy men, with some attribution to myocardial damage during the race. This directly supports that BNP increases due to", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["11320362", "12417808", "12890912", "14523304", "16125505", "16338248", "16446686", "16879068", "17289431", "17395308", "18076361", "18184752", "18248532", "18630737", "19092706", "19638823", "22653984", "23304255"], "ideal_answer": "BNP and NTproBNP increase early after exercise in healthy athletes performing different types of sports. It is unknown the reason of this increase. The transient increases in BNP, NT-pro-BNP and troponin T are more likely to reflect myocardial stunning than cardiomyocyte damage."}
{"question_id": "56bf3a79ef6e39474100000f", "question": "What is the association of estrogen replacement therapy and intracranial meningioma risk?", "retrieved_chunks": [{"doc_id": "24138870", "chunk_id": "24138870_0", "score": 7.877739906311035, "text": "Several studies indicate that use of hormone replacement therapy (HRT) is associated with an increased risk of intracranial meningioma, while associations between HRT use and risk of other brain tumors have been less explored."}, {"doc_id": "17580362", "chunk_id": "17580362_1", "score": 5.603789806365967, "text": "available data suggest an association between the use of hormone replacement therapy and increased meningioma risk."}, {"doc_id": "17580362", "chunk_id": "17580362_0", "score": 5.5330986976623535, "text": "Although not definitive, available data suggest an association between the use of hormone replacement therapy and increased meningioma risk."}], "context": "[24138870:24138870_0] Several studies indicate that use of hormone replacement therapy (HRT) is associated with an increased risk of intracranial meningioma, while associations between HRT use and risk of other brain tumors have been less explored.\n[17580362:17580362_1] available data suggest an association between the use of hormone replacement therapy and increased meningioma risk.\n[17580362:17580362_0] Although not definitive, available data suggest an association between the use of hormone replacement therapy and increased meningioma risk.", "answer": "<think> Okay, let's tackle this question. The user is asking about the association between estrogen replacement therapy and intracranial meningioma risk. First, I need to look at the provided evidence. There are three documents mentioned. Let me check each one. The first document [24138870:24138870_0] says that several studies show HRT is linked to an increased risk of intracranial meningioma, but other brain tumors have less explored associations. So this points to a positive association with meningiomas. The second document [17580362:17580362_1] mentions available data suggesting an association between HRT and increased meningioma", "citations": [{"doc_id": "24138870", "chunk_id": "24138870_0"}, {"doc_id": "17580362", "chunk_id": "17580362_1"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the association between estrogen replacement therapy and intracranial meningioma risk. First, I need to look at the provided evidence. There are three documents mentioned. Let me check each one. The first document [24138870:24138870_0] says that several studies show HRT is linked to an increased risk of intracranial meningioma, but other brain tumors have less explored associations. So this points to a positive association with meningiomas. The second document [17580362:17580362_1] mentions available data suggesting an association between HRT and increased meningioma", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the association between estrogen replacement therapy (ERT) and the risk of intracranial meningioma. First, I need to look at the provided evidence. There are three references here. Let me go through each one. The first evidence [24138870:24138870_0] says that several studies show HRT use is linked to an increased risk of intracranial meningioma, while other brain tumors have less explored associations. So this directly mentions an association with meningioma. The second [17580362:17580362_1] states that available data suggest an association between H", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is about the association between estrogen replacement therapy and intracranial meningioma risk. Looking at the evidence, there are three chunks. The first one (24138870:24138870_0) says that several studies show HRT is linked to increased risk of intracranial meningioma, while other brain tumors have less explored associations. The next two chunks (17580362:17580362_1 and 24138870:17580362_0) both mention available data suggesting an association between HRT and increased", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking about the association between estrogen replacement therapy and intracranial meningioma risk. First, I need to look at the evidence provided. There are three references here. Let me go through each one. The first one, [24138870:24138870_0], says that several studies show HRT is linked to an increased risk of intracranial meningioma. The other brain tumors aren't as well explored. So this directly mentions the association with meningioma. The second reference, [17580362:17580362_1], states that available data suggest an association between HRT and", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the association between estrogen replacement therapy (ERT) and the risk of intracranial meningioma. First, I need to look at the provided evidence. There are three references here. Let me go through each one. The first piece [24138870:24138870_0] says that several studies show HRT is linked to an increased risk of intracranial meningioma, but other brain tumors have less explored associations. So this directly mentions an association with meningioma. The second reference [17580362:17580362_1] states that available data suggest an association between H", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the association between estrogen replacement therapy and intracranial meningioma risk. First, I need to look at the evidence provided. There are three references here. Let me go through each one. The first one, [24138870:24138870_0], says that several studies show HRT is linked to increased risk of intracranial meningioma. The other two references, [17580362:17580362_1] and [17580362:17580362_0], both mention available data suggesting an association between HRT", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the association between estrogen replacement therapy and the risk of intracranial meningioma. First, I need to look at the provided evidence. There are three chunks here. Let me read through them carefully. The first chunk (24138870:2413887So) says that several studies show HRT is linked to increased risk of intracranial meningioma, but other brain tumors have less explored associations. The second chunk (17580362:17580362_1) mentions available data suggesting an association between HRT and increased meningioma risk. The third one (175803", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the association between estrogen replacement therapy and intracranial meningioma risk. First, I need to look at the evidence provided. There are three references here. Let me check each one. The first piece of evidence [24138870:24138870_0] says that several studies show HRT is linked to an increased risk of intracranial meningioma, but other brain tumors have less explored associations. So that's a direct mention of meningioma and HRT. The second evidence [17580362:17580362_1] states that available data suggest an association between HRT", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["15006250", "16570277", "16759391", "17580362", "20091865", "20730482", "20738039", "20802020", "21067422", "22287638", "23101448", "24138870", "25335165"], "ideal_answer": "The association between hormone replacement therapy and meningioma risk is controversial. Increased risk of meningioma was demonstrated in estrogen-only hormonal replacement therapy. However, other studies did not find an association between hormonal replacement therapy and meningioma risk."}
{"question_id": "54fefff26ad7dcbc1200000b", "question": "Are there web based self management strategies for chronic pain ?", "retrieved_chunks": [{"doc_id": "23538392", "chunk_id": "23538392_0", "score": 8.74492073059082, "text": "Web-based interventions may also be effective in enhancing self-management for individuals with chronic pain, but little is known about long-term effects. Research on Web-based interventions to support self-management following participation in pain management programs is limited. OBJECTIVE: The aim is to examine the long-term effects of a 4-week smartphone-intervention"}, {"doc_id": "23859438", "chunk_id": "23859438_0", "score": 7.57433557510376, "text": "Results suggest the potential value of self-management for chronic pain patients and the potential acceptability of web-based delivery of intervention content."}, {"doc_id": "21375412", "chunk_id": "21375412_0", "score": 3.698030471801758, "text": "therapy adaptation and the resultant specification for the SMART2 project-a technology-based self-management system for assisting long-term health conditions, including chronic pain"}], "context": "[23538392:23538392_0] Web-based interventions may also be effective in enhancing self-management for individuals with chronic pain, but little is known about long-term effects. Research on Web-based interventions to support self-management following participation in pain management programs is limited. OBJECTIVE: The aim is to examine the long-term effects of a 4-week smartphone-intervention\n[23859438:23859438_0] Results suggest the potential value of self-management for chronic pain patients and the potential acceptability of web-based delivery of intervention content.\n[21375412:21375412_0] therapy adaptation and the resultant specification for the SMART2 project-a technology-based self-management system for assisting long-term health conditions, including chronic pain", "answer": "<think> Okay, let's tackle this question. The user is asking if there are web-based self-management strategies for chronic pain. I need to look at the evidence provided to form an answer. First, I'll go through each of the evidence snippets. The first document (23538392) mentions that web-based interventions may be effective in enhancing self-management for chronic pain patients. It also says there's limited research on long-term effects. So this suggests that such strategies exist but the long-term effectiveness isn't well studied. The second snippet (23859438) states that results show potential value of self-management for chronic pain patients and that web-based delivery is acceptable. This supports the idea that there are web-based strategies, and they're", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if there are web-based self-management strategies for chronic pain. I need to look at the evidence provided to form an answer. First, I'll go through each of the evidence snippets. The first document (23538392) mentions that web-based interventions may be effective in enhancing self-management for chronic pain patients. It also says there's limited research on long-term effects. So this suggests that such strategies exist but the long-term effectiveness isn't well studied. The second snippet (23859438) states that results show potential value of self-management for chronic pain patients and that web-based delivery is acceptable. This supports the idea that there are web-based strategies, and they're", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking if there are web-based self-management strategies for chronic pain. I need to look at the evidence provided to form a concise answer with citations and a confidence level. First, I'll check each of the three evidence snippets. The first one (23538392:23538392_0) mentions that web-based interventions may be effective in enhancing self-management for chronic pain, but there's limited research on long-term effects. So this supports the existence of such strategies, though the evidence is about the potential effectiveness and limited study. The second snippet (23859438:23859438_0) states that results show the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking if there are web-based self-management strategies for chronic pain. I need to look at the evidence provided. First, document 23538392 mentions that web-based interventions may help with self-management for chronic pain, but there's limited research on long-term effects. That's a positive sign, indicating that such strategies exist but need more study. Then, document 23859438 says results show the potential value of self-management and that web-based delivery is acceptable. This supports the idea that web-based methods are viable. The third document, 21375412, talks about a technology-based system called SMART2 for long-term conditions, including chronic pain.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking if there are web-based self-management strategies for chronic pain. I need to look at the provided evidence to form an answer. First, check each document. The first one (23538392) mentions web-based interventions being effective for enhancing self-management in chronic pain, but notes limited research on long-term effects. The second (23859438) says results show potential value of self-management and acceptability of web-based delivery. The third (21375412) talks about a technology-based system called SMART2 for long-term conditions, including chronic pain. So, combining these, there are web-based strategies. The first document mentions interventions, the second supports", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking if there are web-based self-management strategies for chronic pain. I need to look at the provided evidence to form an answer. First, looking at the evidence documents. The first one (23538392:23538392_0) mentions that web-based interventions may enhance self-management for chronic pain but notes limited research on long-term effects. The second document (23859438:23859438_0) says results show the potential value of self-management and acceptability of web-based delivery. The third one (21375412:21375412_0) talks about", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking if there are web-based self-management strategies for chronic pain. I need to look at the provided evidence to form an answer. First, I check each of the three evidence snippets. The first one (23538392) mentions that web-based interventions may enhance self-management for chronic pain, but there's limited research on long-term effects. The second snippet (23859438) says results suggest the potential value of self-management and acceptability of web-based delivery. The third one (21375412) talks about a technology-based system called SMART2 for long-term conditions, including chronic pain. So, combining these, there are indeed web-based strategies", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The question is whether there are web-based self-management strategies for chronic pain. Let me look at the evidence. First, document 23538392:23538392_0 mentions that web-based interventions may be effective in enhancing self-management for chronic pain, but there's limited research on long-term effects. So this suggests that such strategies exist but their long-term effectiveness isn't well studied. Then, document 23859438:23859438_0 says results show the potential value of self-management for chronic pain patients and that web-based delivery is acceptable. This supports the existence of web-based strategies. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking if there are web-based self-management strategies for chronic pain. I need to look at the provided evidence to form an answer. First, evidence document 23538392:23538392_0 mentions that web-based interventions may enhance self-management for chronic pain, but long-term effects are not well studied. The study looked at a 4-week smartphone intervention. So that's a positive point, but it's about the potential effectiveness. Then there's 23859438:23859438_0 which says results suggest the value of self-management for chronic pain patients and that web-based delivery is acceptable. This supports the idea", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["23538392", "23768119", "23859438", "24067267", "24251273"], "ideal_answer": "Results suggest the potential value of self-management for chronic pain patients and the potential acceptability of web-based delivery of intervention content. Yes, there are successful web based self management strategies for chronic pain."}
{"question_id": "571f34ac0fd6f91b68000005", "question": "Is Weaver syndrome similar to Sotos?", "retrieved_chunks": [{"doc_id": "22287508", "chunk_id": "22287508_2", "score": 9.422014236450195, "text": "Weaver syndrome is closely related to Sotos syndrome,"}, {"doc_id": "22287508", "chunk_id": "22287508_1", "score": 9.268279075622559, "text": "Clinically, Weaver syndrome is closely related to Sotos syndrome, which is frequently caused by mutations in NSD1."}, {"doc_id": "22287508", "chunk_id": "22287508_0", "score": 9.163851737976074, "text": "Clinically, Weaver syndrome is closely related to Sotos syndrome, which is frequently caused by mutations in NSD1"}], "context": "[22287508:22287508_2] Weaver syndrome is closely related to Sotos syndrome,\n[22287508:22287508_1] Clinically, Weaver syndrome is closely related to Sotos syndrome, which is frequently caused by mutations in NSD1.\n[22287508:22287508_0] Clinically, Weaver syndrome is closely related to Sotos syndrome, which is frequently caused by mutations in NSD1", "answer": "<think> Okay, let's tackle this question. The user wants to know if Weaver syndrome is similar to Sotos. The evidence provided mentions that they are closely related. All the chunks from the same document (22287508) point out that clinically, Weaver and Sotos syndromes are closely related, with Sotos often caused by NSD1 mutations. First, I need to confirm if the answer is straightforward. The evidence directly states they are closely related, so the answer should reflect that. The citations are all from the same document, so I can reference them as [22287508:chunk_id]. The answer needs to be concise. So, \"Yes, Weaver syndrome is closely related to Sotos syndrome [22", "citations": [{"doc_id": "22287508", "chunk_id": "chunk_id"}], "candidates": [{"answer": "<think> Okay, the user is asking if Weaver syndrome is similar to Sotos. Let me check the evidence provided. Looking at the evidence, there are three chunks. All of them mention that Weaver syndrome is closely related to Sotos syndrome. The first chunk says they are closely related. The second and third chunks add that Sotos is often caused by mutations in the NSD1 gene. Wait, but the user is asking about similarities, not the cause. However, the evidence does state they are closely related clinically. So the answer should reflect that similarity. The base confidence here is high because all three pieces of evidence point to their close relationship. The model can be confident in this factual correctness. So the answer should be a concise statement citing the relevant chunk. Since chunks 2", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if Weaver syndrome is similar to Sotos. Looking at the evidence provided, there are three chunks from the same source, all pointing to a close relationship between the two syndromes. First, I need to check the evidence. All the chunks mention that Weaver syndrome is closely related to Sotos syndrome. The key point here is that they are similar in clinical features and that both are caused by mutations in the NSD1 gene. Wait, but wait—actually, the evidence says that Sotos syndrome is frequently caused by mutations in NSD1, while Weaver syndrome is related to Sotos. But I remember from my previous knowledge that Weaver syndrome is actually caused by mutations in the NF1 gene, whereas Sotos is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking if Weaver syndrome is similar to Sotos. Let me look at the evidence provided. The evidence has three chunks from the same document ID. All of them mention that Weaver syndrome is closely related to Sotos syndrome. The first chunk says they are closely related. The other two mention that clinically, they are closely related, and that Sotos is often caused by mutations in NSD1. Wait, but the user is asking about similarity, so the key point here is that the document states they are closely related. So the answer should be yes, based on the evidence. The confidence would be high since all three chunks support this. But I need to check if there's any conflicting info. No, all sources agree. So the answer is correct", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking if Weaver syndrome is similar to Sotos. Let me look at the evidence provided. The evidence has three chunks from the same document ID. All of them mention that Weaver syndrome is closely related to Sotos syndrome. The first chunk says they are closely related. The other two chunks add that clinically, they are closely related and that Sotos is often caused by mutations in the NSD1 gene. So the answer should state that they are similar, citing the document. The confidence level is high because all three chunks support the same point. The base_confidence can be 1.0 since the evidence is consistent across multiple chunks. I need to make sure the JSON is strict and only includes the answer and base_confidence keys. No extra text", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking if Weaver syndrome is similar to Sotos. Let me look at the evidence provided. The evidence has three chunks from the same document ID. All of them mention that Weaver syndrome is closely related to Sotos syndrome. The first chunk says they are closely related. The other two mention that clinically, they are closely related, and Sotos is often caused by mutations in NSD1. Wait, but the user is asking about similarity, so the key point here is that the document states they are closely related. So the answer should be yes, based on the evidence. The confidence level would be high because all three chunks support this. But I need to check if there's any conflicting information. No, all sources agree. So base_confidence can", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if Weaver syndrome is similar to Sotos. The evidence provided mentions that they are closely related. First, I need to check the evidence. All three chunks from the same document (22287508) say that Weaver and Sotos syndromes are closely related. The clinical aspects are similar, and both are caused by mutations in the NSD1 gene. Wait, but the user is asking for a biomedical answer. So I should confirm if they are indeed similar. The evidence directly states they are closely related, so the answer should reflect that. Now, the answer needs to be concise with citations. The document ID is 22287508, and the chunks", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if Weaver syndrome is similar to Sotos. The evidence provided mentions that they are closely related. All the chunks from the same document (22287508) point out that clinically, Weaver and Sotos syndromes are closely related, with Sotos often caused by NSD1 mutations. First, I need to confirm if the answer is straightforward. The evidence directly states they are closely related, so the answer should reflect that. The citations are all from the same document, so I can reference them as [22287508:chunk_id]. The answer needs to be concise. So, \"Yes, Weaver syndrome is closely related to Sotos syndrome [22", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if Weaver syndrome is similar to Sotos. The evidence provided mentions that they are closely related. All the chunks from the same document (22287508) point to their close relationship. First, I need to check the evidence. Each chunk says that clinically, Weaver and Sotos are closely related, and Sotos is often due to NSD1 mutations. Wait, but isn't NSD1 also involved in Weaver? Let me recall. Actually, Sotos syndrome is caused by mutations in NSD1, and Weaver syndrome is caused by mutations in the NKMAR1 gene. But the evidence here says that both are closely related, even though their causative genes are different. So the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["12464997", "12807965", "19011474", "22287508", "23592277", "24214728", "24852293", "9781911"], "ideal_answer": "Overgrowth conditions are a heterogeneous group of disorders characterised by increased growth and variable features, including macrocephaly, distinctive facial appearance and various degrees of learning difficulties and intellectual disability. Among them, Sotos and Weaver syndromes are clinically well defined and due to heterozygous mutations in NSD1 and EZH2, respectively. NSD1 and EZH2 are both histone-modifying enzymes Constitutional NSD1 and EZH2 mutations cause Sotos and Weaver syndromes respectively, overgrowth syndromes with considerable phenotypic overlap. NSD1 and EZH2 are SET domain-containing histone methyltransferases that play key roles in the regulation of transcription through histone modification and chromatin modeling."}
{"question_id": "54e0d1491388e8454a000014", "question": "Which enzyme is targeted by Evolocumab?", "retrieved_chunks": [{"doc_id": "24661068", "chunk_id": "24661068_0", "score": 6.792755126953125, "text": "AREAS COVERED: Evolocumab (AMG145) is a monoclonal antibody inhibiting the proprotein convertase subtilisin/kexin type 9 that binds to the liver LDL receptor and prevents it from normal recycling by targeting it for degradation."}, {"doc_id": "24961142", "chunk_id": "24961142_0", "score": 6.360899448394775, "text": "AREAS COVERED: Evolocumab and alirocumab are fully human monoclonal antibodies inhibiting the proprotein convertase subtilisin/kexin type 9 (PCSK9) that binds to hepatic LDL receptor and prevents it from normal recycling by targeting it for degradation."}, {"doc_id": "25282520", "chunk_id": "25282520_0", "score": 5.342667579650879, "text": "Evolocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), reduced LDL cholesterol by 16% in a pilot study."}], "context": "[24661068:24661068_0] AREAS COVERED: Evolocumab (AMG145) is a monoclonal antibody inhibiting the proprotein convertase subtilisin/kexin type 9 that binds to the liver LDL receptor and prevents it from normal recycling by targeting it for degradation.\n[24961142:24961142_0] AREAS COVERED: Evolocumab and alirocumab are fully human monoclonal antibodies inhibiting the proprotein convertase subtilisin/kexin type 9 (PCSK9) that binds to hepatic LDL receptor and prevents it from normal recycling by targeting it for degradation.\n[25282520:25282520_0] Evolocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), reduced LDL cholesterol by 16% in a pilot study.", "answer": "<think> Okay, let's tackle this question. The user is asking which enzyme is targeted by Evolocumab. I need to look at the evidence provided. First, looking at the evidence documents. The first one says Evolocumab is a monoclonal antibody that inhibits PCSK9 and binds to the liver LDL receptor. The second document mentions that both Evolocumab and alirocumab inhibit PCSK9 and bind to the hepatic LDL receptor. The third document states that Evolocumab targets PCSK9, reducing LDL cholesterol. So all three documents point to PCSK9 as the enzyme targeted by Evolocumab. The answer should be PCSK9. The confidence is high because all three sources consistently mention PCSK", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which enzyme is targeted by Evolocumab. I need to look at the evidence provided. First, looking at the evidence documents. The first one says Evolocumab is a monoclonal antibody that inhibits PCSK9 and binds to the liver LDL receptor. The second document mentions that both Evolocumab and alirocumab inhibit PCSK9 and bind to the hepatic LDL receptor. The third document states that Evolocumab targets PCSK9, reducing LDL cholesterol. So all three documents point to PCSK9 as the enzyme targeted by Evolocumab. The answer should be PCSK9. The confidence is high because all three sources consistently mention PCSK", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking which enzyme is targeted by Evolocumab. Let me look at the evidence provided. First evidence document 24661068:24661068_0 says Evolocumab inhibits PCSK9 and binds to the liver LDL receptor. So PCSK9 is the enzyme here. Then document 24961142:24961142_0 also mentions that both Evolocumab and alirocumab inhibit PCSK9, which binds to the LDL receptor. This reinforces that PCSK9 is the target. The third document 25282520:25282520_", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which enzyme is targeted by Evolocumab. I need to look at the evidence provided. First, looking at the evidence documents. The first one, 24661068:24661068_0, says that Evolocumab is a monoclonal antibody that inhibits PCSK9 and binds to the liver LDL receptor. It mentions preventing normal recycling by targeting it for degradation. So PCSK9 is involved here. The second document, 24961142:24961142_0, also states that Evolocumab and alirocumab inhibit PCSK9, which binds to", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which enzyme is targeted by Evolocumab. I need to look at the evidence provided. First, looking at the evidence snippets. The first one says Evolocumab is a monoclonal antibody that inhibits PCSK9 and binds to the liver LDL receptor. The second snippet mentions that both Evolocumab and alirocumab inhibit PCSK9 and bind to the hepatic LDL receptor. The third snippet states that Evolocumab targets PCSK9, reducing LDL cholesterol. So all three sources point to PCSK9 as the enzyme targeted by Evolocumab. The answer should be PCSK9. Now, checking the citations. The first evidence is 2", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking which enzyme is targeted by Evolocumab. Let me look at the evidence provided. First document: It says Evolocumab inhibits PCSK9 and binds to the liver LDL receptor, preventing it from recycling by targeting degradation. So PCSK9 is the enzyme here. Second document confirms that both Evolocumab and Alirocumab inhibit PCSK9, which binds to the hepatic LDL receptor. That's another citation pointing to PCSK9. Third document mentions Evolocumab targets PCSK9, reducing LDL cholesterol. So all three sources point to PCSK9 as the target enzyme. The answer should be PCSK9 with citations from the first and second documents. The confidence is high", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which enzyme is targeted by Evolocumab. I need to look at the evidence provided. First, looking at the evidence documents. The first one says Evolocumab is a monoclonal antibody that inhibits PCSK9 and binds to the liver LDL receptor. The second document mentions that both Evolocumab and Alirocumab inhibit PCSK9 and bind to the hepatic LDL receptor. The third document states that Evolocumab targets PCSK9, reducing LDL cholesterol. So all three documents point to PCSK9 as the enzyme targeted by Evolocumab. The answer should be PCSK9. Now, checking the citations. The first document mentions PCSK", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which enzyme is targeted by Evolocumab. Looking at the evidence provided, there are three documents. First, document 24661068:24661068_0 mentions that Evolocumab is a monoclonal antibody that inhibits PCSK9 and binds to the liver LDL receptor. So PCSK9 is the enzyme here. Then document 24961142:24961142_0 also states that both Evolocumab and Alirocumab inhibit PCSK9, which binds to the hepatic LDL receptor. This reinforces the idea that PCSK9 is the target. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking which enzyme is targeted by Evolocumab. Let me look at the evidence provided. First, the first evidence document says Evolocumab inhibits PCSK9 and binds to the liver LDL receptor. The second document mentions that both Evolocumab and alirocumab inhibit PCSK9 and bind to the hepatic LDL receptor. The third document states that Evolocumab targets PCSK9, reducing LDL cholesterol. So all three documents point to PCSK9 as the target enzyme. The answer should be PCSK9 with citations from the first and second documents. The confidence is high since all sources agree. I need to format the answer as JSON with the answer and base_confidence. Let me check the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["24255061", "24284914", "24373748", "24477778", "24481874", "24509273", "24598985", "24661068", "24662398", "24678979", "24691094", "24694531", "24825642", "24859266", "24953393", "24953396", "24961142", "25002170", "25052769", "25079474", "25282519", "25282520", "25410046", "25470376"], "ideal_answer": "Evolocumab (AMG145) is a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9) that demonstrated marked reductions in plasma low-density lipoprotein cholesterol concentrations in statin-intolerant patients."}
{"question_id": "553a8d78f321868558000003", "question": "Are ultraconserved elements often transcribed?", "retrieved_chunks": [{"doc_id": "23393190", "chunk_id": "23393190_5", "score": 6.222445487976074, "text": "The majority of these regions map onto ultraconserved elements and we demonstrate that they can act as functional enhancers within the organism of origin, as well as in cross-transgenesis experiments, and that they are transcribed in extant species of Olfactores. We refer to the elements as 'Olfactores conserved non-coding elements'"}, {"doc_id": "23393190", "chunk_id": "23393190_4", "score": 6.159970760345459, "text": "The majority of these regions map onto ultraconserved elements and we demonstrate that they can act as functional enhancers within the organism of origin, as well as in cross-transgenesis experiments, and that they are transcribed in extant species of Olfactores."}, {"doc_id": "23393190", "chunk_id": "23393190_3", "score": 5.898499488830566, "text": "The majority of these regions map onto ultraconserved elements and we demonstrate that they can act as functional enhancers within the organism of origin, as well as in cross-transgenesis experiments, and that they are transcribed in extant species of Olfactores"}], "context": "[23393190:23393190_5] The majority of these regions map onto ultraconserved elements and we demonstrate that they can act as functional enhancers within the organism of origin, as well as in cross-transgenesis experiments, and that they are transcribed in extant species of Olfactores. We refer to the elements as 'Olfactores conserved non-coding elements'\n[23393190:23393190_4] The majority of these regions map onto ultraconserved elements and we demonstrate that they can act as functional enhancers within the organism of origin, as well as in cross-transgenesis experiments, and that they are transcribed in extant species of Olfactores.\n[23393190:23393190_3] The majority of these regions map onto ultraconserved elements and we demonstrate that they can act as functional enhancers within the organism of origin, as well as in cross-transgenesis experiments, and that they are transcribed in extant species of Olfactores", "answer": "<think> Okay, let's see. The user is asking if ultraconserved elements are often transcribed. The evidence provided has three chunks from the same document, all referencing the same study. Looking at the evidence, each chunk says that \"they are transcribed in extant species of Olfactores.\" The key here is \"transcribed\" which directly answers the question. The term \"ultraconserved elements\" is mentioned in each chunk, so they're referring to those elements. The answer needs to be concise and include citations. The document ID is 23393190, and the chunks are 3, 4, and 5. But since all three chunks are similar, maybe the first one is sufficient. However, the user might", "citations": [], "candidates": [{"answer": "<think> Okay, let's see. The user is asking if ultraconserved elements are often transcribed. The evidence provided has three chunks from the same document, all referencing the same study. Looking at the evidence, each chunk says that \"they are transcribed in extant species of Olfactores.\" The key here is \"transcribed\" which directly answers the question. The term \"ultraconserved elements\" is mentioned in each chunk, so they're referring to those elements. The answer needs to be concise and include citations. The document ID is 23393190, and the chunks are 3, 4, and 5. But since all three chunks are similar, maybe the first one is sufficient. However, the user might", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this. The question is whether ultraconserved elements are often transcribed. The evidence provided has three chunks from the same document, all pointing to the same conclusion. Looking at the chunks, each mentions that \"they are transcribed in extant species of Olfactores.\" The key here is \"transcribed\" which directly answers the question. The confidence level should be high because all three sources agree. However, I need to check if there's any conflicting information, but there isn't. All chunks support the same point. So the answer is yes, and the confidence is 1.0 since the evidence clearly states this without contradiction. </think> { \"answer\": \"Yes, ultraconserved elements are transcribed in extant species of", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if ultraconserved elements are often transcribed. The evidence provided has three chunks from the same document, all referencing a study on \"Olfactores conserved non-coding elements.\" Each chunk says that these regions map onto ultraconserved elements and that they are transcribed in extant species of Olfactores. First, I need to parse the evidence. All three chunks mention that the elements are transcribed in extant species. The key point here is that the study demonstrates transcription of these elements. The answer should be based on this evidence. The question is about whether ultraconserved elements are often transcribed. The evidence directly states that they are transcribed, so the answer would be yes.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if ultraconserved elements are often transcribed. The evidence provided has three chunks from the same document, all referencing the same study (23393190) with different chunk IDs. Looking at the evidence, each chunk states that \"they are transcribed in extant species of Olfactores.\" The key here is \"transcribed\" which directly answers the question. The term \"ultraconserved elements\" is mentioned in each chunk, so the answer should link to those elements. The study mentions that these regions map onto ultraconserved elements and that they are transcribed. So the answer is yes, they are often transcribed. The confidence level is high because the same study repeatedly", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if ultraconserved elements are often transcribed. The evidence provided has three chunks from the same document, all referencing the same study. Looking at the evidence, each chunk says that the regions map onto ultraconserved elements and that they are transcribed in extant species of Olfactores. The key part here is \"they are transcribed in extant species of Olfactores.\" So the answer should be based on that statement. The study mentions that these elements are transcribed, so the answer is yes. The confidence level is high because the same point is repeated in all three chunks. The citations are from the same document, so the base confidence can be set to 1.0 since the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if ultraconserved elements are often transcribed. The evidence provided has three chunks from the same document, all referencing the same study. Looking at the evidence, each chunk says that \"they are transcribed in extant species of Olfactores.\" The key here is that the study shows these regions (which map onto ultraconserved elements) are transcribed. So the answer should be yes, based on the citations provided. Now, checking the confidence. All three chunks support the same point, so the model is confident. The confidence level is 1.0 since all sources agree without conflicting information. </think> { \"answer\": \"Yes, ultraconserved elements are often transcribed, as evidenced by", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if ultraconserved elements are often transcribed. The evidence provided has three chunks from the same document, all pointing to the same conclusion. First, I need to parse each chunk. All three mention that the regions map onto ultraconserved elements and that they are transcribed in extant species of Olfactores. The key part here is \"that they are transcribed in extant species of Olfactores.\" So the answer should be yes, they are transcribed. Now, checking the confidence. Since all three chunks support this statement, the model can be confident. But I need to make sure there's no conflicting information. The chunks are repetitive, so no contradictions. The confidence level would be high", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if ultraconserved elements are often transcribed. The evidence provided has three chunks from the same document, all referencing the same study (23393190). Looking at the evidence, each chunk says that \"they are transcribed in extant species of Olfactores.\" The key term here is \"transcribed,\" which directly answers the question. The chunks are repetitive but consistent. The study mentions that these regions (which map to ultraconserved elements) are transcribed in existing species of Olfactores. I need to make sure that the answer is concise and cites the correct document chunk. Since all three chunks are the same, I can pick one, like chunk 3.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["16705037", "19660540", "20202189", "21187392", "22094949", "22328099", "22617881", "23393190", "24037088", "24384562"], "ideal_answer": "Yes. Especially, a large fraction of non-exonic UCEs is transcribed across all developmental stages examined from only one DNA strand."}
{"question_id": "51404dd723fec90375000002", "question": "What is the methyl donor of DNA (cytosine-5)-methyltransferases?", "retrieved_chunks": [{"doc_id": "8065896", "chunk_id": "8065896_0", "score": 8.325078010559082, "text": "The DNA (cytosine-5)-methyltransferase (m5C-MTase) M.BspRI is able to accept the methyl group from the methyl donor S-adenosyl-L-methionine (AdoMet) in the absence of DNA. Transfer of the methyl group to the enzyme is a slow reaction relative to DNA methylation. S"}, {"doc_id": "8441637", "chunk_id": "8441637_0", "score": 6.531011581420898, "text": "All DNA (cytosine-5)-methyltransferases contain a single conserved cysteine. It has been proposed that this cysteine initiates catalysis by attacking the C6 of cytosine and thereby activating the normally inert C5 position."}, {"doc_id": "9576871", "chunk_id": "9576871_0", "score": 6.51622200012207, "text": "Most prokaryotic (cytosine-5)-DNA methyltransferases increase the frequency of deamination at the cytosine targeted for methylation in vitro in the absence of the cofactor S-adenosylmethionine (AdoMet) or the reaction product S-adenosylhomocysteine (AdoHcy)."}], "context": "[8065896:8065896_0] The DNA (cytosine-5)-methyltransferase (m5C-MTase) M.BspRI is able to accept the methyl group from the methyl donor S-adenosyl-L-methionine (AdoMet) in the absence of DNA. Transfer of the methyl group to the enzyme is a slow reaction relative to DNA methylation. S\n[8441637:8441637_0] All DNA (cytosine-5)-methyltransferases contain a single conserved cysteine. It has been proposed that this cysteine initiates catalysis by attacking the C6 of cytosine and thereby activating the normally inert C5 position.\n[9576871:9576871_0] Most prokaryotic (cytosine-5)-DNA methyltransferases increase the frequency of deamination at the cytosine targeted for methylation in vitro in the absence of the cofactor S-adenosylmethionine (AdoMet) or the reaction product S-adenosylhomocysteine (AdoHcy).", "answer": "<think> Okay, let's tackle this question. The user is asking about the methyl donor for DNA (cytosine-5)-methyltransferases. I need to look at the provided evidence to find the correct answer. Looking at the first evidence snippet [8065896:8065896_0], it mentions that the enzyme M.BspRI can accept a methyl group from S-adenosyl-L-methionine (AdoMet) in the absence of DNA. The text says that transferring the methyl group to the enzyme is a slow reaction compared to DNA methylation. So AdoMet is mentioned here as the methyl donor. The second snippet [8441637:8441637", "citations": [{"doc_id": "8065896", "chunk_id": "8065896_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the methyl donor for DNA (cytosine-5)-methyltransferases. I need to look at the provided evidence to find the correct answer. Looking at the first evidence snippet [8065896:8065896_0], it mentions that the enzyme M.BspRI can accept a methyl group from S-adenosyl-L-methionine (AdoMet) in the absence of DNA. The text says that transferring the methyl group to the enzyme is a slow reaction compared to DNA methylation. So AdoMet is mentioned here as the methyl donor. The second snippet [8441637:8441637", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the methyl donor for DNA (cytosine-5)-methyltransferases. I need to look at the provided evidence to find the correct answer. Looking at the first evidence snippet, it mentions that M.BspRI, a DNA methyltransferase, can accept the methyl group from S-adenosyl-L-methionine (AdoMet) in the absence of DNA. The text says that transferring the methyl group to the enzyme is a slow reaction compared to DNA methylation. So AdoMet is mentioned here as the methyl donor. The second snippet talks about a conserved cysteine in the enzymes, but it's about the mechanism of attacking cytosine's C6, not the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the methyl donor for DNA (cytosine-5)-methyltransferases. I need to look at the evidence provided to find the correct answer. Looking at the first piece of evidence, it mentions that M.BspRI, a DNA methyltransferase, can accept the methyl group from S-adenosyl-L-methionine (AdoMet) in the absence of DNA. The text says that transfer of the methyl group to the enzyme is a slow reaction compared to DNA methylation. So AdoMet is mentioned here as the methyl donor. The second evidence talks about a conserved cysteine in the enzyme, but it doesn't mention the methyl donor. It discusses the mechanism of attacking", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to figure out the methyl donor for DNA (cytosine-5)-methyltransferases based on the given evidence. Let me look at the evidence provided. The first document, 8065896:8065896_0, says that the enzyme M.BspRI can accept a methyl group from S-adenosyl-L-methionine (AdoMet) when DNA is absent. It also mentions that transferring the methyl group to the enzyme is a slow reaction compared to DNA methylation. So AdoMet is mentioned here as the methyl donor. The second document, 8441637:8441637_0, talks about a conserved cyste", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to figure out the methyl donor for DNA (cytosine-5)-methyltransferases based on the given evidence. Let me look at the evidence provided. First, the first document says that M.BspRI, a DNA (cytosine-5)-methyltransferase, can accept the methyl group from S-adenosyl-L-methionine (AdoMet) in the absence of DNA. The transfer of the methyl group to the enzyme is slow compared to DNA methylation. So that's a direct mention of AdoMet as the methyl donor. The second document talks about a conserved cysteine in all these enzymes, but it doesn't mention the methyl donor. It explains the mechanism involving the cysteine attacking", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the methyl donor for DNA (cytosine-5)-methyltransferases. I need to look at the evidence provided to find the correct answer. First, I check the first piece of evidence: [8065896:8065896_0]. It says that M.BspRI can accept a methyl group from S-adenosyl-L-methionine (AdoMet) in the absence of DNA. That seems directly relevant. The text mentions AdoMet as the methyl donor here. The second evidence [8441637:8441637_0] talks about a conserved cysteine in the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the methyl donor for DNA (cytosine-5)-methyltransferases. I need to look at the evidence provided to find the correct answer. First, looking at the evidence documents. The first one, 8065896:8065896_0, mentions that the enzyme M.BspRI can accept a methyl group from S-adenosyl-L-methionine (AdoMet) in the absence of DNA. That seems directly relevant. The second document talks about a conserved cysteine in the enzymes but doesn't mention the methyl donor. The third one discusses deamination and mentions AdoMet and AdoHcy as cofactors,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the methyl donor for DNA (cytosine-5)-methyltransferases. I need to look at the evidence provided to find the correct answer. Looking at the first evidence snippet, it mentions that M.BspRI, a DNA (cytosine-5)-methyltransferase, can accept the methyl group from S-adenosyl-L-methionine (AdoMet) in the absence of DNA. The text says that transfer of the methyl group to the enzyme is a slow reaction compared to DNA methylation. So AdoMet is mentioned here as the methyl donor. The second snippet talks about a conserved cysteine in the enzymes, but it doesn't mention the methyl donor", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["11208790", "15273274", "1584813", "7578083", "7607467", "8065896", "8441638"], "ideal_answer": "S-adenosyl-L-methionine (AdoMet, SAM) is the methyl donor of DNA (cytosine-5)-methyltransferases. DNA (cytosine-5)-methyltransferases catalyze the transfer of a methyl group from S-adenosyl-L-methionine to the C-5 position of cytosine residues in DNA."}
{"question_id": "552fa6f5bc4f83e828000002", "question": "Is peripheral neuroepithelioma related to Ewing sarcoma?", "retrieved_chunks": [{"doc_id": "7513503", "chunk_id": "7513503_1", "score": 9.991371154785156, "text": "Ewings sarcoma (ES) and peripheral neuroepithelioma (PN) are closely related tumors, and it can be difficult to distinguish them from other small-round-cell tumors (SRCTs)."}, {"doc_id": "1283315", "chunk_id": "1283315_1", "score": 9.887290954589844, "text": "Ewing's sarcoma (ES) and peripheral neuroepithelioma (PN) are related tumors, possibly of neural crest origin, which are cytogenetically characterized by the specific translocation t(11;22)(q24;q12)."}, {"doc_id": "7513503", "chunk_id": "7513503_0", "score": 9.874422073364258, "text": "Ewing's sarcoma (ES) and peripheral neuroepithelioma (PN) are closely related tumors, and it can be difficult to distinguish them from other small-round-cell tumors (SRCTs)"}], "context": "[7513503:7513503_1] Ewings sarcoma (ES) and peripheral neuroepithelioma (PN) are closely related tumors, and it can be difficult to distinguish them from other small-round-cell tumors (SRCTs).\n[1283315:1283315_1] Ewing's sarcoma (ES) and peripheral neuroepithelioma (PN) are related tumors, possibly of neural crest origin, which are cytogenetically characterized by the specific translocation t(11;22)(q24;q12).\n[7513503:7513503_0] Ewing's sarcoma (ES) and peripheral neuroepithelioma (PN) are closely related tumors, and it can be difficult to distinguish them from other small-round-cell tumors (SRCTs)", "answer": "<think> Okay, so the user is asking if peripheral neuroepithelioma is related to Ewing sarcoma. Let me look at the evidence provided. The first document says that Ewing's sarcoma (ES) and peripheral neuroepithelioma (PN) are closely related tumors and it's hard to tell them apart from other SRCTs. The second document mentions they're related, possibly of neural crest origin, with a specific translocation t(11;22)(q24;q12). The third document is similar to the first, repeating that they're closely related and difficult to distinguish. So all three sources indicate a close relationship between the two tumors. The key points are their closeness, difficulty in differentiation, and possible shared origin. The confidence", "citations": [], "candidates": [{"answer": "<think> Okay, so the user is asking if peripheral neuroepithelioma is related to Ewing sarcoma. Let me look at the evidence provided. The first document says that Ewing's sarcoma (ES) and peripheral neuroepithelioma (PN) are closely related tumors and it's hard to tell them apart from other SRCTs. The second document mentions they're related, possibly of neural crest origin, with a specific translocation t(11;22)(q24;q12). The third document is similar to the first, repeating that they're closely related and difficult to distinguish. So all three sources indicate a close relationship between the two tumors. The key points are their closeness, difficulty in differentiation, and possible shared origin. The confidence", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking if peripheral neuroepithelioma is related to Ewing sarcoma. Let me look at the evidence provided. The first piece of evidence from 7513503:7513503_1 says that Ewing's sarcoma (ES) and peripheral neuroepithelioma (PN) are closely related tumors, and it's hard to tell them apart from other SRCTs. That seems like a direct answer. Then there's another chunk from the same document, 7513503:7513503_0, which repeats the same point. The third evidence is from 1283315:1283315_", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to determine if peripheral neuroepithelioma is related to Ewing sarcoma based on the provided evidence. Let me look at the evidence chunks. The first chunk from 7513503:7513503_1 says that Ewing's sarcoma (ES) and peripheral neuroepithelioma (PN) are closely related tumors and it's hard to distinguish them from other SRCTs. That suggests a close relationship. The second chunk, 1283315:1283315_1, mentions they are related tumors possibly of neural crest origin with the same translocation t(11;22)(q24;q12). This genetic link supports their", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking if peripheral neuroepithelioma is related to Ewing sarcoma. Let me look at the evidence provided. The first evidence snippet says that Ewing's sarcoma (ES) and peripheral neuroepithelioma (PN) are closely related tumors and it's hard to tell them apart from other small-round-cell tumors. The second one mentions they are related, possibly of neural crest origin, with a specific translocation t(11;22). The third snippet is similar to the first, repeating that they're closely related and difficult to distinguish. So all three sources indicate a close relationship between the two tumors. They even mention similar genetic markers. The answer should confirm that they are related, citing the documents. The confidence level should", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking if peripheral neuroepithelioma is related to Ewing sarcoma. Let me look at the evidence provided. First, there are three chunks of evidence. The first one says that Ewing's sarcoma (ES) and peripheral neuroepithelioma (PN) are closely related tumors, and it's hard to distinguish them from other SRCTs. The second chunk mentions they are related tumors possibly of neural crest origin with the same translocation t(11;22)(q24;q12). The third chunk is similar to the first one, repeating the close relationship and difficulty in differentiation. So all three sources indicate a close relationship between the two tumors. The key points here are that they are closely related, possibly", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if peripheral neuroepithelioma is related to Ewing sarcoma. Looking at the evidence provided, there are three chunks. First, chunk 7513503_1 says they're closely related and hard to distinguish from other SRCTs. Then chunk 1283315_1 mentions they're related tumors possibly of neural crest origin with the same translocation t(11;22). The third chunk is similar to the first, repeating the closeness and difficulty in distinction. So, all the evidence points to them being closely related. The answer should state that they are related, citing the documents. The confidence level is high because multiple sources confirm this relationship. I", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking if peripheral neuroepithelioma is related to Ewing sarcoma. Let me look at the evidence provided. The first document says that Ewing's sarcoma (ES) and peripheral neuroepithelioma (PN) are closely related tumors and hard to distinguish from other SRCTs. The second document mentions they are related, possibly of neural crest origin, with a specific translocation t(11;22)(q24;q12). The third document is the same as the first one, repeating the same point. So all three sources confirm that these two tumors are closely related. They even mention similar genetic characteristics. The key here is that they are considered related, possibly sharing a common origin and similar cytogenetic", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking if peripheral neuroepithelioma is related to Ewing sarcoma. Let me look at the evidence provided. The first piece of evidence from 7513503:7513503_1 says that ES and PN are closely related tumors and hard to distinguish from other SRCTs. The second one, 1283315:1283315_1, mentions they're related, possibly of neural crest origin, with the same translocation t(11;22). The third chunk is similar to the first, repeating the closeness of the tumors. So all three sources indicate a close relationship between the two tumors. They even mention similar genetic markers. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["10968707", "1283315", "25303625", "3390826", "3760036", "7513503", "7595741", "7771924", "8204006", "8321753", "8644855", "9825003"], "ideal_answer": "Experimental data support the concept that Ewing sarcoma and peripheral neuroepithelioma are both peripheral primitive neuroectodermal neoplasms, differing only in the extent of neuroectodermal phenotype and morphological differentiation."}
{"question_id": "56d0451c3975bb303a00000e", "question": "Which signaling pathway does sonidegib inhibit?", "retrieved_chunks": [{"doc_id": "25981810", "chunk_id": "25981810_0", "score": 7.353166103363037, "text": "Hedgehog pathway signalling is aberrantly activated in around 95% of tumours. We assessed the antitumour activity of sonidegib, a Hedgehog signalling inhibitor, in patients with advanced basal cell carcinoma."}, {"doc_id": "25473003", "chunk_id": "25473003_1", "score": 5.5475172996521, "text": "The association between Hh activation status and tumor response to the Hh pathway inhibitor sonidegib (LDE225) was analyzed."}, {"doc_id": "24613036", "chunk_id": "24613036_0", "score": 5.544329643249512, "text": "Among such pathways, RAS/RAF/MEK/ERK, PI3K/AKT/mTOR, EGFR, and Notch are of particular interest because agents that selectively inhibit these pathways are available and can be readily combined with agents such as vismodegib, sonidegib (LDE225), and BMS-833923, which target smoothened-a key Hh pathway regulator."}], "context": "[25981810:25981810_0] Hedgehog pathway signalling is aberrantly activated in around 95% of tumours. We assessed the antitumour activity of sonidegib, a Hedgehog signalling inhibitor, in patients with advanced basal cell carcinoma.\n[25473003:25473003_1] The association between Hh activation status and tumor response to the Hh pathway inhibitor sonidegib (LDE225) was analyzed.\n[24613036:24613036_0] Among such pathways, RAS/RAF/MEK/ERK, PI3K/AKT/mTOR, EGFR, and Notch are of particular interest because agents that selectively inhibit these pathways are available and can be readily combined with agents such as vismodegib, sonidegib (LDE225), and BMS-833923, which target smoothened-a key Hh pathway regulator.", "answer": "<think> Okay, let's tackle this question. The user is asking which signaling pathway sonidegib inhibits. Looking at the evidence provided, there are three documents. First, document 25981810:25981810_0 mentions that sonidegib is a Hedgehog signalling inhibitor. That's pretty direct. Then, document 25473003:25473003_1 also talks about Hh activation and sonidegib as an Hh pathway inhibitor. The third document, 24613036:24613036_0, mentions that sonidegib targets smoothened, which is a key regulator", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which signaling pathway sonidegib inhibits. Looking at the evidence provided, there are three documents. First, document 25981810:25981810_0 mentions that sonidegib is a Hedgehog signalling inhibitor. That's pretty direct. Then, document 25473003:25473003_1 also talks about Hh activation and sonidegib as an Hh pathway inhibitor. The third document, 24613036:24613036_0, mentions that sonidegib targets smoothened, which is a key regulator", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which signaling pathway sonidegib inhibits. Looking at the evidence provided, there are three references. First, document 25981810 mentions that sonidegib is a Hedgehog signalling inhibitor. That seems direct. Then, document 25473003 also talks about Hh activation and sonidegib as an inhibitor. The third document, 24613036, refers to smoothened-a key Hh pathway regulator, which is part of the Hedgehog pathway. So all three sources point to the Hedgehog (Hh) pathway. The answer should be Hedgehog signaling pathway. The confidence is high because multiple documents", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which signaling pathway sonidegib inhibits. Looking at the evidence provided, there are three references. First, document 25981810 mentions that sonidegib is a Hedgehog signalling inhibitor. That's pretty direct. Then, document 25473003 talks about Hh activation and sonidegib as an inhibitor. The third document, 24613036, lists sonidegib along with others that target smoothened, which is part of the Hedgehog pathway. So all three pieces of evidence point to the Hedgehog pathway. The answer should be Hedgehog signaling pathway. The confidence is high because multiple sources", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which signaling pathway sonidegib inhibits. Looking at the evidence provided, there are three references. First, document 25981810:25981810_0 mentions that sonidegib is a Hedgehog signalling inhibitor. That's pretty direct. Then, document 25473003:25473003_1 also talks about Hh activation and sonidegib as an Hh pathway inhibitor. The third document, 24613036:24613036_0, mentions that sonidegib targets smoothened, which is a key regulator", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which signaling pathway sonidegib inhibits. Looking at the evidence provided, there are three documents mentioned. First, document 25981810:25981810_0 states that sonidegib is a Hedgehog signalling inhibitor. That's pretty direct. Then, document 25473003:25473003_1 mentions Hh activation status and sonidegib as an Hh pathway inhibitor. The third document, 24613036:24613036_0, talks about the Hh pathway regulator smoothened and mentions sonidegib", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which signaling pathway sonidegib inhibits. I need to look at the provided evidence to find the answer. First, looking at the evidence documents. The first one, 25981810:25981810_0, mentions that sonidegib is a Hedgehog signaling inhibitor. That seems directly relevant. The second document, 25473003:25473003_1, talks about Hh activation status and sonidegib as an Hh pathway inhibitor. The third document, 24613036:24613036_0, mentions that son", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which signaling pathway sonidegib inhibits. Looking at the evidence provided, there are three references. First, the document 25981810:25981810_0 mentions that sonidegib is a Hedgehog signalling inhibitor. That's pretty direct. Then, 25473003:25473003_1 also talks about Hh activation and sonidegib as an inhibitor. The third one, 24613036:24613036_0, mentions that sonidegib targets smoothened, which is a key regulator of the H", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which signaling pathway sonidegib inhibits. Looking at the evidence provided, there are three documents. First, document 25981810:25981810_0 mentions that sonidegib is a Hedgehog signalling inhibitor. That's pretty direct. Then, document 25473003:25473003_1 also talks about Hh activation and sonidegib as an Hh pathway inhibitor. The third document, 24613036:24613036_0, refers to smoothened-a key Hh pathway regulator, which is part of", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["24523439", "24598114", "24613036", "24817600", "24928708", "25473003", "25646180", "25981810"], "ideal_answer": "Sonidegib is a Hedghog signalling pathway inhibitor."}
{"question_id": "54ede8c594afd61504000009", "question": "In which phase of the cell cycle arrest is impaired in Fanconi anemia?", "retrieved_chunks": [{"doc_id": "11035915", "chunk_id": "11035915_1", "score": 8.095922470092773, "text": "Arrest of S-phase progression is impaired in Fanconi anemia cells."}, {"doc_id": "11035915", "chunk_id": "11035915_0", "score": 7.926003932952881, "text": "Arrest of S-phase progression is impaired in Fanconi anemia cells"}, {"doc_id": "11749045", "chunk_id": "11749045_0", "score": 6.368258953094482, "text": "The 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase."}], "context": "[11035915:11035915_1] Arrest of S-phase progression is impaired in Fanconi anemia cells.\n[11035915:11035915_0] Arrest of S-phase progression is impaired in Fanconi anemia cells\n[11749045:11749045_0] The 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase.", "answer": "<think> Okay, let's tackle this question. The user is asking which phase of the cell cycle is impaired in Fanconi anemia. The evidence provided has three chunks. First, I need to understand what each chunk says. The first two chunks (both from 11035915) mention that arrest of S-phase progression is impaired in Fanconi anemia cells. So that's directly pointing to the S phase. The third chunk (from 11749045) talks about a 4N cell cycle delay reflecting growth arrest in late S phase. So, the key here is that multiple sources mention the S phase. The first two chunks are duplicates, so they reinforce each other. The third chunk adds more detail by specifying \"late", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which phase of the cell cycle is impaired in Fanconi anemia. The evidence provided has three chunks. First, I need to understand what each chunk says. The first two chunks (both from 11035915) mention that arrest of S-phase progression is impaired in Fanconi anemia cells. So that's directly pointing to the S phase. The third chunk (from 11749045) talks about a 4N cell cycle delay reflecting growth arrest in late S phase. So, the key here is that multiple sources mention the S phase. The first two chunks are duplicates, so they reinforce each other. The third chunk adds more detail by specifying \"late", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to figure out the answer to the question about which phase of the cell cycle is impaired in Fanconi anemia based on the given evidence. Let me start by looking at the evidence provided. The first two entries from document 11035915 mention that \"Arrest of S-phase progression is impaired in Fanconi anemia cells.\" So that's a direct statement about the S phase. The third entry from document 11749045 says that the 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase. Wait, the term \"4N\" refers to cells with twice the amount of DNA, which is typical after replication, so that's probably referring to the S phase where", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which phase of the cell cycle is impaired in Fanconi anemia. The evidence provided has three chunks. First, I need to understand what each chunk says. The first two chunks (both from 11035915) mention that arrest of S-phase progression is impaired in Fanconi anemia cells. The third chunk (from 11749045) says that the 4N cell cycle delay reflects growth arrest in late S phase. So, the key here is to determine if the answer is about the S phase. The first two chunks directly state that S-phase progression is impaired. The third chunk adds that the delay is in late S phase. But the question is about", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which phase of the cell cycle is impaired in Fanconi anemia. The evidence provided has three entries. First, I need to look at the evidence. The first two entries (both from 11035915) mention that arrest of S-phase progression is impaired in Fanconi anemia cells. The third entry (from 11749045) says that the 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase. So, the key term here is \"S-phase.\" The first two pieces of evidence directly state that the S-phase progression is impaired. The third one talks about a 4N delay, which is related to the S", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which phase of the cell cycle is impaired in Fanconi anemia. The evidence provided has three chunks. First, I need to understand what each chunk says. The first two chunks (both from 11035915) mention that arrest of S-phase progression is impaired in Fanconi anemia cells. The third chunk (from 11749045) states that the 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase. So, the key here is the S-phase. The first two chunks directly mention S-phase progression being impaired. The third one talks about a 4N delay, which I think refers to cells with twice the normal", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which phase of the cell cycle is impaired in Fanconi anemia. The evidence provided has three entries. First, I need to understand what each of these evidence points says. The first two entries (11035915:11035915_1 and 0) both mention that arrest of S-phase progression is impaired in Fanconi anemia cells. So that's a direct statement about the S phase. The third entry (11749045:11749045_0) talks about a 4N cell cycle delay reflecting growth arrest in late S phase. The term \"late S phase\" is part of the S", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which phase of the cell cycle is impaired in Fanconi anemia. The evidence provided has three chunks. First, I need to understand what each chunk says. The first two chunks (11035915_1 and 11035915_0) both mention that arrest of S-phase progression is impaired in Fanconi anemia cells. So that's a key point. The third chunk (11749045_0) says that the 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase. Now, the question is about which phase is impaired. The term \"S-phase progression\" is mentioned in the first two", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which phase of the cell cycle is impaired in Fanconi anemia. The evidence provided has three chunks. First, I need to understand what each chunk says. The first two chunks (both from 11035915) mention that arrest of S-phase progression is impaired in Fanconi anemia cells. The third chunk (from 11749045) talks about a 4N cell cycle delay reflecting growth arrest in late S phase. So, the key here is to determine if the impairment is in the S phase. The first two chunks directly state that S-phase progression is impaired. The third chunk mentions late S phase, which is part of the S phase. So all", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["11035915", "11749045", "14988723", "9414295", "9650445"], "ideal_answer": "In response to damage induced by DNA cross-linking agents, the S-phase checkpoint is inefficient in Fanconi anemia (FA) cells, leading to accumulation of secondary lesions, such as single- and double-strand breaks and gaps. The prolonged time in G2 phase seen in FA cells therefore exists in order to allow the cells to remove lesions which accumulated during the preceding abnormal S phase."}
{"question_id": "56c3327c50c68dd41600000c", "question": "Which DNA sequences are more prone for the formation of R-loops?", "retrieved_chunks": [{"doc_id": "24743386", "chunk_id": "24743386_1", "score": 7.385017395019531, "text": "Finally, non-denaturing bisulfite mapping of the displaced single-stranded DNA confirmed R-loop formation at the endogenous FMR1 locus and further indicated that R-loops formed over CGG repeats may be prone to structural complexities, including hairpin formation, not commonly associated with other R-loops."}, {"doc_id": "24743386", "chunk_id": "24743386_0", "score": 7.1751389503479, "text": "Finally, non-denaturing bisulfite mapping of the displaced single-stranded DNA confirmed R-loop formation at the endogenous FMR1 locus and further indicated that R-loops formed over CGG repeats may be prone to structural complexities, including hairpin formation, not commonly associated with other R-loops"}, {"doc_id": "22464440", "chunk_id": "22464440_0", "score": 4.766057968139648, "text": "Ginno et al. (2012) describe unusual sequence features at promoter CpG islands that can lead to formation of persistent RNA-DNA hybrids (R loops), which are proposed to prevent genomic DNA methylation"}], "context": "[24743386:24743386_1] Finally, non-denaturing bisulfite mapping of the displaced single-stranded DNA confirmed R-loop formation at the endogenous FMR1 locus and further indicated that R-loops formed over CGG repeats may be prone to structural complexities, including hairpin formation, not commonly associated with other R-loops.\n[24743386:24743386_0] Finally, non-denaturing bisulfite mapping of the displaced single-stranded DNA confirmed R-loop formation at the endogenous FMR1 locus and further indicated that R-loops formed over CGG repeats may be prone to structural complexities, including hairpin formation, not commonly associated with other R-loops\n[22464440:22464440_0] Ginno et al. (2012) describe unusual sequence features at promoter CpG islands that can lead to formation of persistent RNA-DNA hybrids (R loops), which are proposed to prevent genomic DNA methylation", "answer": "<think> Okay, the user is asking which DNA sequences are more prone to forming R-loops. Let me look at the evidence provided. First, there's a document [24743386:24743386_1] that mentions R-loop formation at the FMR1 locus involving CGG repeats. It says these R-loops are prone to structural complexities like hairpins. Another chunk from the same doc [24743386:24743386_0] repeats this info. Then there's [22464440:2246444So_0] which talks about promoter CpG islands with unusual sequences leading to R-loops, possibly preventing", "citations": [{"doc_id": "24743386", "chunk_id": "24743386_1"}, {"doc_id": "24743386", "chunk_id": "24743386_0"}, {"doc_id": "22464440", "chunk_id": "2246444So_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which DNA sequences are more prone to forming R-loops. The evidence provided has three chunks. First, chunk 24743386_1 and 会影响 the same thing: they mention that R-loops formed over CGG repeats are prone to structural complexities like hairpin formation. So that's a direct citation pointing to CGG repeats. Then there's chunk 22464440_0, which talks about promoter CpG islands having unusual sequence features leading to R-loop formation. But the key here is that the first part specifically mentions CGG repeats, which are a type of repetitive sequence. The other chunk mentions CpG islands, but it's more general.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which DNA sequences are more prone to forming R-loops. The evidence provided has three chunks. First, looking at the first two chunks from 24743386: they mention that R-loops formed over CGG repeats are prone to structural complexities like hairpin formation. That seems directly relevant. The third chunk from 22464440 talks about promoter CpG islands with unusual sequence features leading to R-loop formation, but it doesn't specify the exact sequences. So, the main point here is that CGG repeats are mentioned as being associated with structural complexities that make R-loops more likely. The other chunk mentions CpG islands, but since the question is about specific", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which DNA sequences are more prone to forming R-loops. The evidence provided has three documents. First, looking at the first two documents (24743386), they mention that R-loops formed over CGG repeats may be prone to structural complexities like hairpin formation. That seems directly relevant. The third document (22464440) talks about promoter CpG islands having unusual sequence features that lead to R-loop formation, but it doesn't specify the exact sequences. The question is about which sequences are more prone. The first two documents specifically point to CGG repeats. The third one mentions CpG islands, but the answer needs to be based on the evidence. Since", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which DNA sequences are more prone to forming R-loops. The evidence provided has three chunks. First, looking at the first two chunks from 24743386: they mention that R-loops formed over CGG repeats may be prone to structural complexities like hairpin formation. That seems directly relevant. The third chunk from 22464440 talks about promoter CpG islands with unusual sequence features leading to R-loop formation, but it doesn't specify the exact sequences. So, the key points here are CGG repeats and CpG islands. However, the first two chunks specifically point to CGG repeats being associated with structural issues that make R-loops more likely. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which DNA sequences are more prone to forming R-loops. The evidence provided has three chunks. First, looking at the first two chunks from 24743386: they mention that R-loops formed over CGG repeats are prone to structural complexities like hairpin formation. That seems directly relevant. The third chunk from 22464440 talks about promoter CpG islands with unusual sequence features leading to R-loop formation, but it's more general. So the key point here is that CGG repeats are mentioned specifically in the first two chunks as being associated with structural issues that make R-loops more likely. The other chunk mentions CpG islands but doesn't specify a particular sequence", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which DNA sequences are more prone to forming R-loops. The evidence provided has three chunks. First, looking at the first two chunks from 24743386: they mention that R-loops formed over CGG repeats are prone to structural complexities like hairpin formation. That seems directly relevant. The third chunk from 22464440 talks about promoter CpG islands having unusual sequences leading to R-loop formation, but it's a bit more general. So the key point here is that CGG repeats, as mentioned in the first two chunks, are associated with structural issues that make R-loops more likely. The other chunk mentions CpG islands, but the specific sequence feature", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking which DNA sequences are more prone to forming R-loops. Let me look at the evidence provided. First, there's a document [24743386:24743386_1] that mentions R-loop formation at the FMR1 locus involving CGG repeats. It says these R-loops are prone to structural complexities like hairpins. Another chunk from the same doc [24743386:24743386_0] repeats this info. Then there's [22464440:2246444So_0] which talks about promoter CpG islands with unusual sequences leading to R-loops, possibly preventing", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which DNA sequences are more prone to forming R-loops. The evidence provided has three chunks. First, looking at the first two chunks from 24743386: they mention that R-loops formed over CGG repeats are prone to structural complexities like hairpin formation. That's a direct statement about CGG repeats being more likely to form R-loops. The third chunk from 22464440 talks about promoter CpG islands having unusual sequences leading to R-loop formation, but it doesn't specify the exact sequence features. So the main evidence pointing to a specific sequence is the CGG repeats in the first two chunks. The other chunk mentions CpG islands but doesn", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["15531884", "16793409", "18986989", "20080737", "22464440", "24743386", "24787137", "24843019", "25147206", "25296254", "25972891"], "ideal_answer": "R-loops, transcriptionally-induced RNA:DNA hybrids, occurring at repeat tracts (CTG)n, (CAG)n, (CGG)n, (CCG)n and (GAA)n, are associated with diseases including myotonic dystrophy, Huntington's disease, fragile X and Friedreich's ataxia. Physiological R-loop formation at CpG island promoters can contribute to DNA replication origin specification at these regions, the most efficient replication initiation sites in mammalian cells. R-loops may also possess beneficial effects, as their widespread formation has been detected over CpG island promoters in human genes. R-loops are particularly enriched over G-rich terminator elements."}
{"question_id": "551c23bc6b348bb82c00000b", "question": "Mutation of which gene is implicated in the familial isolated pituitary adenoma?", "retrieved_chunks": [{"doc_id": "23371967", "chunk_id": "23371967_0", "score": 8.3985013961792, "text": "Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene."}, {"doc_id": "22527616", "chunk_id": "22527616_1", "score": 8.271871566772461, "text": "Genetic analysis in a patient presenting with meningioma and familial isolated pituitary adenoma (FIPA) reveals selective involvement of the R81X mutation of the AIP gene in the pathogenesis of the pituitary tumor."}, {"doc_id": "24078436", "chunk_id": "24078436_0", "score": 8.087667465209961, "text": "Familial isolated pituitary adenoma caused by a Aip gene mutation not described before in a family context."}], "context": "[23371967:23371967_0] Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.\n[22527616:22527616_1] Genetic analysis in a patient presenting with meningioma and familial isolated pituitary adenoma (FIPA) reveals selective involvement of the R81X mutation of the AIP gene in the pathogenesis of the pituitary tumor.\n[24078436:24078436_0] Familial isolated pituitary adenoma caused by a Aip gene mutation not described before in a family context.", "answer": "<think> Okay, let's tackle this question. The user is asking which gene mutation is implicated in familial isolated pituitary adenoma (FIPA). The evidence provided has three references. First, I need to look at each of the evidence points. The first one says that FIPA is linked to mutations in the AIP gene. The second mention also talks about the R81X mutation of the AIP gene in a patient with meningioma and FIPA. The third reference mentions a new Aip gene mutation in a family context. So all three sources point to the AIP gene. The answer should be AIP. Now, checking the confidence. Since all three pieces of evidence consistently cite AIP, the confidence is high. The model is confident because there's no", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which gene mutation is implicated in familial isolated pituitary adenoma (FIPA). The evidence provided has three references. First, I need to look at each of the evidence points. The first one says that FIPA is linked to mutations in the AIP gene. The second mention also talks about the R81X mutation of the AIP gene in a patient with meningioma and FIPA. The third reference mentions a new Aip gene mutation in a family context. So all three sources point to the AIP gene. The answer should be AIP. Now, checking the confidence. Since all three pieces of evidence consistently cite AIP, the confidence is high. The model is confident because there's no", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which gene mutation is associated with familial isolated pituitary adenoma (FIPA). The evidence provided has three references. First, I need to look at each of the evidence points. The first one says that FIPA is linked to mutations in the AIP gene. The second mention also talks about the R81X mutation in the AIP gene being involved. The third reference mentions a new Aip mutation in a family context. All three sources point to the AIP gene. The answer should be AIP. The confidence is high because all three studies mention it. But I need to check if there's any conflicting information. No, all are consistent. So the answer is AIP with citations from the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which gene mutation is implicated in familial isolated pituitary adenoma (FIPA). The evidence provided has three references. First, I need to look at each of the evidence points. The first one says that FIPA is linked to mutations in the AIP gene. The second mention also talks about the R81X mutation in the AIP gene being involved. The third reference also points to the Aip gene mutation causing familial isolated pituitary adenoma. All three sources consistently mention the AIP gene. The first one directly states that mutations in the AIP gene are responsible. The second and third references provide more specific details about the mutation (R81X) and confirm the gene's role again", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to figure out which gene mutation is associated with familial isolated pituitary adenoma based on the given evidence. Let me look at the references provided. The first document, 23371967:23371967_0, mentions that FIPA is linked to mutations in the AIP gene. The second one, 22527616:22527616_1, specifically talks about the R81X mutation of the AIP gene in a patient with meningioma and FIPA. The third document, 24078436:24078437_0, also points to the Aip gene mutation in", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which gene mutation is implicated in familial isolated pituitary adenoma (FIPA). The evidence provided has three references. First, I need to look at each of the evidence points. The first one says that FIPA is linked to mutations in the AIP gene. The second reference mentions the R81X mutation of the AIP gene in a patient with meningioma and FIPA. The third evidence states that a new Aip gene mutation causes familial isolated pituitary adenoma. So all three sources point to the AIP gene. The first one directly states that, the second provides a specific mutation within AIP, and the third confirms AIP again. The question is about the gene, not the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which gene mutation is associated with familial isolated pituitary adenoma (FIPA). Looking at the evidence provided, there are three references. First, the document 23371967 mentions that AIP gene mutations are involved in FIPA. Then, 22527616 talks about the R81X mutation in the AIP gene being linked to FIPA. The third one, 24078436, also points to the AIP gene mutation causing familial cases. So all three sources point to the AIP gene. The answer should be AIP. The confidence is high since all three pieces of evidence support this. I need to make", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which gene mutation is implicated in familial isolated pituitary adenoma (FIPA). The evidence provided has three references. First, I need to look at each of the evidence points. The first one says that FIPA is linked to mutations in the AIP gene. The second mention also talks about the R81X mutation of the AIP gene being involved. The third reference mentions a new Aip gene mutation in a family context. All three sources point to the AIP gene. The answer should be straightforward: AIP gene. The confidence is high because all three pieces of evidence consistently mention AIP. However, I need to check if there's any conflicting information. No, all three are in agreement", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to figure out which gene mutation is associated with familial isolated pituitary adenoma based on the given evidence. Let me look at the evidence provided. The first document, 23371967:23371967_0, mentions that FIPA is linked to mutations in the AIP gene. The second one, 22527616:22527616_1, specifically talks about the R81X mutation of the AIP gene in a patient with meningioma and FIPA. The third document, 24078436:24078439_0, states that a new Aip gene mutation causes", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["17244780", "17893250", "17961654", "17993773", "19883897", "20457215", "20506337", "20570174", "20616498", "20616502", "20669561", "20833337", "21450940", "21454441", "21498161", "21778740", "22291433", "22527616", "22584704", "22915287", "23038625", "23286415", "23310926", "23371967", "23633209", "23652674", "23743763", "24050928", "24078436", "24366639", "24423289", "24789813", "24996936"], "ideal_answer": "Mutation of aryl hydrocarbon receptor interacting protein (AIP) gene was implicated in the familial isolated pituitary adenoma (FIPA) syndrome. About 20% of the families with FIPA harbor inactivating mutation in AIP gene."}
{"question_id": "5314a7a4dae131f847000003", "question": "which mutations of troponin C gene have been found to cause hypertrophic cardiomyopathy?", "retrieved_chunks": [{"doc_id": "18285522", "chunk_id": "18285522_0", "score": 8.698280334472656, "text": "The cardiac troponin C (cTnC) mutation, L29Q, has been found in a patient with familial hypertrophic cardiomyopathy."}, {"doc_id": "21262074", "chunk_id": "21262074_1", "score": 8.68394660949707, "text": "We report the first frameshift mutation (c.363dupG or p.Gln122AlafsX30) in Troponin C causing hypertrophic cardiomyopathy (and sudden cardiac death) in a 19-year-old male, and have demonstrated that the mutation segregates with hypertrophic cardiomyopathy within the family."}, {"doc_id": "22815480", "chunk_id": "22815480_0", "score": 8.005660057067871, "text": "A mutation in TNNC1-encoded cardiac troponin C, TNNC1-A31S, predisposes to hypertrophic cardiomyopathy and ventricular fibrillation."}], "context": "[18285522:18285522_0] The cardiac troponin C (cTnC) mutation, L29Q, has been found in a patient with familial hypertrophic cardiomyopathy.\n[21262074:21262074_1] We report the first frameshift mutation (c.363dupG or p.Gln122AlafsX30) in Troponin C causing hypertrophic cardiomyopathy (and sudden cardiac death) in a 19-year-old male, and have demonstrated that the mutation segregates with hypertrophic cardiomyopathy within the family.\n[22815480:22815480_0] A mutation in TNNC1-encoded cardiac troponin C, TNNC1-A31S, predisposes to hypertrophic cardiomyopathy and ventricular fibrillation.", "answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The question is about which mutations of the troponin C gene cause hypertrophic cardiomyopathy. Looking at the evidence, there are three references. Let me check each one: First, [18285522:18285522_0] mentions the L29Q mutation in cTnC causing familial HCM. That's one mutation. Second, [21262074:21262074_1] talks about a frameshift mutation c.363dupG leading to p.Gln122AlafsX30 in Troponin C, causing HCM and sudden death", "citations": [{"doc_id": "18285522", "chunk_id": "18285522_0"}, {"doc_id": "21262074", "chunk_id": "21262074_1"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which mutations in the troponin C gene cause hypertrophic cardiomyopathy. The evidence provided has three references. First, I need to look at each of the three pieces of evidence. The first one mentions the L29Q mutation in cTnC linked to familial HCM. The second talks about a frameshift mutation c.363dupG leading to p.Gln122AlafsX30, causing HCM and sudden death. The third reference points out TNNC1-A31S mutation in TNNC1 associated with HCM and ventricular fibrillation. So the answer should list these mutations. Each has a citation. The user wants a concise answer with citations", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking which mutations in the troponin C gene cause hypertrophic cardiomyopathy. Let me look at the evidence provided. First, there's the L29Q mutation mentioned in document 18285522. That's one example. Then there's the frameshift mutation c.363dupG leading to p.Gln122AlafsX30 from 21262074. That's another one. The third piece of evidence is TNNC1-A31S from 22815480. So, the answer needs to list these mutations. Each has a citation. The user wants a concise answer with citations in [doc_id:chunk_id", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's see. The user is asking which mutations of the troponin C gene have been found to cause hypertrophic cardiomyopathy. The evidence provided has three references. First, I need to extract the specific mutations from each document. The first one mentions L29Q. The second talks about a frameshift mutation c.363dupG leading to p.Gln122AlafsX30. The third reference states TNNC1-A31S. I should list all these mutations as the answer. Each has a citation. Now, the base confidence. The model's confidence here is based on the number of references provided. Since there are three different mutations each from separate studies, the confidence would be high. But I need", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking which mutations of the troponin C gene have been found to cause hypertrophic cardiomyopathy. Let me look at the evidence provided. First, there's a mutation called L29Q in the cardiac troponin C gene (cTnC) that's associated with familial hypertrophic cardiomyopathy. That's from document 18285522:18285522_0. Then there's another one, a frameshift mutation c.363dupG leading to p.Gln122AlafsX30 in Troponin C, which causes HCM and sudden cardiac death. That's from 21262074:2126", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's see. The user is asking which mutations in the troponin C gene cause hypertrophic cardiomyopathy. The evidence provided has three references. First, reference 18285522 mentions L29Q mutation. Then, 21262074 talks about a frameshift mutation c.363dupG leading to p.Gln122AlafsX30. The third one, 22815480, points out TNNC1-A31S. I need to list all these mutations as answers. Each has a citation. The answer should be concise, so maybe list them all with their respective document IDs and chunk IDs. The confidence is based on the number", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The question is about which mutations of the troponin C gene cause hypertrophic cardiomyopathy. Looking at the evidence, there are three references. Let me check each one: First, [18285522:18285522_0] mentions the L29Q mutation in cTnC causing familial HCM. That's one mutation. Second, [21262074:21262074_1] talks about a frameshift mutation c.363dupG leading to p.Gln122AlafsX30 in Troponin C, causing HCM and sudden death", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, the user is asking which mutations of the troponin C gene have been found to cause hypertrophic cardiomyopathy. Let me look at the evidence provided. First, there's the L29Q mutation mentioned in document 18285522. That's one example. Then, the frameshift mutation c.363dupG leading to p.Gln122AlafsX30 from document 21262074. That's another one. The third piece of evidence is TNNC1-A31S from document 22815480. So, the answer needs to list these three mutations. Each has a citation. The user wants a concise answer with citations in", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which mutations in the troponin C gene are associated with hypertrophic cardiomyopathy. The evidence provided has three documents. First, I need to look at each of the citations. The first one mentions L29Q mutation in cTnC causing familial HCM. The second talks about a frameshift mutation c.363dupG leading to p.Gln122AlafsX30, which is linked to HCM and sudden death. The third cites TNNC1-A31S mutation in TNNC1 causing HCM and ventricular fibrillation. So the answer should list all three mutations mentioned. Each has a specific citation. Now, I need to make sure each", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["16302972", "18285522", "18572189", "19439414", "19506933", "20459070", "20566645", "21262074", "22489623", "22815480", "23425245", "24260207"], "ideal_answer": "The following mutations of troponin C gene have been found to cause hypertrophic cardiomyopathy: L29Q; A8V; A31S; E134D; c.363dupG; A23Q; D145E and C84Y"}
{"question_id": "535d78137d100faa09000005", "question": "What is known about the effect of acupuncture in smoking cessation ?", "retrieved_chunks": [{"doc_id": "15861492", "chunk_id": "15861492_0", "score": 5.501813888549805, "text": "auricular acupuncture in smoking cessation has some effect."}, {"doc_id": "18405159", "chunk_id": "18405159_0", "score": 5.015536308288574, "text": "Acupuncture combined with auricular point sticking and pressing has reliable therapeutic effect for smoking cessation"}, {"doc_id": "17264832", "chunk_id": "17264832_0", "score": 4.5480427742004395, "text": "Auricular acupuncture appears to be effective for smoking cessation, but the effect may not depend on point location."}], "context": "[15861492:15861492_0] auricular acupuncture in smoking cessation has some effect.\n[18405159:18405159_0] Acupuncture combined with auricular point sticking and pressing has reliable therapeutic effect for smoking cessation\n[17264832:17264832_0] Auricular acupuncture appears to be effective for smoking cessation, but the effect may not depend on point location.", "answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is about the effect of acupuncture in smoking cessation. Let me look at the evidence provided. First, evidence [15861492:15861492_0] says that auricular acupuncture has some effect. Then [18405159:18405159_0] mentions acupuncture combined with auricular point sticking and pressing has a reliable therapeutic effect. The third evidence [17264832:17264832_0] states that auricular acupuncture is effective but the effect may not depend on point location. So, combining these, the answer should mention that", "citations": [{"doc_id": "15861492", "chunk_id": "15861492_0"}, {"doc_id": "18405159", "chunk_id": "18405159_0"}, {"doc_id": "17264832", "chunk_id": "17264832_0"}], "candidates": [{"answer": "<think> Okay, so the user is asking about the effect of acupuncture in smoking cessation. Let me look at the evidence provided. First, there's the evidence from 15861492:15861492_0 which says auricular acupuncture has some effect. Then 18405159:18405159_0 mentions combining acupuncture with auricular point sticking and pressing has a reliable therapeutic effect. Lastly, 17264832:17264832_0 states that auricular acupuncture is effective but the effect might not depend on point location. I need to synthesize these points into a concise answer. The key points are that auricular acupuncture is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so I need to generate a JSON answer about the effect of acupuncture in smoking cessation based on the given evidence. Let me start by looking at the evidence provided. The user has three references. The first one says that auricular acupuncture in smoking cessation has some effect. The second mentions that combining acupuncture with auricular point sticking and pressing has a reliable therapeutic effect. The third states that auricular acupuncture is effective for smoking cessation, but the effect might not depend on point location. I need to synthesize this information into a concise answer. The key points here are that auricular acupuncture is effective, and when combined with other methods like pressing, it's reliable. Also, there's mention that the effectiveness might not rely on specific points. So the answer should state that aur", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the effect of acupuncture in smoking cessation. I need to look at the provided evidence to form a concise answer with citations and a confidence level. First, I'll go through each piece of evidence. The first one says that auricular acupuncture has some effect on smoking cessation. The second mentions that combining acupuncture with auricular point sticking and pressing has a reliable therapeutic effect. The third states that auricular acupuncture is effective, but the effect might not depend on point location. So, all three sources support the effectiveness of acupuncture, particularly auricular acupuncture, in smoking cessation. However, the third source adds that the effect might not be dependent on the specific points used. That's an important nuance. I need to combine", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is about the effect of acupuncture in smoking cessation. Let me look at the evidence provided. First, evidence [15861492:15861492_0] says that auricular acupuncture has some effect. Then [18405159:18405159_0] mentions acupuncture combined with auricular point sticking and pressing has a reliable therapeutic effect. The third evidence [17264832:17264832_0] states that auricular acupuncture is effective but the effect may not depend on point location. So, combining these, the answer should mention that", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this query. The user is asking about the effect of acupuncture in smoking cessation. I need to generate a concise answer based on the provided evidence and return it in strict JSON format. First, I'll look at the evidence given. There are three chunks: 1. [15861492:15861492_0] mentions auricular acupuncture has some effect. 2. [18405159:18405159_0] states that combining acupuncture with auricular point sticking and pressing has a reliable therapeutic effect. 3. [17264832:17264832_0] says auricular acupuncture is effective but", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this query. The user wants a JSON answer about acupuncture's effect on smoking cessation, based on the provided evidence. First, I need to look at the evidence snippets. There are three references here. All of them mention auricular acupuncture in the context of smoking cessation. The first one says it has \"some effect.\" The second mentions combining acupuncture with other methods like auricular point sticking and pressing gives a \"reliable therapeutic effect.\" The third states that auricular acupuncture is effective, but the effect might not depend on point location. So, the main points are that auricular acupuncture is effective, possibly when combined with other techniques, and the effectiveness isn't necessarily tied to specific points. The confidence here would be moderate because all sources agree but the exact strength", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking about the effect of acupuncture in smoking cessation. I need to look at the provided evidence to form a concise answer with citations and a confidence level. First, looking at the evidence: 1. [15861492:15861492_0] mentions auricular acupuncture has some effect. 2. [18405159:18405159_0] states that acupuncture combined with auricular point sticking and pressing has a reliable therapeutic effect. 3. [17264832:17264832_0] says auricular acupuncture is effective but the effect may not depend on point location", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this query. The user is asking about the effect of acupuncture in smoking cessation. I need to generate a concise answer based on the provided evidence and return it in strict JSON format. First, I'll look at the evidence given. There are three references. Let me parse each one: 1. [15861492:15861492_0] mentions auricular acupuncture in smoking cessation has some effect. So that's a positive point, but it's phrased as \"some effect,\" which is a bit vague. 2. [18405159:18405159_0] states that combining acupuncture with auricular point sticking and pressing has a reliable", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["10024707", "11154059", "12356614", "12416359", "15004442", "15861492", "16566674", "17264832", "17698433", "18405159", "22373002", "24030452"], "ideal_answer": "Ear acupressure (EAP) and ear acupuncture have been used for smoking cessation, and some positive results have been reported. Auricular (ear) acupressure has been purported to be beneficial in achieving smoking cessation in some studies, while in others has been deemed insignificant. The combined acupuncture-education group showing the greatest effect from treatment."}
{"question_id": "56c6dd275795f9a73e000008", "question": "Which post-translational histone modifications are characteristic of constitutive heterochromatin?", "retrieved_chunks": [{"doc_id": "12581305", "chunk_id": "12581305_0", "score": 4.429203033447266, "text": "Histone modifications in Arabidopsis- high methylation of H3 lysine 9 is dispensable for constitutive heterochromatin"}, {"doc_id": "17891782", "chunk_id": "17891782_0", "score": 4.23682165145874, "text": "Constitutive heterochromatin during mouse oogenesis: the pattern of histone H3 modifications and localization of HP1alpha and HP1beta proteins."}, {"doc_id": "18592385", "chunk_id": "18592385_0", "score": 3.8797664642333984, "text": "At the SUMO-1 labelled areas, the presence of HP1alpha protein, as well as of trimethylated H3-K9 and H4-K20 histone modifications, supports a role for SUMO-1 in constitutive heterochromatin organization."}], "context": "[12581305:12581305_0] Histone modifications in Arabidopsis- high methylation of H3 lysine 9 is dispensable for constitutive heterochromatin\n[17891782:17891782_0] Constitutive heterochromatin during mouse oogenesis: the pattern of histone H3 modifications and localization of HP1alpha and HP1beta proteins.\n[18592385:18592385_0] At the SUMO-1 labelled areas, the presence of HP1alpha protein, as well as of trimethylated H3-K9 and H4-K20 histone modifications, supports a role for SUMO-1 in constitutive heterochromatin organization.", "answer": "<think> Okay, let's tackle this question. The user is asking about post-translational histone modifications characteristic of constitutive heterochromatin. I need to look at the provided evidence to find the answer. First, I'll check each document. Document [12581305:12581305_0] mentions high methylation of H3 lysine 9 being dispensable for constitutive heterochromatin. Wait, that suggests that trimethylation of H3K9 might not be necessary, but maybe other modifications are. But the key here is that it's talking about H3K9 methylation being dispensable, so perhaps other marks are more important. Next, [1789178", "citations": [{"doc_id": "12581305", "chunk_id": "12581305_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about post-translational histone modifications characteristic of constitutive heterochromatin. The evidence provided has three references. First, I need to parse each document. The first one says that high methylation of H3 lysine 9 is dispensable for constitutive heterochromatin in Arabidopsis. So, maybe H3K9me3 isn't necessary here? But the question is about characteristic modifications, so maybe other ones are more relevant. The second reference mentions that during mouse oogenesis, there's a pattern of histone H3 modifications and localization of HP1alpha and beta. I'm not sure what specific modifications they discuss here. Maybe H3K9me3 is involved since it's", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about post-translational histone modifications characteristic of constitutive heterochromatin. The evidence provided has three documents. First, I need to understand what constitutive heterochromatin is. From what I remember, constitutive heterochromatin is a type of heterochromatin that's always present in cells, unlike facultative heterochromatin which can be turned on or off. It's usually associated with repetitive DNA sequences and is tightly packed. Now, looking at the evidence: Document 12581305: It says high methylation of H3 lysine 9 (H3K9me3) is dispensable for constitutive heterochromatin in Arabidopsis", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about post-translational histone modifications characteristic of constitutive heterochromatin. The evidence provided has three references. First, I need to recall what constitutive heterochromatin is. It's a type of heterochromatin that's present in all cell types, unlike facultative heterochromatin which is cell-type specific. Histone modifications play a key role in chromatin structure and function. Looking at the evidence: The first reference (12581305) says that high methylation of H3K9 is dispensable for constitutive heterochromatin in Arabidopsis. Wait, \"dispensable\" here might mean it's not required? But the question is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about post-translational histone modifications characteristic of constitutive heterochromatin. The evidence provided has three references. First, I need to recall what constitutive heterochromatin is. It's a type of heterochromatin that's present in all cell types, unlike facultative heterochromatin which is cell-type specific. Histone modifications play a key role in chromatin structure and function. Looking at the evidence: 1. The first reference says that high methylation of H3 lysine 9 (H3K9me3) is dispensable for constitutive heterochromatin in Arabidopsis. Wait, \"dispensable\" here might mean it's not necessary? But that", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about post-translational histone modifications characteristic of constitutive heterochromatin. The evidence provided includes three studies. First, I need to recall what constitutive heterochromatin is. It's a type of heterochromatin that's present in all cells, unlike facultative heterochromatin which can be modified. Histone modifications play a key role in chromatin structure and function. Looking at the evidence: 1. The first study (12581305) mentions high methylation of H3 lysine 9 being dispensable for constitutive heterochromatin. Wait, if it's dispensable, that suggests that maybe other modifications are more important? Or perhaps this study", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about post-translational histone modifications characteristic of constitutive heterochromatin. I need to look at the provided evidence to find the relevant modifications. First, looking at the evidence documents: Document 12581305: It says that high methylation of H3 lysine 9 is dispensable for constitutive heterochromatin. Wait, so if it's dispensable, maybe other modifications are more important? But this might not be the answer because it's saying that H3K9me3 isn't necessary. However, another document mentions trimethylated H3-K9 and H4-K20. Document 17891782: Talks about", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about post-translational histone modifications characteristic of constitutive heterochromatin. I need to look at the provided evidence to find the answer. First, I'll check each document. Document [12581305:12581305_0] mentions high methylation of H3 lysine 9 being dispensable for constitutive heterochromatin. Wait, that suggests that trimethylation of H3K9 might not be necessary, but maybe other modifications are. But the key here is that it's talking about H3K9 methylation being dispensable, so perhaps other marks are more important. Next, [1789178", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about post-translational histone modifications characteristic of constitutive heterochromatin. I need to look at the evidence provided. First, evidence document [12581305:12581305_0] says that high methylation of H3 lysine 9 is dispensable for constitutive heterochromatin. Wait, \"dispensable\" here might mean it's not required, so maybe other modifications are more important. But I need to check if this is a characteristic. However, the next document [17891782:17891782_0] talks about H3 modifications during mouse oogenesis, but", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["11356363", "11740497", "12581305", "17710556", "17891782", "18592385", "18987983", "20532208", "21541345", "21803857", "22319459", "22572731"], "ideal_answer": "H3K9me3 is the major marker of constitutive heterochromatin. Other histone methylation marks usually found in constitutive heterochromatin, are H4K20me3 and H3K79me3. Classical histone modifications associated with heterochromatin include H3K9me2, H3K27me1 and H3K27me2. Histone H3 trimethylation at lysine 36 is associated with constitutive and facultative heterochromatin. H3S10 phosphorylation marks constitutive heterochromatin during interphase in early mouse embryos until the 4-cell stage"}
{"question_id": "56c1f02cef6e39474100004c", "question": "GV1001 vaccine targets which enzyme?", "retrieved_chunks": [{"doc_id": "19388882", "chunk_id": "19388882_0", "score": 6.686008453369141, "text": "Human telomerase reverse transcriptase (hTERT), the rate-limiting subunit of the telomerase complex, is therefore an attractive target for cancer vaccination. The present review provides an update on the development of GV1001, a peptide vaccine representing a 16-aa hTERT sequence."}, {"doc_id": "24439482", "chunk_id": "24439482_0", "score": 5.650123596191406, "text": "GV1001 is a 16-amino-acid vaccine peptide derived from the human telomerase reverse transcriptase sequence."}, {"doc_id": "24815142", "chunk_id": "24815142_0", "score": 5.186768531799316, "text": "Peptide GV1001 is a peptide vaccine representing a 16-amino acid human telomerase reverse transcriptase sequence, which has been reported to possess potential antineoplastic and anti-inflammatory activity."}], "context": "[19388882:19388882_0] Human telomerase reverse transcriptase (hTERT), the rate-limiting subunit of the telomerase complex, is therefore an attractive target for cancer vaccination. The present review provides an update on the development of GV1001, a peptide vaccine representing a 16-aa hTERT sequence.\n[24439482:24439482_0] GV1001 is a 16-amino-acid vaccine peptide derived from the human telomerase reverse transcriptase sequence.\n[24815142:24815142_0] Peptide GV1001 is a peptide vaccine representing a 16-amino acid human telomerase reverse transcriptase sequence, which has been reported to possess potential antineoplastic and anti-inflammatory activity.", "answer": "<think> Okay, let's tackle this question. The user is asking which enzyme the GV1001 vaccine targets. The evidence provided has three documents. First, document [19388882:19388882_0] mentions that hTERT is the rate-limiting subunit of telomerase and that GV1001 is a peptide vaccine based on a 16-aa hTERT sequence. So that's a clear link between GV1001 and hTERT. Then, document [24439482:24439482_0] states that GV1001 is derived from the human telomerase reverse transcriptase sequence. This reinforces", "citations": [{"doc_id": "19388882", "chunk_id": "19388882_0"}, {"doc_id": "24439482", "chunk_id": "24439482_0"}], "candidates": [{"answer": "<think> Okay, I need to figure out which enzyme the GV1001 vaccine targets based on the provided evidence. Let me look at the evidence again. The first document says that hTERT is the rate-limiting subunit of telomerase and that GV1001 is a peptide vaccine from the hTERT sequence. The second document states that GV1001 is derived from the human telomerase reverse transcriptase sequence. The third one confirms that GV1001 is a 16-aa peptide from hTERT and mentions its antineoplastic activity. So, putting this together, all three documents point to hTERT as the target. The answer should be human telomerase reverse transcriptase, with citations from the first", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which enzyme the GV1001 vaccine targets. The evidence provided has three documents. First, document [19388882:19388882_0] mentions that hTERT is the rate-limiting subunit of telomerase and that GV1001 is a peptide vaccine based on a 16-aa hTERT sequence. So that's a clear link between GV1001 and hTERT. Then, document [24439482:24439482_0] states that GV1001 is derived from the human telomerase reverse transcriptase sequence. This reinforces", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which enzyme the GV1001 vaccine targets. The evidence provided has three documents. First, I need to look at each document. Document 19388882:19388882_0 mentions human telomerase reverse transcriptase (hTERT) as the target. It says hTERT is the rate-limiting subunit of telomerase, making it an attractive target for cancer vaccination. Then GV1001 is a peptide vaccine based on a 16-aa hTERT sequence. Document 24439482:24439482_0 states that GV1001 is a", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which enzyme the GV1001 vaccine targets. The evidence provided has three documents. First, looking at document [19388882:19388882_0], it mentions human telomerase reverse transcriptase (hTERT) as the target. It says hTERT is the rate-limiting subunit of telomerase, making it an attractive target for cancer vaccination. The review talks about GV1001 being a peptide vaccine based on a 16-aa hTERT sequence. Then document [24439482:24439482_0] states that GV1001 is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which enzyme the GV1001 vaccine targets. The evidence provided has three chunks. First, chunk 19388882:19388882_0 mentions that hTERT is the rate-limiting subunit of telomerase and that GV1001 is a peptide vaccine based on a 16-aa hTERT sequence. So that's a direct mention of hTERT. Chunk 24439482:24439482_0 says GV1001 is derived from the human telomerase reverse transcriptase sequence, which again points to hTERT. Chunk 248", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which enzyme the GV1001 vaccine targets. The evidence provided has three documents. First, document 19388882:19388882_0 mentions that hTERT is the rate-limiting subunit of telomerase and that GV1001 is a peptide vaccine based on a 16-aa hTERT sequence. So that's a direct citation pointing to hTERT. Document 24439482:24439482_0 states that GV1001 is derived from the human telomerase reverse transcriptase sequence. Again, this confirms the same enzyme, hTERT", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which enzyme the GV1001 vaccine targets. The evidence provided mentions several sources. First, looking at the evidence documents. Document 19388882:19388882_0 states that hTERT is the target, as it's the rate-limiting subunit of telomerase. Then, document 24439482:24439482_0 says GV1001 is a 16-amino-acid peptide from the hTERT sequence. Document 24815142:24815142_0 confirms that GV1001 is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which enzyme the GV1001 vaccine targets. The evidence provided has three documents. First, looking at document [19388882:19388882_0], it mentions human telomerase reverse transcriptase (hTERT) as the target. It also states that GV1001 is a peptide vaccine based on a 16-aa hTERT sequence. That seems directly relevant. Then, document [24439482:24439482_0] confirms that GV1001 is derived from the hTERT sequence. So this reinforces the same information. The third document, [", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["19072345", "19388882", "20822343", "21377838", "21586625", "22841437", "23827187", "24411674", "24439482", "24815142", "24919654", "24954781"], "ideal_answer": "GV1001 is a 16-amino-acid vaccine peptide derived from the human telomerase reverse transcriptase sequence. It has been developed as a vaccine against various cancers."}
{"question_id": "550af222c2af5d5b7000000b", "question": "Which is the E3 ubiquitin ligase which ubiquitinates IkB leading to its proteasomal degradation?", "retrieved_chunks": [{"doc_id": "12832479", "chunk_id": "12832479_0", "score": 6.744091987609863, "text": "MDM2 is an E3 ubiquitin ligase that targets p53 for proteasomal degradation. Recent studies have shown, however, that the ring-finger domain (RFD) of MDM2, where the ubiquitin E3 ligase activity resides, is necessary but not sufficient for p53 ubiquitination, suggesting that an additional activity of MDM2 might be required."}, {"doc_id": "22666487", "chunk_id": "22666487_1", "score": 6.625942707061768, "text": "The p53 transcription factor and tumor suppressor is regulated primarily by the E3 ubiquitin ligase Mdm2, which ubiquitinates p53 to target it for proteasomal degradation. Aside from its ubiquitin ligase function, Mdm2 has been believed to be capable of suppressing p53's transcriptional activity by binding with and masking the transactivation domain of p53."}, {"doc_id": "15013777", "chunk_id": "15013777_1", "score": 6.396766662597656, "text": "Mdm2 is a RING finger E3 ubiquitin ligase, which promotes ubiquitination and proteasomal degradation of the p53 tumor suppressor protein. Acetylation of p53 regulates p53's transcriptional activity and inhibits Mdm2-mediated p53 ubiquitination and degradation."}], "context": "[12832479:12832479_0] MDM2 is an E3 ubiquitin ligase that targets p53 for proteasomal degradation. Recent studies have shown, however, that the ring-finger domain (RFD) of MDM2, where the ubiquitin E3 ligase activity resides, is necessary but not sufficient for p53 ubiquitination, suggesting that an additional activity of MDM2 might be required.\n[22666487:22666487_1] The p53 transcription factor and tumor suppressor is regulated primarily by the E3 ubiquitin ligase Mdm2, which ubiquitinates p53 to target it for proteasomal degradation. Aside from its ubiquitin ligase function, Mdm2 has been believed to be capable of suppressing p53's transcriptional activity by binding with and masking the transactivation domain of p53.\n[15013777:15013777_1] Mdm2 is a RING finger E3 ubiquitin ligase, which promotes ubiquitination and proteasomal degradation of the p53 tumor suppressor protein. Acetylation of p53 regulates p53's transcriptional activity and inhibits Mdm2-mediated p53 ubiquitination and degradation.", "answer": "<think> Okay, let's tackle this question. The user is asking which E3 ubiquitin ligase ubiquitinates IkB, leading to its proteasomal degradation. The evidence provided mentions MDM2 and Mdm2 in several chunks. First, I need to check if any of the evidence directly mentions IkB. Looking at the evidence: Chunk 12832479_0 talks about MDM2 targeting p53, not IkB. Chunk 22666487_1 also mentions Mdm2 and p53. Chunk 15013777_1 again refers to Mdm2 and p53. None of these mention IkB. Wait, maybe there's a confusion here. The", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which E3 ubiquitin ligase ubiquitinates IkB, leading to its proteasomal degradation. The evidence provided mentions MDM2 and Mdm2 in several chunks. First, I need to check if any of the evidence directly mentions IkB. Looking at the evidence: Chunk 12832479_0 talks about MDM2 targeting p53, not IkB. Chunk 22666487_1 also mentions Mdm2 and p53. Chunk 15013777_1 again refers to Mdm2 and p53. None of these mention IkB. Wait, maybe there's a confusion here. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the question is asking which E3 ubiquitin ligase ubiquitinates IkB leading to its proteasomal degradation. Let me look at the evidence provided. First, I need to recall what I know about E3 ubiquitin ligases and their role in degrading proteins like IkB. From my knowledge, MDM2 is a well-known E3 ligase that targets p53 for degradation. But the question is about IkB, not p53. However, the evidence provided only mentions Mdm2 and p53. Wait, maybe there's a confusion here between IkB and p53? Or perhaps the answer is still MDM2 even though the evidence doesn't explicitly mention IkB? Looking at the evidence again: all three", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let me try to figure this out. The question is asking which E3 ubiquitin ligase ubiquitinates IkB, leading to its proteasomal degradation. The evidence provided mentions MDM2 and Mdm2 in several chunks. Looking at the first chunk (12832479:12832479_0), it says MDM2 is an E3 ligase that targets p53 for degradation. But the question is about IkB, not p53. However, the second chunk (22666487:22666487_1) also talks about Mdm2 ubiquitinating p53. The third chunk (150137", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which E3 ubiquitin ligase ubiquitinates IkB, leading to its proteasomal degradation. The evidence provided mentions MDM2 and Mdm2 in several chunks. First, I need to check if any of the evidence directly mentions IkB. Looking at the evidence: Chunk 12832479_0 talks about MDM2 targeting p53, not IkB. Chunk 22666487_1 also discusses Mdm2 and p53. Chunk 15013777_1 again mentions Mdm2 and p53. None of these chunks mention IkB. Wait, but the question is about IkB", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's see. The question is asking which E3 ubiquitin ligase ubiquitinates IkB, leading to its proteasomal degradation. Looking at the evidence provided, all three chunks mention MDM2 (or Mdm2) as the E3 ubiquitin ligase. The first chunk says MDM2 targets p53 for degradation, but the question is about IkB. Wait, maybe there's a confusion here. Because in the evidence, the mentions are about p53, not IkB. But the user is asking about IkB. Hmm, but the evidence provided doesn't mention IkB at all. The chunks talk about MDM2 and p53. Maybe there's a mistake here? Or perhaps the answer is still MDM", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which E3 ubiquitin ligase ubiquitinates IkB, leading to its proteasomal degradation. The evidence provided mentions MDM2 and Mdm2 in several chunks. First, I need to check if any of the evidence directly mentions IkB. Looking at the evidence: Chunk 12832479_0 talks about MDM2 targeting p53, not IkB. Chunk 22666487_1 also mentions Mdm2 ubiquitinates p53. Chunk 15013777_1 again refers to Mdm2 ubiquitinating p53. None of these chunks mention IkB. Wait, maybe there", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which E3 ubiquitin ligase ubiquitinates IkB, leading to its proteasomal degradation. The evidence provided mentions MDM2 and Mdm2 in several chunks. First, I need to check if any of the evidence directly mention IkB. Looking at the evidence: - The first chunk talks about MDM2 targeting p53, not IkB. - The second chunk also discusses Mdm2 and p53, not IkB. - The third chunk again mentions Mdm2 and p53. Wait, none of the chunks mention IkB. But the question is about IkB, but the evidence only talks about p53. Maybe there's a confusion here? Or perhaps the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which E3 ubiquitin ligase ubiquitinates IκB, leading to its proteasomal degradation. The evidence provided mentions MDM2 and Mdm2 in several chunks. First, I need to check if any of the evidence directly mentions IκB. Looking through the evidence: Chunk 12832479_0 talks about MDM2 targeting p53, not IκB. Chunk 22666487_1 also mentions Mdm2 and p53. Chunk 15013777_1 again refers to Mdm2 and p53. None of these chunks mention IκB. Wait, but the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["10837071", "16778892", "17001349", "20028970", "22435548"], "ideal_answer": "IκB degradation involves ubiquitination mediated by a specific E3 ubiquitin ligase SCF(β-TrCP). SCF(β-TrCP) -mediated IκB ubiquitination and degradation is a very efficient process, often resulting in complete degradation of the key inhibitor IκBα within a few minutes of cell stimulation. IkappaB degradation is dependent upon its phosphorylation by the IkappaB kinase (IKK) complex and subsequent ubiquitination facilitated by beta-Trcp E3 ubiquitin ligase.Sequence comparison analysis showed sequence motif identity between CLU and beta-transducin repeat-containing protein (beta-TrCP), a main E3 ubiquitin ligase involved in IkappaB-alpha degradation. IkappaB degradation is dependent upon its phosphorylation by the IkappaB kinase (IKK) complex and subsequent ubiquitination facilitated by beta-Trcp E3 ubiquitin ligase. SCF(β-TrCP) -mediated IκB ubiquitination and degradation is a very efficient process, often resulting in complete degradation of the key inhibitor IκBα within a few minutes of cell stimulation."}
{"question_id": "5318a955b166e2b806000020", "question": "Is c-met involved in the activation of the Akt pathway?", "retrieved_chunks": [{"doc_id": "16278380", "chunk_id": "16278380_0", "score": 8.796241760253906, "text": "Activation of C-MET enhances XIAP through the Akt pathway."}, {"doc_id": "18262389", "chunk_id": "18262389_4", "score": 7.9973673820495605, "text": "These observations indicate that HGF and c-Met can regulate the early stages of dendrite maturation via activation of the Akt/GSK-3beta pathway."}, {"doc_id": "18234991", "chunk_id": "18234991_0", "score": 7.928978443145752, "text": "HGF was found to enhance cell migration, and that HGF-induced migration depends on PI3K/Akt pathway. The activation of PI3K/Akt pathway induced by the HGF/c-Met axis is involved in the downregulation of cell adhesion molecules E-cadherin and beta-catenin, contributing to the attenuation of cell-cell adhesion and promoting the enhanced motility and migration of uveal melanoma cells."}], "context": "[16278380:16278380_0] Activation of C-MET enhances XIAP through the Akt pathway.\n[18262389:18262389_4] These observations indicate that HGF and c-Met can regulate the early stages of dendrite maturation via activation of the Akt/GSK-3beta pathway.\n[18234991:18234991_0] HGF was found to enhance cell migration, and that HGF-induced migration depends on PI3K/Akt pathway. The activation of PI3K/Akt pathway induced by the HGF/c-Met axis is involved in the downregulation of cell adhesion molecules E-cadherin and beta-catenin, contributing to the attenuation of cell-cell adhesion and promoting the enhanced motility and migration of uveal melanoma cells.", "answer": "<think> Okay, let's tackle this question. The user wants to know if c-met is involved in activating the Akt pathway. The evidence provided has three references. First, looking at reference [16278380:16278380_0], it says that activation of C-MET enhances XIAP through the Akt pathway. So this directly links c-Met to the Akt pathway. That's a clear yes. Next, reference [18262389:18262389_4] mentions HGF and c-Met regulating dendrite maturation via Akt/GSK-3beta pathway. Again, this shows c-Met is involved in the Akt pathway. The third reference [18", "citations": [{"doc_id": "16278380", "chunk_id": "16278380_0"}, {"doc_id": "18262389", "chunk_id": "18262389_4"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants to know if c-met is involved in activating the Akt pathway. The evidence provided has three references. First, looking at reference [16278380:16278380_0], it says that activation of C-MET enhances XIAP through the Akt pathway. So this directly links c-Met to the Akt pathway. That's a clear yes. Next, reference [18262389:18262389_4] mentions HGF and c-Met regulating dendrite maturation via Akt/GSK-3beta pathway. Again, this shows c-Met is involved in the Akt pathway. The third reference [18", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if c-met is involved in activating the Akt pathway. Looking at the evidence provided, there are three references. First, reference [16278380:16278380_0] says that activation of C-MET enhances XIAP through the Akt pathway. So this directly connects c-met to the Akt pathway. That's a clear point. Then, reference [18262389:18262389_4] mentions HGF and c-Met regulating dendrite maturation via the Akt/GSK-3beta pathway. Again, this shows that c-met is linked to the Akt pathway. The third reference [", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if c-met is involved in activating the Akt pathway. Looking at the evidence provided, there are three references. First, reference [16278380:16278380_0] says that activation of C-MET enhances XIAP through the Akt pathway. So this directly links c-met to the Akt pathway. Then, [18262389:18262389_4] mentions HGF and c-Met regulating dendrite maturation via Akt/GSK-3beta pathway. That's another mention of the Akt pathway being involved when c-Met is active. The third reference, [182", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, so the user is asking if c-met is involved in activating the Akt pathway. Let me look at the evidence provided. First, evidence [16278380:16278380_0] says that activation of C-MET enhances XIAP through the Akt pathway. That directly connects c-Met to the Akt pathway. Then, [18262389:18262389_4] mentions HGF and c-Met regulating dendrite maturation via Akt/GSK-3beta pathway. So again, c-Met is linked to Akt. The third evidence [18234991:18234999_0]", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if c-MET is involved in activating the Akt pathway. I need to look at the evidence provided. First, evidence [16278380:16278380_0] says that activation of C-MET enhances XIAP through the Akt pathway. So this directly connects c-MET to the Akt pathway. That's a clear mention. Then, [18262389:18262389_4] talks about HGF and c-Met regulating dendrite maturation via Akt/GSK-3beta pathway. Again, this shows that c-Met is linked to the Akt pathway. The third evidence [182", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if c-met is involved in activating the Akt pathway. The evidence provided has three chunks. First chunk: [16278380:16278380_0] says activation of C-MET enhances XIAP through the Akt pathway. So here, C-MET's activation is linked to the Akt pathway. That's a direct mention. Second chunk: [18262389:18262389_4] mentions HGF and c-Met regulating dendrite maturation via Akt/GSK-3beta pathway. So again, c-Met is connected to Akt pathway activation. Third chunk: [18234", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if c-met is involved in activating the Akt pathway. I need to look at the evidence provided. First, check each of the three evidence points. The first one says that activation of C-MET enhances XIAP through the Akt pathway. So here, c-Met is linked to the Akt pathway. That's a direct mention. The second evidence mentions HGF and c-Met regulating dendrite maturation via the Akt/GSK-3beta pathway. Again, c-Met is associated with the Akt pathway here. Third evidence states that HGF-induced migration depends on the PI3K/Akt pathway, which is the same as the Akt pathway. The HGF/c-Met axis activates this pathway.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if c-met is involved in activating the Akt pathway. Looking at the evidence provided, there are three references. First, reference [16278380:16278380_0] says that activation of C-MET enhances XIAP through the Akt pathway. So this directly links c-Met to the Akt pathway. Then, reference [18262389:18262389_4] mentions HGF and c-Met regulating dendrite maturation via Akt/GSK-3beta pathway. This also connects c-Met to Akt. The third one, [18234991:1", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["10714768", "11821397", "14570904", "15522281", "16278380", "17258200", "17464994", "17942284", "18234991", "18262389", "19850646", "20233866", "21536148", "21687953", "22789825", "22820099", "23229794", "23345546"], "ideal_answer": "HGF-induced activation of c-Met is playing a pivotal role in the stimulation of c-Src activation, resulting in induction of phosphatidylinositol 3-kinase complexes p85α/p110α and p85α/p110δ, which is required for Akt-mediated activation of mammalian target of rapamycin, with consequent inhibition of IκB kinase and nuclear factor-κB activation, resulting in enhanced cell survival."}
{"question_id": "531a3fe3b166e2b806000038", "question": "Is pregnancy an additional risk during during H1N1 infection?", "retrieved_chunks": [{"doc_id": "21252793", "chunk_id": "21252793_0", "score": 6.863368988037109, "text": "Emerging data suggest that pregnancy conveys high risk for severe complications from the 2009 pandemic influenza A virus (2009 H1N1) infection"}, {"doc_id": "19643469", "chunk_id": "19643469_0", "score": 6.651741027832031, "text": "Pregnant women might be at increased risk for complications from pandemic H1N1 virus infection."}, {"doc_id": "22782418", "chunk_id": "22782418_1", "score": 6.643764972686768, "text": "To investigate whether exposure to an adjuvanted influenza A(H1N1)pdm09 vaccine during pregnancy was associated with increased risk of adverse fetal outcomes."}], "context": "[21252793:21252793_0] Emerging data suggest that pregnancy conveys high risk for severe complications from the 2009 pandemic influenza A virus (2009 H1N1) infection\n[19643469:19643469_0] Pregnant women might be at increased risk for complications from pandemic H1N1 virus infection.\n[22782418:22782418_1] To investigate whether exposure to an adjuvanted influenza A(H1N1)pdm09 vaccine during pregnancy was associated with increased risk of adverse fetal outcomes.", "answer": "<think> Okay, the user is asking if pregnancy is an additional risk during H1N1 infection. Let me look at the evidence provided. First evidence: [21252793:21252793_0] says that pregnancy conveys high risk for severe complications from 2009 H1N1. That's a direct statement linking pregnancy to increased risk. Second piece: [19643469:19643469_0] mentions pregnant women might be at increased risk for complications from pandemic H1N1. Again, supports the idea that pregnancy is a risk factor. Third evidence: [22782418:2278241", "citations": [{"doc_id": "21252793", "chunk_id": "21252793_0"}, {"doc_id": "19643469", "chunk_id": "19643469_0"}], "candidates": [{"answer": "<think> Okay, the user is asking if pregnancy is an additional risk during H1N1 infection. Let me look at the evidence provided. The first piece of evidence from 21252793 says that pregnancy conveys high risk for severe complications from the 2009 H1N1 virus. That's a direct statement linking pregnancy to increased risk. The second one, 19643469, also mentions pregnant women might be at increased risk for complications from the pandemic H1N1 virus. Both of these support the idea that pregnancy is a risk factor. The third evidence, 22782418, talks about a study investigating if the flu vaccine during pregnancy affects fetal outcomes. But the question is about", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking if pregnancy is an additional risk during H1N1 infection. Let me look at the evidence provided. First, the evidence has three documents. The first one says that pregnancy conveys high risk for severe complications from 2009 H1N1. The second mentions that pregnant women might be at increased risk for complications from pandemic H1N1. The third is about a study investigating vaccine exposure during pregnancy and adverse outcomes, but it's not directly about the infection itself. So, the first two documents clearly state that pregnancy increases the risk of complications from H1N1. The third document is about vaccination, not the infection. Therefore, the answer should be based on the first two citations. The model's confidence should be high", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking if pregnancy increases the risk during H1N1 infection. Let me look at the evidence provided. The first evidence, 21252793:21252793_0, says that pregnancy conveys high risk for severe complications from 2009 H1N1. That's a direct statement. The second one, 19643469:19643469_0, mentions pregnant women might be at increased risk for complications from the pandemic H1N1 virus. Both of these support the idea that pregnancy is a risk factor. The third evidence, 22782418:22782418", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking if pregnancy is an additional risk during H1N1 infection. Let me look at the evidence provided. First, the evidence has three chunks. The first one says that pregnancy conveys high risk for severe complications from 2009 H1N1. The second chunk mentions pregnant women might be at increased risk for complications from pandemic H1N1. The third chunk is about a study investigating if the vaccine during pregnancy is linked to adverse outcomes, but that's about the vaccine, not the infection itself. So the answer should focus on the first two chunks. Both indicate that pregnancy increases the risk of complications from H1N1. The third chunk isn't directly relevant because it's about vaccination rather than the infection. The confidence level", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if pregnancy is an additional risk during H1N1 infection. I need to look at the evidence provided. First, the evidence has three chunks. The first one says that pregnancy conveys high risk for severe complications from 2009 H1N1. The second chunk mentions pregnant women might be at increased risk for complications from pandemic H1N1. The third chunk is about a study investigating if the vaccine during pregnancy is linked to adverse outcomes, but that's about vaccination, not infection itself. So the answer should focus on the first two chunks. Both indicate that pregnancy increases the risk of complications from H1N1. The third chunk isn't directly relevant because it's about the vaccine, not the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if pregnancy increases the risk during H1N1 infection. The evidence provided has three documents. First, I need to check each document's content. The first one says that pregnancy conveys high risk for severe complications from 2009 H1N1. The second mentions pregnant women might be at increased risk for complications from pandemic H1N1. The third is about a study on vaccine exposure during pregnancy, but it's about adverse fetal outcomes, not directly the infection itself. So, the first two documents directly address the risk of H1N1 infection in pregnant women. The third seems more about vaccination effects rather than the infection risk. Therefore, the answer should be based on the first two documents.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking if pregnancy increases the risk during H1N1 infection. Let me look at the evidence provided. First, the evidence has three chunks. The first one says that pregnancy conveys high risk for severe complications from 2009 H1N1. The second chunk mentions pregnant women might be at increased risk for complications from pandemic H1N1. The third chunk is about a study investigating vaccine exposure during pregnancy and adverse outcomes, but it's not directly about the infection itself. So, the first two chunks directly address the risk of H1เหล1 infection in pregnant women. They both indicate that pregnancy is a risk factor. The third chunk is about vaccination, which is related but not the same as infection. The answer needs to be", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking if pregnancy is an additional risk during H1N1 infection. Let me look at the evidence provided. First evidence: [21252793:21252793_0] says that pregnancy conveys high risk for severe complications from 2009 H1N1. That's a direct statement linking pregnancy to increased risk. Second piece: [19643469:19643469_0] mentions pregnant women might be at increased risk for complications from pandemic H1N1. Again, supports the idea that pregnancy is a risk factor. Third evidence: [22782418:2278241", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["19643469", "20100064", "20148081", "20531946", "21252793", "21596080", "21756329", "21913391", "22030045", "22120858", "22272853", "22331165", "22411229", "22482974", "22515877", "22551713", "22564554", "22782418", "22851818", "22859826", "22901103", "23116790", "24051575"], "ideal_answer": "Pregnant women are at increased risk for complications from pandemic influenza H1N1 virus infection. Pregnant women, because of their altered immunity and physiological adaptations, are at higher risk of developing pulmonary complications, especially in the second and third trimesters. Pregnancy, particularly during the third trimester, increases the risk of complications and early antiviral treatment is associated with improved outcomes."}
{"question_id": "51757bbb8ed59a060a00002e", "question": "Are long non coding RNAs as conserved in sequence as protein coding genes?", "retrieved_chunks": [{"doc_id": "21619633", "chunk_id": "21619633_5", "score": 4.922537803649902, "text": "They are therefore functionally related to a number of key protein coding developmental genes, that form genomic regulatory blocks (GRBs) with arrays of highly conserved non-coding elements (HCNEs) functioning as long-range enhancers that collaboratively regulate the expression of their target genes."}, {"doc_id": "27990773", "chunk_id": "27990773_0", "score": 3.7512528896331787, "text": "p53 functions primarily as a sequence-specific transcription factor that controls the expression of hundreds of protein-coding genes and noncoding RNAs, including microRNAs (miRNAs) and long noncoding RNAs (lncRNAs)."}, {"doc_id": "36875647", "chunk_id": "36875647_0", "score": 3.514025926589966, "text": "Circular RNAs (circRNAs) are a novel category of covalently-closed non-coding RNAs mainly derived from the back-splicing of exons or introns of protein-coding genes."}], "context": "[21619633:21619633_5] They are therefore functionally related to a number of key protein coding developmental genes, that form genomic regulatory blocks (GRBs) with arrays of highly conserved non-coding elements (HCNEs) functioning as long-range enhancers that collaboratively regulate the expression of their target genes.\n[27990773:27990773_0] p53 functions primarily as a sequence-specific transcription factor that controls the expression of hundreds of protein-coding genes and noncoding RNAs, including microRNAs (miRNAs) and long noncoding RNAs (lncRNAs).\n[36875647:36875647_0] Circular RNAs (circRNAs) are a novel category of covalently-closed non-coding RNAs mainly derived from the back-splicing of exons or introns of protein-coding genes.", "answer": "<think> Okay, let's tackle this question. The user is asking if long non-coding RNAs (lncRNAs) are as conserved in sequence as protein-coding genes. First, I need to look at the evidence provided. Let me check each of the three references. The first evidence [21619633:21619633_5] talks about lncRNAs being functionally related to protein coding developmental genes and mentions genomic regulatory blocks (GRBs) with highly conserved non-coding elements (HCNEs). But this doesn't directly address sequence conservation, more about functional relationships. The second evidence [27990773:27990773_0] states", "citations": [{"doc_id": "21619633", "chunk_id": "21619633_5"}, {"doc_id": "27990773", "chunk_id": "27990773_0"}], "candidates": [{"answer": "<think> Okay, I need to answer whether long non-coding RNAs (lncRNAs) are as conserved in sequence as protein-coding genes. Let me look at the evidence provided. First, the first evidence snippet says that lncRNAs are functionally related to key protein coding developmental genes and form genomic regulatory blocks with highly conserved non-coding elements (HCNEs) acting as enhancers. This suggests that there's some conservation because HCNEs are highly conserved. But does this directly relate to the sequence conservation of lncRNAs themselves? The second snippet mentions p53 controlling expression of lncRNAs, but it doesn't talk about conservation. The third snippet discusses circular RNAs (circRNAs) which are a different type of", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to answer whether long non-coding RNAs (lncRNAs) are as conserved in sequence as protein-coding genes. Let me look at the evidence provided. First, the first evidence snippet says that lncRNAs are functionally related to key protein coding developmental genes and form genomic regulatory blocks with highly conserved non-coding elements (HCNEs) acting as enhancers. This suggests that there's some conservation because they work together in regulatory regions. But does this mean their sequence is conserved? The second snippet mentions p53 controlling expression of lncRNAs, but it doesn't directly talk about sequence conservation. The third snippet discusses circular RNAs (circRNAs) derived from protein-coding genes via back-splicing.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if long non-coding RNAs (lncRNAs) are as conserved in sequence as protein-coding genes. First, I need to look at the evidence provided. Let me check each of the three references. The first evidence [21619633:21619633_5] talks about lncRNAs being functionally related to protein coding developmental genes and mentions genomic regulatory blocks (GRBs) with highly conserved non-coding elements (HCNEs). But this doesn't directly address sequence conservation, more about functional relationships. The second evidence [27990773:27990773_0] states", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if long non-coding RNAs (lncRNAs) are as conserved in sequence as protein-coding genes. I need to look at the evidence provided to form an answer. First, I'll review each of the evidence chunks. The first one [21619633:21619633_5] mentions that lncRNAs are functionally related to key protein coding genes and are part of genomic regulatory blocks with conserved non-coding elements. However, this talks about functional conservation rather than sequence conservation. It doesn't directly state whether their sequences are as conserved as protein-coding genes. The second chunk [2799077", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if long non-coding RNAs (lncRNAs) are as conserved in sequence as protein-coding genes. I need to look at the provided evidence to find answers. First, looking at the evidence documents. The first one [21619633:21619633_5] mentions that lncRNAs are functionally related to key protein coding developmental genes and part of genomic regulatory blocks with highly conserved non-coding elements (HCNEs) as long-range enhancers. This suggests that there are conserved elements associated with lncRNAs, but does it say they are as conserved in sequence as protein-coding genes? Not directly,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to answer whether long non coding RNAs (lncRNAs) are as conserved in sequence as protein coding genes. Let me look at the evidence provided. First, the evidence from [21619633:21619633_5] mentions that lncRNAs are functionally related to key protein coding developmental genes and form genomic regulatory blocks with highly conserved non-coding elements (HCNEs) as long-range enhancers. This suggests that there are conserved elements associated with lncRNAs, but does it say they're as conserved in sequence as protein-coding genes? Maybe not directly. Next, [27990773:279907", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if long non-coding RNAs (lncRNAs) are as conserved in sequence as protein-coding genes. I need to look at the provided evidence to form an answer. First, I'll review each of the three evidence chunks. The first one mentions that lncRNAs are functionally related to key protein coding developmental genes and part of genomic regulatory blocks with highly conserved non-coding elements. The term \"highly conserved\" here might suggest some level of conservation, but it's talking about non-coding elements, not the lncRNAs themselves. So maybe this indicates that some elements are conserved, but not sure if that's directly about lncRNA sequences. The second", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if long non-coding RNAs (lncRNAs) are as conserved in sequence as protein-coding genes. I need to look at the provided evidence to form an answer. First, I'll review each of the evidence snippets. The first snippet [21619633:21619633_5] mentions that lncRNAs are functionally related to protein-coding developmental genes and that they form genomic regulatory blocks with highly conserved non-coding elements (HCNEs) acting as enhancers. This suggests that there's some conservation, but it's about functional relationships rather than sequence conservation directly. The second snippet [279907", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["20428234", "20587619", "20624288", "21112873", "21622663", "22707570", "22708672", "22844254", "22955988", "23028352", "23454638", "23463798", "23467124"], "ideal_answer": "No. Most long non coding RNAs (lncRNAs) are under lower sequence constraints than protein-coding genes."}
{"question_id": "56c1f03bef6e394741000053", "question": "Mutation of which gene is implicated in the Brain-lung-thyroid syndrome?", "retrieved_chunks": [{"doc_id": "26196025", "chunk_id": "26196025_0", "score": 8.195072174072266, "text": "The disorder is caused by mutations to the NKX2.1 (TITF1) gene and also forms part of the \"brain-lung-thyroid syndrome\", in which additional developmental abnormalities of lung and thyroid tissue are observed."}, {"doc_id": "23430038", "chunk_id": "23430038_0", "score": 8.14413833618164, "text": "Mutations in the gene encoding thyroid transcription factor, NKX2-1, result in neurologic abnormalities, hypothyroidism, and neonatal respiratory distress syndrome (RDS) that together are known as the brain-thyroid-lung syndrome."}, {"doc_id": "19336474", "chunk_id": "19336474_4", "score": 7.832055568695068, "text": "Thyroid transcription factor 1 (NKX2-1/TITF1) mutations cause brain-lung-thyroid syndrome, characterized by congenital hypothyroidism (CH), infant respiratory distress syndrome (IRDS) and benign hereditary chorea (BHC). The objectives of the present study were (i) detection of NKX2-1 mutations in patients with CH associated with pneumopathy and/or BHC, (ii) functional analysis of new mutations in vitro and (iii) description of the phenotypic spectrum of brain-lung-thyroid syndrome."}], "context": "[26196025:26196025_0] The disorder is caused by mutations to the NKX2.1 (TITF1) gene and also forms part of the \"brain-lung-thyroid syndrome\", in which additional developmental abnormalities of lung and thyroid tissue are observed.\n[23430038:23430038_0] Mutations in the gene encoding thyroid transcription factor, NKX2-1, result in neurologic abnormalities, hypothyroidism, and neonatal respiratory distress syndrome (RDS) that together are known as the brain-thyroid-lung syndrome.\n[19336474:19336474_4] Thyroid transcription factor 1 (NKX2-1/TITF1) mutations cause brain-lung-thyroid syndrome, characterized by congenital hypothyroidism (CH), infant respiratory distress syndrome (IRDS) and benign hereditary chorea (BHC). The objectives of the present study were (i) detection of NKX2-1 mutations in patients with CH associated with pneumopathy and/or BHC, (ii) functional analysis of new mutations in vitro and (iii) description of the phenotypic spectrum of brain-lung-thyroid syndrome.", "answer": "<think> Okay, let's tackle this question. The user is asking which gene mutation is implicated in Brain-lung-thyroid syndrome. I need to look at the provided evidence to find the answer. Looking at the first evidence snippet: [26196025:26196025_0] mentions mutations in the NKX2.1 (TITF1) gene causing the disorder, which is part of the brain-lung-thyroid syndrome. The second snippet [23430038:23430038_0] also talks about NKX2-1 mutations leading to similar symptoms. The third one [19336474:193364", "citations": [{"doc_id": "26196025", "chunk_id": "26196025_0"}, {"doc_id": "23430038", "chunk_id": "23430038_0"}], "candidates": [{"answer": "<think> Okay, I need to figure out which gene mutation is implicated in Brain-lung-thyroid syndrome based on the evidence provided. Let me look at the evidence again. The first document says the disorder is caused by mutations in the NKX2.1 (TITF1) gene and is part of the brain-lung-thyroid syndrome. The second document mentions mutations in the NKX2-1 gene leading to neurologic abnormalities, hypothyroidism, and RDS, which are part of the same syndrome. The third document also states that mutations in thyroid transcription factor 1 (NKX2-1/TITF1) cause the brain-lung-thyroid syndrome. So all three documents point to NKX2.1 (or NKX2", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which gene mutation is implicated in Brain-lung-thyroid syndrome. I need to look at the provided evidence to find the answer. Looking at the first evidence snippet: [26196025:26196025_0] mentions mutations in the NKX2.1 (TITF1) gene causing the disorder, which is part of the brain-lung-thyroid syndrome. The second snippet [23430038:23430038_0] also talks about NKX2-1 mutations leading to similar symptoms. The third one [19336474:193364", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which gene mutation is implicated in Brain-lung-thyroid syndrome. I need to look at the evidence provided. Looking at the first evidence snippet: It mentions mutations in the NKX2.1 (TITF1) gene and links it to brain-lung-thyroid syndrome. The second snippet also talks about mutations in the NKX2-1 gene causing similar symptoms. The third one again refers to NKX2-1/TITF1 mutations causing the same syndrome. All three sources consistently point to NKX2.1 as the gene involved. I should check if there's any conflicting information, but all three documents agree. So the answer is NKX2.1. The confidence level", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so I need to figure out which gene mutation is implicated in Brain-lung-thyroid syndrome based on the evidence provided. Let me look at the three references given. First, the first document says that the disorder is caused by mutations in the NKX2.1 (TITF1) gene and is part of the brain-lung-thyroid syndrome. The second document mentions mutations in the gene encoding thyroid transcription factor NKX2-1 leading to neurologic abnormalities, hypothyroidism, and RDS, which are part of the same syndrome. The third one also talks about mutations in NKX2-1/TITF1 causing the brain-lung-thyroid syndrome with congenital hypothyroidism, IRDS, and BHC.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to figure out which gene mutation is implicated in Brain-lung-thyroid syndrome based on the evidence provided. Let me look at the evidence again. The first document says the disorder is caused by mutations in the NKX2.1 (TITF1) gene and is part of the brain-lung-thyroid syndrome. The second one mentions mutations in the gene encoding thyroid transcription factor NKX2-1 leading to neurologic abnormalities, hypothyroidism, and RDS, which are part of the same syndrome. The third document also states that mutations in thyroid transcription factor 1 (NKX2-1/TITF1) cause the brain-lung-thyroid syndrome. All three sources consistently point to NKX2.1 (", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which gene mutation is implicated in Brain-lung-thyroid syndrome. I need to look at the evidence provided. Looking at the first evidence snippet: it mentions mutations in the NKX2.1 (TITF1) gene and links it to the brain-lung-thyroid syndrome. The second one also talks about NKX2-1 gene mutations causing neurologic abnormalities, hypothyroidism, and RDS, which are part of the same syndrome. The third snippet again references NKX2-1/TITF1 mutations causing the syndrome, with symptoms like congenital hypothyroidism, IRDS, and BHC. All three sources point to NKX2.1 (TITF", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which gene mutation is implicated in Brain-lung-thyroid syndrome. I need to look at the provided evidence to find the answer. Looking at the first evidence snippet: It mentions mutations in the NKX2.1 (TITF1) gene and links it to the brain-lung-thyroid syndrome. The second snippet also talks about mutations in the NKX2-1 gene causing neurologic abnormalities, hypothyroidism, and RDS, which are part of the same syndrome. The third snippet again points to NKX2-1/TITF1 mutations causing the syndrome. All three sources consistently mention NKX2.1 or NKX2-1 as the gene involved. I should", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which gene mutation is implicated in Brain-lung-thyroid syndrome. I need to look at the evidence provided. First, looking at the evidence documents. The first one [26196025:26196025_0] mentions mutations in the NKX2.1 (TITF1) gene causing the disorder and refers to it as brain-lung-thyroid syndrome. The second document [23430038:23430038_0] also talks about mutations in the NKX2-1 gene leading to similar symptoms. The third one [19336474:1933", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["19336474", "20020530", "21867529", "22166853", "22488412", "23430038", "24129101", "24171694", "25759798", "26196025"], "ideal_answer": "Brain-lung-thyroid syndrome (BLTS) characterized by congenital hypothyroidism, respiratory distress syndrome, and benign hereditary chorea is caused by thyroid transcription factor 1 (NKX2-1/TTF1) mutations."}
{"question_id": "52d946c798d023950500000a", "question": "What is clathrin?", "retrieved_chunks": [{"doc_id": "19793827", "chunk_id": "19793827_0", "score": 7.592948913574219, "text": "Clathrin is involved in the endocytosis and exocytosis of cellular proteins and the process of virus infection."}, {"doc_id": "26206992", "chunk_id": "26206992_0", "score": 6.641265869140625, "text": "Clathrin-independent endocytosis ( CIE ) is the process of cellular uptake of various particles , including pathogens , without the coat protein clathrin"}, {"doc_id": "28814502", "chunk_id": "28814502_0", "score": 6.349461555480957, "text": "Clathrin-mediated endocytosis is a major regulator of cell-surface protein internalization."}], "context": "[19793827:19793827_0] Clathrin is involved in the endocytosis and exocytosis of cellular proteins and the process of virus infection.\n[26206992:26206992_0] Clathrin-independent endocytosis ( CIE ) is the process of cellular uptake of various particles , including pathogens , without the coat protein clathrin\n[28814502:28814502_0] Clathrin-mediated endocytosis is a major regulator of cell-surface protein internalization.", "answer": "<think> Okay, I need to generate a candidate biomedical answer for the question \"What is clathrin?\" using the provided evidence. Let me start by understanding the question and the given evidence. The user wants a concise answer that cites the documents and chunk IDs. The answer should be in JSON format with keys \"answer\" and \"base_confidence\". The base confidence is a float between 0 and 1. Looking at the evidence: 1. [19793827:19793827_0] says clathrin is involved in endocytosis, exocytosis of proteins, and virus infection. 2. [26206992:26206992_0]", "citations": [{"doc_id": "19793827", "chunk_id": "19793827_0"}, {"doc_id": "26206992", "chunk_id": "26206992_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants a JSON answer about clathrin, based on the provided evidence. First, I need to understand what clathrin is. Looking at the evidence, there are three chunks. The first one says clathrin is involved in endocytosis and exocytosis of proteins and virus infection. The second mentions clathrin-independent endocytosis, which doesn't use clathrin. The third talks about clathrin-mediated endocytosis being a major regulator for internalizing cell-surface proteins. The question is straightforward: What is clathrin? So the answer should define it. The first chunk directly states its role in endocytosis and exocytosis, and virus infection. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer for the question \"What is clathrin?\" using the provided evidence. Let me start by understanding the question and the given evidence. The user wants a concise answer that cites the documents and chunk IDs. The answer should be in JSON format with keys \"answer\" and \"base_confidence\". The base confidence is a float between 0 and 1. Looking at the evidence: 1. [19793827:19793827_0] says clathrin is involved in endocytosis, exocytosis of proteins, and virus infection. 2. [26206992:26206992_0]", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer for the question \"What is clathrin?\" using the provided evidence. Let me start by reading through the evidence carefully. The first piece of evidence says that clathrin is involved in endocytosis and exocytosis of cellular proteins and virus infection. The second mentions clathrin-independent endocytosis, which doesn't use clathrin. The third states that clathrin-mediated endocytosis regulates cell-surface protein internalization. So, the answer should define clathrin based on its role in these processes. The key points are endocytosis, exocytosis, virus infection, and clathrin-mediated endocytosis. I need to mention that it's a major", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer about what clathrin is based on the provided evidence. Let me start by understanding the question and the given evidence. The user asked, \"What is clathrin?\" The evidence has three chunks. Let me read each one carefully. First chunk (19793827:19793827_0) says clathrin is involved in endocytosis and exocytosis of proteins and virus infection. So that's a key point. Second chunk (26206992:26206992_0) talks about clathrin-independent endocytosis, which is a process without clathrin. But the question is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a biomedical answer about clathrin based on the given evidence. Let me start by reading through the user's question and the provided evidence. The question is \"What is clathrin?\" The evidence has three chunks. Let me parse each one: 1. [19793827:19793827_0] says clathrin is involved in endocytosis, exocytosis of proteins, and virus infection. 2. [26206992:26206992_0] mentions clathrin-independent endocytosis, which doesn't use clathrin. 3. [28814502:28", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer for the question \"What is clathrin?\" using the provided evidence. Let me start by understanding what the user is asking. The question is about defining clathrin, so I should look at the evidence to find key points. Looking at the evidence: 1. [19793827:19793827_0] says clathrin is involved in endocytosis and exocytosis of proteins and virus infection. 2. [26206992:26206992_0] mentions clathrin-independent endocytosis, which doesn't use clathrin. 3. [288145", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user wants a biomedical answer about clathrin in JSON format with citations and confidence. First, I need to understand what clathrin is based on the evidence provided. The evidence mentions clathrin's role in endocytosis and exocytosis, virus infection, and clathrin-independent processes. The answer should be concise. From the evidence, the main point is that clathrin is involved in endocytosis and exocytosis of proteins and virus infection. Also, there's mention of clathrin-mediated vs. independent endocytosis. But the question is just asking for what clathrin is, so I should focus on its primary function. Looking at the citations: [19", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence about clathrin. Let me start by understanding the question: \"What is clathrin?\" The user provided three evidence snippets. First, looking at the evidence: 1. [19793827:19793827_0] says clathrin is involved in endocytosis, exocytosis of proteins, and virus infection. 2. [26206992:26206992_0] mentions clathrin-independent endocytosis, which doesn't use clathrin. 3. [28814502:28814502_0", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["12952941", "19809570", "21445329", "22042622", "23093191", "24257253", "24263003", "24280271", "24299503", "24307937", "24322426"], "ideal_answer": "Clathrin helps build small vesicles in order to safely transport molecules within and between cells."}
{"question_id": "5322d9339b2d7acc7e000011", "question": "What are the main results of PRKAR1A Knockdown?", "retrieved_chunks": [{"doc_id": "22795129", "chunk_id": "22795129_1", "score": 3.5982704162597656, "text": "Like the other TSC-TBC components, TBC1D7 knockdown results in increased mTORC1 signaling, delayed induction of autophagy, and enhanced cell growth under poor growth conditions."}, {"doc_id": "23480756", "chunk_id": "23480756_0", "score": 0.1200663149356842, "text": "Suppression of protein kinase A regulatory subunit 1 alpha (PRKAR1A) has been proven to inhibit cholangiocarcinoma (CCA) cell growth and enhance apoptosis."}, {"doc_id": "22795129", "chunk_id": "22795129_2", "score": -0.7751121520996094, "text": "TBC1D7 knockdown decreases the association of TSC1 and TSC2 leading to decreased Rheb-GAP activity, without effects on the localization of TSC2 to the lysosome."}], "context": "[22795129:22795129_1] Like the other TSC-TBC components, TBC1D7 knockdown results in increased mTORC1 signaling, delayed induction of autophagy, and enhanced cell growth under poor growth conditions.\n[23480756:23480756_0] Suppression of protein kinase A regulatory subunit 1 alpha (PRKAR1A) has been proven to inhibit cholangiocarcinoma (CCA) cell growth and enhance apoptosis.\n[22795129:22795129_2] TBC1D7 knockdown decreases the association of TSC1 and TSC2 leading to decreased Rheb-GAP activity, without effects on the localization of TSC2 to the lysosome.", "answer": "<think> Okay, let's tackle this question. The user is asking about the main results of PRKAR1A Knockdown. First, I need to look through the provided evidence to find any mentions of PRKAR1A. Looking at the evidence, there's a document [23480756:23480756_0] that says suppression of PRKAR1A inhibits cholangiocarcinoma cell growth and enhances apoptosis. That seems directly relevant. The other documents talk about TBC1D7 knockdown affecting mTORC1 signaling and autophagy, but those are related to TBC1D7, not PRKAR1A. So the only relevant evidence here is the third document. The", "citations": [{"doc_id": "23480756", "chunk_id": "23480756_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the main results of PRKAR1A Knockdown. First, I need to look through the provided evidence to find any mentions of PRKAR1A. Looking at the evidence, there's a document [23480756:23480756_0] that says suppression of PRKAR1A inhibits cholangiocarcinoma cell growth and enhances apoptosis. That seems directly relevant. The other documents talk about TBC1D7 knockdown affecting mTORC1 signaling and autophagy, but those are related to TBC1D7, not PRKAR1A. So the only relevant evidence here is the third document. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the main results of PRKAR1A Knockdown. First, I need to look through the provided evidence to find any mentions of PRKAR1A. Looking at the evidence, there's a document [23480756:23480756_0] that says suppression of PRKAR1A inhibits cholangiocarcinoma (CCA) cell growth and enhances apoptosis. That seems directly relevant. The other documents talk about TBC1D7 knockdown affecting mTORC1 signaling, autophagy, and cell growth, but those are related to TBC1D7, not PRKAR1A. So the main result", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the main results of PRKAR1A knockdown. First, I need to look through the provided evidence to find any mentions of PRKAR1A. Looking at the evidence, there's a document [23480756:23480756_0] that says suppression of PRKAR1A inhibits cholangiocarcinoma cell growth and enhances apoptosis. That seems directly relevant. The other documents talk about TBC1D7 knockdown and its effects on mTORC1 signaling, but those aren't related to PRKAR1A. So the answer should be based on that single citation. The main results here are inhibited cell", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's see. The user is asking about the main results of PRKAR1A Knockdown. The evidence provided has three chunks. First, chunk 22795129_1 talks about TBC1D7 knockdown affecting mTORC1 signaling, autophagy, and cell growth. But that's about TBC1D7, not PRKAR1A. So maybe not directly relevant. Then chunk 23480756_0 mentions that suppressing PRKAR1A inhibits CCA cell growth and enhances apoptosis. That seems directly related to the question. So the answer here would be that PRKAR1A knockdown inhibits cholangiocarcinoma cell growth and increases apoptosis", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the main results of PRKAR1A knockdown. First, I need to look through the provided evidence to find any mentions of PRKAR1A. Looking at the evidence, there's a document with ID 23480756:23480756_0 that says suppression of PRKAR1A inhibits cholangiocarcinoma cell growth and enhances apoptosis. That seems directly relevant. The other documents talk about TBC1D7 knockdown and its effects on mTORC1 signaling, but those aren't related to PRKAR1A. So the main result here is that knocking down PRKAR1A inhibits cancer", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the main results of PRKAR1A Knockdown. The evidence provided has three chunks. First, I need to look at each chunk and see what they say. The first chunk talks about TBC1D7 knockdown leading to increased mTORC1 signaling, delayed autophagy, and enhanced cell growth under poor conditions. But that's about TBC1D7, not PRKAR1A. So maybe not directly relevant. The second chunk mentions suppression of PRKAR1A inhibiting cholangiocarcinoma (CCA) cell growth and enhancing apoptosis. That seems directly related to the question. So here, PRKAR1A being suppressed (which is similar to knockdown", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the main results of PRKAR1A knockdown. First, I need to look through the provided evidence to find any mentions of PRKAR1A. Looking at the evidence, there's a document [23480756:23480756_0] that says suppression of PRKAR1A inhibits cholangiocarcinoma cell growth and enhances apoptosis. So that's directly related to PRKAR1A knockdown. The other documents talk about TBC1D7 and TSC components, which aren't relevant here. The answer should be concise, citing the document. The confidence is based on the direct evidence provided. Since there", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this query. The user is asking about the main results of PRKAR1A knockdown. First, I need to look through the provided evidence to find any mentions of PRKAR1A. Looking at the evidence, there's a document [23480756:23480756_0] that says suppression of PRKAR1A inhibits cholangiocarcinoma cell growth and enhances apoptosis. That seems directly relevant. The other documents talk about TBC1D7 knockdown and mTORC1 signaling, but those are about a different gene, TBC1D7, not PRKAR1A. So the only relevant citation here is the one from 23", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["16937372", "20824711", "23480756", "24122441"], "ideal_answer": "Suppression of protein kinase A regulatory subunit 1 alpha (PRKAR1A) has been proven to inhibit cholangiocarcinoma (CCA) cell growth and enhance apoptosis. Also, Knockdown of the cAMP-dependent protein kinase (PKA) Type Ialpha regulatory subunit in mouse oocytes disrupts meiotic arrest and results in meiotic spindle defects."}
{"question_id": "535d75ab7d100faa09000004", "question": "Is TENS machine effective in pain?", "retrieved_chunks": [{"doc_id": "7644247", "chunk_id": "7644247_0", "score": 2.169318675994873, "text": "The results of this study have provided evidence of the hypoalgesic effects of TENS upon experimental ischaemic pain which were found to be frequency specific with the lower frequency used here (4 Hz) demonstrating the only significant effect"}, {"doc_id": "33664472", "chunk_id": "33664472_0", "score": -3.5784177780151367, "text": "All the methods analysed has shown to be effective in reducing pain"}, {"doc_id": "19818032", "chunk_id": "19818032_0", "score": -5.745018005371094, "text": "BoNT/A is an effective analgesic for chronic arthritis pain, but not for acute arthritis pain. Hi"}], "context": "[7644247:7644247_0] The results of this study have provided evidence of the hypoalgesic effects of TENS upon experimental ischaemic pain which were found to be frequency specific with the lower frequency used here (4 Hz) demonstrating the only significant effect\n[33664472:33664472_0] All the methods analysed has shown to be effective in reducing pain\n[19818032:19818032_0] BoNT/A is an effective analgesic for chronic arthritis pain, but not for acute arthritis pain. Hi", "answer": "<think> Okay, let's tackle this query. The user is asking if TENS machines are effective in pain relief. I need to look at the provided evidence to form a concise answer with citations and a confidence score. First, looking at the evidence: The first document [7644247:7644247_0] mentions that TENS has hypoalgesic effects on experimental ischaemic pain, specifically noting that lower frequency (4 Hz) was significant. That's a direct mention of effectiveness in a specific type of pain. The second document [33664472:33664472_0] states that all methods analyzed were effective in reducing pain. Since TENS is one of those methods", "citations": [{"doc_id": "7644247", "chunk_id": "7644247_0"}, {"doc_id": "33664472", "chunk_id": "33664472_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this query. The user is asking if TENS machines are effective in pain. The evidence provided has three chunks. First chunk (7644247) says that TENS has hypoalgesic effects on experimental ischemic pain, specifically at 4 Hz. So that's a direct mention of effectiveness in pain, but it's about ischemic pain and a specific frequency. Second chunk (33664472) states all methods analyzed were effective in reducing pain. But the methods here aren't specified. Wait, maybe this refers to TENS? The question is about TENS, so if this chunk is talking about TENS methods, then it supports effectiveness. But the user hasn't provided the exact content of that", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking if TENS machines are effective in pain relief. I need to look at the provided evidence to form a concise answer with citations and a confidence score. First, looking at the evidence: The first document [7644247:7644247_0] mentions that TENS has hypoalgesic effects on experimental ischaemic pain, specifically noting that lower frequency (4 Hz) was significant. That's a direct mention of effectiveness in a specific type of pain. The second document [33664472:33664472_0] states that all methods analyzed were effective in reducing pain. Since TENS is one of those methods", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, the user is asking if TENS machines are effective for pain. Let me look at the evidence provided. First, there's the document 7644247:7644247_0. It says that TENS has hypoalgesic effects on experimental ischemic pain and that the effect is frequency-specific, with 4 Hz being significant. That seems like a direct mention of effectiveness. Then there's 33664472:33664472_0 which states all methods analyzed were effective in reducing pain. The term \"all methods\" might refer to TENS, but I'm not sure. Maybe it's a broader study including other treatments? But the user is specifically asking about", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about the effectiveness of TENS machines in pain relief. The user wants a JSON answer with the answer and base confidence. First, I need to look at the evidence provided. There are three chunks here. Let me check each one. The first chunk (7644247:7644247_0) says that TENS has hypoalgesic effects on experimental ischaemic pain, specifically frequency-specific, with 4 Hz being significant. So this suggests that TENS can be effective, but maybe only under certain conditions. The second chunk (33664472:33664472_0) states that all methods analyzed have shown effectiveness in reducing pain.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if TENS machines are effective in pain, and they've provided some evidence. I need to generate a JSON answer based on that. First, look at the evidence. The first document (7644247) says that TENS has hypoalgesic effects, specifically mentioning lower frequency (4 Hz) was significant for ischaemic pain. So that's a positive point. The second document (33664472) states all methods analyzed were effective in reducing pain, which probably includes TENS. The third one (19818032) talks about BoNT/A being effective for chronic arthritis pain but not acute. But the question is general about pain,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if a TENS machine is effective in pain, and they provided some evidence. First, I need to look at the evidence given. There are three chunks here. Let me read through them carefully. The first chunk from 7644247:7644247_0 says that a study found TENS has hypoalgesic effects on experimental ischemic pain, specifically frequency-specific, with 4 Hz being significant. That seems to directly address the effectiveness of TENS in pain relief, but it's about ischemic pain and a specific frequency. The second chunk from 33664472:33664472_0 states that", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about the effectiveness of TENS machines in pain relief. The user wants a JSON answer with the answer and base confidence. First, I need to look at the evidence provided. There are three chunks here. Let me parse each one. The first chunk [7644247:7644247_0] says that TENS has hypoalgesic effects on experimental ischaemic pain, specifically mentioning lower frequency (4 Hz) was significant. So this suggests TENS works for certain types of pain, maybe ischemic pain. The second chunk [33664472:33664472_0] states that all methods analyzed were effective in reducing pain. Wait", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if a TENS machine is effective in pain, and they provided some evidence. First, I need to look at the evidence given. The first piece of evidence (7644247:7644247_0) says that TENS has hypoalgesic effects on experimental ischemic pain, specifically mentioning lower frequencies like 4 Hz were significant. So that's a study showing effectiveness in a specific type of pain. The second evidence (33664472:33664472_0) states that all methods analyzed have shown effectiveness in reducing pain. This seems more general, but I need to check if it's referring to T", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["17333874", "7644247"], "ideal_answer": "Transcutaneous electrical nerve stimulation is widely used in pain management"}
{"question_id": "56d1d14567f0cb3d66000003", "question": "Is there any algorithm for enhancer identification from chromatin state?", "retrieved_chunks": [{"doc_id": "23526891", "chunk_id": "23526891_2", "score": 9.26327896118164, "text": "RFECS: a random-forest based algorithm for enhancer identification from chromatin state."}, {"doc_id": "23526891", "chunk_id": "23526891_3", "score": 8.476518630981445, "text": "We developed a Random-Forest based algorithm, RFECS (Random Forest based Enhancer identification from Chromatin States) to integrate histone modification profiles for identification of enhancers, and used it to identify enhancers in a number of cell-types."}, {"doc_id": "23526891", "chunk_id": "23526891_0", "score": 6.6106672286987305, "text": "Here, we address this issue by exploring genome-wide profiles of 24 histone modifications in two distinct human cell types, embryonic stem cells and lung fibroblasts. We developed a Random-Forest based algorithm, RFECS (Random Forest based Enhancer identification from Chromatin States) to integrate histone modification profiles for identification of enhancers, and used it to identify enhancers in a number of cell-types."}], "context": "[23526891:23526891_2] RFECS: a random-forest based algorithm for enhancer identification from chromatin state.\n[23526891:23526891_3] We developed a Random-Forest based algorithm, RFECS (Random Forest based Enhancer identification from Chromatin States) to integrate histone modification profiles for identification of enhancers, and used it to identify enhancers in a number of cell-types.\n[23526891:23526891_0] Here, we address this issue by exploring genome-wide profiles of 24 histone modifications in two distinct human cell types, embryonic stem cells and lung fibroblasts. We developed a Random-Forest based algorithm, RFECS (Random Forest based Enhancer identification from Chromatin States) to integrate histone modification profiles for identification of enhancers, and used it to identify enhancers in a number of cell-types.", "answer": "<think> Okay, let's tackle this query. The user is asking if there's an algorithm for enhancer identification from chromatin state. Looking at the evidence provided, there's a mention of RFECS, which is a random-forest based algorithm. First, I need to check the evidence documents. Document [23526891:23526891_2] directly mentions RFECS as the algorithm. Then, chunks 23526891_3 and qualities also talk about RFECS being developed to integrate histone modifications for enhancer identification. The key points here are that RFECS uses random forest, which is a machine learning algorithm, and it's designed to work with chromatin state", "citations": [{"doc_id": "23526891", "chunk_id": "23526891_2"}], "candidates": [{"answer": "<think> Okay, let's tackle this query. The user is asking if there's an algorithm for enhancer identification from chromatin state. Looking at the evidence provided, there's a mention of RFECS, which is a random-forest based algorithm. First, I need to check the evidence documents. Document [23526891:23526891_2] directly mentions RFECS as the algorithm. Then, chunks 23526891_3 and qualities also talk about RFECS being developed to integrate histone modifications for enhancer identification. The key points here are that RFECS uses random forest, which is a machine learning algorithm, and it's designed to work with chromatin state", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this query. The user is asking if there's an algorithm for enhancer identification from chromatin state. Looking at the evidence provided, there's a mention of RFECS, which is a random-forest based algorithm. The documents all point to RFECS being developed to integrate histone modification profiles for identifying enhancers. First, I need to confirm that RFECS is indeed the algorithm they're referring to. The key points are that it uses random forest, which is a machine learning method, and it's designed to work with chromatin state data, specifically histone modifications. The answer should mention RFECS and its basis in random-forest, citing the document IDs. The confidence level here is pretty high because the evidence directly states", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there's an algorithm for enhancer identification from chromatin state. Looking at the evidence provided, there's a mention of RFECS, which is a random-forest based algorithm. First, I need to check the evidence documents. Document [23526891:23526891_2] directly mentions RFECS as a random-forest algorithm for enhancer identification from chromatin state. Then, chunks 23526891_3 and ight 0 also talk about RFECS being developed to integrate histone modification profiles for identifying enhancers in various cell types. So the answer should state that yes, there is such an", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this query. The user is asking if there's an algorithm for enhancer identification from chromatin state. Looking at the evidence provided, there's a mention of RFECS, which is a random-forest based algorithm. The documents all refer to RFECS as the method developed to integrate histone modification profiles for identifying enhancers. So, the answer should mention RFECS and cite the relevant document. The confidence level should be high because the evidence directly states that RFECS was developed for this purpose. The base_confidence can be set to 1.0 since the information is explicitly stated in the provided sources. I need to make sure the JSON structure is correct with the answer and base_confidence keys. Also, check that the citation", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking if there's an algorithm for enhancer identification from chromatin state. Let me look at the evidence provided. The evidence has three chunks. The first one mentions RFECS as a random-forest based algorithm for enhancer identification from chromatin state. The second chunk says they developed RFECS using Random Forest to integrate histone modifications for identifying enhancers. The third chunk also talks about developing RFECS to integrate histone profiles and use it in various cell types. So, the answer should mention RFECS and cite the relevant chunks. The confidence is high because multiple chunks refer to the same algorithm. The base_confidence should be 1.0 since all evidence points to RFECS being the algorithm. I need to structure the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking if there's an algorithm for enhancer identification from chromatin state. Looking at the evidence provided, there's a mention of RFECS, which is a random-forest based algorithm. First, I need to check the evidence documents. Document 23526891 has several chunks. Chunk 23526891_2 mentions RFECS as a random-forest algorithm for enhancer identification from chromatin state.Chunk 23526891_3 talks about developing RFECS to integrate histone modifications for enhancer identification. Chunk 23526891_0 also describes RFECS and its use in identifying enh", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there's an algorithm for enhancer identification from chromatin state. Looking at the evidence provided, there's a mention of RFECS, which is a random-forest based algorithm. The evidence has three chunks. Chunk 23526891_2 directly mentions RFECS as the algorithm. Chunk 23526891_3 explains that they developed RFECS to integrate histone modification profiles for enhancer identification. Chunk 23526891_0 also talks about RFECS being developed to do that. So all three chunks support the existence of RFECS as the algorithm. The answer needs to be concise with citations. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking if there's an algorithm for enhancer identification from chromatin state. Let me look at the evidence provided. The evidence has three chunks. The first one mentions RFECS as a random-forest based algorithm for enhancer identification from chromatin state. The second chunk says they developed RFECS using Random Forest to integrate histone modifications for identifying enhancers. The third chunk also talks about developing RFECS to integrate histone profiles and use it in various cell types. So, the answer should mention RFECS and cite the relevant chunks. The confidence is high because the evidence directly states that RFECS exists and is based on random forest. The base_confidence would be 1.0 since the information is explicitly provided in the evidence", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["22328731", "23526891"], "ideal_answer": "yes Yes. RFECS is a random-forest based algorithm for enhancer identification from chromatin state. It integrates histone modification profiles for the identification of enhancers, and can be used to identify enhancers in a number of cell-types. RFECS not only leads to more accurate and precise prediction of enhancers than previous methods, but also helps identify the most informative and robust set of three chromatin marks for enhancer prediction."}
{"question_id": "532498959b2d7acc7e000017", "question": "Which enzyme is targeted by the drug Imetelstat?", "retrieved_chunks": [{"doc_id": "26332545", "chunk_id": "26332545_1", "score": 7.462790012359619, "text": "Imetelstat is a 13-mer lipid-conjugated oligonucleotide that targets the RNA template of human telomerase reverse transcriptase.METHODS: We sought to obtain preliminary information on the therapeutic activity and safety of imetelstat in patients with high-risk or intermediate-2-risk myelofibrosis."}, {"doc_id": "23545855", "chunk_id": "23545855_2", "score": 6.191839218139648, "text": "This enzyme is expressed in approximately 90% of human tumors, but not in the majority of normal somatic cells. imetelstat sodium (GRN163L), is a 13-mer oligonucleotide N3'→P5' thio-phosphoramidate lipid conjugate, which represents the latest generation of telomerase inhibitors targeting the template region of the human functional telomerase RNA (hTR) subunit."}, {"doc_id": "22906540", "chunk_id": "22906540_4", "score": 4.5024590492248535, "text": "We sought to evaluate the potential of the thio-phosphoramidate oligonucleotide inhibitor of telomerase, imetelstat, as a drug candidate for treatment of esophageal cancer. Our results showed that imetelstat inhibited telomerase activity in a dose-dependent manner in esophageal cancer cells"}], "context": "[26332545:26332545_1] Imetelstat is a 13-mer lipid-conjugated oligonucleotide that targets the RNA template of human telomerase reverse transcriptase.METHODS: We sought to obtain preliminary information on the therapeutic activity and safety of imetelstat in patients with high-risk or intermediate-2-risk myelofibrosis.\n[23545855:23545855_2] This enzyme is expressed in approximately 90% of human tumors, but not in the majority of normal somatic cells. imetelstat sodium (GRN163L), is a 13-mer oligonucleotide N3'→P5' thio-phosphoramidate lipid conjugate, which represents the latest generation of telomerase inhibitors targeting the template region of the human functional telomerase RNA (hTR) subunit.\n[22906540:22906540_4] We sought to evaluate the potential of the thio-phosphoramidate oligonucleotide inhibitor of telomerase, imetelstat, as a drug candidate for treatment of esophageal cancer. Our results showed that imetelstat inhibited telomerase activity in a dose-dependent manner in esophageal cancer cells", "answer": "<think> Okay, so the question is asking which enzyme Imetelstat targets. Let me look at the evidence provided. First document: 26332545:26332545_1 says Imetelstat targets the RNA template of human telomerase reverse transcriptase. That's a direct mention of the enzyme, but it's talking about the RNA component. Wait, telomerase is an enzyme itself, right? So maybe they're referring to the telomerase enzyme's RNA component? Second document: 23545855:23545855_2 mentions that the enzyme is expressed in 90% of tumors but not in normal cells. It also says imetel", "citations": [], "candidates": [{"answer": "<think> Okay, so the question is asking which enzyme Imetelstat targets. Let me look at the evidence provided. First document: 26332545:26332545_1 says Imetelstat targets the RNA template of human telomerase reverse transcriptase. That's a direct mention of the enzyme, but it's talking about the RNA component. Wait, telomerase is an enzyme itself, right? So maybe they're referring to the telomerase enzyme's RNA component? Second document: 23545855:23545855_2 mentions that the enzyme is expressed in 90% of tumors but not in normal cells. It also says imetel", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which enzyme Imetelstat targets. Looking at the evidence provided, there are three documents. First document (26332545:26332545_1) says Imetelstat targets the RNA template of human telomerase reverse transcriptase. That's a key point. The second document (23545855:23545855_2) mentions that the enzyme is expressed in 90% of tumors but not in normal cells, and it's the telomerase RNA (hTR) subunit. So the enzyme here is telomerase, specifically the RNA component. The third document (229", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking which enzyme Imetelstat targets. Let me look at the evidence provided. First document: It says Imetelstat targets the RNA template of human telomerase reverse transcriptase. That's a key point. The second document mentions that the enzyme is expressed in 90% of tumors but not in normal cells, and it's about telomerase inhibitors targeting the hTR subunit. The third document talks about imetelstat inhibiting telomerase activity in cancer cells. So putting this together, the enzyme in question is telomerase. Specifically, the RNA component of telomerase, which is the reverse transcriptase part. The documents consistently point to telomerase as the target. The answer should be telomerase", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which enzyme Imetelstat targets. I need to look at the evidence provided. First, looking at the first evidence snippet: it says Imetelstat targets the RNA template of human telomerase reverse transcriptase. That seems direct. The second snippet mentions that the enzyme is expressed in 90% of tumors but not in normal cells, and that Imetelstat is a telomerase inhibitor targeting the template region of hTR. The third snippet also talks about imetelstat inhibiting telomerase activity in cancer cells. So all three sources point to telomerase being the target. The first one specifically mentions the RNA template of telomerase reverse transcriptase, which is part of the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which enzyme Imetelstat targets. Looking at the evidence provided, there are three documents. First, document 26332545:26332545_1 mentions that Imetelstat targets the RNA template of human telomerase reverse transcriptase. That seems like a direct answer. Then, document 23545855:23545857 also talks about targeting the template region of the human functional telomerase RNA (hTR) subunit. Wait, the chunk ID here is 23545855_2, but maybe that's a typo? Anyway, both documents 263", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking which enzyme Imetelstat targets. Let me look at the evidence provided. First, document 26332545:26332545_1 says that Imetelstat targets the RNA template of human telomerase reverse transcriptase. That seems like a direct answer. Then, document 23545855:23545855_2 mentions that the enzyme is expressed in 90% of tumors but not in normal cells, and that Imetelstat is a telomerase inhibitor targeting the template region of hTR. So both documents point to telomerase. The third document, 22906540:", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which enzyme Imetelstat targets. I need to look through the provided evidence to find the answer. First, looking at the first evidence snippet (26332545:26332545_1), it says Imetelstat targets the RNA template of human telomerase reverse transcriptase. That seems like a direct mention of the enzyme. But wait, telomerase is an enzyme itself, so maybe they're referring to the telomerase enzyme's RNA component? Then there's another snippet (23545855:23545857_2) which mentions that the enzyme is expressed in 90% of tumors", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which enzyme Imetelstat targets. I need to look at the evidence provided. First, looking at the first document: it says Imetelstat targets the RNA template of human telomerase reverse transcriptase. So that's a key point. The second document mentions that the enzyme is expressed in 90% of tumors but not in normal cells, and it's the telomerase RNA (hTR) subunit. The third document confirms that Imetelstat inhibits telomerase activity in cancer cells. Putting this together, the enzyme targeted is telomerase. Specifically, the RNA component of telomerase, which is the hTR subunit. The documents consistently point to telomerase", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["19908230", "20048334", "20072842", "20232321", "20824134", "21062983", "21208905", "21332640", "21549308", "21845093", "22382179", "22870217", "22906540", "23272238", "23326372", "23386830", "23467584", "23516479", "23521791", "23545855", "23558965", "23727752", "24327604"], "ideal_answer": "Imetelstat sodium (GRN163L), is a 13-mer oligonucleotide N3'→P5' thio-phosphoramidate lipid conjugate, which represents the latest generation of telomerase inhibitors targeting the template region of the human functional telomerase RNA subunit. In preclinical trials, this compound has been found to inhibit telomerase activity in multiple cancer cell lines, as well as in vivo xenograft mouse models."}
{"question_id": "56c1f005ef6e39474100003a", "question": "Which interleukins are inhibited by Dupilumab?", "retrieved_chunks": [{"doc_id": "26836729", "chunk_id": "26836729_1", "score": 8.000005722045898, "text": "OBJECTIVE: To assess inhibition of interleukins 4 and 13 with dupilumab in patients with chronic sinusitis and nasal polyposis."}, {"doc_id": "25006719", "chunk_id": "25006719_1", "score": 7.312871932983398, "text": "BACKGROUND: Dupilumab, a fully human monoclonal antibody that blocks interleukin-4 and interleukin-13, has shown efficacy in patients with asthma and elevated eosinophil levels. The blockade by dupilumab of these key drivers of type 2 helper T-cell (Th2)-mediated inflammation could help in the treatment of related diseases, including atopic dermatitis."}, {"doc_id": "26454361", "chunk_id": "26454361_0", "score": 6.365976333618164, "text": "Data from early-stage studies suggested that interleukin (IL)-4 and IL-13 are requisite drivers of atopic dermatitis, evidenced by marked improvement after treatment with dupilumab, a fully-human monoclonal antibody that blocks both pathways."}], "context": "[26836729:26836729_1] OBJECTIVE: To assess inhibition of interleukins 4 and 13 with dupilumab in patients with chronic sinusitis and nasal polyposis.\n[25006719:25006719_1] BACKGROUND: Dupilumab, a fully human monoclonal antibody that blocks interleukin-4 and interleukin-13, has shown efficacy in patients with asthma and elevated eosinophil levels. The blockade by dupilumab of these key drivers of type 2 helper T-cell (Th2)-mediated inflammation could help in the treatment of related diseases, including atopic dermatitis.\n[26454361:26454361_0] Data from early-stage studies suggested that interleukin (IL)-4 and IL-13 are requisite drivers of atopic dermatitis, evidenced by marked improvement after treatment with dupilumab, a fully-human monoclonal antibody that blocks both pathways.", "answer": "<think> Okay, so the user is asking which interleukins are inhibited by Dupilumab. Let me look at the evidence provided. First, there's the document 25006719:25006719_1. It states that Dupilumab blocks IL-4 and IL-13. Then, another document 26836729:26836729_1 mentions the same interleukins, talking about chronic sinusitis and nasal polyposis. The third one, 26454361:26454361_0, also says Dupilumab blocks both IL-4 and IL-13. All", "citations": [], "candidates": [{"answer": "<think> Okay, so the user is asking which interleukins are inhibited by Dupilumab. Let me look at the evidence provided. First, there's the document 25006719:25006719_1. It states that Dupilumab blocks IL-4 and IL-13. Then, another document 26836729:26836729_1 mentions the same interleukins, talking about chronic sinusitis and nasal polyposis. The third one, 26454361:26454361_0, also says Dupilumab blocks both IL-4 and IL-13. All", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which interleukins are inhibited by Dupilumab. Looking at the evidence provided, there are three references. First, the document 26836729:26836729_1 mentions that dupilumab inhibits IL-4 and IL-13 in patients with chronic sinusitis and nasal polyposis. That's a direct statement. Then, 25006719:25006719_1 says Dupilumab blocks IL-4 and IL-13, which are key drivers of Th2 inflammation. This reinforces the same answer. The third document, 26454", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking which interleukins are inhibited by Dupilumab. Let me look at the evidence provided. First document: 26836729:26836729_1 mentions that dupilumab inhibits IL-4 and IL-13 in patients with chronic sinusitis and nasal polyposis. That's a direct statement. Second document: 25006719:25006719_1 says Dupilumab blocks IL-4 and IL-13, which are key in Th2-mediated inflammation. This supports the first point. Third document: 26454361:26454", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which interleukins are inhibited by Dupilumab. I need to look at the provided evidence to find the answer. First, I'll check each of the evidence snippets. The first one, 26836729:26836729_1, mentions that dupilumab inhibits IL-4 and IL-13 in patients with chronic sinusitis and nasal polyposis. That's a direct statement. The second evidence, 25006719:25006719_1, says Dupilumab blocks IL-4 and IL-13, which are key drivers of type 2 inflammation", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which interleukins are inhibited by Dupilumab. I need to look at the provided evidence to find the answer. First, looking at the evidence documents. The first one, 26836729:26836729_1, mentions that dupilumab inhibits IL-4 and IL-13 in patients with chronic sinusitis and nasal polyposis. That's a direct statement. The second document, 25006719:25006719_1, says Dupilumab blocks IL-4 and IL-13, which are key drivers of Th2 inflammation. This confirms the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which interleukins are inhibited by Dupilumab. Looking at the evidence provided, there are three references. First, the document 26836729:26836729_1 mentions that dupilumab inhibits IL-4 and IL-13 in patients with chronic sinusitis and nasal polyposis. That's a direct mention. Then, 25006719:25006719_1 states that Dupilumab blocks IL-4 and IL-13, which are key in Th2-mediated inflammation. This reinforces the same answer. The third document, 2645", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking which interleukins are inhibited by Dupilumab. Let me look at the evidence provided. First, there's the document 25006719:25006719_1. It says that Dupilumab blocks interleukin-4 and interleukin-13. That's a direct mention. Then, another document 26836729:26836729_1 also talks about inhibition of IL-4 and IL-13 in chronic sinusitis patients. The third document, 26454361:26454361_0, again confirms that dupilumab blocks both", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which interleukins are inhibited by Dupilumab. Looking at the evidence provided, there are three documents. First, document 26836729:26836729_1 mentions that dupilumab inhibits IL-4 and IL-13 in patients with chronic sinusitis and nasal polyposis. That's a direct statement. Then, document 25006719:25006719_1 states that Dupilumab blocks IL-4 and IL-13, which are key drivers of Th2 inflammation. This reinforces the same answer. Document 26454361", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["23688323", "24275927", "25006719", "25214796", "25482871", "25584909", "25645542"], "ideal_answer": "Dupilumab, a fully human monoclonal antibody that blocks interleukin-4 and interleukin-13, has shown efficacy in patients with asthma and elevated eosinophil levels."}
{"question_id": "513ce3c8bee46bd34c000008", "question": "Which human genes are more commonly related to craniosynostosis?", "retrieved_chunks": [{"doc_id": "19530187", "chunk_id": "19530187_1", "score": 6.263801097869873, "text": "craniosynostosis genes (FGFR2, FGFR3)"}, {"doc_id": "12407713", "chunk_id": "12407713_0", "score": 6.244341850280762, "text": "Mutations in five genes (FGFR1-, -2, -3, TWIST, and MSX2) causing craniosynostosis as the main clinical feature were described."}, {"doc_id": "15880747", "chunk_id": "15880747_0", "score": 5.983407020568848, "text": "loinsufficiency of the human TWIST1 gene, which causes the craniosynostosis disorder Saethre-Chotzen syndrome (SCS), is related to failure to repress transcription of CDKN1A (which encodes p21/WAF1/CIP1), promoting osteoblast differentiation. We have e"}], "context": "[19530187:19530187_1] craniosynostosis genes (FGFR2, FGFR3)\n[12407713:12407713_0] Mutations in five genes (FGFR1-, -2, -3, TWIST, and MSX2) causing craniosynostosis as the main clinical feature were described.\n[15880747:15880747_0] loinsufficiency of the human TWIST1 gene, which causes the craniosynostosis disorder Saethre-Chotzen syndrome (SCS), is related to failure to repress transcription of CDKN1A (which encodes p21/WAF1/CIP1), promoting osteoblast differentiation. We have e", "answer": "<think> Okay, let's tackle this question. The user wants to know which human genes are more commonly related to craniosynostosis. The evidence provided has three chunks. First chunk: [19530187:19530187_1] mentions FGFR2 and FGFR3. Second chunk: [12407713:12407713_0] lists FGFR1, FGFR2, FGFR3, TWIST, and MSX2. Third chunk: [15880747:15880747_0] talks about TWIST1 related to Saethre-Chotzen syndrome, which is a type of cran", "citations": [{"doc_id": "19530187", "chunk_id": "19530187_1"}, {"doc_id": "12407713", "chunk_id": "12407713_0"}, {"doc_id": "15880747", "chunk_id": "15880747_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants to know which human genes are more commonly related to craniosynostosis. The evidence provided has three references. First, I need to look at each of the evidence points. The first one mentions FGFR2 and FGFR3. The second reference lists five genes: FGFR1, FGFR2, FGFR3, TWIST, and MSX2. The third talks about TWIST1 and CDKN1A, but it's more about Saethre-Chotzen syndrome. So the main genes mentioned across the references are FGFR1, FGFR2, FGFR3, TWIST, MSX2, and TWIST1. However, the question is about which are \"more commonly\"", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which human genes are more commonly related to craniosynostosis. The evidence provided has three chunks. First, chunk 19530187 mentions FGFR2 and FGFR3 as craniosynostosis genes. Then, chunk 12407713 lists five genes: FGFR1, FGFR2, FGFR3, TWIST, and MSX2. The third chunk talks about TWIST1 being related to Saethre-Chotzen syndrome, which is a type of craniosynostosis. So, combining these, the main genes mentioned are FGFRs (1,2,3) and TWIST, MSX2,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which human genes are more commonly related to craniosynostosis. The evidence provided has three chunks. First chunk mentions FGFR2 and FGFR3. The second one lists FGFR1, FGFR2, FGFR3, TWIST, and MSX2. The third talks about TWIST1 and CDKN1A, but the main focus here is on TWIST1 related to Saethre-Chotzen syndrome. So I need to compile these genes. The question is about which are \"more commonly\" related. The first chunk specifically names FGFR2 and FGFR3. The second chunk adds more genes, including TWIST and MSX2. The third mentions TWIST1 again.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which human genes are more commonly related to craniosynostosis. The evidence provided has three chunks. First chunk: 19530187 mentions FGFR2 and FGFR3. Second chunk: 12407713 lists FGFR1, -2, -3, TWIST, and MSX2. Third chunk: 15880747 talks about TWIST1 and CDKN1A, but the main genes here are TWIST1 related to Saethre-Chotzen syndrome. So, combining these, the main genes mentioned are FGFR1, FGFR2, FGFR3, TWIST, and MSX2", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which human genes are more commonly related to craniosynostosis. The evidence provided has three chunks. First chunk: [19530187:19530187_1] mentions FGFR2 and FGFR3. Second chunk: [12407713:12407713_0] lists FGFR1, FGFR2, FGFR3, TWIST, and MSX2. Third chunk: [15880747:15880747_0] talks about TWIST1 related to Saethre-Chotzen syndrome, which is a type of cran", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which human genes are more commonly related to craniosynostosis. The evidence provided has three chunks. First chunk mentions FGFR2 and FGFR3. The second one lists FGFR1, FGFR2, FGFR3, TWIST, and MSX2. The third talks about TWIST1 and CDKN1A, but the main point here is TWIST1 related to Saethre-Chotzen syndrome, which is a type of craniosynostosis. So, I need to compile the genes from the evidence. The first two chunks list FGFR1, FGFR2, FGFR3, TWIST, MSX2. The third chunk adds TWIST1. Wait", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which human genes are more commonly related to craniosynostosis. The evidence provided has three chunks. First chunk mentions FGFR2 and FGFR3. The second one lists FGFR1, FGFR2, FGFR3, TWIST, and MSX2. The third talks about TWIST1 and CDKN1A, but the main focus here is on TWIST1 causing Saethre-Chotzen syndrome, which is a type of craniosynostosis. So, I need to compile the genes from the evidence. The first two chunks mention FGFR genes (1-3) and TWIST, MSX2. The third chunk adds TWIST1. However, the question", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which human genes are more commonly related to craniosynostosis. The evidence provided has three chunks. First chunk: 19530187 mentions FGFR2 and FGFR3. Second chunk: 12407713 lists FGFR1, FGFR2, FGFR3, TWIST, and MSX2. Third chunk: 15880747 talks about TWIST1 related to Saethre-Chotzen syndrome, which is a type of craniosynostosis. So the main genes here are FGFRs (1,2,3), TWIST, MSX2, and TWIST1. But wait,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["10914960", "10951518", "11197897", "11341328", "11428324", "11484208", "11746040", "11820058", "12407713", "14672347", "15964893", "16258006", "17042739", "17955513", "18000908", "19530187", "20643727", "8106171", "9042914", "9600744", "9917362", "9934984"], "ideal_answer": "The genes that are most commonly linked to craniosynostoses are the members of the Fibroblast Growth Factor Receptor family FGFR3 and to a lesser extent FGFR1 and FGFR2. Some variants of the disease have been associated with the triplication of the MSX2 gene and mutations in NELL-1. NELL-1 is being regulated bu RUNX2, which has also been associated to cases of craniosynostosis. Other genes reported to have a role in the development of the disease are RECQL4, TWIST, SOX6 and GNAS."}
{"question_id": "553f78c7ab98a37113000008", "question": "Are transcribed ultraconserved regions involved in cancer?", "retrieved_chunks": [{"doc_id": "21298224", "chunk_id": "21298224_1", "score": 9.260063171386719, "text": "The transcribed-ultraconserved regions: a novel class of long noncoding RNAs involved in cancer susceptibility."}, {"doc_id": "18323801", "chunk_id": "18323801_1", "score": 9.163840293884277, "text": "Moreover, the recent demonstration that other ncRNAs, the ultraconserved genes (UCGs) or transcribed ultraconserved regions (T-UCRs), are involved in human cancerogenesis, suggests that the wider family of ncRNAs (including both miRNAs and UCGs) could contribute to the development of the malignant phenotype."}, {"doc_id": "18323801", "chunk_id": "18323801_0", "score": 9.045459747314453, "text": "Moreover, the recent demonstration that other ncRNAs, the ultraconserved genes (UCGs) or transcribed ultraconserved regions (T-UCRs), are involved in human cancerogenesis, suggests that the wider family of ncRNAs (including both miRNAs and UCGs) could contribute to the development of the malignant phenotype"}], "context": "[21298224:21298224_1] The transcribed-ultraconserved regions: a novel class of long noncoding RNAs involved in cancer susceptibility.\n[18323801:18323801_1] Moreover, the recent demonstration that other ncRNAs, the ultraconserved genes (UCGs) or transcribed ultraconserved regions (T-UCRs), are involved in human cancerogenesis, suggests that the wider family of ncRNAs (including both miRNAs and UCGs) could contribute to the development of the malignant phenotype.\n[18323801:18323801_0] Moreover, the recent demonstration that other ncRNAs, the ultraconserved genes (UCGs) or transcribed ultraconserved regions (T-UCRs), are involved in human cancerogenesis, suggests that the wider family of ncRNAs (including both miRNAs and UCGs) could contribute to the development of the malignant phenotype", "answer": "<think> Okay, let's tackle this question. The user is asking if transcribed ultraconserved regions (T-UCRs) are involved in cancer. The evidence provided has three documents. Let me check each one. First, document [21298224:21298224_1] mentions that T-UCRs are a novel class of long noncoding RNAs involved in cancer susceptibility. That's a direct statement linking T-UCRs to cancer. The confidence here is high because it's a direct claim. Then, document [18323801:18323801_1] says that UCGs or T-UCRs are involved in human cancerogenesis, suggesting that nc", "citations": [{"doc_id": "21298224", "chunk_id": "21298224_1"}, {"doc_id": "18323801", "chunk_id": "18323801_1"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if transcribed ultraconserved regions (T-UCRs) are involved in cancer. Looking at the evidence provided, there are two documents mentioned. First, document 21298224:21298224_1 mentions that T-UCRs are a novel class of long noncoding RNAs involved in cancer susceptibility. That's a direct statement linking T-UCRs to cancer. The confidence here is pretty high because it's a specific mention. Then, document 18323801 has two chunks. Both chunks (18323801_1 and 18323801_0) talk about other", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if transcribed ultraconserved regions (T-UCRs) are involved in cancer. I need to look at the provided evidence to form an answer. Looking at the evidence, there are three references. The first one, 21298224:21298224_1, mentions that T-UCRs are a novel class of long noncoding RNAs involved in cancer susceptibility. That's a direct statement linking T-UCRs to cancer. The second reference, 18323801:18323801_1, says that UCGs or T-UCRs are involved in human cancerogenesis. The term \"", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking if transcribed ultraconserved regions (T-UCRs) are involved in cancer. I need to look at the provided evidence to form a concise answer with citations and a confidence level. First, checking the evidence documents. Document 21298224:21298224_1 has a title that directly mentions T-UCRs being involved in cancer susceptibility. That's a strong point. Then document 18323801 has two chunks. Both chunks mention that UCGs or T-UCRs are involved in human cancerogenesis, suggesting ncRNAs contribute to malignant phenotype. So the answer should state that yes, T-UCRs are", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if transcribed ultraconserved regions (T-UCRs) are involved in cancer. The evidence provided has three documents. Let me check each one. First, document [21298224:21298224_1] mentions that T-UCRs are a novel class of long noncoding RNAs involved in cancer susceptibility. That's a direct statement linking T-UCRs to cancer. The confidence here is high because it's a direct claim. Then, document [18323801:18323801_1] says that UCGs or T-UCRs are involved in human cancerogenesis, suggesting that nc", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if transcribed ultraconserved regions (T-UCRs) are involved in cancer. Looking at the evidence provided, there are two documents mentioned. First, document [21298224:21298224_1] directly states that T-UCRs are a novel class of long noncoding RNAs involved in cancer susceptibility. That's a direct citation. Then, document [18323801:18323801_1] and [18323801:18323801_0] both mention that UCGs or T-UCRs are involved in human cancerogenesis", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if transcribed ultraconserved regions (T-UCRs) are involved in cancer. The evidence provided has three documents. First, I need to look at each piece of evidence. Document 21298224:21298224_1 mentions that T-UCRs are a novel class of long noncoding RNAs involved in cancer susceptibility. That directly answers the question with a citation. Then document 18323801:18323801_1 and 18323801:18323801_0 both talk about T-UCRs being involved in human cancerogenesis", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is whether transcribed ultraconserved regions (T-UCRs) are involved in cancer. Let me look at the evidence provided. First, document [21298224:21298224_1] mentions that T-UCRs are a novel class of long noncoding RNAs involved in cancer susceptibility. That's a direct statement linking T-UCRs to cancer. Then, document [18323801:18323801_1] and [18323801:18323801_0] both talk about how other ncRNAs like", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if transcribed ultraconserved regions (T-UCRs) are involved in cancer. The evidence provided has three references. First, looking at the first document [21298224:21298224_1], the title itself says \"The transcribed-ultraconserved regions: a novel class of long noncoding RNAs involved in cancer susceptibility.\" That directly mentions T-UCRs being involved in cancer, so that's a strong point. The confidence here is high because it's a direct statement. Then, the second and third documents [18323801:18323801_1] and [183", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["18323801", "20383195", "20802525", "21298224", "22328099", "22617881", "24037088", "24247010"], "ideal_answer": "Yes, it appears that there is widespread T-UCR (Transcribed - UltraConserved Region) involvement in diverse cellular processes that are deregulated in the process of tumourigenesis. Transcribed ultraconserved regions (T-UCRs) are a subset of 481 sequences longer than 200 bp, which are absolutely conserved between orthologous regions of human, rat and mouse genomes, and are actively transcribed. It has recently been proven in cancer systems that differentially expressed T-UCRs could alter the functional characteristics of malignant cells."}
{"question_id": "56d06e043975bb303a000011", "question": "In which breast cancer patients can palbociclib be used?", "retrieved_chunks": [{"doc_id": "25524798", "chunk_id": "25524798_0", "score": 6.14046573638916, "text": "We aimed to assess the safety and efficacy of palbociclib in combination with letrozole as first-line treatment of patients with advanced, oestrogen receptor-positive, HER2-negative breast cancer."}, {"doc_id": "26236140", "chunk_id": "26236140_0", "score": 4.330217361450195, "text": "Women with hormone receptor-positive, human epidermal growth factor receptor 2- negative breast cancer-the most common subtype-have new options as palbociclib and similar drugs debut."}, {"doc_id": "26642065", "chunk_id": "26642065_0", "score": 4.2563557624816895, "text": "SUMMARY: Palbociclib, abemaciclib and ribociclib have demonstrated very promising clinical activity in breast cancer, liposarcoma, mantel cell lymphoma and melanoma. Moreover, CDK4/6 inhibitors have shown promising preclinical activity in glioblastoma, renal and ovarian cancer models that may provide directions for their future clinical development."}], "context": "[25524798:25524798_0] We aimed to assess the safety and efficacy of palbociclib in combination with letrozole as first-line treatment of patients with advanced, oestrogen receptor-positive, HER2-negative breast cancer.\n[26236140:26236140_0] Women with hormone receptor-positive, human epidermal growth factor receptor 2- negative breast cancer-the most common subtype-have new options as palbociclib and similar drugs debut.\n[26642065:26642065_0] SUMMARY: Palbociclib, abemaciclib and ribociclib have demonstrated very promising clinical activity in breast cancer, liposarcoma, mantel cell lymphoma and melanoma. Moreover, CDK4/6 inhibitors have shown promising preclinical activity in glioblastoma, renal and ovarian cancer models that may provide directions for their future clinical development.", "answer": "<think> Okay, so the user is asking about which breast cancer patients can use palbociclib. Let me look at the evidence provided. First, evidence document 25524798:25524798_0 mentions that palbociclib is used in combination with letrozole as first-line treatment for advanced, estrogen receptor-positive, HER2-negative breast cancer. That's a specific group of patients. Then, document 26236140:26236140_0 says women with hormone receptor-positive, HER2-negative breast cancer have new options with palbociclib. This seems to align with the first evidence, reinforcing that it's for hormone receptor-positive, HER2", "citations": [], "candidates": [{"answer": "<think> Okay, so the user is asking about which breast cancer patients can use palbociclib. Let me look at the evidence provided. First, evidence document 25524798:25524798_0 mentions that palbociclib is used in combination with letrozole as first-line treatment for advanced, estrogen receptor-positive, HER2-negative breast cancer. That's a specific group of patients. Then, document 26236140:26236140_0 says women with hormone receptor-positive, HER2-negative breast cancer have new options with palbociclib. This seems to align with the first evidence, reinforcing that it's for hormone receptor-positive, HER2", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking about which breast cancer patients can use palbociclib. Let me look at the evidence provided. First, evidence 25524798:25524798_0 mentions that palbociclib is used in combination with letrozole as first-line treatment for advanced, estrogen receptor-positive, HER2-negative breast cancer. That's a specific group of patients. Then, evidence 26236140:26236140_0 says women with hormone receptor-positive, HER2-negative breast cancer have new options with palbociclib. This seems to align with the first point, reinforcing that it's for hormone receptor-positive and HER2-negative", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know in which breast cancer patients palbociclib can be used, based on the provided evidence. First, I need to look at the evidence given. There are three chunks here. Let me parse each one. The first chunk (25524798:25524798_0) says that palbociclib is assessed in combination with letrozole as first-line treatment for advanced, estrogen receptor-positive, HER2-negative breast cancer. So that's a specific indication. The second chunk (26236140:2623614ity_0) mentions women with hormone receptor-positive, HER2-negative breast cancer, which", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about when palbociclib can be used in breast cancer patients. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three documents here. Let me go through each one. The first document (25524798:25524798_0) says that palbociclib is used in combination with letrozole as first-line treatment for advanced, estrogen receptor-positive, HER2-negative breast cancer. That's specific. So that's a direct mention of the patient population. The second document (26236140:2623614ity_0) mentions women with", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about palbociclib. The user is asking in which breast cancer patients it can be used. I need to look at the evidence provided. First, evidence document 25524798:25524798_0 mentions that palbociclib is used in combination with letrozole as first-line treatment for advanced, estrogen receptor-positive, HER2-negative breast cancer. That's a specific group of patients. Then, document 26236140:26236140_0 says that women with hormone receptor-positive, HER2-negative breast cancer have new options with palbociclib. This seems to align with the first point,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about when palbociclib can be used in breast cancer patients. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three documents here. Let me read through them carefully. The first document (25524798:25524798_0) says that palbociclib is used in combination with letrozole as first-line treatment for advanced, estrogen receptor-positive, HER2-negative breast cancer. That's a specific patient population. The second document (26236140:2623614ity_0) mentions women with hormone receptor-positive, HER2-negative breast", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking about which breast cancer patients can use palbociclib. Let me look at the evidence provided. First, document 25524798:25524798_0 mentions that palbociclib is used in combination with letrozole as first-line treatment for advanced, estrogen receptor-positive, HER2-negative breast cancer. That's a specific group of patients. Then, document 26236140:26236140_0 talks about women with hormone receptor-positive, HER2-negative breast cancer, which is the most common subtype. It says palbociclib and similar drugs are available for this group. The third document,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about when palbociclib can be used in breast cancer patients. The user wants a strict JSON answer with the answer and base confidence. First, I need to look at the evidence provided. There are three documents here. Let me go through each one. The first document (25524798:25524798_0) says that palbociclib is used in combination with letrozole as first-line treatment for advanced, estrogen receptor-positive, HER2-negative breast cancer. That's a specific indication. The second document (26236140:2623614added_0) mentions women with hormone receptor-positive, HER2-negative breast", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["25524798", "25792301", "26236140"], "ideal_answer": "Palbociclib is useful for women with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer."}
{"question_id": "56d8b27651531f7e33000003", "question": "Do patients with Pendred syndrome present congenital deafness?", "retrieved_chunks": [{"doc_id": "8979104", "chunk_id": "8979104_0", "score": 8.861767768859863, "text": "Pendred&apos;s syndrome is manifested by congenital sensorineural deafness in association with familial goiter due to defective organic binding of iodine in the thyroid gland. The majority of patients with Pendred&apos;s syndrome are euthyroid. We report on an unusual case of a patient with Pendred&apos;s syndrome presenting with amenorrhea and late-onset hypothyroidism."}, {"doc_id": "1810081", "chunk_id": "1810081_0", "score": 8.521949768066406, "text": "The occurrence of congenital deafness, mutism and goitre unassociated with cretinism or mental retardation in euthyroid patients is known as Pendred&apos;s Syndrome. It has been estimated that 4-10 % of children with congenital deafness suffer from this condition."}, {"doc_id": "8630498", "chunk_id": "8630498_0", "score": 8.521946907043457, "text": "The cause of the congenital deafness in Pendred syndrome is obscure, although a Mondini type malformation of the cochlea exists in some patients."}], "context": "[8979104:8979104_0] Pendred&apos;s syndrome is manifested by congenital sensorineural deafness in association with familial goiter due to defective organic binding of iodine in the thyroid gland. The majority of patients with Pendred&apos;s syndrome are euthyroid. We report on an unusual case of a patient with Pendred&apos;s syndrome presenting with amenorrhea and late-onset hypothyroidism.\n[1810081:1810081_0] The occurrence of congenital deafness, mutism and goitre unassociated with cretinism or mental retardation in euthyroid patients is known as Pendred&apos;s Syndrome. It has been estimated that 4-10 % of children with congenital deafness suffer from this condition.\n[8630498:8630498_0] The cause of the congenital deafness in Pendred syndrome is obscure, although a Mondini type malformation of the cochlea exists in some patients.", "answer": "<think> Okay, let's tackle this question. The user wants to know if patients with Pendred syndrome present congenital deafness. The evidence provided has three documents. First, I need to check each document for information about congenital deafness in Pendred syndrome. Looking at the first evidence [8979104:8979104_0], it says that Pendred's syndrome is manifested by congenital sensorineural deafness associated with familial goiter due to defective iodine binding in the thyroid. It also mentions that most patients are euthyroid. So this directly states that congenital deafness is present. The second evidence [1810081:1810081_0] says that congen", "citations": [{"doc_id": "8979104", "chunk_id": "8979104_0"}, {"doc_id": "1810081", "chunk_id": "1810081_0"}], "candidates": [{"answer": "<think> Okay, I need to answer whether patients with Pendred syndrome present congenital deafness based on the given evidence. Let me look at the evidence provided. First, document 8979104 says that Pendred's syndrome is manifested by congenital sensorineural deafness associated with familial goiter due to defective iodine binding in the thyroid. It also mentions that most patients are euthyroid. So this directly states that congenital deafness is a feature. Then, document 1810081 says that congenital deafness, mutism, and goitre without cretinism or mental retardation in euthyroid patients is Pendred's syndrome. It also estimates that 4-10% of children with congenital deafness", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if patients with Pendred syndrome present congenital deafness. I need to check the evidence provided. Looking at the first evidence snippet: It says Pendred's syndrome is manifested by congenital sensorineural deafness associated with familial goiter due to defective iodine binding in the thyroid. Also mentions that most patients are euthyroid. So this directly states congenital deafness is part of the syndrome. The second snippet confirms that congenital deafness, mutism, and goitre are features of Pendred's syndrome in euthyroid patients. It also says 4-10% of children with deafness have this condition. This reinforces the presence of congenital deafness. The third snippet mentions that the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to answer whether patients with Pendred syndrome present congenital deafness based on the given evidence. Let me look at the evidence provided. First document: It says Pendred's syndrome is manifested by congenital sensorineural deafness associated with familial goiter due to defective iodine binding in the thyroid. Most patients are euthyroid. So this directly states that congenital deafness is a feature. Second document mentions congenital deafness, mutism, and goitre in euthyroid patients, which is Pendred's syndrome. It also says 4-10% of children with congenital deafness have this condition. This reinforces the link between Pendred's and congenital deafness. Third document talks about the cause being obscure but mentions a", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if patients with Pendred syndrome present congenital deafness. I need to check the evidence provided. First, looking at the evidence documents. The first one says that Pendred's syndrome is manifested by congenital sensorineural deafness associated with familial goiter due to defective iodine binding in the thyroid. It also mentions that most patients are euthyroid. So that's a direct statement about congenital deafness. The second document states that congenital deafness, mutism, and goitre without cretinism or mental retardation in euthyroid patients is Pendred's syndrome. It also estimates 4-10% of children with congenital deafness have this condition. This reinforces the presence", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if patients with Pendred syndrome present congenital deafness. I need to check the provided evidence to find answers. Looking at the first evidence snippet: It says Pendred's syndrome is manifested by congenital sensorineural deafness associated with familial goiter due to defective iodine binding. So that directly states congenital deafness is a feature. The confidence here is high because it's a direct mention. The second snippet mentions congenital deafness, mutism, and goitre in euthyroid patients, which aligns with the first point. It also notes that 4-10% of children with congenital deafness have this condition, reinforcing the link between Pendred syndrome and deafness. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if patients with Pendred syndrome present congenital deafness. I need to check the evidence provided. Looking at the first evidence snippet: It says Pendred's syndrome is manifested by congenital sensorineural deafness associated with familial goiter due to defective iodine binding in the thyroid. Also mentions most patients are euthyroid. So that's a direct mention of congenital deafness. The second snippet states that congenital deafness, mutism, and goitre without cretinism or mental retardation in euthyroid patients is Pendred's syndrome. It also says 4-10% of children with congenital deafness have this condition. So again, confirms the presence of congenital deaf", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if patients with Pendred syndrome present congenital deafness. The evidence provided has three documents. First, I need to check each document for information about congenital deafness in Pendred syndrome. Looking at the first evidence [8979104:8979104_0], it says that Pendred's syndrome is manifested by congenital sensorineural deafness associated with familial goiter due to defective iodine binding in the thyroid. It also mentions that most patients are euthyroid. So this directly states that congenital deafness is present. The second evidence [1810081:1810081_0] says that congen", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, so I need to figure out if patients with Pendred syndrome present congenital deafness based on the given evidence. Let me start by looking at the three provided documents. The first document says that Pendred's syndrome is manifested by congenital sensorineural deafness along with familial goiter due to defective iodine binding in the thyroid. It also mentions that most patients are euthyroid. So this directly states that congenital deafness is a feature of the syndrome. The second document refers to congenital deafness, mutism, and goitre in euthyroid patients as Pendred's Syndrome. It adds that 4-10% of children with congenital deafness have this condition. This reinforces the link between Pendred's and congenital deafness", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["10037079", "10443670", "10502702", "10602116", "10700480", "11375792", "11716048", "14727345", "15320950", "16482981", "16924389", "17299139", "1810081", "18250610", "19318451", "21274344", "21551164", "21704276", "22109890", "22717225", "23459462", "8476169", "8630498", "8706311", "8979104", "9070918", "9398842", "9585042", "9920104"], "ideal_answer": "Congenital deafness is one of the characteristics of Pendred syndrome patients."}
{"question_id": "571e1e11bb137a4b0c000004", "question": "List side effects of SGLT2 inhibitors?", "retrieved_chunks": [{"doc_id": "37482684", "chunk_id": "37482684_0", "score": 7.503031253814697, "text": "SGLT2 inhibitors inhibit the reabsorption of sodium and glucose in the proximal tubule of the kidney and then recovers tubuloglomerular feedback, whereby SGLT2 inhibitors reduce glomerular hyperfiltration. This simple demonstration of their beneficial effects has perplexed experts in seeking more plausible and as yet undisclosed explanations for the whole effects of SGLT2 inhibitors, including metabolism reprogramming and the modulation of hypoxia, inflammation, and oxidative stress."}, {"doc_id": "35999803", "chunk_id": "35999803_0", "score": 7.159795761108398, "text": "Large clinical trials now provide strong evidence that SGLT2 inhibitors decrease the risk of cardiovascular death, heart failure, progressive kidney dysfunction, myocardial infarction, stroke and gout."}, {"doc_id": "33336169", "chunk_id": "33336169_2", "score": 6.874668121337891, "text": "Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) are a new type of drug for the treatment of diabetes, and they have been proven to have a good hypoglycemic effect. Several lines of clinical evidence have shown that SGLT2 inhibitors can significantly reduce the risks of atherosclerosis, hospitalization for heart failure, cardiovascular death, and all-cause mortality and delay the progression of chronic kidney disease. Because of the protective effects of SGLT2 inhibitors on the heart and kidney, they are being studied for the treatment of heart failure and chronic kidney disease in patients without diabetes."}], "context": "[37482684:37482684_0] SGLT2 inhibitors inhibit the reabsorption of sodium and glucose in the proximal tubule of the kidney and then recovers tubuloglomerular feedback, whereby SGLT2 inhibitors reduce glomerular hyperfiltration. This simple demonstration of their beneficial effects has perplexed experts in seeking more plausible and as yet undisclosed explanations for the whole effects of SGLT2 inhibitors, including metabolism reprogramming and the modulation of hypoxia, inflammation, and oxidative stress.\n[35999803:35999803_0] Large clinical trials now provide strong evidence that SGLT2 inhibitors decrease the risk of cardiovascular death, heart failure, progressive kidney dysfunction, myocardial infarction, stroke and gout.\n[33336169:33336169_2] Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) are a new type of drug for the treatment of diabetes, and they have been proven to have a good hypoglycemic effect. Several lines of clinical evidence have shown that SGLT2 inhibitors can significantly reduce the risks of atherosclerosis, hospitalization for heart failure, cardiovascular death, and all-cause mortality and delay the progression of chronic kidney disease. Because of the protective effects of SGLT2 inhibitors on the heart and kidney, they are being studied for the treatment of heart failure and chronic kidney disease in patients without diabetes.", "answer": "<think> Okay, let's tackle this question. The user is asking for the side effects of SGLT2 inhibitors. Looking at the evidence provided, I need to check if any of the documents mention side effects. First document: 37482684:37482684_0 talks about how SGLT2 inhibitors work, mentioning their beneficial effects like reducing glomerular hyperfiltration. But it doesn't mention any side effects. It discusses mechanisms and potential explanations for their effects, but nothing on adverse reactions. Second document: 35999803:35999803_0 lists several benefits, such as reduced cardiovascular death, heart failure, kidney dysfunction, etc. Again, these", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking for the side effects of SGLT2 inhibitors. Looking at the evidence provided, I need to check if any of the documents mention side effects. First document: 37482684:37482684_0 talks about how SGLT2 inhibitors work, mentioning their beneficial effects like reducing glomerular hyperfiltration. But it doesn't mention any side effects. It discusses mechanisms and potential explanations for their effects, but nothing on adverse reactions. Second document: 35999803:35999803_0 lists several benefits, such as reduced cardiovascular death, heart failure, kidney dysfunction, etc. Again, these", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer about the side effects of SGLT2 inhibitors based on the provided evidence. Let me start by carefully reading the user's question and the given evidence. The question is asking for the side effects of SGLT2 inhibitors. However, looking at the evidence provided, none of the documents directly mention side effects. Instead, they talk about the mechanisms of action, benefits, and some clinical outcomes like cardiovascular death, heart failure, kidney dysfunction, etc. Wait, but the user wants side effects, not the benefits. The evidence doesn't list any side effects. The first document talks about how SGLT2 inhibitors work and their beneficial effects, but no side effects are mentioned. The second document lists positive outcomes from clinical trials,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer about the side effects of SGLT2 inhibitors based on the provided evidence. Let me look at the evidence given. The first document (37482684) talks about how SGLT2 inhibitors work by inhibiting sodium and glucose reabsorption in the kidney, which leads to tubuloglomerular feedback and reduces glomerular hyperfiltration. It also mentions that this mechanism has perplexed experts, but there are explanations like metabolism reprogramming, hypoxia, inflammation, and oxidative stress. However, this document doesn't mention side effects directly. The second document (35999803) states that SGLT2 inhibitors decrease the risk of cardiovascular death, heart failure", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about the side effects of SGLT2 inhibitors. The user wants a concise answer with citations and a confidence level. First, I need to look through the provided evidence to find any mentions of side effects. Let me check each document: The first document (37482684) talks about how SGLT2 inhibitors work, mentioning their beneficial effects like reducing glomerular hyperfiltration. But it also says that these effects have perplexed experts, suggesting there might be other effects, but it doesn't list specific side effects. The second document (35999803) lists several benefits: reduced cardiovascular death, heart failure, kidney dysfunction, myocardial infarction, stroke, and gout", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking for the side effects of SGLT2 inhibitors. But looking at the provided evidence, none of the documents actually mention side effects. The first document talks about the mechanism of action and benefits, the second discusses cardiovascular benefits, and the third mentions hypoglycemic effects and protective effects on heart and kidney. Hmm, so the user wants side effects, but the evidence given doesn't include any. The answer needs to be a biomedical fact based on the provided documents. Since there's no mention of side effects in the evidence, I can't provide that information. But the user might have expected some common side effects like genitourinary infections or urinary tract issues, which are usually associated with SGLT2 inhibitors", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the side effects of SGLT2 inhibitors. But looking at the provided evidence, none of the documents actually mention side effects. The first document talks about the mechanism of action and some beneficial effects, like reducing glomerular hyperfiltration and metabolic reprogramming. The second document discusses cardiovascular benefits from clinical trials. The third mentions hypoglycemic effects and protective effects on heart and kidney. Wait, so the evidence given doesn't list any side effects. The user wants a biomedical answer based on the evidence, but if there's no mention of side effects in the provided sources, I can't just make that up. The model needs to generate an answer based strictly on the given evidence. Since none of the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer about the side effects of SGLT2 inhibitors based on the provided evidence. Let me start by carefully reading through the evidence given. First, looking at the evidence documents: Document 37482684: This talks about how SGLT2 inhibitors work by inhibiting sodium and glucose reabsorption in the kidney's proximal tubule and restoring tubuloglomerular feedback. It mentions that this mechanism reduces glomerular hyperfiltration, which is beneficial but also notes that experts are seeking more explanations for the overall effects, including metabolism, hypoxia, inflammation, and oxidative stress. Wait, but this seems more about mechanisms rather than side effects. However, the mention of \"hypoxia", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer about the side effects of SGLT2 inhibitors based on the provided evidence. Let me start by looking at the evidence given. The first document (37482684) talks about how SGLT2 inhibitors work by inhibiting sodium and glucose reabsorption in the kidneys, which leads to some beneficial effects like reducing glomerular hyperfiltration. However, it also mentions that this has perplexed experts, suggesting there might be other mechanisms or side effects not immediately obvious. But the document itself doesn't list any specific side effects. The second document (35999803) discusses large clinical trials showing that SGLT2 inhibitors decrease cardiovascular death, heart failure, kidney dysfunction, myocard", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["22977310", "23042029", "23807940", "24341330", "24400675", "24455799", "24631482", "24825435", "25488697", "25962253"], "ideal_answer": "SGLT2 inhibitors can be associated with urogenital infections related to the enhanced glycosuria, and low blood pressure."}
{"question_id": "552fa32fbc4f83e828000001", "question": "Is CD56 useful in Ewing sarcoma prognosis?", "retrieved_chunks": [{"doc_id": "21467162", "chunk_id": "21467162_4", "score": 8.278963088989258, "text": "Excellent prognosis in a subset of patients with Ewing sarcoma identified at diagnosis by CD56 using flow cytometry."}, {"doc_id": "21467162", "chunk_id": "21467162_3", "score": 8.064037322998047, "text": "Excellent prognosis in a subset of patients with Ewing sarcoma identified at diagnosis by CD56 using flow cytometry"}, {"doc_id": "22498946", "chunk_id": "22498946_0", "score": 4.642483234405518, "text": "Three years after diagnosis the patient presented with severe respiratory difficulty and following resection, the final pathology revealed multiple tumors with foci of high grade sarcoma compatible with primitive neuroectodermal tumor/extraskeletal Ewing sarcoma based on morphology and immunohistochemistry (CD99, CD56)."}], "context": "[21467162:21467162_4] Excellent prognosis in a subset of patients with Ewing sarcoma identified at diagnosis by CD56 using flow cytometry.\n[21467162:21467162_3] Excellent prognosis in a subset of patients with Ewing sarcoma identified at diagnosis by CD56 using flow cytometry\n[22498946:22498946_0] Three years after diagnosis the patient presented with severe respiratory difficulty and following resection, the final pathology revealed multiple tumors with foci of high grade sarcoma compatible with primitive neuroectodermal tumor/extraskeletal Ewing sarcoma based on morphology and immunohistochemistry (CD99, CD56).", "answer": "<think> Okay, let's tackle this question. The user is asking if CD56 is useful in the prognosis of Ewing sarcoma. I need to look at the provided evidence to find answers. First, looking at the evidence documents. The first two entries, [21467162:21467162_4] and [21467162:21467162_3], both mention that a subset of Ewing sarcoma patients have an excellent prognosis identified by CD56 using flow cytometry at diagnosis. So that's a direct statement about CD56 being associated with a good prognosis. The third document, [22498946:2249", "citations": [{"doc_id": "21467162", "chunk_id": "21467162_4"}, {"doc_id": "21467162", "chunk_id": "21467162_3"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if CD56 is useful in the prognosis of Ewing sarcoma. The evidence provided has three chunks. First, I need to understand what each chunk says. The first two chunks (21467162:21467162_4 and 21467162:21467162_3) are duplicates, both stating that a subset of Ewing sarcoma patients has an excellent prognosis identified by CD56 using flow cytometry at diagnosis. The third chunk (22498946:22498946_0) mentions a patient with severe respiratory issues later diagnosed with multiple tumors", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if CD56 is useful in the prognosis of Ewing sarcoma. I need to look at the provided evidence to find answers. First, looking at the evidence documents. The first two entries, [21467162:21467162_4] and [21467162:21467162_3], both mention that a subset of Ewing sarcoma patients have an excellent prognosis identified by CD56 using flow cytometry at diagnosis. So that's a direct statement about CD56 being associated with a good prognosis. The third document, [22498946:2249", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if CD56 is useful in the prognosis of Ewing sarcoma. I need to look at the provided evidence to find relevant information. First, I see two entries with the same doc ID and chunk IDs. Both mention that a subset of patients with Ewing sarcoma has an excellent prognosis identified by CD56 using flow cytometry. That seems directly related to the question. The third entry talks about a patient with multiple tumors, including primitive neuroectodermal tumor/extraskeletal Ewing sarcoma, and mentions immunohistochemistry markers like CD99 and CD56. So, CD56 is mentioned in both the first two entries as a factor in prognosis. The third entry confirms that CD", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if CD56 is useful in the prognosis of Ewing sarcoma. The evidence provided has three chunks. First, I need to understand what each chunk says. The first two chunks (21467162:21467162_4 and 21467162:21467162_3) are duplicates, both stating that a subset of Ewing sarcoma patients have an excellent prognosis identified by CD56 using flow cytometry at diagnosis. The third chunk (22498946:22498946_0) mentions a patient with severe respiratory issues who later had tumors with", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if CD56 is useful in the prognosis of Ewing sarcoma. I need to look at the provided evidence to find answers. First, evidence document [21467162:21467162_4] says that a subset of Ewing sarcoma patients have an excellent prognosis identified by CD56 using flow cytometry at diagnosis. Similarly, [21467162:21467162_3] repeats the same point. So both chunks 4 and 3 from the same document indicate that CD56 is a marker for a good prognosis. Then there's another document [22498946", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if CD56 is useful in the prognosis of Ewing sarcoma. The evidence provided has three chunks. First, I need to understand what each chunk says. The first two chunks (21467162:21467162_4 and 21467162:21467162_3) are identical, stating that a subset of Ewing sarcoma patients have an excellent prognosis identified by CD56 using flow cytometry at diagnosis. The third chunk (22498946:22498946_0) mentions a patient with severe respiratory issues later diagnosed with multiple tumors,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if CD56 is useful in the prognosis of Ewing sarcoma. First, I need to look at the evidence provided. There are three chunks here. The first two chunks (21467162:21467162_4 and 21467162:21467162_3) both mention that a subset of Ewing sarcoma patients have an excellent prognosis identified by CD56 using flow cytometry at diagnosis. So that's a direct statement linking CD56 to a good prognosis. The third chunk (22498946:22498946_0)", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if CD56 is useful in the prognosis of Ewing sarcoma. The evidence provided has three chunks. First, I need to understand what each chunk says. The first two chunks (21467162:21467162_4 and 21467162:21467162_3) are identical, stating that a subset of Ewing sarcoma patients has an excellent prognosis identified by CD56 using flow cytometry at diagnosis. The third chunk (22498946:22498946_0) mentions a patient with severe respiratory issues who later had tumors with high", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["21467162", "22498946", "9692823"], "ideal_answer": "Excellent prognosis in a subset of patients with Ewing sarcoma identified at diagnosis by CD56 using flow cytometryIn patients with localized nonpelvic disease, those expressing low/negative CD56 had 100% PFS versus 40% in the high expressing group (P = 0.02) CD56 expression could be used to reveal Ewing sarcoma patients with excellent prognosis or patients predisposed to relapse, thus improving treatment stratification and implementation of personalized therapy."}
{"question_id": "5509f433c2af5d5b70000008", "question": "What is the method FASP used for?", "retrieved_chunks": [{"doc_id": "23603217", "chunk_id": "23603217_0", "score": 7.183816432952881, "text": "filter assisted sample preparation (FASP) method"}, {"doc_id": "24022122", "chunk_id": "24022122_0", "score": 5.113892078399658, "text": "In the second step the isolated cells are lysed and processed using 'filter aided sample preparation' (FASP) technique."}, {"doc_id": "22324799", "chunk_id": "22324799_0", "score": 5.07862663269043, "text": "Filter Aided Sample Preparation (FASP), a type of proteomic reactor, in which samples dissolved in sodium dodecyl sulfate (SDS) are digested in an ultrafiltration unit."}], "context": "[23603217:23603217_0] filter assisted sample preparation (FASP) method\n[24022122:24022122_0] In the second step the isolated cells are lysed and processed using 'filter aided sample preparation' (FASP) technique.\n[22324799:22324799_0] Filter Aided Sample Preparation (FASP), a type of proteomic reactor, in which samples dissolved in sodium dodecyl sulfate (SDS) are digested in an ultrafiltration unit.", "answer": "<think> Okay, let's tackle this question. The user is asking about the method FASP and what it's used for. I need to look at the evidence provided to find the answer. First, looking at the evidence documents: Document [23603217:23603217_0] says \"filter assisted sample preparation (FASP) method\". That seems like a direct statement about what FASP is. But maybe it's just defining the term. Then [24022122:24022122_0] mentions that isolated cells are lysed and processed using FASP technique in the second step. So this explains an application of FASP, probably in a protocol or method. The", "citations": [{"doc_id": "23603217", "chunk_id": "23603217_0"}, {"doc_id": "24022122", "chunk_id": "24022122_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking what the method FASP is used for. I need to look at the provided evidence to find the answer. Looking at the evidence, there are three chunks. The first one says \"filter assisted sample preparation (FASP) method\" – that's a direct mention of FASP being a method. The second chunk mentions that isolated cells are lysed and processed using FASP technique. The third explains FASP as a proteomic reactor where samples are digested in an ultrafiltration unit. So, combining these, FASP is used for sample preparation, particularly in proteomics. The key points are lysis of cells, processing, and digestion in an ultrafiltration unit. The first chunk directly states it's a", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the method FASP and what it's used for. The evidence provided has three chunks. First, I need to look at each chunk to see what they say. The first chunk says \"filter assisted sample preparation (FASP) method\". That seems like a direct statement. The second chunk mentions that isolated cells are lysed and processed using FASP technique. The third chunk describes FASP as a proteomic reactor where samples are digested in an ultrafiltration unit. So, putting this together, FASP is a method used in proteomics. The key points are sample preparation, lysing cells, and using an ultrafiltration unit. The first chunk mentions it's a method, the second talks about processing", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking what the FASP method is used for. I need to look at the provided evidence to find the answer. Looking at the evidence, there are three chunks. The first one says \"filter assisted sample preparation (FASP) method\" which seems like a direct definition. The second mentions that isolated cells are lysed and processed using FASP technique. The third explains that FASP is a proteomic reactor where samples are digested in an ultrafiltration unit. So, the main points here are that FASP is used for sample preparation, particularly in proteomics. The first chunk gives the name of the method, and the third chunk explains its use in digesting samples in an ultrafiltration unit. The second chunk", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking about the method FASP and what it's used for. Let me look at the evidence provided. First, the evidence mentions that FASP is a method, specifically filter assisted sample preparation. The first document says \"filter assisted sample preparation (FASP) method,\" which directly states its use. The second document talks about isolating cells, lysing them, and using the FASP technique. The third one describes it as a proteomic reactor where samples are digested in an ultrafiltration unit. Putting this together, FASP is used for sample preparation, particularly in proteomics. The key points are that it's used to lyse cells and process samples, likely in a proteomic context. The confidence here is high because multiple documents cite", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking about the method FASP and what it's used for. Let me look at the evidence provided. The first piece of evidence says \"filter assisted sample preparation (FASP) method\" which seems to directly state that FASP is a method. The second one mentions that isolated cells are lysed and processed using FASP technique, which is part of the second step. The third evidence describes FASP as a proteomic reactor where samples dissolved in SDS are digested in an ultrafiltration unit. Putting this together, FASP is used for sample preparation, specifically in proteomics. The key points here are that it's a method for processing samples, likely involving lysing cells and using an ultrafiltration unit with SDS. The citations from the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the method FASP and what it's used for. I need to look at the evidence provided to find the answer. First, looking at the evidence documents: Document [23603217:23603217_0] says \"filter assisted sample preparation (FASP) method\". That seems like a direct statement about what FASP is. But maybe it's just defining the term. Then [24022122:24022122_0] mentions that isolated cells are lysed and processed using FASP technique in the second step. So this explains an application of FASP, probably in a protocol or method. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, so the user is asking about the method FASP and what it's used for. Let me look at the evidence provided. First, there's a document that says \"filter assisted sample preparation (FASP) method\". That seems like a direct statement. Then another mentions \"filter aided sample preparation (FASP) technique\" in the context of lysing cells. The third one refers to FASP as a proteomic reactor where samples are digested in an ultrafiltration unit. So putting this together, FASP is used in sample preparation, particularly for proteomics. The key points here are that it's used for preparing samples, involving lysis of cells and digestion in an ultrafiltration unit. The term \"proteomic reactor\" from the third document suggests", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to figure out what the FASP method is used for based on the given evidence. Let me look at the evidence provided. The first document says \"filter assisted sample preparation (FASP) method\" – that's a direct mention of FASP being a method. The second one mentions that isolated cells are lysed and processed using FASP technique, which suggests it's used in cell processing. The third document describes FASP as a proteomic reactor where samples are digested in an ultrafiltration unit. So putting this together, FASP is used in proteomics for sample preparation, specifically involving lysis of cells and digestion in an ultrafiltration unit. The answer should be concise and include citations. The base confidence is high because all three sources point to", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["22092713", "22324799", "22949036", "23126408", "23214492", "23436586", "23603217", "23784971", "24022122", "24051509", "24288579", "24289162", "24309553"], "ideal_answer": "Filter Aided Sample Preparation (FASP), a type of proteomic reactor, in which samples dissolved in sodium dodecyl sulfate (SDS) are digested in an ultrafiltration unit."}
{"question_id": "553fa2201d53b76422000005", "question": "What is the role of extracellular signal-related kinases 1 and 2 (ERK1/2) proteins in craniosynostosis?", "retrieved_chunks": [{"doc_id": "23987506", "chunk_id": "23987506_0", "score": 5.583812236785889, "text": "Here, we show that two scaffold proteins, caveolin-1 and IQGAP1, are required for phosphorylation of the actin associated pool of extracellular signal regulated kinase 1 and 2 (ERK1/2) in response to protein kinase C activation."}, {"doc_id": "24265417", "chunk_id": "24265417_0", "score": 2.600245952606201, "text": "We specifically identified that the Spa homology domain (aa 250-420) of GIT1 is required for GIT1-cortactin complex localization to the leading edge. The mechanisms involved extracellular signal-regulated kinases 1 and 2-mediated Cortactin-S405 phosphorylation and activation of Rac1/Cdc42."}, {"doc_id": "33989615", "chunk_id": "33989615_0", "score": 1.4627001285552979, "text": "Type 1 salt-inducible kinases (SIK1) has been shown to act as a mediator during the cellular adaptation to variations in intracellular sodium in a variety of cell types. Type 2 SIK (SIK2) modulates various biological functions and acts as a signal transmitter in various pathways."}], "context": "[23987506:23987506_0] Here, we show that two scaffold proteins, caveolin-1 and IQGAP1, are required for phosphorylation of the actin associated pool of extracellular signal regulated kinase 1 and 2 (ERK1/2) in response to protein kinase C activation.\n[24265417:24265417_0] We specifically identified that the Spa homology domain (aa 250-420) of GIT1 is required for GIT1-cortactin complex localization to the leading edge. The mechanisms involved extracellular signal-regulated kinases 1 and 2-mediated Cortactin-S405 phosphorylation and activation of Rac1/Cdc42.\n[33989615:33989615_0] Type 1 salt-inducible kinases (SIK1) has been shown to act as a mediator during the cellular adaptation to variations in intracellular sodium in a variety of cell types. Type 2 SIK (SIK2) modulates various biological functions and acts as a signal transmitter in various pathways.", "answer": "<think> Okay, I need to figure out the role of ERK1/2 in craniosynostosis based on the given evidence. Let me start by reading through the provided documents carefully. The first document (23987506) mentions that caveolin-1 and IQGAP1 are scaffold proteins involved in phosphorylating ERK1/2 in response to protein kinase C activation. This suggests that ERK1/2 phosphorylation is part of a signaling pathway triggered by PKC, possibly related to cell structure or movement. The second document (24265417) talks about GIT1's Spa homology domain being necessary for its localization at the leading edge. It connects this to ERK1/2-mediated Cortactin", "citations": [], "candidates": [{"answer": "<think> Okay, I need to figure out the role of ERK1/2 in craniosynostosis based on the given evidence. Let me start by reading through the provided documents carefully. The first document (23987506) mentions that caveolin-1 and IQGAP1 are scaffold proteins involved in phosphorylating ERK1/2 in response to protein kinase C activation. This suggests that ERK1/2 phosphorylation is part of a signaling pathway triggered by PKC, possibly related to cell structure or movement. The second document (24265417) talks about GIT1's Spa homology domain being necessary for its localization at the leading edge. It connects this to ERK1/2-mediated Cortactin", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to figure out the role of ERK1/2 in craniosynostosis based on the given evidence. Let me start by looking at the provided documents. The first document (23987506) mentions that caveolin-1 and IQGAP1 are scaffold proteins needed for phosphorylating ERK1/2 in response to PKC activation. Phosphorylation is a key regulatory mechanism for kinases, so this suggests ERK1/2 are involved in signaling pathways related to actin, which might be relevant to craniosynostosis since it's a bone-related condition. The second document (24265417) talks about GIT1 and its interaction with cortactin, involving ER", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about ERK1/2's role in craniosynostosis. First, I need to recall what craniosynostosis is. It's a condition where one or more of the bones of the skull fuse too early, leading to abnormal head shape and potential developmental issues. Now, the question is about ERK1/2 proteins. Looking at the evidence provided, there are three references. The first one mentions caveolin-1 and IQGAP1 as scaffold proteins needed for phosphorylation of ERK1/2 in response to PKC activation. The second reference talks about GIT1's Spa homology domain being involved in localizing the complex to the leading edge, with ERK1/2 mediating cortactin phosphory", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about ERK1/2's role in craniosynostosis. First, I need to recall what craniosynostosis is. It's a condition where one or more of the bones of the skull fuse too soon, leading to abnormal head shape and potential complications. The question is about ERK1/2 proteins' role here. Looking at the evidence provided, there are three references. Let me check each one. The first reference (23987506) mentions caveolin-1 and IQGAP1 scaffolds being needed for phosphorylating ERK1/2 in response to PKC activation. Phosphorylation is a key regulatory mechanism for kinases, so this suggests that ERK", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about ERK1/2's role in craniosynostosis. First, I need to recall what ERK1/2 are. They're part of the MAPK signaling pathway, involved in cell proliferation, differentiation, and survival. Now, craniosynostosis is a condition where one or more bones of the skull fuse too early, affecting brain development. Looking at the evidence provided: The first document mentions caveolin-1 and IQGAP1 scaffolds being needed for phosphorylating ERK1/2 in response to PKC activation. Phosphorylation is key for signaling, so maybe ERK1/2 are involved in cellular responses that lead to bone fusion. The second document talks about GIT1's role", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about ERK1/2's role in craniosynostosis. First, I need to recall what craniosynostosis is. It's a condition where one or more of the bones in an infant's skull fuse too early, leading to abnormal head shape and potential neurological issues. The question is about the role of ERK1/2 proteins in this condition. Looking at the evidence provided, there are three references. Let me go through each one. The first reference (23987506) talks about scaffold proteins caveolin-1 and IQGAP1 being required for phosphorylation of ERK1/2 in response to protein kinase C activation. Phosphorylation is a key regulatory mechanism for", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about ERK1/2's role in craniosynostosis. First, I need to recall what ERK1/2 are. They're part of the MAPK signaling pathway, involved in cell proliferation, differentiation, and other cellular processes. Now, craniosynostosis is a condition where bones in the skull fuse too early, leading to abnormal head shape and potential neurological issues. Looking at the evidence provided, there are three references. The first one mentions caveolin-1 and IQGAP1 scaffolds being necessary for phosphorylating ERK1/2 in response to PKC activation. Phosphorylation is a key regulatory mechanism for kinases, so this suggests that ERK1/2 are activated here.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about ERK1/2's role in craniosynostosis. First, I need to recall what I know about ERK1/2. They're part of the MAPK signaling pathway, involved in cell proliferation, differentiation, and survival. But how does that relate to craniosynostosis? Looking at the evidence provided. The first document mentions caveolin-1 and IQGAP1 scaffolds being needed for phosphorylating ERK1/2 in response to PKC activation. Phosphorylation is a key regulatory step in kinase activity. So maybe ERK1/2 are involved in signaling pathways that affect bone formation or remodeling, which is crucial in craniosynostosis where bones fuse prematurely. The second", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["23354439"], "ideal_answer": "Reduced dosage of ERF, which encodes an inhibitory ETS transcription factor directly bound by ERK1/2 causes complex craniosynostosis (premature fusion of the cranial sutures) in humans and mice. Features of this newly recognized clinical disorder include multiple-suture synostosis, craniofacial dysmorphism, Chiari malformation and language delay."}
{"question_id": "52fa73c62059c6d71c000058", "question": "Are there any urine biomarkers for chronic kidney disease?", "retrieved_chunks": [{"doc_id": "20425065", "chunk_id": "20425065_0", "score": 7.5342206954956055, "text": "Identification of urine biomarkers has proven to be beneficial in recent years because of ease of handling, stability, and the ability to standardize the various markers to creatinine or other peptides generally already present in the urine. Recent markers such as neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and podocin have garnered a lot of attention. The emergence of these and other biomarkers is largely because of the evolution of novel genomic and proteomic applications in investigations of acute kidney injury and chronic kidney disease."}, {"doc_id": "23952327", "chunk_id": "23952327_0", "score": 7.334392547607422, "text": "Renal biomarkers, especially those present in urine, may be useful for the study of both acute and chronic nephropathies."}, {"doc_id": "21538916", "chunk_id": "21538916_0", "score": 4.137395858764648, "text": "Kidney and urine proteomic biomarkers are considered as promising diagnostic tools to predict CKD progression early in diabetic nephropathy, facilitating timely and selective intervention that may reduce the related health-care expenditures."}], "context": "[20425065:20425065_0] Identification of urine biomarkers has proven to be beneficial in recent years because of ease of handling, stability, and the ability to standardize the various markers to creatinine or other peptides generally already present in the urine. Recent markers such as neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and podocin have garnered a lot of attention. The emergence of these and other biomarkers is largely because of the evolution of novel genomic and proteomic applications in investigations of acute kidney injury and chronic kidney disease.\n[23952327:23952327_0] Renal biomarkers, especially those present in urine, may be useful for the study of both acute and chronic nephropathies.\n[21538916:21538916_0] Kidney and urine proteomic biomarkers are considered as promising diagnostic tools to predict CKD progression early in diabetic nephropathy, facilitating timely and selective intervention that may reduce the related health-care expenditures.", "answer": "<think> Okay, let's tackle this question. The user is asking if there are any urine biomarkers for chronic kidney disease. I need to look at the evidence provided to find answers. First, looking at the first evidence snippet [20425065:20425065_0], it mentions several urine biomarkers like NGAL, KIM-1, and podocin. These are specifically noted for chronic kidney disease. That's a direct answer. The confidence here is high because it's explicitly stating these markers are used for CKD. The second snippet [23952327:23952327_0] talks about renal biomarkers in urine being useful for both acute and chronic neph", "citations": [{"doc_id": "20425065", "chunk_id": "20425065_0"}, {"doc_id": "23952327", "chunk_id": "23952327_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this query. The user is asking if there are any urine biomarkers for chronic kidney disease. I need to check the provided evidence to find relevant information. Looking at the first evidence snippet (20425065:20425065_0), it mentions several recent markers like NGAL, KIM-1, and podocin in urine. These are specifically cited as biomarkers for chronic kidney disease. That's a direct answer. The second snippet (23952327:23952327_0) talks about renal biomarkers in urine being useful for both acute and chronic nephropathies. While it's general, it supports the idea that urine biom", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there are any urine biomarkers for chronic kidney disease. I need to look at the provided evidence to find answers. First, looking at the first evidence snippet (20425065:20425065_0), it mentions several urine biomarkers like NGAL, KIM-1, and podocin. These are specifically noted for chronic kidney disease. That's a direct hit. The second snippet (23952327:23952327_0) talks about renal biomarkers in urine being useful for both acute and chronic nephropathies, which includes CKD. The third snippet (21538", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The question is whether there are urine biomarkers for chronic kidney disease. Looking at the evidence, the first document (20425065) mentions several urine biomarkers like NGAL, KIM-1, and podocin. These are specifically noted as recent markers for CKD. The second document (23952327) says renal biomarkers in urine are useful for both acute and chronic nephropathies, which includes CKD. The third document (21538916) talks about kidney and urine proteomic biomarkers being promising for predicting CKD progression in diabetic nephropathy. So the answer should confirm that there are urine", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking if there are any urine biomarkers for chronic kidney disease. Let me check the evidence provided. First, looking at the first document: it mentions several urine biomarkers like NGAL, KIM-1, and podocin. These are specifically noted as being relevant to both acute and chronic kidney injury. That's a direct hit on the question. The second document says renal biomarkers in urine could be useful for studying both acute and chronic nephropathies. That supports the idea that urine biomarkers exist for chronic conditions. Third document talks about kidney and urine proteomic biomarkers being promising for predicting CKD progression, especially in diabetic nephropathy. This reinforces that there are such biomarkers. So combining these, the answer should list", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there are any urine biomarkers for chronic kidney disease. I need to look at the evidence provided. First, evidence document 20425065:20425065_0 mentions several urine biomarkers like NGAL, KIM-1, and podocin. These are specifically noted in the context of chronic kidney disease. That's a direct hit. Then there's another document, 23952327:23952327_0, which talks about renal biomarkers in urine being useful for both acute and chronic nephropathies. While it's not specific to CKD, it does support the idea that", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there are any urine biomarkers for chronic kidney disease. I need to look at the evidence provided to find answers. First, looking at the first evidence snippet [20425065:20425065_0], it mentions several urine biomarkers like NGAL, KIM-1, and podocin. These are specifically noted for chronic kidney disease. That's a direct answer. The confidence here is high because it's explicitly stating these markers are used for CKD. The second snippet [23952327:23952327_0] talks about renal biomarkers in urine being useful for both acute and chronic neph", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there are any urine biomarkers for chronic kidney disease. I need to look at the provided evidence to find answers. First, looking at the evidence documents. The first one, 20425065:20425065_0, mentions several urine biomarkers like NGAL, KIM-1, and podocin. These are specifically noted for chronic kidney disease. That's a direct answer. The second document, 23952327:23952327_0, talks about renal biomarkers in urine being useful for both acute and chronic nephropathies. So that supports the existence of such markers.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there are any urine biomarkers for chronic kidney disease. I need to look at the provided evidence to find answers. First, looking at the first evidence snippet (20425065:20425065_0), it mentions several urine biomarkers like NGAL, KIM-1, and podocin. These are specifically cited as recent markers for CKD. That's a direct answer. The second snippet (23952327:23952327_0) talks about renal biomarkers in urine being useful for both acute and chronic nephropathies. This supports the idea that urine biomarkers exist for chronic kidney", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["20425065", "21151537", "21286212", "21538916", "21816077", "22189039", "22914685", "23061738", "23339563", "23344473", "23617441", "23758910", "24065527", "24133923", "24152229", "24205707", "24224012", "24281781", "24308223", "24315007"], "ideal_answer": "Chronic kidney disease (CKD), is a progressive loss in renal function over a period of months or years. The symptoms of worsening kidney function are non-specific, and might include feeling generally unwell and experiencing a reduced appetite. Often, chronic kidney disease is diagnosed as a result of screening of people known to be at risk of kidney problems, such as those with high blood pressure or diabetes and those with a blood relative with chronic kidney disease. Chronic kidney disease may also be identified when it leads to one of its recognized complications, such as cardiovascular disease, anemia or pericarditis. It is differentiated from acute kidney disease in that the reduction in kidney function must be present for over 3 months. Yes, there is a number of urine biomarkers used for early detection of chronic kidney disease."}
{"question_id": "533f9df0c45e133714000016", "question": "What is being measured with an accelerometer in back pain patients", "retrieved_chunks": [{"doc_id": "19945334", "chunk_id": "19945334_0", "score": 6.112344264984131, "text": "physical activity (PA) in individuals with chronic low back pain (CLBP). Thirty-eight participants with non-specific CLBP (29=distressed; 9=non-distressed) were recruited. PA levels were measured using an accelerometer (activPAL activity monitor) over a one week period. The following parameters of physical activity were recorded: time upright (standing or walking), time standing, time walking, and step count."}, {"doc_id": "16437292", "chunk_id": "16437292_0", "score": 3.7190608978271484, "text": "nighttime activity data from 18 patients diagnosed with chronic back pain. The patients were followed for 6 days and 5 nights. Pain levels were collected every 90 min between 0800 hours and 2,200 hours using a computerized electronic diary. Activity levels were collected using a wrist accelerometer (Actiwatch AW-64). The Actiwatch sampled activity counts every 1 min. Patients were asked to wear the Actiwatch on their non-dominant arm."}, {"doc_id": "20921030", "chunk_id": "20921030_0", "score": 3.1743996143341064, "text": "objective activity data to determine whether patients with chronic lower back pain report their activity levels as accurately as controls do. DESIGN: A cross-sectional study was performed in patients and controls. SETTING: The study was carried out in the daily environment of the subjects. SUBJECTS: Thirty-two chronic lower back pain patients with symptoms more than three months and 20 healthy controls from the Netherlands, aged 18-65 years. MAIN MEASURES: A tri-axial accelerometer was worn for five weekdays"}], "context": "[19945334:19945334_0] physical activity (PA) in individuals with chronic low back pain (CLBP). Thirty-eight participants with non-specific CLBP (29=distressed; 9=non-distressed) were recruited. PA levels were measured using an accelerometer (activPAL activity monitor) over a one week period. The following parameters of physical activity were recorded: time upright (standing or walking), time standing, time walking, and step count.\n[16437292:16437292_0] nighttime activity data from 18 patients diagnosed with chronic back pain. The patients were followed for 6 days and 5 nights. Pain levels were collected every 90 min between 0800 hours and 2,200 hours using a computerized electronic diary. Activity levels were collected using a wrist accelerometer (Actiwatch AW-64). The Actiwatch sampled activity counts every 1 min. Patients were asked to wear the Actiwatch on their non-dominant arm.\n[20921030:20921030_0] objective activity data to determine whether patients with chronic lower back pain report their activity levels as accurately as controls do. DESIGN: A cross-sectional study was performed in patients and controls. SETTING: The study was carried out in the daily environment of the subjects. SUBJECTS: Thirty-two chronic lower back pain patients with symptoms more than three months and 20 healthy controls from the Netherlands, aged 18-65 years. MAIN MEASURES: A tri-axial accelerometer was worn for five weekdays", "answer": "<think> Okay, let's tackle this question. The user is asking what an accelerometer measures in back pain patients. I need to look at the evidence provided. First, document [19945334:19945334_0] mentions that an accelerometer (activPAL) measured physical activity parameters like time upright, standing, walking, and step count. So that's one point. Then, [16437292:16437292_0] talks about a wrist accelerometer (Actiwatch) collecting activity levels, sampling every minute. It's used to track nighttime activity. But the main thing here is activity levels, which would include movement data. The third document [20921", "citations": [{"doc_id": "19945334", "chunk_id": "19945334_0"}, {"doc_id": "16437292", "chunk_id": "16437292_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking what an accelerometer measures in back pain patients. I need to look at the evidence provided and extract the relevant information. First, looking at the first document: it mentions that PA levels were measured using an accelerometer (activPAL) over a week. The parameters recorded include time upright, standing, walking, and step count. So, the accelerometer is measuring physical activity parameters like these. The second document talks about nighttime activity data using a wrist accelerometer (Actiwatch). It samples activity counts every minute. So here, it's measuring activity levels, possibly including movement intensity or duration. Third document mentions a tri-axial accelerometer worn for five weekdays to collect objective activity data. The main measures likely include similar parameters as the first", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking what an accelerometer measures in back pain patients. I need to look at the evidence provided. First, document 19945334:19945334_0 mentions that PA levels were measured using an accelerometer (activPAL) over a week. They recorded parameters like time upright, standing, walking, and step count. So that's physical activity metrics. Then, document 16437292:16437292_0 talks about nighttime activity data with a wrist accelerometer (Actiwatch AW-64) sampling every minute. They collected activity levels, which likely includes movement data. Document 2092103", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking what an accelerometer measures in back pain patients. I need to look at the evidence provided and find the relevant information. First, looking at the first document: it mentions that PA levels were measured using an accelerometer (activPAL) over a week. The parameters recorded include time upright, standing, walking, and step count. So, this indicates that accelerometers measure physical activity parameters like time spent in different activities and step counts. The second document talks about nighttime activity data using a wrist accelerometer (Actiwatch). It samples activity counts every minute. So here, the accelerometer is tracking activity levels over time, possibly including movement patterns. Third document mentions a tri-axial accelerometer worn for five weekdays to collect objective activity data.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to figure out what an accelerometer measures in back pain patients based on the given evidence. Let me look through each of the three documents provided. The first document mentions that PA levels were measured using an accelerometer (activPAL) over a week. The parameters recorded include time upright, standing, walking, and step count. So here, the accelerometer is measuring physical activity parameters like duration of standing, walking, and steps taken. The second document talks about nighttime activity data from 18 patients with chronic back pain. They used a wrist accelerometer (Actiwatch) to collect activity levels. It samples every minute. So this is also about activity levels, possibly including movement intensity or frequency. Third document says that a tri-axial accelerometer was worn to determine if patients", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking what an accelerometer measures in back pain patients. I need to look at the evidence provided. First, document [19945334:19945334_0] mentions that an accelerometer (activPAL) measured physical activity parameters like time upright, standing, walking, and step count. So that's one point. Then, [16437292:16437292_0] talks about a wrist accelerometer (Actiwatch) collecting activity levels, sampling every minute. It's used to track nighttime activity. But the main thing here is activity levels, which would include movement data. The third document [20921", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer based on the evidence provided. The question is about what an accelerometer measures in back pain patients. Let me look through the evidence again. First, document 19945334:19945334_0 talks about physical activity in chronic low back pain patients. They used an activPAL monitor to measure parameters like time upright, standing, walking, and step count. So that's physical activity metrics. Then, document 16437292:16437292_0 mentions a wrist accelerometer (Actiwatch) for nighttime activity data. It sampled activity counts every minute. So this is about activity levels, possibly including movement intensity or duration.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking what an accelerometer measures in back pain patients. I need to look at the evidence provided and find the relevant information. First, looking at the first evidence snippet [19945334:19945334_0], it mentions that PA levels were measured using an accelerometer over a week. The parameters recorded include time upright, time standing, time walking, and step count. So here, the accelerometer is measuring physical activity parameters like duration of standing, walking, and steps. The second snippet [16437292:16437292_0] talks about nighttime activity data using a wrist accelerometer. It records activity levels every 1 minute", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking what an accelerometer measures in back pain patients. I need to look at the evidence provided and find the relevant information. First, looking at the first document: it mentions that PA levels were measured using an accelerometer (activPAL) over a week. The parameters recorded include time upright, time standing, time walking, and step count. So, this indicates that accelerometers measure physical activity parameters like these. The second document talks about nighttime activity data using a wrist accelerometer (Actiwatch AW-64). It samples activity counts every 1 minute. So here, the accelerometer is tracking activity levels, possibly movement intensity or duration. Third document mentions a tri-axial accelerometer worn for five weekdays to collect objective activity data.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["11387574", "15271728", "16426878", "16437292", "18752975", "19402888", "19895697", "19945334", "19945891", "20457489", "20921030", "21195646", "21872993", "23560880", "23865908"], "ideal_answer": "Accelerometer assessment measuring overall physical activity (PAL), constant strain postures (CSP), standing time (ST) and lying time (LT)... The following parameters of physical activity were recorded: time upright (standing or walking), time standing, time walking, and step count."}
{"question_id": "56a3a386496b62f23f000007", "question": "List the releases of JASPAR database", "retrieved_chunks": [{"doc_id": "31701148", "chunk_id": "31701148_0", "score": 6.770306587219238, "text": "JASPAR (http://jaspar.genereg.net) is an open-access database of curated, non-redundant transcription factor (TF)-binding profiles stored as position frequency matrices (PFMs) for TFs across multiple species in six taxonomic groups. In this 8th release of JASPAR, the CORE collection has been expanded with 245 new PFMs (169 for vertebrates, 42 for plants, 17 for nematodes, 10 for insects, and 7 for fungi), and 156 PFMs were updated (125 for vertebrates, 28 for plants and 3 for insects). These new profiles represent an 18% expansion compared to the previous release. JASPAR 2020 comes with a novel collection of unvalidated TF-binding profiles for which our curators did not find orthogonal supporting evidence in the literature. This collection has a dedicated web form to engage the community in the curation of unvalidated TF-binding profiles. Moreover, we created a Q&A forum to ease the communication between the user community and JASPAR curators. Finally, we updated the genomic tracks, inference tool, and TF-binding profile similarity clusters. All the data is available through the JASPAR website, its associated RESTful API, and through the JASPAR2020 R/Bioconductor package."}, {"doc_id": "34850907", "chunk_id": "34850907_1", "score": 6.43587589263916, "text": "JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles."}, {"doc_id": "37962376", "chunk_id": "37962376_0", "score": 6.349301338195801, "text": "JASPAR (https://jaspar.elixir.no/) is a widely-used open-access database presenting manually curated high-quality and non-redundant DNA-binding profiles for transcription factors (TFs) across taxa. In this 10th release and 20th-anniversary update, the CORE collection has expanded with 329 new profiles. We updated three existing profiles and provided orthogonal support for 72 profiles from the previous release's UNVALIDATED collection. Altogether, the JASPAR 2024 update provides a 20% increase in CORE profiles from the previous release."}], "context": "[31701148:31701148_0] JASPAR (http://jaspar.genereg.net) is an open-access database of curated, non-redundant transcription factor (TF)-binding profiles stored as position frequency matrices (PFMs) for TFs across multiple species in six taxonomic groups. In this 8th release of JASPAR, the CORE collection has been expanded with 245 new PFMs (169 for vertebrates, 42 for plants, 17 for nematodes, 10 for insects, and 7 for fungi), and 156 PFMs were updated (125 for vertebrates, 28 for plants and 3 for insects). These new profiles represent an 18% expansion compared to the previous release. JASPAR 2020 comes with a novel collection of unvalidated TF-binding profiles for which our curators did not find orthogonal supporting evidence in the literature. This collection has a dedicated web form to engage the community in the curation of unvalidated TF-binding profiles. Moreover, we created a Q&A forum to ease the communication between the user community and JASPAR curators. Finally, we updated the genomic tracks, inference tool, and TF-binding profile similarity clusters. All the data is available through the JASPAR website, its associated RESTful API, and through the JASPAR2020 R/Bioconductor package.\n[34850907:34850907_1] JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles.\n[37962376:37962376_0] JASPAR (https://jaspar.elixir.no/) is a widely-used open-access database presenting manually curated high-quality and non-redundant DNA-binding profiles for transcription factors (TFs) across taxa. In this 10th release and 20th-anniversary update, the CORE collection has expanded with 329 new profiles. We updated three existing profiles and provided orthogonal support for 72 profiles from the previous release's UNVALIDATED collection. Altogether, the JASPAR 2024 update provides a 20% increase in CORE profiles from the previous release.", "answer": "<think> Okay, let's tackle this query. The user is asking to list the releases of the JASPAR database based on the provided evidence. First, I need to look through the evidence documents to find mentions of JASPAR releases. Looking at the first document [31701148:31701148_0], it mentions the 8th release, which is JASPAR 2020. Then there's a mention of the 9th release in [34850907:34850907_1] as JASPAR 2022. The third document [37962376:37962376", "citations": [{"doc_id": "31701148", "chunk_id": "31701148_0"}, {"doc_id": "34850907", "chunk_id": "34850907_1"}], "candidates": [{"answer": "<think> Okay, so the user is asking for the releases of the JASPAR database. Let me look at the evidence provided. First, there's a document that mentions the 8th release, JASPAR 2020. It talks about expansions and updates. Then another document says JASPAR 2022 is the 9th release. The third one refers to the 10th release and 20th anniversary update as JASPAR 2024. Wait, but the user wants a list of releases. Let me check each entry again. The first evidence says \"8th release of JASPAR\" with details about 2020. Then the second mentions \"JASPAR 2022:", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking to list the releases of the JASPAR database based on the provided evidence. First, I need to look through the evidence documents to find mentions of JASPAR releases. Looking at the first document [31701148:31701148_0], it mentions the 8th release, which is JASPAR 2020. Then there's a mention of the 9th release in [34850907:34850907_1] as JASPAR 2022. The third document [37962376:37962376", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The user is asking for the releases of the JASPAR database. Looking at the evidence, there are three documents. The first one mentions the 8th release (JASPAR 2020) with details about expansions and updates. The second document refers to the 9th release (JASPAR 2022). The third document talks about the 10th release (JASPAR 2024), which is also a 20th-anniversary update. So, the releases listed are 8th, 9th, and 10th. Each has specific details. The answer should list these releases with their respective information. The confidence", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let me try to figure out how to answer the user's question about the releases of the JASPAR database. The user wants a JSON with an answer and a base confidence. First, I need to look at the evidence provided. There are three documents here. Let me check each one. The first document mentions the 8th release of JASPAR, which was updated in 2020. It talks about adding new PFMs and updates. The second document says JASPAR 2022 is the 9th release. The third document refers to the 10th release and a 20th-anniversary update, which would be 2024. Wait, but the user is asking for the releases.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let me try to figure this out. The user is asking for the releases of the JASPAR database. Looking at the evidence provided, there are three documents mentioning different versions. The first document says it's the 8th release, JASPAR 2020. Then there's a mention of JASPAR 2022 as the 9th release. The third document talks about the 10th release and a 20th-anniversary update, which would be JASPAR 2024. Wait, but the user wants a list of releases. So I need to check each document's content. The first one is about the 8th release (JASPAR 2020), the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking for the releases of the JASPAR database. Let me look at the evidence provided. First, there's a document that mentions the 8th release, JASPAR 2020. It talks about expansions and updates. Then another document says JASPAR 2022 is the 9th release. The third one refers to the 10th release and a 20th-anniversary update, which would be JASPAR 2024. Wait, but the user wants a list of releases. Let me check each document again. The first one is about the 8th release, then the second mentions 9th (2022), and the third is 1", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let me try to figure this out. The user is asking for the releases of the JASPAR database. Looking at the evidence provided, there are three documents mentioned. First, document [31701148:31701148_0] talks about the 8th release, JASPAR 2020. Then, [34850907:34850907_1] mentions the 9th release, JASPAR . Finally, [37962376:37962376_0] refers to the 10th release and a 20th-anniversary update, which would be", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this query. The user is asking to list the releases of the JASPAR database based on the provided evidence. First, I need to look through the evidence documents to find mentions of JASPAR releases. Let me check each one: The first document [31701148:31701148_0] talks about the 8th release, JASPAR 2020. It mentions that this is the 8th release and includes details about new PFMs and updates. Then there's a mention of JASPAR 2022 as the 9th release in [34850907:34850907_1]. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["14681366", "16381983", "18006571", "19906716", "24194598"], "ideal_answer": "JASPAR, JASPAR CORE, JASPAR FAM, JASPAR phyloFACTS, JASPAR 2008 update, JASPAR 2010, JASPAR 2014."}
{"question_id": "56c1f038ef6e394741000051", "question": "List symptoms of the IFAP syndrome.", "retrieved_chunks": [{"doc_id": "10694306", "chunk_id": "10694306_0", "score": 7.237981796264648, "text": "Atrichia, ichthyosis, follicular hyperkeratosis, chronic candidiasis, keratitis, seizures, mental retardation and inguinal hernia: a severe manifestation of IFAP syndrome?"}, {"doc_id": "25685152", "chunk_id": "25685152_0", "score": 6.121890068054199, "text": "The IFAP syndrome is a rare X-linked genetic disorder characterized by the triad of follicular ichthyosis, atrichia, and photophobia."}, {"doc_id": "10326971", "chunk_id": "10326971_0", "score": 5.426234245300293, "text": "Ichthyosis follicularis, atrichia, and photophobia (IFAP) are typical features of a rare neuroichthyosis termed IFAP syndrome."}], "context": "[10694306:10694306_0] Atrichia, ichthyosis, follicular hyperkeratosis, chronic candidiasis, keratitis, seizures, mental retardation and inguinal hernia: a severe manifestation of IFAP syndrome?\n[25685152:25685152_0] The IFAP syndrome is a rare X-linked genetic disorder characterized by the triad of follicular ichthyosis, atrichia, and photophobia.\n[10326971:10326971_0] Ichthyosis follicularis, atrichia, and photophobia (IFAP) are typical features of a rare neuroichthyosis termed IFAP syndrome.", "answer": "<think> Okay, the user is asking for symptoms of IFAP syndrome. Let me look at the evidence provided. First document: It lists several symptoms like Atrichia, ichthyosis, follicular hyperkeratosis, chronic candidiasis, keratitis, seizures, mental retardation, and inguinal hernia. That's a lot. The second document mentions the triad of follicular ichthyosis, atrichia, and photophobia. The third one repeats the triad plus mentions ichthyosis follicaris, atrichia, and photophobia. So the main symptoms from the evidence are atrichia, ichthyosis (specifically follicular), photophobia, and then some others like chronic candidiasis, keratitis, seizures, mental", "citations": [], "candidates": [{"answer": "<think> Okay, the user is asking for symptoms of IFAP syndrome. Let me look at the evidence provided. First document: It lists several symptoms like Atrichia, ichthyosis, follicular hyperkeratosis, chronic candidiasis, keratitis, seizures, mental retardation, and inguinal hernia. That's a lot. The second document mentions the triad of follicular ichthyosis, atrichia, and photophobia. The third one repeats the triad plus mentions ichthyosis follicaris, atrichia, and photophobia. So the main symptoms from the evidence are atrichia, ichthyosis (specifically follicular), photophobia, and then some others like chronic candidiasis, keratitis, seizures, mental", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking for symptoms of IFAP syndrome. Let me look at the evidence provided. First document: 10694306 mentions Atrichia, ichthyosis, follicular hyperkeratosis, chronic candidiasis, keratitis, seizures, mental retardation, and inguinal hernia. That's a list of several symptoms. Second document: 25685152 states the triad is follicular ichthyosis, atrichia, and photophobia. So those three are key features. Third document: 10326971 also lists ichthyosis follicularis, atrichia, and photophobia as typical features. So that's the same as the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is asking for symptoms of IFAP syndrome. Let me look at the evidence provided. The first document mentions Atrichia, ichthyosis, follicular hyperkeratosis, chronic candidiasis, keratitis, seizures, mental retardation, and inguinal hernia as part of a severe manifestation of IFAP syndrome. That's a list of symptoms. The second document states that IFAP is characterized by the triad of follicular ichthyosis, atrichia, and photophobia. These are three key symptoms. The third document confirms that ichthyosis follicularis, atrichia, and photophobia are typical features of IFAP syndrome. So these", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is asking for symptoms of IFAP syndrome. Let me look at the evidence provided. First document: 10694306 mentions Atrichia, ichthyosis, follicular hyperkeratosis, chronic candidiasis, keratitis, seizures, mental retardation, and inguinal hernia as part of a severe manifestation of IFAP syndrome. That's a list of symptoms. Second document: 25685152 states the triad is follicular ichthyosis, atrichia, and photophobia. So those are three main symptoms. Third document: 10326971 repeats the triad of ich", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer about the symptoms of IFAP syndrome based on the provided evidence. Let me start by carefully reading the question and the evidence. The user is asking for a list of symptoms of IFAP syndrome. The evidence has three documents. Let me check each one: Document 10694306: It lists several symptoms: Atrichia, ichthyosis, follicular hyperkeratosis, chronic candidiasis, keratitis, seizures, mental retardation, and inguinal hernia. That's a lot of symptoms. Document 25685152: It mentions the triad of follicular ichthyosis, atrichia, and photophobia. So those are three main", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking for symptoms of IFAP syndrome, and they provided three evidence documents. I need to extract the relevant symptoms from each document. First, looking at document 10694306: It lists several symptoms—Atrichia, ichthyosis, follicular hyperkeratosis, chronic candidiasis, keratitis, seizures, mental retardation, and inguinal hernia. That's a lot of symptoms. Document 25685152 mentions the triad of follicular ichthyosis, atrichia, and photophobia. So those three are key features. Document 10326971 also states that ichthyosis follicular", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The question is asking for symptoms of IFAP syndrome. Let me look at the evidence. First document: 10694306 mentions Atrichia, ichthyosis, follicular hyperkeratosis, chronic candidiasis, keratitis, seizures, mental retardation, and inguinal hernia. That's a list of symptoms. Second document: 25685152 says the triad is follicular ichthyosis, atrichia, and photophobia. So those are three main symptoms. Third document: 10326971 repeats the triad plus mentions ichthyosis follicularis, atrichia", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is asking for symptoms of IFAP syndrome. Let me look at the evidence provided. First document: 10694306 mentions Atrichia, ichthyosis, follicular hyperkeratosis, chronic candidiasis, keratitis, seizures, mental retardation, and inguinal hernia. That's a list of symptoms. Second document: 25685152 says the triad is follicular ichthyosis, atrichia, and photophobia. So those are three main features. Third document: 10326971 repeats the triad of ichthyosis, atrichia, photophobia", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["10326971", "10398262", "10694306", "12004300", "1456297", "14708109", "15370546", "16268889", "1915513", "19689518", "21315478", "21886760", "24090718", "24313295", "25685152"], "ideal_answer": "The IFAP syndrome is a rare X-linked genetic disorder characterized by the triad of follicular ichthyosis, atrichia, and photophobia."}
{"question_id": "531a34d5b166e2b806000036", "question": "Which gene is required for the efficient function of clopidogrel?", "retrieved_chunks": [{"doc_id": "22088980", "chunk_id": "22088980_0", "score": 3.451876640319824, "text": "Variants in the CYP2C19 gene influence the pharmacologic and clinical response to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel. OBJECTIVE: To test whether higher doses (up to 300 mg daily) improve the response to clopidogrel in the setting of loss-of-function CYP2C19 genotypes."}, {"doc_id": "22154242", "chunk_id": "22154242_0", "score": 2.7283222675323486, "text": "The antiplatelet effect of clopidogrel has been linked to cytochrome P450 2C19 (CYP2C19) carrier status. The presence of loss of function and gain of function variants were found to have a gene-dose effect on clopidogrel metabolism. However, genotyping is only one aspect of predicting response to clopidogrel and several platelet function tests are available to measure platelet response."}, {"doc_id": "15933261", "chunk_id": "15933261_1", "score": 2.6336846351623535, "text": "ssociation of a functional polymorphism in the clopidogrel target receptor gene, P2Y12"}], "context": "[22088980:22088980_0] Variants in the CYP2C19 gene influence the pharmacologic and clinical response to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel. OBJECTIVE: To test whether higher doses (up to 300 mg daily) improve the response to clopidogrel in the setting of loss-of-function CYP2C19 genotypes.\n[22154242:22154242_0] The antiplatelet effect of clopidogrel has been linked to cytochrome P450 2C19 (CYP2C19) carrier status. The presence of loss of function and gain of function variants were found to have a gene-dose effect on clopidogrel metabolism. However, genotyping is only one aspect of predicting response to clopidogrel and several platelet function tests are available to measure platelet response.\n[15933261:15933261_1] ssociation of a functional polymorphism in the clopidogrel target receptor gene, P2Y12", "answer": "<think> Okay, let's tackle this question. The user is asking which gene is required for the efficient function of clopidogrel. The evidence provided has three documents. First, looking at document [22088980:22088980_0], it mentions that variants in the CYP2C19 gene influence the pharmacologic and clinical response to clopidogrel. That seems directly relevant. The objective of the study is about higher doses of clopidogrel in patients with loss-of-function CYP2C19 genotypes, which suggests that CYP2C19 is involved in metabolizing clopidogrel, affecting its efficacy. Then there's document [22154242:2", "citations": [{"doc_id": "22088980", "chunk_id": "22088980_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which gene is required for the efficient function of clopidogrel. The evidence provided has three documents. First, looking at document 22088980: it mentions that variants in the CYP2C19 gene influence the pharmacologic and clinical response to clopidogrel. That's a strong clue pointing towards CYP2C19. Then document 22154242 also talks about the antiplatelet effect being linked to CYP2C19 carrier status, again reinforcing that CYP2C19 is involved. The third document mentions a polymorphism in the P2Y12 gene, which is the target receptor for clopidog", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which gene is required for the efficient function of clopidogrel. The evidence provided has three documents. First, looking at document 22088980: it mentions that variants in the CYP2C19 gene influence the pharmacologic and clinical response to clopidogrel. That's a strong hint that CYP2C19 is involved. The objective of the study is about higher doses of clopidogrel in patients with loss-of-function CYP2C19 genotypes, which suggests that CYP2C19 is necessary for metabolizing clopidogrel properly. Then document 22154242: it directly states that the antiplate", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to figure out which gene is required for the efficient function of clopidogrel based on the given evidence. Let me look at the evidence provided. The first document (22088980:2208898ity_0) says that variants in the CYP2C19 gene affect the pharmacologic and clinical response to clopidogrel. It also mentions that higher doses might improve response in cases of loss-of-function CYP2C19 genotypes. So this suggests that CYP2C19 is involved in how clopidogrel works. The second document (22154242:22154242_0) connects the antiplatelet effect", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which gene is required for the efficient function of clopidogrel. The evidence provided has three documents. Looking at the first document, it mentions that variants in the CYP2C19 gene influence the pharmacologic and clinical response to clopidogrel. That suggests CYP2C19 is involved in how the drug works. The second document also links the antiplatelet effect of clopidogrel to CYP2C19 carrier status, talking about loss-of-function and gain-of-function variants affecting metabolism. The third document mentions a functional polymorphism in the P2Y12 gene, which is the target receptor for clopidogrel. Wait, but the question is about the gene", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which gene is required for the efficient function of clopidogrel. The evidence provided has three documents. First, looking at document 22088980: it mentions that variants in the CYP2C19 gene affect the pharmacologic and clinical response to clopidogrel. The objective is about higher doses improving response in loss-of-function CYP2C19 genotypes. So this suggests CYP2C19 is involved in metabolizing clopidogrel, which would impact its effectiveness. Next, document 22154242: it directly states that the antiplatelet effect of clopidogrel is linked to CYP2C19 carrier", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so I need to figure out which gene is required for the efficient function of clopidogrel based on the given evidence. Let me look at the evidence provided. First, the first document (22088980:2208898ity) says that variants in the CYP2C19 gene influence the pharmacologic and clinical response to clopidogrel. The study mentions that higher doses of clopidogrel might be better in cases where there's a loss-of-function CYP2C19 genotype. That suggests that CYP2C19 is involved in metabolizing clopidogrel, which would affect its efficiency. The second document (22154242:2215", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which gene is required for the efficient function of clopidogrel. The evidence provided has three chunks. First chunk (22088980) mentions that variants in CYP2C19 influence the pharmacologic and clinical response to clopidogrel. The objective is about higher doses improving response in loss-of-function CYP2C19 genotypes. So this suggests CYP2C19 is involved. Second chunk (22154242) also links clopidogrel's antiplatelet effect to CYP2C19 carrier status. It talks about gene-dose effects on metabolism, which again points to CYP2C19 being crucial for", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which gene is required for the efficient function of clopidogrel. The evidence provided has three documents. First, looking at document [22088980:22088980_0], it mentions that variants in the CYP2C19 gene influence the pharmacologic and clinical response to clopidogrel. That seems directly relevant. The objective of the study is about higher doses of clopidogrel in patients with loss-of-function CYP2C19 genotypes, which suggests that CYP2C19 is involved in metabolizing clopidogrel, affecting its efficacy. Then there's document [22154242:2", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["15933261", "19463375", "20826260", "21099121", "21806387", "23150151", "23506580"], "ideal_answer": "The prodrug clopidogrel requires activation by cytochrome P-450 (CYP) enzymes for its antiplatelet effect. Variability in clopidogrel response might be influenced by polymorphisms in genes coding for drug metabolism enzymes (cytochrome P450 CYP2C19), transport proteins (P-glycoprotein) and/or target proteins for the drug (adenosine diphosphate-receptor P2Y12). The CYP2C19 loss-of-function alleles had a gene dose effect on the pharmacodynamics and composite ischemic events of clopidogrel in our study population. Neither the ABCB1 nor the PON1 genotype significantly influenced the antiplatelet effect and clinical outcomes of clopidogrel in these patients"}
{"question_id": "56c1f029ef6e39474100004a", "question": "Is valproic acid effective for glioblastoma treatment?", "retrieved_chunks": [{"doc_id": "23523186", "chunk_id": "23523186_3", "score": 9.02035903930664, "text": "Valproic acid use during radiation therapy for glioblastoma associated with improved survival."}, {"doc_id": "23523186", "chunk_id": "23523186_2", "score": 8.75424575805664, "text": "Valproic acid use during radiation therapy for glioblastoma associated with improved survival"}, {"doc_id": "24328881", "chunk_id": "24328881_1", "score": 8.459839820861816, "text": "Several retrospective studies in seizure patients with glioblastoma treated with chemotherapy have provided evidence for a moderately improved survival with the use of valproic acid, possibly due to inhibition of histone deacetylase."}], "context": "[23523186:23523186_3] Valproic acid use during radiation therapy for glioblastoma associated with improved survival.\n[23523186:23523186_2] Valproic acid use during radiation therapy for glioblastoma associated with improved survival\n[24328881:24328881_1] Several retrospective studies in seizure patients with glioblastoma treated with chemotherapy have provided evidence for a moderately improved survival with the use of valproic acid, possibly due to inhibition of histone deacetylase.", "answer": "<think> Okay, I need to answer whether valproic acid is effective for glioblastoma treatment based on the given evidence. Let me look at the evidence provided. First, there are three citations. The first two are from the same document ID [23523186:23523186_3] and [23523186:23523186_2]. Both mention that using valproic acid during radiation therapy for glioblastoma is associated with improved survival. The third citation [24328881:24328881_1] talks about retrospective studies in seizure patients with glioblastoma treated with chemotherapy showing moderately improved survival", "citations": [{"doc_id": "23523186", "chunk_id": "23523186_3"}, {"doc_id": "23523186", "chunk_id": "23523186_2"}, {"doc_id": "24328881", "chunk_id": "24328881_1"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if valproic acid is effective for glioblastoma treatment. The evidence given has three chunks. First, I need to check each chunk. The first two chunks (23523186:23523186_3 and 23523186:23523186_2) both mention that using valproic acid during radiation therapy for glioblastoma is associated with improved survival. The third chunk (24328881:24328881_1) says that retrospective studies in seizure patients with glioblastoma treated with chemotherapy show moderately improved survival with valproic", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if valproic acid is effective for glioblastoma treatment. The evidence given has three chunks. First, I need to check each chunk. The first two chunks (23523186:23523186_3 and 23523186:23523186_2) both mention that using valproic acid during radiation therapy for glioblastoma is associated with improved survival. That's a direct statement about effectiveness. The third chunk (24328881:24328881_1) talks about retrospective studies in seizure patients with glioblastoma treated with chemotherapy", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if valproic acid is effective for glioblastoma treatment. The evidence given has three chunks. First, I need to check each chunk. The first two chunks are the same: they mention that using valproic acid during radiation therapy for glioblastoma is associated with improved survival. The third chunk talks about retrospective studies in seizure patients with glioblastoma treated with chemotherapy showing moderately improved survival with valproic acid, possibly due to HDAC inhibition. So, the answer needs to combine these points. Valproic acid seems effective in two contexts: during radiation therapy and in chemotherapy settings. The confidence level should be moderate because the evidence is from studies, but maybe not all clinical trials. The base", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if valproic acid is effective for glioblastoma treatment. The evidence provided has three chunks. First, I need to check each chunk. The first two chunks (23523186:23523186_3 and 23523186:23523186_2) both mention that using valproic acid during radiation therapy for glioblastoma is associated with improved survival. The third chunk (24328881:24328881_1) talks about retrospective studies in seizure patients with glioblastoma treated with chemotherapy showing moderately improved survival with valproic", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is whether valproic acid is effective for glioblastoma treatment. Let me look at the evidence provided. First, there are three citations. The first two are from 23523186:23523186_3 and 23523186:23523186_2. Both mention that using valproic acid during radiation therapy for glioblastoma is associated with improved survival. The third citation, 24328881:24328881_1, says that retrospective studies in seizure patients with glioblastoma treated with chemotherapy show", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to answer whether valproic acid is effective for glioblastoma treatment based on the given evidence. Let me look at the evidence provided. First, there are three citations. The first two are from the same document ID [23523186:23523186_3] and [23523186:23523186_2]. Both mention that using valproic acid during radiation therapy for glioblastoma is associated with improved survival. The third citation [24328881:24328881_1] talks about retrospective studies in seizure patients with glioblastoma treated with chemotherapy showing moderately improved survival", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if valproic acid is effective for treating glioblastoma. The evidence given has three chunks. First, I need to check each chunk. The first two chunks (23523186:23523186_3 and 23523186:23523186_2) both mention that using valproic acid during radiation therapy for glioblastoma is associated with improved survival. That's pretty direct evidence. The third chunk (24328881:24328881_1) talks about retrospective studies in seizure patients with glioblastoma treated with chemotherapy showing moderately", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if valproic acid is effective for glioblastoma treatment. The evidence provided has three chunks. First, I need to check each chunk. The first two chunks (23523186:23523186_3 and 23523186:23523186_2) both mention that using valproic acid during radiation therapy for glioblastoma is associated with improved survival. That's a direct statement about effectiveness. The third chunk (24328881:24328881_1) talks about retrospective studies in seizure patients with glioblastoma treated with chemotherapy", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["21880994", "23523186", "23680820", "24874578", "24899645", "25066904", "26194676"], "ideal_answer": "Yes, valproic acid prolong survival of glioblastoma patients. Valproic acid is an antiepileptic agent with histone deacetylase inhibitor activity shown to sensitize glioblastoma cells to radiation in preclinical models."}
{"question_id": "56cdf40d5795f9a73e00003d", "question": "Which transcription factor is considered as a master regulator of lysosomal genes?", "retrieved_chunks": [{"doc_id": "25060788", "chunk_id": "25060788_0", "score": 9.593612670898438, "text": "Transcription factor EB (TFEB) is the only known transcription factor that is a master regulator of lysosomal biogenesis although its role in macrophages has not been studied."}, {"doc_id": "22343943", "chunk_id": "22343943_1", "score": 9.345966339111328, "text": "Here, we show that the Transcription Factor EB (TFEB), a master regulator of lysosomal biogenesis, colocalizes with master growth regulator mTOR complex 1 (mTORC1) on the lysosomal membrane."}, {"doc_id": "23604321", "chunk_id": "23604321_1", "score": 9.21290397644043, "text": "the transcription factor EB (TFEB), a master regulator of lysosomal biogenesis and autophagy, is induced by starvation through an autoregulatory feedback loop and exerts a global transcriptional control on lipid catabolism"}], "context": "[25060788:25060788_0] Transcription factor EB (TFEB) is the only known transcription factor that is a master regulator of lysosomal biogenesis although its role in macrophages has not been studied.\n[22343943:22343943_1] Here, we show that the Transcription Factor EB (TFEB), a master regulator of lysosomal biogenesis, colocalizes with master growth regulator mTOR complex 1 (mTORC1) on the lysosomal membrane.\n[23604321:23604321_1] the transcription factor EB (TFEB), a master regulator of lysosomal biogenesis and autophagy, is induced by starvation through an autoregulatory feedback loop and exerts a global transcriptional control on lipid catabolism", "answer": "<think> Okay, I need to figure out which transcription factor is the master regulator of lysosomal genes based on the evidence provided. Let me look at the evidence again. The first document says that TFEB is the only known transcription factor that's a master regulator of lysosomal biogenesis, even though its role in macrophages hasn't been studied. The second one mentions TFEB again as a master regulator of lysosomal biogenesis and colocalizes with mTORC1 on lysosomal membranes. The third document also talks about TFEB being a master regulator of lysosomal biogenesis and autophagy, induced by starvation and controlling lipid catabolism. So all three sources consistently mention TFEB as the master regulator. The answer should be TFEB. The citations are from different", "citations": [], "candidates": [{"answer": "<think> Okay, I need to figure out which transcription factor is the master regulator of lysosomal genes based on the evidence provided. Let me look at the evidence again. The first document says that TFEB is the only known transcription factor that's a master regulator of lysosomal biogenesis, even though its role in macrophages hasn't been studied. The second one mentions TFEB again as a master regulator of lysosomal biogenesis and colocalizes with mTORC1 on lysosomal membranes. The third document also talks about TFEB being a master regulator of lysosomal biogenesis and autophagy, induced by starvation and controlling lipid catabolism. So all three sources consistently mention TFEB as the master regulator. The answer should be TFEB. The citations are from different", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking which transcription factor is considered a master regulator of lysosomal genes. Let me look at the evidence provided. First, the first document says that TFEB is the only known transcription factor that's a master regulator of lysosomal biogenesis, even though its role in macrophages isn't studied. The second document mentions TFEB again as a master regulator of lysosomal biogenesis and colocalizes with mTORC1 on lysosomal membranes. The third document also states that TFEB is a master regulator of lysosomal biogenesis and autophagy, induced by starvation and controlling lipid catabolism. All three sources consistently point to TFEB as the master regulator. The key here is that all citations refer to TFEB. The answer should", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking which transcription factor is considered a master regulator of lysosomal genes. Let me look at the evidence provided. First, the evidence has three chunks. The first one says TFEB is the only known transcription factor that's a master regulator of lysosomal biogenesis, even though its role in macrophages isn't studied. The second chunk mentions TFEB again as a master regulator of lysosomal biogenesis and colocalizes with mTORC1 on lysosomal membranes. The third chunk also talks about TFEB being a master regulator for lysosomal biogenesis and autophagy, induced by starvation and controlling lipid catabolism. All three sources point to TFEB as the master regulator. The first chunk explicitly states that TFEB is the only", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which transcription factor is considered a master regulator of lysosomal genes. The evidence provided has three chunks. First, I need to look at each chunk to see if they mention a transcription factor related to lysosomal genes. The first chunk says TFEB is the only known transcription factor that's a master regulator of lysosomal biogenesis. The second chunk also mentions TFEB as a master regulator of lysosomal biogenesis and its colocalization with mTORC1. The third chunk again refers to TFEB as a master regulator of lysosomal biogenesis and autophagy. So all three chunks point to TFEB. The question is about the master regulator of lysosomal genes, and the evidence consistently states that TFEB is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which transcription factor is considered a master regulator of lysosomal genes. The evidence provided has three chunks. First, I need to identify the key information in each chunk. The first chunk says TFEB is the only known transcription factor that's a master regulator of lysosomal biogenesis, though its role in macrophages isn't studied. The second chunk reiterates that TFEB is a master regulator of lysosomal biogenesis and colocalizes with mTORC1 on lysosomal membranes. The third chunk mentions TFEB again as a master regulator of lysosomal biogenesis and autophagy, induced by starvation. All three chunks consistently point to TFEB as the master regulator. The answer should be TFEB. Now", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which transcription factor is considered a master regulator of lysosomal genes. The evidence provided has three chunks. First, I need to look at each chunk to see if they mention a transcription factor related to lysosomal genes. The first chunk says TFEB is the only known transcription factor that's a master regulator of lysosomal biogenesis. That's a direct mention. The second chunk also mentions TFEB as a master regulator of lysosomal biogenesis, and the third one again refers to TFEB as such. All three chunks consistently point to TFEB. The question is about \"lysosomal genes,\" and the evidence uses \"lysosomal biogenesis.\" Since biogenesis involves the formation and function of lysosomes, it's", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the question is asking which transcription factor is considered a master regulator of lysosomal genes. Let me look at the evidence provided. First, the first evidence document says that TFEB is the only known transcription factor that's a master regulator of lysosomal biogenesis, even though its role in macrophages hasn't been studied. The second document mentions TFEB again as a master regulator of lysosomal biogenesis and colocalizes with mTORC1 on lysosomal membranes. The third document also refers to TFEB as a master regulator of lysosomal biogenesis and autophagy, and talks about it being induced by starvation. All three sources consistently mention TFEB as the master regulator for lysosomal genes. The answer should be TFEB. Now, checking the confidence", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which transcription factor is considered a master regulator of lysosomal genes. The evidence provided has three chunks. First chunk (25060788:25060788_0) says TFEB is the only known transcription factor that's a master regulator of lysosomal biogenesis, though its role in macrophages isn't studied. That directly mentions TFEB as the master regulator for lysosomal genes. Second chunk (22343943:22343948_1) also talks about TFEB being a master regulator of lysosomal biogenesis and colocalizes with mTORC1 on lysosomal membranes. This reinforces that TFEB is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["21617040", "21752829", "21804531", "22343943", "23393155", "23401004", "23457305", "23524842", "23604321", "23609508", "23830905", "25060788", "25315655", "25605940", "25750174"], "ideal_answer": "Transcription factor EB (TFEB) is a master regulator of lysosomal biogenesis and autophagy, driving lysosome adaptation to environmental cues, such as starvation, and therefore targeting of TFEB may provide a novel therapeutic strategy for modulating lysosomal function in human disease."}
{"question_id": "571529efcb4ef8864c000001", "question": "Which antibiotics target peptidoglycan biosynthesis?", "retrieved_chunks": [{"doc_id": "9210483", "chunk_id": "9210483_3", "score": 8.609790802001953, "text": "The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation."}, {"doc_id": "7590155", "chunk_id": "7590155_0", "score": 8.544648170471191, "text": "Bacitracin and other antibiotics that inhibit late stages in peptidoglycan biosynthesis induce vancomycin resistance in a high-level, inducibly vancomycin-resistant strain of Enterococcus faecium."}, {"doc_id": "21867549", "chunk_id": "21867549_1", "score": 8.408501625061035, "text": "Antibiotics which inhibit bacterial peptidoglycan biosynthesis are the most widely used in current clinical practice."}], "context": "[9210483:9210483_3] The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation.\n[7590155:7590155_0] Bacitracin and other antibiotics that inhibit late stages in peptidoglycan biosynthesis induce vancomycin resistance in a high-level, inducibly vancomycin-resistant strain of Enterococcus faecium.\n[21867549:21867549_1] Antibiotics which inhibit bacterial peptidoglycan biosynthesis are the most widely used in current clinical practice.", "answer": "<think> Okay, let's tackle this question. The user is asking which antibiotics target peptidoglycan biosynthesis. I need to look at the provided evidence to find the answer. First, looking at the evidence: The first piece [9210483:9210483_3] mentions that mersacidin, a lantibiotic, inhibits peptidoglycan biosynthesis at the transglycosylation level. So mersacidin is one such antibiotic. The second evidence [7590155:7590155_0] talks about bacitracin and other antibiotics that inhibit late stages in peptidoglycan biosynthesis. Bacitracin is", "citations": [{"doc_id": "9210483", "chunk_id": "9210483_3"}, {"doc_id": "7590155", "chunk_id": "7590155_0"}], "candidates": [{"answer": "<think> Okay, so the user is asking which antibiotics target peptidoglycan biosynthesis. Let me look at the evidence provided. First, the evidence has three chunks. The first one mentions mersacidin, a lantibiotic, inhibiting peptidoglycan biosynthesis at transglycosylation. The second chunk talks about bacitracin and others that inhibit late stages of peptidoglycan biosynthesis, leading to vancomycin resistance. The third chunk states that antibiotics inhibiting bacterial peptidoglycan biosynthesis are the most widely used clinically. The question is about which antibiotics target this process. The answer needs to be concise with citations. The first chunk mentions mersacidin, the second mentions bacitracin", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which antibiotics target peptidoglycan biosynthesis. I need to look at the provided evidence to find the answer. First, looking at the evidence: The first piece [9210483:9210483_3] mentions that mersacidin, a lantibiotic, inhibits peptidoglycan biosynthesis at the transglycosylation level. So mersacidin is one such antibiotic. The second evidence [7590155:7590155_0] talks about bacitracin and other antibiotics that inhibit late stages in peptidoglycan biosynthesis. Bacitracin is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which antibiotics target peptidoglycan biosynthesis. The evidence provided has three chunks. First, chunk [9210483:9210483_3] mentions mersacidin, a lantibiotic that inhibits peptidoglycan biosynthesis at transglycosylation. That's a specific example. Then, chunk [7590155:7590155_0] talks about bacitracin and other antibiotics that inhibit late stages of peptidoglycan biosynthesis, leading to vancomycin resistance. So bacitracin is mentioned here. The third chunk [2186", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which antibiotics target peptidoglycan biosynthesis. The evidence provided has three chunks. First, chunk [9210483:9210483_3] mentions mersacidin, a lantibiotic, inhibiting peptidoglycan biosynthesis at transglycosylation. That's a specific example. Then, [7590155:7590155_0] talks about bacitracin and others that inhibit late stages of peptidoglycan biosynthesis, leading to vancomycin resistance. So bacitracin is another one. The third chunk [2186754", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which antibiotics target peptidoglycan biosynthesis. The evidence provided has three chunks. First, chunk 9210483:3 mentions mersacidin, a lantibiotic that inhibits peptidoglycan biosynthesis at transglycosylation. That's a direct mention of an antibiotic targeting this process. Then chunk 7590155:0 talks about bacitracin and others that inhibit late stages of peptidoglycan biosynthesis, leading to vancomycin resistance. So bacitracin is another one. The third chunk, 21867549:1, states that antibiotics inhibiting pept", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which antibiotics target peptidoglycan biosynthesis. The evidence provided has three chunks. First, chunk 9210483:3 mentions mersacidin, a lantibiotic that inhibits peptidoglycan biosynthesis at transglycosylation. That's a direct mention of an antibiotic targeting this process. Then, chunk 7590155:0 talks about bacitracin and other antibiotics inhibiting late stages of peptidoglycan biosynthesis, leading to vancomycin resistance. So bacitracin is another example here. Chunk 21867549:1 states that antibiotics inhibiting peptid", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which antibiotics target peptidoglycan biosynthesis. The evidence provided has three chunks. First, chunk 9210483:3 mentions mersacidin, a lantibiotic that inhibits peptidoglycan biosynthesis at transglycosylation. That's a direct example of an antibiotic targeting this process. Then, chunk 7590155:0 talks about bacitracin and other antibiotics that inhibit late stages in peptidoglycan biosynthesis. This also points to antibiotics affecting the same pathway, though it's later stages. So bacitracin is mentioned here. Chunk 21867549:1", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking which antibiotics target peptidoglycan biosynthesis. Let me look at the evidence provided. First, the evidence has three chunks. The first one mentions mersacidin, a lantibiotic that inhibits peptidoglycan biosynthesis at transglycosylation. The second chunk talks about bacitracin and other antibiotics that inhibit late stages in peptidoglycan biosynthesis, leading to vancomycin resistance. The third chunk states that antibiotics inhibiting peptidoglycan biosynthesis are the most widely used clinically. The question is asking for antibiotics that target this process. From the first evidence, mersacidin is one. The second mentions bacitracin and others. The third", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["10801476", "11751110", "12197711", "12440876", "16832063", "18558445", "20515462", "21091161", "21867549", "22280885", "22815801", "2334153", "25224006", "7590155", "7793878", "8891144", "9210483"], "ideal_answer": "Under some conditions, both ramoplanin and vancomycin probes produce helicoid staining patterns along the cylindrical walls of B. subtilis cells. This work has implications for the design of ramoplanin derivatives and may influence how other proposed substrate binding antibiotics are studied. This was confirmed by in vitro studies involving a wall-membrane particulate fraction from Gaffkya homari in which peptidoglycan synthesis from UDP-MurNAc-tetrapeptide was inhibited by ramoplanin but not by vancomycin. New results support a two-state model for septal and peripheral PG synthesis at mid-cell, involvement of essential cell division proteins in PG remodeling, and mid-cell localization of proteins that organize PG biosynthesis and that form the protein translocation apparatus. Antibiotics which inhibit bacterial peptidoglycan biosynthesis are the most widely used in current clinical practice. Cells treated with ampicillin, D-cycloserine, or fosfomycin had only one chloroplast after cell division, suggesting that the cells divided without chloroplast division. The antibiotics bacitracin and vancomycin showed no obvious effect. Colchicine inhibits Closterium cell elongation after division. Surprisingly, also cinnamycin of Streptomyces cinnamoneus cinnamoneus), previously known to bind specifically to phosphatidylethanolamin of biological membranes, provoked strong cell wall biosynthetic stress. Other substances include fluorescent derivatives of two PG-binding antibiotics, vancomycin and ramoplanin. The muraymycins constitute a new antibiotic family whose core structure contains a glycosylated uronic acid derivative joined by an aminopropane group to a hexahydro-2-imino-4-pyrimidylglycyl residue (epicapreomycidine) containing dipeptide that is further extended by a urea-valine moiety. The muraymycins inhibited peptidoglycan biosynthesis. Ramoplanin is a cyclicdepsipeptide antibiotic that inhibits peptidoglycan biosynthesis. The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation. Ramoplanin, a new lipoglycopeptide antibiotic, inhibits cell wall peptidoglycan biosynthesis in gram-positive bacteria."}
{"question_id": "52b2ec744003448f55000001", "question": "Can Levoxyl (levothyroxine sodium) cause insomnia?", "retrieved_chunks": [{"doc_id": "19701833", "chunk_id": "19701833_0", "score": 0.06616200506687164, "text": "METHODS: Seventy-one patients diagnosed with primary hypothyroidism were randomly allocated into two study groups: the first group received usual dose of levothyroxine and the second group received combination of levothyroxine and liothyronine for at least 4 months. The main outcomes were psychosocial problems (Goldberg's General Health Questionnaire, GHQ-28), bodyweight, heart rate, blood pressure, and serum lipid levels. RESULTS: In both groups serum thyroid-stimulating hormone levels remained unchanged compared with baseline. Psychosocial scores, body weight, heart rate, blood pressure, and lipid profile in the two groups remained constant. The only exception was a small but significant reduction in anxiety/insomnia in combined treatment group as compared with monotherapy."}, {"doc_id": "16449486", "chunk_id": "16449486_0", "score": -1.9887151718139648, "text": "Adverse experiences included nausea, dizziness, and insomnia."}, {"doc_id": "36473030", "chunk_id": "36473030_0", "score": -2.662900686264038, "text": "Daridorexant is a novel dual orexin receptor antagonist used in treating insomnia disorder."}], "context": "[19701833:19701833_0] METHODS: Seventy-one patients diagnosed with primary hypothyroidism were randomly allocated into two study groups: the first group received usual dose of levothyroxine and the second group received combination of levothyroxine and liothyronine for at least 4 months. The main outcomes were psychosocial problems (Goldberg's General Health Questionnaire, GHQ-28), bodyweight, heart rate, blood pressure, and serum lipid levels. RESULTS: In both groups serum thyroid-stimulating hormone levels remained unchanged compared with baseline. Psychosocial scores, body weight, heart rate, blood pressure, and lipid profile in the two groups remained constant. The only exception was a small but significant reduction in anxiety/insomnia in combined treatment group as compared with monotherapy.\n[16449486:16449486_0] Adverse experiences included nausea, dizziness, and insomnia.\n[36473030:36473030_0] Daridorexant is a novel dual orexin receptor antagonist used in treating insomnia disorder.", "answer": "<think> Okay, let's tackle this question. The user wants to know if Levoxyl (levothyroxine sodium) can cause insomnia. The evidence provided has three documents. First, looking at document [19701833:19701833_0], it talks about a study with patients on levothyroxine. The results mention that psychosocial scores, including anxiety/insomnia, were similar between the two groups. However, there was a small significant reduction in anxiety/insomnia in the combined treatment group. Wait, but the question is about whether levothyroxine alone causes insomnia. The study compared monotherapy (just levothyroxine) with combination therapy. The result says that the combined", "citations": [{"doc_id": "19701833", "chunk_id": "19701833_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants to know if Levoxyl (levothyroxine sodium) can cause insomnia. The evidence provided has three documents. First, looking at document [19701833:19701833_0], it talks about a study with patients on levothyroxine. The results mention that psychosocial scores, including anxiety/insomnia, were similar between the two groups. However, there was a small significant reduction in anxiety/insomnia in the combined treatment group. Wait, but the question is about whether levothyroxine alone causes insomnia. The study compared monotherapy (just levothyroxine) with combination therapy. The result says that the combined", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if Levoxyl (levothyroxine sodium) can cause insomnia. The evidence provided has three references. First, looking at the first study (19701833), it mentions that in both groups, psychosocial scores, including anxiety and insomnia, remained constant. However, there was a small significant reduction in anxiety/insomnia in the combined treatment group. Wait, but the question is about whether Levoxyl alone causes insomnia. The study compared monotherapy with combination therapy. The result says that in the combined group, there was a reduction in anxiety/insomnia. But does that mean that Levoxil alone might not cause it? Or maybe the combination reduced it? Hmm", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if Levoxyl (levothyroxine sodium) can cause insomnia. I need to look at the provided evidence to find any mentions of that. First, looking at the first document: it talks about a study with two groups taking levothyroxine either alone or combined with liothyronine. The results mention that psychosocial scores, including anxiety and insomnia, were similar between the groups. However, there's a note that the combined treatment group had a small significant reduction in anxiety/insomnia compared to monotherapy. Wait, so the study found that combining levothyroxine with another hormone led to less insomnia. But does that mean levothyroxine alone can cause insomnia?", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if Levoxyl (levothyroxine sodium) can cause insomnia. I need to look at the provided evidence to find any mentions of insomnia related to levothyroxine. First, evidence document [19701833:19701833_0] talks about a study with 71 patients with hypothyroidism. They had two groups: one on levothyroxine alone and the other on levothyroxine plus liothyronine. The results mention that psychosocial scores, including anxiety/insomnia, were similar between groups, but there was a small reduction in anxiety/insomnia in the combined treatment group. Wait", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if Levoxyl (levothyroxine sodium) can cause insomnia. The evidence provided has three documents. First, looking at document 19701833: It mentions a study with two groups taking levothyroxine alone or combined with liothyronine. The results say that psychosocial scores, including anxiety and insomnia, were mostly stable. However, there was a small significant reduction in anxiety/insomnia in the combined treatment group compared to monotherapy. Wait, so the study found that combining levothyroxine with another drug led to less anxiety and insomnia. But the question is about levothyroxine alone causing insomnia. Hmm, maybe this study", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if Levoxyl (levothyroxine sodium) can cause insomnia. I need to look at the evidence provided. First, check the evidence documents. The first one (19701833) talks about a study with 71 patients with hypothyroidism. They were given either levothyroxine alone or combined with liothyronine. The results mention that psychosocial scores, including anxiety and insomnia, were mostly stable. However, the combined group had a small significant reduction in anxiety/insomnia compared to monotherapy. Wait, so the study found that combining levothyroxine with another thyroid hormone led to less insomnia. But the question is about whether", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if Levoxyl (levothyroxine sodium) can cause insomnia. The evidence provided has three documents. First, looking at document [19701833:19701833_0], it mentions a study with two groups: one taking just levothyroxine and the other combining it with liothyronine. The results say that psychosocial scores, including anxiety/insomnia, were mostly stable. However, there was a small significant reduction in anxiety/insomnia in the combined treatment group compared to monotherapy. Wait, so the study found that combining levothyroxine with another drug reduced insomnia, but does that mean levo", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if Levoxyl (levothyroxine sodium) can cause insomnia. The evidence provided has three documents. First, looking at document [19701833:19701833_0], it mentions a study where patients with hypothyroidism were given either levothyroxine alone or combined with liothyronine. The results state that psychosocial scores, including anxiety and insomnia, were mostly unchanged. However, there was a small significant reduction in anxiety/insomnia in the combined treatment group compared to monotherapy. Wait, so the combined treatment had less insomnia, but does that mean levothyroxine alone could cause it? The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["19701833"], "ideal_answer": "Levoxyl monotherapy is associated with increased insomnia compared to a combination of levothyroxine and liothyronine."}
{"question_id": "530e42e65937551c09000007", "question": "Is fatigue prevalent in patients receiving treatment for glioblastoma?", "retrieved_chunks": [{"doc_id": "21514945", "chunk_id": "21514945_1", "score": 6.969281196594238, "text": "This study demonstrated a progressive increase in physical fatigue in patients with glioblastoma relapse treated with irinotecan-bevacizumab."}, {"doc_id": "26902850", "chunk_id": "26902850_2", "score": 5.355546951293945, "text": "CONCLUSIONS: While treatment was well-tolerated, an 8-week course of armodafinil did not improve fatigue or QOL in glioma patients undergoing RT in this pilot study."}, {"doc_id": "26902850", "chunk_id": "26902850_5", "score": 5.135473728179932, "text": "While treatment was well-tolerated, an 8-week course of armodafinil did not improve fatigue or QOL in glioma patients undergoing RT in this pilot study."}], "context": "[21514945:21514945_1] This study demonstrated a progressive increase in physical fatigue in patients with glioblastoma relapse treated with irinotecan-bevacizumab.\n[26902850:26902850_2] CONCLUSIONS: While treatment was well-tolerated, an 8-week course of armodafinil did not improve fatigue or QOL in glioma patients undergoing RT in this pilot study.\n[26902850:26902850_5] While treatment was well-tolerated, an 8-week course of armodafinil did not improve fatigue or QOL in glioma patients undergoing RT in this pilot study.", "answer": "<think> Okay, let's tackle this question. The user is asking if fatigue is prevalent in patients receiving treatment for glioblastoma. The evidence provided has three entries. First, looking at the first piece of evidence [21514945:21514945_1], it says there's a progressive increase in physical fatigue in patients with glioblastoma relapse treated with irinotecan-bevacizumab. That directly mentions fatigue being prevalent in these patients. So that's a strong point. Then the next two pieces, [26902850:26902850_2] and [26902850:26902850", "citations": [{"doc_id": "21514945", "chunk_id": "21514945_1"}, {"doc_id": "26902850", "chunk_id": "26902850_2"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if fatigue is prevalent in patients treated for glioblastoma. The evidence provided has three chunks. First, chunk 21514945_1 says that a study found a progressive increase in physical fatigue in patients with glioblastoma relapse treated with irinotecan-bevacizumab. That directly mentions fatigue being prevalent in treatment. Then there are two other chunks (26902850_2 and 26902850_5) which are duplicates. They state that armodafinil didn't improve fatigue or QOL in patients undergoing RT. However, this doesn't directly address the prevalence of fatigue but rather its non-im", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if fatigue is prevalent in patients treated for glioblastoma. The evidence provided has three chunks. First chunk (21514945_1) says that a study found a progressive increase in physical fatigue in patients with glioblastoma relapse treated with irinotecan-bevacizumab. That directly supports the idea that fatigue is prevalent. The other two chunks (26902850_2 and 26902850_5) are duplicates, mentioning that armodafinil didn't improve fatigue or QOL in patients undergoing RT. However, these studies don't confirm prevalence; they just show that a treatment didn't help.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if fatigue is prevalent in patients treated for glioblastoma. The evidence given has three chunks. First, chunk 21514945_1 says that a study found a progressive increase in physical fatigue in patients with glioblastoma relapse treated with irinotecan-bevacizumab. That directly addresses the prevalence of fatigue during treatment. So that's a strong point for saying fatigue is prevalent. Then, chunks 26902850_2 and 26902850_5 are the same, mentioning that armodafinil didn't improve fatigue or QOL in patients undergoing RT. However, this study doesn't show prevalence", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if fatigue is prevalent in patients treated for glioblastoma. The evidence provided has three chunks. First chunk (21514945_1) says that a study found a progressive increase in physical fatigue in patients with glioblastoma relapse treated with irinotecan-bevacizumab. That directly addresses fatigue prevalence during treatment. The other two chunks (26902850_2 and 5) are duplicates, mentioning that armodafinil didn't improve fatigue or QOL in patients undergoing RT. However, these studies don't measure prevalence but rather the effectiveness of a treatment. So they support that fatigue exists but don't quantify its prevalence.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if fatigue is prevalent in patients treated for glioblastoma. The evidence provided has three chunks. First chunk (21514945_1) says that a study found a progressive increase in physical fatigue in patients with glioblastoma relapse treated with irinotecan-bevacizumab. That directly addresses the prevalence of fatigue during treatment. So that's a positive indicator. Then there are two chunks (26902850_2 and 5) which are duplicates. They mention a pilot study where armodafinil didn't improve fatigue or QOL in glioma patients undergoing RT. However, this doesn't directly state prevalence but rather that a treatment", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if fatigue is prevalent in patients receiving treatment for glioblastoma. The evidence provided has three entries. First, looking at the first piece of evidence [21514945:21514945_1], it says there's a progressive increase in physical fatigue in patients with glioblastoma relapse treated with irinotecan-bevacizumab. That directly mentions fatigue being prevalent in these patients. So that's a strong point. Then the next two pieces, [26902850:26902850_2] and [26902850:26902850", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if fatigue is prevalent in patients treated for glioblastoma. The evidence given has three chunks. First, chunk 21514945_1 says that a study found a progressive increase in physical fatigue in patients with glioblastoma relapse treated with irinotecan-bevacizumab. That directly mentions fatigue being prevalent in this treatment context. So that's a strong point for the answer. Then, chunks 26902850_2 and 26902850_5 are the same, stating that armodafinil didn't improve fatigue or QOL in glioma patients undergoing RT. However, this doesn't say if", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if fatigue is prevalent in patients treated for glioblastoma. I need to look at the evidence provided. First, there's the study with ID 21514945:21514945_1. It says that physical fatigue increases progressively in patients with glioblastoma relapse treated with irinotecan-bevacizumab. That suggests fatigue is a common issue here. Then, there are two entries from 26902850:26902850_2 and 26902850:26902850_5. Both mention that armodafinil", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["14649883", "18477765", "18581057", "18758912", "18990027", "19593660", "19904263", "20200024", "20308655", "20510539", "20665891", "20729242", "21514945", "2168357", "21986722", "22079725", "22090453", "22832897", "23086432", "23184145", "23419575", "23422478", "23642624", "3008359"], "ideal_answer": "Yes, fatigue is a common complication of glioblastoma patients receiving chemotherapy or radiotherapy."}
{"question_id": "53358cd2d6d3ac6a3400004e", "question": "List two common features of Tay syndrome.", "retrieved_chunks": [{"doc_id": "18376101", "chunk_id": "18376101_0", "score": 7.093444347381592, "text": "Tay syndrome or IBIDS is a rare autosomal recessive genetic disorder characterized by congenital ichthyosis and abnormal brittle hair (trichothiodystrophy). Other features include photosensitivity, abnormal nails and multiple developmental defects affecting organs mainly derived from neuroectoderm."}, {"doc_id": "10797890", "chunk_id": "10797890_0", "score": 3.905810832977295, "text": "Tay-syndrome is a rare monogen-inherited ektodermal dysplastic syndrome with ichtyosis, fragility of the hair and physical and mental retardation. The congenital ichtyosis is ubiquitous. Only the skin on the flexion side of the extremity joints are not involved (orthocerathosis combined with paraceratotic strings)."}, {"doc_id": "9050052", "chunk_id": "9050052_1", "score": 3.506389856338501, "text": "We present a case of Tay syndrome in which a cranial MRI revealed an almost total lack of myelin within the cerebral hemispheres and a patchy hypomyelination of the cerebellum. In accordance, a strongly prolonged visual evoked response pointed to a dysfunction of the white matter in Tay syndrome."}], "context": "[18376101:18376101_0] Tay syndrome or IBIDS is a rare autosomal recessive genetic disorder characterized by congenital ichthyosis and abnormal brittle hair (trichothiodystrophy). Other features include photosensitivity, abnormal nails and multiple developmental defects affecting organs mainly derived from neuroectoderm.\n[10797890:10797890_0] Tay-syndrome is a rare monogen-inherited ektodermal dysplastic syndrome with ichtyosis, fragility of the hair and physical and mental retardation. The congenital ichtyosis is ubiquitous. Only the skin on the flexion side of the extremity joints are not involved (orthocerathosis combined with paraceratotic strings).\n[9050052:9050052_1] We present a case of Tay syndrome in which a cranial MRI revealed an almost total lack of myelin within the cerebral hemispheres and a patchy hypomyelination of the cerebellum. In accordance, a strongly prolonged visual evoked response pointed to a dysfunction of the white matter in Tay syndrome.", "answer": "<think> Okay, let's tackle this question. The user wants two common features of Tay syndrome based on the provided evidence. First, I need to look through the evidence documents to find the key points. Looking at document [18376101:18376101_0], it mentions congenital ichthyosis and abnormal brittle hair (trichothiodystrophy) as features. Also, photosensitivity, abnormal nails, and developmental defects are noted. So ichthyosis and brittle hair are two points here. Document [10797890:10797890_0] also talks about ichtyosis, fragility of the hair, and physical and mental retardation. It adds", "citations": [{"doc_id": "18376101", "chunk_id": "18376101_0"}, {"doc_id": "10797890", "chunk_id": "10797890_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking for two common features of Tay syndrome based on the provided evidence. First, I need to look through the evidence documents to find the key points mentioned about Tay syndrome. Let me go through each one. The first document says Tay syndrome is characterized by congenital ichthyosis and abnormal brittle hair (trichothiodystrophy). It also mentions photosensitivity, abnormal nails, and developmental defects affecting organs from neuroectoderm. So that's a few features here. The second document talks about ichtyosis, fragility of the hair, physical and mental retardation. It also notes that congenital ichthyosis is widespread except for the skin on the flexion side of the extremity joints. So that's", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants two common features of Tay syndrome based on the provided evidence. First, I need to look through the evidence documents to find the key points. Looking at document [18376101:18376101_0], it mentions congenital ichthyosis and abnormal brittle hair (trichothiodystrophy) as features. Also, photosensitivity, abnormal nails, and developmental defects are noted. So ichthyosis and brittle hair are two points here. Document [10797890:10797890_0] also talks about ichtyosis, fragility of the hair, and physical and mental retardation. It adds", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence for the question about two common features of Tay syndrome. Let me start by reading through the provided evidence carefully. The first document says that Tay syndrome is characterized by congenital ichthyosis and abnormal brittle hair (trichothiodystrophy). It also mentions photosensitivity, abnormal nails, and developmental defects affecting organs from neuroectoderm. So ichthyosis and brittle hair are definitely two features here. The second document refers to ichtyosis, fragility of the hair, physical and mental retardation. Again, ichtyosis and hair fragility are mentioned. The third document talks about myelin issues in the brain and visual evoked response problems, but those seem more specific and maybe not", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking for two common features of Tay syndrome based on the provided evidence. First, I need to look through the evidence documents to find the key points mentioned about Tay syndrome. Looking at the first document [18376101:18376101_0], it mentions congenital ichthyosis and abnormal brittle hair (trichothiodystrophy) as characteristics. It also talks about photosensitivity, abnormal nails, and developmental defects affecting neuroectoderm-derived organs. So that's a couple of features. The second document [10797890:10797890_0] repeats some of these points, like ichthyosis", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user wants two common features of Tay syndrome based on the provided evidence. First, I need to look through the evidence snippets. The first document mentions congenital ichthyosis and abnormal brittle hair (trichothiodystrophy) as key points. It also talks about photosensitivity, abnormal nails, and developmental defects in neuroectoderm-derived organs. The second snippet says Tay-syndrome has ichtyosis, fragility of the hair, physical and mental retardation. It specifies that congenital ichthyosis is widespread except for the skin on the flexion side of joints. The third document talks about MRI findings of hypomyelination in the cerebral hemispheres and cerebellum, along with prolonged", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so I need to generate a JSON answer based on the evidence provided for the question about two common features of Tay syndrome. Let's start by reading through the evidence carefully. First, looking at the first document: It mentions congenital ichthyosis and abnormal brittle hair (trichothiodystrophy) as characteristics. Also, photosensitivity, abnormal nails, and developmental defects affecting organs from neuroectoderm are noted. So that's a few features here. The second document talks about ichtyosis, fragility of the hair, physical and mental retardation. It also specifies that congenital ichthyosis is widespread except for the skin on the flexion side of the extremity joints. So again, ichthyosis and brittle hair are mentioned, along with", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants two common features of Tay syndrome based on the provided evidence. First, I need to look through the evidence documents. Let me check each one. Document 18376101: It mentions congenital ichthyosis and abnormal brittle hair (trichothiodystrophy) as key features. Also, photosensitivity, abnormal nails, and developmental defects in neuroectoderm-derived organs. So ichthyosis and brittle hair are definitely there. Document 10797890: This one also talks about ichthyosis, fragility of hair, and physical and mental retardation. The mention of \"congenital ichtyosis is ubiquitous\" reinforces that. Also, the part", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking for two common features of Tay syndrome based on the provided evidence. First, I need to look through the evidence documents to find the key points mentioned. Looking at document [18376101:18376101_0], it mentions congenital ichthyosis and abnormal brittle hair (trichothiodystrophy) as two features. It also talks about photosensitivity, nail abnormalities, and developmental defects affecting neuroectoderm-derived organs. So that's a good start. Document [10797890:10797890_0] repeats ichthyosis and fragile hair, and adds physical and mental retardation. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["10797890", "17504703", "18376101", "20687499", "2087835", "6538137", "9050052"], "ideal_answer": "Tay syndrome is a rare autosomal recessive genetic disorder characterized by congenital ichthyosis and trichothiodystrophy (abnormal brittle hair). Other less common features of this syndrome are photosensitivity, low birth weight, short stature, mental retardation, delayed neuromuscular development and other CNS anomalies, dysplasia of nails, hypoplasia of subcutaneous fatty tissue, prematurely aged facial appearance, hypogonadism, cataracts, osteosclerosis, dysphonia, and increased susceptibility to infections."}
{"question_id": "52b2d405f828ad283c000009", "question": "Which cell types are known to be driving Rheumatoid Arthritis?", "retrieved_chunks": [{"doc_id": "16567358", "chunk_id": "16567358_2", "score": 5.197886943817139, "text": "These rheumatoid arthritis synovial fibroblasts (RASFs) constitute a quite unique cell type that distinguishes RA from other inflammatory conditions of the joints"}, {"doc_id": "22586171", "chunk_id": "22586171_0", "score": 4.091127395629883, "text": "Mesenchymal stem cells are conditionally therapeutic in preclinical models of rheumatoid arthritis."}, {"doc_id": "19863844", "chunk_id": "19863844_0", "score": 2.269672393798828, "text": "MSC interaction with B cells provides stimuli for B-cell survival and therefore may contribute to the pathogenesis of rheumatoid arthritis"}], "context": "[16567358:16567358_2] These rheumatoid arthritis synovial fibroblasts (RASFs) constitute a quite unique cell type that distinguishes RA from other inflammatory conditions of the joints\n[22586171:22586171_0] Mesenchymal stem cells are conditionally therapeutic in preclinical models of rheumatoid arthritis.\n[19863844:19863844_0] MSC interaction with B cells provides stimuli for B-cell survival and therefore may contribute to the pathogenesis of rheumatoid arthritis", "answer": "<think> Okay, let's tackle this question. The user is asking which cell types are known to drive Rheumatoid Arthritis (RA). The evidence provided has three snippets. First snippet [16567358:16567358_2] mentions rheumatoid arthritis synovial fibroblasts (RASFs) as a unique cell type that distinguishes RA from other joint inflammations. That seems directly relevant. The second snippet [22586171:22586171_0] talks about mesenchymal stem cells (MSCs) being conditionally therapeutic in preclinical RA models. So MSCs are mentioned here, but the context is about their therapeutic potential,", "citations": [{"doc_id": "16567358", "chunk_id": "16567358_2"}, {"doc_id": "22586171", "chunk_id": "22586171_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which cell types are known to drive Rheumatoid Arthritis (RA). The evidence provided has three snippets. First snippet [16567358:16567358_2] mentions rheumatoid arthritis synovial fibroblasts (RASFs) as a unique cell type that distinguishes RA from other joint inflammations. That seems directly relevant. The second snippet [22586171:22586171_0] talks about mesenchymal stem cells (MSCs) being conditionally therapeutic in preclinical RA models. So MSCs are mentioned here, but the context is about their therapeutic potential,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which cell types are known to drive Rheumatoid Arthritis (RA). The evidence provided has three chunks. First chunk [16567358:16567358_2] mentions rheumatoid arthritis synovial fibroblasts (RASFs) as a unique cell type that distinguishes RA from other joint inflammatory conditions. So RASFs are definitely a key player here. Second chunk [22586171:22586171_0] talks about mesenchymal stem cells (MSCs) being conditionally therapeutic in preclinical RA models. That suggests MSCs might be involved, but the wording is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which cell types are known to drive Rheumatoid Arthritis (RA). The evidence provided has three chunks. First, chunk 16567358 mentions rheumatoid arthritis synovial fibroblasts (RASFs) as a unique cell type that distinguishes RA from other joint inflammation. That's a direct mention of a specific cell type involved in RA. Then chunk 22586171 talks about mesenchymal stem cells (MSCs) being conditionally therapeutic in preclinical models of RA. So MSCs are mentioned here, but the context is their therapeutic potential, not necessarily their role in driving the disease. However, the fact that they're involved", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which cell types are known to drive Rheumatoid Arthritis (RA). The evidence provided has three chunks. First chunk [16567358:16567358_2] mentions rheumatoid arthritis synovial fibroblasts (RASFs) as a unique cell type that distinguishes RA from other joint inflammatory conditions. That seems directly relevant. The second chunk [22586171:22586171_0] talks about mesenchymal stem cells (MSCs) being conditionally therapeutic in preclinical models of RA. So MSCs are mentioned here, but the context is about their therapeutic potential", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's see. The user is asking which cell types are driving Rheumatoid Arthritis based on the provided evidence. Looking at the evidence: First piece [16567358:16567358_2] mentions rheumatoid arthritis synovial fibroblasts (RASFs) as a unique cell type that distinguishes RA from other joint inflammation. So RASFs are definitely mentioned here. Second evidence [22586171:22586171_0] talks about mesenchymal stem cells (MSCs) being conditionally therapeutic in preclinical models of RA. That suggests MSCs might be involved, but the wording is \"conditionally therapeutic,\" which", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which cell types are known to drive Rheumatoid Arthritis (RA). The evidence provided includes three chunks. First, chunk 16567358:2 mentions rheumatoid arthritis synovial fibroblasts (RASFs) as a unique cell type distinguishing RA from other joint inflammation. That's a direct mention of RASFs being involved. Then, chunk 22586171:0 talks about mesenchymal stem cells (MSCs) being conditionally therapeutic in preclinical RA models. So MSCs are implicated here, but the wording is \"conditionally therapeutic,\" which might mean they have a role, possibly as a driver or a target. Chunk", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which cell types are driving Rheumatoid Arthritis (RA) based on the provided evidence. First, I need to look at the evidence given. There are three references here. Let me go through each one. The first piece of evidence [16567358:16567358_2] mentions \"rheumatoid arthritis synovial fibroblasts (RASFs)\" as a unique cell type that distinguishes RA from other joint inflammatory conditions. So RASFs are definitely mentioned here as a key player. The second reference [22586171:22586171_0] talks about mesenchym", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this query. The user is asking which cell types are known to drive Rheumatoid Arthritis (RA). The evidence provided has three chunks. First chunk [16567358:16567358_2] mentions rheumatoid arthritis synovial fibroblasts (RASFs) as a unique cell type distinguishing RA from other joint inflammatory conditions. That seems directly relevant. Second chunk [22586171:22586171_0] talks about mesenchymal stem cells (MSCs) being conditionally therapeutic in preclinical RA models. But the question is about cell types driving the disease, not therapies. However, the fact that", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["12060849", "15641091", "15692990", "16567358", "17875202", "18613841", "19863844", "20519953", "21160042", "23036591", "24276088"], "ideal_answer": "Macrophages, T cells and their respective cytokines play a pivotal role in RA. Rheumatoid arthritis synovial fibroblasts (RASFs) constitute a quite unique cell type that distinguishes RA from other inflammatory conditions of the joints. Activated synovial fibroblasts (SFs) have the ability to invade joint cartilage, actively contributing to joint destruction in RA."}
{"question_id": "550324d7e9bde6963400002f", "question": "What is the association between personality trait of neuroticism and risk for Alzheimer's disease?", "retrieved_chunks": [{"doc_id": "23040035", "chunk_id": "23040035_1", "score": 6.989013195037842, "text": "Neuroticism (r = 0.26), low agreeableness (r = -0.34), and some facets were also significantly associated with advanced stages of neurofibrillary tangles, but the associations between personality traits and risk of clinical dementia were mostly unchanged by controlling for the extent of neurofibrillary tangles and A� neuritic plaques."}, {"doc_id": "23040035", "chunk_id": "23040035_0", "score": 4.656019687652588, "text": "Individuals with higher baseline scores on vulnerability to stress, anxiety, and depression (neuroticism: odds ratio, 2.0; 95% confidence interval, 1.2-3.5), or lower scores on order and competence (conscientiousness: odds ratio, 0.4; 95% confidence interval, 0.2-0.9) were less likely to remain asymptomatic in the presence of AD neuropathology. Neuroticism (r = 0.26), low agreeableness (r = -0.34), and some facets were also significantly associated with advanced stages of neurofibrillary tangles, but the associations between personality traits and risk of clinical dementia were mostly unchanged by controlling for the extent of neurofibrillary tangles and Aβ neuritic plaques."}, {"doc_id": "10718200", "chunk_id": "10718200_1", "score": 3.856438398361206, "text": "Multiple studies of individuals with Alzheimer disease have substantiated significant levels of informant-rated change in several domains and facets of the Neuroticism-Extraversion-Openness Personality Inventory, including increases in Neuroticism and decreases in Extraversion and Conscientiousness relative to premorbid personality traits."}], "context": "[23040035:23040035_1] Neuroticism (r = 0.26), low agreeableness (r = -0.34), and some facets were also significantly associated with advanced stages of neurofibrillary tangles, but the associations between personality traits and risk of clinical dementia were mostly unchanged by controlling for the extent of neurofibrillary tangles and A� neuritic plaques.\n[23040035:23040035_0] Individuals with higher baseline scores on vulnerability to stress, anxiety, and depression (neuroticism: odds ratio, 2.0; 95% confidence interval, 1.2-3.5), or lower scores on order and competence (conscientiousness: odds ratio, 0.4; 95% confidence interval, 0.2-0.9) were less likely to remain asymptomatic in the presence of AD neuropathology. Neuroticism (r = 0.26), low agreeableness (r = -0.34), and some facets were also significantly associated with advanced stages of neurofibrillary tangles, but the associations between personality traits and risk of clinical dementia were mostly unchanged by controlling for the extent of neurofibrillary tangles and Aβ neuritic plaques.\n[10718200:10718200_1] Multiple studies of individuals with Alzheimer disease have substantiated significant levels of informant-rated change in several domains and facets of the Neuroticism-Extraversion-Openness Personality Inventory, including increases in Neuroticism and decreases in Extraversion and Conscientiousness relative to premorbid personality traits.", "answer": "<think> Okay, let's tackle this question. The user is asking about the association between neuroticism and Alzheimer's disease risk. First, I need to look at the evidence provided. There are three documents mentioned. Let me check each one. Looking at document [23040035:23040035_1], it says that neuroticism (r = 0.26) is associated with advanced stages of neurofibrillary tangles. However, the associations between personality traits and clinical dementia risk remained mostly unchanged even after controlling for these factors. So there's a correlation here, but it's not clear if it's a direct risk factor. Then document [23040035:2304", "citations": [{"doc_id": "23040035", "chunk_id": "23040035_1"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the association between neuroticism and Alzheimer's disease risk. First, I need to look at the evidence provided. There are three documents here. Let me check each one. The first document says that neuroticism (r = 0.26) is associated with advanced stages of neurofibrillary tangles. But it also mentions that the associations between personality traits and clinical dementia risk weren't changed when controlling for those tangles and plaques. So, there's a correlation, but maybe not a direct cause. The second document has an odds ratio for neuroticism (2.0) indicating higher scores are linked to less likelihood of remaining asymptomatic with AD neuropathology. That seems like a", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the association between neuroticism and Alzheimer's disease risk. First, I need to look at the evidence provided. There are three documents here. Let me check each one. Document 23040035: The first chunk says that neuroticism (r = 0.26) is associated with advanced stages of neurofibrillary tangles. But when controlling for those factors, the association between personality traits and clinical dementia risk didn't change much. So there's a correlation here, but it's not clear if it's a direct risk factor. The second chunk from the same document mentions that higher neuroticism (odds ratio 2.0) is linked to less likelihood", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the association between neuroticism and Alzheimer's disease risk. I need to look at the evidence provided. First, looking at the evidence documents. Document 23040035 has two chunks. The first chunk says that neuroticism (r=0.26) is associated with advanced stages of neurofibrillary tangles. But then it mentions that the associations between personality traits and clinical dementia risk weren't changed when controlling for those tangles and plaques. So maybe neuroticism is linked to earlier stages but not necessarily the risk of developing Alzheimer's? The second chunk from the same document talks about higher neuroticism scores (odds ratio 2.0) being associated", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about neuroticism and Alzheimer's risk. The user wants a JSON answer with the answer and base confidence. First, I need to look at the evidence provided. There are three documents here. Let me parse each one. The first document (23040035:23040035_1) mentions that neuroticism has a correlation of 0.26 with advanced stages of neurofibrillary tangles. However, the associations between personality traits and clinical dementia risk didn't change much even after controlling for those tangles and plaques. So this suggests some link but maybe not strong enough to say it's a significant risk factor. The second document (2304003", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the association between neuroticism and Alzheimer's disease risk. First, I need to look at the evidence provided. There are three documents here. Let me check each one. Document 23040035: The first chunk says that neuroticism has a correlation of 0.26 with advanced stages of neurofibrillary tangles. But when controlling for those factors, the association between personality traits and clinical dementia risk remains mostly unchanged. So there's a link here, but it's not clear if it's direct or mediated by other factors. The second chunk from the same document mentions that higher neuroticism (odds ratio 2.0) is associated with less likelihood of", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the association between neuroticism and Alzheimer's disease risk. First, I need to look at the evidence provided. There are three documents here. Let me check each one. Document 23040035: This mentions that neuroticism (r = 0.26) is associated with advanced stages of neurofibrillary tangles. However, when controlling for those factors and Aβ plaques, the association between personality traits and clinical dementia risk remains mostly unchanged. So there's a correlation here, but it's not clear if it's a direct risk factor once other factors are considered. Document 23040035 again (same ID) talks about higher neuro", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the association between neuroticism and Alzheimer's disease risk. First, I need to look at the evidence provided. There are three documents mentioned. Let me check each one. Looking at document [23040035:23040035_1], it says that neuroticism (r = 0.26) is associated with advanced stages of neurofibrillary tangles. However, the associations between personality traits and clinical dementia risk remained mostly unchanged even after controlling for these factors. So there's a correlation here, but it's not clear if it's a direct risk factor. Then document [23040035:2304", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user wants to know the association between neuroticism and Alzheimer's disease risk. Looking at the evidence provided, there are a few documents to consider. First, document [23040035:23040035_1] mentions that neuroticism (r = 0.26) is associated with advanced stages of neurofibrillary tangles. However, the associations between personality traits and clinical dementia risk remained mostly unchanged even after controlling for these factors. So, there's a correlation here, but it's not clear if it's a direct risk factor. Then, document [23040035:23040035_0] states", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["10679843", "10718200", "12767492", "15358438", "16252381", "16314587", "16974109", "17244848", "18079420", "18590355", "18694539", "19153372", "20438208", "20973606", "21427641", "21835104", "21905097", "22040898", "23040035", "23079898", "23567438", "23706517", "25274849", "7493597", "9924832"], "ideal_answer": "High neuroticism is associated with increased risk to develop Alzheimer's disease. Greater neuroticism is also associated more advanced Alzheimer's disease neuropathology and younger age of dementia onset. Neuroticism's association with late-life dementia mainly reflects vulnerability to stress and anxiety. Neuroticism moderates the relationship between APOE-4 genotype and cognitive outcomes in elderly. Neuroticism also predicts Mild Cognitive Impairment, Aging-Associated Cognitive Decline and cognitive decline among elderly. Alzheimer's disease patients have greater neuroticism relative to controls."}
{"question_id": "52f125332059c6d71c000007", "question": "What is the mode of action of everolimus?", "retrieved_chunks": [{"doc_id": "16625599", "chunk_id": "16625599_0", "score": 4.762641906738281, "text": "Target of rapamycin inhibitors (TOR-I) (sirolimus, everolimus) are immunosuppressive agents with a novel mode of action"}, {"doc_id": "21279702", "chunk_id": "21279702_0", "score": 4.04683780670166, "text": "Although the mTOR inhibitor everolimus is effective for the treatment of patients who have failed TKI therapy, it is important to consider all available treatment options before switching therapy mode of action."}, {"doc_id": "22136276", "chunk_id": "22136276_1", "score": 1.8632574081420898, "text": "Everolimus is an orally administered inhibitor of the mammalian target of rapamycin (mTOR). Everolimus (starting dosage 3.0 mg/m(2)) was associated with a significant reduction in the volume of the largest subependymal giant cell astrocytoma (SEGA) in 28 patients aged ≥3 years with tuberous sclerosis complex (TSC) in a phase II trial (C2485)."}], "context": "[16625599:16625599_0] Target of rapamycin inhibitors (TOR-I) (sirolimus, everolimus) are immunosuppressive agents with a novel mode of action\n[21279702:21279702_0] Although the mTOR inhibitor everolimus is effective for the treatment of patients who have failed TKI therapy, it is important to consider all available treatment options before switching therapy mode of action.\n[22136276:22136276_1] Everolimus is an orally administered inhibitor of the mammalian target of rapamycin (mTOR). Everolimus (starting dosage 3.0 mg/m(2)) was associated with a significant reduction in the volume of the largest subependymal giant cell astrocytoma (SEGA) in 28 patients aged ≥3 years with tuberous sclerosis complex (TSC) in a phase II trial (C2485).", "answer": "<think> Okay, let's tackle this question about the mode of action of everolimus. The user wants a biomedical answer from the provided evidence, in strict JSON format. First, I need to look at the evidence given. There are three references here. Let me go through each one. The first one says that everolimus is a TOR-I (Target of Rapamycin inhibitor) and that it's an immunosuppressive agent with a novel mode of action. So that's a direct statement about its mechanism. The second reference mentions that everolimus is an mTOR inhibitor, which is similar to the first. The third one also states that everolimus inhibits mTOR and gives a specific example of its use in a trial. Now, the question is specifically about", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question about the mode of action of everolimus. The user wants a biomedical answer from the provided evidence, in strict JSON format. First, I need to look at the evidence given. There are three references here. Let me go through each one. The first one says that everolimus is a TOR-I (Target of Rapamycin inhibitor) and that it's an immunosuppressive agent with a novel mode of action. So that's a direct statement about its mechanism. The second reference mentions that everolimus is an mTOR inhibitor, which is similar to the first. The third one also states that everolimus inhibits mTOR and gives a specific example of its use in a trial. Now, the question is specifically about", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to figure out the mode of action of everolimus based on the provided evidence. Let's look at the three references given. The first one says that everolimus is a TOR-I, which stands for Target of Rapamycin inhibitors. It mentions that they have a novel mode of action as immunosuppressive agents. So that's a key point. The second reference talks about everolimus being an mTOR inhibitor and its effectiveness in treating patients who haven't responded to TKI therapy. It also mentions considering other treatments before switching, but the main point here is again the mTOR inhibition. The third evidence states that everolimus is an orally administered inhibitor of mTOR. It also references a phase II trial where it reduced SEGA volume in", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about the mode of action of everolimus. The user wants a biomedical answer from the provided evidence, in strict JSON format. First, I need to understand what the question is asking. The mode of action refers to how the drug works at a molecular or biochemical level. Looking at the evidence, there are three references. Let me go through each one. The first reference says that everolimus is a TOR-I (Target of Rapamycin inhibitor) and that it's an immunosuppressive agent with a novel mode of action. So that's a key point. The second mentions that it's an mTOR inhibitor, which is the same as TOR. The third states that everolimus inhibits the mammalian target of rapam", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so I need to figure out the mode of action of everolimus based on the given evidence. Let me look at the evidence provided. The first piece of evidence says that everolimus is a Target of Rapamycin inhibitor (TOR-I) and that it's an immunosuppressive agent with a novel mode of action. The second one mentions that it's an mTOR inhibitor, which is part of the TOR pathway. The third evidence states that everolimus inhibits the mammalian target of rapamycin (mTOR) and talks about its use in a trial for TSC. So putting this together, the key point here is that everolimus inhibits mTOR. The first and third documents both mention this. The second document refers to it", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to figure out the mode of action of everolimus based on the provided evidence. Let's look at the evidence snippets. The first one says that everolimus is a Target of Rapamycin inhibitor (TOR-I) and that it's an immunosuppressive agent with a novel mode of action. So that's a direct statement about its mechanism. The second snippet mentions that it's an mTOR inhibitor, which is part of the TOR pathway. The third evidence states that everolimus inhibits the mammalian target of rapamycin (mTOR) and talks about a phase II trial where it reduced SEGA volume in TSC patients. Putting this together, the key point is that everolimus inhibits mTOR. The first and third", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about the mode of action of everolimus. The user wants a biomedical answer from the provided evidence. First, I need to look at the evidence given. There are three references here. Let me go through each one. The first one says that everolimus is a TOR-I (Target of Rapamycin inhibitor) and that it's an immunosuppressive agent with a novel mode of action. So that's a direct statement about its mechanism. The second reference mentions that everolimus is an mTOR inhibitor, which is similar to the first. The third one also states that everolimus inhibits mTOR and gives a specific example of its use in a trial. Now, the question is specifically about the mode of action.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so I need to figure out the mode of action of everolimus based on the given evidence. Let me start by looking at the evidence provided. The first piece of evidence says that everolimus is a Target of Rapamycin inhibitor (TOR-I) and that it's an immunosuppressive agent with a novel mode of action. The second mention refers to it as an mTOR inhibitor, which is part of the TOR pathway. The third evidence states that everolimus inhibits the mammalian target of rapamycin (mTOR) and mentions a phase II trial where it reduced SEGA volume in TSC patients. So putting this together, the key point here is that everolimus inhibits mTOR. The first document directly states that, and", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about the mode of action of everolimus. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three references here. Let me go through each one. The first one says that everolimus is a TOR-I (target of rapamycin inhibitor) and has a novel mode of action. That's a direct statement about its mechanism. The second reference mentions it's an mTOR inhibitor but doesn't specify the exact mechanism. The third one also states it's an inhibitor of mTOR, and gives some context about its use in TSC. So combining these, the main point is that everolimus inhibits mTOR. The first and third documents both mention", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["16625599", "16699448", "17890266", "18025810", "19299048", "19620795", "20384580", "21279702", "22139982", "24183081"], "ideal_answer": "Everolimus is a drug that binds to mTORC1 and inhibits activation of the mTOR signalling pathway. It is used in targeted cancer therapy protocols or after transplantation for maintenance immunosuppression, against allograft rejection."}
{"question_id": "5158a5b8d24251bc05000097", "question": "Have Quantitative Trait Loci affecting splicing (splicing QTLs) been linked to disease?", "retrieved_chunks": [{"doc_id": "24586654", "chunk_id": "24586654_0", "score": 3.467390537261963, "text": "Quantitative trait locus (QTL) analysis identified seven genomic loci influencing fibrosis phenotypes (pQTLs) with genome-wide significance on chromosomes 4, 5, 7, 12, and 17."}, {"doc_id": "18464913", "chunk_id": "18464913_1", "score": 2.7305212020874023, "text": "The identification of protein quantitative trait loci (pQTLs) may be a powerful complementary method of improving our understanding of disease pathways."}, {"doc_id": "25480033", "chunk_id": "25480033_0", "score": -0.12967151403427124, "text": "By studying the genetic variation affecting gene expression levels (cis expression quantitative trait loci [cis-eQTLs]) and protein levels (cis protein QTLs [cis-pQTLs]), we determined that young, primate-specific genes are enriched in cis-eQTLs and cis-pQTLs."}], "context": "[24586654:24586654_0] Quantitative trait locus (QTL) analysis identified seven genomic loci influencing fibrosis phenotypes (pQTLs) with genome-wide significance on chromosomes 4, 5, 7, 12, and 17.\n[18464913:18464913_1] The identification of protein quantitative trait loci (pQTLs) may be a powerful complementary method of improving our understanding of disease pathways.\n[25480033:25480033_0] By studying the genetic variation affecting gene expression levels (cis expression quantitative trait loci [cis-eQTLs]) and protein levels (cis protein QTLs [cis-pQTLs]), we determined that young, primate-specific genes are enriched in cis-eQTLs and cis-pQTLs.", "answer": "<think> Okay, let's tackle this question. The user is asking if Quantitative Trait Loci affecting splicing (splicing QTLs) have been linked to disease. The evidence provided includes three studies. First, I need to check each of the evidence chunks to see if they mention splicing QTLs or their link to disease. Looking at the first evidence: [24586654:24586654_0] talks about QTLs influencing fibrosis phenotypes, but it's about pQTLs (protein QTLs) and mentions chromosomes 4,5,7,12,17. However, this is about fibrosis, not splicing specifically. Also, the term \"splicing", "citations": [{"doc_id": "24586654", "chunk_id": "24586654_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if Quantitative Trait Loci affecting splicing (splicing QTLs) have been linked to disease. The evidence provided includes three references. First, I need to check each of the evidence chunks to see if they mention splicing QTLs or link them to diseases. Looking at the first reference: it talks about QTL analysis finding seven loci influencing fibrosis phenotypes, but these are pQTLs on specific chromosomes. However, there's no mention of splicing here. So this might not directly answer the question. The second reference mentions protein QTLs (pQTLs) as a method to understand disease pathways. While it's about pQTLs, the connection to sp", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if Quantitative Trait Loci affecting splicing (splicing QTLs) have been linked to disease. The evidence provided includes three studies. First, I need to check each of the evidence chunks to see if they mention splicing QTLs or their link to disease. Looking at the first evidence: [24586654:24586654_0] talks about QTLs influencing fibrosis phenotypes, but it's about pQTLs (protein QTLs) and mentions chromosomes 4,5,7,12,17. However, this is about fibrosis, not splicing specifically. Also, the term \"splicing", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let me try to work through this. The user is asking if Quantitative Trait Loci affecting splicing, called splicing QTLs, have been linked to disease. The evidence provided includes three references. First, I need to check each of the evidence points. The first one talks about pQTLs (protein QTLs) being a complementary method to understand disease pathways. The second mentions cis-eQTLs and cis-pQTLs related to gene expression and protein levels, with young primate-specific genes enriched in these. The third reference is about fibrosis phenotypes linked to pQTLs on specific chromosomes. Wait, the question is specifically about splicing QTLs. But the evidence here mentions pQTLs (protein QTL", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if Quantitative Trait Loci affecting splicing (splicing QTLs) have been linked to disease. The evidence provided includes three studies. First, I need to check each document to see if they mention splicing QTLs or their link to disease. Looking at the first evidence: [24586654:24586654_0] talks about QTLs influencing fibrosis phenotypes on specific chromosomes. But it's about fibrosis, not splicing specifically. Also, this is a pQTL (protein QTL), but the question is about splicing QTLs. So maybe not directly relevant. Second evidence: [1846", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if Quantitative Trait Loci affecting splicing (splicing QTLs) have been linked to disease. The evidence provided includes three different studies. First, I need to check each of the evidence points. The first one mentions pQTLs linked to fibrosis phenotypes, but that's about fibrosis, not splicing. The second study talks about pQTLs as a method to understand disease pathways, which is relevant but doesn't specifically mention splicing. The third study discusses cis-eQTLs and cis-pQTLs related to gene expression and protein levels, but again, not splicing. Wait, the question is about splicing QTLs. The evidence given doesn't mention sp", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let me tackle this question. The user is asking if Quantitative Trait Loci affecting splicing (splicing QTLs) have been linked to disease. The evidence provided includes three studies. First, I need to check each document for mentions of splicing QTLs or their link to disease. Looking at the first evidence: [24586654:24586654_0] talks about pQTLs linked to fibrosis phenotypes on specific chromosomes. But it's about fibrosis, not directly splicing. However, pQTLs might relate to protein levels, which could be part of splicing mechanisms. But the term \"splicing QTLs\" isn't mentioned here. The second", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if Quantitative Trait Loci affecting splicing, known as splicing QTLs, have been linked to disease. The evidence provided includes three references. First, I need to check each of the evidence points. The first one mentions pQTLs (protein QTLs) related to fibrosis phenotypes, but it's about fibrosis, not directly splicing. The second reference talks about pQTLs as a method to understand disease pathways, which is somewhat related but not specific to splicing. The third evidence discusses cis-eQTLs and cis-pQTLs in young primate genes, but again, not specifically splicing QTLs. Wait, the question is about splicing Q", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking if Quantitative Trait Loci affecting splicing (splicing QTLs) have been linked to disease. Let me look at the evidence provided. First, the evidence has three chunks. The first one mentions QTL analysis finding seven loci influencing fibrosis phenotypes, but they're pQTLs related to genome-wide significant chromosomes. The second chunk talks about pQTLs being a method to understand disease pathways. The third chunk discusses cis-eQTLs and cis-pQTLs linked to young primate-specific genes. Wait, the question is specifically about splicing QTLs. But the evidence doesn't mention splicing directly. The chunks talk about pQTLs (protein QTLs), eQTLs", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["20707912", "20856809", "21846806", "22784570"], "ideal_answer": "Yes, mutations in the DNA that affect the splicing pattern of genes have been linked in transcriptome population studies to a number of diseases."}
{"question_id": "553653a5bc4f83e828000007", "question": "Which technique is used for detection of EWS/FLI1 fusion transcripts?", "retrieved_chunks": [{"doc_id": "16157025", "chunk_id": "16157025_0", "score": 8.568425178527832, "text": "Molecular detection of EWS-Fli1 fusion transcripts in formalin-fixed paraffin-embedded material by nested RT-PCR is feasible and is useful for the diagnosis and differential diagnosis of ES/pPNETs."}, {"doc_id": "15565546", "chunk_id": "15565546_0", "score": 7.7695841789245605, "text": "Using our different sets of exon specific primer pairs, it was possible to detect 4 different breakpoints of ews/fli1 fusion transcripts and the ews/erg fusion by RT-PCR in RNA isolates from formalin-fixed, paraffin-embedded Ewing's tumor tissue."}, {"doc_id": "15363317", "chunk_id": "15363317_0", "score": 7.717473983764648, "text": "[Detection of EWS-FLI1 fusion transcript in Ewing's sarcoma/peripheral primitive neuroectodermal tumors by one-step RT-PCR using paraffin-embedded tissues]."}], "context": "[16157025:16157025_0] Molecular detection of EWS-Fli1 fusion transcripts in formalin-fixed paraffin-embedded material by nested RT-PCR is feasible and is useful for the diagnosis and differential diagnosis of ES/pPNETs.\n[15565546:15565546_0] Using our different sets of exon specific primer pairs, it was possible to detect 4 different breakpoints of ews/fli1 fusion transcripts and the ews/erg fusion by RT-PCR in RNA isolates from formalin-fixed, paraffin-embedded Ewing's tumor tissue.\n[15363317:15363317_0] [Detection of EWS-FLI1 fusion transcript in Ewing's sarcoma/peripheral primitive neuroectodermal tumors by one-step RT-PCR using paraffin-embedded tissues].", "answer": "<think> Okay, let's tackle this question. The user is asking which technique is used for detecting EWS/FLI1 fusion transcripts. The evidence provided has three documents. First, I need to look at each of the three pieces of evidence. The first document says that nested RT-PCR is used for detecting EWS-Fli1 fusion transcripts in formalin-fixed paraffin-embedded material. It mentions that this technique is feasible and useful for diagnosis. So that's one method: nested RT-PCR. The second document talks about using different exon-specific primer pairs to detect 4 breakpoints of EWS/FLI1 fusion transcripts and others via RT-PCR. Here, RT-PCR is mentioned again, but with specific primers. However, the key point here is", "citations": [], "candidates": [{"answer": "<think> Okay, let me try to work through this. The user is asking which technique is used for detecting EWS/FLI1 fusion transcripts. The evidence provided has three documents. First, document 16157025:16157025_0 mentions nested RT-PCR for detecting EWS-Fli1 fusion transcripts in formalin-fixed paraffin-embedded material. That's one technique. Then, document 15565546:15565546_0 talks about using different exon-specific primer pairs to detect 4 breakpoints of EWS/FLI1 and EWS/ERG fusion transcripts via RT-PCR. So here, they also use RT-PCR, but with", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to figure out which technique is used for detecting EWS/FLI1 fusion transcripts based on the provided evidence. Let me look at the evidence again. The first piece of evidence says that nested RT-PCR is used for detecting EWS-Fli1 fusion transcripts in formalin-fixed paraffin-embedded material. It mentions that this method is feasible and useful for diagnosis. The second evidence talks about using different exon-specific primer pairs to detect 4 breakpoints of EWS/FLI1 fusion transcripts and others via RT-PCR in RNA from paraffin-embedded tissue. The third evidence states that one-step RT-PCR using paraffin-embedded tissues detects EWS-FLI1 fusion transcripts. So, the techniques mentioned are nested RT-PCR", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which technique is used for detecting EWS/FLI1 fusion transcripts. The evidence provided has three documents. First, I need to look at each document to see what technique they mention. Document 16157025: It says molecular detection using nested RT-PCR in formalin-fixed paraffin-embedded material is feasible and useful for diagnosis. So that's nested RT-PCR. Document 15565546: They used different exon-specific primer pairs to detect 4 breakpoints and the EWS/ERG fusion with RT-PCR. So here, it's RT-PCR, but they mention using specific primers. However, the question is about EWS", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking which technique is used for detecting EWS/FLI1 fusion transcripts. Let me look at the evidence provided. First, evidence document 16157025 mentions nested RT-PCR for detecting EWS-Fli1 fusion transcripts in paraffin-embedded tissues. That's a technique called nested RT-PCR. Then, another document 15565546 talks about using specific primer pairs with RT-PCR to detect the fusion transcripts, also in formalin-fixed paraffin-embedded tissue. The third document 15363317 mentions one-step RT-PCR using paraffin-embedded tissues. So all three sources mention RT-PCR techniques. But the first one specifies", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let me try to work through this. The question is asking which technique is used for detecting EWS/FLI1 fusion transcripts. The evidence provided has three references. Looking at the first piece of evidence: It mentions nested RT-PCR as a method for detecting EWS-Fli1 fusion transcripts in formalin-fixed paraffin-embedded material. That's a specific technique. The second evidence talks about using different primer pairs and RT-PCR to detect various breakpoints, including EWS/FLI1. The third one refers to one-step RT-PCR with paraffin-embedded tissues. So the answer needs to be a technique. The terms used are nested RT-PCR, RT-PCR, and one-step RT-PCR. The question is about which technique", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking which technique is used for detecting EWS/FLI1 fusion transcripts. Let me look at the evidence provided. First, the evidence has three chunks. The first one mentions nested RT-PCR for detecting EWS-Fli1 in formalin-fixed paraffin-embedded material. The second chunk talks about using different primer pairs to detect 4 breakpoints of EWS/FLI1 and EWS/ERG fusion transcripts via RT-PCR in RNA from paraffin-embedded tissue. The third chunk refers to one-step RT-PCR using paraffin-embedded tissues for detecting EWS-FLI1. So, the answer needs to be a technique. The first chunk says nested RT-PCR, the second mentions RT-PCR,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which technique is used for detecting EWS/FLI1 fusion transcripts. The evidence provided has three documents. First, I need to look at each of the three pieces of evidence. The first document says that nested RT-PCR is used for detecting EWS-Fli1 fusion transcripts in formalin-fixed paraffin-embedded material. It mentions that this technique is feasible and useful for diagnosis. So that's one method: nested RT-PCR. The second document talks about using different exon-specific primer pairs to detect 4 breakpoints of EWS/FLI1 fusion transcripts and others via RT-PCR. Here, RT-PCR is mentioned again, but with specific primers. However, the key point here is", "base_prob": 0.5, "critic": {"rel_label": "Rel", "rel_prob": 0.95, "sup_label": "Fully", "sup_prob": 1.0, "use_score": 4, "use_prob": 0.98, "notes": "All three evidence snippets directly mention RT-PCR techniques for detecting EWS/FLI1 fusion transcripts, with specific methods like nested RT-PCR and one-step RT-PCR. The candidate answer correctly identifies RT-PCR as the technique, supported by multiple evidence sources."}, "score": 6.4159999999999995, "safe": true, "has_citation": 0}, {"answer": "<think> Okay, the user is asking which technique is used for detecting EWS/FLI1 fusion transcripts. Let me look at the evidence provided. The first evidence snippet mentions nested RT-PCR for detecting EWS-Fli1 fusion transcripts in formalin-fixed paraffin-embedded materials. That's a technique called nested RT-PCR. The second snippet talks about using exon-specific primer pairs with RT-PCR to detect breakpoints and other fusions, also mentioning RT-PCR. The third one refers to one-step RT-PCR using paraffin-embedded tissues. So the answer needs to be a concise statement citing the documents. The key here is that multiple sources mention RT-PCR techniques, specifically nested RT-PCR and one-step RT-PCR. However, the question asks", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 6.4159999999999995, "gold_docs": ["10379685", "15363317", "15565546", "16157025", "17154184", "20231617", "23475435", "24293381", "9135495", "9552022"], "ideal_answer": "Molecular detection of EWS-FLI1 chimeric transcripts in Ewing family tumors is carried out by reverse transcription-polymerase chain reaction (RT-PCR)."}
{"question_id": "5344310baeec6fbd0700000c", "question": "Does the CTCF protein co-localize with cohesin?", "retrieved_chunks": [{"doc_id": "22952237", "chunk_id": "22952237_0", "score": 8.85129451751709, "text": "Recent genome-wide studies mapping the binding sites of CTCF and its interacting partner, cohesin, using chromatin immunoprecipitation coupled with deep sequencing (ChIP-seq) revealded that CTCF globally co-localizes with cohesin"}, {"doc_id": "28368372", "chunk_id": "28368372_2", "score": 7.01765251159668, "text": "Using an in vivo biotinylation tagging approach in mice, we show that the nucleotide excision repair (NER) structure-specific endonuclease ERCC1-XPF complex interacts with the insulator binding protein CTCF, the cohesin subunits SMC1A and SMC3 and with MBD2; the factors co-localize with ATRX at the promoters and control regions (ICRs) of imprinted genes during postnatal hepatic development. Loss of Ercc1 or exposure to MMC triggers the localization of CTCF to heterochromatin, the dissociation of the CTCF-cohesin complex and ATRX from promoters and ICRs, altered histone marks and the aberrant developmental expression of imprinted genes without altering DNA methylation. We propose that ERCC1-XPF cooperates with CTCF and cohesin to facilitate the developmental silencing of imprinted genes and that persistent DNA damage triggers chromatin changes that affect gene expression programs associated with NER disorders."}, {"doc_id": "21550623", "chunk_id": "21550623_0", "score": 6.858308792114258, "text": "CTCF colocalizes with cohesin but not RNA Polymerase II."}], "context": "[22952237:22952237_0] Recent genome-wide studies mapping the binding sites of CTCF and its interacting partner, cohesin, using chromatin immunoprecipitation coupled with deep sequencing (ChIP-seq) revealded that CTCF globally co-localizes with cohesin\n[28368372:28368372_2] Using an in vivo biotinylation tagging approach in mice, we show that the nucleotide excision repair (NER) structure-specific endonuclease ERCC1-XPF complex interacts with the insulator binding protein CTCF, the cohesin subunits SMC1A and SMC3 and with MBD2; the factors co-localize with ATRX at the promoters and control regions (ICRs) of imprinted genes during postnatal hepatic development. Loss of Ercc1 or exposure to MMC triggers the localization of CTCF to heterochromatin, the dissociation of the CTCF-cohesin complex and ATRX from promoters and ICRs, altered histone marks and the aberrant developmental expression of imprinted genes without altering DNA methylation. We propose that ERCC1-XPF cooperates with CTCF and cohesin to facilitate the developmental silencing of imprinted genes and that persistent DNA damage triggers chromatin changes that affect gene expression programs associated with NER disorders.\n[21550623:21550623_0] CTCF colocalizes with cohesin but not RNA Polymerase II.", "answer": "<think> Okay, let's tackle this question. The user is asking if the CTCF protein co-localizes with cohesin. I need to look at the provided evidence to find supporting information. First, looking at the evidence, there are three references. The first one [22952237:22952237_0] says that genome-wide studies using ChIP-seq showed CTCF co-localizes with cohesin. That's a direct answer. Then there's [21550623:21550623_0], which states that CTCF colocalizes with cohesin but not RNA Polymerase II. This also supports the answer. The third reference [", "citations": [{"doc_id": "22952237", "chunk_id": "22952237_0"}, {"doc_id": "21550623", "chunk_id": "21550623_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if the CTCF protein co-localizes with cohesin. I need to look at the provided evidence to find supporting information. First, looking at the evidence, there are three references. The first one [22952237:22952237_0] says that genome-wide studies using ChIP-seq showed CTCF co-localizes with cohesin. That's a direct answer. Then there's [21550623:21550623_0], which states that CTCF colocalizes with cohesin but not RNA Polymerase II. This also supports the answer. The third reference [", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the CTCF protein co-localizes with cohesin. I need to look at the provided evidence to find the answer. First, looking at the evidence documents. The first one, 22952237:22952237_0, says that genome-wide studies using ChIP-seq showed CTCF globally co-localizes with cohesin. That's a direct statement. Then there's another document, 21550623:21550623_0, which also states that CTCF colocalizes with cohesin but not RNA Polymerase II. So both of these documents support the answer", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the CTCF protein co-localizes with cohesin. I need to check the provided evidence to find the answer. Looking at the first evidence snippet [22952237:22952237_0], it says that genome-wide studies using ChIP-seq showed CTCF globally co-localizes with cohesin. That's a direct statement confirming their co-localization. Then there's another snippet [21550623:21550623_0] which also states that CTCF colocalizes with cohesin but not RNA Polymerase II. This reinforces the first point. The third", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking whether the CTCF protein co-localizes with cohesin. I need to look at the provided evidence to find the answer. First, looking at the evidence, there are three references. Let me check each one. The first reference [22952237:22952237_0] says that genome-wide studies using ChIP-seq showed that CTCF globally co-localizes with cohesin. That's a direct answer to the question. The confidence here is high because it's a study using a specific technique. The second reference [28368372:28368372_2] talks about interactions", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the CTCF protein co-localizes with cohesin. I need to look at the provided evidence to find the answer. First, looking at the evidence, there are three references. The first one, 22952237:22952237_0, says that genome-wide studies using ChIP-seq showed that CTCF globally co-localizes with cohesin. That directly answers the question with a yes. The second reference, 28368372:28368372_2, mentions that CTCF and cohesin subunits co-localize with ATRX at certain regions. But", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let me tackle this question. The user is asking if the CTCF protein co-localizes with cohesin. I need to look at the evidence provided. First, looking at the evidence documents. The first one, 22952237:22952237_0, says that genome-wide studies using ChIP-seq showed CTCF globally co-localizes with cohesin. That's a direct answer. Then there's 28368372:28368372_2, which mentions that CTCF and cohesin subunits co-localize with ATRX at certain regions. But this is in the context of imprinted genes during development", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the CTCF protein co-localizes with cohesin. I need to look at the provided evidence to find the answer. First, looking at the evidence snippets. The first one, [22952237:22952237_0], says that genome-wide studies using ChIP-seq showed CTCF globally co-localizes with cohesin. That's a direct answer. Then there's [21550623:21550623_0] which also states that CTCF colocalizes with cohesin but not RNA Polymerase II. So this confirms the first point again. The third", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the CTCF protein co-localizes with cohesin. I need to look at the provided evidence to find the answer. First, evidence document [22952237:22952237_0] says that genome-wide studies using ChIP-seq showed CTCF globally co-localizes with cohesin. That's a direct statement. Then there's [21550623:21550623_0], which also states that CTCF colocalizes with cohesin but not RNA Polymerase II. So both of these documents support the answer. The third document, [2836", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["18550811", "18623068", "19109133", "19158269", "19308701", "19369356", "20133600", "20219941", "21106760", "21444719", "21606361", "21628529", "21876668", "21880767", "21948239", "21970734", "22440186", "22550178", "22780989", "22952237", "23010778", "23204437", "23295672", "23498937", "23804403", "23945083", "24257606", "24321385"], "ideal_answer": "Recent genome-wide studies mapping the binding sites of CTCF and its interacting partner, cohesin, using chromatin immunoprecipitation coupled with deep sequencing (ChIP-seq) revealded that CTCF globally co-localizes with cohesin. Recent genome-wide studies mapping the binding sites of CTCF and its interacting partner, cohesin, using chromatin immunoprecipitation coupled with deep sequencing (ChIP-seq) revealded that CTCF globally co-localizes with cohesin"}
{"question_id": "56c868a95795f9a73e000017", "question": "What is the application of the Bimolecular Fluorescence Complementation (BiFC) assay in Drosophila embryos?", "retrieved_chunks": [{"doc_id": "25151172", "chunk_id": "25151172_0", "score": 8.351340293884277, "text": "Bimolecular fluorescence complementation (BiFC) is a powerful method for studying protein-protein interactions in different cell types and organisms. This method was recently developed in the fruit fly Drosophila melanogaster, allowing analyzing protein interaction properties in a physiologically relevant developing context. Here we present a detailed protocol for performing BiFC with the Venus fluorescent protein in live Drosophila embryos, taking the Hox-PBC partnership as an illustrative test case. This protocol applies to any transcription factor and split fluorescent protein in general."}, {"doc_id": "21276241", "chunk_id": "21276241_3", "score": 8.002887725830078, "text": "The bimolecular fluorescence complementation (BiFC) technology offers this possibility as it enables the direct visualization of protein interactions in living cells. However, its potential has rarely been applied in embryos of animal model organisms and was only performed under transient protein expression levels."}, {"doc_id": "19771334", "chunk_id": "19771334_0", "score": 7.822848320007324, "text": "The bimolecular fluorescence complementation (BiFC) assay provides an approach for the visualization of protein interactions and modifications in living cells."}], "context": "[25151172:25151172_0] Bimolecular fluorescence complementation (BiFC) is a powerful method for studying protein-protein interactions in different cell types and organisms. This method was recently developed in the fruit fly Drosophila melanogaster, allowing analyzing protein interaction properties in a physiologically relevant developing context. Here we present a detailed protocol for performing BiFC with the Venus fluorescent protein in live Drosophila embryos, taking the Hox-PBC partnership as an illustrative test case. This protocol applies to any transcription factor and split fluorescent protein in general.\n[21276241:21276241_3] The bimolecular fluorescence complementation (BiFC) technology offers this possibility as it enables the direct visualization of protein interactions in living cells. However, its potential has rarely been applied in embryos of animal model organisms and was only performed under transient protein expression levels.\n[19771334:19771334_0] The bimolecular fluorescence complementation (BiFC) assay provides an approach for the visualization of protein interactions and modifications in living cells.", "answer": "<think> Okay, I need to generate a biomedical answer using the provided evidence about the application of BiFC in Drosophila embryos. Let me start by understanding the question. The user is asking specifically about the application of BiFC in Drosophila embryos. Looking at the evidence, there are three documents. Let me check each one for relevant information. First document: [25151172:25151172_0] mentions that BiFC was developed in Drosophila melanogaster to analyze protein interactions in a physiologically relevant context. It also says they presented a protocol using Venus fluorescent protein with Hox-PBC as an example, applicable to any transcription factor and split fluorescent protein. Second document: [21", "citations": [{"doc_id": "25151172", "chunk_id": "25151172_0"}], "candidates": [{"answer": "<think> Okay, I need to generate a candidate biomedical answer based on the provided evidence. Let me start by understanding the question: What is the application of the Bimolecular Fluorescence Complementation (BiFC) assay in Drosophila embryos? Looking at the evidence, there are three documents. The first one mentions that BiFC was developed in Drosophila melanogaster to analyze protein interactions in a physiologically relevant context, using Venus fluorescent protein in live embryos with Hox-PBC as an example. The second document says that BiFC allows visualization of protein interactions in living cells but has rarely been applied in animal embryos, only under transient expression. The third states that BiFC provides a method for visualizing protein interactions and modifications. So the main points are:", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know the application of the BiFC assay in Drosophila embryos. First, I need to look at the evidence provided. Looking at the first evidence snippet (25151172:25151172_0), it says that BiFC was developed in Drosophila melanogaster to analyze protein interactions in a developing context. They mention using Venus fluorescent protein in live embryos with Hox-PBC as an example. So this seems like a direct application. The second snippet (21276241:21276241_3) talks about BiFC enabling visualization of protein interactions but notes that its use in animal embryos is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a biomedical answer using the provided evidence about the application of BiFC in Drosophila embryos. Let me start by understanding the question. The user is asking specifically about the application of BiFC in Drosophila embryos. Looking at the evidence, there are three documents. Let me check each one for relevant information. First document: [25151172:25151172_0] mentions that BiFC was developed in Drosophila melanogaster to analyze protein interactions in a physiologically relevant context. It also says they presented a protocol using Venus fluorescent protein with Hox-PBC as an example, applicable to any transcription factor and split fluorescent protein. Second document: [21", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, so I need to figure out the application of the Bimolecular Fluorescence Complementation (BiFC) assay in Drosophila embryos based on the given evidence. Let's look at the evidence provided. First, the first document says that BiFC was developed in Drosophila melanogaster, allowing analysis of protein interactions in a physiologically relevant developing context. They mention using Venus fluorescent protein in live embryos with Hox-PBC as an example. That seems to directly answer the question about application in Drosophila embryos. The second document mentions that BiFC enables direct visualization of protein interactions in living cells but notes that its potential has been rarely applied in animal embryo models, only done under transient expression. So this suggests that while it's possible", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the application of BiFC in Drosophila embryos. First, I need to look at the provided evidence to find relevant information. Looking at the first evidence snippet (25151172:25151172_0), it mentions that BiFC was developed in Drosophila melanogaster to analyze protein interactions in a physiologically relevant context. It also says they present a protocol using Venus fluorescent protein in live embryos with Hox-PBC as an example. This seems directly related to the application in embryos. The second snippet (21276241:21276241_3) talks about BiFC enabling visualization", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer using the provided evidence. Let me start by understanding the question: What is the application of the Bimolecular Fluorescence Complementation (BiFC) assay in Drosophila embryos? Looking at the evidence, there are three documents. The first one [25151172:25151172_0] mentions that BiFC was developed in Drosophila melanogaster to analyze protein interactions in a physiologically relevant context, using Venus fluorescent protein in live embryos with Hox-PBC as an example. The second document [21276241:21276241_3] says that BiFC allows visualization of protein", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the application of BiFC in Drosophila embryos. I need to look at the provided evidence to find the answer. First, looking at the first evidence snippet (25151172:25151172_0), it mentions that BiFC was developed in Drosophila melanogaster to analyze protein interactions in a physiologically relevant context. It also says they present a protocol using Venus fluorescent protein in live embryos with Hox-PBC as an example. So this suggests that BiFC is used to study protein interactions in developing embryos. The second snippet (21276241:21276241_3)", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know the application of BiFC in Drosophila embryos. Looking at the evidence provided, there are three documents. First document (25151172) mentions that BiFC was developed in Drosophila melanogaster to analyze protein interactions in a developing context, using Venus fluorescent protein and Hox-PBC as an example. That's a direct application in embryos. Second document (21276241) says that BiFC enables visualization of protein interactions in living cells but notes it's rarely applied in animal embryos, only done with transient expression. So it's a potential application but maybe not widely used yet. Third document (19771334)", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["16454041", "17406412", "17534848", "18155474", "18573091", "19771334", "21091444", "21276241", "23317900", "25151172"], "ideal_answer": "Bimolecular fluorescence complementation (BiFC) is a powerful method for studying protein-protein interactions in different cell types and organisms. This method was recently developed in the fruit fly Drosophila melanogaster, allowing analyzing protein interaction properties in a physiologically relevant developing context."}
{"question_id": "54dcb29dc0bb8dce23000004", "question": "Which pathological condition of the heart is known as hypertrophic cardiomyopathy (HCM)?", "retrieved_chunks": [{"doc_id": "21507890", "chunk_id": "21507890_0", "score": 8.439990043640137, "text": "Hypertrophic cardiomyopathy (HCM) is a clinically heterogeneous autosomal dominant heart disease characterised by left ventricular hypertrophy in the absence of another cardiac or systemic disease that is capable of producing significant wall thickening."}, {"doc_id": "23782526", "chunk_id": "23782526_0", "score": 7.941522598266602, "text": "Hypertrophic cardiomyopathy (HCM) is a clinically heterogeneous genetic heart disease characterized by left ventricular hypertrophy in the absence of another disease that could explain the wall thickening."}, {"doc_id": "22665960", "chunk_id": "22665960_0", "score": 7.792171955108643, "text": "Hypertrophic cardiomyopathy (HCM) is an autosomal dominant inherited genetic disease characterized by compensatory pathological left ventricle (LV) hypertrophy due to sarcomere dysfunction."}], "context": "[21507890:21507890_0] Hypertrophic cardiomyopathy (HCM) is a clinically heterogeneous autosomal dominant heart disease characterised by left ventricular hypertrophy in the absence of another cardiac or systemic disease that is capable of producing significant wall thickening.\n[23782526:23782526_0] Hypertrophic cardiomyopathy (HCM) is a clinically heterogeneous genetic heart disease characterized by left ventricular hypertrophy in the absence of another disease that could explain the wall thickening.\n[22665960:22665960_0] Hypertrophic cardiomyopathy (HCM) is an autosomal dominant inherited genetic disease characterized by compensatory pathological left ventricle (LV) hypertrophy due to sarcomere dysfunction.", "answer": "<think> Okay, let's tackle this question. The user is asking which pathological condition of the heart is known as hypertrophic cardiomyopathy (HCM). The evidence provided has three chunks. First, I need to understand what each chunk says. The first chunk mentions HCM as an autosomal dominant heart disease with left ventricular hypertrophy and no other disease causing the thickening. The second chunk repeats similar info, emphasizing genetic aspect. The third chunk adds that it's an inherited disease due to sarcomere dysfunction. The question is straightforward: what is HCM? The answer should be that HCM is a condition characterized by left ventricular hypertrophy without another cause. All three chunks point to this. The confidence here is high because all sources agree on the definition. So the", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which pathological condition of the heart is known as hypertrophic cardiomyopathy (HCM). The evidence provided has three chunks. First, I need to understand what each chunk says. The first chunk mentions HCM as an autosomal dominant heart disease with left ventricular hypertrophy and no other disease causing the thickening. The second chunk repeats similar info, emphasizing genetic aspect. The third chunk adds that it's an inherited disease due to sarcomere dysfunction. The question is straightforward: what is HCM? The answer should be that HCM is a condition characterized by left ventricular hypertrophy without another cause. All three chunks point to this. The confidence here is high because all sources agree on the definition. So the", "base_prob": 0.5, "critic": {"rel_label": "Rel", "rel_prob": 1.0, "sup_label": "Fully", "sup_prob": 1.0, "use_score": 5, "use_prob": 1.0, "notes": "Candidate answer directly matches evidence definition of HCM as a genetic heart disease with left ventricular hypertrophy without other causes."}, "score": 6.5, "safe": true, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which pathological condition of the heart is known as hypertrophic cardiomyopathy (HCM). The evidence provided has three chunks. First, I need to understand what each chunk says. All three mention HCM as a genetic or autosomal dominant heart disease with left ventricular hypertrophy. The first two chunks both say it's characterized by left ventricular hypertrophy without another disease causing the thickening. The third one adds that it's an inherited genetic disease due to sarcomere dysfunction. So, the answer should be HCM itself, as per the evidence. All the sources define HCM as a condition with left ventricular hypertrophy and no other cause. The base confidence is high because all three chunks agree on the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking which pathological condition of the heart is known as hypertrophic cardiomyopathy (HCM). Let me look at the evidence provided. The first document says HCM is a clinically heterogeneous autosomal dominant heart disease with left ventricular hypertrophy and no other disease causing the thickening. The second one mentions it's a genetic heart disease with similar symptoms. The third one adds that it's an inherited genetic disease due to sarcomere dysfunction. All three sources agree that HCM is a genetic condition characterized by left ventricular hypertrophy without another cause. The key points are autosomal dominant, genetic, and left ventricular hypertrophy. The answer should be concise, citing the documents. The confidence level is high since all three sources consistently describe HCM", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which pathological condition of the heart is known as hypertrophic cardiomyopathy (HCM). The evidence provided has three chunks. First, I need to understand what each chunk says. The first chunk mentions HCM as an autosomal dominant heart disease with left ventricular hypertrophy and no other disease causing the thickening. The second chunk is similar but uses \"genetic\" instead of \"autosomal dominant.\" The third chunk refers to it as an inherited genetic disease with sarcomere dysfunction. So, all three chunks define HCM as a condition with left ventricular hypertrophy, but they differ slightly in terms of inheritance (autosomal dominant vs. inherited genetic) and the cause (sarcomere dysfunction). However,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which pathological condition of the heart is known as hypertrophic cardiomyopathy (HCM). The evidence provided has three chunks. First, I need to understand what each chunk says. The first one mentions HCM as an autosomal dominant heart disease with left ventricular hypertrophy and no other disease causing the thickening. The second chunk is similar, calling it a genetic heart disease with the same characteristics. The third chunk refers to it as an inherited genetic disease due to sarcomere dysfunction. The question is asking for the pathological condition, so I need to identify the correct term. All the chunks refer to HCM as the condition. But wait, the user is asking for the answer, which is HCM itself", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which pathological condition of the heart is known as hypertrophic cardiomyopathy (HCM). The evidence provided has three chunks. First, I need to understand what each chunk says. All three mention HCM as a genetic or autosomal dominant heart disease with left ventricular hypertrophy. The key points are that it's a genetic condition, characterized by LV hypertrophy without another disease causing the thickening. The answer should be concise and cite the documents. Looking at the chunks, they all point to HCM being a genetic disorder with left ventricular hypertrophy. The first two mention \"autosomal dominant heart disease,\" while the third says \"autosomal dominant inherited genetic disease.\" So the main thing is that it's", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking which pathological condition of the heart is known as hypertrophic cardiomyopathy (HCM). Let me look at the evidence provided. The first document says HCM is a clinically heterogeneous autosomal dominant heart disease with left ventricular hypertrophy and no other disease causing the thickening. The second one mentions it's a genetic heart disease with similar characteristics. The third one refers to it as an autosomal dominant inherited genetic disease due to sarcomere dysfunction. All three documents consistently define HCM as a condition characterized by left ventricular hypertrophy without another cause. The key points are that it's genetic, autosomal dominant, and involves left ventricular thickening without other diseases. The answer should be straightforward, pointing out that HCM is the condition", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking which pathological condition of the heart is known as hypertrophic cardiomyopathy (HCM). Let me look at the evidence provided. The first evidence snippet says HCM is a clinically heterogeneous autosomal dominant heart disease characterized by left ventricular hypertrophy without another disease causing thickening. The second one mentions it's a genetic heart disease with the same hallmark. The third one adds that it's an inherited genetic disease due to sarcomere dysfunction. All three sources agree that HCM is a genetic condition, specifically autosomal dominant, leading to left ventricular hypertrophy without other causes. The key here is that the answer should be the name of the condition itself, which is hypertrophic cardiomyopathy. But wait, the question is asking for the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 6.5, "gold_docs": ["21507890", "22665960", "23782526", "25044876", "25081404", "25191275", "25209314", "25228955", "25309450", "25328416"], "ideal_answer": "Hypertrophic cardiomyopathy (HCM) has been recently recognized as the most common inherited cardiovascular disorder, affecting 1 in 500 adults worldwide. HCM is characterized by myocyte hypertrophy resulting in thickening of the ventricular wall, myocyte disarray, interstitial and/or replacement fibrosis, decreased ventricular cavity volume and diastolic dysfunction. HCM is also the most common cause of sudden death in the young particularly among athletes. A large proportion of patients diagnosed with HCM have mutations in sarcomeric proteins. HCM is the most prevalent genetic disorder affecting the heart and is typically inherited in an autosomal dominant pattern. Adults with cardiomyopathy suffer SCD or adverse events such as stroke and heart failure from HCM."}
{"question_id": "516e5f41298dcd4e5100007f", "question": "What is the genetic basis of Rubinstein-Taybi syndrome?", "retrieved_chunks": [{"doc_id": "15706485", "chunk_id": "15706485_1", "score": 5.573284149169922, "text": "Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease"}, {"doc_id": "16359492", "chunk_id": "16359492_1", "score": 5.386285305023193, "text": "Mutations in the CREBBP (CREB-binding protein gene) cause Rubinstein-Taybi syndrome (RSTS)."}, {"doc_id": "20689175", "chunk_id": "20689175_1", "score": 4.817389965057373, "text": "Rubinstein-Taybi syndrome (RSTS), a developmental disorder comprising abnormalities that include mental retardation, an unusual facial appearance, broad thumbs and big toes is frequently associated with molecular lesions in the CREB-binding protein gene, CREBBP"}], "context": "[15706485:15706485_1] Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease\n[16359492:16359492_1] Mutations in the CREBBP (CREB-binding protein gene) cause Rubinstein-Taybi syndrome (RSTS).\n[20689175:20689175_1] Rubinstein-Taybi syndrome (RSTS), a developmental disorder comprising abnormalities that include mental retardation, an unusual facial appearance, broad thumbs and big toes is frequently associated with molecular lesions in the CREB-binding protein gene, CREBBP", "answer": "<think> Okay, let's tackle this question. The user is asking about the genetic basis of Rubinstein-Taybi syndrome. I need to look at the provided evidence to find the answer. First, I'll check each document. Document [15706485:15706485_1] says that there's genetic heterogeneity, with mutations in both CBP and EP300 genes causing the disease. So that's two genes mentioned here. Then, [16359492:16359492_1] specifically mentions CREBBP (CREB-binding protein gene) mutations causing RSTS. That's one gene. The third document [20689175", "citations": [{"doc_id": "15706485", "chunk_id": "15706485_1"}, {"doc_id": "16359492", "chunk_id": "16359492_1"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the genetic basis of Rubinstein-Taybi syndrome. I need to look at the provided evidence to find the answer. First, I'll check each of the three evidence points. The first one says that there's genetic heterogeneity, with mutations in both CBP and EP300 genes causing the disease. So that's two genes mentioned here. The second evidence mentions CREBBP (CREB-binding protein gene) mutations cause RSTS. So CREBBP is another gene involved. The third evidence also points to molecular lesions in the CREB-binding protein gene, CREBBP, which aligns with the second point. Wait, but the first evidence talks about CBP and EP3", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking about the genetic basis of Rubinstein-Taybi syndrome. Let me look at the evidence provided. The first document says that there's genetic heterogeneity, with mutations in both CBP and EP300 genes causing the disease. The second mentions CREBBP (CREB-binding protein gene) mutations are responsible. The third one also points to CREB-binding protein gene (CREBBP) lesions being associated with RSTS. Wait, but the first document talks about both CBP and EP300, while the others mention CREBBP. I need to check if CBP and CREBBP are the same thing. Oh right, CBP is the same as CREBBP. The gene is called CREBBP, and", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer about the genetic basis of Rubinstein-Taybi syndrome based on the provided evidence. Let me start by looking at the evidence given. The first document says that there's genetic heterogeneity, with mutations in both CBP and EP300 genes causing the disease. The second mentions CREBBP gene mutations. The third also talks about CREB-binding protein gene (CREBBP) lesions. So, the main points here are that CREBBP and possibly CBP/EP300 are involved. Wait, the first document says both CBP and EP300, but the others mention CREBBP. I should check if CBP is the same as CREBBP. Oh right, CBP is the same", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about the genetic basis of Rubinstein-Taybi syndrome. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three references here. Let me go through each one. The first one says that there's genetic heterogeneity, with mutations in both CBP and EP300 genes causing the disease. So that's two genes mentioned here. The second reference mentions CREBBP (CREB-binding protein gene) mutations cause RSTS. The third one also points to CREB-binding protein gene (CREBBP) with molecular lesions. Wait, so the first document says both CBP and EP300, but the others mention CREBBP. I need", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer about the genetic basis of Rubinstein-Taybi syndrome based on the provided evidence. Let me start by understanding the question. The user wants to know the genetic cause, so I should look at the evidence given. Looking at the evidence, there are three references. The first one says that both CBP and EP300 gene mutations cause the disease. The second mentions CREBBP (CREB-binding protein) mutations. The third also points to CREBBP gene lesions. Wait, but the first one talks about CBP and EP300. But CBP is the same as CREBBP? Maybe there's a confusion here. Let me check: CBP is the catalytic subunit of the p30", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking about the genetic basis of Rubinstein-Taybi syndrome. Let me look at the evidence provided. First, the evidence mentions that mutations in both CBP and EP300 genes cause the disease. Then there's a mention of CREBBP (CREB-binding protein gene) being involved. Another document says that molecular lesions in CREB-binding protein gene, CREBBP, are associated with RSTS. Wait, but the first one said both CBP and EP300. But then others refer to CREBBP. Hmm, I need to check if CBP and CREBBP are the same gene. Oh right, CBP is the same as CREBBP. So the first document might have a typo or just refers", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the genetic basis of Rubinstein-Taybi syndrome. I need to look at the provided evidence to find the answer. First, I'll check each document. Document [15706485:15706485_1] says that there's genetic heterogeneity, with mutations in both CBP and EP300 genes causing the disease. So that's two genes mentioned here. Then, [16359492:16359492_1] specifically mentions CREBBP (CREB-binding protein gene) mutations causing RSTS. That's one gene. The third document [20689175", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a JSON answer about the genetic basis of Rubinstein-Taybi syndrome based on the provided evidence. Let me start by reading through the question and the evidence carefully. The user is asking for the genetic basis, so I should focus on the genes involved. The evidence mentions several documents. Let's look at each one: Document [15706485:15706485_1] says that there's genetic heterogeneity, with mutations in both CBP and EP300 causing the disease. So that's two genes here. Then [16359492:16359492_1] specifically mentions CREBBP (CREB-binding protein gene) causing", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["14974086", "15706485", "16359492", "18773673", "20684013", "20689175", "22269667", "22303793", "22991675", "23432975", "7630403"], "ideal_answer": "Rubinstein-Taybi syndrome (RTS) is a rare autosomal dominant disorder (prevalence 1:125,000) characterised by broad thumbs and halluces, facial dysmorphism, psychomotor development delay, skeletal defects, abnormalities in the posterior fossa and short stature. The known genetic causes are a microdeletion at 16p13.3 or mutations or deletions of the cAMP-response element binding protein-BP (CREBBP) (50-60% of the cases) and of the homologous gene E1A-binding protein (EP300) at 22q13 (5%). Direct sequencing of CREBBP performed in 13 RSTS patients identified the three zinc fingers (CH1, CH2, CH3) and HAT domain as mutational hotspots. Thus about 55% of patients have cytogenetic or molecular abnormalities in the Crebbp or E1A binding protein p300 (Ep300) gene, leaving the diagnosis in 45% of patients to rest on clinical features only."}
{"question_id": "511a51331159fa8212000009", "question": "What is the function of the viral KP4 protein?", "retrieved_chunks": [{"doc_id": "21116630", "chunk_id": "21116630_0", "score": 6.323906898498535, "text": "Killer protein 4 (KP4) is a well studied viral toxin secreted by the maize smut fungus Ustilago maydis that kills sensitive Ustilago strains as well as inhibits Fusarium and plant root growth by inhibiting calcium uptake."}, {"doc_id": "17522822", "chunk_id": "17522822_0", "score": 5.440125942230225, "text": "The viral gene for the killer protein 4 (KP4) has been explored for its antifungal effect"}, {"doc_id": "11901234", "chunk_id": "11901234_0", "score": 3.2708823680877686, "text": "KP4 is a virally encoded fungal toxin secreted by the P4 killer strain of Ustilago maydis."}], "context": "[21116630:21116630_0] Killer protein 4 (KP4) is a well studied viral toxin secreted by the maize smut fungus Ustilago maydis that kills sensitive Ustilago strains as well as inhibits Fusarium and plant root growth by inhibiting calcium uptake.\n[17522822:17522822_0] The viral gene for the killer protein 4 (KP4) has been explored for its antifungal effect\n[11901234:11901234_0] KP4 is a virally encoded fungal toxin secreted by the P4 killer strain of Ustilago maydis.", "answer": "<think> Okay, let's tackle this question. The user wants to know the function of the viral KP4 protein. Looking at the evidence provided, there are three documents. First, document [21116630:21116630_0] says that KP4 is a viral toxin secreted by the maize smut fungus Ustilago maydis. It kills sensitive strains of Ustilago and inhibits Fusarium and plant root growth by blocking calcium uptake. So that's a direct function. Then, document [17522822:17522822_0] mentions the viral gene for KP4 has been explored for its antifungal effect. That suggests it has antif", "citations": [{"doc_id": "21116630", "chunk_id": "21116630_0"}, {"doc_id": "17522822", "chunk_id": "17522822_0"}], "candidates": [{"answer": "<think> Okay, I need to figure out the function of the viral KP4 protein based on the given evidence. Let's look at the three references provided. The first one says that KP4 is a viral toxin secreted by the maize smut fungus Ustilago maydis. It kills sensitive strains of Ustilago and inhibits Fusarium and plant root growth by blocking calcium uptake. So that's a direct function: killing other Ustilago strains and inhibiting fungal and plant growth through calcium inhibition. The second reference mentions that the viral gene for KP4 has been explored for its antifungal effect. That supports the idea that it has antifungal properties, which aligns with the first point about killing other Ustilago strains and inhibiting Fusarium", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know the function of the viral KP4 protein. Looking at the evidence provided, there are three documents. First, document [21116630:21116630_0] says that KP4 is a viral toxin secreted by the maize smut fungus Ustilago maydis. It kills sensitive strains of Ustilago and inhibits Fusarium and plant root growth by blocking calcium uptake. So that's a direct function. Then, document [17522822:17522822_0] mentions the viral gene for KP4 has been explored for its antifungal effect. That suggests it has antif", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, so I need to figure out the function of the viral KP4 protein based on the given evidence. Let's look at the evidence provided. The first document says that KP4 is a viral toxin secreted by the maize smut fungus Ustilago maydis. It kills sensitive Ustilago strains and inhibits Fusarium and plant root growth by inhibiting calcium uptake. That seems like a direct function: it's a toxin that has multiple effects, including killing other fungal strains and affecting plants by blocking calcium absorption. The second document mentions the viral gene for KP4 has been explored for its antifungal effect. So that's another point—antifungal properties. But wait, the first document says it kills sensitive Ustilago strains, which might", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so I need to figure out the function of the viral KP4 protein based on the given evidence. Let me start by looking at each of the three documents provided. The first document says that KP4 is a viral toxin secreted by the maize smut fungus Ustilago maydis. It kills sensitive Ustilago strains and inhibits Fusarium and plant root growth by blocking calcium uptake. That seems to directly state the function: it's a toxin that has multiple effects, including killing other Ustilago strains and inhibiting fungal and plant growth through calcium uptake inhibition. The second document mentions that the viral gene for KP4 has been explored for its antifungal effect. So this suggests that KP4 has an antifungal property, which might be", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know the function of the viral KP4 protein. Looking at the evidence provided, there are three documents. First, document [21116630:21116630_0] says that KP4 is a viral toxin secreted by the maize smut fungus Ustilago maydis. It kills sensitive strains and inhibits growth of Fusarium and plant roots by blocking calcium uptake. That seems to directly answer the function. Then, document [17522822:17522822_0] mentions that the viral gene for KP4 has been explored for its antifungal effect. So that's another point about its function", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, so the user is asking about the function of the viral KP4 protein. Let me look at the evidence provided. First, document 21116630:21116630_0 says that KP4 is a viral toxin secreted by the maize smut fungus Ustilago maydis. It kills sensitive strains of Ustilago and inhibits growth of Fusarium and plant roots by blocking calcium uptake. That seems like a direct function. Then, document 17522822:17522822_0 mentions the viral gene for KP4 has been explored for antifungal effects. So that's another point about its function, maybe related to inhibiting other fungi", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know the function of the viral KP4 protein. Looking at the evidence provided, there are three chunks. First chunk says KP4 is a viral toxin secreted by the maize smut fungus Ustilago maydis. It kills sensitive strains and inhibits Fusarium and plant root growth by blocking calcium uptake. That's a direct function. Second chunk mentions the viral gene for KP4 has been explored for antifungal effects. So that's another aspect of its function, maybe related to killing other fungi. Third chunk states KP4 is a virally encoded toxin secreted by the P4 killer strain. This reinforces that it's a toxin, but doesn't specify the function beyond what's in the first chunk.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know the function of the viral KP4 protein. Looking at the evidence provided, there are three documents. First document says KP4 is a viral toxin secreted by the maize smut fungus that kills sensitive strains and inhibits growth by affecting calcium uptake. Second mentions the gene for KP4 has been explored for antifungal effects. Third states KP4 is a virally encoded toxin by the P4 killer strain of Ustilago maydis. So, the main function seems to be killing other Ustilago strains and inhibiting fungal and plant growth via calcium uptake. The antifungal effect might be part of that. But the first document specifically mentions inhibiting calcium uptake as the mechanism. The answer needs", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["10748529", "11532143", "11901234", "17522822", "17849147", "21116630", "21303448", "7582897", "7966296", "8145639", "8616260", "8809749"], "ideal_answer": "The virally encoded fungal toxin KP4 specifically blocks L-type voltage-gated calcium channels."}
{"question_id": "56ed27012ac5ed145900000b", "question": "What is the function of the AIRE gene at the embryonic stage?", "retrieved_chunks": [{"doc_id": "22540148", "chunk_id": "22540148_4", "score": 6.223471641540527, "text": "The recent discovery of Aire expression in stem cells and early embryonic cells and its function in the self-renewal of embryonic stem (ES) cells highlight the importance of Aire in these cells. In this study, we present evidence that Aire promotes the expression of the pluripotent factor Lin28 and the self-renewal of ES cells."}, {"doc_id": "20226168", "chunk_id": "20226168_2", "score": 6.099332332611084, "text": "Aire regulates the expression of differentiation-associated genes and self-renewal of embryonic stem cells."}, {"doc_id": "20226168", "chunk_id": "20226168_1", "score": 5.756678104400635, "text": "Aire regulates the expression of differentiation-associated genes and self-renewal of embryonic stem cells"}], "context": "[22540148:22540148_4] The recent discovery of Aire expression in stem cells and early embryonic cells and its function in the self-renewal of embryonic stem (ES) cells highlight the importance of Aire in these cells. In this study, we present evidence that Aire promotes the expression of the pluripotent factor Lin28 and the self-renewal of ES cells.\n[20226168:20226168_2] Aire regulates the expression of differentiation-associated genes and self-renewal of embryonic stem cells.\n[20226168:20226168_1] Aire regulates the expression of differentiation-associated genes and self-renewal of embryonic stem cells", "answer": "<think> Okay, let's tackle this question. The user is asking about the function of the AIRE gene at the embryonic stage. I need to look at the provided evidence to find the answer. First, I'll go through each of the evidence snippets. The first one, [22540148:22540148_4], says that Aire is expressed in stem cells and early embryonic cells and helps in the self-renewal of ES cells. It mentions promoting Lin28 expression, which is a pluripotent factor. So this suggests AIRE is involved in maintaining the self-renewal of embryonic stem cells. The next two entries, [20226168:202", "citations": [{"doc_id": "22540148", "chunk_id": "22540148_4"}], "candidates": [{"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is about the function of the AIRE gene at the embryonic stage. Looking at the evidence, there are three references. The first one (22540148) mentions that Aire promotes the expression of Lin28 and self-renewal of ES cells. The other two (20226168) say Aire regulates differentiation-associated genes and self-renewal of embryonic stem cells. So, combining these, the answer should mention both promoting self-renewal and regulating differentiation genes. The confidence is high because multiple sources support this. I'll need to cite the relevant chunks. The first chunk from 2254014", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the function of the AIRE gene at the embryonic stage. I need to look at the provided evidence to find the answer. First, I'll go through each of the evidence snippets. The first one, [22540148:22540148_4], says that Aire is expressed in stem cells and early embryonic cells and helps in the self-renewal of ES cells. It mentions promoting Lin28 expression, which is a pluripotent factor. So this suggests AIRE is involved in maintaining the self-renewal of embryonic stem cells. The next two entries, [20226168:202", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the function of the AIRE gene at the embryonic stage. I need to look at the provided evidence to find the answer. First, looking at the evidence documents. Document 22540148 mentions that Aire is expressed in stem cells and early embryonic cells, and it promotes the self-renewal of ES cells by enhancing Lin28 expression. That's a key point. Then, documents 20226168 (both chunks) state that Aire regulates differentiation-associated genes and self-renewal of embryonic stem cells. So, combining these, the main functions mentioned are promoting self-renewal of ES cells and regulating genes related to differentiation.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the function of the AIRE gene at the embryonic stage. I need to look at the provided evidence to find relevant information. First, I'll go through each of the evidence chunks. The first one, 22540148:22540148_4, mentions that Aire is expressed in stem cells and early embryonic cells, and it promotes the expression of Lin28, a pluripotent factor, which helps in the self-renewal of ES cells. So this suggests that AIRE's function here is related to self-renewal of embryonic stem cells. The next two chunks, 20226168:", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the function of the AIRE gene at the embryonic stage. I need to look at the provided evidence to find relevant information. First, I'll check each evidence snippet. The first one mentions that Aire is expressed in stem cells and early embryonic cells, and it promotes the self-renewal of ES cells by enhancing Lin28 expression. The second and third snippets both state that Aire regulates differentiation-associated genes and self-renewal of embryonic stem cells. So, combining these, the main points are that AIRE is involved in self-renewal of embryonic stem cells and regulating genes related to differentiation. The question specifically asks about the embryonic stage, so the answer should focus on", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking about the function of the AIRE gene during the embryonic stage. Let me look at the evidence provided. First, there's a document (22540148) that mentions Aire expression in early embryonic cells and its role in self-renewal of ES cells. It specifically says Aire promotes Lin28 expression and self-renewal. Then, two other documents (20226168) state that Aire regulates differentiation-associated genes and self-renewal of ES cells. I need to combine these points. The key functions here are self-renewal of embryonic stem cells and regulation of genes involved in differentiation. The answer should mention both aspects. The confidence level is moderate because", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking about the function of the AIRE gene at the embryonic stage. Let me look at the evidence provided. First, there's a citation from 22540148:4. It says that Aire is expressed in stem cells and early embryonic cells, and it promotes the expression of Lin28, a pluripotent factor, which helps in the self-renewal of ES cells. That seems directly relevant to the embryonic stage. Then there are two citations from 20226168:2 and 1. Both mention that Aire regulates differentiation-associated genes and self-renewal of embryonic stem cells. So, these also support the role in self-renewal and differentiation", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to answer the question about the function of the AIRE gene at the embryonic stage using the provided evidence. Let me look through the evidence first. The user provided three chunks from different studies. The first one (22540148:22540148_4) says that Aire is expressed in stem cells and early embryonic cells and helps in the self-renewal of ES cells by promoting Lin28 expression. The other two chunks (20226168:20226168_2 and 1) mention that Aire regulates differentiation-associated genes and self-renewal of embryonic stem cells. So, combining these, the main points are that A", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["19008896", "19302042", "20226168", "21952165", "22540148"], "ideal_answer": "Aire regulates the expression of differentiation-associated genes and self-renewal of embryonic stem cells. Aire and Deaf1 help regulate the ectopic expression of diverse tissue-specific antigens to establish self-immune tolerance. Knockdown of Aire in mouse ESCs resulted in significantly decreased clone-forming efficiency as well as attenuated cell cycle, suggesting Aire plays a role in ESC self-renewal. Aire promotes the expression of the pluripotent factor Lin28 and the self-renewal of ES cells. Autoimmune regulator (Aire) is one of the most well-characterized molecules in autoimmunity, but its function outside the immune system is largely unknown. The recent discovery of Aire expression in stem cells and early embryonic cells and its function in the self-renewal of embryonic stem (ES) cells highlight the importance of Aire in these cells. The recent discovery of Aire expression in stem cells and early embryonic cells and its function in the self-renewal of embryonic stem (ES) cells highlight the importance of Aire in these cells. The correlation between Aire and Lin28 expression in germ cells and early embryos indicated an in vivo function for Aire in toti- and pluripotent stem cells. Moreover, it presents the first evidence that microRNAs contribute to the regulatory function of Aire and highlights a novel function of Aire in stem cell biology and reproduction. Monitoring Aire expression in MSCs may thus be a critical parameter for clinical use."}
{"question_id": "533c388dc45e133714000008", "question": "What is the principle of the PAR-CLIP methodology?", "retrieved_chunks": [{"doc_id": "22844102", "chunk_id": "22844102_0", "score": 4.5211286544799805, "text": "Photo-Activatable Ribonucleoside-enhanced CrossLinking and ImmunoPrecipitation (PAR-CLIP) method was recently developed for global identification of RNAs interacting with proteins."}, {"doc_id": "22152485", "chunk_id": "22152485_0", "score": 4.404881000518799, "text": "A recent method, PAR-CLIP, uses photoreactive nucleosides to crosslink RBPs to target RNAs in cells prior to immunoprecipitation."}, {"doc_id": "21572407", "chunk_id": "21572407_0", "score": 3.6989479064941406, "text": "We developed a method for CLIP data analysis, and applied it to compare CLIP with photoactivatable ribonucleoside-enhanced CLIP (PAR-CLIP) and to uncover how differences in cross-linking and ribonuclease digestion affect the identified sites."}], "context": "[22844102:22844102_0] Photo-Activatable Ribonucleoside-enhanced CrossLinking and ImmunoPrecipitation (PAR-CLIP) method was recently developed for global identification of RNAs interacting with proteins.\n[22152485:22152485_0] A recent method, PAR-CLIP, uses photoreactive nucleosides to crosslink RBPs to target RNAs in cells prior to immunoprecipitation.\n[21572407:21572407_0] We developed a method for CLIP data analysis, and applied it to compare CLIP with photoactivatable ribonucleoside-enhanced CLIP (PAR-CLIP) and to uncover how differences in cross-linking and ribonuclease digestion affect the identified sites.", "answer": "<think> Okay, so I need to figure out the principle of the PAR-CLIP methodology based on the given evidence. Let me start by reading through the evidence provided. The first evidence snippet says that PAR-CLIP is a method for global identification of RNAs interacting with proteins. It mentions using photoreactive nucleosides to crosslink RBPs (RNA-binding proteins) to target RNAs before immunoprecipitation. The second snippet also talks about PAR-CLIP using photoreactive nucleosides to crosslink RBPs to RNAs prior to immunoprecipitation. The third snippet mentions that they developed a method for CLIP data analysis and applied it to compare CLIP with PAR-CLIP, noting differences in cross-linking and ribonuclease", "citations": [], "candidates": [{"answer": "<think> Okay, so I need to figure out the principle of the PAR-CLIP methodology based on the given evidence. Let me start by reading through the evidence provided. The first evidence snippet says that PAR-CLIP is a method for global identification of RNAs interacting with proteins. It mentions using photoreactive nucleosides to crosslink RBPs (RNA-binding proteins) to target RNAs before immunoprecipitation. The second snippet also talks about PAR-CLIP using photoreactive nucleosides to crosslink RBPs to RNAs prior to immunoprecipitation. The third snippet mentions that they developed a method for CLIP data analysis and applied it to compare CLIP with PAR-CLIP, noting differences in cross-linking and ribonuclease", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so I need to figure out the principle of the PAR-CLIP methodology based on the given evidence. Let me start by reading through the provided documents carefully. The first document says that PAR-CLIP is a method for global identification of RNAs interacting with proteins. It mentions using photoreactive nucleosides to crosslink RBPs (RNA-binding proteins) to target RNAs before immunoprecipitation. The second document also talks about PAR-CLIP using photoreactive nucleosides to crosslink RBPs to RNAs prior to immunoprecipitation. The third document mentions that they developed a method for CLIP data analysis and applied it to compare CLIP with PAR-CLIP, highlighting differences in cross-linking and ribonuclease", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the principle of the PAR-CLIP methodology. I need to look at the evidence provided to form an answer. First, I'll review each of the three evidence chunks. The first one says that PAR-CLIP uses photoreactive nucleosides to crosslink RBPs to target RNAs before immunoprecipitation. The second chunk mentions that it's a method using photoreactive nucleosides to crosslink RBPs to RNAs in cells prior to immunoprecipitation. The third chunk talks about applying the method to compare CLIP with PAR-CLIP, focusing on cross-linking and digestion effects. So, the common element here is the use of photoreactive nucleos", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking about the principle of the PAR-CLIP methodology. Let me look at the evidence provided. First, document 22844102:22844102_0 says that PAR-CLIP uses photoreactive nucleosides to crosslink RBPs to target RNAs before immunoprecipitation. That seems like a key point. Then, document 22152485:22152485_0 also mentions using photoreactive nucleosides for crosslinking RBPs to RNAs prior to immunoprecipitation. The third document talks about analyzing CLIP data and comparing with PAR-CLIP, but it's more about the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The question is about the principle of the PAR-CLIP methodology. Looking at the evidence, there are three documents. Let me check each one. The first document says that PAR-CLIP uses photoreactive nucleosides to crosslink RBPs to target RNAs before immunoprecipitation. The second document mentions the same thing: using photoreactive nucleosides for crosslinking. The third talks about analyzing CLIP data and comparing with PAR-CLIP, but it's more about analysis than the principle. So the key point is that PAR-CLIP uses photoreactive nucleosides to crosslink RNA-binding proteins (RBPs) to their target RNAs,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the principle of the PAR-CLIP methodology. I need to look at the evidence provided to form an answer. First, I'll check each of the three evidence snippets. The first one says PAR-CLIP uses photoreactive nucleosides to crosslink RBPs to target RNAs before immunoprecipitation. The second mentions the same thing: photoreactive nucleosides for crosslinking RBPs to RNAs prior to immunoprecipitation. The third talks about analyzing CLIP data and comparing with PAR-CLIP, but it's more about analysis than the principle itself. So the key points are photoreactive nucleosides, crosslinking of RBPs to RN", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about the PAR-CLIP methodology. The user wants the principle of PAR-CLIP explained based on the provided evidence. First, I need to look at the evidence snippets. There are three documents here. Let me read through them carefully. The first one says that PAR-CLIP is a method for identifying RNAs interacting with proteins using photoactivatable ribonucleosides. The second mentions that PAR-CLIP uses photoreactive nucleosides to crosslink RBPs to target RNAs before immunoprecipitation. The third talks about analyzing CLIP data and comparing it with PAR-CLIP, noting differences in cross-linking and digestion affecting the sites identified. So the key points are: photoactivatable ribon", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so I need to figure out the principle of the PAR-CLIP methodology based on the given evidence. Let me start by reading through the provided documents carefully. The first document says that PAR-CLIP is a method for global identification of RNAs interacting with proteins. It mentions using photoreactive nucleosides to crosslink RBPs (RNA-binding proteins) to target RNAs before immunoprecipitation. The second document also talks about PAR-CLIP using photoreactive nucleosides to crosslink RBPs to RNAs prior to immunoprecipitation. The third one refers toPAR-CLIP as a method that's compared with CLIP, and it involves differences in cross-linking and ribonuclease digestion affecting identified sites. So", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["20371350", "20644507", "21559008", "21572407", "21816340", "21851591", "22152485", "22213601", "22844102", "22885304", "22926237", "23368412", "23706177", "24297251"], "ideal_answer": "In particular, PAR-CLIP utilizes a photoactivatable nucleoside for more efficient crosslinking. A recent method, PAR-CLIP, uses photoreactive nucleosides to crosslink RBPs to target RNAs in cells prior to immunoprecipitation. One characteristic feature of cDNA libraries prepared by PAR-CliP is that the precise position of crosslinking can be identified by mutations residing in the sequenced cDNA. A powerful cell-based crosslinking approach to determine at high resolution and transcriptome-wide the binding sites of cellular RBPs and miRNPs was termed PAR-CliP (Photoactivatable-Ribonucleoside-Enhanced Crosslinking and Immunoprecipitation). PAR-CLIP shows high efficiency of RNA co-immunoprecipitation, but it also lead to T to C conversion in miRNA-RNA-protein crosslinking regions. It relies on the intracellular incorporation of photoactivatable ribonucleoside analogs into nascent transcripts, and yields characteristic sequence changes upon crosslinking that facilitate the separation of signal from noise. AR-CliP--a method to identify transcriptome-wide the binding sites of RNA binding proteinsOne characteristic feature of cDNA libraries prepared by PAR-CliP is that the precise position of crosslinking can be identified by mutations residing in the sequenced cDNA. In particular, PAR-CLIP utilizes a photoactivatable nucleoside for more efficient crosslinking. A recent method, PAR-CLIP, uses photoreactive nucleosides to crosslink RBPs to target RNAs in cells prior to immunoprecipitation. In particular, PAR-CLIP utilizes a photoactivatable nucleoside for more efficient crosslinking. A recent method, PAR-CLIP, uses photoreactive nucleosides to crosslink RBPs to target RNAs in cells prior to immunoprecipitation. One characteristic feature of cDNA libraries prepared by PAR-CliP is that the precise position of crosslinking can be identified by mutations residing in the sequenced cDNA. Photo-Activatable Ribonucleoside-enhanced CrossLinking and ImmunoPrecipitation (PAR-CLIP) method was recently developed for global identification of RNAs interacting with proteins. PAR-CLIP shows high efficiency of RNA co-immunoprecipitation, but it also lead to T to C conversion in miRNA-RNA-protein crosslinking regions"}
{"question_id": "518cb4b5310faafe08000006", "question": "Which drugs are utilized to treat amiodarone-induced thyroitoxicosis?", "retrieved_chunks": [{"doc_id": "7946779", "chunk_id": "7946779_1", "score": 7.66983699798584, "text": "Two patients with amiodarone-induced thyrotoxicosis were treated successfully with potassium perchlorate and carbimazole while treatment with amiodarone was continued."}, {"doc_id": "16544025", "chunk_id": "16544025_1", "score": 7.4176177978515625, "text": "the addition of lithium carbonate to the two other drugs resulted in a successful and safety therapy in controlling amiodarone-induced thyrotoxicosis."}, {"doc_id": "9217642", "chunk_id": "9217642_0", "score": 6.463123321533203, "text": "lithium is a useful and safe medication for treatment of iodine-induced thyrotoxicosis caused by amiodarone."}], "context": "[7946779:7946779_1] Two patients with amiodarone-induced thyrotoxicosis were treated successfully with potassium perchlorate and carbimazole while treatment with amiodarone was continued.\n[16544025:16544025_1] the addition of lithium carbonate to the two other drugs resulted in a successful and safety therapy in controlling amiodarone-induced thyrotoxicosis.\n[9217642:9217642_0] lithium is a useful and safe medication for treatment of iodine-induced thyrotoxicosis caused by amiodarone.", "answer": "<think> Okay, I need to answer the question about drugs used to treat amiodarone-induced thyrotoxicosis based on the given evidence. Let me look at the evidence provided. First, the user mentioned three documents. The first one says that potassium perchlorate and carbimazole were used successfully in two patients while continuing amiodarone treatment. So those are two drugs. The second document mentions adding lithium carbonate to the two other drugs, which I assume refers to the previous drugs (potassium perchlorate and carbimazole) plus lithium carbonate. But wait, the first document says \"two other drugs,\" but in the first case, it was potassium perchlorate and carbimazole. So maybe that's three drugs? Or maybe the two other drugs are", "citations": [], "candidates": [{"answer": "<think> Okay, I need to answer the question about drugs used to treat amiodarone-induced thyrotoxicosis based on the given evidence. Let me look at the evidence provided. First, the user mentioned three documents. The first one says that potassium perchlorate and carbimazole were used successfully in two patients while continuing amiodarone treatment. So those are two drugs. The second document mentions adding lithium carbonate to the two other drugs, which I assume refers to the previous drugs (potassium perchlorate and carbimazole) plus lithium carbonate. But wait, the first document says \"two other drugs,\" but in the first case, it was potassium perchlorate and carbimazole. So maybe that's three drugs? Or maybe the two other drugs are", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which drugs are used to treat amiodarone-induced thyrotoxicosis. Looking at the evidence provided, there are three chunks. First chunk (7946779:7946779_1) mentions potassium perchlorate and carbimazole were used successfully along with continuing amiodarone treatment. So those two drugs are mentioned here. Second chunk (16544025:16544025_1) talks about adding lithium carbonate to the two other drugs. Wait, the two other drugs would be potassium perchlorate and carbimazole from the first chunk? Or maybe it's referring to other drugs besides lithium?", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which drugs are used to treat amiodarone-induced thyrotoxicosis. The evidence provided has three chunks. First chunk says potassium perchlorate and carbimazole were used successfully while continuing amiodarone. Second chunk mentions lithium carbonate added to two other drugs. Third chunk states lithium is useful and safe for iodine-induced thyrotoxicosis from amiodarone. Wait, the question is about amiodarone-induced, but the third chunk talks about iodine-induced. But amiodarone is a drug that can cause thyroid issues, so maybe there's a mix-up here. However, the user's evidence includes these three sources. So, from the first chunk: potassium", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is about drugs used to treat amiodarone-induced thyrotoxicosis. Looking at the evidence, there are three chunks. The first one mentions potassium perchlorate and carbimazole being used while continuing amiodarone. The second says adding lithium carbonate to two other drugs worked safely. The third states that lithium is useful and safe for iodine-induced thyrotoxicosis from amiodarone. So the answer should list the drugs. From chunk 7946779, potassium perchlorate and carbimazole are mentioned. Then in chunk 16544025, lithium carbonate is added to two other drugs (maybe the first", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is about drugs used to treat amiodarone-induced thyrotoxicosis. Looking at the evidence, there are three chunks. The first one mentions potassium perchlorate and carbimazole being used while continuing amiodarone. The second says adding lithium carbonate to two other drugs worked safely. The third states that lithium is useful and safe for iodine-induced thyrotoxicosis from amiodarone. So the answer should list the drugs. From chunk 7946779, potassium perchlorate and carbimazole are mentioned. Chunk 16544025 adds lithium carbonate. Chunk 9217642 confirms lithium", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which drugs are used to treat amiodarone-induced thyrotoxicosis. The evidence provided has three chunks. First chunk: Potassium perchlorate and carbimazole were used successfully with continued amiodarone treatment. So those two drugs are mentioned here. Second chunk mentions lithium carbonate added to two other drugs. Wait, the first chunk already listed two drugs. So maybe the \"two other drugs\" refer to potassium perchlorate and carbimazole? But that might not make sense. Alternatively, maybe the second chunk is adding lithium carbonate along with another drug. But the wording is a bit unclear. However, the third chunk directly states that lithium is useful for this condition. So combining all", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which drugs are used to treat amiodarone-induced thyrotoxicosis. Looking at the evidence provided, there are three chunks. First chunk: Potassium perchlorate and carbimazole were used successfully in two patients while continuing amiodarone treatment. So those two drugs are mentioned here. Second chunk: Adding lithium carbonate to the two other drugs resulted in successful and safe therapy. The \"two other drugs\" likely refer to the ones from the first chunk, so that's potassium perchlorate, carbimazole, and lithium carbonate. Third chunk: Lithium is noted as a useful and safe medication for iodine-induced thyrotoxicosis caused by amiodarone. This reinforces the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which drugs are used to treat amiodarone-induced thyrotoxicosis. Looking at the evidence provided, there are three chunks. First chunk (7946779:7946779_1) mentions potassium perchlorate and carbimazole were used successfully along with continuing amiodarone treatment. So those two drugs are mentioned here. Second chunk (16544025:16544025_1) talks about adding lithium carbonate to the two other drugs. Wait, the \"two other drugs\" would be potassium perchlorate and carbimazole from the first chunk? Or maybe it's referring to another pair?", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["11901034", "12727944", "16544025", "16910349", "19675515", "21135419", "2781955", "7946779", "9217642"], "ideal_answer": "Amiodarone-induced thyrotoxicosis treatment includes anti-thyroid drugs and steroid therapy Radio Iodine Treatment (RIT) may be a safe and useful method of AIT therapy in patients with low RAIU, in whom other treatment methods are contraindicated. Lithium is a useful and safe medication for treatment of iodine-induced thyrotoxicosis caused by amiodarone. Thyrodectomy may be necessary in presence of unresponsiveness to standard medical treatments"}
{"question_id": "56c3323a50c68dd416000009", "question": "How is spastic diplegia diagnosed?", "retrieved_chunks": [{"doc_id": "23085499", "chunk_id": "23085499_2", "score": 4.601202964782715, "text": "Hereditary spastic paraplegia (HSP) and spastic diplegia (SD) patients share a strong clinical resemblance. Thus, HSP patients are frequently misdiagnosed with a mild form of SD. Clinical gait analysis (CGA) has been highlighted as a possible tool to support the differential diagnosis of HSP and SD"}, {"doc_id": "24182356", "chunk_id": "24182356_0", "score": 3.9041900634765625, "text": "The aim of this study was to explore the physical status and gait patterns of children with spastic diplegia secondary to human immunodeficiency virus encephalopathy (HIVE). A cross-sectional study was conducted on children diagnosed with HIVE and spastic diplegia."}, {"doc_id": "1743414", "chunk_id": "1743414_0", "score": 3.2611911296844482, "text": "Hip flexion combined with knee extension (leg elevation) and isolated knee movements were not seen in diplegic infants, but were seen in all control preterm infants with a good prognosis, after five and six months corrected age, respectively. The absence of these movements is a useful diagnostic item for spastic diplegia."}], "context": "[23085499:23085499_2] Hereditary spastic paraplegia (HSP) and spastic diplegia (SD) patients share a strong clinical resemblance. Thus, HSP patients are frequently misdiagnosed with a mild form of SD. Clinical gait analysis (CGA) has been highlighted as a possible tool to support the differential diagnosis of HSP and SD\n[24182356:24182356_0] The aim of this study was to explore the physical status and gait patterns of children with spastic diplegia secondary to human immunodeficiency virus encephalopathy (HIVE). A cross-sectional study was conducted on children diagnosed with HIVE and spastic diplegia.\n[1743414:1743414_0] Hip flexion combined with knee extension (leg elevation) and isolated knee movements were not seen in diplegic infants, but were seen in all control preterm infants with a good prognosis, after five and six months corrected age, respectively. The absence of these movements is a useful diagnostic item for spastic diplegia.", "answer": "<think> Okay, the user is asking how spastic diplegia is diagnosed. Let me look at the evidence provided. First, there's the document [23085499:23085499_2] which mentions that clinical gait analysis (CGA) can help differentiate between HSP and SD. That seems relevant because it talks about a diagnostic tool. Then, [24182356:24182356_0] discusses a study on children with HIVE and spastic diplegia, but it's more about their physical status and gait patterns rather than a specific diagnostic method. Maybe not as directly relevant. The third document [1743414:", "citations": [{"doc_id": "23085499", "chunk_id": "23085499_2"}, {"doc_id": "24182356", "chunk_id": "24182356_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question about diagnosing spastic diplegia. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three documents here. Let me go through each one. The first document says that HSP and SD have similar clinical features, so they can be misdiagnosed. It mentions clinical gait analysis (CGA) as a tool to differentiate between them. That's relevant because it talks about using CGA in diagnosis. The second document is about children with HIVE and spastic diplegia. It mentions a cross-sectional study on their physical status and gait patterns. While this shows that gait analysis is used, it doesn't directly explain the diagnostic method.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking how spastic diplegia is diagnosed. Let me look at the evidence provided. First, there's the document 23085499:23085499_2. It mentions that HSP and SD are clinically similar, so CGA (clinical gait analysis) is a tool to differentiate them. That's relevant because it suggests a diagnostic method involving gait analysis. Then, document 24182356:24182356_0 talks about a study on children with HIVE and spastic diplegia. It says they did a cross-sectional study on physical status and gait patterns. So maybe assessing gait is part of the diagnosis here", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking how spastic diplegia is diagnosed. Let me look at the evidence provided. First, there's the document [23085499:23085499_2] which mentions that clinical gait analysis (CGA) can help differentiate between HSP and SD. That seems relevant because it talks about a diagnostic tool. Then, [24182356:24182356_0] discusses a study on children with HIVE and spastic diplegia, but it's more about their physical status and gait patterns rather than a specific diagnostic method. Maybe not as directly relevant. The third document [1743414:", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence about how spastic diplegia is diagnosed. Let me start by understanding the question: How is spastic diplegia diagnosed? Looking at the evidence provided, there are three documents. The first one mentions that clinical gait analysis (CGA) can help differentiate between HSP and SD. The second document talks about a study on children with HIVE and spastic diplegia, but it's more about their physical status and gait patterns rather than diagnosis. The third document states that the absence of certain movements (hip flexion with knee extension and isolated knee movements) is a useful diagnostic item for spastic diplegia. So, the key points here are: clinical gait analysis and specific", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let me tackle this question about how spastic diplegia is diagnosed. The user wants a strict JSON answer with the answer and base confidence. First, I need to look at the evidence provided. There are three chunks here. Let's break them down. The first chunk (23085499:23085499_2) talks about HSP and SD being clinically similar, leading to misdiagnosis. It mentions clinical gait analysis (CGA) as a tool to differentiate between HSP and SD. So that's a point about using CGA. The second chunk (24182356:24182356_0) is about a study on children with H", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so I need to generate a JSON answer about how spastic diplegia is diagnosed based on the given evidence. Let me start by reading through the evidence carefully. First, the user provided three documents. The first one mentions that HSP and SD patients look similar, leading to misdiagnosis. They suggest clinical gait analysis (CGA) as a tool for differential diagnosis between HSP and SD. So CGA is mentioned here as a possible diagnostic method. The second document talks about a study on children with spastic diplegia due to HIV encephalopathy. It says they did a cross-sectional study on those diagnosed with HIVE and SD. But this doesn't really explain the diagnosis process, more about the patient population. Third document states that in", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer for the question \"How is spastic diplegia diagnosed?\" based on the provided evidence. Let me start by understanding what the user is asking. They want a concise answer with citations and a confidence score. First, I'll look at the evidence given. There are three documents: 1. [23085499:23085499_2] talks about HSP and SD being clinically similar, so CGA is used to differentiate them. 2. [24182356:24182356_0] mentions a study on children with HIVE and spastic diplegia, using a cross-sectional study to explore their physical status", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. Let's start by understanding the question: How is spastic diplegia diagnosed? Looking at the evidence provided, there are three documents. The first one mentions that clinical gait analysis (CGA) can help differentiate between HSP and SD. The second document talks about a study on children with HIVE and spastic diplegia, but it's more about their physical status and gait patterns rather than diagnosis. The third document states that the absence of certain movements (hip flexion with knee extension and isolated knee movements) is a useful diagnostic item for spastic diplegia. So, the key points here are the clinical signs like specific movement patterns. The third document directly mentions these movements as", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["10427678", "12549749", "15157997", "16344032", "1743414", "17509240", "17826455", "20829081", "21310339", "23085499", "23121133", "24182356", "24239880", "24409030", "24901761", "25276040", "25700542", "2600179", "2816867", "7270517"], "ideal_answer": "Diagnosis of spastic diplegia is mainly carried out with through clinical gait analysis (CGA), with variations such as 1-minute walk, LSU, and 10-meter walk tests, or Gross Motor Function Measure-88 (GMFM-88). Other methods used for evaluation of patients include brain magnetic resonance imaging (MRI) and motor function, presence of epileptic episodes, and IQ or developmental quotient. Clinical gait analysis (CGA) has been highlighted as a possible tool to support the differential diagnosis of Hereditary Spastic Paraplegia (HSP) and Spastic Diplegia (SD). Argininaimia should be considered more frequently in the differential diagnosis of a patient with slowly progressive neurologic manifestations, especially progressive spastic diplegia. Gait Analysis (GA) complements traditional clinical evaluations, making it possible to distinguish, clearly, between motor ability in HSP and in SD patients; the duration of the knee hyperextension during midstance was found to discriminate between the two gait patterns."}
{"question_id": "52f223e02059c6d71c00000e", "question": "Which is the genetic defect causing Neurofibromatosis type 1?", "retrieved_chunks": [{"doc_id": "16835897", "chunk_id": "16835897_2", "score": 8.793728828430176, "text": "Neurofibromatosis type 1 (NF1), characterized by skin neurofibromas and an excess of café-au-lait spots, is due to mutations in the neurofibromin (NF1) gene. Identifying the genetic defect in individuals with the disease represents a significant challenge because the gene is extremely large with a high incidence of sporadic mutations across the entire gene ranging from single nucleotide substitutes to large deletions."}, {"doc_id": "19117870", "chunk_id": "19117870_2", "score": 7.752963542938232, "text": "Neurofibromatosis type 1 (NF1) is an autosomal dominant condition with a worldwide incidence of approximately 1 per 2500 to 3000 individuals. Caused by a germ-line-inactivating mutation in the NF1 gene on chromosome 17, the disease is associated with increased morbidity and mortality. In the past several years, significant progress has been made in standardizing management of the major clinical features of neurofibromatosis type 1."}, {"doc_id": "17573495", "chunk_id": "17573495_0", "score": 6.448944568634033, "text": "Neurofibromatosis type 1 (NF1) is a common disorder of dysregulated tissue growth secondary to mutations in the tumor suppressor gene NF1"}], "context": "[16835897:16835897_2] Neurofibromatosis type 1 (NF1), characterized by skin neurofibromas and an excess of café-au-lait spots, is due to mutations in the neurofibromin (NF1) gene. Identifying the genetic defect in individuals with the disease represents a significant challenge because the gene is extremely large with a high incidence of sporadic mutations across the entire gene ranging from single nucleotide substitutes to large deletions.\n[19117870:19117870_2] Neurofibromatosis type 1 (NF1) is an autosomal dominant condition with a worldwide incidence of approximately 1 per 2500 to 3000 individuals. Caused by a germ-line-inactivating mutation in the NF1 gene on chromosome 17, the disease is associated with increased morbidity and mortality. In the past several years, significant progress has been made in standardizing management of the major clinical features of neurofibromatosis type 1.\n[17573495:17573495_0] Neurofibromatosis type 1 (NF1) is a common disorder of dysregulated tissue growth secondary to mutations in the tumor suppressor gene NF1", "answer": "<think> Okay, let's tackle this question. The user wants to know the genetic defect causing Neurofibromatosis type 1. Looking at the evidence provided, there are three references. First, reference [16835897:16835897_2] says that NF1 is due to mutations in the neurofibromin (NF1) gene. That seems directly relevant. Then, [19117870:19117870_2] mentions a germ-line-inactivating mutation in the NF1 gene on chromosome 17. The third reference, [17573495:17573495_0], also points to mutations", "citations": [{"doc_id": "16835897", "chunk_id": "16835897_2"}, {"doc_id": "19117870", "chunk_id": "19117870_2"}, {"doc_id": "17573495", "chunk_id": "17573495_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants to know the genetic defect causing Neurofibromatosis type 1. Looking at the evidence provided, there are three references. First, reference [16835897:16835897_2] says that NF1 is due to mutations in the neurofibromin (NF1) gene. That seems directly relevant. Then, [19117870:19117870_2] mentions a germ-line-inactivating mutation in the NF1 gene on chromosome 17. The third reference, [17573495:17573495_0], also points to mutations", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the genetic defect causing Neurofibromatosis type 1. I need to look at the evidence provided and find the correct answer. First, looking at the evidence documents: Document [16835897:16835897_2] says that NF1 is due to mutations in the neurofibromin (NF1) gene. That's a direct statement linking the genetic defect to the NF1 gene. Document [19117870:19117870_2] also mentions a germ-line-inactivating mutation in the NF1 gene on chromosome 17. This reinforces the same answer. Document [17", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the genetic defect causing Neurofibromatosis type 1. I need to look at the provided evidence to find the correct answer. Looking at the first evidence snippet: It says that NF1 is due to mutations in the neurofibromin (NF1) gene. That's a direct statement. The second snippet mentions a germ-line-inactivating mutation in the NF1 gene on chromosome 17. The third one also points to mutations in the tumor suppressor gene NF1. So all three sources agree that the defect is in the NF1 gene. The first one specifies the neurofibromin (NF1) gene, and the others mention the tumor suppressor gene NF1. The key here", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the genetic defect causing Neurofibromatosis type 1. I need to look at the provided evidence to find the correct answer. First, I'll go through each of the evidence chunks. The first one says that NF1 is due to mutations in the neurofibromin (NF1) gene. That's a direct statement. The second chunk mentions a germ-line-inactivating mutation in the NF1 gene on chromosome 17. The third chunk refers to mutations in the tumor suppressor gene NF1. All three sources point to the NF1 gene as the cause. The first and second chunks specifically mention mutations in the NF1 gene, while the third confirms it's a tumor suppressor", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the genetic defect causing Neurofibromatosis type 1. I need to look at the provided evidence to find the correct answer. First, I'll go through each of the evidence chunks. The first chunk [16835897:16835897_2] says that NF1 is due to mutations in the neurofibromin (NF1) gene. That seems directly relevant. It also mentions the gene is large with various mutation types, but the key point here is the NF1 gene. The second chunk [19117870:19117870_2] states that NF1 is caused by a", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the genetic defect causing Neurofibromatosis type 1. I need to look at the provided evidence to find the correct answer. First, I'll go through each of the evidence chunks. The first one says that NF1 is due to mutations in the neurofibromin (NF1) gene. That seems directly relevant. The second chunk mentions a germ-line-inactivating mutation in the NF1 gene on chromosome 17. The third chunk states that it's caused by mutations in the tumor suppressor gene NF1. All three sources point to the NF1 gene as the cause. The first and second chunks specifically mention mutations in the NF1 gene, while the third refers to the tumor", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to figure out the genetic defect causing Neurofibromatosis type 1 based on the provided evidence. Let me look at the evidence snippets. The first snippet says that NF1 is due to mutations in the neurofibromin (NF1) gene. The second mentions a germ-line-inactivating mutation in the NF1 gene on chromosome 17. The third one also points to mutations in the tumor suppressor gene NF1. All three sources consistently mention the NF1 gene as the cause. The first snippet specifically says \"mutations in the neurofibromin (NF1) gene,\" and the others refer to \"NF1 gene.\" So the answer should be that the genetic defect is a mutation in the NF1 gene. Now, checking", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the genetic defect causing Neurofibromatosis type 1. I need to look at the provided evidence to find the correct answer. First, I'll go through each of the evidence chunks. The first chunk [16835897:16835897_2] says that NF1 is due to mutations in the neurofibromin (NF1) gene. That's a direct statement. It also mentions the gene is large with various types of mutations, but the key point here is the NF1 gene. The second chunk [19117870:19117870_2] states that NF1 is caused", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["14722917", "16323217", "16835897", "2129297", "21567923"], "ideal_answer": "Neurofibromatosis type 1 (NF1) is due to all types of mutations in the neurofibromin (NF1) gene."}
{"question_id": "5343caffaeec6fbd07000002", "question": "Which is the human selenoprotein that contains several Se-Cys residues?", "retrieved_chunks": [{"doc_id": "15777501", "chunk_id": "15777501_0", "score": 5.630316734313965, "text": "Human selenoprotein P (HSelP) is unique protein that contains 10 selenocysteines encoded by 10 inframe UGA"}, {"doc_id": "20417644", "chunk_id": "20417644_0", "score": 4.525123596191406, "text": "selenoprotein P and several other selenoproteins are known to contain multiple selenocysteines"}, {"doc_id": "10692426", "chunk_id": "10692426_0", "score": 3.756789207458496, "text": "Selenoprotein P is unique in that its mRNA encodes 10-12 selenocysteine residues"}], "context": "[15777501:15777501_0] Human selenoprotein P (HSelP) is unique protein that contains 10 selenocysteines encoded by 10 inframe UGA\n[20417644:20417644_0] selenoprotein P and several other selenoproteins are known to contain multiple selenocysteines\n[10692426:10692426_0] Selenoprotein P is unique in that its mRNA encodes 10-12 selenocysteine residues", "answer": "<think> Okay, let's tackle this question. The user is asking which human selenoprotein contains several Se-Cys residues. The evidence provided mentions three sources. First, looking at the evidence: - The first source [15777501:15777501_0] says Human selenoprotein P (HSelP) has 10 selenocysteines encoded by 10 in-frame UGA. That's a direct mention of HSelP containing multiple Se-Cys. - The second source [20417644:20417644_0] mentions that selenoprotein P and others have multiple selenocysteines. So it", "citations": [{"doc_id": "15777501", "chunk_id": "15777501_0"}, {"doc_id": "20417644", "chunk_id": "20417644_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants to know which human selenoprotein contains several Se-Cys residues. The evidence provided has three documents. First, looking at the evidence: Document 15777501 says that human selenoprotein P (HSelP) has 10 selenocysteines encoded by 10 inframe UGA. That's a direct mention of HSelP containing multiple Se-Cys. Document 20417644 mentions that selenoprotein P and others have multiple selenocysteines. So this supports the idea that HSelP is one such protein. Document 10692426 states that Selenoprotein", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which human selenoprotein contains several Se-Cys (selenocysteine) residues. The evidence provided has three chunks. First, I need to recall what selenoproteins are. They're proteins that contain selenium in the form of selenocysteine (Sec), which is incorporated via a UGA stop codon. The question specifies \"several\" Se-Cys residues, so the answer should be a protein known for having multiple selenocysteines. Looking at the evidence: Chunk 15777501: Talks about human selenoprotein P (HSelP) containing 10 selenocysteines encoded by 1", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which human selenoprotein contains several Se-Cys residues. The evidence provided mentions three sources. First, looking at the evidence: - The first source [15777501:15777501_0] says Human selenoprotein P (HSelP) has 10 selenocysteines encoded by 10 in-frame UGA. That's a direct mention of HSelP containing multiple Se-Cys. - The second source [20417644:20417644_0] mentions that selenoprotein P and others have multiple selenocysteines. So it", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which human selenoprotein contains several Se-Cys residues. The evidence provided has three documents. First, I need to understand what a selenoprotein is. Selenoproteins are proteins that contain selenium in the form of selenocysteine (Sec), which is incorporated into the protein structure via UGA codons. The question specifically mentions \"several Se-Cys residues,\" so we're looking for a protein with multiple selenocysteines. Looking at the evidence: Document 15777501: It says Human selenoprotein P (HSelP) has 10 selenocysteines encoded by 10 in-frame U", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which human selenoprotein contains several Se-Cys residues. The evidence provided has three documents. First, looking at the evidence: Document 15777501 mentions that Human selenoprotein P (HSelP) has 10 selenocysteines encoded by 10 in-frame UGA. That's a direct mention of HSelP containing multiple selenocysteines. Document 20417644 states that selenoprotein P and others have multiple selenocysteines. So this supports the idea that HSelP is one such protein. Document 10692426 says Selenop", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which human selenoprotein contains several Se-Cys (selenocysteine) residues. The evidence provided has three references. First, I need to recall what selenoproteins are. They're proteins that contain selenium in the form of selenocysteine (Sec), which is a substituted cysteine. The question specifically asks for the human one with multiple Se-Cys residues. Looking at the evidence: 1. Reference 15777501: It mentions Human selenoprotein P (HSelP) has 10 selenocysteines encoded by 10 in-frame UGA codons. So this directly points to HSelP", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which human selenoprotein contains several Se-Cys (selenocysteine) residues. The evidence provided has three references. First, I need to recall what selenoproteins are. They're proteins that contain selenium in the form of selenocysteine (Sec), which is a substituted cysteine. The question specifies \"several\" Se-Cys residues, so the answer should be a protein known for having multiple selenocysteines. Looking at the evidence: - Reference 15777501: Mentions human selenoprotein P (HSelP) has 10 selenocysteines encoded by 10 in", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which human selenoprotein contains several Se-Cys residues. The evidence provided has three documents. First, I need to understand what a selenoprotein is. Selenoproteins are proteins that contain selenium in the form of selenocysteine (Sec), which is a substituted cysteine. The question specifically mentions \"Se-Cys residues,\" which likely refers to selenocysteine residues. Looking at the evidence: Document 15777501: It says Human selenoprotein P (HSelP) has 10 selenocysteines encoded by 10 in-frame UGA. So this directly mentions HSelP with multiple", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["10692426", "11122377", "15104205", "15777501", "17000762", "19345254", "20417644", "7637580", "9288402"], "ideal_answer": "Selenoprotein P, that contains 10 selenocysteines."}
{"question_id": "56a39d60496b62f23f000006", "question": "Which package is available for analysing genomic interactions in R/Bioconductor?", "retrieved_chunks": [{"doc_id": "23671339", "chunk_id": "23671339_2", "score": 7.724725723266602, "text": "r3Cseq: an R/Bioconductor package for the discovery of long-range genomic interactions from chromosome conformation capture and next-generation sequencing data."}, {"doc_id": "23671339", "chunk_id": "23671339_1", "score": 7.5556960105896, "text": "r3Cseq: an R/Bioconductor package for the discovery of long-range genomic interactions from chromosome conformation capture and next-generation sequencing data"}, {"doc_id": "26424858", "chunk_id": "26424858_5", "score": 6.306248664855957, "text": "regioneR: an R/Bioconductor package for the association analysis of genomic regions based on permutation tests"}], "context": "[23671339:23671339_2] r3Cseq: an R/Bioconductor package for the discovery of long-range genomic interactions from chromosome conformation capture and next-generation sequencing data.\n[23671339:23671339_1] r3Cseq: an R/Bioconductor package for the discovery of long-range genomic interactions from chromosome conformation capture and next-generation sequencing data\n[26424858:26424858_5] regioneR: an R/Bioconductor package for the association analysis of genomic regions based on permutation tests", "answer": "<think> Okay, let's tackle this question. The user is asking which package is available for analyzing genomic interactions in R/Bioconductor. The evidence provided has three entries. First, I need to look at each piece of evidence. The first two entries both mention \"r3Cseq\" as an R/Bioconductor package for discovering long-range genomic interactions from chromosome conformation capture and next-gen sequencing data. The third entry talks about \"regioneR\" for association analysis of genomic regions using permutation tests. The question is specifically about analyzing genomic interactions, so the key here is to match the package to the correct purpose. The r3Cseq is directly mentioned in the context of long-range genomic interactions, which aligns with the question. The regioneR, while related", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which package is available for analyzing genomic interactions in R/Bioconductor. The evidence provided has three entries. First, I need to look at each piece of evidence. The first two entries both mention \"r3Cseq\" as an R/Bioconductor package for discovering long-range genomic interactions from chromosome conformation capture and next-gen sequencing data. The third entry talks about \"regioneR\" for association analysis of genomic regions using permutation tests. The question is specifically about analyzing genomic interactions, so the key here is to match the package to the correct purpose. The r3Cseq is directly mentioned in the context of long-range genomic interactions, which aligns with the question. The regioneR, while related", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which R/Bioconductor package is available for analyzing genomic interactions. The evidence provided has three entries. First, I need to look at the evidence. The first two entries both mention \"r3Cseq\" as an R/Bioconductor package for discovering long-range genomic interactions using chromosome conformation capture and next-generation sequencing data. The third entry talks about \"regioneR\" but it's for association analysis of genomic regions based on permutation tests. The question specifically asks about analyzing genomic interactions, which aligns with the description of r3Cseq. The other package, regioneR, seems related to different type of analysis (association tests) rather than interaction analysis. So the correct answer should be r", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's see. The user is asking which package is available for analyzing genomic interactions in R/Bioconductor. The evidence provided has three entries. First, I need to look at each piece of evidence. The first two entries both mention \"r3Cseq\" as an R/Bioconductor package for discovering long-range genomic interactions from chromosome conformation capture and next-gen sequencing data. The third entry talks about \"regioneR\" for association analysis of genomic regions using permutation tests. The question is specifically about analyzing genomic interactions, so the key term here is \"genomic interactions.\" The r3Cseq package is directly mentioned in the context of discovering long-range genomic interactions, which matches the query. The regioneR package, while related to genomic regions,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which package is available for analysing genomic interactions in R/Bioconductor. The evidence provided has three entries. First, I need to look at each piece of evidence. The first two entries both mention \"r3Cseq: an R/Bioconductor package for the discovery of long-range genomic interactions...\" So that's a direct match to the question. The third entry talks about \"regioneR\" which is for association analysis of genomic regions, but not specifically about interactions. So the answer should be r3Cseq. The confidence is high because two different chunks mention the same package in the context of genomic interactions. The other package isn't related to interactions. I need to make sure the JSON structure", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which package is available for analysing genomic interactions in R/Bioconductor. The evidence provided has three entries. First, I need to look at each of the evidence points. The first two entries both mention \"r3Cseq\" as an R/Bioconductor package for discovering long-range genomic interactions from chromosome conformation capture and next-gen sequencing data. The third entry talks about \"regioneR\" but it's for association analysis of genomic regions using permutation tests. The question specifically asks about analysing genomic interactions, which aligns with the description of r3Cseq. The other package, regioneR, seems more about association analysis rather than interaction analysis. So, the correct answer should be r3", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which package is available for analyzing genomic interactions in R/Bioconductor. The evidence provided has three entries. First, I need to look at each piece of evidence. The first two entries both mention \"r3Cseq\" as an R/Bioconductor package for discovering long-range genomic interactions from chromosome conformation capture and next-generation sequencing data. The third entry talks about \"regioneR\" for association analysis of genomic regions using permutation tests. The question specifically asks about analyzing genomic interactions, which aligns with the description of r3Cseq. The other package, regioneR, is mentioned in the context of association analysis, which might not be directly about interactions. So, the correct answer should be r", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which package is available for analyzing genomic interactions in R/Bioconductor. The evidence provided has three entries. First, I need to look at each piece of evidence. The first two entries both mention \"r3Cseq\" as an R/Bioconductor package for discovering long-range genomic interactions using chromosome conformation capture and next-gen sequencing data. The third entry talks about \"regioneR\" for association analysis of genomic regions via permutation tests. The question is specifically about analyzing genomic interactions, which aligns with the description of r3Cseq. The other package, regioneR, seems more about association analysis rather than interactions. So, the correct answer should be r3Cseq. Now, checking", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which package is available for analyzing genomic interactions in R/Bioconductor. The evidence provided has three entries. First, I need to look at each piece of evidence. The first two entries both mention \"r3Cseq\" as an R/Bioconductor package for discovering long-range genomic interactions using chromosome conformation capture and next-gen sequencing data. The third entry talks about \"regioneR\" for association analysis of genomic regions via permutation tests. The question specifically asks about analyzing genomic interactions, which aligns with the description of r3Cseq. The other package, regioneR, is mentioned in the context of association analysis, which might not be directly about interactions but rather statistical associations. However, the user", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["23671339"], "ideal_answer": "r3Cseq is an R/Bioconductor package designed to perform 3C-seq data analysis in a number of different experimental designs. The package reads a common aligned read input format, provides data normalization, allows the visualization of candidate interaction regions and detects statistically significant chromatin interactions, thus greatly facilitating hypothesis generation and the interpretation of experimental results."}
{"question_id": "5150b807d24251bc05000072", "question": "How many clinical trials for off-label drugs in neonates are cited in the literature.", "retrieved_chunks": [{"doc_id": "20821198", "chunk_id": "20821198_0", "score": 5.636474609375, "text": "Of the 17 Paediatric Investigation Plans submitted, 14 have resulted in an EMA Decision, 3 were withdrawn by the applicants, 8 were granted a full waiver from development, and 1 resulted in a negative opinion. Decisions as issued included 15 clinical trials, with at least 1,282 children to be recruited into studies across five different products. Neonates were included in four of the products. CONCLUSIONS: The small number of submissions indicates a lack of new drugs being developed for the management of pain. Ethical concerns that too many vulnerable children will be recruited into clinical trials must be balanced against limiting the number of off-label prescribing and obtaining age-appropriate information on paediatric use."}, {"doc_id": "23093633", "chunk_id": "23093633_1", "score": -0.7523602247238159, "text": "Treatment of PE typically involves pharmacotherapy, particularly when lifelong. Although there are numerous reports on the off-label use of selective serotonin reuptake inhibitors (SSRIs) and other compounds, only 2 treatments have been evaluated in randomized controlled phase 3 clinical trials: PSD502 and dapoxetine (SSRI)"}, {"doc_id": "23700188", "chunk_id": "23700188_0", "score": -3.842088222503662, "text": "<AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">In our study, off-label rituximab was mainly used for the treatment of hematological, kidney, and systemic connective tissue disorders, and the response among our patient cohort was variable depending on the specific disease."}], "context": "[20821198:20821198_0] Of the 17 Paediatric Investigation Plans submitted, 14 have resulted in an EMA Decision, 3 were withdrawn by the applicants, 8 were granted a full waiver from development, and 1 resulted in a negative opinion. Decisions as issued included 15 clinical trials, with at least 1,282 children to be recruited into studies across five different products. Neonates were included in four of the products. CONCLUSIONS: The small number of submissions indicates a lack of new drugs being developed for the management of pain. Ethical concerns that too many vulnerable children will be recruited into clinical trials must be balanced against limiting the number of off-label prescribing and obtaining age-appropriate information on paediatric use.\n[23093633:23093633_1] Treatment of PE typically involves pharmacotherapy, particularly when lifelong. Although there are numerous reports on the off-label use of selective serotonin reuptake inhibitors (SSRIs) and other compounds, only 2 treatments have been evaluated in randomized controlled phase 3 clinical trials: PSD502 and dapoxetine (SSRI)\n[23700188:23700188_0] <AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">In our study, off-label rituximab was mainly used for the treatment of hematological, kidney, and systemic connective tissue disorders, and the response among our patient cohort was variable depending on the specific disease.", "answer": "<think> Okay, let's tackle this question. The user is asking how many clinical trials for off-label drugs in neonates are cited in the literature. The evidence provided has three documents. First, looking at document [20821198:20821198_0], it mentions that there are 15 clinical trials mentioned in the decisions. However, this is in the context of Paediatric Investigation Plans, and neonates were included in four of the products. But the document doesn't explicitly state how many of those trials specifically involve off-label drugs. It talks about a lack of new drugs for pain management and mentions ethical concerns, but not directly the number of off-label trials. Next, [23093633", "citations": [{"doc_id": "20821198", "chunk_id": "20821198_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking how many clinical trials for off-label drugs in neonates are cited in the literature based on the provided evidence. First, I need to look through each of the evidence documents to find mentions of clinical trials related to off-label drugs in neonates. Looking at the first document (20821198:20821198_0), it talks about 15 clinical trials as part of the EMA decisions. It also mentions that neonates were included in four of the products. However, the document doesn't explicitly state how many of those trials are off-label. It does mention that the small number of submissions indicates a lack of new drugs for pain management, but this is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking how many clinical trials for off-label drugs in neonates are cited in the literature. The evidence provided has three documents. First, I need to look at each document to see if they mention clinical trials involving neonates and off-label drugs. Looking at the first document (20821198:20821198_0), it talks about 15 clinical trials across five products, with neonates included in four of the products. However, the document doesn't explicitly state that these trials are for off-label drugs. It mentions that some drugs were waived from development, but the trials mentioned here might be for approved drugs. The conclusion part says there's a lack of new", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking how many clinical trials for off-label drugs in neonates are cited in the literature, based on the provided evidence. First, I need to look through the evidence snippets to find any mentions of clinical trials specifically involving neonates and off-label drugs. Looking at the first document (20821198:20821198_0), it talks about 15 clinical trials as part of the EMA decisions. It also mentions that neonates were included in four of the products. However, this document doesn't explicitly state how many of those trials were for off-label drugs. The mention of \"off-label prescribing\" is there, but the number of trials specifically for neonates", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking how many clinical trials for off-label drugs in neonates are cited in the literature based on the provided evidence. First, I need to look through the evidence documents to find any mentions of clinical trials specifically involving neonates and off-label drugs. Looking at the first document (20821198:20821198_0), it mentions that there are 15 clinical trials as part of the EMA decisions, with neonates included in four of the products. However, this document doesn't explicitly state how many of those trials are off-label. It talks about Paediatric Investigation Plans and waivers, but the key point here is that neonates were part of four products", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking how many clinical trials for off-label drugs in neonates are cited in the literature based on the provided evidence. First, I need to look through each of the evidence documents to find mentions of clinical trials involving neonates and off-label drugs. Looking at the first document (20821198:20821198_0), it mentions that there are 15 clinical trials included in the decisions, with neonates included in four of the products. However, this is about Paediatric Investigation Plans and EMA decisions. The conclusion part says that only 15 trials were decided, but it's not clear how many of those are specifically for off-label drugs. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking how many clinical trials for off-label drugs in neonates are cited in the literature. The evidence provided has three documents. First, looking at document [20821198:20821198_0], it mentions that there are 15 clinical trials mentioned in the decisions. However, this is in the context of Paediatric Investigation Plans, and neonates were included in four of the products. But the document doesn't explicitly state how many of those trials specifically involve off-label drugs. It talks about a lack of new drugs for pain management and mentions ethical concerns, but not directly the number of off-label trials. Next, [23093633", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking how many clinical trials for off-label drugs in neonates are cited in the literature. The evidence provided has three documents. First, I need to look through each document to find mentions of clinical trials involving neonates and off-label drugs. Looking at the first document (20821198:20821198_0), it talks about 15 clinical trials across five products, with neonates included in four of the products. However, the document doesn't specify how many of those trials were for off-label drugs. It mentions that some drugs were developed with a full waiver, but that's more about development rather than off-label use. The conclusion part says there are ethical", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking how many clinical trials for off-label drugs in neonates are cited in the literature based on the provided evidence. First, I need to look through the evidence documents to find any mentions of clinical trials specifically involving neonates and off-label drugs. Let me check each document one by one. Looking at the first document (20821198:20821198_0), it talks about 15 clinical trials as part of the EMA decisions. It mentions that neonates were included in four of the products. However, the document doesn't specify how many of those trials were off-label. The conclusion says there's a lack of new drugs for pain management and mentions ethical concerns", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["20821198"], "ideal_answer": "There are no reports on clinical trials of off-label drugs in neonates. An analysis of Pediatric Investigation Plans submitted between 2007 and 2010 shows that neonates were included in the study of 4 products, but it is unknown if the trial drugs are off-label and if the trials are being conducted at all."}
{"question_id": "56c81fd15795f9a73e00000c", "question": "Are stress granules involved in the pathogenesis of Amyotrophic Lateral Sclerosis?", "retrieved_chunks": [{"doc_id": "24090136", "chunk_id": "24090136_2", "score": 8.315494537353516, "text": "Amyotrophic lateral sclerosis (ALS)-linked fused in sarcoma/translocated in liposarcoma (FUS/TLS or FUS) is concentrated within cytoplasmic stress granules under conditions of induced stress. Since only the mutants, but not the endogenous wild-type FUS, are associated with stress granules under most of the stress conditions reported to date, the relationship between FUS and stress granules represents a mutant-specific phenotype and thus may be of significance in mutant-induced pathogenesis."}, {"doc_id": "20699327", "chunk_id": "20699327_2", "score": 6.118817329406738, "text": "Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules."}, {"doc_id": "20699327", "chunk_id": "20699327_1", "score": 5.525748252868652, "text": "Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules"}], "context": "[24090136:24090136_2] Amyotrophic lateral sclerosis (ALS)-linked fused in sarcoma/translocated in liposarcoma (FUS/TLS or FUS) is concentrated within cytoplasmic stress granules under conditions of induced stress. Since only the mutants, but not the endogenous wild-type FUS, are associated with stress granules under most of the stress conditions reported to date, the relationship between FUS and stress granules represents a mutant-specific phenotype and thus may be of significance in mutant-induced pathogenesis.\n[20699327:20699327_2] Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules.\n[20699327:20699327_1] Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules", "answer": "<think> Okay, let's tackle this question. The user is asking if stress granules are involved in the pathogenesis of ALS. The evidence provided has three documents. First, I need to understand what each document says. Document 24090136:24090136_2 mentions that ALS-linked FUS/TLS is concentrated in stress granules under stress conditions. It also notes that only mutant FUS, not the wild-type, associates with these granules, suggesting a mutant-specific phenotype relevant to pathogenesis. Then, documents 20699327:20699327_2 and oint 1 both state that mutant FUS proteins causing ALS incorporate into stress granules. So,", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if stress granules are involved in the pathogenesis of ALS. The evidence provided has three documents. First, I need to understand what each document says. Document 24090136:24090136_2 mentions that ALS-linked FUS/TLS is concentrated in stress granules under stress conditions. It also notes that only mutant FUS, not the wild-type, associates with these granules, suggesting a mutant-specific phenotype relevant to pathogenesis. Then, documents 20699327:20699327_2 and oint 1 both state that mutant FUS proteins causing ALS incorporate into stress granules. So,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if stress granules are involved in the pathogenesis of ALS. The evidence provided has three documents. First, I need to understand what each document says. Document 24090136:24090136_2 mentions that ALS-linked FUS/TLS is found in stress granules under stress conditions. It also notes that only mutant FUS, not the wild-type, associates with these granules, suggesting a possible role in pathogenesis. Then document 20699327:20699327_2 and 1 both state that mutant FUS proteins causing ALS incorporate into stress granules. So, the key points here", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to answer whether stress granules are involved in the pathogenesis of ALS based on the given evidence. Let me look at the evidence provided. First, document 24090136:24090136_2 says that ALS-linked FUS/TLS is concentrated in stress granules under stress conditions. It also mentions that only mutant FUS, not the wild-type, associates with stress granules under most stress conditions. So this suggests a link between mutant FUS and stress granules, which might be relevant to pathogenesis. Then, document 20699327:20699327_2 and 1 both state that mutant FUS proteins causing ALS incorporate into stress", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking if stress granules are involved in the pathogenesis of ALS. Let me look at the evidence provided. First, there's the document 24090136:24090136_2. It says that ALS-linked FUS/TLS is concentrated in stress granules under stress conditions. But it mentions that only the mutant forms are associated with these granules, not the wild-type. So this suggests that the mutant FUS specifically interacts with stress granules, which might be relevant to the pathogenesis. Then there's 20699327:20699327_2 and 1, both stating that mutant FUS proteins causing ALS incorporate into stress", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking if stress granules are involved in the pathogenesis of ALS. Let me look at the evidence provided. First, there's a document (24090136:24090136_2) that says ALS-linked FUS/TLS is concentrated in stress granules under stress conditions. It mentions that only mutant FUS, not the wild-type, associates with these granules. So this suggests a link between mutant FUS and stress granules, which might be part of the pathogenesis. Another document (20699327:20699327_2 and 1) states that mutant FUS proteins causing ALS incorporate into stress granules. These are", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if stress granules are involved in the pathogenesis of ALS. The evidence provided has three chunks. First, I need to understand what each chunk says. The first chunk (24090136:24090136_2) mentions that ALS-linked FUS/TLS is concentrated in stress granules under stress conditions. It also states that only mutant FUS, not the wild-type, is associated with these granules under most stress conditions. So this suggests a link between mutant FUS and stress granules, which might be relevant to pathogenesis. The second chunk (20699327:20699327_2) says", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is whether stress granules are involved in the pathogenesis of ALS. Let me look at the evidence provided. First, there's the document 24090136:24090136_2. It says that ALS-linked FUS/TLS is concentrated in stress granules under stress conditions. But only mutant FUS, not the wild-type, is associated with these granules. So this suggests a link between mutant FUS and stress granules, which might be relevant to pathogenesis. Then document 20699327:20699327_2 and 1 both mention that mutant FUS proteins", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if stress granules are involved in the pathogenesis of ALS. The evidence provided has three chunks. First, I need to understand what each chunk says. The first one (24090136:24090136_2) mentions that ALS-linked FUS/TLS is concentrated in stress granules under stress conditions. It also states that only mutant FUS, not the wild-type, associate with these granules, suggesting a role in pathogenesis. The second chunk (20699327:20699327_2) says mutant FUS proteins cause ALS and incorporate into stress granules. The third chunk is a duplicate of", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["19765185", "20606625", "20674093", "20699327", "21173160", "22405725", "23152885", "23257289", "23474818", "23629963", "24013423", "24090136", "24297750", "24312274", "24336168", "24920614", "25216585", "25429138", "25888396", "26557057"], "ideal_answer": "Stress granules are cytoplasmic inclusions that repress translation of a subset of RNAs in times of cellular stress, and several proteins implicated in neurodegeneration (i.e. Ataxin-2 and SMN) interact with stress granules. Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules. ALS-linked mutations in profilin 1 alter stress granule dynamics, providing further evidence for the potential role of stress granules in ALS pathogenesis. ALS mutations in FUS NLS can impair FUS nuclear localization, induce cytoplasmic inclusions and stress granules, and potentially perturb RNA metabolism. Yes, stress granules (SGs) have been linked to several pathologies including inflammatory diseases, cancer, viral infection, and neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)."}
{"question_id": "52f5083d2059c6d71c00001e", "question": "Does TGF-beta play a role in cardiac regeneration after myocardial infarction?", "retrieved_chunks": [{"doc_id": "15883211", "chunk_id": "15883211_0", "score": 8.152061462402344, "text": "TGF-beta conducted the myogenic differentiation of CD117+ stem cells by upregulating GATA-4 and NKx-2.5 expression. Therefore, the intramyocardial implantation of TGF-beta-preprogrammed CD117+ cells effectively assisted the myocardial regeneration and induced therapeutic angiogenesis, contributing to functional cardiac regeneration."}, {"doc_id": "18620057", "chunk_id": "18620057_0", "score": 6.200766563415527, "text": "Transforming growth factor (TGF)-beta plays a crucial role in cardiac repair by suppressing inflammation while promoting myofibroblast phenotypic modulation and extracellular matrix deposition."}, {"doc_id": "22146760", "chunk_id": "22146760_1", "score": 5.676668643951416, "text": "To investigate whether transmyocardial drilling revascularization combined with heparinized basic fibroblast growth factor (bFGF)-incorporating degradable stent implantation (TMDRSI) can promote myocardial regeneration after acute myocardial infarction"}], "context": "[15883211:15883211_0] TGF-beta conducted the myogenic differentiation of CD117+ stem cells by upregulating GATA-4 and NKx-2.5 expression. Therefore, the intramyocardial implantation of TGF-beta-preprogrammed CD117+ cells effectively assisted the myocardial regeneration and induced therapeutic angiogenesis, contributing to functional cardiac regeneration.\n[18620057:18620057_0] Transforming growth factor (TGF)-beta plays a crucial role in cardiac repair by suppressing inflammation while promoting myofibroblast phenotypic modulation and extracellular matrix deposition.\n[22146760:22146760_1] To investigate whether transmyocardial drilling revascularization combined with heparinized basic fibroblast growth factor (bFGF)-incorporating degradable stent implantation (TMDRSI) can promote myocardial regeneration after acute myocardial infarction", "answer": "<think> Okay, let's tackle this question. The user is asking if TGF-beta plays a role in cardiac regeneration after a myocardial infarction. I need to look at the provided evidence to find answers. First, evidence document [15883211:15883211_0] says that TGF-beta helps myogenic differentiation of CD117+ stem cells by upregulating GATA-4 and NKx-2.5. This leads to myocardial regeneration and therapeutic angiogenesis. So that's a direct mention of TGF-beta's role in cardiac regeneration. Then, document [18620057:18620057_0] states that TGF-beta is", "citations": [{"doc_id": "15883211", "chunk_id": "15883211_0"}, {"doc_id": "18620057", "chunk_id": "18620057_0"}], "candidates": [{"answer": "<think> Okay, so the user is asking if TGF-beta plays a role in cardiac regeneration after a heart attack. Let me look at the evidence provided. First, document 15883211:15883211_0 says that TGF-beta helps myogenic differentiation of CD117+ stem cells by upregulating GATA-4 and NKx-2.5. This leads to myocardial regeneration and therapeutic angiogenesis. That's a direct mention of TGF-beta's role in cardiac regeneration. Then, document 18620057:18620057_0 states that TGF-beta is crucial in cardiac repair by suppressing inflammation and promoting myofibroblast phenotyp", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if TGF-beta plays a role in cardiac regeneration after a myocardial infarction. I need to look at the provided evidence to find relevant information. First, looking at the first evidence snippet: It says that TGF-beta helps in myogenic differentiation of CD117+ stem cells by upregulating GATA-4 and NKx-2.5. This leads to myocardial regeneration and therapeutic angiogenesis. So that's a direct mention of TGF-beta's role in cardiac regeneration. The second snippet mentions TGF-beta suppressing inflammation and promoting myofibroblast phenotypic modulation and ECM deposition, which are part of the repair process. That also supports a role in cardiac repair. The third", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if TGF-beta plays a role in cardiac regeneration after a myocardial infarction. I need to look at the evidence provided. First, evidence document 15883211:15883211_0 mentions that TGF-beta helps in myogenic differentiation of CD117+ stem cells by upregulating GATA-4 and NKx-2.5. This leads to myocardial regeneration and therapeutic angiogenesis. So that's a direct role in cardiac regeneration. Then, document 18620057:18620057_0 states that TGF-beta is crucial for cardiac repair by suppressing inflammation and promoting my", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if TGF-beta plays a role in cardiac regeneration after a myocardial infarction. I need to look at the provided evidence to find answers. First, evidence document [15883211:15883211_0] says that TGF-beta helps myogenic differentiation of CD117+ stem cells by upregulating GATA-4 and NKx-2.5. This leads to myocardial regeneration and therapeutic angiogenesis. So that's a direct mention of TGF-beta's role in cardiac regeneration. Then, document [18620057:18620057_0] states that TGF-beta is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to answer whether TGF-beta plays a role in cardiac regeneration after myocardial infarction based on the given evidence. Let's look at the evidence provided. First evidence: [15883211:15883211_0] says that TGF-beta helps in myogenic differentiation of CD117+ stem cells by upregulating GATA-4 and NKx-2.5. This leads to myocardial regeneration and therapeutic angiogenesis. So this directly supports a role in cardiac regeneration. Second evidence: [18620057:18620057_0] states that TGF-beta is crucial for cardiac repair by suppressing inflammation, promoting myofib", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if TGF-beta plays a role in cardiac regeneration after a myocardial infarction. I need to look at the evidence provided. First, evidence document 15883211:15883211_0 says that TGF-beta helps myogenic differentiation of CD117+ stem cells by upregulating GATA-4 and NKx-2.5. This leads to myocardial regeneration and therapeutic angiogenesis. So that's a direct mention of TGF-beta's role in cardiac regeneration. Then, document 18620057:18620057_0 states that TGF-beta is crucial in cardiac repair by", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if TGF-beta plays a role in cardiac regeneration after a myocardial infarction. I need to look at the evidence provided. First, evidence document 15883211:15883211_0 says that TGF-beta helps myogenic differentiation of CD117+ stem cells by upregulating GATA-4 and NKx-2.5. This leads to myocardial regeneration and therapeutic angiogenesis. So that's a direct mention of TGF-beta contributing to cardiac regeneration. Then document 18620057:18620057_0 states that TGF-beta is crucial in cardiac repair by suppressing inflammation", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if TGF-beta plays a role in cardiac regeneration after a myocardial infarction. I need to look at the evidence provided to form an answer. First, looking at the evidence documents. The first one, 15883211:15883211_0, says that TGF-beta helps myogenic differentiation of CD117+ stem cells by upregulating GATA-4 and NKx-2.5. This leads to myocardial regeneration and therapeutic angiogenesis. So that's a direct role in cardiac regeneration. The second document, 18620057:18620057_0, mentions T", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["10198196", "12374778", "15883211", "16842199", "17322368", "18985280", "19966054", "22513374", "23293297"], "ideal_answer": "TGFβ signaling orchestrates the beneficial interplay between scar-based repair and cardiomyocyte-based regeneration to achieve complete heart regeneration."}
{"question_id": "56cf413f3975bb303a000009", "question": "Is there a genetic component for happiness?", "retrieved_chunks": [{"doc_id": "22885141", "chunk_id": "22885141_0", "score": 3.399440288543701, "text": "Although twin studies estimate that genetic factors account for 35-50% of the variance in human happiness, knowledge of specific genes is limited."}, {"doc_id": "26060713", "chunk_id": "26060713_0", "score": 3.2153449058532715, "text": "inally, a systematic review performed based on existing information. Results of studies on genetic factors indicated an average effectiveness of genetic about 35 -50 percent on happiness."}, {"doc_id": "20440640", "chunk_id": "20440640_0", "score": 2.9747071266174316, "text": "Biometric studies have shown that happiness is strongly affected by genes."}], "context": "[22885141:22885141_0] Although twin studies estimate that genetic factors account for 35-50% of the variance in human happiness, knowledge of specific genes is limited.\n[26060713:26060713_0] inally, a systematic review performed based on existing information. Results of studies on genetic factors indicated an average effectiveness of genetic about 35 -50 percent on happiness.\n[20440640:20440640_0] Biometric studies have shown that happiness is strongly affected by genes.", "answer": "<think> Okay, the user is asking if there's a genetic component to happiness. Let me look at the evidence provided. First, evidence document 22885141 says twin studies show genetics account for 35-50% of variance in happiness, but specific genes are limited. Then, 26060713 repeats that genetic factors have an average effectiveness of 35-50% on happiness. And 20440640 mentions biometric studies show genes strongly affect happiness. So all three sources agree that genetics play a role, with the percentage ranging around 35-50%. The answer should state that there is a genetic component, citing these documents. The confidence level is high since multiple studies", "citations": [], "candidates": [{"answer": "<think> Okay, the user is asking if there's a genetic component to happiness. Let me look at the evidence provided. First, evidence document 22885141 says twin studies show genetics account for 35-50% of variance in happiness, but specific genes are limited. Then, 26060713 repeats that genetic factors have an average effectiveness of 35-50% on happiness. And 20440640 mentions biometric studies show genes strongly affect happiness. So all three sources agree that genetics play a role, with the percentage ranging around 35-50%. The answer should state that there is a genetic component, citing these documents. The confidence level is high since multiple studies", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking if there's a genetic component to happiness. Let me look at the evidence provided. First, there are three documents. The first one says twin studies estimate genetics account for 35-50% of variance in happiness, but specific genes aren't well understood. The second document is similar, mentioning a systematic review with average effectiveness of 35-50% from genetic factors. The third states that biometric studies show happiness is strongly affected by genes. So all three sources point to a genetic component, with the percentage ranging between 35-50%. The answer should combine these points. The user wants a concise answer with citations in the format [doc_id:chunk_id]. Also, the base confidence is a float between", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking if there's a genetic component to happiness. Let me look at the evidence provided. First, there are three documents. The first one says twin studies estimate genetic factors account for 35-50% of variance in happiness, but specific genes aren't well known. The second document is similar, mentioning a systematic review with average effectiveness of genetic factors at 35-50%. The third states that biometric studies show happiness is strongly affected by genes. So, all three sources agree that genetics play a significant role, with the percentage ranging between 35-50%. The answer should reflect that there is a genetic component, citing these studies. The confidence level should be high since multiple sources support this. But I need to make", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking if there's a genetic component to happiness. Let me look at the evidence provided. First, there's a twin study mentioned that says genetic factors account for 35-50% of variance in happiness. That's from document 22885141. Then another source, 26060713, also mentions studies showing genetic effectiveness around 35-50%. The third one, 20440640, says biometric studies show genes strongly affect happiness. So all three pieces of evidence point to a genetic component, with percentages ranging from 35-50%. The confidence here is pretty high since multiple studies are cited. The model's base confidence should", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking if there's a genetic component to happiness. Let me look at the evidence provided. First, there are three documents. The first one says twin studies show genetics account for 35-50% of variance in happiness, but specific genes aren't well known. The second document mentions a systematic review finding an average effectiveness of genetic factors at 35-50% on happiness. The third states that biometric studies show happiness is strongly affected by genes. So all three pieces of evidence point to a genetic component, with the percentage ranging between 35-50%. The answer needs to be concise and include citations. The confidence level should reflect the consensus among the sources. Since all three mention similar percentages and the general agreement, I", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking if there's a genetic component to happiness. Let me look at the evidence provided. First, there are three documents. The first one says twin studies estimate genetic factors account for 35-50% of variance in happiness, but specific genes aren't well known. The second document is similar, mentioning a systematic review with average effectiveness of 35-50% from genetic factors. The third states that biometric studies show happiness is strongly affected by genes. So all three sources agree that genetics play a significant role, with the percentage ranging between 35-50%. The answer needs to be concise and include citations. The confidence level should be high since multiple studies support this. But I need to check if there's any conflicting", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking if there's a genetic component to happiness. Let me look at the evidence provided. First, there are three documents. The first one says twin studies show genetics account for 35-50% of variance in happiness, but specific genes aren't well known. The second document is similar, mentioning a systematic review with average effectiveness of 35-50% from genetic factors. The third states that biometric studies show happiness is strongly affected by genes. So all three pieces of evidence point to a genetic component, with the percentage ranging between 35-50%. The answer needs to be concise and include citations. The confidence should be high since multiple sources agree. I need to make sure the answer is in JSON format with the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking if there's a genetic component to happiness. Let me look at the evidence provided. First, evidence from 22885141:22885141_0 mentions twin studies showing genetics account for 35-50% of variance in happiness, but specific genes are not well understood. Then 26060713:26060713_0 repeats the 35-50% effectiveness of genetic factors. The third piece, 20440640:20440640_0, states biometric studies show genes strongly affect happiness. So all three sources agree that genetics play a significant role, with", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["19569406", "19728071", "20397744", "20440640", "20981772", "22885141", "23769682", "24690898", "26060713"], "ideal_answer": "Results of studies on genetic factors indicated an average effectiveness of genetic about 35 -50 percent on happiness. The MAOA gene predicts happiness in women. The heritability of happiness was estimated at 22% for males and 41% in females."}
{"question_id": "56c1d857ef6e394741000033", "question": "What enzyme is inhibied by Opicapone?", "retrieved_chunks": [{"doc_id": "24925090", "chunk_id": "24925090_2", "score": 2.872832775115967, "text": "Opicapone is a novel third generation catechol-O-methyltransferase (COMT) inhibitor."}, {"doc_id": "23248072", "chunk_id": "23248072_1", "score": 2.8310461044311523, "text": "Opicapone is a novel catechol-O-methyltransferase (COMT) inhibitor."}, {"doc_id": "24925090", "chunk_id": "24925090_0", "score": 2.387336492538452, "text": "BACKGROUND AND OBJECTIVES: Opicapone is a novel third generation catechol-O-methyltransferase (COMT) inhibitor. The purpose of this study was to compare the levodopa pharmacokinetic profile throughout a day driven by the COMT inhibition either following repeated doses of opicapone or concomitant administration with entacapone."}], "context": "[24925090:24925090_2] Opicapone is a novel third generation catechol-O-methyltransferase (COMT) inhibitor.\n[23248072:23248072_1] Opicapone is a novel catechol-O-methyltransferase (COMT) inhibitor.\n[24925090:24925090_0] BACKGROUND AND OBJECTIVES: Opicapone is a novel third generation catechol-O-methyltransferase (COMT) inhibitor. The purpose of this study was to compare the levodopa pharmacokinetic profile throughout a day driven by the COMT inhibition either following repeated doses of opicapone or concomitant administration with entacapone.", "answer": "<think> Okay, let's tackle this question. The user is asking which enzyme is inhibited by Opicapone. Looking at the evidence provided, there are several documents mentioning Opicapone as a catechol-O-methyltransferase (COMT) inhibitor. Specifically, documents [24925090:24925090_2], [23248072:23248072_1], and [24925090:24925090_0] all state that Opicapone is a COMT inhibitor. The answer should be COMT, and the citations would be those documents. The confidence level is high since all three sources agree. So", "citations": [{"doc_id": "24925090", "chunk_id": "24925090_2"}, {"doc_id": "23248072", "chunk_id": "23248072_1"}, {"doc_id": "24925090", "chunk_id": "24925090_0"}], "candidates": [{"answer": "<think> Okay, so the user is asking which enzyme is inhibited by Opicapone. Let me look at the evidence provided. The evidence has three entries. The first one, 24925090:24925090_2, says Opicapone is a novel third generation catechol-O-methyltransferase (COMT) inhibitor. The second entry, 23248072:23248072_1, also states that Opicapone is a novel COMT inhibitor. The third one, 24925090:24925090_0, mentions the same thing again in the background and objectives. All three pieces of", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking which enzyme is inhibited by Opicapone. Let me look at the evidence provided. The evidence has three entries. The first one, 24925090:24925090_2, says Opicapone is a novel third-generation catechol-O-methyltransferase (COMT) inhibitor. The second entry, 23248072:23248072_1, also mentions it's a novel COMT inhibitor. The third one, 24925090:24925090_0, talks about the same thing again, mentioning COMT inhibition. All three sources consistently state that", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which enzyme is inhibited by Opicapone. Looking at the evidence provided, there are three entries. The first one, 24925090:24925090_2, mentions that Opicapone is a novel third-generation catechol-O-methyltransferase (COMT) inhibitor. The second entry, 23248072:23248072_1, repeats the same information about COMT inhibition. The third entry, 24925090:24925090_0, also states that Opicapone is a COMT inhibitor, with some background on its", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which enzyme is inhibited by Opicapone. Looking at the evidence provided, there are several documents mentioning Opicapone as a catechol-O-methyltransferase (COMT) inhibitor. Specifically, documents [24925090:24925090_2], [23248072:23248072_1], and [24925090:24925090_0] all state that Opicapone is a COMT inhibitor. The answer should be COMT, and the citations would be those documents. The confidence level is high since all three sources agree. So", "base_prob": 0.5, "critic": {"rel_label": "Rel", "rel_prob": 0.98, "sup_label": "Fully", "sup_prob": 1.0, "use_score": 5, "use_prob": 1.0, "notes": "All three evidence snippets explicitly state Opicapone inhibits COMT, directly answering the question with high confidence."}, "score": 6.676, "safe": true, "has_citation": 1}, {"answer": "<think> Okay, so the user is asking which enzyme is inhibited by Opicapone. Let me look at the evidence provided. The evidence has three entries. The first one, 24925090:24925090_2, says Opicapone is a novel third-generation catechol-O-methyltransferase (COMT) inhibitor. The second entry, 23248072:23248072_1, also mentions it's a novel COMT inhibitor. The third one, 24925090:24925090_0, talks about the same thing, noting it's a third-generation COMT inhibitor. All three", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to figure out which enzyme Opicapone inhibits based on the provided evidence. Let me look at the evidence again. The user provided three evidence points. The first one says Opicapone is a novel third-generation catechol-O-methyltransferase (COMT) inhibitor. The second also mentions it's a novel catechol-O-methyltransferase inhibitor. The third one is about a study comparing levodopa pharmacokinetics with COMT inhibition using opicapone. So all three pieces of evidence point to COMT as the enzyme being inhibited. The answer should be COMT. The citations are from documents 24925090 and 23248072. The confidence is high because all", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking which enzyme is inhibited by Opicapone. Let me look at the evidence provided. The evidence has three entries. The first one, 24925090:24925090_2, says Opicapone is a novel third-generation catechol-O-methyltransferase (COMT) inhibitor. The second entry, 23248072:23248072_1, also mentions it's a novel COMT inhibitor. The third one, 24925090:24925090_0, talks about the same thing, stating it's a third-generation COMT inhibitor. All three", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which enzyme is inhibited by Opicapone. Looking at the evidence provided, there are several documents mentioning Opicapone as a catechol-O-methyltransferase (COMT) inhibitor. Specifically, documents [24925090:24925090_2], [23248072:23248072_1], and [24925090:24925090_0] all state that Opicapone is a COMT inhibitor. The answer should be COMT, and the citations would be from those documents. The confidence level is high since multiple sources agree on this", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 6.676, "gold_docs": ["23248072", "23336248", "24148813", "24271646", "24925090"], "ideal_answer": "Opicapone is a novel catechol-O-methyltransferase (COMT) inhibitor to be used as adjunctive therapy in levodopa-treated patients with Parkinson's disease"}
{"question_id": "5140569623fec90375000003", "question": "What kind of affinity purification would you use in order to isolate soluble lysosomal proteins?", "retrieved_chunks": [{"doc_id": "18370023", "chunk_id": "18370023_0", "score": 6.215539455413818, "text": "This chapter describes the process of production, purification, separation, and mass spectrometry identification of soluble lysosomal proteins. The rationale for purification of these proteins resides in their characteristic sugar, the mannose-6-phosphate (M6P), which allows an easy purification by affinity chromatography on immobilized M6P receptor (MPR"}, {"doc_id": "15789345", "chunk_id": "15789345_0", "score": 5.750038146972656, "text": "Proteins containing mannose 6-phosphate (Man6-P), a carbohydrate modification used for targeting resident soluble lysosomal proteins to the lysosome, were affinity-purified using immobilized Man6-P receptor."}, {"doc_id": "11079561", "chunk_id": "11079561_0", "score": 4.473684787750244, "text": "Since lysosomal soluble proteins are characterized by the presence of mannose-6-phosphate, they were purified on an affinity support bearing mannose-6-phosphate receptor"}], "context": "[18370023:18370023_0] This chapter describes the process of production, purification, separation, and mass spectrometry identification of soluble lysosomal proteins. The rationale for purification of these proteins resides in their characteristic sugar, the mannose-6-phosphate (M6P), which allows an easy purification by affinity chromatography on immobilized M6P receptor (MPR\n[15789345:15789345_0] Proteins containing mannose 6-phosphate (Man6-P), a carbohydrate modification used for targeting resident soluble lysosomal proteins to the lysosome, were affinity-purified using immobilized Man6-P receptor.\n[11079561:11079561_0] Since lysosomal soluble proteins are characterized by the presence of mannose-6-phosphate, they were purified on an affinity support bearing mannose-6-phosphate receptor", "answer": "<think> Okay, I need to figure out what kind of affinity purification is used for isolating soluble lysosomal proteins based on the given evidence. Let's look at the evidence provided. The first document (18370023:18370023_0) mentions that the rationale for purifying these proteins is their characteristic sugar, mannose-6-phosphate (M6P), which allows purification via affinity chromatography on immobilized M6P receptor. So that's a key point. The second document (15789345:15789345_0) states that proteins with Man6-P were affinity-purified using immobilized Man6-P receptor. Wait, the terms here are M", "citations": [], "candidates": [{"answer": "<think> Okay, I need to figure out what kind of affinity purification is used for isolating soluble lysosomal proteins based on the given evidence. Let's look at the evidence provided. The first document (18370023:18370023_0) mentions that the rationale for purifying these proteins is their characteristic sugar, mannose-6-phosphate (M6P), which allows purification via affinity chromatography on immobilized M6P receptor. So that's a key point. The second document (15789345:15789345_0) states that proteins with Man6-P were affinity-purified using immobilized Man6-P receptor. Wait, the terms here are M", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the type of affinity purification used to isolate soluble lysosomal proteins. Looking at the evidence provided, all three sources mention mannose-6-phosphate (M6P) and the Man6P receptor. First, I need to recall what affinity chromatography involves. It's a technique where a protein is purified by binding to a specific ligand attached to a matrix. In this case, the key is the M6P modification on lysosomal proteins. The first evidence mentions immobilized M6P receptor (MPR). The second and third references talk about using the Man6-P receptor. Wait, are MPR and Man6P receptor the same thing? Probably yes, since they're both related to mann", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the type of affinity purification used to isolate soluble lysosomal proteins. Looking at the evidence provided, all three sources mention mannose-6-phosphate (M6P) and the Man6P receptor. First, I need to recall what affinity chromatography involves. It's a technique where a protein is bound to a solid support based on a specific interaction, like a ligand-receptor pair. In this case, the key is the M6P tag on the lysosomal proteins. The first evidence mentions immobilized M6P receptor (MPR) for purification. The second and third references talk about using the Man6-P receptor. Wait, there's a slight variation in the terminology: M6P", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the type of affinity purification used to isolate soluble lysosomal proteins. The evidence provided has three chunks. First, chunk 18370023 mentions mannose-6-phosphate (M6P) as a characteristic sugar, and that affinity chromatography on immobilized M6P receptor is used. Then chunk 15789345 talks about Man6-P receptor being used for affinity purification. The third chunk, 11079561, also refers to mannose-6-phosphate receptor. All three sources point to using the M6P receptor for affinity purification. The key here is that lysosomal proteins have M6P, so the affinity", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the type of affinity purification used to isolate soluble lysosomal proteins. Looking at the evidence provided, all three sources mention mannose-6-phosphate (M6P) and the Man6P receptor. The first document says that the M6P allows purification via immobilized MPR. The second mentions using immobilized Man6P receptor for affinity purification. The third also refers to mannose-6-phosphate receptor. So, the key here is that the method relies on the presence of M6P in these proteins, which binds to the receptor. I need to make sure the answer is concise and includes citations. The answer should state that affinity chromatography using immobilized MPR or Man6P receptor", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking about affinity purification for isolating soluble lysosomal proteins. Let me look at the evidence provided. The first document mentions mannose-6-phosphate (M6P) and immobilized M6P receptor for affinity chromatography. The second one talks about Man6-P receptor used in affinity purification. The third also refers to mannose-6-phosphate receptor. All three sources consistently point to using the M6P receptor for affinity purification. The answer should be straightforward: affinity chromatography using immobilized M6P receptor. The confidence is high since all three evidence chunks support this method. I need to make sure the citations are correctly formatted as per the example. Let me check the document IDs and chunk IDs again. The first one is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the type of affinity purification used to isolate soluble lysosomal proteins. Looking at the evidence provided, all three documents mention mannose-6-phosphate (M6P) and the Man6-P receptor. Document 18370023:18370023_0 talks about using immobilized M6P receptor for affinity chromatography because of the characteristic sugar M6P in these proteins. Document 15789345:15789345_0 mentions affinity-purifying proteins with Man6-P using immobilized Man6-P receptor. Document 11079561:11079", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the type of affinity purification used to isolate soluble lysosomal proteins. Looking at the evidence provided, all three sources mention mannose-6-phosphate (M6P) and the Man6-P receptor. First, I need to recall what affinity chromatography involves. It's a technique where a molecule (like a protein) is purified by binding to a specific ligand attached to a support. The key here is the M6P on lysosomal proteins. The first evidence mentions immobilized M6P receptor. The second and third also refer to Man6-P receptor and mannose-6-phosphate receptor. So, the common method is using an affinity support with the M6P receptor. All three sources", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["11079561", "15789345", "16145712", "16399764", "16709564", "17258946", "18370023", "18507433", "18977398", "19383612", "22158965"], "ideal_answer": "The rationale for purification of the soluble lysosomal proteins resides in their characteristic sugar, the mannose-6-phosphate (M6P), which allows an easy purification by affinity chromatography on immobilized M6P receptors."}
{"question_id": "552faa43bc4f83e828000004", "question": "Which are the genes thought to be regulated by EWS/FLI?", "retrieved_chunks": [{"doc_id": "17114343", "chunk_id": "17114343_1", "score": 7.314212799072266, "text": "The gene that was most reproducibly up-regulated by EWS/FLI was NR0B1."}, {"doc_id": "17114343", "chunk_id": "17114343_0", "score": 7.126935958862305, "text": "The gene that was most reproducibly up-regulated by EWS/FLI was NR0B1"}, {"doc_id": "18927503", "chunk_id": "18927503_0", "score": 6.539081573486328, "text": "We recently showed that EWS/FLI interacts with GGAA-microsatellites to regulate some of its target genes, including NR0B1, an EWS/FLI-regulated gene that is required for the oncogenic phenotype of Ewings sarcoma."}], "context": "[17114343:17114343_1] The gene that was most reproducibly up-regulated by EWS/FLI was NR0B1.\n[17114343:17114343_0] The gene that was most reproducibly up-regulated by EWS/FLI was NR0B1\n[18927503:18927503_0] We recently showed that EWS/FLI interacts with GGAA-microsatellites to regulate some of its target genes, including NR0B1, an EWS/FLI-regulated gene that is required for the oncogenic phenotype of Ewings sarcoma.", "answer": "<think> Okay, let's tackle this query. The user is asking which genes are thought to be regulated by EWS/FLI. The evidence provided has three chunks. First, I need to parse each chunk. The first two chunks (both [17114343:17114343_0] and [17114343:17114343_1]) both mention that the gene most reproducibly up-regulated by EWS/FLI is NR0B1. So that's a strong indication that NR0B1 is regulated by EWS/FLI. The third chunk [18927503:18927501_", "citations": [{"doc_id": "17114343", "chunk_id": "17114343_0"}, {"doc_id": "17114343", "chunk_id": "17114343_1"}], "candidates": [{"answer": "<think> Okay, let's tackle this query. The user is asking which genes are thought to be regulated by EWS/FLI. The evidence provided has three chunks. First, I need to parse each chunk. The first two chunks both mention that NR0B1 is the most reproducibly up-regulated gene by EWS/FLI. The third chunk says that EWS/FLI interacts with GGAA microsatellites to regulate some target genes, including NR0B1, which is required for the oncogenic phenotype of Ewing's sarcoma. So, NR0B1 is mentioned multiple times as a regulated gene. The third chunk also mentions that NR0B1 is an EWS/FLI-regulated gene. Therefore, the answer should be NR", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which genes are thought to be regulated by EWS/FLI. The evidence provided has three chunks. First, I need to look at each chunk. The first two chunks both mention that NR0B1 is the gene most reproducibly up-regulated by EWS/FLI. So that's a strong indication that NR0B1 is regulated by EWS/FLI. The third chunk adds that EWS/FLI interacts with GGAA microsatellites to regulate some target genes, including NR0B1, which is required for the oncogenic phenotype. This reinforces that NR0B1 is indeed a regulated gene. So putting this together, the answer should be NR0B1, citing", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which genes are thought to be regulated by EWS/FLI, based on the provided evidence. Looking at the evidence, there are three entries. The first two both mention that NR0B1 is the most reproducibly up-regulated gene by EWS/FLI. The third one says that EWS/FLI interacts with GGAA microsatellites to regulate some target genes, including NR0B1, which is required for the oncogenic phenotype of Ewing's sarcoma. So, NR0B1 is mentioned multiple times as a gene regulated by EWS/FLI. The third document also mentions that NR0B1 is an EWS/FLI-regulated gene. Therefore", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking which genes are thought to be regulated by EWS/FLI. The evidence provided has three chunks. First, I need to look at each chunk. The first two chunks both say that NR0B1 is the most reproducibly up-regulated gene by EWS/FLI. The third chunk mentions that EWS/FLI interacts with GGAA microsatellites to regulate some target genes, including NR0B1, which is required for the oncogenic phenotype of Ewing sarcoma. So, NR0B1 is mentioned in all three sources. The other chunks don't mention any other genes. The answer should be concise, citing the relevant documents. The base confidence is high because NR0B", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which genes are thought to be regulated by EWS/FLI, based on the provided evidence. First, I need to look at the evidence given. There are three chunks here. The first two chunks from document 17114343 both mention that NR0B1 is the gene most reproducibly up-regulated by EWS/FLI. The third chunk from document 18927503 says that EWS/FLI interacts with GGAA microsatellites to regulate some target genes, including NR0B1, which is an EWS/FLI-regulated gene important for the oncogenic phenotype of Ewing sarcoma. So, NR0B", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which genes are thought to be regulated by EWS/FLI. The evidence provided has three chunks. First, I need to look at each chunk. The first two chunks from 17114343 both mention that the gene most reproducibly up-regulated by EWS/FLI is NR0B1. So that's a strong indication that NR0B1 is regulated by EWS/FLI. The third chunk from 18927503 says that EWS/FLI interacts with GGAA microsatellites to regulate some target genes, including NR0B1, which is an EWS/FLI-regulated gene required for the oncogenic phenotype", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking which genes are thought to be regulated by EWS/FLI. The evidence provided has three chunks. First, I need to look at each chunk. The first two chunks (17114343_1 and 17114343_0) both mention that the most reproducibly up-regulated gene by EWS/FLI is NR0B1. So that's a strong citation pointing to NR0B1. The third chunk (18927503_0) says that EWS/FLI interacts with GGAA microsatellites to regulate some target genes, including NR0B1, which is an EWS/FLI", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking which genes are thought to be regulated by EWS/FLI. The evidence provided has three chunks. First, I need to parse each chunk. The first two chunks (both [17114343:17114343_0] and [17114343:17114343_1]) both mention that the gene most reproducibly up-regulated by EWS/FLI is NR0B1. So that's a strong indication that NR0B1 is regulated by EWS/FLI. The third chunk [18927503:18927501_", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["15492248", "16697960", "17114343", "18927503", "19718047", "19920188", "23527175"], "ideal_answer": "The EWS/FLI translocation product is the causative oncogene in Ewing sarcoma and acts as an aberrant transcription factor. EWS/FLI dysregulates gene expression during tumorigenesis by abnormally activating or repressing genes. The expression levels of a significant number of genes are affected in Ewing sarcoma, some of which are known to be directly or indirectly regulated by EWS/FLI. Such genes are BCL11B, NRoB1, GSTM4, NKX2.2 and p53."}
{"question_id": "52fe58f82059c6d71c00007a", "question": "Do archaeal genomes contain one or multiple origins of replication?", "retrieved_chunks": [{"doc_id": "15337158", "chunk_id": "15337158_0", "score": 8.68394660949707, "text": "Until recently, the only archaeon for which a bona fide origin of replication was reported was Pyrococcus abyssi, where a single origin was identified. Although several in silico analyses have suggested that some archaeal species might contain more than one origin, this has only been demonstrated recently."}, {"doc_id": "24822028", "chunk_id": "24822028_1", "score": 7.2660698890686035, "text": "In bacteria and eukaryotes, replication initiates from single and multiple origins, respectively, while archaea can adopt either of the two modes."}, {"doc_id": "22978470", "chunk_id": "22978470_1", "score": 7.046987533569336, "text": "While multiple replication origins have been observed in archaea, considerably less is known about their evolutionary processes."}], "context": "[15337158:15337158_0] Until recently, the only archaeon for which a bona fide origin of replication was reported was Pyrococcus abyssi, where a single origin was identified. Although several in silico analyses have suggested that some archaeal species might contain more than one origin, this has only been demonstrated recently.\n[24822028:24822028_1] In bacteria and eukaryotes, replication initiates from single and multiple origins, respectively, while archaea can adopt either of the two modes.\n[22978470:22978470_1] While multiple replication origins have been observed in archaea, considerably less is known about their evolutionary processes.", "answer": "<think> Okay, let's tackle this question. The user is asking whether archaeal genomes have one or multiple origins of replication. The evidence provided has three chunks. First chunk [15337158:15337158_0] mentions that Pyrococcus abyssi had a single origin, but some in silico analyses suggested others might have multiple, though this hasn't been demonstrated yet. So this seems to indicate that while there's one example of a single origin, there's potential for multiple, but not confirmed. Second chunk [24822028:24822028_1] states that archaea can adopt either mode, meaning they might have either single or multiple origins. That's a", "citations": [{"doc_id": "15337158", "chunk_id": "15337158_0"}, {"doc_id": "24822028", "chunk_id": "24822028_1"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants to know if archaeal genomes have one or multiple origins of replication. Looking at the evidence provided, there are three references. The first one mentions that Pyrococcus abyssi, an archaeon, had a single origin identified. However, some in silico analyses suggested other species might have more than one, but this hasn't been demonstrated yet. The second reference states that bacteria use single origins, eukaryotes use multiple, and archaea can use either mode. That's a bit confusing. Wait, the first part says \"archaea can adopt either of the two modes.\" So that suggests that some archaea might have one, others multiple? But the third reference says that multiple origins have been observed in archae", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if archaeal genomes have one or multiple origins of replication. The evidence provided has three documents. First, document 15337158:15337158_0 mentions that Pyrococcus abyssi, an archaeon, had a single origin reported until recently. However, some in silico analyses suggested other species might have multiple origins, but this hasn't been demonstrated yet. So this document says that there's at least one archaeon with a single origin, but others might have multiple, though not confirmed. Document 24822028:24822028_1 states that bacteria use single origins, eukaryotes", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking whether archaeal genomes have one or multiple origins of replication. The evidence provided has three chunks. First chunk [15337158:15337158_0] mentions that Pyrococcus abyssi had a single origin, but some in silico analyses suggested others might have multiple, though this hasn't been demonstrated yet. So this seems to indicate that while there's one example of a single origin, there's potential for multiple, but not confirmed. Second chunk [24822028:24822028_1] states that archaea can adopt either mode, meaning they might have either single or multiple origins. That's a", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if archaeal genomes have one or multiple origins of replication. The evidence provided has three chunks. First chunk [15337158:15337158_0] mentions that Pyrococcus abyssi had a single origin, but some in silico analyses suggested others might have multiple, though this hasnure been demonstrated yet. So this suggests that while some may have one, others might have multiple, but it's not confirmed. Second chunk [24822028:24822028_1] states that archaea can adopt either single or multiple origins, similar to bacteria and eukaryotes. This seems to directly answer", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking whether archaeal genomes have one or multiple origins of replication. I need to look at the evidence provided. First, evidence [15337158:15337158_0] says that until recently, only Pyrococcus abyssi was known to have a single origin. But some in silico analyses suggested others might have multiple, though this hasn't been demonstrated yet. So this implies that there's some uncertainty, but maybe some archaea have multiple. Then [24822028:24822028_1] states that archaea can use either single or multiple origins, similar to bacteria and eukaryotes. That", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking whether archaeal genomes have one or multiple origins of replication. The evidence provided has three documents. First, document 15337158:15337158_0 mentions that Pyrococcus abyssi, an archaeon, had a single origin identified. However, some in silico analyses suggested other species might have multiple origins, but this hasn't been demonstrated yet. So this document indicates that there's some evidence for multiple origins but it's not confirmed. Then, document 24822028:24822028_1 states that archaea can use either single or multiple origins, similar to bacteria and eukaryotes.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking whether archaeal genomes have one or multiple origins of replication. I need to look at the provided evidence to form an answer. First, looking at evidence [15337158:15337158_0], it mentions that Pyrococcus abyssi, an archaeon, has a single origin. However, some in silico analyses suggested other species might have multiple origins, but this hasnure been demonstrated recently. So this evidence points to both possibilities but notes that only one is confirmed. Then, evidence [24822028:24822028_1] states that archaea can use either single or multiple origins, similar to", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking whether archaeal genomes have one or multiple origins of replication. The evidence provided has three documents. First, document [15337158:15337158_0] mentions that Pyrococcus abyssi, an archaeon, had a single origin identified. However, it also says that some species might have more than one, but this hasn't been demonstrated yet. So this suggests that while some may have multiple, it's not confirmed for all. Then, document [24822028:24822028_1] states that archaea can use either single or multiple origins, similar to bacteria and eukaryotes.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["11521661", "11967086", "12237132", "12646230", "14526006", "15197606", "15337158", "15876567", "16249118", "16321966", "16980466", "17350933", "17392430", "17511521", "17956224", "18922777", "20667100", "20850498", "20978102", "21364800", "21784908", "22812406", "22942672", "22978470", "23375370", "24185008", "2541880"], "ideal_answer": "Some archaea replicate from single origins but most archaea and all eukaryotes replicate using multiple origins. Multiple functional sites of origin of replication may exist in the genomes of most archaea. This has only been demonstrated recently. Two studies have shown that multiple origins of replication function in two archaeal species."}
{"question_id": "533c3af6c45e13371400000d", "question": "Which pathological conditions are caused by mutations in the CYLD gene?", "retrieved_chunks": [{"doc_id": "20838385", "chunk_id": "20838385_0", "score": 5.68389368057251, "text": "In contrast with previous studies showing the development of benign tumors by mutations in the CYLD gene, here we provide evidence that the occurrence of mutations in the CYLD gene in tumorigenic epidermal cells (carrying previous mutations) increases the aggressiveness of carcinomas, mainly through enhancement of the expression of angiogenic factors, having therefore a key role in epidermal cancer malignancy"}, {"doc_id": "17851586", "chunk_id": "17851586_1", "score": 5.580933094024658, "text": "rooke-Spiegler syndrome, familial cylindromatosis, and familial trichoepithelioma are autosomal-dominant genetic predispositions for benign tumors of skin appendages caused by mutations in the CYLD gene localized on chromosome 16q12-q13"}, {"doc_id": "19076795", "chunk_id": "19076795_0", "score": 4.799892902374268, "text": "Mutations in the CYLD gene, which is also the gene responsible for familial cylindromatosis, have been reported recently"}], "context": "[20838385:20838385_0] In contrast with previous studies showing the development of benign tumors by mutations in the CYLD gene, here we provide evidence that the occurrence of mutations in the CYLD gene in tumorigenic epidermal cells (carrying previous mutations) increases the aggressiveness of carcinomas, mainly through enhancement of the expression of angiogenic factors, having therefore a key role in epidermal cancer malignancy\n[17851586:17851586_1] rooke-Spiegler syndrome, familial cylindromatosis, and familial trichoepithelioma are autosomal-dominant genetic predispositions for benign tumors of skin appendages caused by mutations in the CYLD gene localized on chromosome 16q12-q13\n[19076795:19076795_0] Mutations in the CYLD gene, which is also the gene responsible for familial cylindromatosis, have been reported recently", "answer": "<think> Okay, let's tackle this question. The user wants to know which pathological conditions are caused by mutations in the CYLD gene. Looking at the evidence provided, there are three references. First, reference [17851586:17851586_1] mentions that rooke-Spiegler syndrome, familial cylindromatosis, and familial trichoepithelioma are autosomal-dominant genetic conditions for benign skin tumors caused by CYLD gene mutations. That's a direct mention of specific diseases linked to the gene. Then, reference [20838385:20838385_0] talks about mutations in CYLD increasing the aggressiveness of carcinomas, suggesting", "citations": [{"doc_id": "17851586", "chunk_id": "17851586_1"}, {"doc_id": "20838385", "chunk_id": "20838385_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants to know which pathological conditions are caused by mutations in the CYLD gene. Looking at the evidence provided, there are three references. First, reference [17851586:17851586_1] mentions that rooke-Spiegler syndrome, familial cylindromatosis, and familial trichoepithelioma are autosomal-dominant genetic conditions for benign skin tumors caused by CYLD gene mutations. That's a direct mention of specific diseases linked to the gene. Then, reference [20838385:20838385_0] talks about mutations in CYLD increasing the aggressiveness of carcinomas, suggesting", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which pathological conditions are caused by mutations in the CYLD gene. Looking at the evidence provided, there are three references. First, reference 20838385 talks about CYLD mutations leading to more aggressive carcinomas, involving angiogenic factors. But the question is about pathological conditions, so this might relate to cancer malignancy. Then, reference 17851586 mentions rooke-Spiegler syndrome, familial cylindromatosis, and familial trichoepithelioma as autosomal dominant conditions causing benign skin tumors due to CYLD mutations. That seems directly relevant. The third reference, 19076795, confirms that CYLD", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which pathological conditions are caused by mutations in the CYLD gene. Looking at the evidence provided, there are three references. First, reference [17851586:17851586_1] mentions that rooke-Spiegler syndrome, familial cylindromatosis, and familial trichoepithelioma are autosomal-dominant genetic conditions for benign skin tumors caused by CYLD gene mutations. That's a direct answer. Then, reference [20838385:20838385_0] talks about CYLD mutations leading to more aggressive carcinomas through angiogenic factors. So that's a pathological condition", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which pathological conditions are caused by mutations in the CYLD gene. Looking at the evidence provided, there are three references. First, reference [17851586:17851586_1] mentions that rooke-Spiegler syndrome, familial cylindromatosis, and familial trichoepithelioma are autosomal-dominant conditions caused by CYLD gene mutations. That's a direct answer. Then, reference [20838385:20838385_0] talks about CYLD mutations leading to more aggressive carcinomas through angiogenic factors. So that's a pathological condition related to cancer.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to figure out which pathological conditions are caused by mutations in the CYLD gene based on the provided evidence. Let me look at the evidence given. The first document (20838385) talks about CYLD gene mutations leading to more aggressive carcinomas through angiogenic factors. So that's a condition related to cancer, specifically carcinomas being more aggressive. The second document (17851586) mentions rooke-Spiegler syndrome, familial cylindromatosis, and familial trichoepithelioma as autosomal-dominant conditions causing benign skin tumors due to CYLD mutations. These are all benign tumors, so that's different from the first one. The third document (19076", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which pathological conditions are caused by mutations in the CYLD gene. I need to look at the evidence provided to find the answer. Looking at the first evidence snippet (20838385:20838385_0), it mentions that mutations in CYLD lead to more aggressive carcinomas, involving angiogenic factors. But this seems to be about cancer malignancy, not a specific condition. However, the key here is that it's related to epidermal cancers. The second snippet (17851586:17851586_1) talks about three conditions: rooke-Spiegler syndrome, familial cylindromat", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking about pathological conditions caused by mutations in the CYLD gene. Let me look at the evidence provided. First, the evidence from 20838385 talks about carcinomas becoming more aggressive due to CYLD mutations, involving angiogenic factors. That seems like a malignant condition. Then there's 17851586 which mentions rooke-Spiegler syndrome, familial cylindromatosis, and trichoepithelioma as benign tumors caused by CYLD mutations. Also, 19076795 repeats that CYLD is responsible for familial cylindromatosis. So the answer needs to include both benign and malignant conditions. The first evidence mentions carcinomas (malign", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which pathological conditions are caused by mutations in the CYLD gene. The evidence provided has three chunks. First chunk (20838385) talks about CYLD mutations leading to more aggressive carcinomas through angiogenic factors. So that's a condition related to cancer, specifically carcinomas being more aggressive. But the question is about pathological conditions, so this might be relevant. Second chunk (17851586) mentions rooke-Spiegler syndrome, familial cylindromatosis, and trichoepithelioma as benign tumors caused by CYLD mutations. These are all genetic disorders with benign tumors, so those are clear conditions. Third chunk (1907", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["12190880", "15024746", "15541090", "16922728", "17083363", "17851586", "18806492", "19076795", "19668078", "19730223", "19911186", "19917957", "20132422", "20151946", "20607853", "20838385", "20972631", "21345146", "21389835", "21552290", "21577203", "21598248", "22077640", "23404581", "23426135", "23641715", "23694822"], "ideal_answer": "Since loss of CYLD expression can be observed in different types of human cancer, it is now well established that CYLD acts as a tumor suppressor gene. Pathogenic mutations in CYLD can be identified in patients affected with Brooke-Spiegler syndrome, (Familial) Cylindromatosis or multiple familial trichoepithelioma. CYLD expression has also been reported to be dramatically downregulated in basal cell carcinoma (BCC), the most common cancer in humans."}
{"question_id": "56c5fd325795f9a73e000005", "question": "Which is the genetic basis of Spinal Muscular Atrophy (SMA)?", "retrieved_chunks": [{"doc_id": "17076267", "chunk_id": "17076267_0", "score": 10.008273124694824, "text": "The molecular genetic basis of spinal muscular atrophy (SMA), an autosomal recessive neuromuscular disorder, is the loss of function of the survival motor neuron gene (SMN1)"}, {"doc_id": "30368521", "chunk_id": "30368521_0", "score": 8.076568603515625, "text": "Spinal Muscular Atrophy (SMA) is caused by genetic mutations in the SMN1 gene, resulting in drastically reduced levels of Survival of Motor Neuron (SMN) protein."}, {"doc_id": "29799103", "chunk_id": "29799103_0", "score": 7.4662556648254395, "text": "Spinal muscular atrophy (SMA) is an autosomal recessive genetic disorder caused by survival motor neuron (SMN) protein deficiency leading the loss of motor neurons in the anterior horns of the spinal cord and brainstem."}], "context": "[17076267:17076267_0] The molecular genetic basis of spinal muscular atrophy (SMA), an autosomal recessive neuromuscular disorder, is the loss of function of the survival motor neuron gene (SMN1)\n[30368521:30368521_0] Spinal Muscular Atrophy (SMA) is caused by genetic mutations in the SMN1 gene, resulting in drastically reduced levels of Survival of Motor Neuron (SMN) protein.\n[29799103:29799103_0] Spinal muscular atrophy (SMA) is an autosomal recessive genetic disorder caused by survival motor neuron (SMN) protein deficiency leading the loss of motor neurons in the anterior horns of the spinal cord and brainstem.", "answer": "<think> Okay, let's tackle this question. The user is asking for the genetic basis of Spinal Muscular Atrophy (SMA). I need to look at the provided evidence to find the correct answer. First, I'll go through each of the evidence points. The first piece [17076267:17076267_0] mentions that the molecular genetic basis of SMA is the loss of function of the SMN1 gene. That seems directly relevant. The second evidence [30368521:30368521_0] also states that SMA is caused by mutations in the SMN1 gene, leading to reduced SMN protein. The third one [2979", "citations": [{"doc_id": "17076267", "chunk_id": "17076267_0"}, {"doc_id": "30368521", "chunk_id": "30368521_0"}], "candidates": [{"answer": "<think> Okay, I need to generate a JSON answer for the question about the genetic basis of Spinal Muscular Atrophy (SMA). Let me start by looking at the evidence provided. The user provided three references. All of them mention the SMN1 gene as being involved in SMA. The first one says the molecular basis is the loss of function of the SMN1 gene. The second reference also states that mutations in SMN1 cause reduced SMN protein. The third mentions SMN protein deficiency leading to motor neuron loss. So, the common thread here is the SMN1 gene. All three sources point to it. The answer should be that the genetic basis is the SMN1 gene. Now, I need to check if there's any conflicting information. But", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know the genetic basis of Spinal Muscular Atrophy (SMA). Looking at the evidence provided, there are three references. First, reference 17076267 mentions that SMA is caused by loss of function in the SMN1 gene. Then, reference 30368521 also points to mutations in SMN1 leading to reduced SMN protein. The third one, 29799103, talks about SMN protein deficiency due to the same gene. All three sources consistently point to SMN1 as the gene involved. I need to make sure there's no conflicting information here. All citations agree on SMN1 being the genetic basis", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the genetic basis of Spinal Muscular Atrophy (SMA). I need to look at the provided evidence to find the correct answer. Looking at the evidence, there are three documents. The first one says that SMA is caused by loss of function of the SMN1 gene. The second mentions mutations in SMN1 leading to reduced SMN protein. The third document also points to SMN protein deficiency due to genetic mutations in SMN1. All three sources consistently mention SMN1 as the gene involved. The key here is to confirm that all the evidence points to SMN1. The answer should be concise, citing the documents. The confidence level should be high since all three pieces of evidence agree", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the genetic basis of Spinal Muscular Atrophy (SMA). I need to look at the provided evidence to find the correct answer. Looking at the first piece of evidence: it mentions that SMA is caused by loss of function of the SMN1 gene. The second one says mutations in SMN1 lead to reduced SMN protein. The third one also talks about SMN protein deficiency due to the SMN1 gene. All three sources point to SMN1 as the gene involved. The answer should be concise, citing the documents. The confidence level is high since all three pieces of evidence consistently mention SMN1. So the base_confidence would be 1.0. The answer is that", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The question is about the genetic basis of Spinal Muscular Atrophy (SMA). Let me look at the evidence. First, the user provided three references. All of them mention that SMA is caused by mutations in the SMN1 gene. The first one says the molecular basis is loss of function of the SMN1 gene. The second reference also states that genetic mutations in SMN1 lead to reduced SMN protein. The third mentions SMN protein deficiency due to the same gene. So the answer should be that the genetic basis is mutations in the SMN1 gene. All three sources support this. The confidence level should be high since all evidence points to the same conclusion. I'll pick", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know the genetic basis of Spinal Muscular Atrophy (SMA). I need to look at the provided evidence to find the answer. Looking at the first evidence snippet: It mentions that the molecular genetic basis of SMA is the loss of function of the SMN1 gene. That's a direct statement. The second snippet also confirms that SMA is caused by mutations in the SMN1 gene, leading to reduced SMN protein. The third snippet talks about SMN protein deficiency due to the same gene. All three sources point to SMN1 as the key gene. The first two documents specifically mention the SMN1 gene, and the third refers to the survival motor neuron (SMN) protein, which is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the genetic basis of Spinal Muscular Atrophy (SMA). I need to look at the provided evidence to find the correct answer. First, I'll review each of the three evidence points. The first one says that SMA is caused by loss of function of the SMN1 gene. The second mentions mutations in SMN1 leading to reduced SMN protein. The third talks about SMN protein deficiency causing motor neuron loss. All three references point to SMN1 as the key gene. I should check if there's any conflicting information, but all sources agree on SMN1. The confidence here is high because multiple sources cite the same gene. The answer should be that the genetic basis is the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the genetic basis of Spinal Muscular Atrophy (SMA). I need to look at the provided evidence to find the correct answer. First, I'll go through each of the evidence points. The first piece [17076267:17076267_0] mentions that the molecular genetic basis of SMA is the loss of function of the SMN1 gene. That seems directly relevant. The second evidence [30368521:30368521_0] also states that SMA is caused by mutations in the SMN1 gene, leading to reduced SMN protein. The third one [2979", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["10339583", "11442327", "12115944", "12220455", "17076267", "19062530", "19646678", "20225030", "22323744", "22628388", "9073029", "9731538"], "ideal_answer": "The molecular genetic basis of spinal muscular atrophy (SMA), an autosomal recessive neuromuscular disorder, is the loss of function of the survival motor neuron gene (SMN1). Mutations of the SMN1 gene are responsible for SMA. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. A critical question is why only the homozygous loss of SMN1, and not SMN2, results in spinal muscular atrophy (SMA). H4F5 is also highly deleted in type I SMA chromosomes, and thus is a candidate phenotypic modifier for SMA. The molecular genetic basis of spinal muscular atrophy (SMA), an autosomal recessive neuromuscular disorder, is the loss of function of the survival motor neuron gene (SMN1)."}
{"question_id": "571f3b320fd6f91b68000007", "question": "Which are the common symptoms of Cushing's syndrome?", "retrieved_chunks": [{"doc_id": "24062268", "chunk_id": "24062268_0", "score": 8.759344100952148, "text": "Cushing syndrome is the constellation of signs and symptoms caused by protracted exposure to glucocorticoids. The most common cause of Cushing syndrome in children and adolescents is exogenous administration of glucocorticoids. Presenting features commonly include weight gain, growth retardation, hirsutism, obesity, striae, acne and hypertension"}, {"doc_id": "28413388", "chunk_id": "28413388_0", "score": 6.186100006103516, "text": "Cushing's syndrome is a rare endocrine disorder that comprises a large group of signs and symptoms resulting from chronic exposure to excess corticosteroids. Most cases of Cushing's syndrome are due to increased adrenocorticotropic hormone production from a pituitary adenoma, which is referred to as Cushing's disease"}, {"doc_id": "17322955", "chunk_id": "17322955_0", "score": 4.435247898101807, "text": "This is a rare syndrome and its main endocrine manifestation, primary pigmented nodular adrenal disease (PPNAD), is an uncommon cause of adrenocorticotropic hormone-independent Cushing's syndrome.We report the case of a 20-year-old patient with a history of weight gain, hirsutism, acne, secondary amenorrhea and facial lentiginosis."}], "context": "[24062268:24062268_0] Cushing syndrome is the constellation of signs and symptoms caused by protracted exposure to glucocorticoids. The most common cause of Cushing syndrome in children and adolescents is exogenous administration of glucocorticoids. Presenting features commonly include weight gain, growth retardation, hirsutism, obesity, striae, acne and hypertension\n[28413388:28413388_0] Cushing's syndrome is a rare endocrine disorder that comprises a large group of signs and symptoms resulting from chronic exposure to excess corticosteroids. Most cases of Cushing's syndrome are due to increased adrenocorticotropic hormone production from a pituitary adenoma, which is referred to as Cushing's disease\n[17322955:17322955_0] This is a rare syndrome and its main endocrine manifestation, primary pigmented nodular adrenal disease (PPNAD), is an uncommon cause of adrenocorticotropic hormone-independent Cushing's syndrome.We report the case of a 20-year-old patient with a history of weight gain, hirsutism, acne, secondary amenorrhea and facial lentiginosis.", "answer": "<think> Okay, I need to generate a candidate biomedical answer for the question about common symptoms of Cushing's syndrome using the provided evidence. Let me start by carefully reading the user's query and the given evidence. The question is asking for the common symptoms of Cushing's syndrome. The evidence has three chunks from different documents. Let me go through each one to extract relevant information. First, document [24062268:24062268_0] mentions that presenting features include weight gain, growth retardation, hirsutism, obesity, striae, acne, and hypertension. These seem like the main symptoms listed here. Second, document [28413388:28413388", "citations": [{"doc_id": "24062268", "chunk_id": "24062268_0"}], "candidates": [{"answer": "<think> Okay, I need to generate a candidate biomedical answer for the question about common symptoms of Cushing's syndrome using the provided evidence. Let me start by carefully reading the user's query and the given evidence. The question is asking for the common symptoms of Cushing's syndrome. The evidence has three chunks from different documents. Let me go through each one to extract relevant information. First, document [24062268:24062268_0] mentions that presenting features include weight gain, growth retardation, hirsutism, obesity, striae, acne, and hypertension. These seem like the main symptoms listed here. Second, document [28413388:28413388", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The question is about common symptoms of Cushing's syndrome. First, I'll look at the evidence documents. The first one mentions weight gain, growth retardation, hirsutism, obesity, striae, acne, and hypertension. The second document talks about a rare disorder with excess corticosteroids and mentions pituitary adenoma as a cause, but doesn't list symptoms. The third document notes weight gain, hirsutism, acne, secondary amenorrhea, and facial lentiginosis. So the common symptoms across these sources are weight gain, hirsutism, obesity, acne, striae, hypertension, and maybe secondary amenorrhea. But I need to", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so I need to generate a JSON answer about the common symptoms of Cushing's syndrome based on the provided evidence. Let me start by looking at the evidence given. First, the first document (24062268:24062268_0) mentions that presenting features include weight gain, growth retardation, hirsutism, obesity, striae, acne, and hypertension. These seem like the main symptoms listed here. The second document (28413388:28413388_0) talks about Cushing's syndrome being a rare endocrine disorder with signs and symptoms from chronic exposure to excess corticosteroids, but it doesn't list specific symptoms. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer for the question about common symptoms of Cushing's syndrome using the provided evidence. Let me start by carefully reading the user's instructions. The user wants a strict JSON with two keys: \"answer\" and \"base_confidence\". The answer should be concise and include citations in the format [doc_id:chunk_id]. The base_confidence is a float between 0 and 1, representing the model's confidence in the factual correctness of the answer. First, I'll look at the evidence provided. There are three chunks from different documents. Let me parse each one: Chunk 24062268: This mentions that Cushing syndrome is caused by prolonged exposure to glucocorticoids and lists presenting features like", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is about common symptoms of Cushing's syndrome. First, I'll look at the evidence provided. The first document mentions weight gain, growth retardation, hirsutism, obesity, striae, acne, and hypertension as presenting features. The second document talks about a rare disorder with excess corticosteroids and mentions Cushing's disease due to pituitary adenoma. The third document refers to PPNAD and lists weight gain, hirsutism, acne, secondary amenorrhea, and facial lentiginosis. I need to compile the common symptoms from these. The first document has several key points: weight gain, obesity, hirsutism, acne, st", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the common symptoms of Cushing's syndrome, and they provided three evidence snippets. First, I need to parse each document to extract the relevant symptoms. Looking at the first evidence [24062268:24062268_0], it lists weight gain, growth retardation, hirsutism, obesity, striae, acne, and hypertension as presenting features. The second snippet [28413388:28413388_0] mentions a rare disorder with signs from chronic corticosteroid exposure but doesn't list specific symptoms. The third one [17322955:173", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let me try to work through this. The user is asking for common symptoms of Cushing's syndrome, and they provided three evidence documents. First, I need to look at each document and extract the symptoms mentioned. Looking at the first evidence [24062268:24062268_0], it lists weight gain, growth retardation, hirsutism, obesity, striae, acne, and hypertension as common features. That's a lot of symptoms. The second document [28413388:28413388_0] talks about Cushing's disease being caused by a pituitary adenoma but doesn't list specific symptoms. It mentions it's", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let me tackle this question. The user is asking for common symptoms of Cushing's syndrome, and I need to generate a JSON answer based on the provided evidence. First, I'll look at the evidence documents. The first one mentions weight gain, growth retardation, hirsutism, obesity, striae, acne, and hypertension as presenting features. The second document talks about a rare disorder with excess corticosteroids, but it doesn't list symptoms. The third document mentions weight gain, hirsutism, acne, secondary amenorrhea, and facial lentiginosis. So the common symptoms across these documents are weight gain, hirsutism, obesity, acne, striae, hypertension, and maybe secondary amenorrhea and facial lent", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["17322955", "24062268"], "ideal_answer": "Cushing syndrome is the constellation of signs and symptoms caused by protracted exposure to glucocorticoids. Presenting features commonly include weight gain, growth retardation, hirsutism, obesity, striae, acne and hypertension."}
{"question_id": "5319ac99b166e2b806000034", "question": "Which is the third subunit of the TSC1-TSC2 complex upstream of mTORC1?", "retrieved_chunks": [{"doc_id": "22795129", "chunk_id": "22795129_0", "score": 6.695413589477539, "text": "Here, we identify and biochemically characterize TBC1D7 as a stably associated and ubiquitous third core subunit of the TSC1-TSC2 complex. We demonstrate that the TSC1-TSC2-TBC1D7 (TSC-TBC) complex is the functional complex that senses specific cellular growth conditions and possesses Rheb-GAP activity."}, {"doc_id": "32854217", "chunk_id": "32854217_0", "score": 4.389609336853027, "text": "The mammalian target of rapamycin (mTOR) is an evolutionary conserved Ser/Thr protein kinase that senses multiple upstream stimuli to control cell growth, metabolism, and autophagy. mTOR is the catalytic subunit of mTOR complex 1 (mTORC1). A significant amount of research has uncovered the signaling pathways regulated by mTORC1, and the involvement of these signaling cascades in human diseases like cancer, diabetes, and ageing. Here, we review advances in mTORC1 regulation by upstream stimuli."}, {"doc_id": "19245654", "chunk_id": "19245654_0", "score": 3.7657012939453125, "text": "AMPK directly phosphorylates at least two proteins to induce rapid suppression of mTORC1 activity, the TSC2 tumour suppressor and the critical mTORC1 binding subunit raptor."}], "context": "[22795129:22795129_0] Here, we identify and biochemically characterize TBC1D7 as a stably associated and ubiquitous third core subunit of the TSC1-TSC2 complex. We demonstrate that the TSC1-TSC2-TBC1D7 (TSC-TBC) complex is the functional complex that senses specific cellular growth conditions and possesses Rheb-GAP activity.\n[32854217:32854217_0] The mammalian target of rapamycin (mTOR) is an evolutionary conserved Ser/Thr protein kinase that senses multiple upstream stimuli to control cell growth, metabolism, and autophagy. mTOR is the catalytic subunit of mTOR complex 1 (mTORC1). A significant amount of research has uncovered the signaling pathways regulated by mTORC1, and the involvement of these signaling cascades in human diseases like cancer, diabetes, and ageing. Here, we review advances in mTORC1 regulation by upstream stimuli.\n[19245654:19245654_0] AMPK directly phosphorylates at least two proteins to induce rapid suppression of mTORC1 activity, the TSC2 tumour suppressor and the critical mTORC1 binding subunit raptor.", "answer": "<think> Okay, let's tackle this question. The user is asking for the third subunit of the TSC1-TSC2 complex that's upstream of mTORC1. First, I need to look at the evidence provided. The first document (22795129) mentions TBC1D7 as the third core subunit of the TSC1-TSC2 complex. It specifically says that the TSC1-TSC2-TBC1D7 complex is the functional one that senses cellular growth conditions and has Rheb-GAP activity. That seems directly relevant. The other documents talk about mTORC1 and its regulation, but they don't mention the third subunit of the TSC complex. The second document (3285", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking for the third subunit of the TSC1-TSC2 complex that's upstream of mTORC1. First, I need to look at the evidence provided. The first document (22795129) mentions TBC1D7 as the third core subunit of the TSC1-TSC2 complex. It specifically says that the TSC1-TSC2-TBC1D7 complex is the functional one that senses cellular growth conditions and has Rheb-GAP activity. That seems directly relevant. The other documents talk about mTORC1 and its regulation, but they don't mention the third subunit of the TSC complex. The second document (3285", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the third subunit of the TSC1-TSC2 complex that's upstream of mTORC1. First, I need to look at the evidence provided. The first document (22795129) mentions TBC1D7 as the third core subunit of the TSC1-TSC2 complex. It specifically states that the TSC1-TSC2-TBC1D7 complex is the functional one that senses cellular growth conditions and has Rheb-GAP activity. That seems directly relevant. The other documents talk about mTORC1 and its regulation, but they don't mention the third subunit of the TSC complex. The second document (3285", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the third subunit of the TSC1-TSC2 complex that's upstream of mTORC1. First, I need to look at the evidence provided. The first document (22795129) mentions TBC1D7 as the third core subunit of the TSC1-TSC2 complex. It specifically states that the TSC1-TSC2-TBC1D7 complex is the functional one involved in sensing cellular growth conditions and has Rheb-GAP activity. That seems directly relevant. The other documents talk about mTORC1 and its regulation, but not the third subunit of the TSC complex. The second document (328542", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the third subunit of the TSC1-TSC2 complex that's upstream of mTORC1. First, I need to look at the evidence provided. The first document (22795129) mentions TBC1D7 as the third core subunit of the TSC1-TSC2 complex. It specifically states that the TSC1-TSC2-TBC1D7 complex is the functional one and has Rheb-GAP activity. That seems directly relevant. The other documents talk about mTORC1 and its regulation, but not the third subunit of the TSC complex. The second document (32854217) discusses mTOR", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the third subunit of the TSC1-TSC2 complex that's upstream of mTORC1. First, I need to look at the evidence provided. The first document (22795129) mentions TBC1D7 as the third core subunit of the TSC1-TSC2 complex. It specifically states that the TSC1-TSC2-TBC1D7 complex is the functional one involved in sensing cellular growth conditions and has Rheb-GAP activity. That seems directly relevant. The other documents mention mTORC1 and its regulation, but not the third subunit of the TSC complex. The second document talks about mTOR being part of m", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the third subunit of the TSC1-TSC2 complex that's upstream of mTORC1. First, I need to look at the evidence provided. The first document (22795129) mentions TBC1D7 as the third core subunit of the TSC1-TSC2 complex. It specifically says that the TSC1-TSC2-TBC1D7 complex is the functional one that senses cellular growth conditions and has Rheb-GAP activity. That seems directly relevant. The other documents talk about mTORC1 and its regulation, but not the third subunit of the TSC complex. The second document mentions mTOR as the catalytic sub", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the third subunit of the TSC1-TSC2 complex that's upstream of mTORC1. First, I need to look at the evidence provided. The first document (22795129) mentions TBC1D7 as the third core subunit of the TSC1-TSC2 complex. It specifically states that the TSC1-TSC2-TBC1D7 complex is the functional one involved in sensing cellular growth conditions and has Rheb-GAP activity. That seems directly relevant. The other documents talk about mTORC1 and its regulation, but they don't mention the third subunit of the TSC complex. The second document (328", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the third subunit of the TSC1-TSC2 complex that's upstream of mTORC1. First, I need to look at the evidence provided. The first evidence snippet (22795129) mentions TBC1D7 as the third core subunit of the TSC1-TSC2 complex. It specifically states that the TSC1-TSC2-TBC1D7 complex is the functional one and has Rheb-GAP activity. That seems directly relevant. The other snippets talk about mTORC1 and its regulation, but they don't mention the third subunit of the TSC complex. The second snippet (32854217", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["22795129"], "ideal_answer": "TBC1D7 was identified as a stably associated and ubiquitous third core subunit of the TSC1-TSC2 complex. It was demonstrated that TSC1-TSC2-TBC1D7 (TSC-TBC) is the functional complex that senses specific cellular growth conditions and possesses Rheb-GAP activity to negatively regulate mTORC1 activity. In agreement with this, TBC1D7 knockdown was shown to result in increased mTORC1 signaling, delayed induction of autophagy, and enhanced cell growth under poor growth conditions."}
{"question_id": "54f89e1a06d9727f76000001", "question": "Which kinase is inhibited by the small molecule KN-93?", "retrieved_chunks": [{"doc_id": "7690557", "chunk_id": "7690557_0", "score": 6.929267406463623, "text": "A novel Ca2+/calmodulin-dependent protein kinase II (CaM Kinase II) inhibitor, KN-93 potently inhibits gastric acid secretion from parietal cells."}, {"doc_id": "10712242", "chunk_id": "10712242_1", "score": 6.916120529174805, "text": "CaM kinase II activation was inhibited by KN-93 pretreatment (IC(50) approximately 1 microM)."}, {"doc_id": "10712242", "chunk_id": "10712242_0", "score": 6.8043975830078125, "text": "CaM kinase II activation was inhibited by KN-93 pretreatment (IC(50) approximately 1 microM)"}], "context": "[7690557:7690557_0] A novel Ca2+/calmodulin-dependent protein kinase II (CaM Kinase II) inhibitor, KN-93 potently inhibits gastric acid secretion from parietal cells.\n[10712242:10712242_1] CaM kinase II activation was inhibited by KN-93 pretreatment (IC(50) approximately 1 microM).\n[10712242:10712242_0] CaM kinase II activation was inhibited by KN-93 pretreatment (IC(50) approximately 1 microM)", "answer": "<think> Okay, let's tackle this question. The user is asking which kinase is inhibited by the small molecule KN-93. The evidence provided has three entries. First, looking at the evidence documents. The first one [7690557:7690557_0] mentions that KN-93 is a inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaM Kinase II). That seems directly relevant. The other two entries [10712242:10712242_1] and [10712242:10712242_0] both talk about CaM kinase II activation being inhibited by KN-93,", "citations": [{"doc_id": "7690557", "chunk_id": "7690557_0"}, {"doc_id": "10712242", "chunk_id": "10712242_1"}, {"doc_id": "10712242", "chunk_id": "10712242_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which kinase is inhibited by the small molecule KN-93. The evidence provided has three entries. First, looking at the evidence documents. The first one, 7690557:7690557_0, says that KN-93 is a inhibitor of Ca2+/calmodulin-dependent protein kinase II, which is referred to as CaM Kinase II. So that's a direct mention. Then the other two documents, 10712242:10712242_0 and 10712242:10712242_1, both state that CaM kinase II", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which kinase is inhibited by the small molecule KN-93. The evidence provided has three chunks. First, chunk 7690557_0 mentions that KN-93 is a inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaM Kinase II). That's a direct statement. Then, chunks 10712242_1 and 10712242_0 both say that CaM kinase II activation was inhibited by KN-93 pretreatment with an IC50 of about 1 microM. So the two pieces of evidence point to the same kinase: CaM Kinase II. I need to make sure there", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which kinase is inhibited by the small molecule KN-93. The evidence provided has three entries. First, looking at the evidence documents. The first one [7690557:7690557_0] mentions that KN-93 is a inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaM Kinase II). That seems directly relevant. The other two entries [10712242:10712242_1] and [10712242:10712242_0] both talk about CaM kinase II activation being inhibited by KN-93,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which kinase is inhibited by the small molecule KN-93. The evidence provided has three entries. First, looking at the evidence documents. The first one, [7690557:7690557_0], says that KN-93 is a inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaM Kinase II). The other two documents, [10712242:10712242_1] and [10712242:10712242_0], both mention that KN-93 inhibits CaM kinase II activation with an IC50", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which kinase is inhibited by the small molecule KN-93. The evidence provided has three entries. First, looking at the evidence documents. The first one, [7690557:7690557_0], mentions that KN-93 is a inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaM Kinase II). That seems directly relevant. The other two entries, [10712242:10712242_1] and [10712242:10712242_0], both state that CaM kinase II activation was inhibited by KN-9", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which kinase is inhibited by the small molecule KN-93. The evidence provided has three entries. First, looking at the evidence documents. The first one, [7690557:7690557_0], says that KN-93 is a inhibitor of Ca2+/calmodulin-dependent protein kinase II, also known as CaM Kinase II. That's a direct mention. The other two entries, [10712242:10712242_1] and [10712242:10712242_0], both state that KN-93 inhibits Ca", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which kinase is inhibited by the small molecule KN-93. The evidence provided has three entries. First, looking at the evidence documents. The first one, [7690557:7690557_0], mentions that KN-93 is a inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaM Kinase II). That's a direct statement linking KN-93 to CaM Kinase II. The other two documents, [10712242:10712242_1] and [10712242:10712242_0], both", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which kinase is inhibited by the small molecule KN-93. The evidence provided has three entries. First, looking at the evidence documents. Document [7690557:7690557_0] mentions that KN-93 is a inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaM Kinase II). That's a direct mention of the kinase. Then, the other two documents from 10712242 talk about CaM kinase II activation being inhibited by KN-93, with an IC50 value. So all three pieces of evidence point to CaM Kinase II being the target. The answer needs to be concise", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["10712242", "11164895", "11248432", "11827960", "14749212", "15175389", "15569687", "1662507", "16896952", "17457979", "21187407", "22290426", "7690557", "8939965", "9596994", "9864285"], "ideal_answer": "The calcium/calmodulin-dependent protein kinase-II (CaMK-II) is inhibited by the small molecule KN-93. KN-93 is a membrane-permeant calcium/calmodulin- dependent kinase II (CaMK-II)-selective inhibitor"}
{"question_id": "5357bd56f1005d6b58000009", "question": "What is the effect of Chk2 splice variants on wild-type Chk2 kinase activity?", "retrieved_chunks": [{"doc_id": "20080130", "chunk_id": "20080130_1", "score": 9.371012687683105, "text": "Chk2 splice variants express a dominant-negative effect on the wild-type Chk2 kinase activity."}, {"doc_id": "20080130", "chunk_id": "20080130_0", "score": 9.245957374572754, "text": "Chk2 splice variants express a dominant-negative effect on the wild-type Chk2 kinase activity"}, {"doc_id": "20080130", "chunk_id": "20080130_2", "score": 6.583565711975098, "text": "Here we evaluated the function of four Chk2 splice proteins for which mRNA splice variants were identified in human breast carcinomas. These splice variants were stably expressed as nuclear proteins. Two splice forms (Chk2Delta4 and Chk2del(2-3)) expressed kinase activity while variants Chk2Delta11 and Chk2isoI were essentially kinase inactive. Independent of intrinsic kinase activity, each splice variant impaired wild-type Chk2 activity through heterodimerization."}], "context": "[20080130:20080130_1] Chk2 splice variants express a dominant-negative effect on the wild-type Chk2 kinase activity.\n[20080130:20080130_0] Chk2 splice variants express a dominant-negative effect on the wild-type Chk2 kinase activity\n[20080130:20080130_2] Here we evaluated the function of four Chk2 splice proteins for which mRNA splice variants were identified in human breast carcinomas. These splice variants were stably expressed as nuclear proteins. Two splice forms (Chk2Delta4 and Chk2del(2-3)) expressed kinase activity while variants Chk2Delta11 and Chk2isoI were essentially kinase inactive. Independent of intrinsic kinase activity, each splice variant impaired wild-type Chk2 activity through heterodimerization.", "answer": "<think> Okay, let's tackle this question. The user is asking about the effect of Chk2 splice variants on wild-type Chk2 kinase activity. First, I need to look at the evidence provided. There are three documents here. Let me read through each one carefully. Document 1 says that Chk2 splice variants have a dominant-negative effect on wild-type Chk2 kinase activity. That's a direct statement. Document 2 is the same as document 1, so that's redundant but confirms the same point. Document 3 mentions four splice variants, some of which have kinase activity, like Chk2Delta4 and Chk2del(2-3), while others are inactive. It also states that regardless of their intrinsic activity, each variant impairs wild", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the effect of Chk2 splice variants on wild-type Chk2 kinase activity. First, I need to look at the evidence provided. There are three documents here. Let me read through each one carefully. Document 1 says that Chk2 splice variants have a dominant-negative effect on wild-type Chk2 kinase activity. That's a direct statement. Document 2 is the same as document 1, so that's redundant but confirms the same point. Document 3 mentions four splice variants, some of which have kinase activity, like Chk2Delta4 and Chk2del(2-3), while others are inactive. It also states that regardless of their intrinsic activity, each variant impairs wild", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the effect of Chk2 splice variants on the wild-type Chk2 kinase activity. The evidence provided has three chunks. First, I need to parse each chunk. The first two chunks are duplicates, both stating that Chk2 splice variants have a dominant-negative effect. The third chunk provides more details: four splice variants were evaluated. Two (Chk2Delta4 and Chk2del(2-3)) have kinase activity, but others like Chk2Delta11 and Chk2isoI are inactive. Additionally, all variants impair wild-type Chk2 through heterodimerization, regardless of their intrinsic activity. So the answer needs to combine these points. The dominant-negative effect is mentioned", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the effect of Chk2 splice variants on the wild-type Chk2 kinase activity. I need to look at the provided evidence to form an answer. First, looking at the evidence documents. Documents 1 and 2 both say that Chk2 splice variants have a dominant-negative effect on wild-type Chk2 kinase activity. That's a direct statement. Then document 3 adds more details: there are four splice variants, some have kinase activity (Chk2Delta4 and Chk2del(2-3)), but others like Chk2Delta11 and Chk2isoI are inactive. However, all splice variants impair wild-type Chk2 activity through heterodimerization, regardless", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the effect of Chk2 splice variants on the wild-type Chk2 kinase activity. The evidence provided has three chunks. First, I need to parse each chunk. The first two chunks are duplicates, both stating that Chk2 splice variants have a dominant-negative effect. The third chunk adds more detail: four splice variants were evaluated, two (Chk2Delta4 and Chk2del(2-3)) have kinase activity, but others are inactive. Also, all variants impair wild-type Chk2 through heterodimerization, regardless of their intrinsic activity. So the answer should combine these points. The dominant-negative effect is mentioned in chunks 1 and 2, and chunk 3 explains that", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the effect of Chk2 splice variants on wild-type Chk2 kinase activity. I need to look at the provided evidence to form an answer. First, I see that there are three documents mentioned. Documents 1 and 2 both state that the splice variants have a dominant-negative effect. Document 3 adds more details: four splice variants were evaluated, two had kinase activity (Chk2Delta4 and Chk2del(2-3)), while the others were inactive. However, all splice variants impaired wild-type Chk2 activity through heterodimerization, regardless of their intrinsic activity. So the main points are that some variants have kinase activity, but they still impair the wild-type's function.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the effect of Chk2 splice variants on wild-type Chk2 kinase activity. The evidence provided has three chunks. First, I need to parse each chunk. The first two chunks are duplicates, both stating that Chk2 splice variants have a dominant-negative effect. The third chunk adds more details: four splice variants were evaluated, some had kinase activity (like Chk2Delta4 and Chk2del(2-3)), but others were inactive. Additionally, all variants impaired wild-type Chk2 through heterodimerization, regardless of their intrinsic activity. So the answer needs to combine these points. The dominant-negative effect is mentioned in the first two chunks, and the third chunk explains that even if", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the effect of Chk2 splice variants on the wild-type Chk2 kinase activity. The evidence provided has three chunks. First, I need to parse each chunk. The first two chunks are duplicates, both stating that Chk2 splice variants have a dominant-negative effect. The third chunk adds more details: four splice variants were evaluated, some had kinase activity (like Chk2Delta4 and Chk2del(2-3)), while others were inactive (Chk2Delta11 and Chk2isoI). Additionally, all variants impaired wild-type Chk2 activity through heterodimerization, regardless of their intrinsic kinase activity. So the answer needs to combine these points. The dominant-negative effect", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. Let me start by understanding the question: What is the effect of Chk2 splice variants on wild-type Chk2 kinase activity? Looking at the evidence, there are three chunks. The first two chunks (20080130_1 and 20080130_0) both state that Chk2 splice variants have a dominant-negative effect on wild-type Chk2 kinase activity. The third chunk (20080130_2) provides more details: four splice variants were evaluated, two had kinase activity (Chk2Delta4 and Chk2del(2-3)), while the others were inactive. However, all splice", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["20080130"], "ideal_answer": "Chk2 splice variants have been demonstrated to exert a dominant-negative effect on wild-type Chk2 kinase activity."}
{"question_id": "54d65b6b3706e8952800000c", "question": "List genes that have been found mutated in CMT1A (Charcot-Marie-Tooth disease type 1 A).", "retrieved_chunks": [{"doc_id": "8128981", "chunk_id": "8128981_0", "score": 6.516853332519531, "text": "Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common form, exhibiting autosomal dominant inheritance and linkage to chromosome 17p11.2p12."}, {"doc_id": "12872253", "chunk_id": "12872253_1", "score": 6.464328289031982, "text": "In a previous study, we have shown that N-myc downstream-regulated gene 1 (NDRG1), classified in databases as a tumor suppressor and heavy metal-response protein, is mutated in hereditary motor and sensory neuropathy Lom (HMSNL), a severe autosomal recessive form of Charcot-Marie-Tooth (CMT) disease."}, {"doc_id": "8655146", "chunk_id": "8655146_0", "score": 6.375247001647949, "text": "Autosomal dominant Charcot-Marie-Tooth type-1A neuropathy (CMT1A) is a demyelinating peripheral nerve disorder that is commonly associated with a submicroscopic tandem DNA duplication of a 1.5-Mb region of 17p11.2p12 that contains the peripheral myelin gene PMP22."}], "context": "[8128981:8128981_0] Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common form, exhibiting autosomal dominant inheritance and linkage to chromosome 17p11.2p12.\n[12872253:12872253_1] In a previous study, we have shown that N-myc downstream-regulated gene 1 (NDRG1), classified in databases as a tumor suppressor and heavy metal-response protein, is mutated in hereditary motor and sensory neuropathy Lom (HMSNL), a severe autosomal recessive form of Charcot-Marie-Tooth (CMT) disease.\n[8655146:8655146_0] Autosomal dominant Charcot-Marie-Tooth type-1A neuropathy (CMT1A) is a demyelinating peripheral nerve disorder that is commonly associated with a submicroscopic tandem DNA duplication of a 1.5-Mb region of 17p11.2p12 that contains the peripheral myelin gene PMP22.", "answer": "<think> Okay, I need to generate a JSON answer based on the given evidence for the question about genes mutated in CMT1A. Let me start by understanding the user's query and the provided evidence. The question is asking for genes that have been found mutated in CMT1A. The evidence has three chunks. First chunk [8128981:8128981_0] talks about CMT1A being the most common form with autosomal dominant inheritance linked to chromosome 17p11.2p12. But it doesn't mention any specific genes mutated here. Second chunk [12872253:12872253_1] mentions NDRG1 being mutated", "citations": [{"doc_id": "8128981", "chunk_id": "8128981_0"}, {"doc_id": "12872253", "chunk_id": "12872253_1"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants a list of genes mutated in CMT1A. Looking at the evidence provided. First, the first evidence snippet mentions CMT1A is linked to chromosome 17p11.2p12 and talks about PMP22. The third piece of evidence specifically says that CMT1A is associated with a duplication of a region containing the PMP22 gene. So PMP22 is definitely a gene involved here. Then there's the second snippet mentioning NDRG1 being mutated in HMSNL, which is a different type (autosomal recessive) but related to CMT. However, the question is about CMT1A, which is dominant. The user might be confused if", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence for the question about genes mutated in CMT1A. Let me start by understanding the user's query and the provided evidence. The question is asking for genes that have been found mutated in CMT1A. The evidence has three chunks. First chunk [8128981:8128981_0] talks about CMT1A being the most common form with autosomal dominant inheritance linked to chromosome 17p11.2p12. But it doesn't mention any specific genes mutated here. Second chunk [12872253:12872253_1] mentions NDRG1 being mutated", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user wants a list of genes mutated in CMT1A. Looking at the evidence provided. First, the third document mentions that CMT1A is associated with a duplication of the 1.5-Mb region on chromosome 17p11.2p12 containing the PMP22 gene. So PMP22 is definitely a key gene here. That's a strong point. The second document talks about NDRG1 being mutated in HMSNL, which is a different type of CMT (autosomal recessive). But the question specifically asks about CMT1A, which is autosomal dominant. Since HMSNL is a different form, maybe NDRG1 isn't relevant here. However", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants a list of genes mutated in CMT1A. Looking at the evidence provided. First, the first document says CMT1A is linked to chromosome 17p11.2p12 and mentions PMP22 as a gene there. The third evidence chunk specifically states that CMT1A is associated with a duplication of the 1.5-Mb region containing PMP22. So PMP22 is definitely a gene involved here. The second document talks about NDRG1 being mutated in HMSNL, which is a different type (autosomal recessive) of CMT. But the question is about CMT1A, which is dominant. Since the evidence mentions NDR", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The question is asking for genes mutated in CMT1A. Let's look at the evidence. First, the first document says that CMT1A is linked to chromosome 17p11.2p12. Then the third document mentions PMP22 as a gene associated with CMT1A, specifically a duplication of a region containing PMP22. The second document talks about NDRG1 being mutated in another form of CMT, HMSNL, which is a different type (autosomal recessive), not CMT1A. So the answer should focus on PMP22 since that's directly mentioned in the context of CMT1A. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants a list of genes mutated in CMT1A. Looking at the evidence provided. First, the first document says CMT1A is linked to chromosome 17p11.2p12 and mentions PMP22 as a gene there. The third evidence chunk specifically states that CMT1A is associated with a duplication of the 1.5-Mb region containing PMP22. So PMP22 is definitely a gene involved here. The second document talks about NDRG1 being mutated in HMSNL, which is a different type of CMT (autosomal recessive). But the question is about CMT1A, which is autosomal dominant. Since HMSNL is a", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants a list of genes mutated in CMT1A. Looking at the evidence provided, there are three chunks. First chunk [8128981:8128981_0] mentions that CMT1A is linked to chromosome 17p11.2p12. But it doesn't specify any genes. The second chunk [12872253:12872253_1] talks about NDRG1 being mutated in HMSNL, which is a different type of CMT (autosomal recessive), not 1A. The third chunk [8655146:865514", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence for the question about genes mutated in CMT1A. Let me start by reading through the provided evidence carefully. The user is asking specifically for genes mutated in CMT1A. Looking at the evidence: First document [8128981:8128981_0] mentions that CMT1A is linked to chromosome 17p11.2p12, but it doesn't mention any specific gene mutations. Second document [12872253:12872253_1] talks about NDRG1 being mutated in HMSNL, which is a different type of CMT (autosomal recessive", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["24819634", "25150498", "25385046", "25400662", "25429913", "25430934", "25500726", "25519680", "25522693"], "ideal_answer": "PMP22 is the common gene found mutated through a duplication in CMT1A. Other genes are MPZ and SH3TC2"}
{"question_id": "517a8c918ed59a060a000043", "question": "Which viruses are best known to cause myocarditis?", "retrieved_chunks": [{"doc_id": "32720461", "chunk_id": "32720461_2", "score": 9.665445327758789, "text": "other viruses such as Parvovirus B19 and human herpesvirus-6 are increasingly reported as causes of myocarditis in the United States, with the most recent example being the severe acute respiratory syndrome coronavirus 2, causing the Coronavirus Disease-19."}, {"doc_id": "3889351", "chunk_id": "3889351_0", "score": 8.944942474365234, "text": "Coxsackie B viruses (types 1 to 5) are the most frequent reported cause of acute viral myocarditis."}, {"doc_id": "8682098", "chunk_id": "8682098_0", "score": 8.620274543762207, "text": "Overall, the enteroviruses, and particularly the Coxsackie-B viruses, predominate among viruses as the cause of myocarditis. As new molecular biological techniques have become available, the cytomegaloviruses (CMV) seem to have emerged as a more common cause of myocarditis than was previously recognized. Among the bacterial myocarditides, diphtheric myocarditis has become a serious threat in Russia and adjacent states during the 1990s. Among newly identified bacteria, Borrelia burgdorferi infection is accompanied by cardiac involvement in 1-8% of cases, where myocarditis with conduction disturbances is the most prominent feature. Chlamydia pneumoniae may be associated with myocarditis and sudden unexpected death."}], "context": "[32720461:32720461_2] other viruses such as Parvovirus B19 and human herpesvirus-6 are increasingly reported as causes of myocarditis in the United States, with the most recent example being the severe acute respiratory syndrome coronavirus 2, causing the Coronavirus Disease-19.\n[3889351:3889351_0] Coxsackie B viruses (types 1 to 5) are the most frequent reported cause of acute viral myocarditis.\n[8682098:8682098_0] Overall, the enteroviruses, and particularly the Coxsackie-B viruses, predominate among viruses as the cause of myocarditis. As new molecular biological techniques have become available, the cytomegaloviruses (CMV) seem to have emerged as a more common cause of myocarditis than was previously recognized. Among the bacterial myocarditides, diphtheric myocarditis has become a serious threat in Russia and adjacent states during the 1990s. Among newly identified bacteria, Borrelia burgdorferi infection is accompanied by cardiac involvement in 1-8% of cases, where myocarditis with conduction disturbances is the most prominent feature. Chlamydia pneumoniae may be associated with myocarditis and sudden unexpected death.", "answer": "<think> Okay, let's see. The user is asking which viruses are best known to cause myocarditis. I need to look at the evidence provided. First, there's a mention of Coxsackie B viruses (types 1 to 5) being the most frequent reported cause of acute viral myocarditis in [3889351:3889351_0]. That seems like a strong point. Then another part says that enteroviruses, particularly Coxsackie-B, dominate as causes of myocarditis in [8682098:8682098_0]. So Coxsackie B is definitely a key one here. Another part mentions Parvovirus B19 and herpesv", "citations": [{"doc_id": "3889351", "chunk_id": "3889351_0"}, {"doc_id": "8682098", "chunk_id": "8682098_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants to know which viruses are best known to cause myocarditis, and they provided some evidence. First, I need to look through the evidence given. Let me check each chunk: The first chunk mentions Parvovirus B19, human herpesvirus-6, and SARS-CoV-2 as causes. But it says \"increasingly reported,\" so maybe not the most known. The second chunk clearly states that Coxsackie B viruses (types 1-5) are the most frequent reported cause. That seems like a strong point. Third chunk says enteroviruses, particularly Coxsackie-B, dominate. Also mentions CMV emerging as more common. But the question is about viruses best", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which viruses are best known to cause myocarditis. Looking at the evidence provided, there are a few references. First, the third evidence chunk says that Coxsackie B viruses (types 1-5) are the most frequent reported cause of acute viral myocarditis. That's pretty direct. Then another chunk mentions enteroviruses, especially Coxsackie-B, as predominant. Also, there's a mention of Parvovirus B19 and herpesvirus-6 being increasingly reported, and even SARS-CoV-2. But the question is about viruses best known, so maybe the most commonly cited ones. The second evidence chunk specifically highlights Coxsackie B as the most frequent", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which viruses are best known to cause myocarditis, based on the provided evidence. First, I need to look through the evidence snippets. The first one mentions Parvovirus B19, human herpesvirus-6, and SARS-CoV-2 as increasingly reported causes. But the second snippet clearly states that Coxsackie B viruses (types 1-5) are the most frequent reported cause. The third snippet reinforces that enteroviruses, especially Coxsackie-B, predominate. It also mentions CMV emerging as a more common cause, but the question is about viruses best known, so maybe Coxsackie-B is the primary. The answer should be concise", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's see. The user is asking which viruses are best known to cause myocarditis. I need to look at the evidence provided. First, there's a mention of Coxsackie B viruses (types 1 to 5) being the most frequent reported cause of acute viral myocarditis in [3889351:3889351_0]. That seems like a strong point. Then another part says that enteroviruses, particularly Coxsackie-B, dominate as causes of myocarditis in [8682098:8682098_0]. So Coxsackie B is definitely a key one here. Another part mentions Parvovirus B19 and herpesv", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which viruses are best known to cause myocarditis, based on the provided evidence. First, I need to look through the evidence snippets. The first one mentions Parvovirus B19, HSV-6, and SARS-CoV-2. But the second snippet clearly states that Coxsackie B viruses (types 1-5) are the most frequent cause. The third snippet reinforces that enteroviruses, especially Coxsackie-B, are predominant. Also, CMV is noted as emerging as a more common cause. However, the question asks for the best-known viruses, so the primary ones would be Coxsackie B and maybe CMV. But the answer should be concise", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which viruses are best known to cause myocarditis. I need to look at the evidence provided and pick out the main ones. First, looking at the evidence documents: Document [3889351:3889351_0] says Coxsackie B viruses (types 1-5) are the most frequent cause of acute viral myocarditis. That's a strong point. Then document [8682098:8682098_0] mentions enteroviruses, especially Coxsackie-B, as predominant. Also, CMV is noted as emerging as a more common cause. Other viruses like Parvovirus B19", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which viruses are best known to cause myocarditis. Looking at the evidence provided, there are a few mentions. First, the third evidence chunk says that Coxsackie B viruses (types 1-5) are the most frequent reported cause of acute viral myocarditis. That's pretty direct. Then another chunk mentions enteroviruses, particularly Coxsackie-B, as predominant. Also, there's a mention of Parvovirus B19 and human herpesvirus-6 being increasingly reported, and even COVID-19 as a recent example. But the question is about viruses best known, so maybe the most common ones. The second chunk also says that CMV has emerged as a more", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which viruses are best known to cause myocarditis. The evidence provided includes several sources. First, looking at the evidence, [3889351:3889351_0] mentions Coxsackie B viruses (types 1 to 5) as the most frequent cause of acute viral myocarditis. Then [8682098:8682098_0] also talks about enteroviruses, particularly Coxsackie-B, being predominant. Additionally, [32720461:32720461_2] lists other viruses like Parvovirus B19, HHV", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["14993139", "18039618", "18277927", "2641165", "3889351", "8199011"], "ideal_answer": "The most frequent viruses causing myocarditis are Enterovirus, Adenovirus and Coxsackie B viruses."}
{"question_id": "571f2b5bbb137a4b0c000010", "question": "Which genes have been associated with Cerebral Cavernous Malformation?", "retrieved_chunks": [{"doc_id": "25451273", "chunk_id": "25451273_1", "score": 9.703950881958008, "text": "The three cerebral cavernous malformations (CCMs) genes namely CCM1/KRIT1, CCM2/MGC4607 and CCM3/PDCD10 have been identified for which mutations cause cerebral cavernous malformations"}, {"doc_id": "12172908", "chunk_id": "12172908_0", "score": 9.533917427062988, "text": "Mutation and expression analysis of the KRIT1 gene associated with cerebral cavernous malformations (CCM1)."}, {"doc_id": "14697511", "chunk_id": "14697511_1", "score": 9.104315757751465, "text": "At least 45% of families affected with cerebral cavernous malformations harbour a mutation in Krev interaction trapped-1 (Krit1) gene (cerebral cavernous malformation gene-1, CCM1)."}], "context": "[25451273:25451273_1] The three cerebral cavernous malformations (CCMs) genes namely CCM1/KRIT1, CCM2/MGC4607 and CCM3/PDCD10 have been identified for which mutations cause cerebral cavernous malformations\n[12172908:12172908_0] Mutation and expression analysis of the KRIT1 gene associated with cerebral cavernous malformations (CCM1).\n[14697511:14697511_1] At least 45% of families affected with cerebral cavernous malformations harbour a mutation in Krev interaction trapped-1 (Krit1) gene (cerebral cavernous malformation gene-1, CCM1).", "answer": "<think> Okay, let's tackle this question. The user is asking which genes are associated with Cerebral Cavernous Malformation (CCM). I need to look at the provided evidence to find the answer. Looking at the first evidence snippet: [25451273:25451273_1] mentions three genes: CCM1/KRIT1, CCM2/MGC4607, and CCM3/PDCD10. That seems like a direct answer. The other snippets support this by talking about mutations in the KRIT1 gene (which is CCM1) and the percentage of families with mutations in Krit1. The second evidence [12172908:", "citations": [{"doc_id": "25451273", "chunk_id": "25451273_1"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which genes are associated with Cerebral Cavernous Malformation (CCM). I need to look at the evidence provided. First, the evidence has three chunks. The first one mentions three genes: CCM1/KRIT1, CCM2/MGC4607, and CCM3/PDCD10. That's a direct statement from the study with ID 25451273. The second chunk talks about KRIT1 gene related to CCM1, and the third one confirms that 45% of families have mutations in the Krit1 gene, which is CCM1. So, combining these, the main genes are CCM1 (KR", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which genes are associated with Cerebral Cavernous Malformation (CCM). I need to look at the provided evidence to find the answer. First, looking at the evidence snippets. The first one mentions three genes: CCM1/KRIT1, CCM2/MGC4607, and CCM3/PDCD10. That seems like a direct answer. The second snippet talks about KRIT1 gene related to CCM1, and the third says 45% of families have mutations in the Krit1 gene, which is CCM1. So the main genes here are CCM1, CCM2, and CCM3. The first evidence document clearly", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking which genes are associated with Cerebral Cavernous Malformation (CCM). Let me look at the evidence provided. First, the first piece of evidence mentions three genes: CCM1/KRIT1, CCM2/MGC4607, and CCM3/PDCD10. That's a direct statement from a source. The second evidence talks about KRIT1 gene mutations related to CCM1. The third one says that 45% of families have mutations in the Krit1 gene, which is CCM1. So, combining these, the main genes are CCM1, CCM2, and CCM3. The first source clearly lists all three. The other sources support that KR", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking which genes are associated with Cerebral Cavernous Malformation (CCM). Let me look at the evidence provided. First, the first document says that the three CCM genes are CCM1/KRIT1, CCM2/MGC4607, and CCM3/PDCD10. That's a direct statement. Then, the second document mentions mutations in the KRIT1 gene related to CCM1. The third one talks about Krit1 gene mutations in 45% of families with CCM. So, combining these, the main genes are CCM1 (KRIT1), CCM2 (MGC4607), and CCM3 (PDCD10", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which genes are associated with Cerebral Cavernous Malformation (CCM). I need to look at the provided evidence to find the answer. Looking at the first piece of evidence, it mentions three genes: CCM1/KRIT1, CCM2/MGC4607, and CCM3/PDCD10. That's a direct statement from the source, so that's a strong clue. The other two pieces of evidence talk about KRIT1 (which is CCM1) and mention that 45% of families have mutations in Krit1. But the first source lists all three genes, so that's the main answer here. I should check if there's any", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking which genes are associated with Cerebral Cavernous Malformation (CCM). Let me look at the evidence provided. First, there's a document that mentions three genes: CCM1/KRIT1, CCM2/MGC4607, and CCM3/PDCD10. That seems like a direct answer. Then another document talks about KRIT1 gene mutations related to CCM1. The third one says 45% of families have mutations in the Krit1 gene, which is CCM1. Wait, so the first source lists all three genes, and the others support that KRIT1 is part of that. The question is asking for the genes associated with CCM. So", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking which genes are associated with Cerebral Cavernous Malformation (CCM). Let me look at the evidence provided. The first evidence snippet from 25451273:25451273_1 mentions three genes: CCM1/KRIT1, CCM2/MGC4607, and CCM3/PDCD10. That's a direct statement about the genes linked to CCM. The other two snippets reference KRIT1 (CCM1) specifically, citing mutations and expression analysis. The third snippet also talks about Krit1 gene mutations in 45% of families. So combining these, the main answer should include all three genes mentioned in the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which genes are associated with Cerebral Cavernous Malformation (CCM). I need to look at the provided evidence to find the answer. Looking at the first evidence snippet: [25451273:25451273_1] mentions three genes: CCM1/KRIT1, CCM2/MGC4607, and CCM3/PDCD10. That seems like a direct answer. The other snippets support this by talking about mutations in the KRIT1 gene (which is CCM1) and the percentage of families with mutations in Krit1. The second evidence [12172908:", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["11310633", "12140362", "12172908", "12877753", "14697511", "15543491", "16100539", "16465592", "20592472", "24251678", "24287896", "24466005", "24481819", "24990152", "25086949", "25122144", "25451273", "26246098"], "ideal_answer": "Loss-of-function mutations in genes encoding CCM1 (also known as KRIT1), CCM2 (also known as OSM and malcavernin) or CCM3 (also known as PDCD10) cause cerebral cavernous malformations (CCMs)."}
{"question_id": "52fb4b462059c6d71c00005f", "question": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies", "retrieved_chunks": [{"doc_id": "19903697", "chunk_id": "19903697_0", "score": 4.402287006378174, "text": "Diiodothyropropionic acid (DITPA) and GC-1, a noniodinated thyroid hormone analog,"}, {"doc_id": "16384862", "chunk_id": "16384862_0", "score": 4.2870774269104, "text": ",5-diiodothyropropionic acid (DITPA), a thyroid hormone analog"}, {"doc_id": "15454853", "chunk_id": "15454853_0", "score": 4.100543022155762, "text": "The thyroid analog DITPA enhances endothelial nitric oxide and beta-adrenergic-mediated vasorelaxation by increasing nitric oxide in the vasculature."}], "context": "[19903697:19903697_0] Diiodothyropropionic acid (DITPA) and GC-1, a noniodinated thyroid hormone analog,\n[16384862:16384862_0] ,5-diiodothyropropionic acid (DITPA), a thyroid hormone analog\n[15454853:15454853_0] The thyroid analog DITPA enhances endothelial nitric oxide and beta-adrenergic-mediated vasorelaxation by increasing nitric oxide in the vasculature.", "answer": "<think> Okay, let's tackle this question. The user is asking if DITPA is a thyroid hormone analog used in experimental and clinical studies. I need to check the provided evidence to confirm that. Looking at the evidence, the first document [19903697:19903697_0] mentions DITPA and GC-1 as noniodinated thyroid hormone analogs. The second one [16384862:1638486: Also, the third document [15454853:15454853_0] states that DITPA is a thyroid analog that enhances endothelial nitric oxide and beta-adrenergic-mediated vasore", "citations": [{"doc_id": "19903697", "chunk_id": "19903697_0"}, {"doc_id": "16384862", "chunk_id": "1638486: Also, the third document [15454853:15454853_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if DITPA is a thyroid hormone analog used in experimental and clinical studies. The evidence provided has three chunks. First, looking at chunk 19903697_0: It mentions DITPA and GC-1 as noniodinated thyroid hormone analogs. So that's a direct statement that DITPA is a thyroid hormone analog. Next, chunk 16384862_0 refers to DITPA as a thyroid hormone analog again, which reinforces the same point. Then, chunk 15454853_0 says DITPA enhances nitric oxide and vasorelaxation, which are experimental findings. But does it", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if DITPA is a thyroid hormone analog used in experimental and clinical studies. I need to check the provided evidence to see if that's correct. Looking at the evidence, the first chunk says \"Diiodothyropropionic acid (DITPA) and GC-1, a noniodinated thyroid hormone analog,\" which directly states that DITPA is a thyroid hormone analog. The second chunk mentions \",5-diiodothyropropionic acid (DITPA), a thyroid hormone analog,\" reinforcing that. The third chunk talks about DITPA enhancing nitric oxide and vasorelaxation, indicating it's used in studies, probably experimental. Now, the question also asks about clinical studies. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if DITPA is a thyroid hormone analog used in experimental and clinical studies. I need to check the provided evidence to confirm that. Looking at the evidence, the first document [19903697:19903697_0] mentions DITPA and GC-1 as noniodinated thyroid hormone analogs. The second one [16384862:1638486: Also, the third document [15454853:15454853_0] states that DITPA is a thyroid analog that enhances endothelial nitric oxide and beta-adrenergic-mediated vasore", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if DITPA is a thyroid hormone analog used in experimental and clinical studies. I need to check the evidence provided. Looking at the evidence: First snippet: [19903697:19903697_0] mentions DITPA and GC-1 as noniodinated thyroid hormone analogs. So that's a direct statement that DITPA is a thyroid hormone analog. Second snippet: [16384862:16384863_0] again refers to DITPA as a thyroid hormone analog. That's another confirmation. Third snippet: [15454853:15454", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to answer whether DITPA is a thyroid hormone analog used in experimental and clinical studies. Let's look at the evidence provided. First, the first evidence snippet says: \"Diiodothyropropionic acid (DITPA) and GC-1, a noniodinated thyroid hormone analog,\". So this mentions DITPA as a thyroid hormone analog. The second snippet: \",5-diiodothyropropionic acid (DITPA), a thyroid hormone analog\". That directly states DITPA is a thyroid hormone analog. The third snippet talks about DITPA enhancing endothelial nitric oxide and beta-adrenergic-mediated vasorelaxation, which suggests it's used in experimental studies. The question also asks about clinical studies.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if DITPA is a thyroid hormone analog used in experimental and clinical studies. I need to check the provided evidence to confirm that. Looking at the evidence, the first document says \"Diiodothyropropionic acid (DITPA) and GC-1, a noniodinated thyroid hormone analog,\" which directly states that DITPA is a thyroid hormone analog. The second document mentions \",5-diiodothyropropionic acid (DITPA), a thyroid hormone analog,\" again confirming it's an analog. The third document talks about DITPA enhancing nitric oxide and vasorelaxation, which suggests it's used in experimental studies. Now, the question also asks about clinical studies. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if DITPA is a thyroid hormone analog used in experimental and clinical studies. The evidence provided has three chunks. First, I need to check each chunk for information about DITPA. The first chunk says DITPA is a thyroid hormone analog. The second chunk also mentions DITPA as a thyroid hormone analog. The third chunk states that DITPA is a thyroid analog and explains its effect on nitric oxide and vasorelaxation. So, all three chunks confirm that DITPA is a thyroid hormone analog. Now, the question is about its use in experimental and clinical studies. The third chunk talks about enhancing endothelial nitric oxide and beta-adrenergic-mediated vasorelaxation", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if DITPA is a thyroid hormone analog used in experimental and clinical studies. The evidence provided has three chunks. First, I need to check each chunk for information about DITPA. The first chunk mentions DITPA and GC-1 as a noniodinated thyroid hormone analog. That's a direct mention of it being a thyroid hormone analog. The second chunk also refers to DITPA as a thyroid hormone analog. The third chunk talks about DITPA as a thyroid analog and its effects on nitric oxide and vasorelaxation, which suggests it's used in studies. Now, the answer needs to be concise with citations. The question is about whether DITPA is a thyroid hormone analog.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["10329215", "10474790", "10710355", "10749704", "11040100", "12145478", "12165118", "12414442", "1403782", "15072976", "15148346", "15454853", "15572044", "16384862", "16616210", "17612639", "17710084", "18030062", "18353884", "18954857", "19286941", "19506112", "19903697", "20080837", "20192904", "21131480", "21215270", "21658725", "22993035", "7828308", "8353891", "8936682", "9069582", "9618233"], "ideal_answer": "There is very large body of evidence that DITPA is a true thyroid hormone analog, largely utilized in experimental and clinical studies."}
{"question_id": "56c1d848ef6e39474100002f", "question": "What is Tarlov Cyst?", "retrieved_chunks": [{"doc_id": "23400656", "chunk_id": "23400656_0", "score": 10.25108528137207, "text": "Tarlov cyst syndrome is a rare, often asymptomatic disorder, characterised by isolated or multiple nerve-root cysts, usually occurring in the sacral spine, near the dorsal root ganglion, between the perineurium and endoneurium."}, {"doc_id": "21139800", "chunk_id": "21139800_0", "score": 9.790163040161133, "text": "Tarlov cysts (sacral perineural cysts) are nerve root cysts found most commonly in the sacral roots,"}, {"doc_id": "19110185", "chunk_id": "19110185_0", "score": 9.135313034057617, "text": "Tarlov cysts are sacral perineural cysts. This case report describes the clinical course after biopsy of a very large Tarlov cyst via laparoscopy, which was thought preoperatively to be an adnexal mass."}], "context": "[23400656:23400656_0] Tarlov cyst syndrome is a rare, often asymptomatic disorder, characterised by isolated or multiple nerve-root cysts, usually occurring in the sacral spine, near the dorsal root ganglion, between the perineurium and endoneurium.\n[21139800:21139800_0] Tarlov cysts (sacral perineural cysts) are nerve root cysts found most commonly in the sacral roots,\n[19110185:19110185_0] Tarlov cysts are sacral perineural cysts. This case report describes the clinical course after biopsy of a very large Tarlov cyst via laparoscopy, which was thought preoperatively to be an adnexal mass.", "answer": "<think> Okay, so I need to generate a biomedical answer about Tarlov Cyst based on the provided evidence. Let me start by reading through the question and the evidence carefully. The user is asking for a concise answer that defines Tarlov Cyst, including citations from the given documents. The answer should be in JSON format with two keys: \"answer\" and \"base_confidence\". The confidence is a float between 0 and 1. Looking at the evidence: First document [23400656:23400656_0] says Tarlov cyst syndrome is a rare, often asymptomatic disorder with nerve-root cysts in the sacral spine near the dorsal root ganglion. Second document [2113980", "citations": [{"doc_id": "23400656", "chunk_id": "23400656_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question about Tarlov Cysts. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three chunks here. Let me read through them carefully. The first chunk says Tarlov cyst syndrome is rare, often asymptomatic, with cysts in the sacral spine near the dorsal root ganglion. The second mentions they're commonly found in the sacral roots. The third confirms they're called sacral perineural cysts and talks about a case where a large one was biopsied via laparoscopy. So, the answer should define Tarlov Cyst based on these points. The key elements are that they're nerve root cysts located in the sacral region", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer for the question \"What is Tarlov Cyst?\" using the provided evidence. Let me start by understanding what the user is asking. They want a concise answer with citations and a confidence level. First, I'll look at the evidence given. There are three chunks from different documents. The first chunk (23400656:23400656_0) says Tarlov cyst syndrome is a rare, asymptomatic disorder with nerve-root cysts in the sacral spine near the dorsal root ganglion. The second chunk (21139800:21139800_0) mentions Tarlov cysts as sacral perineural cyst", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so I need to generate a biomedical answer about Tarlov Cyst based on the provided evidence. Let me start by reading through the question and the evidence carefully. The user is asking for a concise answer that defines Tarlov Cyst, including citations from the given documents. The answer should be in JSON format with two keys: \"answer\" and \"base_confidence\". The confidence is a float between 0 and 1. Looking at the evidence: First document [23400656:23400656_0] says Tarlov cyst syndrome is a rare, often asymptomatic disorder with nerve-root cysts in the sacral spine near the dorsal root ganglion. Second document [2113980", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a biomedical answer about Tarlov Cyst based on the provided evidence. Let me start by reading through the evidence carefully. The first document says that Tarlov cyst syndrome is a rare, often asymptomatic disorder with nerve-root cysts in the sacral spine near the dorsal root ganglion. The second mentions that Tarlov cysts are sacral perineural cysts commonly found in the sacral roots. The third one also states they're sacral perineural cysts and talks about a case where a large cyst was biopsied via laparoscopy. So, putting this together, Tarlov cysts are specifically located in the sacral area, associated with nerve roots, and are perineural cysts. The term \"Tar", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a biomedical answer about Tarlov Cysts based on the provided evidence. Let me start by reading through the evidence carefully. The first document (23400656:23400656_0) says that Tarlov cyst syndrome is rare and often asymptomatic, with cysts in the sacral spine near the dorsal root ganglion. The second (21139800:21139800_0) mentions they're nerve root cysts commonly found in the sacral roots. The third (19110185:19110185_0) confirms they're sacral perineural cysts and describes a case", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so I need to generate a JSON answer for the question \"What is Tarlov Cyst?\" based on the provided evidence. Let me start by reading through the evidence carefully. The first document (23400656:23400656_0) says that Tarlov cyst syndrome is a rare, often asymptomatic disorder characterized by isolated or multiple nerve-root cysts usually in the sacral spine near the dorsal root ganglion between the perineurium and endoneurium. The second one (21139800:21139800_0) mentions Tarlov cysts as sacral perineural cysts, commonly found in the sacral roots. The third document", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a biomedical answer about Tarlov Cyst based on the given evidence. Let me start by reading through the provided evidence carefully. The first piece of evidence (23400656:23400656_0) says that Tarlov cyst syndrome is a rare, often asymptomatic disorder with nerve-root cysts usually in the sacral spine near the dorsal root ganglion. The second one (21139800:21139800_0) mentions Tarlov cysts as sacral perineural cysts found commonly in the sacral roots. The third evidence (19110185:19110185_0", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so I need to generate a biomedical answer about Tarlov Cyst based on the provided evidence. Let me start by understanding what the question is asking. The user wants a concise answer that cites the document IDs and chunk IDs, along with a confidence level. Looking at the evidence, there are three chunks. The first one says Tarlov cyst syndrome is a rare, asymptomatic disorder with nerve-root cysts in the sacral spine near the dorsal root ganglion. The second mentions Tarlov cysts as sacral perineural cysts commonly found in the sacral roots. The third describes them as sacral perineural cysts and a case report of a large cyst biopsied via laparoscopy. So, the answer should define Tarlov Cyst", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["10758434", "11453427", "19110185", "19569467", "20102100", "20712856", "21139800", "21830055", "23400656", "25191117", "25216402"], "ideal_answer": "Tarlov or perineural cysts are nerve root cysts found most commonly at the sacral spine level arising between covering layers of the perineurium and the endoneurium near the dorsal root ganglion and are usually asymptomatic."}
{"question_id": "571e275dbb137a4b0c000005", "question": "What are 'vildagliptin', 'sitagliptin', 'saxagliptin', 'alogliptin', 'linagliptin', and 'dutogliptin'?", "retrieved_chunks": [{"doc_id": "22215383", "chunk_id": "22215383_2", "score": 7.2689433097839355, "text": "the words \"sitagliptin,\" \"vildagliptin,\" \"saxagliptin,\" \"alogliptin,\" \"linagliptin,\" and/or \"dutogliptin.\" Completed but unpublished trials were identified through a search of the ClinicalTrials.gov website,"}, {"doc_id": "22106978", "chunk_id": "22106978_0", "score": 6.798078536987305, "text": "An extensive Medline and Embase search for 'vildagliptin', 'sitagliptin', 'saxagliptin', 'alogliptin', 'linagliptin', and 'dutogliptin' was performed, collecting all randomized clinical trials on humans up to March 1, 2011."}, {"doc_id": "24793580", "chunk_id": "24793580_1", "score": 6.570303916931152, "text": "An extensive Medline, Embase, and Cochrane Database search for \"vildagliptin\", \"sitagliptin\", \"saxagliptin\", \"alogliptin\", \"linagliptin\", and \"dutogliptin\" was performed, collecting all randomized clinical trials on humans up to October 1st, 2013."}], "context": "[22215383:22215383_2] the words \"sitagliptin,\" \"vildagliptin,\" \"saxagliptin,\" \"alogliptin,\" \"linagliptin,\" and/or \"dutogliptin.\" Completed but unpublished trials were identified through a search of the ClinicalTrials.gov website,\n[22106978:22106978_0] An extensive Medline and Embase search for 'vildagliptin', 'sitagliptin', 'saxagliptin', 'alogliptin', 'linagliptin', and 'dutogliptin' was performed, collecting all randomized clinical trials on humans up to March 1, 2011.\n[24793580:24793580_1] An extensive Medline, Embase, and Cochrane Database search for \"vildagliptin\", \"sitagliptin\", \"saxagliptin\", \"alogliptin\", \"linagliptin\", and \"dutogliptin\" was performed, collecting all randomized clinical trials on humans up to October 1st, 2013.", "answer": "<think> Okay, the user is asking about these six drugs: vildagliptin, sitagliptin, saxagliptin, alogliptin, linagliptin, and dutogliptin. They want a biomedical answer from the evidence provided. Looking at the evidence, there are three documents. The first one mentions that these words were part of a search on ClinicalTrials.gov, but the trials were completed but unpublished. The second and third documents talk about extensive searches in Medline, Embase, Cochrane Database, and they collected randomized clinical trials up to different dates (March 1, 2011 and October 1, 2013). So the answer should state that these are drugs, likely DPP", "citations": [], "candidates": [{"answer": "<think> Okay, the user is asking about these six drugs: vildagliptin, sitagliptin, saxagliptin, alogliptin, linagliptin, and dutogliptin. They want a biomedical answer from the evidence provided. Looking at the evidence, there are three documents. The first one mentions that these words were part of a search on ClinicalTrials.gov, but the trials were completed but unpublished. The second and third documents talk about extensive searches in Medline, Embase, Cochrane Database, and they collected randomized clinical trials up to different dates (March 1, 2011 and October 1, 2013). So the answer should state that these are drugs, likely DPP", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking about these six drugs: vildagliptin, sitagliptin, saxagliptin, alogliptin, linagliptin, and dutogliptin. They want a concise answer with citations and a confidence score. Looking at the evidence provided, all three documents mention that these are names of drugs. The first document mentions them in the context of trials from ClinicalTrials.gov. The second and third documents talk about extensive searches in Medline, Embase, Cochrane Database, etc., which were done to collect clinical trials up to different dates. So, the answer should state that these are drugs, probably DPP-4 inhibitors, based on their names. But wait, the evidence doesn't explicitly", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's see. The user is asking about these drugs: vildagliptin, sitagliptin, saxagliptin, alogliptin, linagliptin, and dutogliptin. They want a biomedical answer from the evidence provided. Looking at the evidence, there are three documents mentioned. All of them talk about searching for these drug names in medical databases like Medline, Embase, Cochrane, and ClinicalTrials.gov. The first two documents mention that trials were identified up to March 1, 2011 and October 1, 2013 respectively. The third document is from a later date, but the key point is that these drugs are being studied in clinical trials. The answer", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking about the drugs 'vildagliptin', 'sitagliptin', 'saxagliptin', 'alogliptin', 'linagliptin', and 'dutogliptin'. They want a biomedical answer from the provided evidence. First, I need to look at the evidence given. There are three document entries. The first one mentions these drug names in the context of completed but unpublished trials from ClinicalTrials.gov. The second and third documents talk about extensive searches in Medline, Embase, Cochrane Database for clinical trials up to different dates (2011 and 2013). The key here is that all these drugs are DPP-4", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking about these six drugs: vildagliptin, sitagliptin, saxagliptin, alogliptin, linagliptin, and dutogliptin. They want a concise answer with citations and a confidence score. Looking at the evidence provided, all three documents mention that these are drug names, specifically DPP-4 inhibitors. The first document mentions them in the context of trials from ClinicalTrials.gov. The second and third documents talk about extensive searches in Medline, Embase, Cochrane databases, collecting randomized clinical trials up to different dates. So they're all related to these drugs being studied in clinical trials. The answer should state that these are DPP-4 inhibitors used for type 2", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking about the drugs 'vildagliptin', 'sitagliptin', 'saxagliptin', 'alogliptin', 'linagliptin', and 'dutogliptin'. They want a concise answer with citations and a confidence score. First, I need to check the evidence provided. The three documents mention searches for these drugs, focusing on clinical trials up to different dates. All the documents list the same set of drug names, so they're all relevant. The answer should state that these are DPP-4 inhibitors used for type 2 diabetes, citing the sources. Each document is from a different search but all confirm the drugs' existence and use. The confidence can", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking about these six drugs: vildagliptin, sitagliptin, saxagliptin, alogliptin, linagliptin, and dutogliptin. They want a concise answer with citations and a confidence score. Looking at the evidence provided, all three documents mention that these are drug names, specifically DPP-4 inhibitors used for type 2 diabetes. The first document mentions they were part of trials on ClinicalTrials.gov. The second and third documents talk about extensive searches in Medline, Embase, Cochrane databases collecting clinical trials up to different dates. So the answer should state that these are DPP-4 inhibitors for T2D, citing the evidence. The confidence is high because", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking about these six drugs: vildagliptin, sitagliptin, saxagliptin, alogliptin, linagliptin, and dutogliptin. They want a concise answer with citations and a confidence level. Looking at the evidence provided, all three documents mention that these are names of drugs. The first document mentions them in the context of trials from ClinicalTrials.gov. The second and third documents talk about extensive searches in Medline, Embase, Cochrane Database, etc., collecting clinical trials up to different dates. So the answer should state that these are drug names, likely DPP-4 inhibitors, as they're commonly known in the field. The citations are from the three documents,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["17100408", "18223196", "19791828", "20690781", "21320267", "21431099", "21500969", "21913883", "22106978", "22162539", "22215383", "22429011", "22686547", "23136353", "23140189", "23501107", "23743694", "23803146", "23837679", "24186878", "24320733", "24567800", "24793219", "24793580", "24996141", "25687897", "25860270"], "ideal_answer": "\"Sitagliptin,\" \"vildagliptin,\" \"saxagliptin,\" \"alogliptin,\" \"linagliptin,\" and \"dutogliptin\" are dipeptidyl peptidase-4 (DPP-4) inhibitors."}
{"question_id": "51739df58ed59a060a00001c", "question": "Which is the most important prognosis sub-classification in Chronic Lymphocytic Leukemia?", "retrieved_chunks": [{"doc_id": "22560084", "chunk_id": "22560084_0", "score": 5.855644226074219, "text": "One of the most reliable prognostic markers in chronic lymphocytic leukemia (CLL) is the mutational status of immunoglobulin heavy variable (IGHV) genes, which defines 2 subsets, mutated CLL (M-CLL) and unmutated CLL (U-CLL), with different clinical courses."}, {"doc_id": "22150006", "chunk_id": "22150006_0", "score": -0.7385619878768921, "text": "Nine genes that are mutated at significant frequencies were identified, including four with established roles in chronic lymphocytic leukemia (TP53 in 15% of patients, ATM in 9%, MYD88 in 10%, and NOTCH1 in 4%) and five with unestablished roles (SF3B1, ZMYM3, MAPK1, FBXW7, and DDX3X). SF3B1, which functions at the catalytic core of the spliceosome, was the second most frequently mutated gene (with mutations occurring in 15% of patients)."}, {"doc_id": "22362000", "chunk_id": "22362000_0", "score": -0.8143677115440369, "text": "In chronic lymphocytic leukemia (CLL), Syk becomes activated by external signals from the tissue microenvironment, and was targeted in a first clinical trial with R788 (fostamatinib), a relatively nonspecific Syk inhibitor."}], "context": "[22560084:22560084_0] One of the most reliable prognostic markers in chronic lymphocytic leukemia (CLL) is the mutational status of immunoglobulin heavy variable (IGHV) genes, which defines 2 subsets, mutated CLL (M-CLL) and unmutated CLL (U-CLL), with different clinical courses.\n[22150006:22150006_0] Nine genes that are mutated at significant frequencies were identified, including four with established roles in chronic lymphocytic leukemia (TP53 in 15% of patients, ATM in 9%, MYD88 in 10%, and NOTCH1 in 4%) and five with unestablished roles (SF3B1, ZMYM3, MAPK1, FBXW7, and DDX3X). SF3B1, which functions at the catalytic core of the spliceosome, was the second most frequently mutated gene (with mutations occurring in 15% of patients).\n[22362000:22362000_0] In chronic lymphocytic leukemia (CLL), Syk becomes activated by external signals from the tissue microenvironment, and was targeted in a first clinical trial with R788 (fostamatinib), a relatively nonspecific Syk inhibitor.", "answer": "<think> Okay, I need to figure out which is the most important prognosis sub-classification in Chronic Lymphocytic Leukemia based on the given evidence. Let me look at the evidence provided. The first document says that the mutational status of IGHV genes defines two subsets: mutated CLL (M-CLL) and unmutated CLL (U-CLL), which have different clinical courses. That seems like a key point because it directly mentions prognosis sub-classifications. The second document talks about several mutated genes, but it lists them as having significant frequencies. However, the first sentence mentions IGHV mutations as the most reliable prognostic marker. The third document discusses Syk activation and a trial with R788, but that's more about treatment rather", "citations": [], "candidates": [{"answer": "<think> Okay, I need to figure out which is the most important prognosis sub-classification in Chronic Lymphocytic Leukemia based on the given evidence. Let me look at the evidence provided. The first document says that the mutational status of IGHV genes defines two subsets: mutated CLL (M-CLL) and unmutated CLL (U-CLL), which have different clinical courses. That seems like a key point because it directly mentions prognosis sub-classifications. The second document talks about several mutated genes, but it lists them as having significant frequencies. However, the first sentence mentions IGHV mutations as the most reliable prognostic marker. The third document discusses Syk activation and a trial with R788, but that's more about treatment rather", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which is the most important prognosis sub-classification in Chronic Lymphocytic Leukemia (CLL). The evidence provided has three chunks. First chunk (22560084:22560084_0) says that the mutational status of IGHV genes defines two subsets: mutated CLL (M-CLL) and unmutated CLL (U-CLL), with different clinical courses. This directly mentions prognosis sub-classifications based on IGHV mutation status. Second chunk (22150006:22150006_0) talks about several mutated genes, including TP53, ATM, MYD8", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which is the most important prognosis sub-classification in Chronic Lymphocytic Leukemia (CLL). The evidence provided has three chunks. First, chunk 22560084:22560084_0 mentions that the mutational status of IGHV genes defines two subsets: mutated CLL (M-CLL) and unmutated CLL (U-CLL), with different clinical courses. This seems directly related to prognosis since it talks about different clinical outcomes based on mutation status. Chunk 22150006:22150006_0 lists several genes mutated in CLL, including TP53, ATM, MY", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to figure out which is the most important prognosis sub-classification in Chronic Lymphocytic Leukemia based on the given evidence. Let me look at the evidence provided. The first document says that the mutational status of IGHV genes is a reliable prognostic marker, dividing CLL into mutated (M-CLL) and unmutated (U-CLL) subsets with different clinical courses. That seems directly relevant to prognosis. The second document mentions several mutated genes, including TP53, ATM, MYD88, NOTCH1, etc., but it also notes that SF3B1 is the second most frequently mutated gene. However, this document doesn't explicitly link these mutations to prognosis sub-classification. It's more", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which is the most important prognosis sub-classification in Chronic Lymphocytic Leukemia (CLL). The evidence provided has three chunks. First chunk: It mentions that the mutational status of IGHV genes defines two subsets—mutated CLL (M-CLL) and unmutated CLL (U-CLL), with different clinical courses. This seems directly relevant because it's talking about a sub-classification based on mutation status, which is a prognostic marker. Second chunk: Lists several mutated genes, including TP53, ATM, MYD88, NOTCH1, and others. It mentions that SF3B1 is the second most frequently mutated gene. However, this is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so I need to figure out which is the most important prognosis sub-classification in Chronic Lymphocytic Leukemia based on the given evidence. Let's look at the evidence provided. The first document (22560084:22560084_0) says that the mutational status of IGHV genes is a reliable prognostic marker, dividing CLL into mutated (M-CLL) and unmutated (U-CLL) subsets with different clinical courses. That seems directly relevant to prognosis. The second document (22150006:22150006_0) lists several genes mutated in CLL, including TP53, ATM, MYD8", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the most important prognosis sub-classification in Chronic Lymphocytic Leukemia (CLL). The evidence provided has three chunks. First chunk says that the mutational status of IGHV genes defines two subsets: mutated CLL (M-CLLL) and unmutated CLL (U-CLL), which have different clinical courses. That seems directly related to prognosis. The second chunk talks about several genes mutated in CLL, like TP53, ATM, MYD88, NOTCH1, etc. It mentions that IGHV mutational status is a key prognostic marker. But the question is about the most important sub-classification. The first chunk explicitly states that IGHV", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which is the most important prognosis sub-classification in Chronic Lymphocytic Leukemia (CLL). The evidence provided has three chunks. First, chunk 22560084:22560084_0 mentions that the mutational status of IGHV genes defines two subsets: mutated CLL (M-CLL) and unmutated CLL (U-CLL), which have different clinical courses. This seems directly relevant because it talks about a sub-classification based on IGHV mutation status. Then, chunk 22150006:22150006_0 lists several genes mutated in CLL, like TP5", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["16014569", "16083281", "16825496", "17786276", "19127482", "19500131", "20090781", "20353875", "22560084", "23468975"], "ideal_answer": "The mutational status of the immunoglobulin heavy variable (IGHV) genes, defines two subsets: mutated and unmutated CLL. Unmutated CLL patients show a shorter progression-free and overall survival than mutated CLL patients."}
{"question_id": "5168023b298dcd4e51000061", "question": "Is MammaPrint cleared by the United States Food and Drug Administration?", "retrieved_chunks": [{"doc_id": "19546609", "chunk_id": "19546609_0", "score": 8.190268516540527, "text": "The MammaPrint assay has the advantages of a 510(k) clearance by the US Food and Drug Administration, a larger gene number which may enhance further utility, and the potentially wider patient eligibility including lymph node-positive, ER-negative,"}, {"doc_id": "19879448", "chunk_id": "19879448_0", "score": 5.072415828704834, "text": "on MammaPrint, the first and only assay for breast cancer management that has been cleared by the FDA."}, {"doc_id": "21479927", "chunk_id": "21479927_4", "score": 3.8779995441436768, "text": "n FDA-cleared 70-gene signature of MammaPrint panel"}], "context": "[19546609:19546609_0] The MammaPrint assay has the advantages of a 510(k) clearance by the US Food and Drug Administration, a larger gene number which may enhance further utility, and the potentially wider patient eligibility including lymph node-positive, ER-negative,\n[19879448:19879448_0] on MammaPrint, the first and only assay for breast cancer management that has been cleared by the FDA.\n[21479927:21479927_4] n FDA-cleared 70-gene signature of MammaPrint panel", "answer": "<think> Okay, let's tackle this question. The user is asking if MammaPrint is cleared by the US Food and Drug Administration. I need to check the provided evidence to find the answer. Looking at the first document: [19546609:19546609_0] mentions that the MammaPrint assay has 510(k) clearance by the FDA. The 510(k) is a process for medical devices, so this indicates approval. Then there's another document [19879448:19879448_0] which states that MammaPrint is the first and only assay cleared by the FDA. The third document [2147992", "citations": [{"doc_id": "19546609", "chunk_id": "19546609_0"}, {"doc_id": "19879448", "chunk_id": "19879448_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if MammaPrint is cleared by the US Food and Drug Administration. I need to check the evidence provided. Looking at the evidence, there are three documents. The first one mentions that the MammaPrint assay has 510(k) clearance by the FDA. The second document states that MammaPrint is the first and only assay for breast cancer management cleared by the FDA. The third document refers to it as an FDA-cleared 70-gene signature. All three sources consistently state that MammaPrint has received FDA clearance. The first document specifically mentions 510(k) clearance, which is a pathway for Class II medical devices. The second confirms it's cleared by the FDA. The third", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if MammaPrint is cleared by the US Food and Drug Administration. I need to check the evidence provided. Looking at the evidence, there are three documents. The first one mentions that MammaPrint has a 510(k) clearance by the FDA. The second document states it's the first and only assay for breast cancer management cleared by the FDA. The third talks about an FDA-cleared 70-gene signature. So all three sources indicate that MammaPrint is indeed cleared by the FDA. The confidence here is pretty high since multiple documents confirm this. I should cite the relevant chunks. The first and second documents are direct citations. The third supports it as well. The answer needs to", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if MammaPrint is cleared by the US Food and Drug Administration. I need to check the provided evidence to find the answer. Looking at the first document: [19546609:19546609_0] mentions that the MammaPrint assay has 510(k) clearance by the FDA. The 510(k) is a process for medical devices, so this indicates approval. Then there's another document [19879448:19879448_0] which states that MammaPrint is the first and only assay cleared by the FDA. The third document [2147992", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if MammaPrint is cleared by the US Food and Drug Administration. I need to look at the evidence provided to find the answer. Looking at the first evidence snippet: [19546609:19546609_0] mentions that the MammaPrint assay has 510(k) clearance by the FDA. That's a direct statement. The second snippet [19879448:19879448_0] says it's the first and only assay cleared by the FDA. The third one [21479927:21479927_4] refers to it as", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if MammaPrint is cleared by the US Food and Drug Administration. I need to check the provided evidence. Looking at the first document: [19546609:19546609_0] mentions that the MammaPrint assay has 510(k) clearance by the FDA. The 510(k) is a process for Class II medical devices, so that's relevant. Then there's another document [19879448:19879448_0] which states that MammaPrint is the first and only assay cleared by the FDA. The third one [21479927:", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if MammaPrint is cleared by the US Food and Drug Administration. I need to check the provided evidence to find the answer. Looking at the first document: [19546609:19546609_0] mentions that the MammaPrint assay has a 510(k) clearance by the FDA. That's a direct statement. The second document [19879448:19879448_0] says it's the first and only assay for breast cancer management cleared by the FDA. The third one [21479927:21479927_4] refers", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if MammaPrint is cleared by the US Food and Drug Administration. I need to look at the evidence provided. First, check the evidence documents. The first one, 19546609:19546609_0, mentions that MammaPrint has a 510(k) clearance by the FDA. The second document, 19879448:19879448_0, states that MammaPrint is the first and only assay cleared by the FDA. The third one, 21479927:21479928_4, refers to it as an FDA", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if MammaPrint is cleared by the US Food and Drug Administration. I need to check the provided evidence to find the answer. Looking at the first document: [19546609:19546609_0] mentions that the MammaPrint assay has a 510(k) clearance by the FDA. The 510(k) is a regulatory process for medical devices in the US, so this indicates approval. The confidence here is high because it directly states FDA clearance. The second document [19879448:1987944质_0] says \"the first and only assay for breast cancer management that has", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["18786252", "19506735", "21479927"], "ideal_answer": "Yes. MammaPrint is cleared by the FDA for breast cancer recurrence."}
{"question_id": "530f7cdde3eabad021000001", "question": "Is amantadine effective for treatment of disorders conciousness?", "retrieved_chunks": [{"doc_id": "22375973", "chunk_id": "22375973_1", "score": 3.846940755844116, "text": "Amantadine hydrochloride is one of the most commonly prescribed medications for patients with prolonged disorders of consciousness after traumatic brain injury. Preliminary studies have suggested that amantadine may promote functional recovery."}, {"doc_id": "22375973", "chunk_id": "22375973_0", "score": 3.717376947402954, "text": "Amantadine accelerated the pace of functional recovery during active treatment in patients with post-traumatic disorders of consciousness."}, {"doc_id": "27642581", "chunk_id": "27642581_0", "score": 2.484919309616089, "text": "Amantadine is an N-methyl-D-aspartic acid or N-methyl-D-aspartate (NMDA) receptor antagonist that can be effective against postoperative pain."}], "context": "[22375973:22375973_1] Amantadine hydrochloride is one of the most commonly prescribed medications for patients with prolonged disorders of consciousness after traumatic brain injury. Preliminary studies have suggested that amantadine may promote functional recovery.\n[22375973:22375973_0] Amantadine accelerated the pace of functional recovery during active treatment in patients with post-traumatic disorders of consciousness.\n[27642581:27642581_0] Amantadine is an N-methyl-D-aspartic acid or N-methyl-D-aspartate (NMDA) receptor antagonist that can be effective against postoperative pain.", "answer": "<think> Okay, let's tackle this question. The user wants to know if amantadine is effective for treating disorders of consciousness. The evidence provided has three chunks. First, chunk 22375973_1 says amantadine is commonly prescribed for prolonged disorders of consciousness after traumatic brain injury and that preliminary studies suggest it may promote functional recovery. That's a direct mention of effectiveness. Then chunk 22375973_0 adds that amantadine accelerated functional recovery in post-traumatic disorders of consciousness during active treatment. So two sources from the same document support efficacy. The third chunk, 27642581_0, mentions amantadine as an NMDA receptor antagonist effective against post", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants to know if amantadine is effective for treating disorders of consciousness. The evidence provided has three chunks. First, chunk 22375973_1 says amantadine is commonly prescribed for prolonged disorders of consciousness after traumatic brain injury and that preliminary studies suggest it may promote functional recovery. That's a direct mention of effectiveness. Then chunk 22375973_0 adds that amantadine accelerated functional recovery in post-traumatic disorders of consciousness during active treatment. So two sources from the same document support efficacy. The third chunk, 27642581_0, mentions amantadine as an NMDA receptor antagonist effective against post", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if amantadine is effective for treating disorders of consciousness. The evidence provided has three chunks. First, I need to check each chunk to see if they support the answer. The first chunk says that amantadine is commonly prescribed for prolonged disorders of consciousness after traumatic brain injury and that preliminary studies suggest it may promote functional recovery. That's a direct mention of effectiveness. The second chunk states that amantadine accelerated functional recovery in post-traumatic disorders of consciousness, which reinforces the first point. The third chunk mentions that amantadine is an NMDA antagonist effective against postoperative pain, but that's unrelated to disorders of consciousness. So the answer should be based on the first two chunks.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if amantadine is effective for treating disorders of consciousness. The evidence provided has three chunks. First, chunk 22375973_1 says amantadine is commonly prescribed for prolonged disorders of consciousness after traumatic brain injury and that preliminary studies suggest it may promote functional recovery. That seems directly relevant. Chunk 22375973_0 mentions that amantadine accelerated functional recovery in patients with post-traumatic disorders of consciousness during active treatment. This reinforces the effectiveness. Chunk 27642581_0 talks about amantadine being an NMDA receptor antagonist effective against postoperative pain. But the question is about disorders of", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if amantadine is effective for treating disorders of consciousness. The evidence provided has three chunks. First, chunk 22375973_1 says amantadine is commonly prescribed for prolonged disorders of consciousness after traumatic brain injury and that preliminary studies suggest it may promote functional recovery. That's a direct mention of effectiveness. Chunk 22375973_0 adds that amantadine accelerated functional recovery in post-traumatic disorders of consciousness during active treatment. Another supporting point. Chunk 27642581_0 mentions amantadine as an NMDA receptor antagonist effective against postoperative pain. Wait, postoperative pain isn't exactly", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking if amantadine is effective for treating disorders of consciousness. Let me look at the evidence provided. First, there's the document 22375973:22375973_1 which says that amantadine is commonly prescribed for prolonged disorders of consciousness after traumatic brain injury and that preliminary studies suggest it may promote functional recovery. That seems directly relevant. Then, another chunk from the same document (22375973:22375973_0) mentions that amantadine accelerated functional recovery in patients with post-traumatic disorders of consciousness during active treatment. So both chunks from the same source support the effectiveness of amantadine in this", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if amantadine is effective for treating disorders of consciousness. The evidence provided has three chunks. First, chunk 22375973_1 says amantadine is commonly prescribed for prolonged disorders of consciousness after traumatic brain injury and that preliminary studies suggest it may promote functional recovery. That's a direct mention of effectiveness. Then chunk 22375973_0 states that amantadine accelerated functional recovery in patients with post-traumatic disorders of consciousness during active treatment. This reinforces the earlier point about effectiveness. The third chunk, 27642581_0, mentions amantadine as an NMDA receptor antagonist effective against postoperative", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if amantadine is effective for treating disorders of consciousness. The evidence provided has three chunks. First, chunk 22375973_1 says amantadine is commonly prescribed for prolonged disorders of consciousness after traumatic brain injury and that preliminary studies suggest it may promote functional recovery. That's a direct mention of effectiveness. Chunk 22375973_0 adds that amantadine accelerated functional recovery in post-traumatic disorders of consciousness during active treatment. Another supporting point. Chunk 27642581_0 mentions amantadine as an NMDA receptor antagonist effective against postoperative pain. Wait, the question is about disorders of consciousness", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if amantadine is effective for treating disorders of consciousness. The evidence provided has three chunks. First, chunk 22375973_1 says amantadine is commonly prescribed for prolonged disorders of consciousness after traumatic brain injury and that preliminary studies suggest it may promote functional recovery. That's a direct mention of effectiveness. Chunk 22375973_0 adds that amantadine accelerated functional recovery in post-traumatic disorders of consciousness during active treatment. Another supporting point. Chunk 27642581_0 mentions amantadine as an NMDA receptor antagonist effective against postoperative pain. But the question is about disorders of consciousness", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["15759228", "15825541", "18540467", "19404190", "19894299", "20129511", "20460949", "20658796", "22375973", "24025054", "24025056", "24025057"], "ideal_answer": "Amantadine, a dopaminergic agent, has been shown to be effective for induction of recovery from disorders of consciousness. Amantadine is a commonly prescribed medication for patients with prolonged disorders of consciousness after traumatic brain injury. Amantadine accelerates the pace of functional recovery during active treatment in patients with post-traumatic disorders of consciousness. Higher dosing of amantadine may be considered in the setting of brain injury."}
{"question_id": "56e857ae42442bac75000004", "question": "What is needed for MMP proteins to be functional?", "retrieved_chunks": [{"doc_id": "26013370", "chunk_id": "26013370_0", "score": -0.9851698875427246, "text": "matrix metalloproteinase (MMP)-9"}, {"doc_id": "26087627", "chunk_id": "26087627_0", "score": -2.5397515296936035, "text": "matrix metalloproteinase-3 (MMP-3) gene"}, {"doc_id": "26613891", "chunk_id": "26613891_0", "score": -2.581878662109375, "text": "Kupffer cells (KCs) are the main source of MMP."}], "context": "[26013370:26013370_0] matrix metalloproteinase (MMP)-9\n[26087627:26087627_0] matrix metalloproteinase-3 (MMP-3) gene\n[26613891:26613891_0] Kupffer cells (KCs) are the main source of MMP.", "answer": "<think> Okay, so the user is asking what's needed for MMP proteins to be functional. Let me look at the evidence provided. First, the evidence includes three documents. The first one is about MMP-9, the second about MMP-3 gene, and the third talks about Kupffer cells being the main source of MMP. Hmm, the question is about the requirements for MMP proteins to be functional. The answer needs to be concise with citations. Let me think. The MMP-3 gene is mentioned, which suggests that the gene's presence or proper function is necessary. Also, Kupffer cells are the main source, so maybe they produce MMPs, but that's about their origin rather than functionality. Wait, the question is about what's needed for them to be", "citations": [], "candidates": [{"answer": "<think> Okay, so the user is asking what's needed for MMP proteins to be functional. Let me look at the evidence provided. First, the evidence includes three documents. The first one is about MMP-9, the second about MMP-3 gene, and the third talks about Kupffer cells being the main source of MMP. Hmm, the question is about the requirements for MMP proteins to be functional. The answer needs to be concise with citations. Let me think. The MMP-3 gene is mentioned, which suggests that the gene's presence or proper function is necessary. Also, Kupffer cells are the main source, so maybe they produce MMPs, but that's about their origin rather than functionality. Wait, the question is about what's needed for them to be", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking what's needed for MMP proteins to be functional. The evidence provided includes three documents. First, I need to look at each document to find relevant information. The first one is about MMP-9. I remember that MMPs are matrix metalloproteinases, which are enzymes that can break down extracellular matrix components. For them to function, they usually require certain conditions like proper folding, post-translational modifications, and maybe cofactors. The second document mentions the MMP-3 gene. Genes code for proteins, so this might relate to the necessity of the gene being expressed. But the question is about what's needed for the proteins to be functional, not just their existence. So maybe the presence of the gene", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking what's needed for MMP proteins to be functional. The evidence provided includes three documents. First, I need to understand what each document says. The first one mentions matrix metalloproteinase (MMP)-9. The second talks about the MMP-3 gene. The third discusses Kupffer cells being the main source of MMP. Wait, the question is about what's needed for MMPs to be functional. So I need to look for information on factors required for their function. The third document says Kupffer cells are the main source, but that's about where they're produced, not necessarily what's needed for them to function. The first two documents mention specific MMPs (MMP-9 and", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking what's needed for MMP proteins to be functional. The evidence provided includes three different documents. First, I need to understand what each document says. The first one is about MMP-9. The second is about the MMP-3 gene. The third mentions Kupffer cells being the main source of MMP. Wait, the question isn't about the sources but the requirements for functionality. So, looking at the evidence, maybe the MMP-3 gene's description could be relevant. But the third document talks about Kupffer cells producing MMP, which is about where they're sourced from, not the functional requirements. Hmm, the answer needs to be concise with citations. The key here is that for MMP proteins to function", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking what's needed for MMP proteins to be functional. The evidence provided includes three different references. First, I need to understand what each of these evidence snippets says. The first one is about MMP-9, the second about MMP-3 gene, and the third mentions Kupffer cells as the main source of MMP. Looking at the question, it's about the requirements for MMP proteins to function. So, I should focus on the factors that are necessary for their functionality. The third evidence point talks about Kupffer cells being the main source, which suggests that the presence of these cells is important. However, that's more about where they're produced rather than what's needed for them to be functional. The second", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking what's needed for MMP proteins to be functional. Let me look at the evidence provided. First, the evidence includes three documents. The first one mentions matrix metalloproteinase (MMP)-9. The second talks about the MMP-3 gene. The third says Kupffer cells are the main source of MMP. Wait, the question is about what's needed for MMPs to be functional. So I need to find information on the requirements for their function. The MMP-3 gene might relate to the structure or regulation of MMPs. But the third document mentions that Kupffer cells are the main source, which suggests that the presence of these cells is necessary for MMP activity. However, the question is about what's needed for the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking what's needed for MMP proteins to be functional. The evidence provided includes three documents. Let me look at each one. First, document 26013370:26013370_0 talks about MMP-9. I need to check if it mentions anything about the requirements for functionality. Maybe it discusses the structure or activation process? Next, document 26087627:26087627_0 is about the MMP-3 gene. Genes are involved in coding proteins, so maybe this document explains that the gene needs to be properly transcribed and translated. But does it mention factors required for functional MMPs? Maybe zinc", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking what is needed for MMP proteins to be functional. The evidence provided includes three different documents. First, I need to understand what each document says. The first one is about MMP-9, the second about MMP-3 gene, and the third mentions Kupffer cells as the main source of MMP. Looking at the question, it's about the requirements for MMP proteins to function. So I need to find information in the evidence that explains what factors are necessary for their functionality. The third document says Kupffer cells are the main source, but that's more about where they come from rather than what's needed for them to be functional. The first document mentions matrix metalloproteinase (MMP)-9.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["22257051", "23001203", "24570026", "25360794", "26013370", "26087627", "26150355"], "ideal_answer": "Extracellular matrix metalloproteinases (MMPs) are a family of zinc-dependent neutral endopeptidases."}
{"question_id": "5509c52f1180f13250000004", "question": "What is hyperosmia", "retrieved_chunks": [{"doc_id": "21250223", "chunk_id": "21250223_0", "score": 7.778868675231934, "text": "Hyperosmia is increased olfactory acuity"}, {"doc_id": "24302690", "chunk_id": "24302690_0", "score": 3.917745351791382, "text": "Hyperosmia is suspected in pregnancy; however, no empirical study using validated measures of olfactory function has clearly confirmed the anecdotal reports of this phenomenon."}, {"doc_id": "23520356", "chunk_id": "23520356_0", "score": 3.3061461448669434, "text": "subjective hyperosmia is associated with primarily negative odor-related experiences."}], "context": "[21250223:21250223_0] Hyperosmia is increased olfactory acuity\n[24302690:24302690_0] Hyperosmia is suspected in pregnancy; however, no empirical study using validated measures of olfactory function has clearly confirmed the anecdotal reports of this phenomenon.\n[23520356:23520356_0] subjective hyperosmia is associated with primarily negative odor-related experiences.", "answer": "<think> Okay, I need to generate a JSON answer for the question \"What is hyperosmia?\" based on the provided evidence. Let me look at the evidence again. The first document says hyperosmia is increased olfactory acuity. That's a direct definition. The second mentions it's suspected in pregnancy but no study confirms it. The third talks about subjective hyperosmia being linked to negative odor experiences. The user wants a concise answer with citations. So the answer should be \"Hyperosmia is increased olfactory acuity [21250223:21250223_0]\". Then, the base confidence. The first source is a direct definition, so that's reliable. The other sources are more about associations or suspicions", "citations": [{"doc_id": "21250223", "chunk_id": "21250223_0"}], "candidates": [{"answer": "<think> Okay, I need to generate a JSON answer for the question \"What is hyperosmia?\" based on the provided evidence. Let me look at the evidence again. The first document says hyperosmia is increased olfactory acuity. That's a direct definition. The second mentions it's suspected in pregnancy but no study confirms it. The third talks about subjective hyperosmia being linked to negative odor experiences. The user wants a concise answer with citations. So the answer should be \"Hyperosmia is increased olfactory acuity [21250223:21250223_0]\". Then, the base confidence. The first source is a direct definition, so that's reliable. The other sources are more about associations or suspicions", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a JSON answer for the question \"What is hyperosmia?\" based on the provided evidence. Let me start by understanding what hyperosmia is. From the evidence, the first document says it's increased olfactory acuity. That seems like the direct definition. The other documents mention associations with pregnancy and negative odor experiences, but those are more about related phenomena rather than the definition. The user wants a concise answer with citations in the format [doc_id:chunk_id]. So the main point is hyperosmia being increased olfactory acuity, citing the first document. The confidence level should be high since that's a direct definition. The other points are additional info but not part of the basic definition. I need to make sure the answer is strict", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer for the question \"What is hyperosmia?\" using the provided evidence. Let me start by understanding what hyperosmia is. From the evidence given, there are three chunks. First chunk says hyperosmia is increased olfactory acuity. That seems like a direct definition. The second chunk mentions it's suspected in pregnancy but no empirical study has confirmed it. The third chunk talks about subjective hyperosmia being linked to negative odor experiences. The question is asking for a definition, so the first chunk is the most relevant. The answer should be concise and include citations. The base confidence is a float between 0 and 1. Since the first chunk directly defines hyperosmia, that's the main source. However,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is about hyperosmia. Let me look at the evidence provided. First piece of evidence: [21250223:21250223_0] says hyperosmia is increased olfactory acuity. That seems like a direct definition. The second one mentions pregnancy but notes no empirical study has confirmed it. The third talks about subjective experiences being negative. The answer should be concise, so the main point is that hyperosmia is increased olfactory acuity, citing the first document. The confidence level: the first source is a direct definition, while others are more about associations or lack of studies. So base confidence should be high, maybe", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a JSON answer based on the provided evidence. The question is \"What is hyperosmia?\" and there are three evidence chunks. First, looking at the evidence: - [21250223:21250223_0] says hyperosmia is increased olfactory acuity. That's a direct definition. So that's a good source for the answer. - [24302690:24302690_0] talks about it being suspected in pregnancy but no study confirmed it. This seems like a supporting point but not the main definition. - [23520356:23520356_0]", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, so I need to generate a candidate biomedical answer for the question \"What is hyperosmia?\" based on the provided evidence. Let me start by understanding what hyperosmia is. From the evidence given, there are three chunks. First chunk: Hyperosmia is increased olfactory acuity. That's a direct definition. The second chunk mentions that it's suspected in pregnancy but no study has confirmed it. The third chunk says subjective hyperosmia is linked to negative odor experiences. The question is asking for what hyperosmia is, so the answer should define it. The first chunk provides a clear definition. The other chunks add context, like association with pregnancy and negative experiences, but the main definition comes from the first one. I need to make sure the answer", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is \"What is hyperosmia?\" and there are three evidence chunks provided. First, let me look at each chunk. The first one says hyperosmia is increased olfactory acuity. That's a direct definition. The second mentions it's suspected in pregnancy but no study has confirmed it. The third talks about subjective hyperosmia being linked to negative odor experiences. The answer needs to be concise and include citations. The main point from the evidence is that hyperosmia is increased olfactory acuity, as per the first chunk. The other chunks provide additional context but aren't directly defining it. So the answer should primarily use the first citation. For confidence, the first source is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking for a JSON answer about hyperosmia based on the provided evidence. First, I need to understand what hyperosmia is. Looking at the evidence, the first document says it's increased olfactory acuity. That's a direct definition. The other documents mention it in pregnancy and negative odor experiences, but those are more about associations rather than the definition. The user wants a concise answer with citations. The answer should be based on the most relevant evidence. The first chunk clearly defines hyperosmia, so that's the key point. The other chunks provide context but aren't necessary for the basic definition. For the confidence level, the first source is a direct definition, so I can be confident about that. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["21250223", "23520356", "24302690"], "ideal_answer": "Hyperosmia is increased olfactory acuity increased olfactory acuity"}
{"question_id": "535d2cf09a4572de6f000004", "question": "What is the number of long non coding RNAs in the human genome", "retrieved_chunks": [{"doc_id": "23369519", "chunk_id": "23369519_0", "score": 8.83507251739502, "text": "BACKGROUND: Over 10,000 long intergenic non-coding RNAs (lincRNAs) have been identified in the human genome."}, {"doc_id": "17270048", "chunk_id": "17270048_0", "score": 4.220420837402344, "text": "Our genome-wide screens in two mammalian species reveal no more than three abundant large non-coding polyadenylated RNAs in the nucleus; the canonical large noncoding RNA XIST and NEAT1 and NEAT2"}, {"doc_id": "26207516", "chunk_id": "26207516_0", "score": 4.079282760620117, "text": "Protein-coding genes account for only 2% of the human genome, whereas the vast majority of transcripts are noncoding RNAs including long noncoding RNAs. LncRNAs are involved in the regulation of a diverse array of biological processes, including cancer progression"}], "context": "[23369519:23369519_0] BACKGROUND: Over 10,000 long intergenic non-coding RNAs (lincRNAs) have been identified in the human genome.\n[17270048:17270048_0] Our genome-wide screens in two mammalian species reveal no more than three abundant large non-coding polyadenylated RNAs in the nucleus; the canonical large noncoding RNA XIST and NEAT1 and NEAT2\n[26207516:26207516_0] Protein-coding genes account for only 2% of the human genome, whereas the vast majority of transcripts are noncoding RNAs including long noncoding RNAs. LncRNAs are involved in the regulation of a diverse array of biological processes, including cancer progression", "answer": "<think> Okay, let's tackle this question. The user is asking for the number of long non-coding RNAs (lncRNAs) in the human genome. I need to look at the provided evidence to find the answer. Looking at the first piece of evidence: [23369519:23369519_0] says that over 10,000 lincRNAs have been identified. The term \"lincRNAs\" here probably refers to long intergenic non-coding RNAs, which are a type of lncRNA. So that's a direct mention of the number. The other evidence mentions NEAT1 and NEAT2 as examples of large non-coding polyadenylated RN", "citations": [{"doc_id": "23369519", "chunk_id": "23369519_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking for the number of long non-coding RNAs (lncRNAs) in the human genome. First, I'll look at the evidence provided. The first document says that over 10,000 lincRNAs have been identified. The second mentions three abundant large non-coding polyadenylated RNAs, but those are specific examples, not the total number. The third talks about the percentage of protein-coding genes and mentions lncRNAs in general but doesn't give a number. The key point here is that the first evidence directly states \"over 10,000 long intergenic non-coding RNAs (lincRNAs) have been identified.\" The term", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the number of long non-coding RNAs (lncRNAs) in the human genome. I need to look at the provided evidence to find the answer. Looking at the first piece of evidence: [23369519:23369519_0] says that over 10,000 lincRNAs have been identified. The term \"lincRNAs\" here probably refers to long intergenic non-coding RNAs, which are a type of lncRNA. So that's a direct mention of the number. The other evidence mentions NEAT1 and NEAT2 as examples of large non-coding polyadenylated RN", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question about the number of long non-coding RNAs (lncRNAs) in the human genome. The user provided some evidence from different documents. First, looking at the evidence: - Document 23369519 says there are over 10,000 lincRNAs identified. But wait, the question is about \"long non-coding RNAs\" in general, not just lincRNAs. The term \"lincRNAs\" might be a subset of lncRNAs. However, the answer here mentions \"long intergenic non-coding RNAs (lincRNAs)\", so maybe that's a specific type. Another document, 17270048,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about the number of long non-coding RNAs (lncRNAs) in the human genome. The user provided some evidence from different documents. First, looking at the evidence: The first document [23369519:23369519_0] says that over 10,000 lincRNAs have been identified. But wait, the question is about \"long non coding RNAs\" in general, not specifically lincRNAs. However, the term \"lincRNAs\" is a subset of long non-coding RNAs. So maybe that's a key point here. The second document [17270048:1727", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the number of long non-coding RNAs (lncRNAs) in the human genome. Looking at the evidence provided, there's a reference that says \"Over 10,000 long intergenic non-coding RNAs (lincRNAs) have been identified in the human genome.\" That seems like a direct answer. But I need to check if there are other mentions that might conflict or add more info. Another evidence point mentions three abundant large non-coding polyadenylated RNAs, but those are specific examples (XIST, NEAT1, NEAT2) and not the total number. The third evidence talks about protein-coding genes making up 2% and most", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the number of long non-coding RNAs (lncRNAs) in the human genome. I need to look at the provided evidence to find the answer. First, looking at the evidence documents: The first document [23369519:23369519_0] says that over 10,000 long intergenic non-coding RNAs (lincRNAs) have been identified. The term \"lincRNAs\" is specified here, which is a type of lncRNA. So this seems like a direct answer. But wait, the question just says \"long non coding RNAs,\" not specifically lincRNAs. However", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the number of long non-coding RNAs (lncRNAs) in the human genome. I need to look at the provided evidence to find the answer. First, I'll check each evidence snippet. The first one says that over 10,000 lincRNAs have been identified. The second mentions three abundant large non-coding polyadenylated RNAs, but those are specific examples, not the total number. The third talks about the percentage of protein-coding genes and the majority being noncoding, but it doesn't give a number. So the key evidence is the first snippet which states \"over 10,000 long intergenic non-coding RNAs (", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about the number of long non-coding RNAs (lncRNAs) in the human genome. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. The first piece of evidence, [23369519:23369519_0], says that over 10,000 lincRNAs have been identified. The term \"lincRNAs\" here probably refers to long intergenic non-coding RNAs, which are a type of lncRNA. So that's a direct mention of the number. The other evidence mentions NEAT1 and NEAT2 as examples of large non-coding polyaden", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["23126680", "23369519", "23846593"], "ideal_answer": "Different estimates put currently the number of human long non coding RNAs between 10,000 and 20,000"}
{"question_id": "55475dc2f35db75526000001", "question": "Which is the most known bacterium responsible for botulism (sausage-poisoning)?", "retrieved_chunks": [{"doc_id": "21130733", "chunk_id": "21130733_0", "score": 5.988029479980469, "text": "The botulinum neurotoxins (BoNTs) produced by different strains of the bacterium Clostridium botulinum are responsible for the disease botulism and include a group of immunologically distinct serotypes (A, B, E, and F) that are considered to be the most lethal natural proteins known for humans."}, {"doc_id": "23025151", "chunk_id": "23025151_0", "score": 5.031538009643555, "text": "Botulism is caused by botulinum neurotoxin produced by the bacterium Clostridium botulinum."}, {"doc_id": "24253240", "chunk_id": "24253240_0", "score": 4.231901168823242, "text": "Botulism is a serious foodborne neuroparalytic disease, caused by botulinum neurotoxin (BoNT), produced by the anaerobic bacterium Clostridium botulinum."}], "context": "[21130733:21130733_0] The botulinum neurotoxins (BoNTs) produced by different strains of the bacterium Clostridium botulinum are responsible for the disease botulism and include a group of immunologically distinct serotypes (A, B, E, and F) that are considered to be the most lethal natural proteins known for humans.\n[23025151:23025151_0] Botulism is caused by botulinum neurotoxin produced by the bacterium Clostridium botulinum.\n[24253240:24253240_0] Botulism is a serious foodborne neuroparalytic disease, caused by botulinum neurotoxin (BoNT), produced by the anaerobic bacterium Clostridium botulinum.", "answer": "<think> Okay, let's tackle this question. The user is asking which is the most known bacterium responsible for botulism, also called sausage-poisoning. I need to look at the evidence provided to find the answer. Looking at the evidence documents: First document [21130733:21130733_0] says that botulinum neurotoxins from different strains of Clostridium botulinum cause botulism. It mentions serotypes A, B, E, F. So the bacterium here is Clostridium botulinum. Second document [23025151:2302515ight_0] states that botulism is caused by bot", "citations": [{"doc_id": "21130733", "chunk_id": "21130733_0"}, {"doc_id": "23025151", "chunk_id": "2302515ight_0"}], "candidates": [{"answer": "<think> Okay, I need to figure out the answer to the question about which bacterium is most known for causing botulism. The user provided three evidence snippets. Looking at the first snippet, it mentions that botulinum neurotoxins from Clostridium botulinum cause botulism and lists serotypes A, B, E, F. The second snippet says botulism is caused by BoNT from C. botulinum. The third one repeats similar info, stating it's caused by BoNT from the anaerobic bacterium C. botulinum. All three sources point to Clostridium botulinum as the culprit. The question asks for the most known bacterium responsible. The answer should be Clostridium botulinum.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which is the most known bacterium responsible for botulism, also called sausage-poisoning. I need to look at the evidence provided. Looking at the evidence, all three documents mention Clostridium botulinum as the source of the botulinum neurotoxin that causes botulism. The first document specifies that BoNTs from this bacterium are responsible for the disease and lists serotypes A, B, E, F. The second and third documents also confirm that it's Clostridium botulinum producing the toxin. The question is about the \"most known\" bacterium, so I need to check if there's any other bacterium mentioned. But all sources point to C", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which is the most known bacterium responsible for botulism, also called sausage-poisoning. I need to look at the evidence provided to find the answer. Looking at the evidence documents: First document [21130733:21130733_0] says that botulinum neurotoxins from different strains of Clostridium botulinum cause botulism. It mentions serotypes A, B, E, F. So the bacterium here is Clostridium botulinum. Second document [23025151:2302515ight_0] states that botulism is caused by bot", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, so the user is asking which is the most known bacterium responsible for botulism, also called sausage-poisoning. Let me look at the evidence provided. The first document says that botulinum neurotoxins from Clostridium botulinum cause botulism and mentions serotypes A, B, E, F. The second document states that botulism is caused by the toxin from Clostridium botulinum. The third one confirms that it's the anaerobic bacterium C. botulinum producing BoNT. All three sources consistently point to Clostridium botulinum as the cause. The question is about the most known bacterium, and all evidence supports that it's C. botulinum. There's", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the most known bacterium responsible for botulism, which is also called sausage-poisoning. I need to look at the evidence provided. First, looking at the evidence snippets. The first one mentions that Clostridium botulinum produces BoNTs which cause botulism. The second and third documents also state that Botulism is caused by the neurotoxin from Clostridium botulinum. All three sources consistently point to Clostridium botulinum as the culprit. The question is about the \"most known\" bacterium, so I should check if there's any other bacterium mentioned. But in all the evidence, it's only Clostridium botulin", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which is the most known bacterium responsible for botulism, also called sausage-poisoning. I need to look at the evidence provided. Looking at the evidence documents: The first one [21130733:21130733_0] mentions that botulinum neurotoxins from Clostridium botulinum cause botulism and lists serotypes A, B, E, F. So it's pointing to C. botulinum. The second document [23025151:2302515So] states that botulism is caused by the toxin from Clostridium botulinum. Same", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's see. The user is asking which is the most known bacterium responsible for botulism, also called sausage-poisoning. I need to look at the evidence provided. Looking at the evidence documents: First one: 21130733:21130733_0 mentions that Clostridium botulinum produces BoNTs which cause botulism. It also lists serotypes A, B, E, F as the most lethal. So this document points to C. botulinum. Second document: 23025151:23025157_0 says botulism is caused by BoNT from C. botulinum. Same as first", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the most known bacterium responsible for botulism, which is also called sausage-poisoning. I need to look at the evidence provided. First, looking at the evidence documents. Document 21130733 mentions that Clostridium botulinum produces botulinum neurotoxins which cause botulism. The same is stated in document 23025151 and . So all three documents point to Clostridium botulinum as the causative bacterium. The answer should be concise, citing the relevant documents. The base confidence is high here since all three sources agree. So the answer is Clostridium botulinum, with", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["11153358", "15027048", "15839401", "16080379", "17458494", "18388640", "19573697", "20569065", "20961439", "21130733", "21171846", "21747146", "21975066", "23025151", "23239346", "23421373", "23523511", "23971804", "23971806", "23971808", "24206405", "24246230", "24252222", "24252701", "24253240", "24961027", "24997242"], "ideal_answer": "Botulism is a severe neuroparalytic disease caused by botulinum neurotoxin (BoNT), and affects humans, all warm-blooded animals, birds, and some fishes. Botulinum toxin is produced under anaerobic conditions by the bacterium Clostridium botulinum, which is the most known etiological agent of the disease, and some other clostridia, and is one of the most dangerous toxin in the world."}
{"question_id": "56c073fcef6e394741000020", "question": "What is the association of spermidine with α-synuclein neurotoxicity?", "retrieved_chunks": [{"doc_id": "25483063", "chunk_id": "25483063_3", "score": 5.142975807189941, "text": "Spermidine protects against α-synuclein neurotoxicity."}, {"doc_id": "25483063", "chunk_id": "25483063_2", "score": 4.860856533050537, "text": "Spermidine protects against α-synuclein neurotoxicity"}, {"doc_id": "22662273", "chunk_id": "22662273_0", "score": 4.129438877105713, "text": "Together with the fact that spermidine facilitates late stages of α-Syn aggregation, our data demonstrate that spermidine promotes the very early stages of protein aggregation including α-Syn misfolding and dimerization. This finding suggests that increased levels of spermidine and potentially other polyamines can initiate the disease-related process of α-Syn."}], "context": "[25483063:25483063_3] Spermidine protects against α-synuclein neurotoxicity.\n[25483063:25483063_2] Spermidine protects against α-synuclein neurotoxicity\n[22662273:22662273_0] Together with the fact that spermidine facilitates late stages of α-Syn aggregation, our data demonstrate that spermidine promotes the very early stages of protein aggregation including α-Syn misfolding and dimerization. This finding suggests that increased levels of spermidine and potentially other polyamines can initiate the disease-related process of α-Syn.", "answer": "<think> Okay, let's tackle this question. The user is asking about the association between spermidine and α-synuclein neurotoxicity. The evidence provided has three entries. First, I need to understand what each piece of evidence says. The first two entries [25483063:25483063_3] and [25483063:25483063_2] both state that spermidine protects against α-synuclein neurotoxicity. That's pretty straightforward. The third entry [22662273:22662273_0] says that spermidine facilitates late stages of α-Syn", "citations": [{"doc_id": "25483063", "chunk_id": "25483063_3"}, {"doc_id": "25483063", "chunk_id": "25483063_2"}, {"doc_id": "22662273", "chunk_id": "22662273_0"}], "candidates": [{"answer": "<think> Okay, so the user is asking about the association between spermidine and α-synuclein neurotoxicity. Let me look at the evidence provided. First, there are three pieces of evidence. The first two are from the same document (25483063) and both say that spermidine protects against α-synuclein neurotoxicity. The third one (22662273) mentions that spermidine facilitates late stages of α-Syn aggregation but also promotes early stages like misfolding and dimerization. It suggests that increased spermidine might initiate the disease process. Hmm, so there's a contradiction here. The first two points say protection, while the third says it promotes aggregation. But", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the association between spermidine and α-synuclein neurotoxicity. First, I need to look at the evidence provided. There are three chunks here. The first two chunks from 25483063 say that spermidine protects against α-synuclein neurotoxicity. The third chunk from 22662273 mentions that spermidine facilitates late stages of α-Syn aggregation but also promotes early stages like misfolding and dimerization, suggesting it might initiate the disease process. Wait, there's a contradiction here. Some sources say spermidine protects against neurotoxicity, while others indicate it might promote aggregation. But the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the association between spermidine and α-synuclein neurotoxicity. The evidence provided has three entries. First, I need to understand what each piece of evidence says. The first two entries [25483063:25483063_3] and [25483063:25483063_2] both state that spermidine protects against α-synuclein neurotoxicity. That's pretty straightforward. The third entry [22662273:22662273_0] says that spermidine facilitates late stages of α-Syn", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the association between spermidine and α-synuclein neurotoxicity. The evidence provided has three chunks. First, I need to understand what each chunk says. The first two chunks (25483063:25483063_3 and 25483063:25483063_2) both state that spermidine protects against α-synuclein neurotoxicity. That's a direct statement. The third chunk (22662273:22662273_0) mentions that spermidine facilitates late stages of α-Syn aggregation but also", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the association between spermidine and α-synuclein neurotoxicity. I need to look at the provided evidence to form a correct answer. First, I'll check the evidence documents. There are three chunks here. The first two chunks (25483063:25483063_3 and 25483063:25483063_2) both state that spermidine protects against α-synuclein neurotoxicity. That's a direct statement. The third chunk (22662273:22662273_0) mentions that spermid", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the association between spermidine and α-synuclein neurotoxicity. The evidence provided has three chunks. First, I need to understand what each chunk says. The first two chunks (25483063:25483063_3 and 25483063:25483063_2) both state that spermidine protects against α-synuclein neurotoxicity. That seems straightforward. The third chunk (22662273:22662273_0) mentions that spermidine facilitates late stages of α-Syn aggregation but also promotes early", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the association between spermidine and α-synuclein neurotoxicity. I need to look at the provided evidence to form an answer. Looking at the evidence, there are three entries. The first two [25483063:25483063_3] and [25483063:25483063_2] both state that spermidine protects against α-synuclein neurotoxicity. That's pretty straightforward. The third entry [22662273:22662273_0] says that spermidine facilitates late stages of α-S", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the association between spermidine and α-synuclein neurotoxicity. I need to look at the provided evidence to form a correct answer. First, I'll check the evidence documents. Document 25483063 has two chunks that both state spermidine protects against α-synuclein neurotoxicity. Then there's another document, 22662273, which mentions that spermidine facilitates late stages of α-Syn aggregation but also promotes early stages like misfolding and dimerization. This suggests a complex relationship. The question is about the association. The answer needs to be concise with citations. The first part says spermidine", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["22662273", "25483063"], "ideal_answer": "Spermidine protects against α-synuclein neurotoxicity. In the fruit fly, simple feeding with spermidine inhibited loss of climbing activity and early organismal death upon heterologous expression of human α-synuclein, which is thought to be the principal toxic trigger of Parkinson's Disease (PD). In this line, administration of spermidine rescued α-synuclein-induced loss of dopaminergic neurons, a hallmark of PD, in nematodes. Alleviation of PD-related neurodegeneration by spermidine was accompanied by induction of autophagy, suggesting that this cytoprotective process may be responsible for the beneficial effects of spermidine administration."}
{"question_id": "550320cbe9bde6963400002d", "question": "List symptoms of 4H leukodystrophy.", "retrieved_chunks": [{"doc_id": "22451160", "chunk_id": "22451160_0", "score": 6.0272369384765625, "text": "OBJECTIVE: To report a novel clinical and genetic presentation of a patient with 4H syndrome, which is a recently described leukodystrophy syndrome characterized by ataxia, hypomyelination, hypodontia, and hypogonadotropic hypogonadism."}, {"doc_id": "23307887", "chunk_id": "23307887_1", "score": 5.465768814086914, "text": "4H syndrome is a rare and distinct leukodystrophy characterized by hypomyelination, hypogonadotropic hypogonadism, and hypodontia."}, {"doc_id": "23307887", "chunk_id": "23307887_0", "score": 5.309710502624512, "text": "4H syndrome is a rare and distinct leukodystrophy characterized by hypomyelination, hypogonadotropic hypogonadism, and hypodontia"}], "context": "[22451160:22451160_0] OBJECTIVE: To report a novel clinical and genetic presentation of a patient with 4H syndrome, which is a recently described leukodystrophy syndrome characterized by ataxia, hypomyelination, hypodontia, and hypogonadotropic hypogonadism.\n[23307887:23307887_1] 4H syndrome is a rare and distinct leukodystrophy characterized by hypomyelination, hypogonadotropic hypogonadism, and hypodontia.\n[23307887:23307887_0] 4H syndrome is a rare and distinct leukodystrophy characterized by hypomyelination, hypogonadotropic hypogonadism, and hypodontia", "answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The question is asking for symptoms of 4H leukodystrophy. Looking at the evidence, there are three documents. Let me check each one. First document [22451160:22451160_0] mentions ataxia, hypomyelination, hypodontia, and hypogonadotropic hypogonadism. That's four symptoms. The second and third documents [23307887:23307887_1 and 0] both list hypomyelination, hypogonadotropic hypogonadism, and hypodontia. Wait, that's", "citations": [{"doc_id": "22451160", "chunk_id": "22451160_0"}, {"doc_id": "23307887", "chunk_id": "23307887_1 and 0"}], "candidates": [{"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The question is asking for symptoms of 4H leukodystrophy. Looking at the evidence, there are three documents. Let me check each one. First document [22451160:22451160_0] mentions ataxia, hypomyelination, hypodontia, and hypogonadotropic hypogonadism. That's four symptoms. The second and third documents [23307887:23307887_1 and 0] both list hypomyelination, hypogonadotropic hypogonadism, and hypodontia. Wait, that's", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, the user is asking for symptoms of 4H leukodystrophy. Let me look at the evidence provided. First, document 22451160 mentions ataxia, hypomyelination, hypodontia, and hypogonadotropic hypogonadism. Then, documents 23307887 both mention hypomyelination, hypogonadotropic hypogonadism, and hypodontia. Wait, the first one also includes ataxia. But the other two don't mention ataxia. However, the user is asking for symptoms, so I need to list all the symptoms mentioned across the evidence. But wait, the answer should be concise. The key symptoms are hypomy", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's see. The user is asking for the symptoms of 4H leukodystrophy. I need to look at the evidence provided. First, document 22451160:22451160_0 mentions that 4H syndrome has ataxia, hypomyelination, hypodontia, and hypogonadotropic hypogonadism. That's four symptoms. Then, documents 23307887:23307887_1 and 0 both list hypomyelination, hypogonadotropic hypogonadism, and hypodontia as the characteristics. Wait, but the first one also includes ataxia. So the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user wants a JSON answer with the symptoms of 4H leukodystrophy. First, I need to look at the evidence provided. Looking at the evidence, there are three documents. The first one mentions ataxia, hypomyelination, hypodontia, and hypogonadotropic hypogonadism. The other two documents from 23307887 mention hypomyelination, hypogonadotropic hypogonadism, and hypodontia. Wait, the first document includes ataxia, but the others don't. So I need to check if ataxia is a symptom. The question asks for symptoms, so I should list all mentioned symptoms. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user wants me to generate a candidate biomedical answer for the symptoms of 4H leukodystrophy. Let me look at the evidence provided. First, the evidence has three documents. The first one, 22451160:22451160_0, mentions that 4H syndrome has ataxia, hypomyelination, hypodontia, and hypogonadotropic hypogonadism. The other two documents, 23307887:23307887_1 and 0, both state that 4H syndrome is characterized by hypomyelination, hypogonadotropic hypogonadism, and hypodontia", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking for the symptoms of 4H leukodystrophy. I need to look at the provided evidence to find the relevant information. First, checking the evidence documents. The first one, 22451160:22451160_0, mentions that 4H syndrome has ataxia, hypomyelination, hypodontia, and hypogonadotropic hypogonadism. That's four symptoms. Then, the next two documents, 23307887:23307887_1 and 0, both state that 4H syndrome is characterized by hypomyelination, hypogon", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking for the symptoms of 4H leukodystrophy. Let me look at the evidence provided. First, evidence document 22451160 mentions \"ataxia, hypomyelination, hypodontia, and hypogonadotropic hypogonadism.\" That's four symptoms. Then, documents 23307887 both mention hypomyelination, hypogonadotropic hypogonadism, and hypodontia. Wait, but the first one adds ataxia. So the answer should include those symptoms. The question is about listing symptoms, so I need to make sure all the mentioned symptoms are included. The key points here are hypomyelination, hypogon", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The question is asking for symptoms of 4H leukodystrophy. Let me look at the evidence. First document: 22451160:22451160_0 mentions ataxia, hypomyelination, hypodontia, and hypogonadotropic hypogonadism. The second document, 23307887:23307887_1 and 0, both state hypomyelination, hypogonadotropic hypogonadism, and hypodontia. So the symptoms listed are ataxia, hypomyelination, hypodontia, and", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["18671210", "21855841", "22451160", "22855961", "23242285", "23307887", "24190003", "25339210"], "ideal_answer": "Hypomyelination, hypodontia, and hypogonadotropic hypogonadism are major symptoms of 4H leukodystrophy."}
{"question_id": "53312464d6d3ac6a3400003a", "question": "What is the extracellular core \"matrisome\"?", "retrieved_chunks": [{"doc_id": "21937732", "chunk_id": "21937732_0", "score": 6.092093467712402, "text": "Completion of genome sequences for many organisms allows a reasonably complete definition of the complement of extracellular matrix (ECM) proteins. In mammals this \"core matrisome\" comprises ∼300 proteins."}, {"doc_id": "23539364", "chunk_id": "23539364_0", "score": 3.829200029373169, "text": "Over 300 ECM molecules have been defined as comprising the \"core matrisome\" in mammals through the analysis of whole genome sequences."}, {"doc_id": "22159717", "chunk_id": "22159717_0", "score": 1.637834906578064, "text": "we have developed a bioinformatic approach to predict the in silico \"matrisome\" defined as the ensemble of ECM proteins and associated factors."}], "context": "[21937732:21937732_0] Completion of genome sequences for many organisms allows a reasonably complete definition of the complement of extracellular matrix (ECM) proteins. In mammals this \"core matrisome\" comprises ∼300 proteins.\n[23539364:23539364_0] Over 300 ECM molecules have been defined as comprising the \"core matrisome\" in mammals through the analysis of whole genome sequences.\n[22159717:22159717_0] we have developed a bioinformatic approach to predict the in silico \"matrisome\" defined as the ensemble of ECM proteins and associated factors.", "answer": "<think> Okay, I need to generate a candidate biomedical answer about the extracellular core \"matrisome\" based on the provided evidence. Let me start by understanding what the question is asking. The user wants to know what the matrisome is, specifically the extracellular core part. Looking at the evidence, there are three references. The first one says that genome sequences allow a complete definition of ECM proteins, and in mammals, the \"core matrisome\" comprises about 300 proteins. The second reference confirms this, stating over 300 ECM molecules make up the core matrisome in mammals through whole genome analysis. The third mention is about a bioinformatic approach to predict the matrisome, including ECM proteins and associated factors. So the answer should define", "citations": [], "candidates": [{"answer": "<think> Okay, I need to generate a candidate biomedical answer about the extracellular core \"matrisome\" based on the provided evidence. Let me start by understanding what the question is asking. The user wants to know what the matrisome is, specifically the extracellular core part. Looking at the evidence, there are three references. The first one says that genome sequences allow a complete definition of ECM proteins, and in mammals, the \"core matrisome\" comprises about 300 proteins. The second reference confirms this, stating over 300 ECM molecules make up the core matrisome in mammals through whole genome analysis. The third mention is about a bioinformatic approach to predict the matrisome, including ECM proteins and associated factors. So the answer should define", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking about the extracellular core \"matrisome.\" Let me look at the evidence provided. First, document 21937732 says that genome sequences allow a complete definition of ECM proteins, and in mammals, the \"core matrisome\" comprises about 300 proteins. Then, document 23539364 reinforces this, stating over 300 ECM molecules make up the core matrisome in mammals through whole genome analysis. The third document mentions a bioinformatic approach to predict the matrisome, but it's more about the method than the definition. So the answer should state that the core matrisome is approximately 300 proteins, citing both documents 21", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about the extracellular core \"matrisome.\" The user wants a concise answer with citations and a confidence score. First, I need to understand what the matrisome is based on the provided evidence. Looking at the evidence, there are three references. The first one says that genome sequences allow a complete definition of ECM proteins, and in mammals, the \"core matrisome\" comprises about 300 proteins. The second reference confirms this, stating over 300 ECM molecules make up the core matrisome. The third talks about a bioinformatic approach to predict the matrisome, but that's more about the method than the definition. So the answer should mention that the core matrisome in mammals consists of around", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about the extracellular core \"matrisome.\" The user wants a concise answer with citations and a confidence score. First, I need to understand what the matrisome is. From the evidence provided, there are three documents. The first two mention that the core matrisome in mammals comprises around 300 proteins. Document 21937732 says \"core matrisome\" is about 300 proteins. Document 23539364 also states over 300 ECM molecules make up the core matrisome. The third document talks about predicting the matrisome but doesn't specify the number. So, the answer should state that the core matrisome consists of approximately", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is about the extracellular core \"matrisome.\" Let me look at the evidence provided. First, document 21937732:21937732_0 says that genome sequences allow a complete definition of ECM proteins, and in mammals, the \"core matrisome\" comprises about 300 proteins. Then, document 23539364:23539364_0 mentions over 300 ECM molecules defined as the core matrisome in mammals through whole genome analysis. The third document is about a bioinformatic approach to predict the matrisome, but it doesn't specify", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking about the extracellular core \"matrisome.\" Let me look at the evidence provided. First, document 21937732 says that genome sequences allow a complete definition of ECM proteins, and in mammals, the \"core matrisome\" comprises around 300 proteins. Then, document 23539364 confirms this, stating over 300 ECM molecules make up the core matrisome in mammals through whole genome analysis. The third document mentions a bioinformatic approach to predict the matrisome, which includes ECM proteins and associated factors. The question is asking for the definition of the extracellular core \"matrisome.\" The answer needs to be concise with citations. The key", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about the extracellular core \"matrisome.\" The user wants a concise answer with citations and a confidence score. First, I need to understand what the matrisome is based on the provided evidence. Looking at the evidence, there are three references. The first one says that genome sequences allow a complete definition of ECM proteins, and in mammals, the \"core matrisome\" comprises about 300 proteins. The second reference confirms this, stating over 300 ECM molecules make up the core matrisome. The third mentions a bioinformatic approach to predict the matrisome, which includes ECM proteins and associated factors. So the answer should state that the core matrisome refers to around 300 ECM proteins", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking about the extracellular core \"matrisome.\" First, I need to understand what exactly they're looking for. From the evidence provided, there are three documents mentioned. Looking at the first document (21937732:21937732_0), it states that genome sequences allow a complete definition of ECM proteins, and in mammals, the \"core matrisome\" comprises about 300 proteins. The second document (23539364:23539364_0) confirms this, mentioning over 300 ECM molecules as part of the core matrisome. The third document (22159", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["21937732", "22159717", "23539364"], "ideal_answer": "The \"matrisome\" is defined as the ensemble of extracellular matrix proteins (ECM) proteins and associated factors. The core matrisome have been defined in mammals through the analysis of whole genome sequences and comprises of ~ 300 proteins."}
{"question_id": "56f3f6b12ac5ed145900001a", "question": "Is GAGA associated with nucleosome-free regions (NFR)?", "retrieved_chunks": [{"doc_id": "7737124", "chunk_id": "7737124_0", "score": 4.937474250793457, "text": "The interactions of GAGA factor and heat shock factor with their binding sites in chromatin occurred in two modes. Their interaction with binding sites in the nucleosome-free regions did not require ATP. In the presence of ATP both factors interacted also with nucleosomal binding sites, causing nucleosome rearrangements and a refinement of nucleosome positions"}, {"doc_id": "11158316", "chunk_id": "11158316_0", "score": 4.5600175857543945, "text": "The HS3 sequence contains consensus binding sites for the GAGA factor, a protein implicated in the formation of nucleosome-free regions of chromatin, and Pleiohomeotic (Pho), a Polycomb group protein that is related to the mammalian transcription factor YY1."}, {"doc_id": "15579691", "chunk_id": "15579691_0", "score": 4.08709716796875, "text": "One of the three nuclease hypersensitive sites in the Fab-7 boundary, HS1, contains multiple consensus-binding sequences for the GAGA factor, a protein known to be involved in the formation and/or maintenance of nucleosome-free regions of chromatin."}], "context": "[7737124:7737124_0] The interactions of GAGA factor and heat shock factor with their binding sites in chromatin occurred in two modes. Their interaction with binding sites in the nucleosome-free regions did not require ATP. In the presence of ATP both factors interacted also with nucleosomal binding sites, causing nucleosome rearrangements and a refinement of nucleosome positions\n[11158316:11158316_0] The HS3 sequence contains consensus binding sites for the GAGA factor, a protein implicated in the formation of nucleosome-free regions of chromatin, and Pleiohomeotic (Pho), a Polycomb group protein that is related to the mammalian transcription factor YY1.\n[15579691:15579691_0] One of the three nuclease hypersensitive sites in the Fab-7 boundary, HS1, contains multiple consensus-binding sequences for the GAGA factor, a protein known to be involved in the formation and/or maintenance of nucleosome-free regions of chromatin.", "answer": "<think> Okay, let's tackle this question. The user is asking if GAGA is associated with nucleosome-free regions (NFR). I need to check the provided evidence to find answers. Looking at the first evidence snippet [7737124:7737124_0], it mentions that the GAGA factor interacts with binding sites in nucleosome-free regions without ATP. Also, in the presence of ATP, it can interact with nucleosomal sites, causing rearrangements. This suggests that GAGA does interact with NFRs. The second snippet [11158316:11158316_0] states that the HS3 sequence has a binding site for GAGA, which", "citations": [{"doc_id": "7737124", "chunk_id": "7737124_0"}, {"doc_id": "11158316", "chunk_id": "11158316_0"}], "candidates": [{"answer": "<think> Okay, I need to determine if GAGA is associated with nucleosome-free regions (NFR) based on the provided evidence. Let me look at each piece of evidence. First, document 7737124 mentions that the GAGA factor interacts with binding sites in nucleosome-free regions without ATP. It also says that in the presence of ATP, the factors can interact with nucleosomal sites, leading to rearrangements. So this suggests that GAGA is involved with NFRs. Then document 11158316 states that the HS3 sequence has binding sites for GAGA, which is implicated in forming NFRs. That directly links GAGA to NFRs. Document 15579", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to answer whether GAGA is associated with nucleosome-free regions (NFR) based on the provided evidence. Let's look at the evidence snippets. First, document 7737124 mentions that the GAGA factor interacts with binding sites in nucleosome-free regions without ATP. It also says that in the presence of ATP, they can interact with nucleosomal sites, causing rearrangements. So this suggests GAGA is involved with NFRs. Then document 11158316 states that HS3 has a consensus site for GAGA, which is implicated in forming NFRs. That directly links GAGA to NFRs. Document 15579691 mentions HS", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if GAGA is associated with nucleosome-free regions (NFR). I need to check the provided evidence to find answers. Looking at the first evidence snippet [7737124:7737124_0], it mentions that the GAGA factor interacts with binding sites in nucleosome-free regions without ATP. Also, in the presence of ATP, it can interact with nucleosomal sites, causing rearrangements. This suggests that GAGA does interact with NFRs. The second snippet [11158316:11158316_0] states that the HS3 sequence has a binding site for GAGA, which", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to determine if GAGA is associated with nucleosome-free regions (NFR) based on the provided evidence. Let me look at the evidence documents one by one. First, document 7737124:0 mentions that the GAGA factor interacts with binding sites in nucleosome-free regions without ATP. It also says that in the presence of ATP, these factors can interact with nucleosomal binding sites, leading to rearrangements and refined positions. This suggests that GAGA is involved in NFRs because it binds there. Then document 11158316:0 states that HS3 has a consensus binding site for GAGA, which is implicated in forming NFRs. The mention of \"n", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to determine if GAGA is associated with nucleosome-free regions (NFR) based on the given evidence. Let me look at each of the three references provided. First, reference [7737124:7737124_0] mentions that the GAGA factor interacts with binding sites in nucleosome-free regions without ATP. It also says that in the presence of ATP, these factors can interact with nucleosomal binding sites, causing rearrangements. So this suggests that GAGA has a role in NFRs because it binds there directly. Then, reference [11158316:11158316_0] states that the HS3 sequence has a consensus", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if GAGA is associated with nucleosome-free regions (NFR). I need to check the provided evidence. Looking at the first evidence snippet [7737124:7737124_0], it mentions that the GAGA factor interacts with binding sites in nucleosome-free regions without requiring ATP. Also, in the presence of ATP, it can interact with nucleosomal sites, causing rearrangements. This suggests that GAGA is involved in NFRs. The second snippet [11158316:11158316_0] states that the HS3 sequence has binding sites for GAGA, which is implicated in", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if GAGA is associated with nucleosome-free regions (NFR). I need to check the provided evidence to find answers. Looking at the first evidence snippet [7737124:7737124_0], it mentions that the GAGA factor interacts with binding sites in nucleosome-free regions without ATP. Also, in the presence of ATP, it can interact with nucleosomal sites, causing rearrangements. This suggests that GAGA is involved with NFRs. The second snippet [11158316:11158316_0] states that the HS3 sequence has a binding site for GAGA, which", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if GAGA is associated with nucleosome-free regions (NFR). I need to look at the evidence provided. First, evidence from [11158316:11158316_0] mentions that the HS3 sequence has a consensus binding site for the GAGA factor, which is \"implicated in the formation of nucleosome-free regions.\" That seems directly relevant. So that's a citation pointing to a connection. Then there's [15579691:15579691_0], which talks about HS1 containing multiple consensus-binding sequences for GAGA, and it says the protein is involved in the formation", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["11158316", "15579691", "7737124", "8474442"], "ideal_answer": "The GAGA factor is a protein known to be involved in the formation and/or maintenance of nucleosome-free regions of chromatin. The interactions of GAGA factor and heat shock factor with their binding sites in chromatin occurred in two modes. Their interaction with binding sites in the nucleosome-free regions did not require ATP. In the presence of ATP both factors interacted also with nucleosomal binding sites, causing nucleosome rearrangements and a refinement of nucleosome positions. While chromatin remodeling upon transcription factor interaction has previously been interpreted to involve nucleosome disruption, the data suggest energy-dependent nucleosome sliding as main principle of chromatin reorganization. The HS3 sequence contains consensus binding sites for the GAGA factor, a protein implicated in the formation of nucleosome-free regions of chromatin, and Pleiohomeotic (Pho), a Polycomb group protein that is related to the mammalian transcription factor YY1. To study the contribution of transcription factors to the establishment of this specific chromatin configuration we assembled nucleosomes on the hsp26 promoter using a cell-free reconstitution system derived from fly embryos. This (CT)n element appears to contribute to formation of the wild-type chromatin structure of hsp26, an organized nucleosome array that leaves the HSEs in nucleosome-free, DNase I-hypersensitive (DH) sites (Q. Lu, L.L. Wallrath, B.D. Allan, R.L. Glaser, J.T. Lis, and S.C.R. Elgin, J. Mol. Biol. Both DH sites were readily reconstituted from extract components. One of the three nuclease hypersensitive sites in the Fab-7 boundary, HS1, contains multiple consensus-binding sequences for the GAGA factor, a protein known to be involved in the formation and/or maintenance of nucleosome-free regions of chromatin."}
{"question_id": "511a4d391159fa8212000003", "question": "Which are the plant DNA (cytosine-5) methyltransferase families?", "retrieved_chunks": [{"doc_id": "18640997", "chunk_id": "18640997_0", "score": 6.045825004577637, "text": "To explore possible relationships between DNA methylation level and accumulation of DNA-(cytosine-5) methyltransferase (DNMT) transcripts, the full-length coding sequences corresponding to three different DNMT families in oil palm, namely the MET, CMT, and DRM classes, have been isolated and characterized."}, {"doc_id": "9680985", "chunk_id": "9680985_0", "score": 5.337103843688965, "text": "In the present study, the isolation and characterization of two distinct cDNAs that code for carrot DNA (cytosine-5)-methyltransferase (DNA-METase) are reported."}, {"doc_id": "15289832", "chunk_id": "15289832_0", "score": 5.209707260131836, "text": "DNA (cytosine-5-)-methyltransferase 1 (DNMT1) plays an important role in the maintenance of DNA methylation patterns via complicated networks including signaling pathways and transcriptional factors, relating to cell differentiation or carcinogenesis."}], "context": "[18640997:18640997_0] To explore possible relationships between DNA methylation level and accumulation of DNA-(cytosine-5) methyltransferase (DNMT) transcripts, the full-length coding sequences corresponding to three different DNMT families in oil palm, namely the MET, CMT, and DRM classes, have been isolated and characterized.\n[9680985:9680985_0] In the present study, the isolation and characterization of two distinct cDNAs that code for carrot DNA (cytosine-5)-methyltransferase (DNA-METase) are reported.\n[15289832:15289832_0] DNA (cytosine-5-)-methyltransferase 1 (DNMT1) plays an important role in the maintenance of DNA methylation patterns via complicated networks including signaling pathways and transcriptional factors, relating to cell differentiation or carcinogenesis.", "answer": "<think> Okay, let's tackle this question. The user is asking about the plant DNA (cytosine-5) methyltransferase families. I need to look at the evidence provided to find the answer. First, looking at the evidence documents. The first one mentions three different DNMT families in oil palm: MET, CMT, and DRM. That seems relevant because it directly lists the families. The second document talks about two distinct cDNAs for carrot DNA-METase, but it doesn't mention other families. The third document discusses DNMT1's role but doesn't list families. So the answer should include the three families from the first source: MET, CMT, and DRM. The confidence is based on the evidence provided. Since the first document explicitly states these", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the plant DNA (cytosine-5) methyltransferase families. I need to look at the evidence provided to find the answer. Looking at the first piece of evidence, it mentions three different DNMT families in oil palm: MET, CMT, and DRM. That seems like a direct answer. The second evidence talks about carrot DNA-METase, which is part of the MET family maybe? The third one discusses DNMT1, but that's more about its role rather than the family it belongs to. Wait, the question specifies plant families. The first evidence explicitly lists three families: MET, CMT, and DRM. The second one mentions carrot, which is a plant, and DNA-M", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the plant DNA (cytosine-5) methyltransferase families. I need to look at the evidence provided to find the answer. Looking at the first piece of evidence, it mentions three different DNMT families in oil palm: MET, CMT, and DRM classes. That's a direct mention of families. The second evidence talks about carrot DNA-METase, which seems to relate to the MET family. The third one discusses DNMT1, which is part of the maintenance methylation, but it doesn't specify a family. So the answer should include the three families mentioned in the first source: MET, CMT, and DRM. The confidence here is based on the direct mention in the evidence", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking about the plant DNA (cytosine-5) methyltransferase families. Let me look at the evidence provided. First, evidence [18640997:18640997_0] mentions three different DNMT families in oil palm: MET, CMT, and DRM. That seems directly relevant. The other evidence talks about carrot DNA-METase and DNMT1's role, but the question is about families. The answer should list the families mentioned in the first source. The user wants a concise answer with citations. The confidence here is high because the first document explicitly lists three families. The other documents don't mention family classifications, just specific enzymes or their roles. So the answer", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the plant DNA (cytosine-5) methyltransferase families. The evidence provided has three documents. First, I need to parse each document to find relevant information. Looking at document [18640997:18640997_0], it mentions three different DNMT families in oil palm: MET, CMT, and DRM classes. That seems directly related to the question. The other documents talk about DNA-METase in carrots and DNMT1's role, but they don't specify family names. The answer should list the families mentioned in the first document. The confidence here is high because the first document explicitly states three families. The other documents", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the plant DNA (cytosine-5) methyltransferase families. The evidence provided has three documents. First, I need to parse each document. The first one mentions three DNMT families in oil palm: MET, CMT, and DRM. The second talks about two cDNAs for carrot DNA-METase. The third discusses DNMT1's role but doesn't specify families. So the answer should list the families mentioned. The first document clearly states MET, CMT, and DRM. The second mentions DNA-METase, which might be part of the MET family. But the question is about families, so the main ones are MET, CMT, and DRM from the first source. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the plant DNA (cytosine-5) methyltransferase families. I need to look at the evidence provided to find the answer. First, looking at the evidence documents. The first one mentions three different DNMT families in oil palm: MET, CMT, and DRM. That seems relevant because it directly lists the families. The second document talks about two distinct cDNAs for carrot DNA-METase, but it doesn't mention other families. The third document discusses DNMT1's role but doesn't list families. So the answer should include the three families from the first source: MET, CMT, and DRM. The confidence is based on the evidence provided. Since the first document explicitly states these", "base_prob": 0.5, "critic": {"rel_label": "Rel", "rel_prob": 0.95, "sup_label": "Fully", "sup_prob": 1.0, "use_score": 5, "use_prob": 1.0, "notes": "Evidence explicitly lists MET, CMT, and DRM as three DNMT families in oil palm, directly answering the question."}, "score": 6.44, "safe": true, "has_citation": 0}, {"answer": "<think> Okay, I need to figure out which plant DNA (cytosine-5) methyltransferase families are mentioned in the evidence. Let me start by looking at each of the provided documents. The first document, [18640997:18640997_0], talks about three different DNMT families in oil palm: MET, CMT, and DRM classes. That seems like a direct answer. The second document, [9680985:9680985_0], mentions two distinct cDNAs for carrot DNA-METase, but it's referring to the MET class maybe? The third document, [15289832:152898", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the plant DNA (cytosine-5) methyltransferase families. I need to look at the provided evidence to find the answer. First, looking at the evidence documents: The first document [18640997:18640997_0] mentions three DNMT families in oil palm: MET, CMT, and DRM. That seems relevant because it directly lists the families. The second document [9680985:9680985_0] talks about two cDNAs for carrot DNA-METase, but it's specifying a particular enzyme (DNA-METase) rather than families. The third document [1", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 6.44, "gold_docs": ["10781108", "10845458", "11353082", "17689048", "18640997", "19132393", "20331964", "21060858", "21542302", "8152926", "8389441", "9680985"], "ideal_answer": "The plant DNA (cytosine-5)methyltransferases are classified into the families: MET, CMT, and the de novo DRM."}
{"question_id": "52fe52702059c6d71c000078", "question": "Where is the histone variant CENPA preferentially localized?", "retrieved_chunks": [{"doc_id": "16248679", "chunk_id": "16248679_0", "score": 2.5027849674224854, "text": "Variant histone H2A.Z is globally localized to the promoters of inactive yeast genes and regulates nucleosome positioning."}, {"doc_id": "22693454", "chunk_id": "22693454_1", "score": 2.5000107288360596, "text": "In budding yeast, as well as in other eukaryotes, the Cse4 histone variant (known in vertebrates as CENP-A) is believed to substitute for histone H3 at the centromeric nucleosome"}, {"doc_id": "22516971", "chunk_id": "22516971_5", "score": 1.742027759552002, "text": "The Mis18 complex has been identified as a critical factor for the centromeric localization of a histone H3 variant, centromeric protein A (CENP-A), which is responsible for the specification of centromere identity in the chromosome."}], "context": "[16248679:16248679_0] Variant histone H2A.Z is globally localized to the promoters of inactive yeast genes and regulates nucleosome positioning.\n[22693454:22693454_1] In budding yeast, as well as in other eukaryotes, the Cse4 histone variant (known in vertebrates as CENP-A) is believed to substitute for histone H3 at the centromeric nucleosome\n[22516971:22516971_5] The Mis18 complex has been identified as a critical factor for the centromeric localization of a histone H3 variant, centromeric protein A (CENP-A), which is responsible for the specification of centromere identity in the chromosome.", "answer": "<think> Okay, let's tackle this question. The user is asking where the histone variant CENPA is preferentially localized. The evidence provided has three references. First, I need to understand what each reference says. The first one talks about H2A.Z in yeast promoters and nucleosome positioning. But the question is about CENPA, so maybe not directly relevant unless there's a connection. The second reference mentions Cse4, which is known as CENP-A in vertebrates. It states that Cse4 substitutes for H3 at centromeric nucleosomes in budding yeast and other eukaryotes. So this suggests that CENPA (Cse4) is localized at centromeres. The third reference discusses the Mis18 complex helping", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking where the histone variant CENPA is preferentially localized. The evidence provided has three references. First, I need to understand what each reference says. The first one talks about H2A.Z in yeast promoters and nucleosome positioning. But the question is about CENPA, so maybe not directly relevant unless there's a connection. The second reference mentions Cse4, which is known as CENP-A in vertebrates. It states that Cse4 substitutes for H3 at centromeric nucleosomes in budding yeast and other eukaryotes. So this suggests that CENPA (Cse4) is localized at centromeres. The third reference discusses the Mis18 complex helping", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking where the histone variant CENPA is preferentially localized. The evidence provided has three references. First, I need to understand what each reference says. The first one mentions H2A.Z in yeast genes, but that's a different histone variant. The second reference talks about Cse4, which is the yeast version of CENP-A, and it's localized at centromeres. The third reference mentions the Mis18 complex helping localize CENP-A to centromeres. So, the question is about CENPA, which is the vertebrate version of Cse4. The second evidence directly states that Cse4 (CENP-A) substitutes for H3 at centromeric", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking where the histone variant CENPA is preferentially localized. The evidence provided has three references. First, looking at the evidence: 1. The first reference talks about H2A.Z being localized to promoters of inactive yeast genes. But the question is about CENPA, so maybe not directly relevant unless there's a connection between H2A.Z and CENPA. But I don't see that here. 2. The second reference mentions Cse4, which is known as CENP-A in vertebrates. It says this variant substitutes for H3 at the centromeric nucleosome. So this suggests that CENP-A (CENPA) is localized to centromeres. 3. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking where the histone variant CENPA is preferentially localized. The evidence provided has three references. First, I need to understand what each reference says. The first one talks about H2A.Z being localized to promoters of inactive yeast genes. But the question is about CENPA, which is mentioned in the second and third references. The second reference states that Cse4 (which is known as CENP-A in vertebrates) substitutes for histone H3 at the centromeric nucleosome in budding yeast and other eukaryotes. So this suggests that CENPA is localized at centromeres. The third reference mentions the Mis18 complex being involved in the centromeric localization of", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking where the histone variant CENPA is preferentially localized. The evidence provided has three chunks. First, I need to look at each chunk to find information about CENPA. The first chunk talks about H2A.Z in yeast genes, but that's a different variant. The second chunk mentions Cse4, which is known as CENP-A in vertebrates, and it substitutes for H3 at centromeric nucleosomes. The third chunk says the Mis18 complex helps localize CENP-A to centromeres. So, putting this together, CENPA (Cse4 in yeast) is involved in centromere localization. The second and third chunks both point to centromeres", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking where the histone variant CENPA is preferentially localized. The evidence provided has three references. First, I need to look at each piece of evidence. The first one talks about H2A.Z in yeast genes promoters, but that's a different variant. The second mention Cse4, which is the yeast version of CENP-A, and it's located at centromeric nucleosomes. The third reference says the Mis18 complex helps localize CENP-A to centromeres. So, CENPA is mentioned in the second and third references. The second says Cse4 (which is the yeast homolog) substitutes for H3 at centromere nucleosomes. The third says C", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking where the histone variant CENPA is preferentially localized. The evidence provided has three chunks. First, I need to look at each chunk and see what they say. The first chunk talks about H2A.Z in yeast genes, but that's a different variant. The second chunk mentions Cse4, which is the yeast version of CENP-A, and it's localized at centromeres. The third chunk discusses the Mis18 complex helping with centromeric localization of CENP-A. So, the key here is to connect CENPA (Cse4 in yeast) to centromeres. The second and third chunks both point to centromeric localization. The question is about where", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking where the histone variant CENPA is preferentially localized. The evidence provided has three references. First, I need to look at each reference. The first one talks about H2A.Z in yeast genes promoters, but that's a different variant, H2A.Z, not CENPA. So maybe not relevant here. The second reference mentions Cse4, which is known as CENP-A in vertebrates. It says this variant substitutes for H3 at the centromeric nucleosome. So this suggests that CENP-A (CENPA) is localized at centromeres. The third reference talks about the Mis18 complex helping localize CENP-A to centromeres.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["10655499", "12011073", "12217960", "12906131", "12953060", "16314512", "18314594", "18411404", "19778997", "20119530", "20940262", "21508988", "21888900", "23439889", "23562479", "24213134", "9465302", "9605877"], "ideal_answer": "Centromere protein A (Cenpa for mouse, CENP-A for other species) is an essential histone H3-like protein that localizes to the centromeric region of eukaryotic chromosomes, where it replaces conventional histone H3 and together with centromere-specific-DNA-binding factors directs the assembly of active kinetochores. THe histone variant CENPA is preferentially located at Centromeric chromatin"}
{"question_id": "517137c18ed59a060a000001", "question": "In which proteins is the chromodomain present?", "retrieved_chunks": [{"doc_id": "18450745", "chunk_id": "18450745_0", "score": 8.233509063720703, "text": "In vertebrates, HP1-like chromodomains are also present in the chromodomain Y chromosome (CDY) family of proteins adjacent to a putative catalytic motif. The human genome encodes three CDY family proteins, CDY, CDYL, and CDYL2."}, {"doc_id": "11956312", "chunk_id": "11956312_0", "score": 8.006998062133789, "text": "The chromodomain (CD) is a highly conserved motif present in a variety of animal and plant proteins, and its probable role is to assemble a variety of macromolecular complexes in chromatin."}, {"doc_id": "20493168", "chunk_id": "20493168_1", "score": 7.554388999938965, "text": "The chromatin organizer modifier domain (chromodomain) is present in proteins that contribute to chromatin organization and mediates their binding to methylated histone H3."}], "context": "[18450745:18450745_0] In vertebrates, HP1-like chromodomains are also present in the chromodomain Y chromosome (CDY) family of proteins adjacent to a putative catalytic motif. The human genome encodes three CDY family proteins, CDY, CDYL, and CDYL2.\n[11956312:11956312_0] The chromodomain (CD) is a highly conserved motif present in a variety of animal and plant proteins, and its probable role is to assemble a variety of macromolecular complexes in chromatin.\n[20493168:20493168_1] The chromatin organizer modifier domain (chromodomain) is present in proteins that contribute to chromatin organization and mediates their binding to methylated histone H3.", "answer": "<think> Okay, the user is asking which proteins contain the chromodomain. Let me look at the evidence provided. First, evidence [18450745:18450745_0] mentions HP1-like chromodomains in the CDY family proteins like CDY, CDYL, and CDYL2. That's a direct mention of specific proteins. Then, [11956312:11956312_0] talks about the chromodomain being present in various proteins but doesn't name any specific ones. It's more general. The third evidence [20493168:20493168_1] also discusses the chromod", "citations": [{"doc_id": "18450745", "chunk_id": "18450745_0"}, {"doc_id": "11956312", "chunk_id": "11956312_0"}, {"doc_id": "20493168", "chunk_id": "20493168_1"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants to know in which proteins the chromodomain is present, based on the given evidence. First, I need to look at each of the three evidence snippets provided. The first one (18450745) mentions HP1-like chromodomains in the CDY family proteins: CDY, CDYL, and CDYL2. So that's a direct mention of specific proteins. The second snippet (11956312) talks about the chromodomain being present in various animal and plant proteins, but it's more general. The third one (20493168) says the chromodomain is in proteins contributing to chromatin organization and binding to methyl", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking which proteins contain the chromodomain. Let me look at the evidence provided. First, evidence [18450745:18450745_0] mentions HP1-like chromodomains in the CDY family proteins like CDY, CDYL, and CDYL2. That's a direct mention of specific proteins. Then, [11956312:11956312_0] talks about the chromodomain being present in various proteins but doesn't name any specific ones. It's more general. The third evidence [20493168:20493168_1] also discusses the chromod", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user wants to know in which proteins the chromodomain is present, based on the given evidence. First, I'll look at each of the three evidence snippets provided. The first one (18450745:18450745_0) mentions HP1-like chromodomains in the CDY family proteins—specifically CDY, CDYL, and CDYL2. So that's a direct answer here. The second snippet (11956312:11956312_0) states that the chromodomain is present in various animal and plant proteins, but it doesn't name specific proteins. However, it does mention that", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know in which proteins the chromodomain is present, based on the provided evidence. First, I need to look at each of the three evidence snippets. The first one (18450745:18450745_0) mentions HP1-like chromodomains in the CDY family proteins—specifically CDY, CDYL, and CDYL2. So that's a direct mention of proteins containing chromodomains. The second snippet (11956312:11956312_0) states that the chromodomain is present in various animal and plant proteins, but it doesn't name specific ones. However,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking which proteins contain the chromodomain. Let me look at the evidence provided. First, evidence document [18450745:18450745_0] mentions HP1-like chromodomains in the CDY family proteins like CDY, CDYL, and CDYL2. That's a direct mention of specific proteins. Then, [11956312:11956312_0] says the chromodomain is present in various proteins but doesn't name any specific ones. The third evidence [20493168:20493168_1] talks about the chromodomain being in proteins that contribute", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, the user is asking which proteins contain the chromodomain. Let me look at the evidence provided. First, evidence [18450745:18450745_0] mentions HP1-like chromodomains in the CDY family proteins like CDY, CDYL, and CDYL2. That's a direct mention of specific proteins. Then, [11956312:11956312_0] says the chromodomain is present in various proteins but doesn't name any specific ones. The third evidence [20493168:20493168_1] talks about chromodomains in proteins involved in chromatin organization", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which proteins contain the chromodomain. The evidence provided has three documents. First, looking at document [18450745:18450745_0], it mentions HP1-like chromodomains in the CDY family proteins: CDY, CDYL, and CDYL2. That's a direct answer. Then, document [11956312:11956312_0] talks about the chromodomain being present in various proteins, but not specific ones. The third document [20493168:20493168_1] also mentions chromodomains in proteins", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which proteins contain the chromodomain. The evidence provided has three references. First, looking at reference [18450745:18450745_0], it mentions HP1-like chromodomains in the CDY family proteins—specifically CDY, CDYL, and CDYL2. That's a direct mention of proteins with chromodomains. Then, reference [11956312:11956312_0] states that the chromodomain is present in various proteins across animals and plants, but it doesn't name specific ones. So this is more general. The third reference [20493", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["10199952", "10908644", "11500496", "11859155", "11956312", "12137948", "12186646", "12397079", "12819141", "15304225", "15457214", "16095617", "16157682", "16183644", "16339723", "16407326", "16412250", "16537902", "16613610", "16738128", "16949368", "17101786", "17224041", "17253929", "17428788", "17542647", "17603073", "18369641", "18450745", "18725928", "18846226", "19029895", "19142019", "19205716", "19279158", "19399177", "19798443", "19808672", "19897549", "19956676", "20308527", "20389031", "20493168", "20568999", "20657587", "20860631", "20950435", "21047797", "21060834", "21094707", "21146514", "21158681", "21177652", "21195088", "21211724", "21224386", "21245376", "21278251", "21358630", "21369828", "21419134", "21447119", "21448134", "21505064", "21596839", "21623345", "21636313", "21646535", "21659642", "21669865", "21720545", "21726377", "21730028", "21799255", "21830056", "21836164", "21860208", "21875659", "21901784", "21953552", "21972924", "21979373", "22009739", "22022377", "22033296", "22033927", "22039057", "22052799", "22073269", "22081013", "22081016", "22083954", "22083958", "22086334", "22145013", "22172672", "22179824", "22186629", "22193973", "22203189", "22212480", "22216243", "22219182", "22223433", "22231402", "22235338", "22242120", "22302795", "22325148", "22412383", "22419124", "22427862", "22462537", "22491446", "22514736", "22528993", "22551706", "22569126", "22569290", "22607268", "22646239", "22683269", "22691070", "22705977", "22715096", "22727667", "22728643", "22768949", "22815475", "22834704", "22855185", "22892537", "22897906", "23020525", "23022495", "23071088", "23071455", "23071553", "23142031", "23202694", "23239876", "23271156", "23282990", "23285124", "23285239", "23314848", "23318260", "23319608", "23320494", "23388053", "23403278", "23417793", "23448600", "23471993", "7720711", "8460153", "8663349"], "ideal_answer": "The chromodomain (chromatin organizer modifier domain) is a highly conserved motif, 40-50 amino acids in length, present in a wide range of animal and plant proteins involved in chromatin organization. Chromodomain-containing proteins can be classified into boader families based, particularly, on the presence of other types of domains. Chromodomain is present in: the heterochromatin proteins HP1 alpha and HP1 beta, chromointgrases (e.g. Tf1 integrase) the chromodomain helicase DNA-binding proteins (CHD) and CHD 1-like (CHD1L), CReMM (chromatin-related mesenchymal modulator), dna methyltransferase 3 (cmt3), the chromointegrase of the LTR-retrotransposons, the Polycomb group (PcG) proteins, the mouse Polycomb homologs (Cbx2, Cbx4, Cbx6, Cbx7, Cbx8), the chromodomain Y chromosome (CDY) family of proteins and the CDY-like protein (CDYL), the histone acetyltransferases TgMYST-A and –B, MRG-1 and -15 (MORF4-Related Gene on chromosome 15), ADP/ATP translocase 1, MPP8, MSL3, NlMof, Chp1, Chriz, dMi-2, Corto, cpSRP43, KISMET, PICKLE (PKL), ScoHET1 and ScoHET2."}
{"question_id": "56b3efc38525abca1e000006", "question": "What is Genomicus?", "retrieved_chunks": [{"doc_id": "23193262", "chunk_id": "23193262_0", "score": 10.184164047241211, "text": "Genomicus (http://www.dyogen.ens.fr/genomicus/) is a database and an online tool that allows easy comparative genomic visualization in &gt;150 eukaryote genomes."}, {"doc_id": "23193262", "chunk_id": "23193262_1", "score": 10.181413650512695, "text": "Genomicus (http://www.dyogen.ens.fr/genomicus/) is a database and an online tool that allows easy comparative genomic visualization in >150 eukaryote genomes."}, {"doc_id": "23193262", "chunk_id": "23193262_2", "score": 10.120392799377441, "text": "Genomicus (http://www.dyogen.ens.fr/genomicus/) is a database and an online tool that allows easy comparative genomic visualization in>150 eukaryote genomes"}], "context": "[23193262:23193262_0] Genomicus (http://www.dyogen.ens.fr/genomicus/) is a database and an online tool that allows easy comparative genomic visualization in &gt;150 eukaryote genomes.\n[23193262:23193262_1] Genomicus (http://www.dyogen.ens.fr/genomicus/) is a database and an online tool that allows easy comparative genomic visualization in >150 eukaryote genomes.\n[23193262:23193262_2] Genomicus (http://www.dyogen.ens.fr/genomicus/) is a database and an online tool that allows easy comparative genomic visualization in>150 eukaryote genomes", "answer": "<think> Okay, let's tackle this query. The user is asking what Genomicus is, and I need to generate a biomedical answer based on the provided evidence. First, I'll look at the evidence given. There are three entries, all with the same document ID and chunk IDs. They all state that Genomicus is a database and online tool for comparative genomic visualization in over 150 eukaryote genomes. The URLs are the same in each case. The answer needs to be concise and include citations in the format [doc_id:chunk_id]. Since all three chunks are identical, I can pick one of them. Let's choose the first one, [23193262:23193262_0].", "citations": [{"doc_id": "23193262", "chunk_id": "23193262_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this query. The user is asking what Genomicus is, and I need to generate a biomedical answer based on the provided evidence. First, I'll look at the evidence. There are three entries, all from the same document ID but different chunk IDs. They all mention that Genomicus is a database and online tool for comparative genomic visualization in over 150 eukaryote genomes. The URLs and the exact wording are similar across the chunks. The answer needs to be concise and include citations in the format [doc_id:chunk_id]. Since all three chunks are essentially the same, I can pick one of them. Let's go with the first chunk, 23193262_0. For the base", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking what Genomicus is, and I need to generate a biomedical answer based on the provided evidence. First, I'll look at the evidence given. There are three entries, all with the same document ID and chunk IDs. They all state that Genomicus is a database and online tool for comparative genomic visualization in over 150 eukaryote genomes. The URLs are the same in each case. The answer needs to be concise and include citations in the format [doc_id:chunk_id]. Since all three chunks are identical, I can pick one of them. Let's choose the first one, [23193262:23193262_0].", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer for the question \"What is Genomicus?\" using the provided evidence. Let me start by carefully reading the evidence. The evidence has three entries, all with the same doc_id and chunk_id. Each says that Genomicus is a database and online tool for comparative genomic visualization in over 150 eukaryote genomes. The URLs are the same in all cases. First, I should check if there's any variation in the information provided. All three chunks are identical, so there's no conflicting evidence here. The key points are: it's a database, an online tool, allows easy comparative genomic visualization, and covers more than 150 eukaryote genomes. The answer needs to be concise", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking about \"What is Genomicus?\" and provided three pieces of evidence. All three chunks say essentially the same thing: Genomicus is a database and online tool for comparative genomic visualization in over 150 eukaryotic genomes. First, I need to create a concise answer that includes citations. The key points are that it's a database, an online tool, and it allows easy comparative genomic visualization in more than 150 eukaryote genomes. The citation should be from the first chunk since all three are duplicates. The base confidence is set as 1.0 because all evidence chunks agree completely. There's no conflicting information here. So the answer should directly quote the first chunk and mention the URL. Make sure", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is \"What is Genomicus?\" and the evidence has three chunks, all pointing to the same information. First, I should check if there's any variation in the evidence. Looking at the chunks, they all say that Genomicus is a database and online tool for comparative genomic visualization in over 150 eukaryote genomes. The only differences are minor typos like \"in &gt;150\" versus \"in>150\", but the meaning remains the same. The answer needs to be concise and include citations with doc_id and chunk_id. Since all three chunks are from the same document (23193262) but different chunks", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking what Genomicus is, and I need to generate a biomedical answer based on the provided evidence. First, I'll look at the evidence given. There are three chunks, all from the same document ID, 23193262, but different chunk IDs. Each of them says that Genomicus is a database and online tool for comparative genomic visualization in over 150 eukaryote genomes. The URLs are the same in each case, so that's consistent. The answer needs to be concise and include citations in the format [doc_id:chunk_id]. Since all three chunks are identical, I can pick one of them. Maybe the first one, 23193", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking what Genomicus is. Let me look at the evidence provided. There are three chunks, all from the same document ID, 23193262, but different chunk IDs. Each of them says that Genomicus is a database and online tool for comparative genomic visualization in over 150 eukaryote genomes. So, the answer needs to be concise and include citations. The key points are that it's a database, an online tool, and used for comparative genomics in more than 150 eukaryotic genomes. The URL is mentioned in the first chunk. I should make sure to mention that. The user wants the answer in JSON with \"answer\" and \"base_confidence\".", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking about Genomicus, and I need to generate a biomedical answer based on the provided evidence. Let me look at the evidence first. The evidence has three entries, all with the same document ID and chunk IDs. They all state that Genomicus is a database and online tool for comparative genomic visualization in over 150 eukaryote genomes. The URLs are the same in each case. So the answer should be concise, mentioning it's a database/tool for comparative genomics in >150 eukaryotes. I need to cite the document ID and chunk IDs. Since all three chunks are identical, maybe pick one, like chunk 23193262_0. The confidence level is 1", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["20185404", "23193262", "25378326"], "ideal_answer": "Genomicus had been developed as a database and a browser to study gene synteny in modern and ancestral genomes. It allows easy comparative genomic visualization in >150 eukaryote genomes and in four different phyla (Vertebrate, Fungi, Metazoan and Plants). It provides a way to explore spatial information related to gene organization within and between genomes and temporal relationships related to gene and genome evolution. For the specific vertebrate phylum, it also provides access to ancestral gene order reconstructions and conserved non-coding elements information. The graphical modules of Genomicus show how it is capable of revealing differential gene loss and gain, segmental or genome duplications and facilitate the study of the evolution of a locus through homology relationships. The Genomicus server provides access to ancestral gene orders, as well as computationally predicted regulatory interactions, thanks to the representation of conserved non-coding elements with their putative gene targets."}
{"question_id": "5509df4ac2af5d5b70000003", "question": "Is amiodarone a class I anti-arrhythmic drug?", "retrieved_chunks": [{"doc_id": "20041841", "chunk_id": "20041841_0", "score": 10.485806465148926, "text": "Although amiodarone is considered a class III anti-arrhythmic agent, it also has class I, II, IV actions, making it a unique and effective anti-arrhythmic agent"}, {"doc_id": "11825323", "chunk_id": "11825323_1", "score": 10.47260856628418, "text": "Amiodarone has been used as an anti-arrhythmic drug since the 1970s and has an established role in the treatment of ventricular tachyarrhythmias. Although considered to be a class III anti-arrhythmic, amiodarone also has class I, II and IV actions, which gives it a unique pharmacological and anti-arrhythmic profile."}, {"doc_id": "11825323", "chunk_id": "11825323_0", "score": 10.18978500366211, "text": "Although considered to be a class III anti-arrhythmic, amiodarone also has class I, II and IV actions, which gives it a unique pharmacological and anti-arrhythmic profile"}], "context": "[20041841:20041841_0] Although amiodarone is considered a class III anti-arrhythmic agent, it also has class I, II, IV actions, making it a unique and effective anti-arrhythmic agent\n[11825323:11825323_1] Amiodarone has been used as an anti-arrhythmic drug since the 1970s and has an established role in the treatment of ventricular tachyarrhythmias. Although considered to be a class III anti-arrhythmic, amiodarone also has class I, II and IV actions, which gives it a unique pharmacological and anti-arrhythmic profile.\n[11825323:11825323_0] Although considered to be a class III anti-arrhythmic, amiodarone also has class I, II and IV actions, which gives it a unique pharmacological and anti-arrhythmic profile", "answer": "<think> Okay, let's tackle this question. The user is asking if amiodarone is a class I anti-arrhythmic drug. The evidence provided has three chunks. First, looking at the evidence, chunk [20041841:20041841_0] says that although amiodarone is considered a class III agent, it also has class I, II, IV actions. So it's not just class III, but also others. Then chunk [11825323:11825323_1] repeats this, mentioning class III but also I, II, IV. The same is stated in chunk [11825323:118", "citations": [{"doc_id": "20041841", "chunk_id": "20041841_0"}, {"doc_id": "11825323", "chunk_id": "11825323_1"}], "candidates": [{"answer": "<think> Okay, the user is asking if amiodarone is a class I anti-arrhythmic drug. Let me look at the evidence provided. The first document says that amiodarone is considered a class III agent but also has class I, II, IV actions. The second and third documents mention similar things, stating it's mainly class III but also has actions from other classes. So, even though it's primarily class III, it does have class I properties. The answer needs to be concise and include citations. The base confidence should reflect that while it's mainly class III, the presence of class I actions is confirmed in the evidence. So the answer should state that amiodarone has class I actions but is primarily class III. The confidence can be high", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking if amiodarone is a class I anti-arrhythmic drug. Let me look at the evidence provided. The first document says that amiodarone is considered a class III agent but also has class I, II, IV actions. The second and third documents mention similar things, stating it's mainly class III but also has I, II, and IV effects. The question is whether it's a class I drug. The answer needs to be concise with citations. From the evidence, amiodarone is primarily class III, but it does have class I actions. However, the main classification is III. But the user is asking if it's a class I, so the answer should reflect that it's not exclusively class I", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if amiodarone is a class I anti-arrhythmic drug. The evidence provided has three chunks. First, looking at the evidence, chunk [20041841:20041841_0] says that although amiodarone is considered a class III agent, it also has class I, II, IV actions. So it's not just class III, but also others. Then chunk [11825323:11825323_1] repeats this, mentioning class III but also I, II, IV. The same is stated in chunk [11825323:118", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if amiodarone is a class I anti-arrhythmic drug. The evidence provided mentions that amiodarone is considered a class III agent but also has actions in classes I, II, and IV. First, I need to recall the classification of anti-arrhythmic drugs. The main classes are I, II, III, and IV. Class I agents block sodium channels and are further divided into subtypes Ia and Ib. Class III drugs prolong the action potential duration, like dofetilide. However, amiodarone is known for having multiple actions. Looking at the evidence, the first source says it's a class III but also has class I, II, IV actions. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if amiodarone is a class I anti-arrhythmic drug. The evidence provided mentions that amiodarone is considered a class III agent but also has actions in classes I, II, and IV. First, I need to recall the classification of anti-arrhythmic drugs. Class I agents are further divided into subclasses Ia and Ib, which block sodium channels. Class III agents block potassium channels. The evidence says amiodarone is mainly class III but also has class I, II, and IV actions. So while it's primarily class III, it does have class I properties. The answer should state that amiodarone is a class III drug but also has class I actions. However", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking if amiodarone is a class I anti-arrhythmic drug. Let me check the evidence provided. Looking at the evidence, there are three documents. The first one says that amiodarone is considered a class III agent but also has class I, II, IV actions. The second and third documents mention similar things, stating it's mainly class III but also has I, II, IV actions. So the question is whether it's a class I drug. The answer should be no, because the evidence says it's primarily class III, even though it has other classes. But the user wants a candidate answer from the evidence. Wait, the user said to generate an answer that's concise with citations and base confidence. The answer", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking if amiodarone is a class I anti-arrhythmic drug. Let me look at the evidence provided. First, the evidence from 20041841:20041841_0 says that amiodarone is considered a class III agent but also has class I, II, IV actions. So it's not just class III, but also others. Then there's 11825323:11825323_1 which mentions that although it's class III, it has class I, II, and IV actions. The same source is mentioned again in 11825323:1182532", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking if amiodarone is a class I anti-arrhythmic drug. Let me look at the evidence provided. First, the evidence mentions that amiodarone is considered a class III agent but also has class I, II, IV actions. So, even though it's mainly class III, it does have class I properties. The answer needs to be concise and cite the documents. The first document (20041841:20041841_0) says it's a class III but also has class I, II, IV actions. The other two documents from 11825323 also mention similar things. So the answer should state that amiodarone is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["11825323", "12491809", "15989900", "17352036", "20041841", "21626366", "21728182"], "ideal_answer": "Although considered to be a class III anti-arrhythmic, amiodarone also has class I, II and IV actions, which gives it a unique pharmacological and anti-arrhythmic profile Amiodarone has been used as an anti-arrhythmic drug since the 1970s and has an established role in the treatment of ventricular tachyarrhythmias. Although considered to be a class III anti-arrhythmic, amiodarone also has class I, II and IV actions, which gives it a unique pharmacological and anti-arrhythmic profile. Common class I agents are excluded due to the inherent abnormal cardiac structure and function in the setting of cardiogenic shock. Class III drug options include dofetilide and amiodarone. Amiodarone has been used as an anti-arrhythmic drug since the 1970s and has an established role in the treatment of ventricular tachyarrhythmias. Although considered to be a class III anti-arrhythmic, amiodarone also has class I, II and IV actions, which gives it a unique pharmacological and anti-arrhythmic profile. No. Common class I agents are excluded due to the inherent abnormal cardiac structure and function in the setting of cardiogenic shock. Although considered to be a class III anti-arrhythmic, amiodarone also has class I, II and IV actions, which gives it a unique pharmacological and anti-arrhythmic profile. Amiodarone, an iodinated benzofuran derivative, introduced in 1960 s as an anti-anginal agent, emerged as a potent anti-arrhythmic agent by 1970 s and is currently one of the most commonly prescribed drugs in US for ventricular and atrial arrhythmias. Although amiodarone is considered a class III anti-arrhythmic agent, it also has class I, II, IV actions, making it a unique and effective anti-arrhythmic agent."}
{"question_id": "5339ecf4d6d3ac6a3400005f", "question": "Which is the prognostic meaning of delayed enhancement documented in patients hypertrophic cardiomyopathy?", "retrieved_chunks": [{"doc_id": "17885521", "chunk_id": "17885521_1", "score": 4.007968425750732, "text": "Patterns of delayed enhancement are different in dilated cardiomyopathy and ischemic cardiomyopathy, reflecting the presence of scarring or various degrees of fibrosis in left ventricular myocardium. The presence of subendocardial or transmural delayed enhancement at contrast-enhanced cardiovascular magnetic resonance allowed distinction between dilated cardiomyopathy and ischemic cardiomyopathy with high sensitivity (88%) and specificity (100%)."}, {"doc_id": "17885521", "chunk_id": "17885521_0", "score": 3.9407756328582764, "text": "In the dilated cardiomyopathy group, only seven (29%) patients showed delayed enhancement and its pattern was characterized by mid-wall, patchy or diffuse location."}, {"doc_id": "19317068", "chunk_id": "19317068_0", "score": 3.1009156703948975, "text": "one case was dilated cardiomyopathy, in which the delayed enhancement was diffuse small midwall spots"}], "context": "[17885521:17885521_1] Patterns of delayed enhancement are different in dilated cardiomyopathy and ischemic cardiomyopathy, reflecting the presence of scarring or various degrees of fibrosis in left ventricular myocardium. The presence of subendocardial or transmural delayed enhancement at contrast-enhanced cardiovascular magnetic resonance allowed distinction between dilated cardiomyopathy and ischemic cardiomyopathy with high sensitivity (88%) and specificity (100%).\n[17885521:17885521_0] In the dilated cardiomyopathy group, only seven (29%) patients showed delayed enhancement and its pattern was characterized by mid-wall, patchy or diffuse location.\n[19317068:19317068_0] one case was dilated cardiomyopathy, in which the delayed enhancement was diffuse small midwall spots", "answer": "<think> Okay, let's tackle this question. The user is asking about the prognostic meaning of delayed enhancement in patients with hypertrophic cardiomyopathy. Wait, but the evidence provided talks about dilated cardiomyopathy and ischemic cardiomyopathy. Hmm, maybe there's a mix-up here. The question mentions hypertrophic cardiomyopathy (HCM), but the evidence is about dilated cardiomyopathy (DCM) and ischemic cardiomyopathy. So first, I need to check if the evidence actually addresses HCM. Looking at the evidence, the first document [17885521:17885521_1] discusses delayed enhancement in DCM and ischemic cardiomyopathy. The second part mentions that in D", "citations": [{"doc_id": "17885521", "chunk_id": "17885521_1"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the prognostic meaning of delayed enhancement in patients with hypertrophic cardiomyopathy. Wait, but the evidence provided talks about dilated and ischemic cardiomyopathies. Hmm, maybe there's a mix-up here. The question mentions hypertrophic cardiomyopathy (HCM), but the evidence given is about dilated (DCM) and ischemic cardiomyopathies. First, I need to check if the evidence actually addresses HCM. Looking at the evidence, the first document says delayed enhancement patterns differ between DCM and ischemic cardiomyopathy. The second mentions that in DCM, 29% had delayed enhancement with mid-wall, patchy, or diffuse locations. The third example is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the prognostic meaning of delayed enhancement in patients with hypertrophic cardiomyopathy. Wait, but the evidence provided talks about dilated cardiomyopathy and ischemic cardiomyopathy. Hmm, maybe there's a mix-up here. The question mentions hypertrophic cardiomyopathy (HCM), but the evidence is about dilated cardiomyopathy (DCM) and ischemic cardiomyopathy. So first, I need to check if the evidence actually addresses HCM. Looking at the evidence, the first document [17885521:17885521_1] discusses delayed enhancement in DCM and ischemic cardiomyopathy. The second part mentions that in D", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the prognostic meaning of delayed enhancement in patients with hypertrophic cardiomyopathy. Wait, but the evidence provided talks about dilated cardiomyopathy and ischemic cardiomyopathy. Hmm, maybe there's a confusion here. The question mentions hypertrophic cardiomyopathy (HCM), but the evidence given is about dilated cardiomyopathy (DCM) and ischemic cardiomyopathy. First, I need to check if the evidence actually addresses HCM. Looking at the evidence snippets: [17885521:17885521_1] discusses patterns in DCM and ischemic cardiomyopathy. The other snippets also mention DCM. So there's", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the prognostic meaning of delayed enhancement in patients with hypertrophic cardiomyopathy. Wait, but the evidence provided talks about dilated cardiomyopathy and ischemic cardiomyopathy. Hmm, maybe there's a mix-up here. Hypertrophic cardiomyopathy (HCM) is different from dilated cardiomyopathy (DCM). The evidence given doesn't mention HCM directly. Let me check the evidence again. Looking at the evidence: the first document talks about delayed enhancement distinguishing DCM from ischemic cardiomyopathy. The second mentions that in DCM, 29% had delayed enhancement with certain patterns. The third example is a case of DCM with diffuse small midwall spots. But", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the prognostic meaning of delayed enhancement in patients with hypertrophic cardiomyopathy. Wait, but the evidence provided talks about dilated cardiomyopathy and ischemic cardiomyopathy. Hmm, maybe there's a mix-up here. The question mentions hypertrophic cardiomyopathy (HCM), but the evidence is about dilated (DCM) and ischemic DCM. First, I need to check if the evidence actually addresses HCM. Looking at the evidence snippets: the first one discusses delayed enhancement distinguishing between DCM and ischemic DCM. The second mentions seven out of 29 patients in DCM showing delayed enhancement. The third example is a case of DCM with diffuse small midwall spots", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the prognostic meaning of delayed enhancement in patients with hypertrophic cardiomyopathy. Wait, but the evidence provided talks about dilated cardiomyopathy and ischemic cardiomyopathy. Hmm, maybe there's a mix-up here. The question mentions hypertrophic cardiomyopathy (HCM), but the evidence is about dilated cardiomyopathy (DCM) and ischemic cardiomyopathy. So first, I need to check if the evidence actually addresses HCM. Looking at the evidence, the first document [17885521:17885521_1] discusses delayed enhancement in DCM and ischemic cardiomyopathy. The second document [178", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to figure out the answer to the question about the prognostic meaning of delayed enhancement in patients with hypertrophic cardiomyopathy. Let me start by looking at the evidence provided. The user mentioned three references. The first one (17885521:17885521_1) talks about patterns of delayed enhancement differing between dilated and ischemic cardiomyopathy. It mentions that delayed enhancement helps distinguish between these two conditions with high sensitivity and specificity. However, the question is about hypertrophic cardiomyopathy, not dilated or ischemic. So maybe this is related but not directly answering the question. The second reference (17885521:17885521_", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the prognostic meaning of delayed enhancement in patients with hypertrophic cardiomyopathy. Wait, but the evidence provided talks about dilated and ischemic cardiomyopathy. Hmm, maybe there's a mix-up here. The question mentions hypertrophic cardiomyopathy (HCM), but the evidence is about dilated and ischemic cardiomyopathies. First, I need to check if there's any mention of HCM in the provided documents. Looking at the evidence: [17885521:17885521_0] mentions dilated cardiomyopathy, and [19317068:19317068_0", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["12224720", "15861263", "18204915", "18208827", "18562248", "19474054", "19477402", "19740409", "19784900", "19808288", "20079992", "20102955", "20339815", "20667520", "20688032", "21234292", "21498307", "22128204", "22135401", "22348519", "22498326", "22687593", "22935464", "23376948"], "ideal_answer": "Delayed enhancement by CMR has prognostic value in predicting adverse cardiovascular events among HCM patients, and is associated with cardiovascular mortality, heart failure death, and all-cause mortality in HCM."}
{"question_id": "56ae35bc0a360a5e45000007", "question": "What is the COUGER tool?", "retrieved_chunks": [{"doc_id": "24861628", "chunk_id": "24861628_6", "score": 6.761025428771973, "text": "Here, we present an interactive web implementation of COUGER, a classification-based framework for identifying protein co-factors that might provide specificity to paralogous TFs. COUGER takes as input two sets of genomic regions bound by paralogous TFs, and it identifies a small set of putative co-factors that best distinguish the two sets of sequences. To achieve this task, COUGER uses a classification approach, with features that reflect the DNA-binding specificities of the putative co-factors. The identified co-factors are presented in a user-friendly output page, together with information that allows the user to understand and to explore the contributions of individual co-factor features. COUGER can be run as a stand-alone tool or through a web interface: http://couger.oit.duke.edu."}, {"doc_id": "24861628", "chunk_id": "24861628_5", "score": 6.428504943847656, "text": "Here, we present an interactive web implementation of COUGER, a classification-based framework for identifying protein co-factors that might provide specificity to paralogous TFs. COUGER takes as input two sets of genomic regions bound by paralogous TFs, and it identifies a small set of putative co-factors that best distinguish the two sets of sequences."}, {"doc_id": "24861628", "chunk_id": "24861628_2", "score": 6.034642219543457, "text": "COUGER takes as input two sets of genomic regions bound by paralogous TFs, and it identifies a small set of putative co-factors that best distinguish the two sets of sequences. To achieve this task, COUGER uses a classification approach, with features that reflect the DNA-binding specificities of the putative co-factors."}], "context": "[24861628:24861628_6] Here, we present an interactive web implementation of COUGER, a classification-based framework for identifying protein co-factors that might provide specificity to paralogous TFs. COUGER takes as input two sets of genomic regions bound by paralogous TFs, and it identifies a small set of putative co-factors that best distinguish the two sets of sequences. To achieve this task, COUGER uses a classification approach, with features that reflect the DNA-binding specificities of the putative co-factors. The identified co-factors are presented in a user-friendly output page, together with information that allows the user to understand and to explore the contributions of individual co-factor features. COUGER can be run as a stand-alone tool or through a web interface: http://couger.oit.duke.edu.\n[24861628:24861628_5] Here, we present an interactive web implementation of COUGER, a classification-based framework for identifying protein co-factors that might provide specificity to paralogous TFs. COUGER takes as input two sets of genomic regions bound by paralogous TFs, and it identifies a small set of putative co-factors that best distinguish the two sets of sequences.\n[24861628:24861628_2] COUGER takes as input two sets of genomic regions bound by paralogous TFs, and it identifies a small set of putative co-factors that best distinguish the two sets of sequences. To achieve this task, COUGER uses a classification approach, with features that reflect the DNA-binding specificities of the putative co-factors.", "answer": "<think> Okay, I need to generate a JSON answer about what the COUGER tool is. Let me look at the evidence provided. The user provided three chunks from the same document, all referring to COUGER. The first chunk mentions that COUGER is a classification-based framework for identifying protein co-factors that provide specificity to paralogous TFs. It takes two sets of genomic regions bound by paralogous TFs and identifies co-factors that distinguish these sequences. It uses a classification approach with features reflecting DNA-binding specificities. The tool can be run as standalone or via a web interface. The second chunk is similar, just shorter. The third chunk repeats the input and output parts again. So the key points are: COUGER is a framework for identifying co", "citations": [], "candidates": [{"answer": "<think> Okay, I need to generate a JSON answer about what the COUGER tool is. Let me look at the evidence provided. The user provided three chunks from the same document, all referring to COUGER. The first chunk mentions that COUGER is a classification-based framework for identifying protein co-factors that provide specificity to paralogous TFs. It takes two sets of genomic regions bound by paralogous TFs and identifies co-factors that distinguish these sequences. It uses a classification approach with features reflecting DNA-binding specificities. The tool can be run as standalone or via a web interface. The second chunk is similar, just shorter. The third chunk repeats the input and output parts again. So the key points are: COUGER is a framework for identifying co", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer about what the COUGER tool is, based on the provided evidence. Let me start by reading through the evidence carefully. The user provided three chunks from the same document (all with doc_id 24861628). Each chunk talks about COUGER. The first two chunks mention that COUGER is an interactive web implementation of a classification-based framework for identifying protein co-factors that provide specificity to paralogous TFs. It takes two sets of genomic regions bound by paralogous TFs and identifies co-factors that distinguish these sequences. The third chunk repeats some of the same information but more concisely. So, the answer should be a concise explanation of COUGER, citing one of", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking what the COUGER tool is. I need to generate a concise answer based on the provided evidence. First, I'll look through the evidence snippets. All three references mention COUGER as a classification-based framework. The main points are that it identifies protein co-factors to distinguish paralogous TFs. The input is two sets of genomic regions bound by these TFs. It uses a classification approach with DNA-binding specificities as features. Also, there's a web implementation and a standalone option. I need to condense this into a single answer. The key elements are: it's a tool for identifying co-factors, uses classification, takes two sets of genomic regions, focuses on DNA-binding specifics, and", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer about what the COUGER tool is. Let me look at the evidence provided. First, there are three chunks from the same document ID. The first chunk mentions that COUGER is a classification-based framework for identifying protein co-factors that provide specificity to paralogous TFs. It takes two sets of genomic regions bound by paralogous TFs and finds co-factors that distinguish them. It also says it uses a classification approach with DNA-binding specificities as features and has a web interface. The second chunk is similar, just shorter. The third chunk repeats the input and output parts. All three chunks are from the same source, so I can use them to form the answer. So the answer should be concise, mentioning", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer about what the COUGER tool is, based on the provided evidence. Let me start by reading through the evidence carefully. The user provided three chunks from the same document (24861628). The first chunk mentions that COUGER is an interactive web implementation of a classification-based framework for identifying protein co-factors that provide specificity to paralogous TFs. It takes two sets of genomic regions bound by paralogous TFs and identifies co-factors that distinguish these sequences. It uses a classification approach with features reflecting DNA-binding specificities. The output is a user-friendly page with information on co-factor contributions. It can be run as a standalone tool or through a web interface. The second chunk is similar", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking what the COUGER tool is. I need to generate a concise answer based on the provided evidence. First, I'll look through the evidence snippets. All three references mention COUGER as a classification-based framework. The key points are that it identifies protein co-factors to provide specificity to paralogous TFs. It takes two sets of genomic regions bound by these TFs and finds co-factors that distinguish them. The tool uses a classification approach based on DNA-binding specificities. Also, there's mention of a web interface. I need to combine these details into a single answer. The answer should include the main purpose, input, method, and maybe the output. Citations are needed, so I'll", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking about the COUGER tool. I need to generate a concise answer based on the provided evidence. First, I'll look at the evidence snippets. All three chunks refer to COUGER as a classification-based framework for identifying protein co-factors that help distinguish paralogous TFs. The key points are: it takes two sets of genomic regions bound by paralogous TFs, uses a classification approach with DNA-binding specificity features, and outputs putative co-factors. There's also mention of a web interface. I need to make sure the answer is accurate and includes citations. The answer should be concise, so I'll combine the essential information from the chunks. The base confidence should be high since the evidence consistently", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer about what the COUGER tool is, based on the provided evidence. Let me start by reading through the evidence carefully. The user provided three chunks from the same document (24861628). All of them talk about COUGER. The first chunk mentions that COUGER is a classification-based framework for identifying protein co-factors that provide specificity to paralogous TFs. It takes two sets of genomic regions bound by paralogous TFs and identifies co-factors that distinguish these sequences. It uses a classification approach with features reflecting DNA-binding specificities. The tool has a web interface. The second chunk is similar, just shorter. The third chunk also repeats the input and output of COUGER", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["24861628"], "ideal_answer": "COUGER takes as input two sets of genomic regions bound by paralogous TFs, and it identifies a small set of putative co-factors that best distinguish the two sets of sequences. COUGER is a classification-based framework for identifying protein co-factors that might provide specificity to paralogous TFs. It takes as input two sets of genomic regions bound by paralogous TFs, and it identifies a small set of putative co-factors that best distinguish the two sets of sequences. To achieve this task, COUGER uses a classification approach, with features that reflect the DNA-binding specificities of the putative co-factors. The identified co-factors are presented in a user-friendly output page, together with information that allows the user to understand and to explore the contributions of individual co-factor features."}
{"question_id": "532083389b2d7acc7e000003", "question": "Are there drugs for Tick-borne Encephalitis?", "retrieved_chunks": [{"doc_id": "23017222", "chunk_id": "23017222_0", "score": 4.434618949890137, "text": "POWV) is a rare tick-borne agent of encephalitis in North America. Historically, confirmed cases occurred mainly in the northeastern United State"}, {"doc_id": "37517630", "chunk_id": "37517630_0", "score": 3.1705055236816406, "text": "Several arboviral vaccines have been licensed for many years and can be used to prevent infection in travelers, namely Japanese encephalitis, yellow fever, and tick-borne encephalitis vaccines. Recommendations on use of these vaccines in pregnancy vary. Other arboviral vaccines have been licensed but are not indicated for use in pregnant travelers (e.g., dengue vaccines) or are in development (e.g., chikungunya, Zika vaccines)."}, {"doc_id": "18471057", "chunk_id": "18471057_0", "score": 2.8067634105682373, "text": "Tick-borne encephalitis virus (TBEV) and Louping ill virus (LIV) are viruses in the Mammalian tick-borne virus group/genus Flavivirus, causing central nervous system disease."}], "context": "[23017222:23017222_0] POWV) is a rare tick-borne agent of encephalitis in North America. Historically, confirmed cases occurred mainly in the northeastern United State\n[37517630:37517630_0] Several arboviral vaccines have been licensed for many years and can be used to prevent infection in travelers, namely Japanese encephalitis, yellow fever, and tick-borne encephalitis vaccines. Recommendations on use of these vaccines in pregnancy vary. Other arboviral vaccines have been licensed but are not indicated for use in pregnant travelers (e.g., dengue vaccines) or are in development (e.g., chikungunya, Zika vaccines).\n[18471057:18471057_0] Tick-borne encephalitis virus (TBEV) and Louping ill virus (LIV) are viruses in the Mammalian tick-borne virus group/genus Flavivirus, causing central nervous system disease.", "answer": "<think> Okay, so the user is asking if there are drugs for Tick-borne Encephalitis. Let me look at the evidence provided. First, the evidence from [37517630:37517630_0] mentions that several arboviral vaccines have been licensed, including tick-borne encephalitis vaccines. Vaccines are used to prevent infection, not drugs. But maybe there's a mention of drugs in another part? Let me check the other documents. The first document [23017222:23017222_0] talks about POWV as a rare agent but doesn't mention treatment. The third document [18471057:", "citations": [{"doc_id": "37517630", "chunk_id": "37517630_0"}, {"doc_id": "23017222", "chunk_id": "23017222_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if there are drugs for Tick-borne Encephalitis. First, I need to look through the provided evidence to find any mention of drugs or treatments. Looking at the first evidence snippet: It talks about POWV being a rare tick-borne agent causing encephalitis in North America. But it doesn't mention any drugs or treatments. The second snippet says that several arboviral vaccines are licensed, including tick-borne encephalitis vaccines. Vaccines are preventive measures, not drugs for treatment. However, the question is about drugs, so maybe there's a confusion between vaccines and drugs here. But the evidence does mention vaccines, so perhaps the answer is that there are vaccines, but not", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there are drugs for Tick-borne Encephalitis. First, I need to look through the provided evidence to find any mentions of drugs or treatments. Looking at the first evidence snippet: It talks about POWV being a rare tick-borne agent of encephalitis but doesn't mention any drugs. The second snippet says several arboviral vaccines are licensed, including tick-borne encephalitis vaccines. Vaccines are preventive, not drugs for treatment. The third snippet mentions TBEV and LIV as viruses causing central nervous system disease but again, no drugs are discussed. Wait, the question is about drugs, not vaccines. The evidence does mention vaccines, which are different from drugs. So", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking if there are drugs for Tick-borne Encephalitis. Let me look at the evidence provided. First, the evidence has three chunks. The first one mentions POWV as a rare tick-borne agent of encephalitis in North America but doesn't talk about drugs. The second chunk says several arboviral vaccines are licensed, including tick-borne encephalitis vaccines. That suggests there are vaccines, but the question is about drugs. Wait, sometimes vaccines and medications can be confused. But the third chunk talks about TBEV and LIV being in the Flavivirus group, causing CNS disease. So the key point here is that the second evidence chunk explicitly states that tick-borne encephalitis vaccines", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there are drugs for Tick-borne Encephalitis. First, I need to look through the provided evidence to find any mentions of drugs or treatments. Looking at the first evidence snippet, it talks about POWV being a rare tick-borne agent causing encephalitis in North America. But it doesn't mention any drugs or treatments. The second snippet says several arboviral vaccines are licensed, including tick-borne encephalitis vaccines. Wait, vaccines are used to prevent infection, not treat it. So maybe the answer is about prevention through vaccines, but the question is about drugs. The third snippet discusses TBEV and LIV as flaviviruses causing CNS disease, but again,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there are drugs for Tick-borne Encephalitis. First, I need to look through the provided evidence to find any mentions of drugs or treatments. Looking at the first evidence snippet, it talks about POWV being a rare tick-borne agent causing encephalitis in North America. But it doesn't mention any drugs or treatments. The second snippet says several arboviral vaccines are licensed, including tick-borne encephalitis vaccines. Vaccines are preventive, not drugs for treatment. The third snippet mentions TBEV and LIV as viruses causing central nervous system disease but again, no drugs are discussed. Wait, the question is about drugs, not vaccines. The evidence does mention vaccines,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there are drugs for Tick-borne Encephalitis. First, I need to look through the provided evidence to find any mention of drugs or treatments. Looking at the first evidence snippet: It talks about POWV being a rare tick-borne agent causing encephalitis in North America. But it doesn't mention any drugs or vaccines. The second snippet says that several arboviral vaccines have been licensed, including tick-borne encephalitis vaccines. So this suggests that there's a vaccine available, but the question is about drugs. Wait, sometimes vaccines are considered as preventive measures rather than drugs for treatment. But maybe in this context, the term \"drugs\" could be referring to vaccines", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking if there are drugs for Tick-borne Encephalitis. Let me look at the evidence provided. First, the evidence from [37517630:37517630_0] mentions that several arboviral vaccines have been licensed, including tick-borne encephalitis vaccines. Vaccines are used to prevent infection, not drugs. But maybe there's a mention of drugs in another part? Let me check the other documents. The first document [23017222:23017222_0] talks about POWV as a rare agent but doesn't mention treatment. The third document [18471057:", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there are drugs for Tick-borne Encephalitis. I need to look at the provided evidence to find information that answers this. First, I'll go through each of the evidence chunks. The first chunk mentions POWV as a rare tick-borne agent causing encephalitis in North America. It talks about confirmed cases in the northeastern US. But there's no mention of drugs here. So maybe not directly relevant. The second chunk is more promising. It states that several arboviral vaccines have been licensed, including tick-borne encephalitis vaccines. The key word here is \"vaccines,\" not drugs. Wait, but the question is about drugs. Vaccines are preventive,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["20656033", "22535622", "22727684", "22730949", "22984545", "23096037", "23259984", "23377671", "23452322", "23638205", "23697658", "23784447", "23919605", "24001228", "24035586", "24076358", "24096319", "24159517", "24225644", "24256889"], "ideal_answer": "No drug therapy available today"}
{"question_id": "571e3d42bb137a4b0c000007", "question": "Is SLC22A3 expressed in the brain?", "retrieved_chunks": [{"doc_id": "19280114", "chunk_id": "19280114_2", "score": 8.831168174743652, "text": "Slc22a3) encodes an isoform of the organic cation transporters and is expressed widely across the whole brain."}, {"doc_id": "19280114", "chunk_id": "19280114_4", "score": 7.8712968826293945, "text": "The organic cation transporter 3 (OCT3; synonymous: extraneuronal monoamine transporter, EMT, Slc22a3) encodes an isoform of the organic cation transporters and is expressed widely across the whole brain."}, {"doc_id": "19280114", "chunk_id": "19280114_3", "score": 7.553462982177734, "text": "The organic cation transporter 3 (OCT3; synonymous: extraneuronal monoamine transporter, EMT, Slc22a3) encodes an isoform of the organic cation transporters and is expressed widely across the whole brain"}], "context": "[19280114:19280114_2] Slc22a3) encodes an isoform of the organic cation transporters and is expressed widely across the whole brain.\n[19280114:19280114_4] The organic cation transporter 3 (OCT3; synonymous: extraneuronal monoamine transporter, EMT, Slc22a3) encodes an isoform of the organic cation transporters and is expressed widely across the whole brain.\n[19280114:19280114_3] The organic cation transporter 3 (OCT3; synonymous: extraneuronal monoamine transporter, EMT, Slc22a3) encodes an isoform of the organic cation transporters and is expressed widely across the whole brain", "answer": "<think> Okay, let's tackle this question. The user is asking if SLC22A3 is expressed in the brain. The evidence provided has three chunks, all from the same document ID, which seems to be a single source. Looking at the evidence, each chunk mentions that Slc22a3 (which is the gene for OCT3) is expressed widely across the whole brain. The first chunk says \"Slc22a3) encodes... and is expressed widely across the whole brain.\" The other two chunks repeat similar information about OCT3 and EMT being expressed in the entire brain. So, all three pieces of evidence point to the same conclusion: SLC22A3 is indeed expressed in the brain. The confidence here is pretty high since there", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if SLC22A3 is expressed in the brain. The evidence provided has three chunks, all from the same document ID, which seems to be a single source. Looking at the evidence, each chunk mentions that Slc22a3 (which is the gene for OCT3) is expressed widely across the whole brain. The first chunk says \"Slc22a3) encodes... and is expressed widely across the whole brain.\" The other two chunks repeat similar information about OCT3 and EMT being expressed in the entire brain. So, all three pieces of evidence point to the same conclusion: SLC22A3 is indeed expressed in the brain. The confidence here is pretty high since there", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if SLC22A3 is expressed in the brain. The evidence provided has three chunks, all from the same document ID. Let me read through them carefully. First chunk: Slc22a3 encodes an isoform of organic cation transporters and is expressed widely across the whole brain. So that's a direct statement. Second and third chunks mention OCT3, which is synonymous with EMT and Slc22a3, and again state it's expressed widely in the whole brain. All three sources agree on the expression in the entire brain. The answer needs to be concise with citations. The document ID is 19280114, and the chunks are 2", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if SLC22A3 is expressed in the brain. The evidence provided has three chunks, all from the same document ID. Let me check each of them. First chunk: It says Slc22a3 encodes an isoform of organic cation transporters and is expressed widely across the whole brain. So that's a direct statement. Second chunk: Same thing, mentioning OCT3 and EMT, also stating it's expressed widely in the whole brain. Third chunk repeats the same information. All three chunks are pretty much duplicates, just slightly different wording. So all three pieces of evidence confirm that SLC22A3 (also known as OCT3) is indeed expressed in the brain", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if SLC22A3 is expressed in the brain. The evidence provided has three chunks, all from the same document ID. Let me check each of them. First chunk: It says Slc22a3 encodes an isoform of organic cation transporters and is expressed widely across the whole brain. So that's a direct answer. The second and third chunks are similar, mentioning OCT3 (which is the same as Slc22a3) and again stating it's expressed widely in the whole brain. All three pieces of evidence point to the same conclusion. The term \"whole brain\" clearly indicates expression in the brain. There's no conflicting information here. The confidence level should be", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if SLC22A3 is expressed in the brain. The evidence provided has three chunks, all from the same document ID. Let me check each of them. Looking at chunk 19280114_2: It says Slc22a3 encodes an isoform of organic cation transporters and is expressed widely across the whole brain. So that's a direct statement. Then chunks 19280114_4 and 19280114_3 both mention OCT3, which is synonymous with Slc22a3, and again state it's expressed widely in the whole brain. All three pieces of evidence point", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if SLC22A3 is expressed in the brain. The evidence provided has three chunks, all from the same document ID, which seems to be a single source. Looking at the evidence, each chunk mentions that Slc22a3 (also known as OCT3) is expressed widely across the whole brain. The first chunk says \"Slc22a3) encodes an isoform... and is expressed widely across the whole brain.\" The other two chunks repeat similar information, confirming the same point. So all three pieces of evidence clearly state that SLC22A3 is expressed in the brain. There's no conflicting information here. The confidence level should be high since all three sources agree", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if SLC22A3 is expressed in the brain. Looking at the evidence provided, there are three chunks. All of them mention that Slc22a3, which is the same as OCT3, is expressed widely across the whole brain. Each chunk reinforces the same point. The model needs to generate a concise answer with citations and a confidence score. First, I need to check if all the evidence points to the same conclusion. All three chunks say that SLC22A3 (OCT3) is expressed in the entire brain. So the answer should be yes. The citations would be from chunk 19280114_2, 192801", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking if SLC22A3 is expressed in the brain. Let me look at the evidence provided. The evidence has three chunks. All of them mention Slc22a3 (which is the gene for OCT3) and state that it's expressed widely across the whole brain. The first chunk says \"Slc22a3) encodes an isoform... and is expressed widely across the whole brain.\" The second and third chunks repeat the same information, mentioning OCT3 and its synonyms, and again that it's expressed widely in the brain. So all three sources confirm that SLC22A3 is indeed expressed in the brain. The answer should be a concise statement citing these documents. Since all three chunks are from the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["15028779", "18513366", "19033200", "19280114", "19702534", "20402963", "21352605"], "ideal_answer": "Yes, SLC22A3 (organic cation transporter (OCT3)) is widely expressed in various organs in humans, and involved in the disposition of many exogenous and endogenous compounds. Several lines of evidence have suggested that OCT3 expressed in the brain plays an important role in the regulation of neurotransmission."}
{"question_id": "53386282d6d3ac6a3400005a", "question": "Has the protein TIEG1 been associated with apoptosis?", "retrieved_chunks": [{"doc_id": "17308981", "chunk_id": "17308981_0", "score": 7.436781883239746, "text": "In human and murine tissues it has been shown that TIEG1 and TIEG2 induce apoptosis and inhibit cell growth"}, {"doc_id": "12065093", "chunk_id": "12065093_0", "score": 6.3900299072265625, "text": "TIEG1 (TGF-beta inducible early gene) is a recently characterized transcription factor regulated by TGF-beta that induces apoptosis when overexpressed in pancreatic adenocarcinoma cell lines"}, {"doc_id": "14743447", "chunk_id": "14743447_0", "score": 6.38329553604126, "text": "overexpression of TIEG1 in OLI-neu cells induced apoptosis"}], "context": "[17308981:17308981_0] In human and murine tissues it has been shown that TIEG1 and TIEG2 induce apoptosis and inhibit cell growth\n[12065093:12065093_0] TIEG1 (TGF-beta inducible early gene) is a recently characterized transcription factor regulated by TGF-beta that induces apoptosis when overexpressed in pancreatic adenocarcinoma cell lines\n[14743447:14743447_0] overexpression of TIEG1 in OLI-neu cells induced apoptosis", "answer": "<think> Okay, let's tackle this question. The user is asking if the protein TIEG1 has been associated with apoptosis. I need to check the provided evidence to find answers. Looking at the first evidence snippet: [17308981:17308981_0] says that both TIEG1 and TIEG2 induce apoptosis and inhibit cell growth in human and murine tissues. That's a direct mention of TIEG1 causing apoptosis. The second snippet: [12065093:12065093_0] states that TIEG1 is a transcription factor regulated by TGF-beta and induces apoptosis when overexpressed in pancreatic adenocarcinoma cell", "citations": [{"doc_id": "17308981", "chunk_id": "17308981_0"}, {"doc_id": "12065093", "chunk_id": "12065093_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if the protein TIEG1 has been associated with apoptosis. I need to check the provided evidence to find answers. Looking at the first evidence snippet: [17308981:17308981_0] says that both TIEG1 and TIEG2 induce apoptosis and inhibit cell growth in human and murine tissues. That's a direct mention of TIEG1 causing apoptosis. The second snippet: [12065093:12065093_0] states that TIEG1 is a transcription factor regulated by TGF-beta and induces apoptosis when overexpressed in pancreatic adenocarcinoma cell", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the protein TIEG1 has been associated with apoptosis. I need to look at the provided evidence to find answers. Looking at the first piece of evidence: [17308981:17308981_0] says that both TIEG1 and TIEG2 induce apoptosis and inhibit cell growth in human and murine tissues. That's a direct statement linking TIEG1 to apoptosis. The second evidence: [12065093:12065093_0] mentions that TIEG1 is a transcription factor regulated by TGF-beta and induces apoptosis when overexpressed in pancreatic adenocarcin", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the protein TIEG1 has been associated with apoptosis. I need to look at the provided evidence to find answers. First, looking at the evidence documents: Document 17308981: It mentions that both TIEG1 and TIEG2 induce apoptosis in human and murine tissues. So this directly states that TIEG1 is linked to apoptosis. Document 12065093: This says TIEG1 is a transcription factor regulated by TGF-beta and induces apoptosis when overexpressed in pancreatic adenocarcinoma cell lines. Again, this supports the association between TIEG1 and apoptosis. Document 147434", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the protein TIEG1 has been associated with apoptosis. I need to look at the evidence provided and see which sources support that. First, looking at the first piece of evidence: [17308981:17308981_0] says that both TIEG1 and TIEG2 induce apoptosis and inhibit cell growth in human and murine tissues. That's a direct mention of TIEG1 causing apoptosis. The second source [12065093:12065093_0] states that TIEG1 is a transcription factor regulated by TGF-beta and induces apoptosis when overexpressed in pancreatic", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the protein TIEG1 has been associated with apoptosis. I need to look at the provided evidence to find answers. First, I check each of the three pieces of evidence. The first evidence [17308981:17308981_0] says that both TIEG1 and TIEG2 induce apoptosis and inhibit cell growth in human and murine tissues. That directly states a link between TIEG1 and apoptosis. The second evidence [12065093:12065093_0] mentions that TIEG1 is a transcription factor regulated by TGF-beta and induces apoptosis when overexpress", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is whether TIEG1 is associated with apoptosis. Let me look at the evidence provided. First, evidence [17308981:17308981_0] says that both TIEG1 and TIEG2 induce apoptosis in human and murine tissues. That's a direct mention of apoptosis. Then, [12065093:12065093_0] states that TIEG1 is a transcription factor regulated by TGF-beta and induces apoptosis when overexpressed in pancreatic cancer cells. Another piece of evidence pointing to apoptosis. The third one, [14743", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the protein TIEG1 has been associated with apoptosis. I need to look at the provided evidence to find answers. First, looking at the evidence documents: Document 17308981: It mentions that both TIEG1 and TIEG2 induce apoptosis in human and murine tissues. So this directly states that TIEG1 is associated with apoptosis. Document 12065093: This says TIEG1 is a transcription factor regulated by TGF-beta and induces apoptosis when overexpressed in pancreatic adenocarcinoma cell lines. Again, this supports the link between TIEG1 and apoptosis. Document 147434", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the protein TIEG1 has been associated with apoptosis. The evidence provided has three references. First, I need to check each of the evidence points. The first one says that both TIEG1 and TIEG2 induce apoptosis in human and murine tissues. That directly answers the question with a yes. The second evidence mentions that TIEG1 is a transcription factor regulated by TGF-beta and induces apoptosis when overexpressed in pancreatic adenocarcinoma cell lines. Again, this supports the association. The third point states that overexpression of TIEG1 in OLI-neu cells induced apoptosis. All three pieces of evidence clearly link TIEG1 to inducing apoptosis. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["10471833", "10573529", "12065093", "12771931", "12788480", "14743447", "17308981", "17659279", "17729309", "17951258", "18798273", "18930345", "20201061", "20691807", "20945337", "21423731", "21524276", "22025675", "22349513", "22563190", "23244828", "23815903"], "ideal_answer": "Yes, TIEG1 (also known as KLF10) seems to play a role in regulating apoptosis."}
{"question_id": "5717d64f29809bbe7a000001", "question": "Which is the cellular localization of the protein Opa1?", "retrieved_chunks": [{"doc_id": "12504110", "chunk_id": "12504110_5", "score": 5.455992698669434, "text": "we identified two isoforms of OPA1 proteins in HeLa cells and examined their submitochondrial localization and complex formations."}, {"doc_id": "12504110", "chunk_id": "12504110_4", "score": 5.361574172973633, "text": "Here, we identified two isoforms of OPA1 proteins in HeLa cells and examined their submitochondrial localization and complex formations."}, {"doc_id": "12504110", "chunk_id": "12504110_3", "score": 5.138701438903809, "text": "Here, we identified two isoforms of OPA1 proteins in HeLa cells and examined their submitochondrial localization and complex formations"}], "context": "[12504110:12504110_5] we identified two isoforms of OPA1 proteins in HeLa cells and examined their submitochondrial localization and complex formations.\n[12504110:12504110_4] Here, we identified two isoforms of OPA1 proteins in HeLa cells and examined their submitochondrial localization and complex formations.\n[12504110:12504110_3] Here, we identified two isoforms of OPA1 proteins in HeLa cells and examined their submitochondrial localization and complex formations", "answer": "<think> Okay, let's tackle this question. The user is asking about the cellular localization of the protein Opa1. The evidence provided has three chunks, all from the same source, document 12504110. Each chunk mentions identifying two isoforms of OPA1 in HeLa cells and examining their submitochondrial localization and complex formations. First, I need to parse what \"submitochondrial localization\" means. The term \"submitochondrial\" suggests that the protein is localized within the mitochondria. The word \"submitochondrial\" is a bit tricky. Wait, maybe it's a typo or a specific term. Let me think. Normally, mitochondrial localization would be referred to as \"mitochondrial,\" but \"submitochondrial\" might mean inside", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the cellular localization of the protein Opa1. The evidence provided has three chunks, all from the same source, document 12504110. Each chunk mentions identifying two isoforms of OPA1 in HeLa cells and examining their submitochondrial localization and complex formations. First, I need to parse what \"submitochondrial localization\" means. The term \"submitochondrial\" suggests that the protein is localized within the mitochondria. The word \"submitochondrial\" is a bit tricky. Wait, maybe it's a typo or a specific term. Let me think. Normally, mitochondrial localization would be referred to as \"mitochondrial,\" but \"submitochondrial\" might mean inside", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the cellular localization of the protein Opa1. The evidence provided are three chunks from a source with ID 12504110. All three chunks mention that two isoforms of OPA1 were identified in HeLa cells and their submitochondrial localization was examined. First, I need to determine what \"submitochondrial localization\" means. The term \"submitochondrial\" suggests that the protein is localized within the mitochondria. The word \"submitochondrial\" is a bit confusing because usually, mitochondrial localization is referred to as being inside the mitochondrion. However, sometimes \"submitochondrial\" might refer to locations within the mitochondria but not the outer membrane, like the matrix or", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the cellular localization of the protein Opa1. The evidence provided are three chunks from a study on OPA1 isoforms in HeLa cells. First, I need to parse the evidence. All three chunks mention identifying two isoforms of OPA1 in HeLa cells and examining their submitochondrial localization. The key term here is \"submitochondrial,\" which means within the mitochondria. The question is about cellular localization, so the answer should reflect that Opa1 is localized to the mitochondria. The study's focus is on submitochondrial localization, so the answer should state that Opa1 is localized to the mitochondria. The confidence level is based on the evidence provided. Since all the chunks", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking about the cellular localization of the protein Opa1. Let me look at the evidence provided. The evidence has three chunks, all from the same document ID 12504110. Each chunk mentions identifying two isoforms of OPA1 in HeLa cells and examining their submitochondrial localization and complex formations. The key term here is \"submitochondrial localization,\" which means the location relative to the mitochondria. So, the answer should state that Opa1 is localized to the mitochondrial inner membrane, specifically the submitochondrial region. The citations are all from the same document, so I'll reference that. The confidence level is based on the evidence provided, and since the documents directly mention the localization, I can set", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the cellular localization of the protein Opa1. The evidence provided includes three chunks from a source with ID 12504110. All three chunks mention identifying two isoforms of OPA1 in HeLa cells and examining their submitochondrial localization and complex formations. First, I need to parse what \"submitochondrial localization\" means. The term \"submitochondrial\" suggests that the protein is localized within the mitochondria. The word \"submitochondrial\" is a bit tricky. Wait, maybe it's a typo or misphrasing. Typically, mitochondrial localization would be referred to as \"mitochondrial,\" but \"submitochondrial\" could mean inside the mitochondria. Alternatively,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the cellular localization of the protein Opa1. The evidence provided has three chunks from the same source, all mentioning that two isoforms of OPA1 were identified in HeLa cells and their submitochondrial localization was examined. First, I need to parse the evidence. All the chunks are references to the same study (12504110) but different chunk IDs. The key part here is \"submitochondrial localization.\" Submitochondrial means related to the mitochondria, specifically within them. So the answer should be that Opa1 is localized in the mitochondria, more precisely, within the submitochondrial region. Now, checking if there's any conflicting information. All three chunks are", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the cellular localization of the protein Opa1. The evidence provided mentions that two isoforms of OPA1 were identified in HeLa cells and their submitochondrial localization was examined. First, I need to parse the evidence. All three chunks refer to the same study (12504110) and mention that OPA1 has two isoforms in HeLa cells. The key phrase here is \"submitochondrial localization,\" which means the localization relative to the mitochondria. The question is about where Opa1 is located in the cell. Since the evidence talks about submitochondrial localization, that suggests the protein is localized within the mitochondria. But wait, submitochondrial might mean", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the cellular localization of the protein Opa1. The evidence provided mentions that two isoforms of OPA1 were found in HeLa cells, and their submitochondrial localization was examined. First, I need to parse the evidence. All the chunks reference the same study (12504110) but different chunk IDs. The key point here is \"submitochondrial localization.\" Submitochondrial means related to the mitochondria, so the protein Opa1 is localized within the mitochondria. The answer should be concise and include citations. The base confidence is a float between 0 and 1. Since the evidence directly mentions submitochondrial localization, I can be confident that's the correct", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["11017079", "11847212", "12123827", "12504110", "14970223", "16413305", "16737747", "17545159", "17709430", "18074630", "18281461", "19168126", "20045077", "20079867", "20652258", "20678484", "21397211", "21459773", "21980395", "21983901", "22406748", "22579715", "23663851", "23906536", "24282027", "24632637", "24633199", "25112877", "25298396", "25579226", "25582749", "25744979", "25847151"], "ideal_answer": "The Opa1 protein localizes to the mitochondria. Opa1 is found normally in the mitochondrial intermembrane space."}
{"question_id": "531d7430267d7dd053000008", "question": "Which are the drugs utilized for the burning mouth syndrome?", "retrieved_chunks": [{"doc_id": "20415926", "chunk_id": "20415926_0", "score": 1.8541138172149658, "text": "Burning mouth syndrome (BMS) is characterized by burning pain in the tongue or other oral mucous membrane often associated with symptoms such as subjective dryness of the mouth, paraesthesia and altered taste for which no medical or dental cause can be found."}, {"doc_id": "18625105", "chunk_id": "18625105_0", "score": 1.8320467472076416, "text": "Burning mouth syndrome (BMS) is a chronic disease characterized by burning of the oral mucosa associated with a sensation of dry mouth and/or taste alterations."}, {"doc_id": "15773524", "chunk_id": "15773524_1", "score": 1.6587865352630615, "text": "Burning mouth syndrome (BMS) is a predominantly oral condition characterized by the occurrence of a chronic burning that commonly involves the anterior tongue, painful sensation, dryness and taste alterations."}], "context": "[20415926:20415926_0] Burning mouth syndrome (BMS) is characterized by burning pain in the tongue or other oral mucous membrane often associated with symptoms such as subjective dryness of the mouth, paraesthesia and altered taste for which no medical or dental cause can be found.\n[18625105:18625105_0] Burning mouth syndrome (BMS) is a chronic disease characterized by burning of the oral mucosa associated with a sensation of dry mouth and/or taste alterations.\n[15773524:15773524_1] Burning mouth syndrome (BMS) is a predominantly oral condition characterized by the occurrence of a chronic burning that commonly involves the anterior tongue, painful sensation, dryness and taste alterations.", "answer": "<think> Okay, let's tackle this question. The user wants to know which drugs are used for burning mouth syndrome. The evidence provided doesn't mention any specific drugs. All the chunks describe the symptoms and characteristics of BMS but don't talk about treatments or medications. So, I need to check if there's any mention of药物 in the evidence. Looking at the three documents: First one says BMS is characterized by burning pain with dryness, paraesthesia, and altered taste, but no medical or dental cause. No drugs mentioned. Second chunk repeats similar info about chronic disease with burning, dry mouth, taste changes. Still no treatment info. Third chunk again describes the symptoms, including chronic burning, anterior tongue, painful sensation, dryness, taste alterations. Again, no drugs", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants to know which drugs are used for burning mouth syndrome. The evidence provided doesn't mention any specific drugs. All the chunks describe the symptoms and characteristics of BMS but don't talk about treatments or medications. So, I need to check if there's any mention of药物 in the evidence. Looking at the three documents: First one says BMS is characterized by burning pain with dryness, paraesthesia, and altered taste, but no medical or dental cause. No drugs mentioned. Second chunk repeats similar info about chronic disease with burning, dry mouth, taste changes. Still no treatment info. Third chunk again describes the symptoms, including chronic burning, anterior tongue, painful sensation, dryness, taste alterations. Again, no drugs", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which drugs are used for burning mouth syndrome. The evidence provided doesn't mention any specific medications. All the chunks describe the symptoms and characteristics of BMS but don't list treatments or drugs. Hmm, so the answer has to be based strictly on the given evidence. Since there's no information about drugs in the sources, I can't provide a factual answer. The model's confidence should reflect that the evidence doesn't support any drug recommendations. Maybe set the confidence to 0 because the answer isn't present in the provided documents. But wait, sometimes there might be other sources outside the given evidence. However, the instructions say to use only the evidence provided. So the answer would be that there's no information on drugs in", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which drugs are used for burning mouth syndrome. Looking at the evidence provided, all three documents describe BMS symptoms but don't mention any specific medications. The first two documents talk about symptoms like burning pain, dryness, and taste changes. The third one adds that it's a chronic condition with burning, pain, dryness, and taste alterations. However, none of the chunks cite any drugs or treatments. Since the evidence doesn't include information about药物, I can't provide a specific answer. The base confidence would be low because there's no factual data in the given evidence to support any drug names. So the answer should state that there's no mention of drugs in the provided evidence. </think> { \"answer", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which drugs are used for burning mouth syndrome. First, I need to look at the provided evidence to see if any of the documents mention specific medications. Looking at the three evidence snippets: The first one mentions symptoms like burning pain, dryness, paraesthesia, and altered taste, but doesn't list any drugs. The second document also describes symptoms but again, no medications are mentioned. The third snippet does the same—describing the condition's features without naming any treatments. Since none of the evidence provided actually lists any drugs used for BMS, I can't find a direct answer here. The user might be expecting common treatments, like antiseptics or antidepressants, but according to the given data, there", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to figure out which drugs are used for burning mouth syndrome based on the given evidence. Let me look at the evidence provided. The first document (20415926:20415926_0) talks about BMS being characterized by burning pain and symptoms like dryness, paraesthesia, and altered taste. But it doesn't mention any drugs. The second document (18625105:18625105_0) also describes BMS as a chronic disease with burning oral mucosa, dry mouth, and taste changes, but again, no medications are listed. The third document (15773524:15773524", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's see. The user is asking which drugs are used for burning mouth syndrome. The evidence provided doesn't mention any specific drugs. All the chunks describe the symptoms and characteristics of BMS but don't talk about treatments or medications. So, I need to check if there's any information in the evidence that could lead to an answer. Looking at the three documents again: they all discuss the symptoms like burning pain, dry mouth, taste changes, but none mention drugs. The first one says \"no medical or dental cause can be found,\" which might imply that it's idiopathic, so treatment might be symptomatic. But the evidence doesn't list any specific medications. Since there's no information about drugs in the provided evidence, I can't give a factual answer", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which drugs are used for burning mouth syndrome. The evidence provided doesn't mention any specific drugs. All the chunks describe the symptoms and characteristics of BMS but don't talk about treatments or medications. So, I need to check if there's any information in the evidence that could lead me to an answer. Looking at each chunk again: the first one says BMS is characterized by burning pain with dryness, paraesthesia, and altered taste, but no medical or dental cause. The second mentions a chronic disease with burning, dry mouth, and taste changes. The third talks about chronic burning, painful sensation, dryness, and taste alterations. None of these mention drugs or treatments. Since the evidence doesn't provide any", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which drugs are used for burning mouth syndrome. The evidence provided doesn't mention any specific药物, right? Let me check the evidence again. The first document says BMS is characterized by burning pain with symptoms like dryness, paraesthesia, and altered taste, but no medical or dental cause found. The second one mentions it's a chronic disease with burning oral mucosa, dry mouth, and taste changes. The third one adds that it's a chronic burning involving the anterior tongue, painful sensation, dryness, and taste alterations. Wait, none of these documents list any drugs. They all describe symptoms and characteristics but don't mention treatments or medications. So the answer would be that there's no information in the provided", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["10425973", "10431669", "10625850", "11441716", "11485137", "11838624", "11871678", "12110042", "12536654", "14650993", "14704612", "14765022", "1508523", "15195716", "15210564", "16637799", "16903201", "17287703", "17541900", "17559486", "1776404", "17849966", "18343329", "18548844", "18558051", "18588600", "18625105", "18976257", "1923398", "19450321", "19658340", "19689438", "19837207", "20415927", "20597947", "20690412", "20969436", "2098940", "21223496", "21528119", "21743413", "21743415", "22040716", "22044166", "22092585", "22260804", "22344742", "22612823", "22669143", "22750263", "22819057", "22957483", "23201368", "23229252", "23429751", "23772971", "24164777", "24558551", "2726203", "2811814", "7629360", "8323246", "8543701", "8725589", "9830647", "9844361"], "ideal_answer": "Dopaminergic drugs should be given in patients with BMS. Catuama reduces the symptoms of BMS and may be a novel therapeutic strategy for the treatment of this disease. Capsaicin, alpha-lipoic acid (ALA), and clonazepam were those that showed more reduction in symptoms of BMS. Treatment with placebos produced a response that was 72% as large as the response to active drugs"}
{"question_id": "55031650e9bde69634000026", "question": "Is PTEN involved in follicular thyroid carcinoma?", "retrieved_chunks": [{"doc_id": "12203792", "chunk_id": "12203792_1", "score": 9.70567512512207, "text": "The transcriptional silencing of PTEN was significantly associated with the anaplastic subtype, suggesting that PTEN is involved in the carcinogenesis of highly malignant or late-stage thyroid cancers, whereas this particular mechanism appears to be of minor importance in differentiated follicular thyroid tumors."}, {"doc_id": "12203792", "chunk_id": "12203792_0", "score": 9.505852699279785, "text": "The transcriptional silencing of PTEN was significantly associated with the anaplastic subtype, suggesting that PTEN is involved in the carcinogenesis of highly malignant or late-stage thyroid cancers, whereas this particular mechanism appears to be of minor importance in differentiated follicular thyroid tumors"}, {"doc_id": "21417916", "chunk_id": "21417916_1", "score": 7.3812456130981445, "text": "Two of the 259 patients (0.8%), with both follicular thyroid carcinoma and macrocephaly, were found to carry a germline mutation in the PTEN gene. The PTEN mutation frequency in unselected cases of follicular thyroid carcinoma was 4.8%"}], "context": "[12203792:12203792_1] The transcriptional silencing of PTEN was significantly associated with the anaplastic subtype, suggesting that PTEN is involved in the carcinogenesis of highly malignant or late-stage thyroid cancers, whereas this particular mechanism appears to be of minor importance in differentiated follicular thyroid tumors.\n[12203792:12203792_0] The transcriptional silencing of PTEN was significantly associated with the anaplastic subtype, suggesting that PTEN is involved in the carcinogenesis of highly malignant or late-stage thyroid cancers, whereas this particular mechanism appears to be of minor importance in differentiated follicular thyroid tumors\n[21417916:21417916_1] Two of the 259 patients (0.8%), with both follicular thyroid carcinoma and macrocephaly, were found to carry a germline mutation in the PTEN gene. The PTEN mutation frequency in unselected cases of follicular thyroid carcinoma was 4.8%", "answer": "<think> Okay, let's tackle this question. The user is asking if PTEN is involved in follicular thyroid carcinoma. I need to look at the evidence provided. First, evidence document [12203792:12203792_1] and [12203792:12203792_0] both mention that PTEN silencing is linked to the anaplastic subtype of thyroid cancers, which are more malignant. However, it says this mechanism is of minor importance in differentiated follicular thyroid tumors. So, these two documents indicate that PTEN's role is more significant in anaplastic (which is a different subtype) rather than follicular. Then there's document [21", "citations": [{"doc_id": "12203792", "chunk_id": "12203792_1"}, {"doc_id": "12203792", "chunk_id": "12203792_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if PTEN is involved in follicular thyroid carcinoma. I need to look at the evidence provided. First, evidence document [12203792:12203792_1] and [12203792:12203792_0] both mention that PTEN silencing is linked to the anaplastic subtype of thyroid cancers, which are more malignant. However, it says this mechanism is of minor importance in differentiated follicular thyroid tumors. So, these two documents indicate that PTEN's role is more significant in anaplastic (which is a different subtype) rather than follicular. Then there's document [21", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let me tackle this question. The user is asking if PTEN is involved in follicular thyroid carcinoma. I need to look at the evidence provided. First, evidence [12203792:12203792_1] and [12203792:12203792_0] both mention that PTEN silencing is linked to the anaplastic subtype of thyroid cancers, which are more aggressive. However, it says this mechanism is of minor importance in differentiated follicular thyroid tumors. So, PTEN's role here seems limited to more malignant types, not the follicular ones. Then there's [21417916:21417", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if PTEN is involved in follicular thyroid carcinoma. I need to look at the evidence provided. First, evidence from [12203792:12203792_1] and [12203792:12203792_0] both mention that PTEN silencing is linked to anaplastic thyroid cancers, which are more aggressive. However, it says this mechanism is of minor importance in differentiated follicular thyroid tumors. So, the evidence here suggests that PTEN isn't a major player in follicular thyroid carcinoma. Then there's [21417916:2141791", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if PTEN is involved in follicular thyroid carcinoma. I need to look at the evidence provided. First, the evidence has three chunks. Let me read through them. Chunk 1 and 2 are similar, both saying that PTEN silencing is linked to anaplastic subtypes of thyroid cancers, which are malignant or late-stage. But it mentions that this mechanism is of minor importance in differentiated follicular thyroid tumors. So here, PTEN's role is more in the anaplastic type, not the follicular. Chunk 3 says that 0.8% of patients with both follicular thyroid carcinoma and macrocephaly had a PTEN germline mutation, and the overall frequency was", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if PTEN is involved in follicular thyroid carcinoma. I need to look at the provided evidence to find answers. First, looking at the evidence from [12203792:12203792_0] and [12203792:12203792_1], both mention that PTEN silencing is associated with anaplastic thyroid cancers, which are more aggressive. However, it says this mechanism is of minor importance in differentiated follicular thyroid tumors. So, the first part suggests PTEN isn't majorly involved in the follicular type. Then there's [21417916:21", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if PTEN is involved in follicular thyroid carcinoma. I need to look at the evidence provided. First, evidence from [12203792:12203792_1] and [12203792:12203792_0] both mention that PTEN silencing is linked to anaplastic thyroid cancers, which are aggressive and late-stage. However, it says this mechanism is of minor importance in differentiated follicular thyroid tumors. So, the evidence here suggests that PTEN isn't a major player in follicular thyroid carcinoma. Then there's [21417916:21417", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if PTEN is involved in follicular thyroid carcinoma. I need to look at the evidence provided. First, evidence document [12203792:12203792_1] says that PTEN silencing is associated with anaplastic subtype, which is a more aggressive form. It mentions that this mechanism is of minor importance in differentiated follicular thyroid tumors. So, this suggests that PTEN's role is less significant here. Then there's another chunk from the same document, repeating the same point. That reinforces the idea that PTEN isn't majorly involved in the follicular type. The third piece of evidence [21417916:2", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if PTEN is involved in follicular thyroid carcinoma. I need to look at the evidence provided. First, evidence from [12203792:12203792_1] and [12203792:12203792_0] both mention that PTEN silencing is linked to anaplastic thyroid cancer, which is more aggressive. However, it says this mechanism is of minor importance in differentiated follicular thyroid tumors. So, the evidence here suggests that PTEN isn't a major factor in follicular carcinoma. Then there's [21417916:21417916", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["11297621", "12203792", "16487009", "18055323", "21417916", "9790504", "9832031"], "ideal_answer": "The PTEN mutation frequency in unselected cases of follicular thyroid carcinoma was 4.8%."}
{"question_id": "56c8f4615795f9a73e00001a", "question": "Which genome browser database for DNA shape annotations is available?", "retrieved_chunks": [{"doc_id": "25326329", "chunk_id": "25326329_4", "score": 9.115104675292969, "text": "GBshape: a genome browser database for DNA shape annotations."}, {"doc_id": "25326329", "chunk_id": "25326329_3", "score": 8.954812049865723, "text": "GBshape: a genome browser database for DNA shape annotations"}, {"doc_id": "25326329", "chunk_id": "25326329_6", "score": 8.713098526000977, "text": "Our Genome Browser for DNA shape annotations (GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/) provides minor groove width, propeller twist, roll, helix twist and hydroxyl radical cleavage predictions for the entire genomes of 94 organisms. Additional genomes can easily be added using the GBshape framework."}], "context": "[25326329:25326329_4] GBshape: a genome browser database for DNA shape annotations.\n[25326329:25326329_3] GBshape: a genome browser database for DNA shape annotations\n[25326329:25326329_6] Our Genome Browser for DNA shape annotations (GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/) provides minor groove width, propeller twist, roll, helix twist and hydroxyl radical cleavage predictions for the entire genomes of 94 organisms. Additional genomes can easily be added using the GBshape framework.", "answer": "<think> Okay, let's tackle this query. The user is asking which genome browser database for DNA shape annotations is available. The evidence provided has three chunks from the same document, all mentioning \"GBshape\". First, I need to extract the relevant information. All three chunks state that GBshape is a genome browser database for DNA shape annotations. The first two are direct statements, and the third provides more details like features and availability. The answer should be concise, citing the document ID and chunk ID. Since all chunks are from the same document, I can use [25326329:25326329_4] as the citation. The confidence level is high because the information is repeated in multiple chunks and provides specific details about GBshape", "citations": [{"doc_id": "25326329", "chunk_id": "25326329_4"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which genome browser database for DNA shape annotations is available. The evidence provided has three chunks from the same document, all mentioning \"GBshape\". First, I need to check if all the evidence points to the same answer. The first two chunks directly state that GBshape is a genome browser database for DNA shape annotations. The third chunk provides more details about GBshape, including its availability and some features. The question is straightforward, so the answer should be \"GBshape\" with citations. The confidence level should be high since all three pieces of evidence consistently mention GBshape as the correct answer. There's no conflicting information here. I need to make sure the JSON structure is correct. The answer key should have the answer", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which genome browser database for DNA shape annotations is available. The evidence provided has three chunks from the same source, all mentioning \"GBshape\". First, I need to check if all the evidence points to the same answer. The first two chunks directly state that GBshape is a genome browser database for DNA shape annotations. The third chunk adds more details about its features and availability. So, the answer should be GBshape. The citations are all from the same document, so the confidence can be high. Since there's no conflicting information, the base_confidence should be 1.0. I need to make sure the answer is concise and includes the correct citation. The JSON structure requires the answer with a citation in [", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which genome browser database for DNA shape annotations is available. The evidence provided has three entries, all pointing to GBshape. First, I need to check if all the evidence chunks are consistent. The first two chunks (25326329:25326329_4 and 25326329:25326329_3) both mention GBshape as the genome browser database for DNA shape annotations. The third chunk (25326329:25326329_6) provides more details about GBshape, including its availability and some features. So, all three pieces of evidence agree", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking which genome browser database for DNA shape annotations is available. The evidence provided has three entries, all pointing to GBshape. First, I need to check if all the evidence chunks are consistent. The first two chunks are duplicates, both stating that GBshape is a genome browser database for DNA shape annotations. The third chunk adds more details, like the website and the organisms it covers. The question is straightforward: identify the database. All the evidence points to GBshape. The confidence here is high because there's consistent information across all chunks. The third chunk also mentions it's freely available, which reinforces that it's a valid answer. I should make sure there are no conflicting pieces of evidence. Since all three references agree", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking which genome browser database for DNA shape annotations is available. The evidence provided has three chunks from the same document, all mentioning \"GBshape\". First, I need to extract the relevant information. All three chunks state that GBshape is a genome browser database for DNA shape annotations. The first two are direct statements, and the third provides more details like features and availability. The answer should be concise, citing the document ID and chunk ID. Since all chunks are from the same document, I can use [25326329:25326329_4] as the citation. The confidence level is high because the information is repeated in multiple chunks and provides specific details about GBshape", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which genome browser database for DNA shape annotations is available. The evidence provided has three chunks from the same document, all mentioning \"GBshape.\" First, I need to check if all the evidence points to the same answer. The first two chunks directly state that GBshape is a genome browser database for DNA shape annotations. The third chunk adds more details about what GBshape offers, like predictions for various DNA features and availability. So, the answer should be GBshape. The citations are all from the same document, so the confidence can be high. Since there's no conflicting information, the base_confidence should be 1.0. I need to make sure the JSON structure is correct with the answer and the confidence.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which genome browser database for DNA shape annotations is available. The evidence provided has three chunks from the same document, all mentioning \"GBshape\". First, I need to check if all the evidence points to the same answer. The first two chunks directly state that GBshape is a genome browser database for DNA shape annotations. The third chunk adds more details about its features and availability. The answer should be concise, citing the document ID and chunk ID. Since all relevant information is in the same document, I can use [25326329:25326329_4] as the citation. The confidence level should be high because all three chunks support the same answer. So the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this query. The user is asking which genome browser database for DNA shape annotations is available. The evidence provided has three chunks from the same document, all mentioning GBshape. First, I need to extract the relevant information. All the chunks point to GBshape as the database. The first two chunks directly state that GBshape is a genome browser for DNA shape annotations. The third chunk adds more details about its features and availability. The answer should be concise, citing the document. Since all the evidence points to GBshape, I can confidently say that's the correct answer. The confidence level is high because there's consistent information across multiple chunks. I'll check if there are any other possible answers, but the evidence doesn't mention anything else. So, the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["25326329"], "ideal_answer": "The Genome Browser for DNA shape annotations (GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/) provides minor groove width, propeller twist, roll, helix twist and hydroxyl radical cleavage predictions for the entire genomes of 94 organisms. Additional genomes can easily be added using the GBshape framework. GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution."}
{"question_id": "54fc97b86ad7dcbc12000002", "question": "What is known about clinical efficacy of ceftriaxone for treatment of amyotrophic lateral sclerosis?", "retrieved_chunks": [{"doc_id": "19008722", "chunk_id": "19008722_0", "score": 6.620931148529053, "text": "OBJECTIVE: Ceftriaxone has been reported to reduce neuronal damage in amyotrophic lateral sclerosis and in an in-vitro model of neuronal ischaemia through increased expression and activity of the glutamate transporter, GLT1."}, {"doc_id": "22680643", "chunk_id": "22680643_0", "score": 6.612826347351074, "text": "Importantly, ceftriaxone is currently in clinical trials for the treatment of amyotrophic lateral sclerosis."}, {"doc_id": "24771634", "chunk_id": "24771634_0", "score": 6.298827171325684, "text": "The cephalosporin antibiotic ceftriaxone was evaluated as a potential therapeutic agent for the treatment of amyotrophic lateral sclerosis (ALS)."}], "context": "[19008722:19008722_0] OBJECTIVE: Ceftriaxone has been reported to reduce neuronal damage in amyotrophic lateral sclerosis and in an in-vitro model of neuronal ischaemia through increased expression and activity of the glutamate transporter, GLT1.\n[22680643:22680643_0] Importantly, ceftriaxone is currently in clinical trials for the treatment of amyotrophic lateral sclerosis.\n[24771634:24771634_0] The cephalosporin antibiotic ceftriaxone was evaluated as a potential therapeutic agent for the treatment of amyotrophic lateral sclerosis (ALS).", "answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. Let me start by understanding the question: What is known about the clinical efficacy of ceftriaxone for treating ALS? Looking at the evidence provided: First document [19008722:19008722_0] says that ceftriaxone reduces neuronal damage in ALS and an in-vitro model of neuronal ischaemia by increasing GLT1 expression and activity. This seems like a mechanism of action, but it's from an in-vitro study. So maybe this indicates some efficacy in animal models or cell cultures, but not clinical trials yet. Second document [22680643:226", "citations": [{"doc_id": "19008722", "chunk_id": "19008722_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this query. The user is asking about the clinical efficacy of ceftriaxone for treating ALS. I need to look at the provided evidence to form an answer. First, evidence document 19008722:19008722_0 mentions that ceftriaxone reduces neuronal damage in ALS and an in-vitro model of neuronal ischaemia by increasing GLT1 transporter activity. That's a study showing potential mechanisms, but it's in vitro. Then document 22680643:22680643_0 states that ceftriaxone is currently in clinical trials for ALS. So there's ongoing research, but", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the provided evidence. Let me start by understanding the question: What is known about the clinical efficacy of ceftriaxone for treating ALS? Looking at the evidence: 1. The first document says that ceftriaxone reduces neuronal damage in ALS and an in-vitro model of neuronal ischemia by increasing GLT1 expression and activity. This seems like a mechanism of action, but does it relate to clinical efficacy? It's from a study, so maybe there's some evidence, but it's in vitro. 2. The second document mentions that ceftriaxone is currently in clinical trials for ALS. So, there's ongoing research, but no results yet. That suggests that while it", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. Let me start by understanding the question: What is known about the clinical efficacy of ceftriaxone for treating ALS? Looking at the evidence provided: First document [19008722:19008722_0] says that ceftriaxone reduces neuronal damage in ALS and an in-vitro model of neuronal ischaemia by increasing GLT1 expression and activity. This seems like a mechanism of action, but it's from an in-vitro study. So maybe this indicates some efficacy in animal models or cell cultures, but not clinical trials yet. Second document [22680643:226", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this query. The user is asking about the clinical efficacy of ceftriaxone for treating ALS. First, I need to look at the provided evidence. The first document says that ceftriaxone reduces neuronal damage in ALS and an in-vitro model of neuronal ischemia by increasing GLT1 expression and activity. That's a mechanism of action, but does it translate to clinical efficacy? The second document mentions that ceftriaxone is in clinical trials for ALS. So there's some evidence from animal models and ongoing human trials. However, the third document just states that it was evaluated as a potential therapeutic agent, which doesn't specify if it's effective yet. The user wants a concise answer with citations and a", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking about the clinical efficacy of ceftriaxone in treating ALS. I need to look at the provided evidence and extract relevant information. First, evidence document 19008722:19008722_0 mentions that ceftriaxone reduces neuronal damage in ALS and an in-vitro model of neuronal ischaemia by increasing GLT1 expression and activity. That's a study showing some efficacy in a lab setting, but it's in vitro. So maybe that's a basis for potential clinical use. Then document 22680643:22680643_0 states that ceftriaxone", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about the clinical efficacy of ceftriaxone for treating ALS. First, I need to look at the evidence provided. The user gave three documents. The first one says that ceftriaxone reduces neuronal damage in ALS and an in-vitro model of neuronal ischaemia by increasing GLT1 expression and activity. That's a study showing some mechanism of action, but it's in vitro. The second document mentions that ceftriaxone is currently in clinical trials for ALS. So there's ongoing research but no conclusive results yet. The third document states that ceftriaxone was evaluated as a potential therapeutic agent for ALS, which is similar to the first point. The question is about clinical efficacy", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking about the clinical efficacy of ceftriaxone in treating ALS. First, I need to look at the evidence provided. The first document says that ceftriaxone reduces neuronal damage in ALS and an in-vitro model of neuronal ischemia by increasing GLT1 transporter activity. That's a study showing some effectiveness in a lab setting. But the user is asking about clinical efficacy, so maybe this is preclinical evidence. The second document mentions that ceftriaxone is currently in clinical trials for ALS. So there's ongoing research, but no results yet. Clinical trials are needed to determine actual efficacy in humans. The third document states that ceftriaxone was evaluated as", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the clinical efficacy of ceftriaxone for treating ALS. I need to look at the provided evidence to form an answer. First, evidence document 19008722:19008722_0 mentions that ceftriaxone reduces neuronal damage in ALS and an in-vitro model of neuronal ischemia by increasing GLT1 expression and activity. That's a study showing some efficacy in a lab setting, but it's not clinical yet. Then document 22680643:22680643_0 states that ceftriaxone is currently in clinical trials for ALS. So there's", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["15635412", "15907788", "16723044", "16832072", "17212618", "18326497", "19008722", "19694903", "19697382", "20638444", "21970974", "22680643", "23613806", "24771634", "25297012", "8161465"], "ideal_answer": "There have been a few case reports to suggest that ceftriaxone can be effective for treatment of amyotrophic lateral sclerosis. However, other case reports did not report clinical benefit of ceftriaxone therapy for ALS. Ceftriaxone has been reported to reduce neuronal damage in amyotrophic lateral sclerosis a through increased expression and activity of the glutamate transporter, GLT1. Clinical trials investigating potential clinical benefits of ceftriaxone in ALS are ongoing."}
{"question_id": "56ccae765795f9a73e000035", "question": "What is the relationship between TailorX and Oncotype?", "retrieved_chunks": [{"doc_id": "23411384", "chunk_id": "23411384_3", "score": 4.149637222290039, "text": "The TAILORx trial uses the Oncotype DX recurrence score to assign estrogen receptor-positive (ER+), node-negative patients to chemotherapy plus hormonal therapy versus hormonal therapy alone."}, {"doc_id": "23643806", "chunk_id": "23643806_0", "score": 3.821352958679199, "text": "Each patient is stratified into a risk category based on a recurrence score (RS) and the TAILORx trial is determining the benefit of chemotherapy for patients with mid-range RSs. We tested if Oncotype DX and TAILORx risk categories could be predicted by standard pathological features and protein markers corresponding to 10 genes in the assay (ER, PR, Ki67, HER2, BCL2, CD68, Aurora A kinase, survivin, cyclin B1 and BAG1) on 52 patients who enrolled on TAILORx."}, {"doc_id": "23411384", "chunk_id": "23411384_2", "score": 3.7790775299072266, "text": "The TAILORx trial uses the Oncotype DX recurrence score to assign estrogen receptor-positive (ER+), node-negative patients to chemotherapy plus hormonal therapy versus hormonal therapy alone"}], "context": "[23411384:23411384_3] The TAILORx trial uses the Oncotype DX recurrence score to assign estrogen receptor-positive (ER+), node-negative patients to chemotherapy plus hormonal therapy versus hormonal therapy alone.\n[23643806:23643806_0] Each patient is stratified into a risk category based on a recurrence score (RS) and the TAILORx trial is determining the benefit of chemotherapy for patients with mid-range RSs. We tested if Oncotype DX and TAILORx risk categories could be predicted by standard pathological features and protein markers corresponding to 10 genes in the assay (ER, PR, Ki67, HER2, BCL2, CD68, Aurora A kinase, survivin, cyclin B1 and BAG1) on 52 patients who enrolled on TAILORx.\n[23411384:23411384_2] The TAILORx trial uses the Oncotype DX recurrence score to assign estrogen receptor-positive (ER+), node-negative patients to chemotherapy plus hormonal therapy versus hormonal therapy alone", "answer": "<think> Okay, so I need to figure out the relationship between TailorX and Oncotype based on the given evidence. Let me start by reading through the provided evidence carefully. First, document [23411384:23411384_3] says that the TAILORx trial uses the Oncotype DX recurrence score to assign ER+ node-negative patients to either chemotherapy plus hormonal therapy or just hormonal therapy. That seems like a direct link between TailorX and Oncotype DX. Then, document [23643806:2364380质6_0] mentions that patients are stratified into risk categories based on the recurrence score (RS) from Oncotype DX, and the TAIL", "citations": [{"doc_id": "23411384", "chunk_id": "23411384_3"}, {"doc_id": "23643806", "chunk_id": "2364380质6_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question about TailorX and Oncotype. First, I need to understand what the user is asking. They want to know the relationship between TailorX and Oncotype. Looking at the evidence provided, there are three chunks. The first and third chunks both mention that the TAILORx trial uses the Oncotype DX recurrence score to assign patients to different treatment groups. So that's a direct link. The second chunk talks about using the recurrence score and the TAILORx risk categories, and how they might be predicted by some markers. But the main point here is that Oncotype DX is used in the TAILORx trial. So the answer should state that TailorX uses Oncotype DX's recurrence score to determine treatment assignments.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The question is about the relationship between TailorX and Oncotype. Looking at the evidence, there are three chunks. The first and third chunks both mention that the TAILORx trial uses the Oncotype DX recurrence score to assign patients to different treatment groups. So that's a direct link. The second chunk talks about how the TAILORx trial determines the benefit of chemotherapy using the recurrence score, which is from Oncotype DX. Also, they tested if the risk categories from Oncotype DX and TAILORx could be predicted by other markers. So the answer should state that TailorX uses Oncotype DX's recurrence score to determine chemotherapy assignment. The citation would be from chunk 2", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to figure out the relationship between TailorX and Oncotype based on the given evidence. Let me look at the evidence provided. First, there are three documents. The first one says that the TAILORx trial uses the Oncotype DX recurrence score to assign patients to different treatment groups. So that's a direct link. The second document mentions that the TAILORx trial is determining the benefit of chemotherapy by looking at the recurrence score and that they tested if Oncotype DX and TAILORx risk categories could be predicted by certain markers. The third document repeats the first point, confirming that Oncotype DX is used in TAILORx. So putting this together, the main relationship is that the TAILORx trial uses the Oncotype DX", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the relationship between TailorX and Oncotype. From the evidence provided, I need to find how they're connected. Looking at the evidence, there are three chunks. The first one says that the TAILORx trial uses the Oncotype DX recurrence score to assign patients to different treatment groups. The second chunk mentions that the TAILORx trial is using the Oncotype DX recurrence score to determine chemotherapy benefits based on risk categories. The third chunk repeats the first point, reinforcing that Oncotype DX is used in TailorX. So the main relationship is that TailorX uses Oncotype DX's recurrence score to decide treatment options. The citations are from the same document IDs, so I should reference them.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so I need to figure out the relationship between TailorX and Oncotype based on the given evidence. Let me start by reading through the provided evidence carefully. First, document [23411384:23411384_3] says that the TAILORx trial uses the Oncotype DX recurrence score to assign ER+ node-negative patients to either chemotherapy plus hormonal therapy or just hormonal therapy. That seems like a direct link between TailorX and Oncotype DX. Then, document [23643806:2364380质6_0] mentions that patients are stratified into risk categories based on the recurrence score (RS) from Oncotype DX, and the TAIL", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the relationship between TailorX and Oncotype. From the evidence provided, I need to find how they are connected. Looking at the first evidence snippet [23411384:23411384_3], it says that the TAILORx trial uses the Oncotype DX recurrence score to assign patients to different treatment groups. So that's a direct link. The same source is mentioned again in [23411384:23411384_2], reinforcing that the Oncotype DX score is used in TAILORx. Another snippet [23643806:2364380", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the relationship between TailorX and Oncotype. From the evidence provided, I need to find how they're connected. Looking at the first evidence snippet [23411384:23411384_3], it says that the TAILORx trial uses the Oncotype DX recurrence score to assign patients to different treatment groups. So that's a direct link. The same source is mentioned again in [23411384:23411384_2], reinforcing that the Oncotype DX score is used in TAILORx. Another snippet [23643806:2364380", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to figure out the relationship between TailorX and Oncotype based on the given evidence. Let me look at the evidence provided. First, document [23411384:23411384_3] says that the TAILORx trial uses the Oncotype DX recurrence score to assign patients to different treatment groups. So there's a direct use of Oncotype DX in the TAILORx trial. Then, document [23643806:2364380So_0] mentions that the TAILORx trial is determining the benefit of chemotherapy by looking at the recurrence score (RS) and the Oncotype DX and TAILORx risk categories. They also", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["18922117", "20665886", "23411384", "23643806", "25240289"], "ideal_answer": "The TAILORx trial uses the Oncotype DX recurrence score to assign estrogen receptor-positive (ER+), node-negative patients to chemotherapy plus hormonal therapy versus hormonal therapy alone."}
{"question_id": "51598b08d24251bc0500009f", "question": "Does strenuous physical activity affect thyroid hormone metabolism?", "retrieved_chunks": [{"doc_id": "16175495", "chunk_id": "16175495_0", "score": 8.087591171264648, "text": "There are controversial results concerning thyroid hormone metabolism during strenuous exercise in adult athletes and only scant data concerning the impact of strenuous exercise on thyroid hormone metabolism in children and adolescents."}, {"doc_id": "7198038", "chunk_id": "7198038_0", "score": 4.207489490509033, "text": "brief strenuous swimming or moderate bicycle exercise had minor or no effect on thyroid hormone concentrations when consideration was given to the attendant hemoconcentration."}, {"doc_id": "2807143", "chunk_id": "2807143_0", "score": 2.991506814956665, "text": "Reductions in plasma T4, T3 and T3/T4 ratio are probably due to inhibition of T4 secretion and 5'-monodeiodination with possible conversion of T4 to reverse T3 (rT3). These processes may represent a mechanism for regulation of thyroid hormone metabolism during strenuous and extended flight."}], "context": "[16175495:16175495_0] There are controversial results concerning thyroid hormone metabolism during strenuous exercise in adult athletes and only scant data concerning the impact of strenuous exercise on thyroid hormone metabolism in children and adolescents.\n[7198038:7198038_0] brief strenuous swimming or moderate bicycle exercise had minor or no effect on thyroid hormone concentrations when consideration was given to the attendant hemoconcentration.\n[2807143:2807143_0] Reductions in plasma T4, T3 and T3/T4 ratio are probably due to inhibition of T4 secretion and 5'-monodeiodination with possible conversion of T4 to reverse T3 (rT3). These processes may represent a mechanism for regulation of thyroid hormone metabolism during strenuous and extended flight.", "answer": "<think> Okay, let's tackle this question. The user is asking if strenuous physical activity affects thyroid hormone metabolism. I need to look at the provided evidence to form an answer. First, looking at evidence [16175495:16175495_0], it says there are controversial results in adults and scant data in children and adolescents. That suggests that the effect isn't clear-cut, especially in different age groups. But then [7198038:7198038_0] mentions that brief strenuous swimming or moderate cycling had minor or no effect on thyroid hormones when considering hemoconcentration. So maybe in some cases, there's no significant change. Then [28071", "citations": [{"doc_id": "16175495", "chunk_id": "16175495_0"}, {"doc_id": "7198038", "chunk_id": "7198038_0"}], "candidates": [{"answer": "<think> Okay, I need to generate a biomedical answer based on the provided evidence. The question is whether strenuous physical activity affects thyroid hormone metabolism. First, let me look at the evidence given. There are three documents here. Document 16175495 says there are controversial results in adults and little data in children and adolescents. So that's a bit conflicting. Then document 7198038 mentions that brief strenuous swimming or moderate cycling had minor or no effect on thyroid hormones, considering hemoconcentration. That suggests maybe no significant effect. But document 2807143 says there are reductions in T4, T3, and the ratio during strenuous activity, possibly due to inhibition of secretion and deiodination,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if strenuous physical activity affects thyroid hormone metabolism. I need to look at the provided evidence to form an answer. First, looking at evidence [16175495:16175495_0], it says there are controversial results in adults and scant data in children and adolescents. That suggests that the effect isn't clear-cut, especially in different age groups. But then [7198038:7198038_0] mentions that brief strenuous swimming or moderate cycling had minor or no effect on thyroid hormones when considering hemoconcentration. So maybe in some cases, there's no significant change. Then [28071", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, so the user is asking if strenuous physical activity affects thyroid hormone metabolism. Let me look at the evidence provided. First, the first piece of evidence says there are controversial results in adults and little data in children and adolescents. That suggests that the answer isn't clear-cut. Then the second study mentions that brief strenuous swimming or moderate cycling had minor or no effect on thyroid hormones when considering hemoconcentration. So maybe in some cases, there's no significant effect. The third study talks about reductions in T4, T3, and the ratio during strenuous activity, pointing to inhibition of secretion and deiodination, which could be a regulatory mechanism. So putting this together, the answer seems to be that strenuous exercise does affect thyroid hormone metabolism, but the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if strenuous physical activity affects thyroid hormone metabolism. I need to look at the evidence provided. First, evidence [16175495:16175495_0] says there are controversial results in adult athletes and little data in children and adolescents. That suggests that the effect isn't clear-cut, especially in different age groups. So maybe the answer should mention controversy. Then, [7198038:7198038_0] talks about brief strenuous swimming or moderate cycling having minor or no effect on thyroid hormones when considering hemoconcentration. Hemoconcentration is when blood becomes more concentrated due to fluid loss, so maybe", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if strenuous physical activity affects thyroid hormone metabolism. I need to look at the provided evidence to form an answer. First, evidence point 16175495:16175495_0 says there are controversial results in adults and little data in children and adolescents. That suggests that the effect isn't clear-cut, especially in different age groups. Then, evidence 7198038:7198038_0 mentions that brief strenuous swimming or moderate cycling had minor or no effect on thyroid hormone concentrations when considering hemoconcentration. So, in some cases, there's no significant change. But hemoconcentration might be a factor", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if strenuous physical activity affects thyroid hormone metabolism. I need to look at the evidence provided. First, document [16175495:16175495_0] says there are controversial results in adults and little data in children. That suggests some studies show effects, but others don't, and not much is known in kids. So that's a bit conflicting. Then [7198038:7198038_0] mentions that brief strenuous swimming or moderate cycling had minor or no effect on thyroid hormone concentrations, considering hemconcentration. So here, short-term exercise doesn't seem to change the levels much. But maybe the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if strenuous physical activity affects thyroid hormone metabolism. I need to look at the provided evidence to form an answer. First, evidence document [16175495:16175495_0] says there are controversial results in adults and little data in children and adolescents. So that's a bit ambiguous. Then [7198038:7198038_0] mentions that brief strenuous exercise like swimming or cycling has minor or no effect on thyroid hormones when considering hemoconcentration. That suggests maybe no significant effect, but the note about hemoconcentration is important—maybe the concentrations are adjusted for that. Next, [2", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if strenuous physical activity affects thyroid hormone metabolism. I need to look at the provided evidence to form an answer. First, evidence document [16175495:16175495_0] says there are controversial results in adults and little data in children and adolescents. That suggests that the effect might not be clear-cut, especially in different age groups. Then, document [7198038:7198038_0] mentions that brief strenuous swimming or moderate cycling had minor or no effect on thyroid hormones when considering hemconcentration. So, maybe short-term exercise doesn't significantly affect the levels, but that's only for brief activities", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["14637241", "16175495", "18057380", "2807143", "3101339", "596247", "7198038", "8325717", "8743723"], "ideal_answer": "YES"}
{"question_id": "56f112932ac5ed145900000d", "question": "Which is the main function of \"RNA sponges\"?", "retrieved_chunks": [{"doc_id": "28018143", "chunk_id": "28018143_1", "score": 6.0878448486328125, "text": "Several circRNAs have been shown to function as microRNA \"sponges\" to counteract microRNA mediated repression of mRNA."}, {"doc_id": "29387208", "chunk_id": "29387208_1", "score": 4.849767684936523, "text": "Presently, certain circRNAs have been reported to function as microRNA sponges and RNA-binding protein sponges to regulate downstream gene transcription, which suggests a potential for circRNAs in cancer diagnosis, prognosis and clinical therapy."}, {"doc_id": "23446346", "chunk_id": "23446346_4", "score": 4.345890045166016, "text": "Natural RNA circles function as efficient microRNA sponges"}], "context": "[28018143:28018143_1] Several circRNAs have been shown to function as microRNA \"sponges\" to counteract microRNA mediated repression of mRNA.\n[29387208:29387208_1] Presently, certain circRNAs have been reported to function as microRNA sponges and RNA-binding protein sponges to regulate downstream gene transcription, which suggests a potential for circRNAs in cancer diagnosis, prognosis and clinical therapy.\n[23446346:23446346_4] Natural RNA circles function as efficient microRNA sponges", "answer": "<think> Okay, I need to generate a JSON answer about the main function of \"RNA sponges\" based on the provided evidence. Let me start by understanding what the question is asking. The user wants to know the primary function of RNA sponges, and they've given three evidence snippets. Looking at the evidence: 1. [28018143:28018143_1] says circRNAs function as microRNA sponges to counteract microRNA-mediated repression of mRNA. So here, the main point is that they bind to microRNAs, preventing them from repressing mRNA. 2. [29387208:29387208_1] mentions circRN", "citations": [{"doc_id": "28018143", "chunk_id": "28018143_1"}, {"doc_id": "29387208", "chunk_id": "29387208_1"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the main function of \"RNA sponges.\" Looking at the evidence provided, there are three references. First, reference 28018143 says that circRNAs act as microRNA sponges to counteract microRNA-mediated repression of mRNA. That's a direct mention of their function. Then, reference 29387208 expands on this, stating that circRNAs can also bind RNA-binding proteins and regulate gene transcription, which might relate to their role as sponges. The third reference, 23446346, mentions natural RNA circles as efficient microRNA sponges, reinforcing the idea. So, the main function seems to", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer about the main function of \"RNA sponges\" based on the provided evidence. Let me start by understanding what the question is asking. The user wants to know the primary function of RNA sponges, and they've given three evidence snippets. Looking at the evidence: 1. [28018143:28018143_1] says circRNAs function as microRNA sponges to counteract microRNA-mediated repression of mRNA. So here, the main point is that they bind to microRNAs, preventing them from repressing mRNA. 2. [29387208:29387208_1] mentions circRN", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a JSON answer about the main function of \"RNA sponges\" based on the provided evidence. Let me look at the evidence again. The first document says that several circRNAs function as microRNA sponges to counteract microRNA-mediated repression of mRNA. The second mentions that circRNAs act as both microRNA and RNA-binding protein sponges, regulating gene transcription, possibly for cancer therapy. The third states that natural RNA circles are efficient microRNA sponges. So the main function seems to be acting as microRNA sponges. The term \"RNA sponges\" is used in the question, but the evidence specifically refers to circRNAs as sponges. However, the answer should be concise and cite the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the main function of \"RNA sponges.\" Looking at the evidence provided, there are three references. First, reference 28018143 says that circRNAs function as microRNA sponges to counteract microRNA-mediated repression of mRNA. So that's one point. Then, reference 29387208 mentions that circRNAs act as both microRNA and RNA-binding protein sponges, regulating gene transcription, which could be relevant to cancer. The third reference, 23446346, states that natural RNA circles are efficient microRNA sponges. The question is about the main function. The term \"RNA sponges", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about the main function of \"RNA sponges.\" The user provided three evidence snippets from different studies. First, I need to understand what each of these evidences is saying. The first evidence says that several circRNAs act as microRNA sponges to counteract microRNA-mediated repression of mRNA. So here, the main point is that they bind to miRNAs, preventing them from repressing mRNA. The second evidence mentions that certain circRNAs function as both microRNA and RNA-binding protein sponges, regulating gene transcription and possibly having roles in cancer. The third evidence states that natural RNA circles (which I think are circRNAs) are efficient microRNA sponges. The question is asking for the main function", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking about the main function of \"RNA sponges.\" Let me look at the evidence provided. First, the evidence mentions that circRNAs function as microRNA sponges to counteract microRNA-mediated repression of mRNA. That's from document 28018143. Then there's another mention that circRNAs act as both microRNA and RNA-binding protein sponges, regulating gene transcription, possibly related to cancer. Document 29387208 talks about this. The third evidence says natural RNA circles are efficient microRNA sponges, from document 23446346. So the main function here seems to be acting as sponges for microRNAs. The term", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking about the main function of \"RNA sponges,\" and they provided some evidence from three different documents. First, I need to understand what \"RNA sponges\" refer to. From the evidence, it seems like they're talking about circRNAs (circular RNAs) that act as sponges for microRNAs. The term \"sponge\" here probably means that these RNA molecules bind to microRNAs, preventing them from interacting with their target mRNAs. This would counteract the repression of mRNA by microRNAs. Looking at the evidence: - Document 28018143 says circRNAs function as microRNA sponges to counteract microRNA-mediated repression", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer about the main function of \"RNA sponges\" based on the provided evidence. Let me start by reading through the question and the evidence carefully. The user is asking for the main function of RNA sponges. The evidence given includes three chunks from different studies. Let me parse each one: First chunk (28018143:28018143_1) says that several circRNAs function as microRNA \"sponges\" to counteract microRNA mediated repression of mRNA. So here, the main point is that they act as sponges for miRNAs, which helps prevent miRNAs from repressing mRNA. Second chunk (293872", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["23446346", "23615404", "25404635", "25483404", "25580223", "25630703", "25957803", "26052092"], "ideal_answer": "Natural RNA circles function as efficient microRNA sponges. Recently, miRNA activity has been shown to be affected by the presence of miRNA sponge transcripts, the so-called competing endogenous RNA in humans and target mimicry in plants. Recently, miRNA activity has been shown to be affected by the presence of miRNA sponge transcripts, the so-called competing endogenous RNA in humans and target mimicry in plants. Natural RNA sponges sequestering cellular noncoding RNA molecules have been found in diverse organisms. In this issue, Lalaouna et al. (2015) report another type of RNA sponge, showing that stable intermediates of bacterial tRNA processing control endogenous small RNAs. Furthermore, survival analysis suggests that high OCT4-pg4 level is significantly correlated with poor prognosis of HCC patients."}
{"question_id": "56cf50253975bb303a00000b", "question": "Is the gene MAOA epigenetically modified by methylation?", "retrieved_chunks": [{"doc_id": "20421737", "chunk_id": "20421737_0", "score": 6.18554162979126, "text": "Given that DNA methylation is linked to the regulation of gene expression, we hypothesized that epigenetic mechanisms factor into the MAOA expression"}, {"doc_id": "22948232", "chunk_id": "22948232_0", "score": 4.726548194885254, "text": "Evidence that the methylation state of the monoamine oxidase A (MAOA) gene predicts brain activity of MAO A enzyme in healthy men."}, {"doc_id": "18454435", "chunk_id": "18454435_0", "score": 4.475069999694824, "text": "In recent years, the role of epigenetic phenomenon, such as methylation, in mediating vulnerability to behavioral illness has become increasingly appreciated. One prominent locus at which epigenetic phenomena are thought to be in play is the monoamine oxidase A (MAOA) locus."}], "context": "[20421737:20421737_0] Given that DNA methylation is linked to the regulation of gene expression, we hypothesized that epigenetic mechanisms factor into the MAOA expression\n[22948232:22948232_0] Evidence that the methylation state of the monoamine oxidase A (MAOA) gene predicts brain activity of MAO A enzyme in healthy men.\n[18454435:18454435_0] In recent years, the role of epigenetic phenomenon, such as methylation, in mediating vulnerability to behavioral illness has become increasingly appreciated. One prominent locus at which epigenetic phenomena are thought to be in play is the monoamine oxidase A (MAOA) locus.", "answer": "<think> Okay, let's tackle this question. The user is asking if the MAOA gene is epigenetically modified by methylation. I need to look at the provided evidence to form an answer. First, I'll review each of the three evidence points. The first piece [20421737:20421737_0] mentions that DNA methylation is linked to gene expression regulation and that epigenetic mechanisms factor into MAOA expression. This suggests that methylation does play a role in regulating MAOA, so it's a positive indicator. The second evidence [22948232:22948232_0] states that the methylation state of the MAOA gene predicts brain", "citations": [{"doc_id": "20421737", "chunk_id": "20421737_0"}, {"doc_id": "22948232", "chunk_id": "22948232_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants to know if the gene MAOA is epigenetically modified by methylation. The evidence provided has three chunks. First chunk: DNA methylation links to gene expression regulation, and they hypothesized that epigenetic mechanisms affect MAOA expression. So this suggests that methylation might be involved. Second chunk: Methylation state of MAOA predicts brain activity of the enzyme in men. This directly connects methylation to MAOA's function, implying an epigenetic modification. Third chunk: Epigenetic phenomena like methylation mediate vulnerability to behavioral illness, and MAOA is a prominent locus here. So this supports that methylation plays a role in MAOA. Putting it all together, the answer should be yes, based", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the gene MAOA is epigenetically modified by methylation. I need to look at the evidence provided and see what each document says. First, document 20421737:20421737_0 mentions that DNA methylation is linked to regulating gene expression and that epigenetic mechanisms factor into MAOA expression. So this suggests that methylation does play a role in MAOA's regulation. Then, document 22948232:22948232_0 states that the methylation state of the MAOA gene predicts brain activity of the MAO A enzyme. This directly connects methylation to the gene's state", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the gene MAOA is epigenetically modified by methylation. I need to look at the provided evidence to find answers. First, looking at the evidence documents. The first one, 20421737:20421737_0, says DNA methylation is linked to regulating gene expression and that epigenetic mechanisms factor into MAOA expression. That suggests methylation does play a role in MAOA's regulation. The second document, 22948232:22948232_0, mentions that the methylation state of the MAOA gene predicts brain activity of the MAO A enzyme. This directly links meth", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the gene MAOA is epigenetically modified by methylation. I need to look at the provided evidence to form an answer. First, looking at the evidence documents. The first one, 20421737:20421737_0, says that DNA methylation is linked to gene expression regulation and that epigenetic mechanisms factor into MAOA expression. That suggests methylation does play a role in MAOA's expression, so it's epigenetically modified. The second document, 22948232:22948232_0, mentions that the methylation state of the MAOA gene predicts brain activity of", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the MAOA gene is epigenetically modified by methylation. I need to look at the provided evidence to form an answer. First, I'll review each of the three evidence points. The first piece [20421737:20421737_0] mentions that DNA methylation is linked to gene expression regulation and that epigenetic mechanisms factor into MAOA expression. This suggests that methylation does play a role in regulating MAOA, so it's a positive indicator. The second evidence [22948232:22948232_0] states that the methylation state of the MAOA gene predicts brain", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the gene MAOA is epigenetically modified by methylation. The evidence provided has three chunks. First chunk (20421737:20421737_0) says DNA methylation is linked to gene expression regulation and that epigenetic mechanisms factor into MAOA expression. So this suggests that methylation does play a role in MAOA expression, which is part of being epigenetically modified. Second chunk (22948232:22948232_0) mentions that the methylation state of the MAOA gene predicts brain activity of the MAO A enzyme. This directly links methylation to the gene's state", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the gene MAOA is epigenetically modified by methylation. The evidence provided has three chunks. First chunk: DNA methylation is linked to gene expression regulation, and they hypothesized that epigenetic mechanisms affect MAOA expression. So that's a mention of methylation (a type of epigenetic modification) influencing MAOA. Second chunk: Methylation state of MAOA predicts brain activity of the enzyme in healthy men. This directly connects methylation (epigenetic) to MAOA gene activity. Third chunk: Epigenetic phenomena like methylation mediate vulnerability to behavioral illness, specifically at the MAOA locus. So again, linking methylation to MAOA. So all three pieces of evidence support", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the gene MAOA is epigenetically modified by methylation. I need to look at the evidence provided and see what each of those documents says. First, document 20421737:20421737_0 mentions that DNA methylation is linked to regulating gene expression and hypothesizes that epigenetic mechanisms, including methylation, affect MAOA expression. So this suggests that methylation does play a role in MAOA regulation. Then document 22948232:22948232_0 states that the methylation state of the MAOA gene predicts brain activity of the MAO A enzyme in healthy men.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["16893905", "18454435", "19777560", "20421737", "20505345", "22139575", "22198720", "22436428", "22906985", "22948232", "23116433"], "ideal_answer": "In recent years, the role of epigenetic phenomenon, such as methylation, in mediating vulnerability to behavioral illness has become increasingly appreciated. One prominent locus at which epigenetic phenomena are thought to be in play is the monoamine oxidase A (MAOA) locus. We conclude that methylation of MAOA may play a significant role in common psychiatric illness and that further examination of epigenetic processes at this locus is in order."}
{"question_id": "5523f1a62c8b63434a000002", "question": "Which mutations of phopspholamban have been found in patients with cardiomyopathy?", "retrieved_chunks": [{"doc_id": "22820313", "chunk_id": "22820313_2", "score": 7.793552398681641, "text": "Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy."}, {"doc_id": "12705874", "chunk_id": "12705874_0", "score": 7.6367998123168945, "text": "Using neonatal rat cardiomyocytes, the mutation, -77A-->G, increased the phospholamban promoter activity. No nucleotide change in the phospholamban coding region was found in 99 patients with cardiomyopathy. We suspect that the mutation plays an important role in the development of hypertrophic cardiomyopathy."}, {"doc_id": "22155237", "chunk_id": "22155237_1", "score": 7.241402626037598, "text": "Phospholamban (PLN) is a key regulator of SR and cardiac function, and PLN mutations in humans have been associated with dilated cardiomyopathy (DCM). We previously reported the deletion of the highly conserved amino acid residue arginine 14 (nucleic acids 39, 40 and 41) in DCM patients."}], "context": "[22820313:22820313_2] Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy.\n[12705874:12705874_0] Using neonatal rat cardiomyocytes, the mutation, -77A-->G, increased the phospholamban promoter activity. No nucleotide change in the phospholamban coding region was found in 99 patients with cardiomyopathy. We suspect that the mutation plays an important role in the development of hypertrophic cardiomyopathy.\n[22155237:22155237_1] Phospholamban (PLN) is a key regulator of SR and cardiac function, and PLN mutations in humans have been associated with dilated cardiomyopathy (DCM). We previously reported the deletion of the highly conserved amino acid residue arginine 14 (nucleic acids 39, 40 and 41) in DCM patients.", "answer": "<think> Okay, let's tackle this question. The user is asking which mutations of phospholamban have been found in patients with cardiomyopathy. I need to look at the provided evidence to find the relevant mutations. First, looking at the evidence: The first document [22820313:22820313_2] mentions a Phospholamban R14del mutation associated with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy. So that's one mutation: R14del. The second document [12705874:12705874_0] talks about a -77A-->G mutation in the promoter region, but it says", "citations": [{"doc_id": "22820313", "chunk_id": "22820313_2"}, {"doc_id": "12705874", "chunk_id": "12705874_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which mutations of phospholamban have been found in patients with cardiomyopathy. The evidence provided has three references. First, I need to look at each document to see what mutations they mention. The first reference (22820313) talks about a R14del mutation linked to dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy. That's one mutation. The second reference (12705874) mentions a -77A-->G mutation in the promoter region, which is associated with hypertrophic cardiomyopathy. However, it also states that there were no nucleotide changes in the coding region in 99 patients. So", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which mutations of phospholamban have been found in patients with cardiomyopathy. I need to look at the provided evidence to find the relevant mutations. First, looking at the evidence: The first document [22820313:22820313_2] mentions a Phospholamban R14del mutation associated with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy. So that's one mutation: R14del. The second document [12705874:12705874_0] talks about a -77A-->G mutation in the promoter region, but it says", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which mutations of phospholamban have been found in patients with cardiomyopathy. I need to look at the provided evidence to find the relevant mutations. First, looking at the evidence documents: Document [22820313:22820313_2] mentions a mutation called R14del, which is associated with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy. So that's one mutation. Next, document [12705874:12705874_0] talks about a -77A-->G mutation in the promoter region. However, it states that there was no nucleotide", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which mutations of phospholamban have been found in patients with cardiomyopathy. The evidence provided has three documents. First, looking at document [22820313:22820313_2], it mentions the R14del mutation in dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy. That's one mutation. Then, document [12705874:12705874_0] talks about a -77A-->G mutation increasing promoter activity. However, it also states that no coding region changes were found in 99 patients. Wait, but the question is about mutations in", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which mutations of phospholamban have been found in patients with cardiomyopathy. I need to look at the evidence provided and extract relevant information. First, looking at the evidence: The first document [22820313:22820313_2] mentions a Phospholamban R14del mutation linked to dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy. That's one mutation. The second document [12705874:12705874_0] talks about a -77A-->G mutation in the promoter region, which is associated with hypertrophic cardiomyopathy.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which mutations of phospholamban have been found in patients with cardiomyopathy. I need to look at the evidence provided to find the answer. First, looking at the evidence: The first document [22820313:22820313_2] mentions a Phospholamban R14del mutation in patients with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy. So that's one mutation: R14del. The second document [12705874:12705874_0] talks about a -77A-->G mutation in the promoter region, but it says", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which mutations of phospholamban have been found in patients with cardiomyopathy. I need to look through the provided evidence to find the relevant information. First, looking at the first evidence document [22820313:22820313_2], it mentions the Phospholamban R14del mutation in patients with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy. That's a specific mutation, so that's a candidate. Next, the second document [12705874:12705874_0] talks about a -77A-->G mutation in the promoter region.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which mutations of phospholamban have been found in patients with cardiomyopathy. I need to look at the evidence provided. First, looking at the evidence documents: The first one, [22820313:22820313_2], mentions a Phospholamban R14del mutation associated with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy. So that's one mutation: R14del. The second document, [12705874:12705874_0], talks about a -77A-->G mutation in the promoter region. However, it says no", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["12610310", "12639993", "16432188", "16829191", "17010801", "21282613", "21332051", "22137083", "22155237", "22707725", "22820313", "23568436", "23871674"], "ideal_answer": "PLN mutation R14del [or c.40_42delAGA(p.Arg14del)] was identified in 12 (12 %) ARVC patients and in 39 (15 %) DCM patients. Another PLN mutation is a T116G point mutation, substituting a termination codon for Leu-39 (L39stop), and it was identified in two families with hereditary heart failure. Hereditary mutants of phospholamban, such as Arg(9) to Cys, Arg(9) to Leu, Arg(9) to His, cause lethal, hereditary dilated cardiomyopathy.in specific, two patients presented a G-T missense mutation at the G26 nucleotide, which encodes an Arg-Leu substitution at codon 9 (R9L).One patient presented a G-A missense mutation at the same nucleotide, which encodes an Arg-His substitution at codon 9 (R9H). A missense mutation in PLN cytoplasmic domain (R9C) triggers dilated cardiomyopathy in humans, leading to premature death."}
{"question_id": "52df8ce798d023950500000d", "question": "Which are the supplemental antioxidant in athletes?", "retrieved_chunks": [{"doc_id": "19838998", "chunk_id": "19838998_0", "score": 6.129538059234619, "text": "Supplementation with antioxidant vitamin E to athletes at 267 mg (400 IUs) or greater has been reported to reduce levels of LP associated with exercise."}, {"doc_id": "21400082", "chunk_id": "21400082_0", "score": 4.592637062072754, "text": "The two strains, L. rhamnosus IMC 501(®) and L. paracasei IMC 502(®), exert strong antioxidant activity. Athletes and all those exposed to oxidative stress may benefit from the ability of these probiotics to increase antioxidant levels and neutralize the effects of reactive oxygen species."}, {"doc_id": "24323888", "chunk_id": "24323888_0", "score": 1.3399267196655273, "text": "Although these supplementations are increasingly used by master athletes, very few data are available on their effects on oxidative stress, muscle recovery, and physical performance. The potential benefits of supplement use in athletes are thus questionable. Some studies indicate no benefits, while others highlight potential negative side effects of vitamin supplementation."}], "context": "[19838998:19838998_0] Supplementation with antioxidant vitamin E to athletes at 267 mg (400 IUs) or greater has been reported to reduce levels of LP associated with exercise.\n[21400082:21400082_0] The two strains, L. rhamnosus IMC 501(®) and L. paracasei IMC 502(®), exert strong antioxidant activity. Athletes and all those exposed to oxidative stress may benefit from the ability of these probiotics to increase antioxidant levels and neutralize the effects of reactive oxygen species.\n[24323888:24323888_0] Although these supplementations are increasingly used by master athletes, very few data are available on their effects on oxidative stress, muscle recovery, and physical performance. The potential benefits of supplement use in athletes are thus questionable. Some studies indicate no benefits, while others highlight potential negative side effects of vitamin supplementation.", "answer": "<think> Okay, let's tackle this question. The user is asking about supplemental antioxidants for athletes. I need to look at the provided evidence and find which specific supplements are mentioned. First, evidence [19838998:19838998_0] talks about vitamin E supplementation at 267 mg or higher reducing LP levels in athletes. So vitamin E is one. Then [21400082:21400082_0] mentions probiotics like L. rhamnosus and L. paracasei having strong antioxidant activity. These are probiotic supplements. The third evidence [24323888:24323888_0]", "citations": [{"doc_id": "19838998", "chunk_id": "19838998_0"}, {"doc_id": "21400082", "chunk_id": "21400082_0"}, {"doc_id": "24323888", "chunk_id": "24323888_0"}], "candidates": [{"answer": "<think> Okay, the user is asking about supplemental antioxidants for athletes. Let me look at the evidence provided. First, document 19838998 mentions that vitamin E supplementation at 267 mg or higher reduces LP levels associated with exercise. So vitamin E is mentioned here as a supplement. Then, document 21400082 talks about probiotics like L. rhamnosus and L. paracasei having strong antioxidant activity. These could be considered supplements too. The third document doesn't specify a particular supplement but mentions that some studies show no benefits or negative side effects of vitamin supplementation. The question is asking for the supplemental antioxidants. The answer should include both vitamin E and the probiotics mentioned. But wait, the user wants", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about supplemental antioxidants for athletes. I need to look at the provided evidence and find which specific supplements are mentioned. First, evidence [19838998:19838998_0] talks about vitamin E supplementation at 267 mg or higher reducing LP levels in athletes. So vitamin E is one. Then [21400082:21400082_0] mentions probiotics like L. rhamnosus and L. paracasei having strong antioxidant activity. These are probiotic supplements. The third evidence [24323888:24323888_0]", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to figure out which supplemental antioxidant is mentioned in the evidence provided. Let's look at each document. First, document [19838998:19838998_0] talks about vitamin E supplementation at 267 mg or more reducing LP levels in athletes. So vitamin E is an antioxidant here. Then, [21400082:21400082_0] mentions probiotics like L. rhamnosus and L. paracasei having strong antioxidant activity. These are probiotics, not vitamins, but they are antioxidants. However, the question is about \"supplemental\" antioxidants. Probiotics can be considered supplements, so maybe these", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question: \"Which are the supplemental antioxidant in athletes?\" The user wants a biomedical answer based on the provided evidence. First, I need to look at the evidence given. There are three documents here. Let me go through each one. Document 19838998: This talks about vitamin E supplementation at 267 mg or higher reducing LP levels associated with exercise. So vitamin E is mentioned as an antioxidant supplement for athletes. Document 21400082: This mentions two probiotic strains, L. rhamnosus and L. paracasei, which have strong antioxidant activity. They can increase antioxidant levels and neutralize reactive oxygen species. These are probiotics, so they're supplements too", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question: \"Which are the supplemental antioxidant in athletes?\" The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three documents here. Let me go through each one. Document 19838998: It mentions vitamin E supplementation at 267 mg or higher reducing LP levels associated with exercise. So vitamin E is an antioxidant mentioned here. The citation is [19838998:19838998_0]. Document 21400082: Talks about two probiotic strains, L. rhamnosus and L. paracasei, having strong antioxidant activity. These are", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, so the user is asking about supplemental antioxidants for athletes. Let me look at the evidence provided. First, the first document says that vitamin E supplementation at 267 mg or more reduces LP levels associated with exercise. So vitamin E is mentioned here as a supplement. Then the second document talks about two probiotic strains that have strong antioxidant activity. They mention that athletes might benefit from these probiotics because they can increase antioxidant levels and neutralize reactive oxygen species. The third document is a bit more cautious, saying that while some supplements are used by master athletes, there's not much data on their effects. Some studies show no benefits or even negative side effects. The question is asking for the supplemental antioxidants in athletes. The answer needs to be concise with citations and a confidence", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking about supplemental antioxidants for athletes. Let me look at the evidence provided. First, document 19838998 mentions vitamin E supplementation at 267 mg or more reducing LP levels associated with exercise. So vitamin E is mentioned here as a supplement. Then, document 21400082 talks about probiotics like L. rhamnosus and L. paracasei having strong antioxidant activity. These are probiotics, which are a type of supplement. The third document, 24323888, is more about the potential benefits being questionable, but it doesn't specify which supplements. The question is asking for \"supplemental antioxidants,\" so both vitamin E and the prob", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about supplemental antioxidants for athletes. I need to look at the provided evidence to find which specific supplements are mentioned. First, evidence document [19838998:19838998_0] talks about vitamin E supplementation at 267 mg or more reducing LP levels in athletes. So vitamin E is one candidate. Then there's [21400082:21400082_0] mentioning two probiotic strains, L. rhamnosus and L. paracasei, which have strong antioxidant activity. These are probiotics, so they're a different type of supplement. The third document [24", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["16575496", "18562771", "19089749", "19597720", "19838998", "20308973", "21116022", "21400082", "21813916", "21830999", "21990004", "22080314", "22212240", "22828460", "23349254", "23436649", "23600891", "23717765", "23717772", "23800565", "23980734", "24323888"], "ideal_answer": "There are several antioxidant supplements belonging to different families, i.e. Vitamins, Polyphenols, alpha-lipoic acid, ubiquinones, n-3- polyunsaturated acids (PUFAs), minerals and others. Nonetheless the widespread use of these supplements, it is still debated their true usefulness, and it is not unanimously advised their use in athletes."}
{"question_id": "5713c4a11174fb1755000013", "question": "Is glycyl-tRNA synthetase gene involved in the development of Charcot-Marie-Tooth disease?", "retrieved_chunks": [{"doc_id": "25420567", "chunk_id": "25420567_1", "score": 7.194414138793945, "text": "A novel mutation in glycyl-tRNA synthetase caused Charcot-Marie-Tooth disease type 2D with facial and respiratory muscle involvement."}, {"doc_id": "22144914", "chunk_id": "22144914_2", "score": 6.991029262542725, "text": "Charcot-Marie-Tooth disease type 2D (CMT2D) is a dominantly inherited peripheral neuropathy caused by missense mutations in the glycyl-tRNA synthetase gene (GARS). In addition to GARS, mutations in three other tRNA synthetase genes cause similar neuropathies, although the underlying mechanisms are not fully understood."}, {"doc_id": "25420567", "chunk_id": "25420567_0", "score": 6.908804416656494, "text": "A novel mutation in glycyl-tRNA synthetase caused Charcot-Marie-Tooth disease type 2D with facial and respiratory muscle involvement"}], "context": "[25420567:25420567_1] A novel mutation in glycyl-tRNA synthetase caused Charcot-Marie-Tooth disease type 2D with facial and respiratory muscle involvement.\n[22144914:22144914_2] Charcot-Marie-Tooth disease type 2D (CMT2D) is a dominantly inherited peripheral neuropathy caused by missense mutations in the glycyl-tRNA synthetase gene (GARS). In addition to GARS, mutations in three other tRNA synthetase genes cause similar neuropathies, although the underlying mechanisms are not fully understood.\n[25420567:25420567_0] A novel mutation in glycyl-tRNA synthetase caused Charcot-Marie-Tooth disease type 2D with facial and respiratory muscle involvement", "answer": "<think> Okay, I need to answer whether the glycyl-tRNA synthetase gene is involved in Charcot-Marie-Tooth disease based on the evidence provided. Let me look at the evidence again. The first document says a novel mutation in glycyl-tRNA synthetase caused CMT2D with facial and respiratory issues. The second one states that CMT2D is dominantly inherited and caused by missense mutations in the GARS gene. It also mentions that mutations in three other tRNA synthetase genes can cause similar neuropathies, but mechanisms aren't fully understood. The third document is a repeat of the first, so it's probably the same study. So, the answer should be yes, the gene is involved. The citations would be from documents", "citations": [], "candidates": [{"answer": "<think> Okay, I need to answer whether the glycyl-tRNA synthetase gene is involved in Charcot-Marie-Tooth disease based on the evidence provided. Let me look at the evidence again. The first document says a novel mutation in glycyl-tRNA synthetase caused CMT2D with facial and respiratory issues. The second one states that CMT2D is dominantly inherited and caused by missense mutations in the GARS gene. It also mentions that mutations in three other tRNA synthetase genes can cause similar neuropathies, but mechanisms aren't fully understood. The third document is a repeat of the first, so it's probably the same study. So, the answer should be yes, the gene is involved. The citations would be from documents", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the glycyl-tRNA synthetase gene is involved in Charcot-Marie-Tooth disease (CMT). Looking at the evidence provided, there are two documents that mention this. First, document 25420567 has two chunks. Both chunks mention a mutation in the glycyl-tRNA synthetase gene causing CMT2D. The second document, 22144914, specifically states that CMT2D is dominantly inherited and caused by missense mutations in the GARS gene. It also notes that other tRNA synthetase genes can cause similar neuropathies, but mechanisms aren't fully understood. So, the answer should confirm that the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the glycyl-tRNA synthetase gene is involved in Charcot-Marie-Tooth disease (CMT). Looking at the evidence provided, there are two documents that mention this. First, document 25420567 has two chunks. Both of them refer to a novel mutation in glycyl-tRNA synthetase causing CMT2D. The second document, 22144914, states that CMT2D is dominantly inherited and caused by missense mutations in the GARS gene. It also mentions other tRNA synthetase genes, but the focus here is on GARS. So, the answer needs to confirm that the gene is involved.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the glycyl-tRNA synthetase gene is involved in Charcot-Marie-Tooth disease (CMT). Looking at the evidence provided, there are two documents that mention this. First, document 25420567 has a chunk that says a novel mutation in glycyl-tRNA synthetase caused CMT2D with facial and respiratory issues. Another chunk from the same doc repeats that. Then, document 22144914 states that CMT2D is dominantly inherited and caused by missense mutations in the GARS gene. It also mentions other tRNA synthetase genes but notes mechanisms aren't fully understood. So, both documents directly link glyc", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the glycyl-tRNA synthetase gene is involved in Charcot-Marie-Tooth disease (CMT). Looking at the evidence provided, there are two references that mention this. First, document 25420567 has two chunks. Both chunks mention a mutation in glycyl-tRNA synthetase causing CMT2D. The second document, 22144914, states that CMT2D is dominantly inherited and caused by missense mutations in the GARS gene. It also notes that other tRNA synthetase genes can cause similar neuropathies, but mechanisms aren't fully understood. So, the answer should confirm that the glycyl-t", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the glycyl-tRNA synthetase gene is involved in Charcot-Marie-Tooth disease (CMT). I need to check the provided evidence. Looking at the evidence, there are two entries with ID 25420567 and one with 22144914. The first one mentions a novel mutation in glycyl-tRNA synthetase causing CMT2D. The second document states that CMT2D is dominantly inherited and caused by missense mutations in the GARS gene. It also notes that other tRNA synthetase genes can cause similar neuropathies, but mechanisms aren't fully understood. So, both documents directly link the glycyl", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the glycyl-tRNA synthetase gene is involved in Charcot-Marie-Tooth disease (CMT). Looking at the evidence provided, there are two documents that mention this. First, document 25420567 has two chunks. Both chunks mention a mutation in glycyl-tRNA synthetase causing CMT2D. The second document, 22144914, states that CMT2D is dominantly inherited and caused by missense mutations in the GARS gene. It also notes that other tRNA synthetase genes can cause similar neuropathies, but mechanisms aren't fully understood. So, the answer should confirm that the glycyl-t", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the glycyl-tRNA synthetase gene is involved in Charcot-Marie-Tooth disease (CMT). I need to check the provided evidence. Looking at the evidence, there are two entries with ID 25420567 and one with 22144914. The first evidence says a novel mutation in glycyl-tRNA synthetase caused CMT2D with facial and respiratory issues. The second evidence states that CMT2D is dominantly inherited and caused by missense mutations in the GARS gene, which is the glycyl-tRNA synthetase gene. Also, another entry mentions that mutations in GARS lead to similar neuropathies.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["12690580", "16982418", "17035524", "17545306", "19470612", "22144914", "23279345", "23990368", "24368416", "24669931", "24898252", "25168514", "25420567"], "ideal_answer": "Dominant mutations in GARS, encoding the essential enzyme glycyl-tRNA synthetase (GlyRS), result in a form of Charcot-Marie-Tooth disease, type 2D (CMT2D), predominantly characterized by lower motor nerve degeneration. Charcot-Marie-Tooth disease type 2D (CMT2D) is an autosomal-dominant axonal peripheral neuropathy characterized by impaired motor and sensory function in the distal extremities. Mutations in the glycyl-tRNA synthetase (GARS) gene cause CMT2D"}
{"question_id": "5311cdcce3eabad021000007", "question": "Is there any software for automated analysis of FISH images?", "retrieved_chunks": [{"doc_id": "21310746", "chunk_id": "21310746_0", "score": 7.469486713409424, "text": "Fluorescence in situ hybridization (FISH) is used to study the organization and the positioning of specific DNA sequences within the cell nucleus. Analyzing the data from FISH images is a tedious process that invokes an element of subjectivity. Automated FISH image analysis offers savings in time as well as gaining the benefit of objective data analysis. While several FISH image analysis software tools have been developed, they often use a threshold-based segmentation algorithm for nucleus segmentation. As fluorescence signal intensities can vary significantly from experiment to experiment, from cell to cell, and within a cell, threshold-based segmentation is inflexible and often insufficient for automatic image analysis, leading to additional manual segmentation and potential subjective bias. To overcome these problems, we developed a graphical software tool called FISH Finder to automatically analyze FISH images that vary significantly. By posing the nucleus segmentation as a classification problem, compound Bayesian classifier is employed so that contextual information is utilized, resulting in reliable classification and boundary extraction. This makes it possible to analyze FISH images efficiently and objectively without adjustment of input parameters. Additionally, FISH Finder was designed to analyze the distances between differentially stained FISH probes."}, {"doc_id": "22935778", "chunk_id": "22935778_1", "score": 3.9800524711608887, "text": "hybridization (FISH) tests provide promising molecular imaging biomarkers to more accurately and reliably detect and diagnose cancers and genetic disorders. Since current manual FISH signal analysis is low-efficient and inconsistent, which limits its clinical utility, developing automated FISH image scanning systems and computer-aided detection (CAD) schemes has been attracting research interests. To acquire high-resolution FISH images in a multi-spectral scanning mode, a huge amount of image data with the stack of the multiple three-dimensional (3-D) image slices is generated from a single specimen. Automated preprocessing these scanned images to eliminate the non-useful and redundant data is important to make the automated FISH tests acceptable in clinical applications. In this study, a dual-detector fluorescence image scanning system was applied to scan four specimen slides with FISH-probed chromosome X. A CAD scheme was developed to detect analyzable interphase cells and map the multiple imaging slices recorded FISH-probed signals into the 2-D projection images. CAD scheme was then applied to each projection image to detect analyzable interphase cells using an adaptive multiple-threshold algorithm, identify FISH-probed signals using a top-hat transform, and compute the ratios between the normal and abnormal cells. To assess CAD performance, the FISH-probed signals were also independently visually detected by an observer. The Kappa coefficients for agreement between CAD and observer ranged from 0.69 to 1.0 in detecting/counting FISH signal spots in four testing samples."}, {"doc_id": "22935778", "chunk_id": "22935778_0", "score": 3.720496654510498, "text": "he study demonstrated the feasibility of automated FISH signal analysis that applying a CAD scheme to the automated generated 2-D projection images."}], "context": "[21310746:21310746_0] Fluorescence in situ hybridization (FISH) is used to study the organization and the positioning of specific DNA sequences within the cell nucleus. Analyzing the data from FISH images is a tedious process that invokes an element of subjectivity. Automated FISH image analysis offers savings in time as well as gaining the benefit of objective data analysis. While several FISH image analysis software tools have been developed, they often use a threshold-based segmentation algorithm for nucleus segmentation. As fluorescence signal intensities can vary significantly from experiment to experiment, from cell to cell, and within a cell, threshold-based segmentation is inflexible and often insufficient for automatic image analysis, leading to additional manual segmentation and potential subjective bias. To overcome these problems, we developed a graphical software tool called FISH Finder to automatically analyze FISH images that vary significantly. By posing the nucleus segmentation as a classification problem, compound Bayesian classifier is employed so that contextual information is utilized, resulting in reliable classification and boundary extraction. This makes it possible to analyze FISH images efficiently and objectively without adjustment of input parameters. Additionally, FISH Finder was designed to analyze the distances between differentially stained FISH probes.\n[22935778:22935778_1] hybridization (FISH) tests provide promising molecular imaging biomarkers to more accurately and reliably detect and diagnose cancers and genetic disorders. Since current manual FISH signal analysis is low-efficient and inconsistent, which limits its clinical utility, developing automated FISH image scanning systems and computer-aided detection (CAD) schemes has been attracting research interests. To acquire high-resolution FISH images in a multi-spectral scanning mode, a huge amount of image data with the stack of the multiple three-dimensional (3-D) image slices is generated from a single specimen. Automated preprocessing these scanned images to eliminate the non-useful and redundant data is important to make the automated FISH tests acceptable in clinical applications. In this study, a dual-detector fluorescence image scanning system was applied to scan four specimen slides with FISH-probed chromosome X. A CAD scheme was developed to detect analyzable interphase cells and map the multiple imaging slices recorded FISH-probed signals into the 2-D projection images. CAD scheme was then applied to each projection image to detect analyzable interphase cells using an adaptive multiple-threshold algorithm, identify FISH-probed signals using a top-hat transform, and compute the ratios between the normal and abnormal cells. To assess CAD performance, the FISH-probed signals were also independently visually detected by an observer. The Kappa coefficients for agreement between CAD and observer ranged from 0.69 to 1.0 in detecting/counting FISH signal spots in four testing samples.\n[22935778:22935778_0] he study demonstrated the feasibility of automated FISH signal analysis that applying a CAD scheme to the automated generated 2-D projection images.", "answer": "<think> Okay, let me tackle this query. The user is asking if there's any software for automated analysis of FISH images. I need to look through the provided evidence to find mentions of such software. Looking at the first document [21310746:21310746_0], it talks about a tool called FISH Finder. That seems like a direct answer. The text says they developed this software to automatically analyze FISH images, using a compound Bayesian classifier. So that's one example. Then the second document [22935778:22935778_1] mentions automated FISH image scanning systems and computer-aided detection (CAD) schemes. It refers to a dual", "citations": [{"doc_id": "21310746", "chunk_id": "21310746_0"}, {"doc_id": "22935778", "chunk_id": "22935778_1"}], "candidates": [{"answer": "<think> Okay, let me tackle this query. The user is asking if there's any software for automated analysis of FISH images. I need to look through the provided evidence to find mentions of such software. Looking at the first document [21310746:21310746_0], it talks about a tool called FISH Finder. That seems like a direct answer. The text says they developed this software to automatically analyze FISH images, using a compound Bayesian classifier. So that's one example. Then the second document [22935778:22935778_1] mentions automated FISH image scanning systems and computer-aided detection (CAD) schemes. It refers to a dual", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there's any software for automated analysis of FISH images. I need to look through the provided evidence to find mentions of such software. First, looking at the first document (21310746:21310746_0), it talks about a tool called FISH Finder. That's a direct mention of software. The article explains that FISH Finder was developed to automatically analyze FISH images, using a compound Bayesian classifier for nucleus segmentation. So that's a clear example of software. Then, the second document (22935778:22935778_1) discusses automated FISH image scanning systems and computer-aid", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The question is whether there's any software for automated analysis of FISH images. Looking at the evidence, the first document mentions \"FISH Finder\" as a graphical software tool developed to automatically analyze FISH images. It uses a compound Bayesian classifier for nucleus segmentation, which addresses the issues with threshold-based methods. So that's one example. The second document talks about developing automated FISH image scanning systems and CAD schemes. They mention a dual-detector system and a CAD scheme that uses an adaptive multiple-threshold algorithm and top-hat transform. While it doesn't name a specific software, it does describe a method for automated analysis. However, the answer should focus on existing software. The first document's F", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking if there's any software for automated analysis of FISH images. I need to look through the provided evidence to find mentions of such software. First, I'll check each document. The first evidence [21310746:21310746_0] talks about a tool called FISH Finder. That's definitely a candidate. It's described as a graphical software tool developed to automatically analyze FISH images, using a compound Bayesian classifier. So that's one example. Then there's [22935778:22935778_1], which mentions automated FISH image scanning systems and computer-aided detection (CAD) schemes", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The question is whether there's software for automated analysis of FISH images. Looking at the evidence, the first document mentions \"FISH Finder\" as a graphical tool developed to automatically analyze FISH images. It uses a compound Bayesian classifier for nucleus segmentation, which is different from threshold-based methods. So that's one example of software. The second document talks about a dual-detector fluorescence image scanning system and a CAD scheme for automated analysis. They mention using an adaptive multiple-threshold algorithm and top-hat transform. This seems like another tool or method, though it's part of a study rather than a specific software name. However, the key point here is that automated systems are being developed. The third document", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking if there's any software for automated analysis of FISH images. I need to look through the provided evidence to find mentions of specific software. First, I check the first document: [21310746:21310746_0]. It talks about a tool called FISH Finder. That's a direct mention of software. The description says it's developed to automatically analyze FISH images with a compound Bayesian classifier. So that's one answer. Next, the second document [22935778:22935778_1] mentions automated FISH image scanning systems and computer-aided detection (CAD) schemes. While it", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there's any software for automated analysis of FISH images. I need to look through the provided evidence to find mentions of such software. Looking at the first document (21310746:21310746_0), it talks about a tool called FISH Finder. That seems like a direct answer. The document explains that FISH Finder was developed to automatically analyze FISH images, using a compound Bayesian classifier for nucleus segmentation. So that's one software mentioned. Then there's the second document (22935778:22935778_1) which mentions automated FISH image scanning systems and computer-aided detection (", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there's any software for automated analysis of FISH images. I need to look through the provided evidence to find mentions of specific software. Looking at the first document, [21310746:21310746_0], it mentions a tool called FISH Finder. That's a direct answer. The second document, [22935778:22935778_1], talks about developing automated systems and CAD schemes but doesn't name specific software. The third document, [22935778:22935778_0], also refers to a CAD scheme but again no specific", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["11818019", "15351517", "15887538", "16749443", "17674627", "17889539", "20639591", "20966547", "21310746", "21656271", "22163442", "22665392", "22935778", "23903043", "24240725"], "ideal_answer": "FISH is a popular molecular cytogenetic method. The output of a single FISH analysis is a set of several tens or hundreds microscopic images — a single evaluated sample is of roughly 20mm diameter. The goal of an automated evaluation is to replace the subjective evaluation of images by the laboratory technician to achieve higher uniformity of results. Following explanation of the principle of the method and the typical contents of images, the processing flow of image segmentation is outlined and the results are presented on several example images. Based on results there are software for automated analysis of FISH images."}
{"question_id": "51659356298dcd4e5100005a", "question": "How do histone methyltransferases cause histone modification?", "retrieved_chunks": [{"doc_id": "32762486", "chunk_id": "32762486_0", "score": 7.150076866149902, "text": "Histone methylation modification affects chromatin through the addition of methyl groups to lysine or arginine residues of histones H3 and H4 by means of histone methyl transferases or histone demethylases."}, {"doc_id": "22483804", "chunk_id": "22483804_0", "score": 6.639518737792969, "text": "Histone methyltransferases catalyze site-specific deposition of methyl groups, enabling recruitment of transcriptional regulators. In mammals, trimethylation of lysine 4 in histone H3, a modification localized at the transcription start sites of active genes, is catalyzed by six enzymes (SET1a and SET1b, MLL1-MLL4) whose specific functions are largely unknown."}, {"doc_id": "17517655", "chunk_id": "17517655_0", "score": 6.20196533203125, "text": "histone modification is catalyzed by protein lysine methyltransferases (PKMTs). PKMTs contain a conserved SET domain"}], "context": "[32762486:32762486_0] Histone methylation modification affects chromatin through the addition of methyl groups to lysine or arginine residues of histones H3 and H4 by means of histone methyl transferases or histone demethylases.\n[22483804:22483804_0] Histone methyltransferases catalyze site-specific deposition of methyl groups, enabling recruitment of transcriptional regulators. In mammals, trimethylation of lysine 4 in histone H3, a modification localized at the transcription start sites of active genes, is catalyzed by six enzymes (SET1a and SET1b, MLL1-MLL4) whose specific functions are largely unknown.\n[17517655:17517655_0] histone modification is catalyzed by protein lysine methyltransferases (PKMTs). PKMTs contain a conserved SET domain", "answer": "<think> Okay, I need to generate a candidate biomedical answer based on the provided evidence. The question is about how histone methyltransferases cause histone modification. Let me look at the evidence given. First, the user provided three chunks from different documents. Let me parse each one. The first chunk [32762486:32762486_0] says that histone methylation involves adding methyl groups to lysine or arginine residues of H3 and H4 by histone methyltransferases or demethylases. So this explains the mechanism, mentioning the addition of methyl groups. The second chunk [22483804:22483804_0] talks about histone methyltransfer", "citations": [{"doc_id": "32762486", "chunk_id": "32762486_0"}, {"doc_id": "22483804", "chunk_id": "22483804_0"}], "candidates": [{"answer": "<think> Okay, the user wants me to generate a candidate biomedical answer based on the provided evidence. Let me first read through the question and the evidence carefully. The question is about how histone methyltransferases cause histone modification. The evidence has three chunks. Let me parse each one. First chunk: It says that histone methylation involves adding methyl groups to lysine or arginine residues of H3 and H4 by histone methyl transferases or demethylases. So this explains the mechanism, mentioning the addition of methyl groups by the enzymes. Second chunk: Histone methyltransferases catalyze site-specific deposition of methyl groups, allowing recruitment of transcriptional regulators. It also mentions that in mammals, trimethylation of K4 in H3 is done by six enzymes", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is about how histone methyltransferases cause histone modification. Let me look at the evidence provided. First, document 32762486 says that histone methylation involves adding methyl groups to lysine or arginine residues of H3 and H4 by histone methyltransferases or demethylases. So that's a key point. Then document 22483804 mentions that these enzymes catalyze site-specific deposition of methyl groups, allowing recruitment of transcriptional regulators. Specifically, they talk about trimethylation of lysine 4 in H3 being done by six enzymes, which is important for active genes. Document 175", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking how histone methyltransferases cause histone modification. Let me look at the evidence provided. First, the evidence mentions that histone methylation involves adding methyl groups to lysine or arginine residues of H3 and H4 by histone methyl transferases or demethylases. That's from doc 32762486. Then, another point says that these enzymes catalyze site-specific deposition of methyl groups, allowing transcriptional regulators to recruit. Specifically, trimethylation of lysine 4 in H3 is done by certain enzymes like SET1a, SET1b, MLL1-MLL4. Also, PKMTs have a conserved SET domain, as per doc 175", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user wants me to generate a candidate biomedical answer based on the provided evidence. Let me start by understanding the question: How do histone methyltransferases cause histone modification? Looking at the evidence, there are three chunks. The first one says that histone methylation involves adding methyl groups to lysine or arginine residues of H3 and H4 via histone methyl transferases or demethylases. The second chunk mentions that these enzymes catalyze site-specific deposition of methyl groups, allowing recruitment of transcriptional regulators. It also specifies that trimethylation of K4 in H3 is done by six enzymes like SET1a, SET1b, MLL1-MLL4. The third chunk states that histone modification is catalyzed by", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking how histone methyltransferases cause histone modification. I need to generate a concise answer with citations and a confidence score. First, looking at the evidence provided. There are three documents. Document 32762486 explains that histone methylation involves adding methyl groups to lysine or arginine residues by histone methyltransferases or demethylases. Document 22483804 mentions that these enzymes catalyze site-specific deposition of methyl groups, allowing recruitment of transcriptional regulators. It also gives an example of trimethylation of H3K4 by specific enzymes. Document 17517655 states that histone modification is done by PKMT", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user wants me to generate a candidate biomedical answer about how histone methyltransferases cause histone modification. Let me look at the evidence provided. First, I need to parse the three pieces of evidence. The first one says that histone methylation involves adding methyl groups to lysine or arginine residues of H3 and H4 by histone methyl transferases or demethylases. The second mentions that these enzymes catalyze site-specific deposition of methyl groups, allowing transcriptional regulators to recruit. Specifically, trimethylation of K4 in H3 is done by six enzymes like SET1a, SET1b, MLL1-MLL4. The third evidence states that histone modification is catalyzed by PKMTs containing a cons", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer based on the provided evidence. The question is about how histone methyltransferases cause histone modification. Let me look at the evidence given. First, the user provided three chunks from different documents. Let me parse each one. The first chunk [32762486:32762486_0] says that histone methylation involves adding methyl groups to lysine or arginine residues of H3 and H4 by histone methyltransferases or demethylases. So this explains the mechanism, mentioning the addition of methyl groups. The second chunk [22483804:22483804_0] talks about histone methyltransfer", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, the user wants me to generate a biomedical answer about how histone methyltransferases cause histone modification. Let me look at the evidence provided. First, I need to parse the three documents. The first one says that histone methylation involves adding methyl groups to lysine or arginine residues of H3 and H4 by histone methyl transferases or demethylases. The second document mentions that these enzymes catalyze site-specific deposition of methyl groups, allowing transcriptional regulators to recruit. It also specifies that trimethylation of K4 in H3 is done by six enzymes like SET1a, SET1b, MLL1-MLL4. The third document states that histone modification is done by PKMTs with a conserved SET domain", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["11316813", "11850410", "12154089", "12893173", "14690609", "15775980", "16409643", "16581777", "17468742", "17548343", "17584191", "17846168", "18058811", "18231586", "18498648", "18846226", "19571682", "20026581", "20305384", "22357272", "22393255", "22476432", "22483804", "23150054", "23195220"], "ideal_answer": "Histone methyltransferases (HMTs) are responsible for the site-specific addition of covalent modifications on the histone tails, which serve as markers for the recruitment of chromatin organization complexes. There are two major types of HMTs: histone-lysine N-Methyltransferases and histone-arginine N-methyltransferases. The former methylate specific lysine (K) residues such as 4, 9, 27, 36, and 79 on histone H3 and residue 20 on histone H4. The latter methylate arginine (R) residues such as 2, 8, 17, and 26 on histone H3 and residue 3 on histone H4. Depending on what residue is modified and the degree of methylation (mono-, di- and tri-methylation), lysine methylation of histones is linked to either transcriptionally active or silent chromatin."}
{"question_id": "54ede5df94afd61504000007", "question": "Is there an increased risk for cancer in Dyskeratosis Congenita?", "retrieved_chunks": [{"doc_id": "23619122", "chunk_id": "23619122_1", "score": 9.735652923583984, "text": "Patients with dyskeratosis congenita (DC) have an increased risk of cancer, but also exhibit heightened radiation sensitivity."}, {"doc_id": "23619122", "chunk_id": "23619122_0", "score": 9.648103713989258, "text": "Patients with dyskeratosis congenita (DC) have an increased risk of cancer, but also exhibit heightened radiation sensitivity"}, {"doc_id": "22932338", "chunk_id": "22932338_2", "score": 8.47535514831543, "text": "Dyskeratosis congenita is a rare condition; however, it is vital to recognise the increased risk of upper aerodigestive tract cancers in these patients."}], "context": "[23619122:23619122_1] Patients with dyskeratosis congenita (DC) have an increased risk of cancer, but also exhibit heightened radiation sensitivity.\n[23619122:23619122_0] Patients with dyskeratosis congenita (DC) have an increased risk of cancer, but also exhibit heightened radiation sensitivity\n[22932338:22932338_2] Dyskeratosis congenita is a rare condition; however, it is vital to recognise the increased risk of upper aerodigestive tract cancers in these patients.", "answer": "<think> Okay, let's tackle this query. The user is asking if there's an increased cancer risk in Dyskeratosis Congenita. The evidence provided has three chunks. First, I need to check each chunk for relevant information. The first two chunks (23619122:23619122_1 and _0) both state that patients with DC have an increased risk of cancer. The third chunk (22932338:22932338_2) mentions an increased risk of upper aerodigestive tract cancers specifically. So, the answer should confirm the increased risk, citing all three sources. Wait, but the third chunk is about a specific type of cancer. The", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this query. The user is asking if there's an increased cancer risk in Dyskeratosis Congenita. The evidence provided has three chunks. First, I need to check each chunk for relevant information. The first two chunks (23619122:23619122_1 and _0) both state that patients with DC have an increased risk of cancer. The third chunk (22932338:22932338_2) mentions an increased risk of upper aerodigestive tract cancers specifically. So, the answer should confirm the increased risk, citing all three sources. Wait, but the third chunk is about a specific type of cancer. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if there's an increased cancer risk in Dyskeratosis Congenita. Looking at the evidence provided, there are three chunks. First chunk (23619122:23619122_1) says patients with DC have an increased cancer risk and heightened radiation sensitivity. The second chunk is a duplicate of the first, so that's redundant. The third chunk (22932338:22932338_2) mentions that DC is rare but important to recognize the increased risk of upper aerodigestive tract cancers. So, all three pieces of evidence point to an increased cancer risk. The answer needs to be concise", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there's an increased cancer risk in Dyskeratosis Congenita. The evidence provided has three chunks. First, I need to check each chunk for relevant information. The first two chunks (23619122_1 and 23619122_0) both state that patients with DC have an increased risk of cancer. The third chunk (22932338_2) mentions that DC is rare but important to recognize the increased risk of upper aerodigestive tract cancers. So, all three pieces of evidence support the idea that there's an increased cancer risk. The answer should be concise, citing the relevant documents. The confidence level should", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if there's an increased cancer risk in Dyskeratosis Congenita. Looking at the evidence provided, there are three chunks. First, chunk 23619122_1 says patients with DC have an increased risk of cancer and heightened radiation sensitivity. Then chunk 23619122_0 is a duplicate of that. Chunk 22932338_2 mentions it's a rare condition but emphasizes the increased risk of upper aerodigestive tract cancers. So, all three pieces of evidence point to an increased cancer risk. The answer should be concise, citing the relevant chunks. The base confidence is high because multiple sources confirm this. I", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there's an increased cancer risk in Dyskeratosis Congenita. The evidence provided has three chunks. First, I need to check each chunk for relevant information. The first two chunks (both from 23619122) state that patients with DC have an increased risk of cancer and heightened radiation sensitivity. The third chunk (22932338) mentions that DC is rare but important to recognize the increased risk of upper aerodigestive tract cancers. So, all three pieces of evidence point to an increased cancer risk. The answer should be concise, citing the relevant documents. The base confidence is high because multiple sources confirm this. I need to make sure the answer", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there's an increased cancer risk in Dyskeratosis Congenita. Looking at the evidence provided, there are three references. First, the two entries with ID 23619122 both mention that patients with DC have an increased risk of cancer and heightened radiation sensitivity. Then, the third entry from 22932338 emphasizes that DC is rare but crucial to recognize the increased risk of upper aerodigestive tract cancers. So, all three pieces of evidence point to an increased cancer risk. The first two are duplicates, so they reinforce each other. The third one specifies the type of cancer, but the main point is still the increased risk. The answer needs", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there's an increased risk of cancer in Dyskeratosis Congenita. The evidence provided has three chunks. First, I need to check each chunk for relevant information. The first two chunks (23619122_1 and 23619122_0) both state that patients with DC have an increased risk of cancer. They also mention heightened radiation sensitivity, but the question is about cancer risk, so that part might not be directly relevant. The third chunk (22932338_2) specifically mentions upper aerodigestive tract cancers, which is a type of cancer. So all three chunks support the idea of increased cancer risk", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there's an increased cancer risk in Dyskeratosis Congenita. Looking at the evidence provided, there are three chunks. First chunk (23619122:23619122_1) says patients with DC have increased cancer risk and heightened radiation sensitivity. The second chunk is a duplicate of the first, so that's redundant. The third chunk (22932338:22932338_2) mentions that DC is rare but important to recognize the increased risk of upper aerodigestive tract cancers. So, all three sources point to an increased cancer risk. The answer needs to be concise with citations. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["17825470", "18054794", "18938267", "19327580", "19558498", "20301779", "20507306", "20925138", "22058220", "22362038", "22932338", "23352883", "23541441", "23619122", "24034063"], "ideal_answer": "People with DC are at increased risk for progressive bone marrow failure (BMF), myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML), solid tumors (usually squamous cell carcinoma of the head/neck or anogenital cancer), and pulmonary fibrosis Yes. Clinical progression of the disease can lead to aplastic anemia (86% of all patients) and to pulmonary or hepatic complications. These patients also have an increased risk of cancer. Adverse events include severe bone marrow failure (BMF), myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML), and solid tumours (ST) People with Dyskeratosis Congenita are at increased risk for progressive bone marrow failure (BMF), myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML), solid tumors (usually squamous cell carcinoma of the head/neck or anogenital cancer), and pulmonary fibrosis."}
{"question_id": "54f4703764850a5854000008", "question": "Does MicroRNA-21 (miR-21) contribute to cardiovascular disease?", "retrieved_chunks": [{"doc_id": "20560046", "chunk_id": "20560046_2", "score": 9.697111129760742, "text": "MicroRNA-21 (miR-21) is a highly expressed microRNA (miRNA) in cardiovascular system. Recent studies have revealed that its expression is deregulated in heart and vasculature under cardiovascular disease conditions such as proliferative vascular disease, cardiac hypertrophy and heart failure, and ischemic heart disease. miR-21 is found to play important roles in vascular smooth muscle cell proliferation and apoptosis, cardiac cell growth and death, and cardiac fibroblast functions. Accordingly, miR-21 is proven to be involved in the pathogenesis of the above-mentioned cardiovascular diseases as demonstrated by both loss-of-function and gain-of-function approaches."}, {"doc_id": "21712654", "chunk_id": "21712654_1", "score": 8.08331298828125, "text": "The small regulatory RNA microRNA-21 (miR-21) plays a crucial role in a plethora of biological functions and diseases including development, cancer, cardiovascular diseases and inflammation."}, {"doc_id": "19043405", "chunk_id": "19043405_2", "score": 8.05282211303711, "text": "Our results validate miR-21 as a disease target in heart failure and establish the therapeutic efficacy of microRNA therapeutic intervention in a cardiovascular disease setting."}], "context": "[20560046:20560046_2] MicroRNA-21 (miR-21) is a highly expressed microRNA (miRNA) in cardiovascular system. Recent studies have revealed that its expression is deregulated in heart and vasculature under cardiovascular disease conditions such as proliferative vascular disease, cardiac hypertrophy and heart failure, and ischemic heart disease. miR-21 is found to play important roles in vascular smooth muscle cell proliferation and apoptosis, cardiac cell growth and death, and cardiac fibroblast functions. Accordingly, miR-21 is proven to be involved in the pathogenesis of the above-mentioned cardiovascular diseases as demonstrated by both loss-of-function and gain-of-function approaches.\n[21712654:21712654_1] The small regulatory RNA microRNA-21 (miR-21) plays a crucial role in a plethora of biological functions and diseases including development, cancer, cardiovascular diseases and inflammation.\n[19043405:19043405_2] Our results validate miR-21 as a disease target in heart failure and establish the therapeutic efficacy of microRNA therapeutic intervention in a cardiovascular disease setting.", "answer": "<think> Okay, let's tackle this query. The user is asking if MicroRNA-21 (miR-21) contributes to cardiovascular disease. I need to look at the provided evidence to form a concise answer with citations and a confidence score. First, I'll check each of the three evidence documents. The first document [20560046:20560046_2] says that miR-21 is highly expressed in the cardiovascular system and its expression is deregulated in various cardiovascular diseases like heart failure, ischemic heart disease, etc. It also mentions roles in vascular smooth muscle cell proliferation, cardiac cell growth/death, and fibroblast functions. They even cite loss-of-function and gain-of-function studies showing", "citations": [{"doc_id": "20560046", "chunk_id": "20560046_2"}], "candidates": [{"answer": "<think> Okay, let's tackle this query. The user is asking if MicroRNA-21 (miR-21) contributes to cardiovascular disease. I need to look at the provided evidence to form a concise answer with citations and a confidence score. First, I'll check each of the three evidence documents. The first document [20560046:20560046_2] says that miR-21 is highly expressed in the cardiovascular system and its expression is deregulated in various cardiovascular diseases like heart failure, ischemic heart disease, etc. It also mentions roles in vascular smooth muscle cell proliferation, cardiac cell growth/death, and fibroblast functions. They even cite loss-of-function and gain-of-function studies showing", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a JSON answer based on the provided evidence. The question is whether MicroRNA-21 (miR-21) contributes to cardiovascular disease. First, I'll look at the evidence documents. Document 20560046:20560046_2 says that miR-21 is highly expressed in the cardiovascular system and its expression is deregulated in various cardiovascular diseases like heart failure, ischemic heart disease, etc. It also mentions roles in vascular smooth muscle cell proliferation, cardiac cell growth and death, and fibroblast functions. The document states that miR-21 is involved in the pathogenesis of these diseases through loss-of-function and gain-of-function studies. Document 2", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the provided evidence. The question is whether MicroRNA-21 (miR-21) contributes to cardiovascular disease. Looking at the evidence: First document [20560046:20560046_2] says that miR-21 is highly expressed in the cardiovascular system and its expression is deregulated in various cardiovascular diseases like heart failure, ischemic heart disease, etc. It also mentions roles in vascular smooth muscle cell proliferation, cardiac cell growth and death, and fibroblast functions. They note that miR-21 is involved in the pathogenesis of these diseases through loss-of-function and gain-of-function studies. Second document [21712", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if MicroRNA-21 (miR-21) contributes to cardiovascular disease. I need to look at the provided evidence to form a concise answer with citations and a confidence level. First, checking the evidence documents. Document 20560046:20560046_2 mentions that miR-21 is highly expressed in the cardiovascular system and its expression is deregulated in various cardiovascular diseases like heart failure, ischemic heart disease, etc. It also states that miR-21 plays roles in vascular smooth muscle cell proliferation, cardiac cell growth and death, and fibroblast functions. The pathogenesis of these diseases is linked to miR-2", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the provided evidence. The question is whether MicroRNA-21 (miR-21) contributes to cardiovascular disease. Let me look at the evidence. First document: 20560046:20560046_2 says that miR-21 is highly expressed in the cardiovascular system and its expression is deregulated in various cardiovascular diseases like heart failure, cardiac hypertrophy, etc. It mentions roles in vascular smooth muscle cell proliferation, apoptosis, cardiac cell growth/death, and fibroblast functions. They also say that miR-21 is involved in the pathogenesis of these diseases through loss-of-function and gain-of-function studies. So this directly supports the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking if MicroRNA-21 (miR-21) contributes to cardiovascular disease. I need to look at the provided evidence and generate a concise answer with citations. First, I'll check each evidence snippet. The first one [20560046:20560046_2] says miR-21 is highly expressed in the cardiovascular system and its expression is deregulated in various cardiovascular diseases like heart failure, cardiac hypertrophy, etc. It also mentions roles in vascular smooth muscle cell proliferation, apoptosis, and cardiac fibroblast functions. The study uses loss-of-function and gain-of-function approaches to show its involvement in pathogenesis. The second evidence [21", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a JSON answer based on the provided evidence. The question is whether MicroRNA-21 (miR-21) contributes to cardiovascular disease. Looking at the evidence: First document [20560046:20560046_2] says that miR-21 is highly expressed in the cardiovascular system and its expression is deregulated in various cardiovascular diseases like heart failure, ischemic heart disease, etc. It mentions roles in vascular smooth muscle cell proliferation, cardiac cell growth and death, and fibroblast functions. Also, loss-of-function and gain-of-function studies show it's involved in pathogenesis. Second document [21712654:217126", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if MicroRNA-21 (miR-21) contributes to cardiovascular disease. I need to look at the provided evidence to form an answer. First, I'll go through each of the evidence chunks. The first one, 20560046:20560046_2, says that miR-21 is highly expressed in the cardiovascular system and that its expression is deregulated in various cardiovascular diseases like heart failure, ischemic heart disease, etc. It also mentions roles in vascular smooth muscle cell proliferation, cardiac cell growth and death, and fibroblast functions. The conclusion here is that miR-21 is involved in the pathogenesis of", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["19043405", "19336275", "19706597", "20015039", "20219857", "20560046", "20649511", "20959496", "20980922", "21464712", "21712654", "22038740", "22859901", "22882958", "22960625", "23691029"], "ideal_answer": "MicroRNA-21 (miR-21) is a highly expressed microRNA (miRNA) in cardiovascular system. Recent studies have revealed that its expression is deregulated in heart and vasculature under cardiovascular disease conditions such as proliferative vascular disease, cardiac hypertrophy and heart failure, and ischemic heart disease. miR-21 is found to play important roles in vascular smooth muscle cell proliferation and apoptosis, cardiac cell growth and death, and cardiac fibroblast functions. Accordingly, miR-21 is proven to be involved in the pathogenesis of the above-mentioned cardiovascular diseases as demonstrated by both loss-of-function and gain-of-function approaches"}
{"question_id": "552421082c8b63434a000005", "question": "What is the enzymatic activity of the breast cancer associated gene BRCA1?", "retrieved_chunks": [{"doc_id": "16479151", "chunk_id": "16479151_0", "score": 6.5967020988464355, "text": "Discovering the precise function of the breast and ovarian specific tumor suppressor, BRCA1, has proven to be quite complicated. It has been determined that BRCA1, together with BARD1, comprise an E3 ubiquitin ligase. Since it is now known that BRCA1 is an enzyme, the challenge for BRCA1 research is to learn how this enzymatic activity functions in normal breast and ovarian cells in order to suppress cancerous transformation."}, {"doc_id": "20681793", "chunk_id": "20681793_0", "score": 6.250486373901367, "text": "E3-ubiquitin ligase activity is the only known enzymatic activity of BRCA1, which is mediated by the N-terminal RING finger domain."}, {"doc_id": "24278741", "chunk_id": "24278741_0", "score": 6.209160804748535, "text": "BRCA1 nuclear transport and ubiquitin E3 ligase enzymatic activity are tightly regulated by the BRCA1 dimeric binding partner BARD1 and further modulated by cancer mutations and diverse signaling pathways."}], "context": "[16479151:16479151_0] Discovering the precise function of the breast and ovarian specific tumor suppressor, BRCA1, has proven to be quite complicated. It has been determined that BRCA1, together with BARD1, comprise an E3 ubiquitin ligase. Since it is now known that BRCA1 is an enzyme, the challenge for BRCA1 research is to learn how this enzymatic activity functions in normal breast and ovarian cells in order to suppress cancerous transformation.\n[20681793:20681793_0] E3-ubiquitin ligase activity is the only known enzymatic activity of BRCA1, which is mediated by the N-terminal RING finger domain.\n[24278741:24278741_0] BRCA1 nuclear transport and ubiquitin E3 ligase enzymatic activity are tightly regulated by the BRCA1 dimeric binding partner BARD1 and further modulated by cancer mutations and diverse signaling pathways.", "answer": "<think> Okay, let's tackle this question. The user is asking about the enzymatic activity of the BRCA1 gene, which is associated with breast cancer. First, I need to look at the evidence provided. There are three documents here. Let me read through each one carefully. The first document (16479151:16479151_0) says that BRCA1, along with BARD1, forms an E3 ubiquitin ligase. It also mentions that BRCA1 is an enzyme, but the exact function in normal cells is still under study. This seems to point towards E3 ligase activity, but it's a bit vague. The second document (20681793:20", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the enzymatic activity of the BRCA1 gene, which is associated with breast cancer. First, I need to look at the evidence provided. There are three documents here. Let me read through each one carefully. The first document (16479151:16479151_0) says that BRCA1, along with BARD1, forms an E3 ubiquitin ligase. It also mentions that BRCA1 is an enzyme, but the exact function in normal cells is still under study. This seems to point towards E3 ligase activity, but it's a bit vague. The second document (20681793:20", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the enzymatic activity of the BRCA1 gene, which is associated with breast cancer. I need to look at the provided evidence to find the correct answer. First, I'll go through each of the evidence chunks. The first one (16479151:1647915ity) mentions that BRCA1 is part of an E3 ubiquitin ligase with BARD1. It also states that BRCA1 is an enzyme, but it doesn't specify the exact activity. The second chunk (20681793:20681793_0) clearly says that the only known enzymatic activity of BRCA1", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about the enzymatic activity of BRCA1. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three documents here. Let me read through them carefully. Document 16479151 says that BRCA1 is an enzyme and part of an E3 ubiquitin ligase with BARD1. It mentions that the challenge is understanding how this enzymatic activity works in normal cells. But it doesn't specify the exact activity. Document 20681793 states that the only known enzymatic activity of BRCA1 is E3-ubiquitin ligase, mediated by the N-terminal RING finger domain. This seems", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the enzymatic activity of the BRCA1 gene, which is associated with breast cancer. I need to look at the provided evidence to find the correct answer. First, I'll check each of the three evidence snippets. The first one says that BRCA1, along with BARD1, forms an E3 ubiquitin ligase. It also mentions that BRCA1 is an enzyme, but it doesn't specify the exact activity. The second snippet clearly states that the only known enzymatic activity of BRCA1 is E3-ubiquitin ligase activity, mediated by the N-terminal RING finger domain. The third snippet talks about BRCA1's nuclear transport and ubiquitin E3 ligase", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about the enzymatic activity of BRCA1. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. The first document says that BRCA1 is part of an E3 ubiquitin ligase with BARD1. The second mentions that the only known enzymatic activity of BRCA1 is E3-ubiquitin ligase activity mediated by the N-terminal RING finger domain. The third document reinforces that BRCA1's enzymatic activity, including ubiquitin E3 ligase function, is regulated by BARD1 and other factors. So the main point here is that BRCA1's enzymatic activity is as an E3 ubiquitin ligase. The key citation", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the enzymatic activity of the BRCA1 gene, which is associated with breast cancer. First, I need to look at the evidence provided. There are three documents here. Let me go through each one. Document 16479151: It mentions that BRCA1, along with BARD1, forms an E3 ubiquitin ligase. It also states that BRCA1 is an enzyme, but the exact function in normal cells is still a research challenge. This suggests that BRCA1 has enzymatic activity related to ubiquitination. Document 20681793: This one clearly says that the only known enzymatic activity of BRCA1 is E3", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the enzymatic activity of the BRCA1 gene, which is associated with breast cancer. First, I need to look at the evidence provided. There are three documents here. Let me go through each one. The first document (16479151:16479151_0) mentions that BRCA1, along with BARD1, forms an E3 ubiquitin ligase. It also states that BRCA1 is an enzyme, but the exact function in normal cells is still under research. So this document points to E3 ubiquitin ligase activity, but it's a bit vague. The second document (20681793:2", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about the enzymatic activity of BRCA1. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three documents here. Let me go through each one. Document 16479151: It says BRCA1 is part of an E3 ubiquitin ligase with BARD1. Also mentions that BRCA1 is an enzyme, but doesn't specify the exact activity. Document 20681793: This one clearly states that the only known enzymatic activity of BRCA1 is E3-ubiquitin ligase activity, mediated by the N-terminal RING finger domain. That's a direct statement. Document", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["15254397", "16479151", "16710298", "17420471", "19088202", "20681793", "22034435", "24278741"], "ideal_answer": "E3-ubiquitin ligase activity is the only known enzymatic activity of BRCA1, which is mediated by the N-terminal RING finger domain.BRCA1 nuclear transport and ubiquitin E3 ligase enzymatic activity are tightly regulated by the BRCA1 dimeric binding partner BARD1 and further modulated by cancer mutations and diverse signaling pathways. Discovering the precise function of the breast and ovarian specific tumor suppressor, BRCA1, has proven to be quite complicated. The protein encoded by BRCA1 interacts in vivo with the related BARD1 protein to form a heterodimeric complex that acts as a ubiquitin E3 ligase. E3-ubiquitin ligase activity is the only known enzymatic activity of BRCA1, which is mediated by the N-terminal RING finger domain."}
{"question_id": "5505b9ff8e1671127b000001", "question": "List markers for autophagy.", "retrieved_chunks": [{"doc_id": "23117929", "chunk_id": "23117929_0", "score": 7.200627326965332, "text": "autophagy marker LC3"}, {"doc_id": "22807527", "chunk_id": "22807527_0", "score": 7.200627326965332, "text": "autophagy marker LC3"}, {"doc_id": "23608825", "chunk_id": "23608825_0", "score": 7.187827110290527, "text": "the autophagy marker LC3,"}], "context": "[23117929:23117929_0] autophagy marker LC3\n[22807527:22807527_0] autophagy marker LC3\n[23608825:23608825_0] the autophagy marker LC3,", "answer": "<think> Okay, the user is asking for markers of autophagy. Let me check the evidence provided. The evidence has three entries. All of them mention LC3 as an autophagy marker. The first two references [23117929:23117929_0] and [22807527:22807527_0] both state that LC3 is an autophagy marker. The third one [23608825:23608829_0] also mentions LC3 as the autophagy marker. So, the answer should be LC3 with citations from all three documents. But wait, the user wants a concise", "citations": [{"doc_id": "23117929", "chunk_id": "23117929_0"}, {"doc_id": "22807527", "chunk_id": "22807527_0"}, {"doc_id": "23608825", "chunk_id": "23608829_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this query. The user is asking for markers of autophagy. From the evidence provided, there are three entries mentioning LC3 as an autophagy marker. The document IDs and chunk IDs all point to different sources but they all agree on LC3. First, I need to confirm that LC3 is indeed a known marker. From my knowledge, LC3 (Microtubule-associated serine/threonine kinase) is a well-established marker for autophagy. It's involved in the formation of autophagosomal membranes. The evidence here consistently lists it, so that's a solid point. The user wants a concise answer with citations. The format requires the answer to include the marker and the corresponding document IDs. Since all three sources mention", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking for markers of autophagy, and the evidence provided mentions LC3 multiple times. First, I need to check the evidence. Each entry in the Evidence array refers to LC3 as an autophagy marker. The first two entries are from different document IDs but both cite LC3. The third one is a bit more verbose, saying \"the autophagy marker LC3,\" which reinforces that LC3 is the key marker here. The user wants a concise answer with citations in the format [doc_id:chunk_id]. Since all the evidence points to LC3, I should list it as the primary marker. The confidence level should be high because multiple sources mention LC3. However, I need to make sure not", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking for markers of autophagy. Let me look at the evidence provided. The evidence has three entries. All of them mention LC3 as an autophagy marker. The first two are from different document IDs but both reference LC3. The third one also mentions LC3 again. I need to make sure that LC3 is indeed a valid marker. From what I remember, LC3 (microtubule-associated protein 1 light chain 3) is a well-known marker for autophagy. It's involved in the formation of autophagosomes. The evidence here consistently points to LC3, so that's a strong indicator. The answer should be concise and include citations. Each citation is in the format doc_id:chunk", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking for markers of autophagy. Let me look at the evidence provided. The evidence has three entries, all mentioning LC3 as an autophagy marker. The first two entries from 23117929 and 22807527 both state that LC3 is an autophagy marker. The third entry from 23608825 also mentions LC3 as the autophagy marker. I need to make sure that LC3 is indeed a recognized marker for autophagy. From what I remember, LC3 (microtubule-associated protein 1 light chain 3) is a well-established marker used to detect autophagosomes. It's involved in the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's see. The user is asking for markers of autophagy. The evidence provided mentions LC3 multiple times as an autophagy marker. I need to make sure that LC3 is indeed a recognized marker. Looking at the evidence, each entry references LC3 as a marker. The document IDs are different, but they all point to LC3. So the answer should list LC3 as the main marker. The user wants a concise answer with citations. The confidence level should be high since multiple sources mention LC3. I'll structure the JSON with the answer and base confidence. Let me check if there's any other marker mentioned, but the evidence only has LC3. So the answer is straightforward. </think> { \"answer\": \"LC3 is a", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking for markers of autophagy. Let me check the evidence provided. The evidence has three entries. All of them mention LC3 as an autophagy marker. The first two references [23117929:23117929_0] and [22807527:22807527_0] both state that LC3 is an autophagy marker. The third one [23608825:23608829_0] also mentions LC3 as the autophagy marker. So, the answer should be LC3 with citations from all three documents. But wait, the user wants a concise", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, so the user is asking for markers of autophagy. The evidence provided mentions LC3 multiple times as an autophagy marker. Let me check the evidence again. First, the evidence has three entries. All of them refer to LC3 as an autophagy marker. The first two are [23117929:23117929_0] and [22807527:22807527_0], both pointing to LC3. The third one is [23608825:23608825_0], which also mentions LC3. So, the answer should be that LC3 is a marker for aut", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is asking for markers of autophagy. Looking at the evidence provided, there are three entries all mentioning LC3 as an autophagy marker. The document IDs and chunk IDs are different, but they all point to LC3 being a marker. First, I should confirm that LC3 is indeed a known marker for autophagy. From what I remember, LC3 (microtubule-associated protein 1 light chain 3) is a well-established marker used to detect autophagosomes. It's commonly used in experiments to monitor the process of autophagy. The evidence here repeats this information from different sources, which increases confidence in the answer. The user wants the answer concise", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["22652752", "22807527", "23117929", "23182945", "23193914", "23437259", "23598404", "23608825", "23626658", "23727153", "23737395", "23822101", "23940944", "24126619", "24141623", "24231340", "24255881", "24291536"], "ideal_answer": "Expression of LC3-II and BECN1 as well as SQSTM1 are used as markers of autophagy activity."}
{"question_id": "56b29bf545561f0573000003", "question": "Are there any statistical methods for normalizing and identifying differential regions in histone modification ChIP-seq data?", "retrieved_chunks": [{"doc_id": "22870189", "chunk_id": "22870189_0", "score": 9.591415405273438, "text": "ChIPnorm: a statistical method for normalizing and identifying differential regions in histone modification ChIP-seq libraries."}, {"doc_id": "22870189", "chunk_id": "22870189_2", "score": 9.457307815551758, "text": "In this paper we propose a two-stage statistical method, called ChIPnorm, to normalize ChIP-seq data, and to find differential regions in the genome, given two libraries of histone modifications of different cell types. We show that the ChIPnorm method removes most of the noise and bias in the data and outperforms other normalization methods."}, {"doc_id": "22870189", "chunk_id": "22870189_1", "score": 9.222414016723633, "text": "In this paper we propose a two-stage statistical method, called ChIPnorm, to normalize ChIP-seq data, and to find differential regions in the genome, given two libraries of histone modifications of different cell types."}], "context": "[22870189:22870189_0] ChIPnorm: a statistical method for normalizing and identifying differential regions in histone modification ChIP-seq libraries.\n[22870189:22870189_2] In this paper we propose a two-stage statistical method, called ChIPnorm, to normalize ChIP-seq data, and to find differential regions in the genome, given two libraries of histone modifications of different cell types. We show that the ChIPnorm method removes most of the noise and bias in the data and outperforms other normalization methods.\n[22870189:22870189_1] In this paper we propose a two-stage statistical method, called ChIPnorm, to normalize ChIP-seq data, and to find differential regions in the genome, given two libraries of histone modifications of different cell types.", "answer": "<think> Okay, let's tackle this question. The user is asking if there are statistical methods for normalizing and identifying differential regions in histone modification ChIP-seq data. The evidence provided mentions a method called ChIPnorm. First, I need to check the evidence documents. Document [22870189:22870189_0] directly states that ChIPnorm is a statistical method for normalizing and identifying differential regions in histone modification ChIP-seq libraries. The other chunks support this by explaining that it's a two-stage method proposed to normalize data and find differential regions between different cell types. They also mention that it outperforms other methods. So the answer should point to ChIPnorm as the method mentioned in the", "citations": [{"doc_id": "22870189", "chunk_id": "22870189_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if there are statistical methods for normalizing and identifying differential regions in histone modification ChIP-seq data. The evidence provided mentions a method called ChIPnorm. First, I need to check the evidence documents. Document [22870189:22870189_0] directly states that ChIPnorm is a statistical method for normalizing and identifying differential regions in histone modification ChIP-seq libraries. The other chunks support this by explaining that it's a two-stage method proposed to normalize data and find differential regions between different cell types. They also mention that it outperforms other methods. So the answer should point to ChIPnorm as the method mentioned in the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there are statistical methods for normalizing and identifying differential regions in histone modification ChIP-seq data. The evidence provided mentions a method called ChIPnorm. First, I need to check the evidence documents. Document 22870189 has three chunks. The first chunk says that ChIPnorm is a statistical method for normalization and identifying differential regions. The second and third chunks elaborate on it, mentioning a two-stage method that works with two libraries of different cell types and that it outperforms other methods. So the answer should state that ChIPnorm exists as per the evidence. The citation would be from the first chunk, which is [22870189:2", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there are statistical methods for normalizing and identifying differential regions in histone modification ChIP-seq data. Looking at the evidence provided, there's a mention of \"ChIPnorm: a statistical method for normalizing and identifying differential regions in histone modification ChIP-seq libraries.\" That directly answers the question. The paper describes it as a two-stage method. The other chunks elaborate on how it works, saying it removes noise and outperforms other methods. So the answer should mention ChIPnorm and cite the relevant document. The confidence level is high because the evidence clearly states that ChIPnorm is such a method. I'll check if there's any conflicting info, but all the chunks support this.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking if there are statistical methods for normalizing and identifying differential regions in histone modification ChIP-seq data. Looking at the evidence provided, there's a document that mentions \"ChIPnorm: a statistical method for normalizing and identifying differential regions in histone modification ChIP-seq libraries.\" That directly answers the question. The other chunks explain that ChIPnorm is a two-stage method used for normalization and finding differential regions between different cell types. They also state that it outperforms other methods, which adds confidence in its effectiveness. So the answer should mention ChIPnorm as the method, cite the relevant document, and note that it's a two-stage statistical approach. The confidence level can be high since the evidence", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking if there are statistical methods for normalizing and identifying differential regions in histone modification ChIP-seq data. The evidence provided mentions a method called ChIPnorm. First, I need to check the evidence documents. Document 22870189 has three chunks. Chunk 0 says that ChIPnorm is a statistical method for normalization and differential regions. Chunk 1 and ight also mention ChIPnorm as a two-stage method for normalizing ChIP-seq data and finding differential regions. The paper claims it removes noise and outperforms other methods. So, the answer should confirm that ChIPnorm exists as such a method. The citation would be from document 22870", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking if there are statistical methods for normalizing and identifying differential regions in histone modification ChIP-seq data. Looking at the evidence provided, there's a mention of \"ChIPnorm\" in several chunks. The first chunk directly states that ChIPnorm is a statistical method for normalization and identifying differential regions. The second and third chunks elaborate on it, explaining it's a two-stage method used for normalizing ChIP-seq data and finding differential regions between different cell types. They also mention that it outperforms other methods. So the answer should point to ChIPnorm as the method. The citation is from document 22870189, and the specific chunks are 0, 1", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking if there are statistical methods for normalizing and identifying differential regions in histone modification ChIP-seq data. The evidence provided mentions a method called ChIPnorm. First, I need to check the evidence documents. Document 22870189 has three chunks. Chunk 0 says ChIPnorm is a statistical method for normalization and identifying differential regions. Chunk 1 and 2 elaborate on it being a two-stage method that normalizes data and finds differential regions between different cell types. They also mention it outperforms other methods. So the answer should reference ChIPnorm as the method mentioned in the evidence. The confidence is high because the documents directly state that ChIPnorm does exactly what the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user is asking if there are statistical methods for normalizing and identifying differential regions in histone modification ChIP-seq data. The evidence provided mentions a method called ChIPnorm. First, I need to check the evidence documents. The first document [22870189:22870189_0] directly states that ChIPnorm is a statistical method for normalization and identifying differential regions. The other chunks elaborate on this, explaining it's a two-stage method used for different cell types. The confidence here is high because the answer is explicitly stated in the evidence. So the answer should be yes, citing the first document. The base_confidence would be 1.0 since the evidence clearly", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["22870189"], "ideal_answer": "Yes. ChIPnorm is a two-stage statistical method to normalize ChIP-seq data, and to find differential regions in the genome, given two libraries of histone modifications of different cell types."}
{"question_id": "52ef7170c8da898910000012", "question": "Is CD84 genetically associated with arthritis?", "retrieved_chunks": [{"doc_id": "23555300", "chunk_id": "23555300_0", "score": 2.0527539253234863, "text": "Our study demonstrates that an allele associated with response to etanercept therapy is also associated with CD84 gene expression, and further that CD84 expression correlates with disease activity"}, {"doc_id": "17341507", "chunk_id": "17341507_0", "score": 1.170168161392212, "text": "Anti-citrullinated peptide antibodies (ACPA) and the C1858T missense single-nucleotide polymorphism (SNP) in the PTPN22 gene are both associated with the development of rheumatoid arthritis (RA)"}, {"doc_id": "17666451", "chunk_id": "17666451_1", "score": 0.36346912384033203, "text": "HLA-DRB1 shared epitope (HLA-SE), PTPN22 and CTLA4 alleles are associated with cyclic citrullinated peptide (CCP) and rheumatoid arthritis (RA)"}], "context": "[23555300:23555300_0] Our study demonstrates that an allele associated with response to etanercept therapy is also associated with CD84 gene expression, and further that CD84 expression correlates with disease activity\n[17341507:17341507_0] Anti-citrullinated peptide antibodies (ACPA) and the C1858T missense single-nucleotide polymorphism (SNP) in the PTPN22 gene are both associated with the development of rheumatoid arthritis (RA)\n[17666451:17666451_1] HLA-DRB1 shared epitope (HLA-SE), PTPN22 and CTLA4 alleles are associated with cyclic citrullinated peptide (CCP) and rheumatoid arthritis (RA)", "answer": "<think> Okay, let's tackle this question. The user is asking if CD84 is genetically associated with arthritis. I need to check the evidence provided. Looking at the first evidence snippet: [23555300:23555300_0] mentions that an allele linked to etanercept response is associated with CD84 gene expression and correlates with disease activity. So this suggests a connection between CD84 and arthritis, maybe rheumatoid arthritis since it's about disease activity. The second snippet [17341507:17341507_0] talks about ACPA and a SNP in PTPN22 related to RA. But that's about PTPN2", "citations": [{"doc_id": "23555300", "chunk_id": "23555300_0"}, {"doc_id": "17341507", "chunk_id": "17341507_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if CD84 is genetically associated with arthritis. I need to check the evidence provided. Looking at the first evidence snippet: [23555300:23555300_0] mentions that an allele linked to etanercept response is associated with CD84 gene expression and correlates with disease activity. So this suggests a connection between CD84 and arthritis, maybe rheumatoid arthritis since it's about disease activity. The second snippet [17341507:17341507_0] talks about ACPA and a SNP in PTPN22 related to RA. But that's about PTPN2", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if CD84 is genetically associated with arthritis. I need to look at the evidence provided. First, check the evidence documents. The first one [23555300:23555300_0] mentions that an allele linked to response to etanercept therapy is associated with CD84 gene expression and correlates with disease activity. So this suggests a connection between CD84 and disease activity, which could relate to arthritis. The second evidence [17341507:17341507_0] talks about ACPA and a SNP in PTPN22 gene associated with RA. But that's about PTP", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if CD84 is genetically associated with arthritis. I need to look at the provided evidence to find any mentions of CD84 and arthritis. Looking at the first evidence snippet: [23555300:23555300_0] says that an allele related to etanercept response is associated with CD84 gene expression, and that CD84 expression correlates with disease activity. So this suggests a link between CD84 and disease activity, which could be part of arthritis. But the study here is about response to therapy and disease activity, not directly arthritis itself. The second snippet [17341507:173415", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if CD84 is genetically associated with arthritis. I need to check the provided evidence to see if there's any mention of CD84 in relation to arthritis. Looking at the first piece of evidence: [23555300:23555300_0] talks about an allele linked to etanercept response and CD84 gene expression, which correlates with disease activity. So that's a direct mention of CD84 and disease activity, which is related to arthritis. But the study here is about a specific allele associated with therapy response and gene expression, not necessarily arthritis itself. The second evidence [17341507:1734", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if CD84 is genetically associated with arthritis. The evidence provided has three chunks. First chunk: It mentions that an allele linked to response to etanercept therapy is associated with CD84 gene expression and correlates with disease activity. So this suggests a connection between CD84 and disease activity, which could relate to arthritis. Second chunk: Talks about ACPA and a SNP in PTPN22 being associated with RA. But that's about PTPN22, not CD84. So maybe not directly relevant here. Third chunk: HLA-DRB1, PTPN22, and CTLA4 are linked to CCP and RA. Again, PTPN22", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if CD84 is genetically associated with arthritis. I need to look at the provided evidence to find any mentions of CD84 and arthritis. First, looking at the first evidence snippet: [23555300:23555300_0] talks about an allele linked to etanercept response and CD84 gene expression, which correlates with disease activity. So this suggests a connection between CD84 and arthritis since disease activity is mentioned. But the study here is about response to therapy, maybe in RA? Next, the second evidence [17341507:17341507_0] mentions ACPA and", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if CD84 is genetically associated with arthritis. I need to look at the provided evidence to find any mention of CD84 and arthritis. First, looking at the first piece of evidence: [23555300:23555300_0] says that an allele linked to response to etanercept therapy is associated with CD84 gene expression and correlates with disease activity. So this suggests a connection between CD84 and disease activity, which could be related to arthritis. But the study here is about response to treatment, not directly arthritis itself. Next, the second evidence: [17341507:1734150", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if CD84 is genetically associated with arthritis. The evidence provided has three chunks. First chunk: 23555300 mentions that an allele linked to response to etanercept therapy is associated with CD84 gene expression and correlates with disease activity. So, this suggests a connection between CD84 and disease activity, which could relate to arthritis. Second chunk: 17341507 talks about ACPA and a SNP in PTPN22 being linked to RA. But that's about PTPN22, not CD84. So maybe not directly relevant here. Third chunk: 17666451 mentions HLA-", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["21094032", "21255096", "23555300"], "ideal_answer": "Three members of this gene family, Ly108, Ly9, and CD84, exhibit polymorphisms that strongly influence susceptibility to systemic autoimmunity, notably in mice, but also in some human populations. Our study demonstrates that an allele associated with response to etanercept therapy is also associated with CD84 gene expression, and further that CD84 expression correlates with Rheumatoid Arthritis disease activity."}
{"question_id": "5719f5b27de986d80d00000c", "question": "What is the function of Neu5Gc (N-Glycolylneuraminic acid)?", "retrieved_chunks": [{"doc_id": "23520510", "chunk_id": "23520510_1", "score": 7.762966156005859, "text": "N-glycolylneuraminic acid (Neu5Gc) is an immunogenic sugar of dietary origin that metabolically incorporates into diverse native glycoconjugates in humans."}, {"doc_id": "25003133", "chunk_id": "25003133_1", "score": 7.173343658447266, "text": "N-Glycolylneuraminic acid (Neu5Gc) is a sialic acid synthesized by animals, but not by humans or birds. However, it can be incorporated in human cells and can trigger immune response."}, {"doc_id": "25517696", "chunk_id": "25517696_0", "score": 7.135473728179932, "text": "Mammals express the sialic acids N-acetylneuraminic acid (Neu5Ac) and N-glycolylneuraminic acid (Neu5Gc) on cell surfaces, where they act as receptors for pathogens, including influenza A virus (IAV). Neu5Gc is synthesized from Neu5Ac by the enzyme cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH)."}], "context": "[23520510:23520510_1] N-glycolylneuraminic acid (Neu5Gc) is an immunogenic sugar of dietary origin that metabolically incorporates into diverse native glycoconjugates in humans.\n[25003133:25003133_1] N-Glycolylneuraminic acid (Neu5Gc) is a sialic acid synthesized by animals, but not by humans or birds. However, it can be incorporated in human cells and can trigger immune response.\n[25517696:25517696_0] Mammals express the sialic acids N-acetylneuraminic acid (Neu5Ac) and N-glycolylneuraminic acid (Neu5Gc) on cell surfaces, where they act as receptors for pathogens, including influenza A virus (IAV). Neu5Gc is synthesized from Neu5Ac by the enzyme cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH).", "answer": "<think> Okay, so I need to figure out the function of Neu5Gc based on the given evidence. Let me start by reading through the evidence provided. The first piece of evidence says that Neu5Gc is an immunogenic sugar from dietary origin that incorporates into human glycoconjugates. The second mentions that it's a sialic acid synthesized by animals but not humans or birds, yet it can be incorporated into human cells and trigger immune responses. The third states that mammals have both Neu5Ac and Neu5Gc on cell surfaces as pathogen receptors, including IAV, and Neu5Gc is made from Neu5Ac via CMAH. Putting this together, the function of Neu5Gc seems to involve its role as a receptor for pathogens", "citations": [], "candidates": [{"answer": "<think> Okay, so I need to figure out the function of Neu5Gc based on the given evidence. Let me start by reading through the evidence provided. The first piece of evidence says that Neu5Gc is an immunogenic sugar from dietary origin that incorporates into human glycoconjugates. The second mentions that it's a sialic acid synthesized by animals but not humans or birds, yet it can be incorporated into human cells and trigger immune responses. The third states that mammals have both Neu5Ac and Neu5Gc on cell surfaces as pathogen receptors, including IAV, and Neu5Gc is made from Neu5Ac via CMAH. Putting this together, the function of Neu5Gc seems to involve its role as a receptor for pathogens", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a biomedical answer about the function of Neu5Gc based on the provided evidence. Let me start by reading through the evidence carefully. First, the user provided three documents. Let's break them down: Document 23520510: It says that Neu5Gc is an immunogenic sugar from dietary origin and incorporates into human glycoconjugates. So that's about its immunogenicity and presence in human cells. Document 25003133: Neu5Gc is a sialic acid synthesized by animals but not humans or birds. However, it can be incorporated into human cells and trigger immune responses. This suggests that even though humans don't make it, they can have it from", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about the function of Neu5Gc. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three chunks here. Let me go through each one. The first chunk says Neu5Gc is an immunogenic sugar from dietary origin that incorporates into human glycoconjugates. So that's about its role in immune response and being dietary. Second chunk mentions that Neu5Gc is a sialic acid synthesized by animals but not humans or birds. However, it can be incorporated into human cells and trigger immune responses. This reinforces the immunogenic aspect and its presence in humans via diet. Third chunk states that mammals have both Neu5Ac and Neu5G", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know the function of Neu5Gc, and I need to generate a biomedical answer based on the provided evidence. First, I'll look at the evidence given. There are three chunks from different documents. Let me parse each one. The first chunk says Neu5Gc is an immunogenic sugar from dietary origin that incorporates into human glycoconjugates. So that's about its immunogenicity and presence in humans via diet. The second chunk mentions that Neu5Gc is a sialic acid made by animals but not humans or birds. However, it can be incorporated into human cells and trigger immune responses. This seems to confirm the first point about immune response, but also adds that even though humans don", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the provided evidence. Let me start by understanding the question: What is the function of Neu5Gc? Looking at the evidence, there are three chunks. The first one says Neu5Gc is an immunogenic sugar from diet that incorporates into human glycoconjugates. The second mentions it's a sialic acid synthesized by animals but not humans or birds, yet it can enter human cells and trigger immune responses. The third states that mammals have Neu5Gc on cell surfaces as receptors for pathogens like IAV, and it's made from Neu5Ac via CMAH. So the function of Neu5Gc would involve its role as a receptor for pathogens, being immunogenic, and possibly triggering", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a biomedical answer about the function of Neu5Gc based on the provided evidence. Let me start by reading through the evidence carefully. First, the user provided three documents. The first one says that Neu5Gc is an immunogenic sugar from dietary origin that incorporates into human glycoconjugates. The second mentions that it's a sialic acid synthesized by animals but not humans or birds, yet it can enter human cells and trigger immune responses. The third document states that mammals have both Neu5Ac and Neu5Gc on cell surfaces, acting as receptors for pathogens like influenza A virus. It also notes that Neu5Gc is made from Neu5Ac via the CMAH enzyme. So the question is about the function", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. Let me start by understanding the question: What is the function of Neu5Gc? Looking at the evidence: First document says Neu5Gc is an immunogenic sugar from dietary origin that incorporates into human glycoconjugates. So that's about its role in immune response. Second document mentions it's a sialic acid synthesized by animals but not humans or birds, yet it can be incorporated into human cells and trigger immune responses. So this reinforces the immunogenic aspect. Third document states that mammals have both Neu5Ac and Neu5Gc on cell surfaces as pathogen receptors, including IAV. Also, Neu5Gc is made from Neu5Ac via CMAH enzyme", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about the function of Neu5Gc. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three chunks here. Let me go through each one. The first chunk says Neu5Gc is an immunogenic sugar from dietary origin that incorporates into human glycoconjugates. So that's about its role in immune response and presence in humans. Second chunk mentions that Neu5Gc is a sialic acid synthesized by animals but not humans or birds. However, it can be incorporated into human cells and trigger immune responses. This reinforces the idea of immune triggering and dietary incorporation. Third chunk states that mammals have both Neu5Ac and Neu5Gc on", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["11786991", "18669916", "23520510", "23945141", "25003133", "25124893"], "ideal_answer": "N-glycolylneuraminic acid (Neu5Gc) is an immunogenic sugar of dietary origin that metabolically incorporates into diverse native glycoconjugates in humans. Humans lack a functional cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH) protein and cannot synthesize the sugar Neu5Gc, an innate mammalian signal of self. N-Glycolylneuraminic acid (Neu5Gc) can be incorporated in human cells and can trigger immune response, a response that is diverse and polyclonal. As dietary Neu5Gc is primarily found in red meat and milk products, it is suggested that this ongoing antigen-antibody reaction may generate chronic inflammation, possibly contributing to the high frequency of diet-related carcinomas and other diseases in humans."}
{"question_id": "532f08b8d6d3ac6a34000029", "question": "Are there any specific antidotes for rivaroxaban?", "retrieved_chunks": [{"doc_id": "23866358", "chunk_id": "23866358_0", "score": 9.071479797363281, "text": "In early 2013 there is no antidote for dabigatran, rivaroxaban or apixaban, nor any specific treatment with proven efficacy for severe bleeding linked to these drugs."}, {"doc_id": "24103671", "chunk_id": "24103671_0", "score": 7.834539413452148, "text": "Novel oral anticoagulants (NOACs)--apixaban, dabigatran, and rivaroxaban--have a significantly smaller risk of intracerebral hemorrhage (ICH). However, two facts make this situation complicated: First, the risk of hematoma expansion is unknown for NOACs. Second, there is no specific antidote for neither of the NOACs."}, {"doc_id": "19351313", "chunk_id": "19351313_0", "score": 7.154416561126709, "text": "Rivaroxaban, which inhibits activated factor X (Xa), is currently in clinical trials and is the most advanced factor Xa inhibitor. The drug offers once-daily oral dosing, with no need for injections, dose titration, or frequent blood tests to monitor the international normalised ratio. It has a rapid onset of action and, although there is no specific antidote, it has a short plasma elimination half-life (about 5-9 hours)."}], "context": "[23866358:23866358_0] In early 2013 there is no antidote for dabigatran, rivaroxaban or apixaban, nor any specific treatment with proven efficacy for severe bleeding linked to these drugs.\n[24103671:24103671_0] Novel oral anticoagulants (NOACs)--apixaban, dabigatran, and rivaroxaban--have a significantly smaller risk of intracerebral hemorrhage (ICH). However, two facts make this situation complicated: First, the risk of hematoma expansion is unknown for NOACs. Second, there is no specific antidote for neither of the NOACs.\n[19351313:19351313_0] Rivaroxaban, which inhibits activated factor X (Xa), is currently in clinical trials and is the most advanced factor Xa inhibitor. The drug offers once-daily oral dosing, with no need for injections, dose titration, or frequent blood tests to monitor the international normalised ratio. It has a rapid onset of action and, although there is no specific antidote, it has a short plasma elimination half-life (about 5-9 hours).", "answer": "<think> Okay, let's tackle this question. The user is asking if there are any specific antidotes for rivaroxaban. I need to look at the provided evidence to find the answer. Looking at the first evidence snippet [23866358:23866358_0], it mentions that in early 2013, there was no antidote for dabigatran, rivaroxaban, or apixaban. That's a direct statement about rivaroxaban having no specific antidote. The second snippet [24103671:24103671_0] also states that there's no specific antidote for either of the NOACs, which includes riv", "citations": [{"doc_id": "23866358", "chunk_id": "23866358_0"}, {"doc_id": "24103671", "chunk_id": "24103671_0"}], "candidates": [{"answer": "<think> Okay, so the user is asking if there are any specific antidotes for rivaroxaban. Let me look at the evidence provided. First, document 23866358 says that in early 2013, there was no antidote for rivaroxaban. Then, document 24103671 also mentions that there's no specific antidote for NOACs, including rivaroxaban. The third document, 19351313, states that there's no specific antidote for rivaroxaban, but it's in clinical trials. So all three sources agree that there's no specific antidote. The confidence here is high because multiple documents mention the lack of an antidote", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there are any specific antidotes for rivaroxaban. I need to look at the provided evidence to find the answer. Looking at the first evidence snippet [23866358:23866358_0], it mentions that in early 2013, there was no antidote for dabigatran, rivaroxaban, or apixaban. That's a direct statement about rivaroxaban having no specific antidote. The second snippet [24103671:24103671_0] also states that there's no specific antidote for either of the NOACs, which includes riv", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question about rivaroxaban antidotes. The user is asking if there are any specific antidotes for rivaroxaban. I need to look at the provided evidence to find answers. First, looking at the evidence documents. Document 23866358 says that in early 2013, there was no antidote for dabigatran, rivaroxaban, or apixaban. Then document 24103671 repeats that there's no specific antidote for the NOACs, including rivaroxaban. The third document, 19351313, mentions that rivaroxaban has no specific antidote but is in clinical trials. So", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there are any specific antidotes for rivaroxaban. I need to look at the provided evidence to find the answer. First, I'll check each of the three evidence snippets. The first one (23866358:23866358_0) says that in early 2013, there was no antidote for rivaroxaban. The second snippet (24103671:24103671_0) also states there's no specific antidote for NOACs, including rivaroxaban. The third snippet (19351313:19351", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to answer whether there are any specific antidotes for rivaroxaban based on the provided evidence. Let me look at the evidence carefully. First, the user provided three documents. Let me check each one. Document 23866358: It says in early 2013 there was no antidote for dabigatran, rivaroxaban, or apixaban. Also, no specific treatment for severe bleeding linked to these drugs. So this indicates that at that time, there were no antidotes. Document 24103671: It mentions that NOACs like rivaroxaban don't have a specific antidote. The second fact here is that there's no specific antidote for", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there are any specific antidotes for rivaroxaban. I need to look at the provided evidence to find the answer. Looking at the first evidence snippet [23866358:23866358_0], it says in early 2013 there was no antidote for rivaroxaban. Then [24103671:24103671_0] mentions that there's no specific antidote for NOACs, including rivaroxaban. The third snippet [19351313:19351313_0] also states there's no specific antid", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there are any specific antidotes for rivaroxaban. I need to look at the provided evidence to find the answer. First, I check the evidence documents. The first one says in early 2013 there was no antidote for rivaroxaban. The second document mentions that there's no specific antidote for NOACs, including rivaroxaban. The third document also states there's no specific antidote for rivaroxaban, even though it's in clinical trials. So all three sources agree that there's no specific antidote for rivaroxaban. The confidence here is high because multiple documents cite the same information. The answer should be that there are no specific antidotes", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there are any specific antidotes for rivaroxaban. I need to look at the provided evidence to find the answer. First, I'll check each of the evidence chunks. The first chunk [23866358:23866358_0] says that in early 2013, there was no antidote for dabigatran, rivaroxaban, or apixaban. So that's a direct statement about rivaroxaban having no specific antidote. The second chunk [24103671:24103671_0] also mentions that there's no specific antidote for either", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["12871541", "19351313", "20858186", "22177763", "22308807", "22353706", "23117666", "23312927", "23460104", "23628464", "23634925", "23657589", "23790307", "23810130", "23821689", "23866358", "23953907", "24103671", "24170233"], "ideal_answer": "Currently, there is no specific antidote for rivaroxaban"}
{"question_id": "5710a592cf1c32585100002a", "question": "Which metabolite activates AtxA?", "retrieved_chunks": [{"doc_id": "8577251", "chunk_id": "8577251_2", "score": 3.6464056968688965, "text": "The atxA gene product activates transcription of the anthrax toxin genes and is essential for virulence."}, {"doc_id": "21911592", "chunk_id": "21911592_0", "score": 3.059494733810425, "text": "The B. anthracis pleiotropic regulator CodY activates toxin gene expression by post-translationally regulating the accumulation of the global regulator AtxA."}, {"doc_id": "9199422", "chunk_id": "9199422_3", "score": 3.0112147331237793, "text": "Regulation of anthrax toxin activator gene (atxA) expression in Bacillus anthracis: temperature, not CO2/bicarbonate, affects AtxA synthesis."}], "context": "[8577251:8577251_2] The atxA gene product activates transcription of the anthrax toxin genes and is essential for virulence.\n[21911592:21911592_0] The B. anthracis pleiotropic regulator CodY activates toxin gene expression by post-translationally regulating the accumulation of the global regulator AtxA.\n[9199422:9199422_3] Regulation of anthrax toxin activator gene (atxA) expression in Bacillus anthracis: temperature, not CO2/bicarbonate, affects AtxA synthesis.", "answer": "<think> Okay, let's tackle this question. The user is asking which metabolite activates AtxA. The evidence provided has three chunks. First, chunk [8577251:8577251_2] says that the atxA gene product activates the anthrax toxin genes and is essential for virulence. But this talks about the gene product itself, not a metabolite. So maybe not directly relevant. Next, chunk [21911592:21911592_0] mentions CodY activating toxin gene expression by regulating AtxA accumulation. Here, CodY is a regulator, but it's post-translationally regulating AtxA. However, the question is about a metabolite, not a regulatory", "citations": [{"doc_id": "8577251", "chunk_id": "8577251_2"}, {"doc_id": "21911592", "chunk_id": "21911592_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which metabolite activates AtxA. The evidence provided has three chunks. First, chunk [8577251:8577251_2] says that the atxA gene product activates the anthrax toxin genes and is essential for virulence. But this talks about the gene product itself, not a metabolite. So maybe not directly relevant. Next, chunk [21911592:21911592_0] mentions CodY activating toxin gene expression by regulating AtxA accumulation. Here, CodY is a regulator, but it's post-translationally regulating AtxA. However, the question is about a metabolite, not a regulatory", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which metabolite activates AtxA. The evidence provided has three chunks. First chunk [8577251:8577251_2] says the atxA gene product activates transcription of anthrax toxin genes and is essential for virulence. But this talks about the gene product itself, not a metabolite. So maybe not directly relevant. Second chunk [21911592:21911592_0] mentions CodY activating toxin gene expression by regulating AtxA accumulation. Here, CodY is a regulator, but it's a protein, not a metabolite. So perhaps this is about regulation rather than activation by a metabolite. Third", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which metabolite activates AtxA. The evidence provided has three references. First, looking at the evidence: [8577251:8577251_2] says that the atxA gene product activates transcription of the anthrax toxin genes and is essential for virulence. But this talks about the gene product itself, not a metabolite. So maybe not directly relevant. [21911592:21911592_0] mentions CodY activating toxin gene expression by regulating AtxA accumulation. Here, CodY is a regulator, but it's post-translationally regulating AtxA. So perhaps CodY is involved, but is it", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which metabolite activates AtxA. The evidence provided has three chunks. First, chunk 8577251_2 says that the atxA gene product activates the anthrax toxin genes and is essential for virulence. But this talks about the gene product itself, not a metabolite. So maybe not directly relevant. Next, chunk 21911592_0 mentions CodY activating toxin gene expression by regulating AtxA accumulation. Here, CodY is a regulator, but it's a protein, not a metabolite. So that might not be the answer either. Then there's chunk 9199422_3 which states that temperature, not CO2/b", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking which metabolite activates AtxA. Let me look at the evidence provided. First, the evidence from [8577251:8577251_2] says that the atxA gene product activates the anthrax toxin genes and is essential for virulence. But this doesn't mention a metabolite, just the gene product itself. Next, [21911592:21911592_0] talks about CodY activating toxin gene expression by regulating AtxA accumulation. This suggests that CodY is involved in controlling AtxA, but again, it's a regulatory protein, not a metabolite. Then there's [9199422:", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which metabolite activates AtxA. The evidence provided has three references. First, looking at the evidence: - [8577251:8577251_2] says that the atxA gene product activates the anthrax toxin genes and is essential for virulence. But this talks about the gene product itself, not a metabolite. So maybe not directly relevant. - [21911592:21911592_0] mentions CodY activating toxin gene expression by regulating AtxA accumulation. Here, CodY is a regulator, but it's a protein, not a metabolite. However, maybe the regulation is through a metabolite", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which metabolite activates AtxA. The evidence provided has three chunks. First, chunk 8577251_2 mentions that the atxA gene product activates transcription of the anthrax toxin genes and is essential for virulence. But this talks about the gene product itself, not a metabolite. So maybe not directly relevant. Next, chunk 21911592_0 says CodY activates toxin gene expression by regulating AtxA's accumulation. Here, CodY is a regulator, but the question is about a metabolite. So maybe CodY is a regulator, but not a metabolite. Unless CodY is a metabolite, but that seems unlikely. Maybe this is a", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which metabolite activates AtxA. The evidence provided has three references. First, I need to look at each piece of evidence. The first one says that the atxA gene product activates the anthrax toxin genes and is essential for virulence. But this is about the gene product itself, not a metabolite. So maybe not directly relevant. The second reference mentions CodY activating toxin gene expression by regulating AtxA accumulation. Here, CodY is a regulator, but it's talking about post-translational regulation. However, the question is about a metabolite. CodY might be a protein, not a metabolite. So maybe this isn't the answer either. The third evidence states that temperature, not CO", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["15149039", "17302798", "21923765", "24661624", "8577251", "9106214", "9199422", "9234759"], "ideal_answer": "Upon infection of a mammalian host, Bacillus anthracis responds to host cues, and particularly to elevated temperature (37°C) and bicarbonate/CO2 concentrations, with increased expression of virulence factors that include the anthrax toxins and extracellular capsular layer. Cultures grown with elevated CO(2) /bicarbonate exhibited increased AtxA dimer/monomer ratios and increased AtxA activity, relative to cultures grown without added CO(2) /bicarbonate, suggesting that this host-associated signal enhances AtxA function by shifting the dimer/monomer equilibrium towards the dimeric state. CO2-enhanced toxin gene transcription is not observed in atx4-null mutants. Overall data indicate a clear association of atxA with CO2-enhanced gene expression in B. anthracis and provide evidence that atxA regulates genes other than the structural genes for the anthrax toxin proteins. Comparison of the resulting protein patterns indicated that synthesis of non-toxin proteins is influenced by growth in elevated CO2 and the toxin gene regulator, atxA. The Bacillus anthracis toxin genes, cya, lef, and pag, can be viewed as a regulon, in which transcription of all three genes is activated in trans by the same regulatory gene, atxA, in response to the same signal, CO2. However, the steady-state level of atxA mRNA in cells grown in elevated CO2/bicarbonate at 37 degrees C is five- to sixfold higher than that observed in cells grown in the same conditions at 28 degrees C. A corresponding difference in AtxA protein was also seen at the different growth temperatures. All mutants multimerized, but one mutation, C402S, prevented cross-linking."}
{"question_id": "57169662cb4ef8864c000008", "question": "What is the function of 6SRNA in bacteria?", "retrieved_chunks": [{"doc_id": "23667906", "chunk_id": "23667906_1", "score": -0.18775302171707153, "text": "The release reaction depends on a characteristic property of 6S RNAs, namely to act as template for the de novo synthesis of small RNAs, termed pRNAs.Here, we used limited hydrolysis with structure-specific RNases and in-line probing of isolated 6S RNA and 6SRNA ∼ pRNA complexes to investigate the molecular details leading to the release reaction."}, {"doc_id": "23667906", "chunk_id": "23667906_0", "score": -0.4380175769329071, "text": "The release reaction depends on a characteristic property of 6S RNAs, namely to act as template for the de novo synthesis of small RNAs, termed pRNAs.Here, we used limited hydrolysis with structure-specific RNases and in-line probing of isolated 6S RNA and 6SRNA ∼ pRNA complexes to investigate the molecular details leading to the release reaction"}, {"doc_id": "21463569", "chunk_id": "21463569_0", "score": -4.963072776794434, "text": "ittle is known about the structure and function of most nucleoid-associated proteins (NAPs) in bacteria"}], "context": "[23667906:23667906_1] The release reaction depends on a characteristic property of 6S RNAs, namely to act as template for the de novo synthesis of small RNAs, termed pRNAs.Here, we used limited hydrolysis with structure-specific RNases and in-line probing of isolated 6S RNA and 6SRNA ∼ pRNA complexes to investigate the molecular details leading to the release reaction.\n[23667906:23667906_0] The release reaction depends on a characteristic property of 6S RNAs, namely to act as template for the de novo synthesis of small RNAs, termed pRNAs.Here, we used limited hydrolysis with structure-specific RNases and in-line probing of isolated 6S RNA and 6SRNA ∼ pRNA complexes to investigate the molecular details leading to the release reaction\n[21463569:21463569_0] ittle is known about the structure and function of most nucleoid-associated proteins (NAPs) in bacteria", "answer": "<think> Okay, let's tackle this question. The user is asking about the function of 6SRNA in bacteria. Looking at the evidence provided, there are three documents mentioned. Let me check each one. First, document [23667906:23667906_1] and [23667906:23667906_0] both say that the release reaction depends on 6S RNAs acting as a template for de novo synthesis of small RNAs called pRNAs. Wait, the question is about 6SRNA, but the evidence mentions 6S RNAs. Are they the same thing? Maybe there's a typo or confusion in the document. But the", "citations": [{"doc_id": "23667906", "chunk_id": "23667906_1"}, {"doc_id": "23667906", "chunk_id": "23667906_0"}], "candidates": [{"answer": "<think> Okay, I need to figure out the function of 6SRNA in bacteria based on the given evidence. Let me look at the evidence provided. The first two documents (23667906:23667906_1 and 23667906:23667906_0) both mention that the release reaction depends on a characteristic property of 6S RNAs, which is acting as a template for de novo synthesis of small RNAs called pRNAs. The third document (21463569:21463569_0) talks about little being known about NAPs, but that's not directly related to 6SR", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the function of 6SRNA in bacteria. Looking at the evidence provided, there are three documents mentioned. First, document 23667906 has two chunks. Both mention that the release reaction depends on 6S RNAs acting as a template for de novo synthesis of small RNAs called pRNAs. The key term here is \"template for the de novo synthesis of small RNAs,\" which is specifically mentioned in both chunks. The other document, 21463569, talks about little being known about NAPs, but that's not directly related to 6SRNA. So the answer should be based on the first two documents. They both state", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to figure out the function of 6SRNA in bacteria based on the given evidence. Let me look at the evidence provided. The first two documents (23667906:23667906_1 and 23667906:23667906_0) both mention that the release reaction depends on a characteristic property of 6S RNAs, which is acting as a template for the de novo synthesis of small RNAs called pRNAs. The term \"6SRNA\" is used here, so I should check if there's a difference between 6S RNA and 6SRNA. Wait, in the first document, it says \"6S", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the function of 6SRNA in bacteria. Looking at the evidence provided, there are three documents. The first two documents (23667906:23667906_1 and 23667906:23667906_0) seem to be duplicates or very similar, both mentioning that the release reaction depends on 6S RNAs acting as a template for de novo synthesis of small RNAs called pRNAs. The third document (21463569:21463569_0) talks about little being known about NAPs in bacteria, but that's", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking about the function of 6SRNA in bacteria. Let me look at the evidence provided. The first two documents (23667906:23667906_1 and 0) both mention that the release reaction depends on a characteristic property of 6S RNAs, which is acting as a template for de novo synthesis of small RNAs called pRNAs. The third document (21463569:21463569_0) talks about little being known about NAPs, but that's not directly related to 6SRNA. Wait, the question is specifically about 6SRNA. The evidence from the first two documents says", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to figure out the function of 6SRNA in bacteria based on the given evidence. Let me look at the evidence provided. The first two documents (23667906:23667906_1 and 23667906:23667906_0) both mention that the release reaction depends on a characteristic property of 6S RNAs, which is acting as a template for the de novo synthesis of small RNAs called pRNAs. The third document (21463569:21463569_0) talks about little being known about NAPs, but that's not directly related to 6", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the function of 6SRNA in bacteria. Looking at the evidence provided, there are three documents. The first two documents (23667906:23667906_1 and 23667906:23667906_0) both mention that the release reaction depends on a characteristic property of 6S RNAs, which is acting as a template for de novo synthesis of small RNAs called pRNAs. The third document (21463569:21463569_0) talks about little being known about NAPs in bacteria, but that's not", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the function of 6SRNA in bacteria. Looking at the evidence provided, there are three documents mentioned. Let me check each one. First, document [23667906:23667906_1] and [23667906:23667906_0] both say that the release reaction depends on 6S RNAs acting as a template for de novo synthesis of small RNAs called pRNAs. Wait, the question is about 6SRNA, but the evidence mentions 6S RNAs. Are they the same thing? Maybe there's a typo or confusion in the document. But the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["15262935", "17332013", "22214309", "23667906", "2579060", "58611"], "ideal_answer": "6S RNA, first described as a ncRNA in E. coli, mimics an open promoter structure, which has a large bulge with two hairpin/stalk structures that regulate transcription through interactions with RNA polymerase. Escherichia coli 6S RNA represents a non-coding RNA (ncRNA), which, based on the conserved secondary structure and previous functional studies, had been suggested to interfere with transcription. The carboxy terminus containing the Arg-Gly-Gly (RGG) repeat domains in these proteins are necessary for cis-repression of transcription activation and HAT activity by the N-terminal glutamine-rich domain. Escherichia coli 6S RNA represents a non-coding RNA (ncRNA), which, based on the conserved secondary structure and previous functional studies, had been suggested to interfere with transcription. 6S RNA-deficient cells are at a disadvantage for survival in stationary phase, a time when 6S RNA regulates transcription. 6S RNA regulation of both sigma(70) and sigma(S) activities contributes to increased cell persistence during nutrient deprivation. 6S RNA acts as a template for the transcription of defined RNA molecules in the absence of DNA. 6S RNA, first described as a ncRNA in E. coli, mimics an open promoter structure, which has a large bulge with two hairpin/stalk structures that regulate transcription through interactions with RNA polymerase. 6S RNA function enhances long-term cell survival."}
{"question_id": "54d77f0e3706e8952800001b", "question": "Is cytisine superior to nicotine replacement therapy for smoking cessation?", "retrieved_chunks": [{"doc_id": "25517706", "chunk_id": "25517706_0", "score": 9.402652740478516, "text": "CONCLUSIONS: When combined with brief behavioral support, cytisine was found to be superior to nicotine-replacement therapy in helping smokers quit smoking, but it was associated with a higher frequency of self-reported adverse events."}, {"doc_id": "25517706", "chunk_id": "25517706_1", "score": 8.057287216186523, "text": "The effectiveness of cytisine for continuous abstinence was superior to that of nicotine-replacement therapy at 1 week, 2 months, and 6 months. In a prespecified subgroup analysis of the primary outcome, cytisine was superior to nicotine-replacement therapy among women and noninferior among men."}, {"doc_id": "17698433", "chunk_id": "17698433_1", "score": 1.96224045753479, "text": "Our results showed that auricular acupuncture did not have a better efficacy in smoking cessation compared to sham acupuncture. Combined acupuncture with behavior counseling or with nicotine replacement therapy should be used in further smoking cessation trials to enhance the success rate of smoking cessation."}], "context": "[25517706:25517706_0] CONCLUSIONS: When combined with brief behavioral support, cytisine was found to be superior to nicotine-replacement therapy in helping smokers quit smoking, but it was associated with a higher frequency of self-reported adverse events.\n[25517706:25517706_1] The effectiveness of cytisine for continuous abstinence was superior to that of nicotine-replacement therapy at 1 week, 2 months, and 6 months. In a prespecified subgroup analysis of the primary outcome, cytisine was superior to nicotine-replacement therapy among women and noninferior among men.\n[17698433:17698433_1] Our results showed that auricular acupuncture did not have a better efficacy in smoking cessation compared to sham acupuncture. Combined acupuncture with behavior counseling or with nicotine replacement therapy should be used in further smoking cessation trials to enhance the success rate of smoking cessation.", "answer": "<think> Okay, let's tackle this question. The user is asking if cytisine is superior to nicotine replacement therapy (NRT) for smoking cessation. First, I need to look at the evidence provided. There are three documents here. Let me check each one. The first document [25517706:25517706_0] says that when combined with brief behavioral support, cytisine was superior to NRT in helping smokers quit. But it also mentions more adverse events. So this suggests cytisine is better but with more side effects. The second document [25517706:25517706_1] talks about effectiveness at 1 week, 2 months,", "citations": [{"doc_id": "25517706", "chunk_id": "25517706_0"}, {"doc_id": "25517706", "chunk_id": "25517706_1"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if cytisine is superior to nicotine replacement therapy (NRT) for smoking cessation. First, I need to look at the evidence provided. There are three documents here. Let me check each one. The first document [25517706:25517706_0] says that when combined with brief behavioral support, cytisine was superior to NRT in helping smokers quit. But it also mentions more adverse events. So this suggests cytisine is better but with more side effects. The second document [25517706:25517706_1] talks about effectiveness at 1 week, 2 months,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if cytisine is superior to nicotine replacement therapy (NRT) for smoking cessation. I need to look at the evidence provided. First, check the evidence snippets. The first one from 25517706:25517706_0 says that when combined with brief behavioral support, cytisine was superior to NRT in helping smokers quit. Also mentions higher adverse events. Then another snippet from the same document (25517706:25517706_1) states that effectiveness for continuous abstinence was better at 1 week, 2 months, and 6 months. Subgroup analysis shows cytisine is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if cytisine is superior to nicotine replacement therapy (NRT) for smoking cessation. First, I need to look at the evidence provided. There are three documents here. Let me check each one. The first document [25517706:25517706_0] says that when combined with brief behavioral support, cytisine was superior to NRT in helping smokers quit. But it also mentions more self-reported adverse events. So this suggests cytisine is better but with more side effects. The second document [25517706:25517706_1] goes into detail, stating that effectiveness for continuous ab", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if cytisine is superior to nicotine replacement therapy (NRT) for smoking cessation. I need to look at the evidence provided and determine the answer based on that. First, looking at the evidence documents. The first one, 25517706:25517706_0, says that when combined with brief behavioral support, cytisine was superior to NRT in helping smokers quit. But it had more self-reported adverse events. Then, the second chunk from the same document (25517706:25517706_1) mentions that cytisine's effectiveness for continuous abstinence was better at 1 week", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if cytisine is superior to nicotine replacement therapy (NRT) for smoking cessation. I need to look at the evidence provided to determine the answer. First, looking at the first evidence chunk [25517706:25517706_0], it says that when combined with brief behavioral support, cytisine was superior to NRT in helping smokers quit. Also, there's a mention of higher adverse events but that's about side effects, not effectiveness. Then the second chunk [25517706:25517706_1] states that cytisine's effectiveness for continuous abstinence was superior at 1 week", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if cytisine is superior to nicotine replacement therapy (NRT) for smoking cessation. I need to look at the evidence provided. First, looking at the first document [25517706:25517706_0], it says that when combined with brief behavioral support, cytisine was found to be superior to NRT in helping smokers quit. Also, there's a mention of higher adverse events but that's about side effects, not effectiveness. Then in [25517706:25517706_1], it specifies that at 1 week, 2 months, and 6 months, cytisine was", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if cytisine is superior to nicotine replacement therapy (NRT) for smoking cessation. I need to look at the provided evidence to form an answer. First, I'll check the evidence documents. The first document [25517706:25517706_0] says that when combined with brief behavioral support, cytisine was superior to NRT in helping smokers quit. But it had more self-reported adverse events. Then, the same document [25517706:25517706_1] mentions that cytisine's effectiveness for continuous abstinence was better at 1 week, 2 months, and", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if cytisine is superior to nicotine replacement therapy (NRT) for smoking cessation. I need to look at the evidence provided and determine the answer based on that. First, looking at the evidence documents. The first document [25517706:25517706_0] says that when combined with brief behavioral support, cytisine was found to be superior to NRT in helping smokers quit. But it also mentions more adverse events. Then, the second chunk from the same doc [25517706:25517706_1] states that cytisine's effectiveness was superior at 1 week, 2", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["17130378", "17220536", "17253581", "17825502", "18076335", "18646137", "20040957", "21154363", "21328282", "21385905", "22104038", "22513936", "23404838", "23728690", "23834141", "23978314", "24574554", "24831822", "25517706"], "ideal_answer": "Yes, one clinical trial that directly compared smoking cessation rates with cytisine versus nicotine replacement therapy reported that cytisine was superior to nicotine-replacement therapy in helping smokers quit smoking, but it was associated with a higher frequency of self-reported adverse events."}
{"question_id": "532366f09b2d7acc7e000015", "question": "Which amino acid residue appears mutated in most of the cases reported with cadasil syndrome?", "retrieved_chunks": [{"doc_id": "23587639", "chunk_id": "23587639_0", "score": 4.318347930908203, "text": "CADASIL is caused mostly by missense mutations in the NOTCH3 gene, invariably involving a cysteine residue."}, {"doc_id": "15304596", "chunk_id": "15304596_0", "score": 3.377903461456299, "text": "The authors report a family with CADASIL carrying a deletion in the Notch3 gene that did not involve a cysteine residue"}, {"doc_id": "21616505", "chunk_id": "21616505_0", "score": 3.2787647247314453, "text": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited cerebrovascular disease due to mutations involving loss or gain of a cysteine residue in the NOTCH3 gene. A cluster of mutations around exons 3 and 4 was originally reported"}], "context": "[23587639:23587639_0] CADASIL is caused mostly by missense mutations in the NOTCH3 gene, invariably involving a cysteine residue.\n[15304596:15304596_0] The authors report a family with CADASIL carrying a deletion in the Notch3 gene that did not involve a cysteine residue\n[21616505:21616505_0] Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited cerebrovascular disease due to mutations involving loss or gain of a cysteine residue in the NOTCH3 gene. A cluster of mutations around exons 3 and 4 was originally reported", "answer": "<think> Okay, let's tackle this question. The user is asking which amino acid residue is mutated in most cases of CADASIL syndrome. The evidence provided has three documents. First, looking at document [23587639:23587639_0], it states that CADASIL is mostly caused by missense mutations in the NOTCH3 gene, specifically involving a cysteine residue. That seems directly relevant. Then there's document [15304596:15304596_0] which mentions a family with CADASIL that had a deletion in Notch3 not involving cysteine. But this is an exception, so maybe it's not the main case. The", "citations": [{"doc_id": "23587639", "chunk_id": "23587639_0"}, {"doc_id": "15304596", "chunk_id": "15304596_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which amino acid residue is mutated in most cases of CADASIL syndrome. The evidence provided has three documents. First, looking at document [23587639:23587639_0], it states that CADASIL is mostly caused by missense mutations in the NOTCH3 gene, specifically involving a cysteine residue. That seems directly relevant. Then there's document [15304596:15304596_0] which mentions a family with CADASIL that had a deletion in Notch3 not involving cysteine. But this is an exception, so maybe it's not the main case. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which amino acid residue is mutated in most cases of CADASIL syndrome. The evidence provided has three documents. First, looking at document [23587639:23587639_0], it states that CADASIL is mostly caused by missense mutations in the NOTCH3 gene, specifically involving a cysteine residue. That seems direct. But then there's another document [15304596:15304596_0] which mentions a family with a deletion in Notch3 not involving cysteine. However, the question is about \"most cases,\" so maybe that's an exception. The third document [", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which amino acid residue is most commonly mutated in CADASIL syndrome. The evidence provided has three documents. First, document [23587639:23587639_0] states that CADASIL is mostly caused by missense mutations in the NOTCH3 gene, specifically involving a cysteine residue. That seems like a direct answer. But then there's another document [15304596:15304596_0] which mentions a family with a deletion in Notch3 not involving cysteine. However, the question is about \"most cases,\" so even though there's an exception, the majority still involve", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which amino acid residue is mutated in most cases of CADASIL syndrome. The evidence provided has three documents. First, looking at document [23587639:23587639_0], it states that CADASIL is mostly caused by missense mutations in the NOTCH3 gene, specifically involving a cysteine residue. That seems directly relevant. Then there's document [15304596:15304596_0] which mentions a family with CADASIL having a deletion in Notch3 not involving cysteine. But this is an exception, so it might not affect the main point. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which amino acid residue is mutated in most cases of CADASIL syndrome. The evidence provided has three documents. First, looking at document [23587639:23587639_0], it states that CADASIL is mostly caused by missense mutations in the NOTCH3 gene, specifically involving a cysteine residue. That seems directly relevant. Then there's document [15304596:15304596_0], which mentions a family with CADASIL having a deletion in Notch3 not involving cysteine. But this is an exception, so it might not affect the general case. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which amino acid residue is mutated in most cases of CADASIL syndrome. The evidence provided has three documents. First, looking at document [23587639:23587639_0], it states that CADASIL is mostly caused by missense mutations in the NOTCH3 gene, specifically involving a cysteine residue. That's a strong clue pointing to cysteine. Then there's document [15304596:15304596_0], which mentions a family with CADASIL that had a deletion in Notch3 not involving cysteine. But this seems like an exception, so it might not", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which amino acid residue is most commonly mutated in CADASIL syndrome. First, I need to look at the evidence provided. The first document says that CADASIL is mostly caused by missense mutations in the NOTCH3 gene, specifically involving a cysteine residue. So that's a strong clue pointing towards cysteine. The second document mentions a family with CADASIL that had a deletion in Notch3 not involving cysteine. But the question is about \"most cases,\" so this might be an exception. The third document again talks about mutations involving loss or gain of a cysteine residue in NOTCH3. So even though there's one case without cysteine, the majority of", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which amino acid residue is most commonly mutated in CADASIL syndrome. The evidence provided has three documents. First, looking at document [23587639:23587639_0], it states that CADASIL is mostly caused by missense mutations in the NOTCH3 gene, specifically involving a cysteine residue. That seems like a direct answer. But then there's another document [15304596:15304596_0] which mentions a family with a deletion in Notch3 not involving cysteine. However, the question is about \"most cases,\" so even though one case doesn't involve cyst", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["11706120", "15304596", "16717210", "17726918", "18313300", "18710532", "19006080", "19043263", "20224942", "21038489", "21616505", "21772710", "22082899", "22367627", "22623959", "23587639", "23597439", "23799017", "24086431"], "ideal_answer": "CADASIL is caused mostly by missense mutations in the NOTCH3 gene, invariably involving a cysteine residue."}
{"question_id": "57090784cf1c325851000011", "question": "Which syndromes are associated with mutations in the EZH2 gene?", "retrieved_chunks": [{"doc_id": "22190405", "chunk_id": "22190405_1", "score": 7.855245590209961, "text": "The EZH2 mutation spectrum in Weaver syndrome shows considerable overlap with the inactivating somatic EZH2 mutations recently reported in myeloid malignancies"}, {"doc_id": "22177091", "chunk_id": "22177091_0", "score": 7.683099269866943, "text": "Mutations in EZH2 cause Weaver syndrome"}, {"doc_id": "22177091", "chunk_id": "22177091_1", "score": 7.58050537109375, "text": "These data show that mutations in EZH2 cause Weaver syndrome"}], "context": "[22190405:22190405_1] The EZH2 mutation spectrum in Weaver syndrome shows considerable overlap with the inactivating somatic EZH2 mutations recently reported in myeloid malignancies\n[22177091:22177091_0] Mutations in EZH2 cause Weaver syndrome\n[22177091:22177091_1] These data show that mutations in EZH2 cause Weaver syndrome", "answer": "<think> Okay, let's tackle this question. The user is asking which syndromes are associated with mutations in the EZH2 gene. The evidence provided has three entries. First, I need to parse each of the evidence points. The first one (22190405:22190405_1) mentions that EZH2 mutations in Weaver syndrome overlap with those in myeloid malignancies. The second (22177091:22177091_0) directly states that EZH2 mutations cause Weaver syndrome. The third (22177091:22177091_1) repeats the same conclusion as the second. So, the", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which syndromes are associated with mutations in the EZH2 gene. The evidence provided has three entries. First, I need to parse each of the evidence points. The first one (22190405:22190405_1) mentions that EZH2 mutations in Weaver syndrome overlap with those in myeloid malignancies. The second (22177091:22177091_0) directly states that EZH2 mutations cause Weaver syndrome. The third (22177091:22177091_1) repeats the same conclusion as the second. So, the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking which syndromes are associated with mutations in the EZH2 gene. Let me look at the evidence provided. The first piece of evidence (22190405:22190405_1) mentions that EZH2 mutations are linked to Weaver syndrome, and there's overlap with somatic mutations in myeloid malignancies. The second evidence (22177091:22177091_0 and 22177091:22177091_1) clearly state that mutations in EZH2 cause Weaver syndrome. So, the main syndrome here is Weaver syndrome. The other part about myeloid", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which syndromes are associated with mutations in the EZH2 gene. The evidence provided has three chunks. First, I need to look at each chunk and see what they say. The first chunk (22190405:22190405_1) mentions that EZH2 mutations in Weaver syndrome overlap with somatic mutations in myeloid malignancies. But the main point here is Weaver syndrome. The second chunk (22177091:22177091_0) states that mutations in EZH2 cause Weaver syndrome. The third chunk (22177091:221770", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which syndromes are associated with mutations in the EZH2 gene. The evidence provided has three entries. First, I need to look at each of the evidence points. The first one mentions that EZH2 mutations in Weaver syndrome overlap with inactivating somatic mutations in myeloid malignancies. The second and third entries both state that mutations in EZH2 cause Weaver syndrome. So, the key point here is that all three pieces of evidence point to Weaver syndrome being linked to EZH2 mutations. The first evidence adds that there's an overlap with some cancer mutations, but the main answer here is Weaver syndrome. The other evidence supports that directly. The user wants a concise answer with citations.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which syndromes are associated with mutations in the EZH2 gene. The evidence provided has three entries. First, I need to look at each piece of evidence. The first one (22190405:22190405_1) mentions that EZH2 mutations in Weaver syndrome overlap with somatic mutations in myeloid malignancies. But the main point here is Weaver syndrome. The second entry (22177091:22177091_0) directly states that mutations in EZH2 cause Weaver syndrome. The third one (22177091:2217709", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking which syndromes are associated with mutations in the EZH2 gene. Let me look at the evidence provided. First, there's a document (22177091:22177091_0) that states mutations in EZH2 cause Weaver syndrome. Another chunk from the same document (22177091:22177091_1) repeats that these data show mutations in EZH2 cause Weaver syndrome. Then there's another document (22190405:22190405_1) mentioning that the EZH2 mutation spectrum in Weaver syndrome overlaps with inactivating somatic EZH2 mutations in", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which syndromes are associated with mutations in the EZH2 gene. The evidence provided has three entries. First, I need to look at each of the evidence points. The first one says that EZH2 mutations in Weaver syndrome overlap with those in myeloid malignancies. The second and third entries both state that mutations in EZH2 cause Weaver syndrome. So, the main point here is that Weaver syndrome is linked to EZH2 mutations. The other mention of myeloid malignancies might be a related condition but the question specifically asks for syndromes. Myeloid malignancies are types of cancers, not syndromes. So the primary answer should be Weaver syndrome. I need to check", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which syndromes are associated with mutations in the EZH2 gene. The evidence provided has three entries. First, I need to look at each piece of evidence. The first one says that EZH2 mutations in Weaver syndrome overlap with somatic mutations in myeloid malignancies. The second and third entries both state that mutations in EZH2 cause Weaver syndrome. So the main point here is that Weaver syndrome is linked to EZH2 mutations. The other mention of myeloid malignancies might be a bit off-topic, but the question is about syndromes, not cancers. However, maybe the user considers myeloid malignancies as a syndrome? Wait, no, syndromes are usually", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["10780782", "21856302", "22177091", "22190405", "22475286", "23099237", "23592277", "24214728", "24218139", "24507812", "24760151", "24852293", "24953053", "25177364"], "ideal_answer": "EZH2 mutations that cause Weaver syndrome are primarily missense variants and the rare truncating mutations reported to date are in the last exon, suggesting that simple haploinsufficiency is unlikely to be generating the overgrowth phenotype although the exact mechanism has not yet been determined. Recent studies have shown that EZH2 mutations are often associated with RUNX1 mutations in MDS patients, although its pathological function remains to be addressed. These data show that mutations in EZH2 cause Weaver syndrome. The EZH2 gene is a homolog of the Drosophila Polycomb group (PcG) gene enhancer of zest, a crucial regulator of homeotic gene expression. Loss-of-function mutations of EZH2, a catalytic component of polycomb repressive complex 2 (PRC2), are observed in ~\\n10% of patients with myelodysplastic syndrome (MDS), but are rare in acute myeloid leukaemia (AML). Constitutional NSD1 and EZH2 mutations cause Sotos and Weaver syndromes respectively, overgrowth syndromes with considerable phenotypic overlap. Mutations at tyrosine 641 (Y641F, Y641N, Y641S and Y641H) in the SET domain of EZH2 have been identified in patients with certain subtypes of non-Hodgkin lymphoma (NHL). The EZH2 gene is involved in the pathogenesis of 7q35-q36 aberrations in myeloid leukaemia."}
{"question_id": "55414a763f2354b713000003", "question": "Which databases exist for experimentally determined topologies of α-helical transmembrane proteins ?", "retrieved_chunks": [{"doc_id": "20601677", "chunk_id": "20601677_1", "score": 8.483235359191895, "text": "ExTopoDB is a publicly accessible database of experimentally derived topological models of transmembrane proteins. It contains information collected from studies in the literature that report the use of biochemical methods for the determination of the topology of α-helical transmembrane proteins. Transmembrane protein topology is highly important in order to understand their function and ExTopoDB provides an up to date, complete and comprehensive dataset of experimentally determined topologies of α-helical transmembrane proteins. Topological information is combined with transmembrane topology prediction resulting in more reliable topological models. AVAILABILITY: http://bioinformatics.biol.uoa.gr/ExTopoDB"}, {"doc_id": "12520035", "chunk_id": "12520035_2", "score": 7.597048282623291, "text": "TMPDB is a database of experimentally-characterized transmembrane (TM) topologies. TMPDB release 6.2 contains a total of 302 TM protein sequences, in which 276 are alpha-helical sequences, 17 beta-stranded, and 9 alpha-helical sequences with short pore-forming helices buried in the membrane. The TM topologies in TMPDB were determined experimentally by means of X-ray crystallography, NMR, gene fusion technique, substituted cysteine accessibility method, N-linked glycosylation experiment and other biochemical methods. TMPDB would be useful as a test and/or training dataset in improving the proposed TM topology prediction methods or developing novel methods with higher performance, and as a guide for both the bioinformaticians and biologists to better understand TM proteins. TMPDB and its subsets are freely available at the following web site: http://bioinfo.si.hirosaki-u.ac.jp/~TMPDB/"}, {"doc_id": "20601677", "chunk_id": "20601677_5", "score": 6.574993133544922, "text": "Transmembrane protein topology is highly important in order to understand their function and ExTopoDB provides an up to date, complete and comprehensive dataset of experimentally determined topologies of α-helical transmembrane proteins."}], "context": "[20601677:20601677_1] ExTopoDB is a publicly accessible database of experimentally derived topological models of transmembrane proteins. It contains information collected from studies in the literature that report the use of biochemical methods for the determination of the topology of α-helical transmembrane proteins. Transmembrane protein topology is highly important in order to understand their function and ExTopoDB provides an up to date, complete and comprehensive dataset of experimentally determined topologies of α-helical transmembrane proteins. Topological information is combined with transmembrane topology prediction resulting in more reliable topological models. AVAILABILITY: http://bioinformatics.biol.uoa.gr/ExTopoDB\n[12520035:12520035_2] TMPDB is a database of experimentally-characterized transmembrane (TM) topologies. TMPDB release 6.2 contains a total of 302 TM protein sequences, in which 276 are alpha-helical sequences, 17 beta-stranded, and 9 alpha-helical sequences with short pore-forming helices buried in the membrane. The TM topologies in TMPDB were determined experimentally by means of X-ray crystallography, NMR, gene fusion technique, substituted cysteine accessibility method, N-linked glycosylation experiment and other biochemical methods. TMPDB would be useful as a test and/or training dataset in improving the proposed TM topology prediction methods or developing novel methods with higher performance, and as a guide for both the bioinformaticians and biologists to better understand TM proteins. TMPDB and its subsets are freely available at the following web site: http://bioinfo.si.hirosaki-u.ac.jp/~TMPDB/\n[20601677:20601677_5] Transmembrane protein topology is highly important in order to understand their function and ExTopoDB provides an up to date, complete and comprehensive dataset of experimentally determined topologies of α-helical transmembrane proteins.", "answer": "<think> Okay, the user is asking about databases for experimentally determined topologies of alpha-helical transmembrane proteins. Let me check the evidence provided. First, there's ExTopoDB mentioned in two chunks. It's described as a database with experimentally derived topological models, specifically for alpha-helical transmembrane proteins. The citation [20601677:20601677_1] and [20601677:20601677_5] both talk about ExTopoDB. Then there's TMPDB in [12520035:12520035_2], which includes alpha-helical sequences among", "citations": [{"doc_id": "20601677", "chunk_id": "20601677_1"}, {"doc_id": "20601677", "chunk_id": "20601677_5"}, {"doc_id": "12520035", "chunk_id": "12520035_2"}], "candidates": [{"answer": "<think> Okay, the user is asking about databases for experimentally determined topologies of alpha-helical transmembrane proteins. Let me check the evidence provided. First, there's ExTopoDB mentioned in two chunks. It's described as a database with experimentally derived topological models, specifically for alpha-helical transmembrane proteins. The citation [20601677:20601677_1] and [20601677:20601677_5] both talk about ExTopoDB. Then there's TMPDB in [12520035:12520035_2], which includes alpha-helical sequences among", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, the user is asking about databases for experimentally determined topologies of alpha-helical transmembrane proteins. Let me look at the evidence provided. First, there's ExTopoDB mentioned in two chunks. The first chunk says it's a database with experimentally derived topological models, specifically for alpha-helical transmembrane proteins. It also mentions that it combines experimental data with predictions. The third chunk reinforces this by stating ExTopoDB provides datasets of experimentally determined topologies. Then there's TMPDB in the second chunk. It says TMPDB contains 302 TM sequences, 276 alpha-helical. The topologies were determined experimentally using methods like X-ray crystallography, NMR, etc. So", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking about databases for experimentally determined topologies of alpha-helical transmembrane proteins. Let me look at the evidence provided. First, there's ExTopoDB mentioned in two chunks. The first one says it's a database with experimentally derived topological models, specifically for alpha-helical transmembrane proteins. It also mentions that it combines experimental data with predictions. The third chunk reiterates that ExTopoDB provides comprehensive datasets for these proteins. Then there's TMPDB in the second chunk. It states that TMPDB has 302 TM sequences, with 276 alpha-helical. The topologies were determined experimentally using various methods like X-ray crystallography, NMR, etc.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking about databases for experimentally determined topologies of alpha-helical transmembrane proteins. Let me check the evidence provided. First, there's ExTopoDB mentioned in two chunks. It's described as a database with experimentally derived topological models, specifically for alpha-helical transmembrane proteins. The citation [20601677:20601677_1] and [20601677:20601677_5] both talk about ExTopoDB. Then there's TMPDB in [12520035:12520035_2], which also includes alpha-helical sequences", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, the user is asking about databases for experimentally determined topologies of alpha-helical transmembrane proteins. Let me look at the evidence provided. First, there's ExTopoDB mentioned in two chunks. The first one says it's a database with experimentally derived topological models, specifically for alpha-helical transmembrane proteins. It also mentions that it combines experimental data with predictions. The third chunk repeats that ExTopoDB provides comprehensive datasets. So that's a solid source. Then there's TMPDB in the second chunk. It states that TMPDB has 302 TM sequences, 276 of which are alpha-helical. The topologies were determined experimentally using various methods like X-ray crystallography, N", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about databases for experimentally determined topologies of α-helical transmembrane proteins. First, I need to look at the evidence provided. There are three documents mentioned. Let me check each one. Document 20601677:1 mentions ExTopoDB, which is described as a database of experimentally derived topological models of transmembrane proteins. It specifically states that it contains information from studies using biochemical methods for α-helical transmembrane proteins. The AVAILABILITY link is provided. Also, document 20601677:5 reiterates that ExTopoDB provides datasets for these proteins. Document 1252003", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's see. The user is asking about databases for experimentally determined topologies of alpha-helical transmembrane proteins. Looking at the evidence provided, there are two main databases mentioned: ExTopoDB and TMPDB. First, ExTopoDB is mentioned in two chunks. It's described as a database with experimentally derived topological models of transmembrane proteins, specifically alpha-helical ones. The citation [20601677:20601677_1] and [20601677:20601677_5] both refer to ExTopoDB. The second chunk about TMPDB is from [1252003", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which databases exist for experimentally determined topologies of α-helical transmembrane proteins. The evidence provided mentions two databases: ExTopoDB and TMPDB. First, I need to check each document to see what they say. Document [20601677:20601677_1] talks about ExTopoDB, stating it's a database of experimentally derived topological models for transmembrane proteins, specifically α-helical ones. It also mentions that it combines experimental data with prediction methods. The AVAILABILITY link is provided. Then there's document [12520035:12520035_", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["12520035", "20601677"], "ideal_answer": "ExTopoDB and TMPDB."}
{"question_id": "55000cc4e9bde69634000004", "question": "Which disease is characterized by congenital absence of intrinsic ganglion cells of the gastrointestinal tract?", "retrieved_chunks": [{"doc_id": "8894691", "chunk_id": "8894691_1", "score": 9.31020736694336, "text": "Hirschsprung disease (HSCR) is a congenital disorder associated with the absence of intrinsic ganglion cells in the distal gastrointestinal tract."}, {"doc_id": "8894691", "chunk_id": "8894691_0", "score": 9.197052001953125, "text": "Hirschsprung disease (HSCR) is a congenital disorder associated with the absence of intrinsic ganglion cells in the distal gastrointestinal tract"}, {"doc_id": "8896569", "chunk_id": "8896569_0", "score": 9.06171989440918, "text": "Hirschsprung disease (HSCR, aganglionic megacolon) is a common congenital malformation leading to bowel obstruction, with an incidence of 1/5,000 live births. It is characterized by the absence of intrinsic ganglion cells in the myenteric and submucosal plexuses along variable lengths of the gastrointestinal tract."}], "context": "[8894691:8894691_1] Hirschsprung disease (HSCR) is a congenital disorder associated with the absence of intrinsic ganglion cells in the distal gastrointestinal tract.\n[8894691:8894691_0] Hirschsprung disease (HSCR) is a congenital disorder associated with the absence of intrinsic ganglion cells in the distal gastrointestinal tract\n[8896569:8896569_0] Hirschsprung disease (HSCR, aganglionic megacolon) is a common congenital malformation leading to bowel obstruction, with an incidence of 1/5,000 live births. It is characterized by the absence of intrinsic ganglion cells in the myenteric and submucosal plexuses along variable lengths of the gastrointestinal tract.", "answer": "<think> Okay, let's tackle this question. The user is asking which disease is characterized by the congenital absence of intrinsic ganglion cells in the gastrointestinal tract. Looking at the evidence provided, there are three chunks cited. First, both [8894691:8894691_1] and [8894691:8894691_0] mention Hirschsprung disease (HSCR) being associated with the absence of intrinsic ganglion cells in the distal gastrointestinal tract. The third chunk, [8896569:8896569_0], also refers to Hirschsprung disease as a condition with absent ganglion cells in the myenteric and", "citations": [{"doc_id": "8894691", "chunk_id": "8894691_1"}, {"doc_id": "8894691", "chunk_id": "8894691_0"}, {"doc_id": "8896569", "chunk_id": "8896569_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which disease is characterized by the congenital absence of intrinsic ganglion cells in the gastrointestinal tract. Looking at the evidence provided, there are three chunks cited. First, both [8894691:8894691_1] and [8894691:8894691_0] mention Hirschsprung disease (HSCR) being associated with the absence of intrinsic ganglion cells in the distal gastrointestinal tract. The third chunk, [8896569:8896569_0], also refers to Hirschsprung disease as a condition with absent ganglion cells in the myenteric and", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which disease is characterized by congenital absence of intrinsic ganglion cells in the gastrointestinal tract. The evidence provided has three chunks, all pointing to Hirschsprung disease (HSCR). First, I need to make sure that all the evidence supports the same answer. Looking at the evidence: - The first two chunks (8894691:8894691_1 and 0) both state that HSCR is associated with absence of ganglion cells in the distal GI tract. - The third chunk (8896569:8896569_0) adds more details, mentioning that it's a common congenital malformation with", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which disease is characterized by congenital absence of intrinsic ganglion cells in the gastrointestinal tract. The evidence provided has three chunks, all pointing to Hirschsprung disease (HSCR). First, I need to make sure that all the evidence supports the same answer. Looking at the evidence: - The first two chunks (8894691:8894691_1 and 0) both state that HSCR is associated with the absence of intrinsic ganglion cells in the distal gastrointestinal tract. - The third chunk (8896569:8896569_0) adds more details, mentioning that HSCR is a common congenital", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which disease is characterized by congenital absence of intrinsic ganglion cells in the gastrointestinal tract. The evidence provided has three chunks, all pointing to Hirschsprung disease (HSCR). First, I need to make sure that all the evidence supports the same answer. Looking at the evidence: Chunk 1 and 2 both state that HSCR is associated with absence of intrinsic ganglion cells in the distal gastrointestinal tract. Chunk 3 adds more details, mentioning the myenteric and submucosal plexuses and variable lengths of the tract. All three chunks consistently mention Hirschsprung disease as the condition. The answer should be concise, citing the document IDs and chunk IDs. The base confidence is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which disease is characterized by congenital absence of intrinsic ganglion cells in the gastrointestinal tract. The evidence provided has three chunks, all mentioning Hirschsprung disease (HSCR). First, I need to check each chunk for the key information. The first two chunks (8894691:8894691_1 and 0) both state that HSCR is a congenital disorder with absence of intrinsic ganglion cells in the distal GI tract. The third chunk (8896569:8896569_0) adds more details, mentioning it's a common malformation leading to bowel obstruction and the absence of ganglion cells in", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which disease is characterized by congenital absence of intrinsic ganglion cells in the gastrointestinal tract. The evidence provided has three chunks, all pointing to Hirschsprung disease (HSCR). First, I need to check each chunk. The first two chunks are identical, both stating that HSCR is a congenital disorder with absence of intrinsic ganglion cells in the distal GI tract. The third chunk adds more details, mentioning it's called aganglionic megacolon, common, and affects varying lengths of the tract. So all three sources consistently mention Hirschsprung disease as the answer. The question is straightforward, and the evidence directly supports HSCR. The confidence here is high because multiple chunks confirm the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which disease is characterized by congenital absence of intrinsic ganglion cells in the gastrointestinal tract. The evidence provided has three chunks, all mentioning Hirschsprung disease (HSCR). First, I need to check each chunk to see if they all point to the same answer. The first two chunks are duplicates, both stating HSCR is associated with the absence of intrinsic ganglion cells in the distal gastrointestinal tract. The third chunk adds more details, like it being a common congenital malformation and mentioning the myenteric and submucosal plexuses. So all three pieces of evidence consistently point to Hirschsprung disease as the answer. The question is straightforward, and the evidence directly answers it.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which disease is characterized by congenital absence of intrinsic ganglion cells in the gastrointestinal tract. The evidence provided has three chunks, all pointing to Hirschsprung disease (HSCR). First, I need to make sure that all the evidence supports the same answer. Looking at the evidence: - The first two chunks (8894691:8894691_1 and 0) both state that HSCR is associated with the absence of intrinsic ganglion cells in the distal gastrointestinal tract. - The third chunk (8896569:8896569_0) mentions HSCR again, describing it as a congenital malformation", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["10980580", "16080919", "16618617", "20860806", "21656899", "22131258", "22184102", "22974608", "23043324", "23272425", "23836442", "8401580", "8894691", "8896569", "9556633"], "ideal_answer": "Hirschsprung disease (HSCR, aganglionic megacolon) is a common congenital malformation leading to bowel obstruction, with an incidence of 1/5,000 live births. It is characterized by the absence of intrinsic ganglion cells in the myenteric and submucosal plexuses along variable lengths of the gastrointestinal tract. The medical condition characterized by the congenital absence of intrinsic ganglion cells in the myenteric and submucosal plexuses along variable lengths of the gastrointestinal tract is called aganlionic megacolon or Hirschsprung disease. Hirschsprung disease (HSCR) is a congenital disorder associated with the absence of intrinsic ganglion cells in the distal gastrointestinal tract.This severe congenital condition is caused by the absence of colonic neural ganglia and thus lack of intrinsic innervation of the colon due in turn to improper colonization of the developing intestines by ENS progenitor cells. Hirschsprungs disease (HSCR), also known as aganglionic megacolon, derives from a congenital malformation of the enteric nervous system (ENS). This severe congenital condition is caused by the absence of colonic neural ganglia and thus lack of intrinsic innervation of the colon due in turn to improper colonization of the developing intestines by ENS progenitor cells."}
{"question_id": "54ede28094afd61504000003", "question": "What is the disease in which patients are sensitive to DNA crosslinking agents, presenting with a high frequency of chromosomal aberrations?", "retrieved_chunks": [{"doc_id": "20132664", "chunk_id": "20132664_0", "score": 6.169626712799072, "text": "FA patients exhibit spontaneous chromosome breakage and FA cells are sensitive to DNA interstrand crosslink agents and expresses high frequency of chromosome breakage"}, {"doc_id": "8876687", "chunk_id": "8876687_1", "score": 5.680403709411621, "text": "Fanconi anemia (FA) is characterized at the cellular level by a high frequency of spontaneous chromosomal aberrations; crosslinking agents cause an abnormal increase in the frequency of chromosomal damage, and semiconservative DNA synthesis is severely inhibited."}, {"doc_id": "7116934", "chunk_id": "7116934_1", "score": 5.602928161621094, "text": "An elevated frequency of chromosome aberrations, which is further exaggerated by exposure of cells to DNA crosslinking agents, is a general feature of Fanconi's anemia."}], "context": "[20132664:20132664_0] FA patients exhibit spontaneous chromosome breakage and FA cells are sensitive to DNA interstrand crosslink agents and expresses high frequency of chromosome breakage\n[8876687:8876687_1] Fanconi anemia (FA) is characterized at the cellular level by a high frequency of spontaneous chromosomal aberrations; crosslinking agents cause an abnormal increase in the frequency of chromosomal damage, and semiconservative DNA synthesis is severely inhibited.\n[7116934:7116934_1] An elevated frequency of chromosome aberrations, which is further exaggerated by exposure of cells to DNA crosslinking agents, is a general feature of Fanconi's anemia.", "answer": "<think> Okay, let's tackle this question. The user is asking about a disease where patients are sensitive to DNA crosslinking agents and have a high frequency of chromosomal aberrations. The evidence provided mentions FA (Fanconi anemia) multiple times. First, I need to check each evidence chunk. The first one says FA patients have spontaneous chromosome breakage and are sensitive to DNA interstrand crosslink agents. The second chunk from 8876687:8876687_1 states that FA is characterized by high frequency of chromosomal aberrations and that crosslinking agents increase damage. The third chunk from 7116934:7116934_1 mentions elevated chromosome aberrations exacerbated by DNA cross", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about a disease where patients are sensitive to DNA crosslinking agents and have a high frequency of chromosomal aberrations. The evidence provided mentions FA (Fanconi anemia) multiple times. First, I need to check each evidence chunk. The first one says FA patients have spontaneous chromosome breakage and are sensitive to DNA interstrand crosslink agents. The second chunk from 8876687:8876687_1 states that FA is characterized by high frequency of chromosomal aberrations and that crosslinking agents increase damage. The third chunk from 7116934:7116934_1 mentions elevated chromosome aberrations exacerbated by DNA cross", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about a disease where patients are sensitive to DNA crosslinking agents and have a high frequency of chromosomal aberrations. The evidence provided mentions three sources, all pointing towards Fanconi anemia (FA). First, I need to make sure I understand the question correctly. The key terms here are \"sensitive to DNA crosslinking agents\" and \"high frequency of chromosomal aberrations.\" The answer should be the name of the disease that fits these criteria. Looking at the evidence: - The first source (20132664) says FA patients have spontaneous chromosome breakage and are sensitive to DNA interstrand crosslink agents. That's a direct hit on both parts of the question. -", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let me tackle this question. The user is asking about a disease where patients are sensitive to DNA crosslinking agents and have a high frequency of chromosomal aberrations. The evidence provided mentions Fanconi anemia (FA) multiple times. First, I need to check each evidence chunk. The first one says FA patients have spontaneous chromosome breakage and are sensitive to DNA interstrand crosslink agents. The second chunk states that FA is characterized by high frequency of spontaneous chromosomal aberrations and that crosslinking agents increase chromosomal damage. The third chunk also mentions elevated chromosome aberrations, especially with exposure to crosslinking agents. All three sources point to Fanconi anemia. The key terms here are DNA crosslinking agents and chromosomal aberrations. The answer", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about a disease where patients are sensitive to DNA crosslinking agents and have high frequency of chromosomal aberrations. The evidence provided mentions FA (Fanconi anemia) multiple times. First, I need to check each evidence chunk. The first one says FA patients have spontaneous chromosome breakage and are sensitive to DNA interstrand crosslink agents. The second chunk from 8876687:8876687_1 states that FA is characterized by high frequency of chromosomal aberrations and that crosslinking agents increase damage. The third chunk from 7116934:7116934_1 mentions that chromosome aberrations are elevated and exacerbated by", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about a disease where patients are sensitive to DNA crosslinking agents and have a high frequency of chromosomal aberrations. The evidence provided mentions three documents. First, I need to identify which disease is being referred to. All three documents mention \"Fanconi anemia (FA)\" or \"Fanconi's anemia.\" The first document says FA patients have spontaneous chromosome breakage and are sensitive to DNA interstrand crosslink agents. The second document states that FA is characterized by high frequency of chromosomal aberrations and that crosslinking agents increase damage. The third one confirms that chromosome aberrations are a feature of FA, especially with exposure to crosslinking agents. So, the answer should be Fanconi anemia.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about a disease where patients are sensitive to DNA crosslinking agents and have a high frequency of chromosomal aberrations. The evidence provided mentions three documents. First, I need to identify which疾病 is being referred to. All the evidence points to Fanconi anemia (FA). Let me check each citation. The first one says FA patients have spontaneous chromosome breakage and are sensitive to DNA interstrand crosslink agents. The second document states that FA is characterized by high frequency of chromosomal aberrations and that crosslinking agents increase damage. The third mentions that chromosome aberrations are elevated and worsened by crosslinking agents, which is a feature of Fanconi's anemia. So all three sources consistently mention", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about a disease where patients are sensitive to DNA crosslinking agents and have high frequency of chromosomal aberrations. The evidence provided mentions FA (Fanconi anemia) multiple times. First, I need to check each of the evidence chunks. The first one says FA patients have spontaneous chromosome breakage and are sensitive to DNA interstrand crosslink agents. The second chunk from 8876687:8876687_1 states that FA is characterized by high frequency of chromosomal aberrations and that crosslinking agents increase damage. The third chunk from 7116934:7116934_1 mentions that chromosome aberrations are elevated and", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about a disease where patients are sensitive to DNA crosslinking agents and have a high frequency of chromosomal aberrations. The evidence provided mentions three documents. First, I need to identify the key terms. The disease in question is likely Fanconi anemia (FA), as all three references point to that. Let me check each citation. The first one says FA patients have spontaneous chromosome breakage and are sensitive to DNA interstrand crosslink agents. The second mentions FA's cellular characteristics include high frequency of chromosomal aberrations and that crosslinking agents increase damage. The third states that chromosome aberrations are elevated and worsened by crosslinking agents, which is a feature of Fanconi's anemia. All", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["16115458", "20132664", "21568838", "7011307", "7116934", "8058745", "8876687"], "ideal_answer": "Fanconi anemia (FA) is an autosomal disorder that causes genome instability and manifests by defects in DNA repair, hypersensitivity to DNA crosslinking agents, and a high degree of chromosomal aberrations. Fanconi anemia (FA) is an autosomal disorder that causes genome instability. FA patients suffer developmental abnormalities, early-onset bone marrow failure, and a predisposition to cancer. The disease is manifested by defects in DNA repair, hypersensitivity to DNA crosslinking agents, and a high degree of chromosomal aberrations. Fanconi anemia (FA) is an autosomal disorder that causes genome instability. FA patients suffer developmental abnormalities, early-onset bone marrow failure, and a predisposition to cancer. The disease is manifested by defects in DNA repair, hypersensitivity to DNA crosslinking agents, and a high degree of chromosomal aberrations."}
{"question_id": "56ecfd572ac5ed1459000002", "question": "How is oprozomib administered?", "retrieved_chunks": [{"doc_id": "24712303", "chunk_id": "24712303_1", "score": 4.230853080749512, "text": "Further, new orally administered second-generation PI oprozomib is being investigated."}, {"doc_id": "24712303", "chunk_id": "24712303_0", "score": 3.957716226577759, "text": "Further, new orally administered second-generation PI oprozomib is being investigated"}, {"doc_id": "24712303", "chunk_id": "24712303_2", "score": 3.9564599990844727, "text": "new orally administered second-generation PI oprozomib is being investigated."}], "context": "[24712303:24712303_1] Further, new orally administered second-generation PI oprozomib is being investigated.\n[24712303:24712303_0] Further, new orally administered second-generation PI oprozomib is being investigated\n[24712303:24712303_2] new orally administered second-generation PI oprozomib is being investigated.", "answer": "<think> Okay, let's tackle this question. The user is asking how oprozomib is administered. The evidence provided has three chunks, all pointing to the fact that it's orally administered. First, I need to check each chunk for relevant information. All three mention \"orally administered,\" so that's consistent. The answer should be concise, stating that it's taken orally. The citations are from the same document, so I'll use the first chunk as the citation. The confidence level is high because all evidence points to the same conclusion. So base_confidence would be 1.0. </think> { \"answer\": \"Oprozomib is administered orally [24712303:24712303_1", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants to know how oprozomib is administered. The evidence provided has three chunks, all pointing to the fact that it's orally administered. First, I need to check each chunk for relevant information. All three chunks mention \"orally administered,\" so that's consistent. The answer should be concise and include citations. The document ID is 24712303, and the chunk IDs are 0, 1, 2. But since they all refer to the same main point, I can pick one chunk_id, maybe the first one. The base confidence is a float between 0 and 1. Since all evidence points to the same conclusion, the confidence should be high. Maybe", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking how oprozomib is administered. The evidence provided has three chunks, all pointing to the fact that it's orally administered. First, I need to check each chunk. All three mention \"orally administered,\" so that's consistent. The document IDs are all the same, 24712303, but the chunk IDs are different. However, the content is repetitive. The answer should be concise and include citations. Since all chunks support the same information, I can reference one of them. Maybe the first chunk, 24712303_1, as it's the first occurrence. The confidence level: the evidence clearly states oral administration, so the model is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking how oprozomib is administered. The evidence provided has three chunks, all pointing to the fact that it's orally administered. First, I need to check each chunk for relevant information. All three chunks mention \"orally administered,\" so that's consistent. The document IDs are all the same, 24712303, but the chunk ids are different. However, the content is repetitive. The answer should be concise and include citations. Since all the evidence points to oral administration, I can reference any of the chunks. Maybe use the first one as it's the initial mention. The confidence level is high because all sources agree. So base_confidence would be 1.0.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking how oprozomib is administered. The evidence provided has three chunks, all pointing to the fact that it's orally administered. First, I need to check each chunk for relevant information. All three mention \"orally administered,\" so that's consistent. The answer should be concise, stating that it's taken orally. The citations are from the same document, so I'll use the first chunk as the citation. The confidence level is high because all evidence points to the same conclusion. So base_confidence would be 1.0. </think> { \"answer\": \"Oprozomib is administered orally [24712303:24712303_1", "base_prob": 0.5, "critic": {"rel_label": "Rel", "rel_prob": 1.0, "sup_label": "Fully", "sup_prob": 1.0, "use_score": 5, "use_prob": 1.0, "notes": "All evidence explicitly states 'orally administered', directly answering the question with consistent information."}, "score": 6.5, "safe": true, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking how oprozomib is administered. The evidence provided has three chunks, all pointing to the fact that it's orally administered. First, I need to check each of the evidence chunks. All three mention \"orally administered,\" so that's consistent. The answer should be concise, stating that it's taken orally. The citation would be from the first chunk since they're all similar but the first one is the initial mention. Now, the base confidence. The model is pretty confident here because all three sources agree on the same point. So a high confidence level, maybe 0.95 or so. But I need to make sure there's no conflicting information. Since there's none, it's safe", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking how oprozomib is administered. The evidence provided has three chunks, all pointing to the fact that it's orally administered. First, I need to check each chunk for relevant information. All three chunks mention \"orally administered,\" so that's consistent. The answer should be straightforward: oprozomib is taken orally. Now, citations. Each chunk is from the same document ID, 24712303, but different chunk IDs. The user probably wants the first citation mentioned in the evidence. The first chunk is [24712303:24712303_1], so that's the one to use. Confidence", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, so the user is asking how oprozomib is administered. Let me look at the evidence provided. The evidence has three chunks, all from the same document ID. Each of them mentions that oprozomib is \"orally administered.\" The key point here is the word \"orally,\" which directly answers the question about administration method. I need to make sure there's no conflicting information. All three chunks agree on the oral route. The confidence level should be high since all sources are consistent. The model's confidence is probably 1.0 here because there's no contradictory evidence. The answer should be concise, citing the document ID and chunk ID. Since all chunks are from the same document, maybe pick one. But the user might accept any", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking how oprozomib is administered. Let me look at the evidence provided. The evidence has three chunks, all from the same document ID. Each chunk mentions that oprozomib is \"orally administered.\" The key point here is the method of administration. The answer needs to be concise and include citations. The base confidence should be a float between 0 and 1. Looking at the chunks, they all state that it's orally administered. There's no conflicting information here. All three chunks support the same fact. So the answer should be that oprozomib is taken orally, citing the document. Since all sources agree, the confidence can be high, maybe 0.95 or so. I need", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 6.5, "gold_docs": ["22763387", "22929803", "24103732", "24239172", "24471924", "24712303", "24915039"], "ideal_answer": "Oprozomib is administered orally."}
{"question_id": "54f57892d0d681a040000009", "question": "What is a Caveolae?", "retrieved_chunks": [{"doc_id": "24308657", "chunk_id": "24308657_0", "score": 9.42665958404541, "text": "Caveolae are flask-shaped plasma membrane invaginations formed by constitutive caveolin proteins and regulatory cavin proteins."}, {"doc_id": "24023653", "chunk_id": "24023653_0", "score": 8.941503524780273, "text": "Caveolae are cholesterol-rich microdomains that form mechanically deformable invaginations of the sarcolemma."}, {"doc_id": "23787000", "chunk_id": "23787000_0", "score": 8.930827140808105, "text": "Caveolae are membrane microdomains where important signalling pathways are assembled and molecular effects transduced."}], "context": "[24308657:24308657_0] Caveolae are flask-shaped plasma membrane invaginations formed by constitutive caveolin proteins and regulatory cavin proteins.\n[24023653:24023653_0] Caveolae are cholesterol-rich microdomains that form mechanically deformable invaginations of the sarcolemma.\n[23787000:23787000_0] Caveolae are membrane microdomains where important signalling pathways are assembled and molecular effects transduced.", "answer": "<think> Okay, I need to generate a candidate biomedical answer for the question \"What is a Caveolae?\" using the provided evidence. Let me start by carefully reading the user's instructions. First, the user wants a strict JSON response with two keys: \"answer\" and \"base_confidence\". The answer should be concise and include citations in the format [doc_id:chunk_id]. The base confidence is a float between 0 and 1, representing the model's confidence in the factual correctness of the answer. Looking at the evidence provided, there are three chunks from different documents. Let me parse each one: 1. [24308657:24308657_0]: Caveolae are flask-shaped plasma membrane invaginations", "citations": [{"doc_id": "24308657", "chunk_id": "24308657_0"}], "candidates": [{"answer": "<think> Okay, I need to generate a biomedical answer about Caveolae based on the provided evidence. Let me start by understanding what the question is asking. The user wants a concise answer that includes citations from the given documents and a confidence score. First, I'll look at the evidence provided. There are three chunks from different document IDs. Each chunk describes Caveolae in a slightly different way. The first mentions they're flask-shaped invaginations formed by caveolin and cavin proteins. The second says they're cholesterol-rich microdomains that are mechanically deformable parts of the sarcolemma. The third talks about them being membrane microdomains where signaling pathways are assembled. I need to synthesize this information into a single answer. The answer should be concise, so I'll have to", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer for the question \"What is a Caveolae?\" using the provided evidence. Let me start by carefully reading the user's instructions. First, the user wants a strict JSON response with two keys: \"answer\" and \"base_confidence\". The answer should be concise and include citations in the format [doc_id:chunk_id]. The base confidence is a float between 0 and 1, representing the model's confidence in the factual correctness of the answer. Looking at the evidence provided, there are three chunks from different documents. Let me parse each one: 1. [24308657:24308657_0]: Caveolae are flask-shaped plasma membrane invaginations", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question about Caveolae. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three chunks from different documents. The first chunk says caveolae are flask-shaped invaginations made of constitutive caveolin and regulatory cavin proteins. The second mentions they're cholesterol-rich microdomains that are mechanically deformable parts of the sarcolemma. The third states they're membrane microdomains where signaling pathways are assembled. I need to combine these points into a single answer. The key elements are their shape, composition (caveolins, cavings), cholesterol content, and function in signaling. Also, the mention of sarcolemma in the second chunk might be important,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about Caveolae. The user wants a concise answer with citations from the provided evidence and a confidence score. First, I need to look at the evidence given. There are three chunks from different documents. Each provides a slightly different angle on what Caveolae are. The first chunk says they're flask-shaped invaginations formed by caveolin and cavin proteins. The second mentions cholesterol-rich microdomains that are mechanically deformable parts of the sarcolemma. The third talks about them being membrane microdomains where signaling pathways are assembled. I need to combine these into a single answer. The key points are their structure (flask-shaped, invaginations), composition (caveolin and cavin proteins, cholesterol-rich), and function (", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so I need to generate a biomedical answer about Caveolae based on the provided evidence. Let me start by understanding what the question is asking. The user wants a concise answer that includes citations from the given documents and a confidence score. First, I'll look at the evidence snippets. There are three pieces of information here. Each comes from different document IDs and chunk IDs. Let me parse each one: 1. [24308657:24308657_0] says Caveolae are flask-shaped plasma membrane invaginations formed by constitutive caveolin proteins and regulatory cavin proteins. 2. [24023653:24023653_0] mentions they're", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question about Caveolae. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three documents. Let me read each one carefully. The first document says Caveolae are flask-shaped invaginations formed by constitutive caveolin and cavin proteins. The second mentions they're cholesterol-rich microdomains that form mechanically deformable invaginations of the sarcolemma. The third states they're membrane microdomains where signaling pathways are assembled. So, the answer needs to combine these points. The key elements are their shape (flask-shaped), composition (caveolin and cavin proteins, cholesterol-rich), function (signaling pathways), and maybe the mechanical deformability from the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is about what Caveolae are. First, looking at the evidence provided. There are three documents. Let me read each one carefully. The first document says Caveolae are flask-shaped plasma membrane invaginations formed by constitutive caveolin proteins and regulatory cavin proteins. That's a definition. The second mentions they're cholesterol-rich microdomains that form mechanically deformable invaginations of the sarcolemma. The third states they're membrane microdomains where important signaling pathways are assembled and molecular effects transduced. So, I need to combine these points into a concise answer. The answer should include key characteristics: structure (flask-shaped invaginations), composition (caveolin and c", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a biomedical answer about Caveolae based on the provided evidence. Let me start by understanding what the user is asking. The question is \"What is a Caveolae?\" and there are three pieces of evidence given from different documents. First, I'll look at each evidence point. The first one says that caveolae are flask-shaped plasma membrane invaginations formed by constitutive caveolin and regulatory cavin proteins. The second mentions they're cholesterol-rich microdomains that form mechanically deformable invaginations of the sarcolemma. The third states they're membrane microdomains where signaling pathways are assembled and molecular effects transduced. I need to combine these points into a concise answer. The answer should mention their structure (flask-shaped invaginations", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["23340574", "23521716", "23593340", "23610576", "23727353", "23787000", "23899671", "24013596", "24013648", "24023653", "24308657", "7407830"], "ideal_answer": "Caveolae, plasma membrane invaginations of 60-80nm in diameter, are a subset of lipid rafts enriched in cholesterol and sphingolipids."}
{"question_id": "56ebfa13107309bc2f000004", "question": "Which are the roles of chromatin compartments in the eukaryotic nucleus?", "retrieved_chunks": [{"doc_id": "9291094", "chunk_id": "9291094_0", "score": 5.984580993652344, "text": "Chromatin domains and nuclear compartments: establishing sites of gene expression in eukaryotic nuclei."}, {"doc_id": "21444719", "chunk_id": "21444719_3", "score": 4.725714683532715, "text": "ecent studies have shown that the protein CTCF, which plays an important role in insulation and in large-scale organization of chromatin within the eukaryotic nucleus, depends for both activities on recruitment of the cohesin complex"}, {"doc_id": "15868422", "chunk_id": "15868422_0", "score": 4.665445327758789, "text": "DNA in eukaryotes is packed into chromatin. The basic component of chromatin is the nucleosome consisting of DNA wrapped around a histone octamer. Inside the cell nucleus, chromatin is folded into higher-order structures through various mechanisms, including repositioning of nucleosomes along the DNA, packing of nucleosomes into more condensed 3-dimensional configurations, looping of chromatin fibres, and tethering of chromosomal regions to nuclear structures."}], "context": "[9291094:9291094_0] Chromatin domains and nuclear compartments: establishing sites of gene expression in eukaryotic nuclei.\n[21444719:21444719_3] ecent studies have shown that the protein CTCF, which plays an important role in insulation and in large-scale organization of chromatin within the eukaryotic nucleus, depends for both activities on recruitment of the cohesin complex\n[15868422:15868422_0] DNA in eukaryotes is packed into chromatin. The basic component of chromatin is the nucleosome consisting of DNA wrapped around a histone octamer. Inside the cell nucleus, chromatin is folded into higher-order structures through various mechanisms, including repositioning of nucleosomes along the DNA, packing of nucleosomes into more condensed 3-dimensional configurations, looping of chromatin fibres, and tethering of chromosomal regions to nuclear structures.", "answer": "<think> Okay, let's tackle this question. The user is asking about the roles of chromatin compartments in the eukaryotic nucleus. I need to look at the provided evidence to form an answer. First, looking at the evidence documents: Document [9291094:9291094_0] talks about chromatin domains and nuclear compartments related to gene expression sites. That's probably a key point here. Then there's [21444719:21444719_3], which mentions CTCF and cohesin complex. CTCF is involved in insulation and large-scale chromatin organization. So this might relate to how chromatin compartments are structured or regulated. The third document", "citations": [{"doc_id": "9291094", "chunk_id": "9291094_0"}, {"doc_id": "21444719", "chunk_id": "21444719_3"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the roles of chromatin compartments in the eukaryotic nucleus. I need to look at the provided evidence to form an answer. First, looking at the evidence documents: Document [9291094:9291094_0] talks about chromatin domains and nuclear compartments related to gene expression sites. That's probably a key point here. Then there's [21444719:21444719_3], which mentions CTCF and cohesin complex. CTCF is involved in insulation and large-scale chromatin organization. So this might relate to how chromatin compartments are structured or regulated. The third document", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a biomedical answer about the roles of chromatin compartments in the eukaryotic nucleus based on the provided evidence. Let me start by understanding what the question is asking. The user wants to know the roles of these compartments, so I should look at the evidence given and extract relevant information. Looking at the evidence: First document [9291094:9291094_0] talks about chromatin domains and nuclear compartments establishing sites of gene expression. That seems directly related to the question. So one role is that they help in setting up locations for gene expression. Second document [21444719:21444719_3] mentions CTCF protein's role", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer based on the provided evidence. The question is about the roles of chromatin compartments in the eukaryotic nucleus. First, let me look at the evidence given. There are three references: 1. [9291094:9291094_0] talks about chromatin domains and nuclear compartments related to gene expression sites. 2. [21444719:21444719_3] mentions CTCF's role in insulation and large-scale chromatin organization, dependent on cohesin complex recruitment. 3. [15868422:15868422_0] describes DNA packing into", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer about the roles of chromatin compartments in the eukaryotic nucleus based on the provided evidence. Let me start by understanding what the question is asking. The user wants to know the roles of these compartments, so I should look at the evidence given. Looking at the evidence, there are three references. The first one mentions chromatin domains and nuclear compartments related to gene expression sites. The second talks about CTCF protein and cohesin complex involved in insulation and large-scale chromatin organization. The third explains that DNA is packed into chromatin, with nucleosomes and higher-order structures like looping and tethering. So, the answer should combine these points. Chromatin compartments likely involve structural organization, gene expression regulation, and maybe", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about the roles of chromatin compartments in the eukaryotic nucleus. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three references here. Let me break them down. The first one, [9291094:9291094_0], talks about chromatin domains and nuclear compartments relating to gene expression sites. That seems relevant because it directly mentions the role of chromatin compartments in establishing gene expression locations. The second reference, [21444719:21444719_3], discusses CTCF and cohesin complex. It says that CTCF is involved", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer about the roles of chromatin compartments in the eukaryotic nucleus based on the provided evidence. Let me start by understanding the question and the given evidence. The user is asking for the roles of chromatin compartments. From the evidence, there are three documents mentioned. Let me go through each one to extract relevant information. First document [9291094:9291094_0] talks about chromatin domains and nuclear compartments, establishing sites of gene expression. So this suggests that chromatin compartments help in locating where genes are expressed. That's a key point. Second document [21444719:21444719_3] mentions C", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the roles of chromatin compartments in the eukaryotic nucleus. I need to look at the provided evidence to form an answer. First, looking at the evidence documents: Document [9291094:9291094_0] talks about chromatin domains and nuclear compartments relating to gene expression sites. That's a good start. It suggests that chromatin compartments help in establishing where genes are expressed. Then document [21444719:21444719_3] mentions CTCF and cohesin complex. CTCF is involved in insulation and organizing chromatin. The cohesin complex is important for these activities", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the roles of chromatin compartments in the eukaryotic nucleus. I need to look at the provided evidence to find relevant information. First, looking at the evidence documents: The first one, [9291094:9291094_0], mentions chromatin domains and nuclear compartments related to gene expression sites. That seems directly relevant. The second document, [21444719:21444719_3], talks about CTCF and cohesin complex involving insulation and large-scale chromatin organization. The third document, [15868422:15868422_0", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["11186332", "11909528", "15140983", "15791412", "18434402", "18974210", "21637796", "22198682", "24002784", "25409831", "9291094", "9587055", "9636146"], "ideal_answer": "The complexity in composition and function of the eukaryotic nucleus is achieved through its organization in specialized nuclear compartments. Chromosome conformation capture approaches have shown that interphase chromatin is partitioned into spatially segregated Mb-sized compartments and sub-Mb-sized topological domains. This compartmentalization is thought to facilitate the matching of genes and regulatory elements. Cohesin-based chromatin interactions enable regulated gene expression within preexisting architectural compartments. Therefore, concentrating proteins needed to perform different steps of RNA synthesis within specialized nuclear compartments is important in orchestrating events required for efficient gene expression."}
{"question_id": "56c0708eef6e39474100001f", "question": "Is the abnormal dosage of ultraconserved elements disfavored in cancer cells?", "retrieved_chunks": [{"doc_id": "25340765", "chunk_id": "25340765_0", "score": 9.857267379760742, "text": "Abnormal dosage of ultraconserved elements is highly disfavored in healthy cells but not cancer cells."}, {"doc_id": "25340765", "chunk_id": "25340765_5", "score": 0.8188755512237549, "text": "Ultraconserved elements (UCEs) are strongly depleted from segmental duplications and copy number variations (CNVs) in the human genome, suggesting that deletion or duplication of a UCE can be deleterious to the mammalian cell."}, {"doc_id": "25340765", "chunk_id": "25340765_4", "score": 0.37329816818237305, "text": "Ultraconserved elements (UCEs) are strongly depleted from segmental duplications and copy number variations (CNVs) in the human genome, suggesting that deletion or duplication of a UCE can be deleterious to the mammalian cell"}], "context": "[25340765:25340765_0] Abnormal dosage of ultraconserved elements is highly disfavored in healthy cells but not cancer cells.\n[25340765:25340765_5] Ultraconserved elements (UCEs) are strongly depleted from segmental duplications and copy number variations (CNVs) in the human genome, suggesting that deletion or duplication of a UCE can be deleterious to the mammalian cell.\n[25340765:25340765_4] Ultraconserved elements (UCEs) are strongly depleted from segmental duplications and copy number variations (CNVs) in the human genome, suggesting that deletion or duplication of a UCE can be deleterious to the mammalian cell", "answer": "<think> Okay, let's tackle this question. The user is asking if abnormal dosage of ultraconserved elements (UCEs) is disfavored in cancer cells. Looking at the evidence provided, there are three chunks from the same document. The first chunk [25340765:25340765_0] says that abnormal dosage of UCEs is highly disfavored in healthy cells but not in cancer cells. That directly answers the question. The other two chunks mention that UCEs are depleted from CNVs and that deleting or duplicating them is harmful, which supports the idea that abnormal dosage is bad in normal cells but not necessarily in cancer. Wait, but the question is specifically about cancer cells. The first chunk explicitly states", "citations": [{"doc_id": "25340765", "chunk_id": "25340765_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if abnormal dosage of ultraconserved elements (UCEs) is disfavored in cancer cells. Looking at the evidence provided, there are three chunks from the same document. The first one says that abnormal dosage of UCEs is highly disfavored in healthy cells but not in cancer cells. That directly answers the question. The other two chunks mention that UCEs are depleted from CNVs and that deleting or duplicating them is deleterious, which suggests they are important. But the key point here is the contrast between healthy cells and cancer cells. So the answer should reference the first chunk, which explicitly states that in cancer cells, abnormal dosage isn't disfavored. The confidence level would be high because", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if abnormal dosage of ultraconserved elements (UCEs) is disfavored in cancer cells. Looking at the evidence provided, there are three chunks from the same document ID. The first chunk says that abnormal dosage of UCEs is highly disfavored in healthy cells but not in cancer cells. That directly answers the question. The other two chunks mention that UCEs are depleted from CNVs and that deleting or duplicating them is deleterious to mammalian cells. But those points are about general cellular context, not specifically cancer. So the key point here is the first chunk explicitly states that in cancer cells, abnormal dosage isn't disfavored. The other chunks support the idea that UCEs are", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if abnormal dosage of ultraconserved elements is disfavored in cancer cells. The evidence provided has three chunks. First, chunk 25340765_25340765_0 says that abnormal dosage of UCEs is highly disfavored in healthy cells but not in cancer cells. That directly answers the question. So the answer would be yes, but with a note that it's not disfavored in cancer cells. Wait, the question is asking if it's disfavored in cancer cells. The evidence says it's not disfavored there. So the answer should be no, but I need to check the other chunks for confirmation. Chunks 25", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if abnormal dosage of ultraconserved elements (UCEs) is disfavored in cancer cells. The evidence provided has three chunks. First, looking at chunk 25340765_0: It states that abnormal dosage of UCEs is highly disfavored in healthy cells but not in cancer cells. That directly answers the question. So the answer would be yes, it's not disfavored in cancer cells. The confidence here is high because this chunk explicitly addresses the question. The other chunks (25340765_4 and 25340765_5) mention that UCEs are depleted from CNVs and that deletion or duplication", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if abnormal dosage of ultraconserved elements is disfavored in cancer cells. The evidence provided has three chunks. First, chunk 25340765_25340765_0 says that abnormal dosage is highly disfavored in healthy cells but not in cancer cells. That directly answers the question. So the answer would be yes, but with a note that it's not disfavored in cancer cells. Wait, the question is asking if it's disfavored in cancer cells. The evidence says it's not disfavored in cancer cells. So the answer should be no, because the abnormal dosage isn't disfavored there. But I need to check the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if abnormal dosage of ultraconserved elements (UCEs) is disfavored in cancer cells. Looking at the evidence provided, there are three chunks from the same document. The first chunk [25340765:25340765_0] says that abnormal dosage of UCEs is highly disfavored in healthy cells but not in cancer cells. That directly answers the question. The other two chunks mention that UCEs are depleted from CNVs and that deleting or duplicating them is harmful, which supports the idea that abnormal dosage is bad in normal cells but not necessarily in cancer. Wait, but the question is specifically about cancer cells. The first chunk explicitly states", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if abnormal dosage of ultraconserved elements (UCEs) is disfavored in cancer cells. First, I need to look at the evidence provided. There are three chunks from the same document ID, 25340765. Chunk 25340765_0 says that abnormal dosage of UCEs is highly disfavored in healthy cells but not in cancer cells. That directly answers the question. So the answer would be based on this chunk. Chunks 25340765_4 and 25340765_5 both mention that UCEs are depleted from CNVs, suggesting that deleting or duplicating them", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if abnormal dosage of ultraconserved elements is disfavored in cancer cells. The evidence provided has three chunks. First, chunk 25340765_25340765_0 says that abnormal dosage of UCEs is highly disfavored in healthy cells but not in cancer cells. That directly answers the question. So the answer would be \"Yes, according to [25340765:25340765_0].\" But wait, the other chunks mention that UCEs are depleted from CNVs and that deleting or duplicating them is detrimental. However, those chunks are about healthy cells. The question specifically asks", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["25340765"], "ideal_answer": "No. Abnormal dosage of ultraconserved elements is highly disfavored in healthy cells but not cancer cells."}
{"question_id": "515ac533d24251bc050000a9", "question": "Does thyroid hormone regulate calcium transient in the myocardium?", "retrieved_chunks": [{"doc_id": "2428004", "chunk_id": "2428004_0", "score": 2.460783004760742, "text": "hese results indicate that the thyroid state influences the time course of the calcium transient and are consistent with the abbreviation in the duration of contraction that is observed in the hyperthyroid state."}, {"doc_id": "9875761", "chunk_id": "9875761_0", "score": 1.618147850036621, "text": "In normal porcine myocardium T3 had no effect on the extent of isometric force generation but accelerated the time course of force development (p < 0.05) and increased the calcium transient (p < 0.001). After induction of myocardial depression by epinephrine exposure T3 accelerated the intracellular calcium transients and reduced diastolic calcium"}, {"doc_id": "20730619", "chunk_id": "20730619_1", "score": 0.5367825627326965, "text": "It has been previously shown that regulators of physiological growth such as thyroid hormone (TH) can favorably remodel the post ischaemic myocardium."}], "context": "[2428004:2428004_0] hese results indicate that the thyroid state influences the time course of the calcium transient and are consistent with the abbreviation in the duration of contraction that is observed in the hyperthyroid state.\n[9875761:9875761_0] In normal porcine myocardium T3 had no effect on the extent of isometric force generation but accelerated the time course of force development (p < 0.05) and increased the calcium transient (p < 0.001). After induction of myocardial depression by epinephrine exposure T3 accelerated the intracellular calcium transients and reduced diastolic calcium\n[20730619:20730619_1] It has been previously shown that regulators of physiological growth such as thyroid hormone (TH) can favorably remodel the post ischaemic myocardium.", "answer": "<think> Okay, let's tackle this question. The user is asking if thyroid hormone regulates the calcium transient in the myocardium. I need to look at the evidence provided to find answers. First, looking at evidence [9875761:9875761_0], it says that T3 (a form of thyroid hormone) accelerated the time course of force development and increased the calcium transient in normal porcine myocardium. There's a p-value mentioned, which suggests statistical significance. So this directly indicates that thyroid hormone does affect the calcium transient. Another piece of evidence [2428004:2428004_0] mentions that thyroid state influences the time course of the calcium transient, consistent with the duration", "citations": [{"doc_id": "9875761", "chunk_id": "9875761_0"}, {"doc_id": "2428004", "chunk_id": "2428004_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if thyroid hormone regulates the calcium transient in the myocardium. I need to look at the evidence provided to find answers. First, looking at evidence [9875761:9875761_0], it says that T3 (a form of thyroid hormone) accelerated the time course of force development and increased the calcium transient in normal porcine myocardium. There's a p-value mentioned, which suggests statistical significance. So this directly indicates that thyroid hormone does affect the calcium transient. Another piece of evidence [2428004:2428004_0] mentions that thyroid state influences the time course of the calcium transient, consistent with the duration", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if thyroid hormone regulates calcium transients in the myocardium. I need to look at the evidence provided to find answers. First, looking at evidence [9875761:9875761_0], it says that T3 (thyroid hormone) accelerates the time course of force development and increases the calcium transient in normal porcine myocardium. There's a p < 0.001, which suggests statistical significance. So this directly supports that thyroid hormone affects calcium transients. Then there's [2428004:2428004_0], which mentions that thyroid state influences the time course of the calcium transient, consistent", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if thyroid hormone regulates the calcium transient in the myocardium. I need to look at the provided evidence to find answers. First, looking at the evidence: The first document (2428004) says that thyroid state affects the time course of the calcium transient, which is consistent with faster contractions in hyperthyroidism. That suggests a connection between thyroid function and calcium transients. The second document (9875761) mentions that T3 (a form of thyroid hormone) accelerates the time course of force development and increases the calcium transient in normal porcine myocardium. This directly links thyroid hormone to changes in calcium transients. The third document (207", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if thyroid hormone regulates the calcium transient in the myocardium. I need to look at the provided evidence to find answers. First, looking at the evidence: The first document (2428004:2428004_0) says that thyroid state affects the time course of the calcium transient and is consistent with the duration of contraction in hyperthyroidism. That suggests a link between thyroid function and calcium transients. The second document (9875761:9875761_0) mentions that T3 (a form of thyroid hormone) accelerates the time course of force development and increases the calcium transient in normal porcine myocardium.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if thyroid hormone regulates calcium transients in the myocardium. I need to look at the evidence provided. First, evidence document [9875761:9875761_0] says that T3 (thyroid hormone) accelerates the time course of force development and increases the calcium transient in normal porcine myocardium. There's a p-value mentioned, which suggests statistical significance. So this directly supports the idea that thyroid hormone affects calcium transients. Another document [2428004:2428004_0] mentions that thyroid state influences the calcium transient's time course, consistent with faster contractions in hyperthyroidism. This", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if thyroid hormone regulates calcium transient in the myocardium. I need to look at the evidence provided. First, evidence from [9875761:9875761_0] says that T3 (thyroid hormone) accelerates the time course of force development and increases the calcium transient in normal porcine myocardium. There's a p-value mentioned, which suggests statistical significance. So this directly supports the idea that thyroid hormone affects calcium transients. Another piece is [2428004:2428004_0], which mentions that thyroid state influences the calcium transient's time course, aligning with the duration of contraction in hyperthy", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if thyroid hormone regulates the calcium transient in the myocardium. I need to look at the provided evidence to find answers. First, looking at evidence [9875761:9875761_0], it says that T3 (thyroid hormone) accelerates the time course of force development and increases the calcium transient in normal porcine myocardium. There's a p-value mentioned, which suggests statistical significance. So this directly supports the idea that thyroid hormone does affect the calcium transient. Another piece is [2428004:2428004_0], which mentions that thyroid state influences the calcium transient's time course, consistent with the duration", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if thyroid hormone regulates calcium transients in the myocardium. I need to look at the evidence provided. First, evidence from [9875761:9875761_0] says that T3 (thyroid hormone) accelerates the time course of force development and increases the calcium transient in normal porcine myocardium. There's a p-value mentioned, which suggests statistical significance. So this directly supports the idea that thyroid hormone affects calcium transients. Another piece is [2428004:2428004_0], which mentions that thyroid state influences the calcium transient's time course, consistent with faster contractions in hyperthyroidism", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["19298522", "2428004", "9773867", "9875761"], "ideal_answer": "YES"}
{"question_id": "533c2230c45e133714000002", "question": "What are the biological roles proposed for proteins containing the SPRY domain?", "retrieved_chunks": [{"doc_id": "23139046", "chunk_id": "23139046_0", "score": 5.252073764801025, "text": "SPRY domain is a protein interaction module found in 77 murine and ~100 human proteins, and is implicated in important biological pathways, including those that regulate innate and adaptive immunity"}, {"doc_id": "23139046", "chunk_id": "23139046_1", "score": 2.7821950912475586, "text": "function of the SPRY/B30.2 domain proteins involved in innate immunity"}, {"doc_id": "12479811", "chunk_id": "12479811_1", "score": 0.8123128414154053, "text": "SPRY-domain and SOCS-box containing protein, GUSTAVUS."}], "context": "[23139046:23139046_0] SPRY domain is a protein interaction module found in 77 murine and ~100 human proteins, and is implicated in important biological pathways, including those that regulate innate and adaptive immunity\n[23139046:23139046_1] function of the SPRY/B30.2 domain proteins involved in innate immunity\n[12479811:12479811_1] SPRY-domain and SOCS-box containing protein, GUSTAVUS.", "answer": "<think> Okay, let's tackle this question. The user is asking about the biological roles of proteins with the SPRY domain. I need to look at the evidence provided. First, evidence [23139046:23139046_0] says that the SPRY domain is involved in regulating innate and adaptive immunity. That's a key point. Then [23139046:23139046_1] specifically mentions the function in innate immunity. The third piece of evidence [12479811:1247981boxed_1] talks about SPRY-domain and SOCS-box containing protein, GUSTAVUS. But I'm not sure if", "citations": [{"doc_id": "23139046", "chunk_id": "23139046_0"}, {"doc_id": "23139046", "chunk_id": "23139046_1"}, {"doc_id": "12479811", "chunk_id": "1247981boxed_1"}], "candidates": [{"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is about the biological roles of proteins with the SPRY domain. Let me look at the evidence provided. First, the evidence has three chunks. The first one says that the SPRY domain is involved in regulating innate and adaptive immunity. The second mentions the SPRY/B30.2 domain's role in innate immunity. The third talks about a specific protein, GUSTAVUS, which contains both SPRY and SOCS-box domains. So, the answer should combine these points. The main roles are in immune pathways, specifically innate and adaptive immunity. The third chunk adds that there's a protein with both SPRY and SOCS-box, but the question is about the SPRY domain", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a biomedical answer about the biological roles of proteins with the SPRY domain. Let me look at the evidence provided. The first evidence snippet says that the SPRY domain is involved in regulating innate and adaptive immunity. The second one mentions the SPRY/B30.2 domain proteins are involved in innate immunity. The third snippet talks about a specific protein, GUSTAVUS, which contains both SPRY and SOCS-box domains. So, combining these, the main roles seem to be in immune pathways. The SPRY domain is part of proteins that regulate both innate and adaptive immunity. The mention of GUSTAVUS might be an example of a specific protein, but the key point is the general role in immunity. I should make sure", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the biological roles of proteins with the SPRY domain. I need to look at the evidence provided. First, evidence [23139046:23139046_0] says that the SPRY domain is involved in regulating innate and adaptive immunity. That's a key point. Then [23139046:23139046_1] specifically mentions the function in innate immunity. The third piece of evidence [12479811:1247981boxed_1] talks about SPRY-domain and SOCS-box containing protein, GUSTAVUS. But I'm not sure if", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the biological roles of proteins with the SPRY domain. I need to look at the provided evidence to form an answer. First, evidence [23139046:23139046_0] says the SPRY domain is involved in pathways regulating innate and adaptive immunity. That's a key point. Then [23139046:23139046_1] specifically mentions the SPRY/B30.2 domain in innate immunity. The third piece, [12479811:1247981质1], talks about a protein with both SPRY and SOCS-box domains,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a biomedical answer about the biological roles of proteins with the SPRY domain based on the provided evidence. Let me start by reviewing the evidence given. The first piece of evidence (23139046:23139046_0) says that the SPRY domain is involved in important pathways regulating innate and adaptive immunity. The second one (23139046:23139046_1) specifically mentions the function of SPRY/B30.2 domain proteins in innate immunity. The third evidence (12479811:12479811_1) talks about a protein called GUSTAVUS, which contains both", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer based on the provided evidence. The question is about the biological roles of proteins with the SPRY domain. Let me look at the evidence given. First, the evidence has three entries. The first one says that the SPRY domain is involved in regulating innate and adaptive immunity. The second mentions that SPRY/B30.2 domain proteins are involved in innate immunity. The third talks about a specific protein, GUSTAVUS, which contains both SPRY and SOCS-box domains. So the main points here are that SPRY domain proteins are implicated in immune pathways, specifically innate and adaptive immunity. The second evidence directly links SPRY/B30.2 to innate immunity. The third example might be an example of a", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the biological roles of proteins with the SPRY domain. I need to look at the provided evidence to form an answer. First, evidence document 23139046:23139046_0 says the SPRY domain is involved in regulating innate and adaptive immunity. That's a key point. Then, 23139046:23139046_1 specifically mentions the SPRY/B30.2 domain proteins being involved in innate immunity. The third piece of evidence, 12479811:12479811_1, talks about a protein with both SPRY and", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the biological roles of proteins with the SPRY domain. The evidence provided has three chunks. First, chunk 23139046_0 says that the SPRY domain is involved in pathways regulating innate and adaptive immunity. That's a key point. Then chunk 23139046_1 mentions the SPRY/B30.2 domain proteins are involved in innate immunity. The third chunk, 12479811_1, talks about a specific protein, GUSTAVUS, which has both SPRY and SOCS-box domains. But that might be more of an example rather than a general role. So the main roles seem to be in", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["12479811", "15689398", "15857996", "16226405", "16313355", "16648259", "17431422", "19184407", "21035437", "22337885", "22872646", "23091002", "23139046", "23775985", "23886867"], "ideal_answer": "defence against retroviral infection innate and adaptative immunity vesicular trafficking neural differentiation embryonic development"}
{"question_id": "511979b04eab811676000003", "question": "How could we infer functional associations from gene fusion events?", "retrieved_chunks": [{"doc_id": "12519996", "chunk_id": "12519996_1", "score": 6.628170967102051, "text": "Functional links between proteins can often be inferred from genomic associations between the genes that encode them: groups of genes that are required for the same function tend to show similar species coverage, are often located in close proximity on the genome (in prokaryotes), and tend to be involved in gene-fusion events. The database STRING is a precomputed global resource for the exploration and analysis of these associations."}, {"doc_id": "12519996", "chunk_id": "12519996_0", "score": 6.149778842926025, "text": "Functional links between proteins can often be inferred from genomic associations between the genes that encode them: groups of genes that are required for the same function tend to show similar species coverage, are often located in close proximity on the genome (in prokaryotes), and tend to be involved in gene-fusion events."}, {"doc_id": "18546511", "chunk_id": "18546511_0", "score": 5.7166643142700195, "text": "The detection of gene fusion events across genomes can be used for the prediction of functional associations of proteins, including physical interactions or complex formation."}], "context": "[12519996:12519996_1] Functional links between proteins can often be inferred from genomic associations between the genes that encode them: groups of genes that are required for the same function tend to show similar species coverage, are often located in close proximity on the genome (in prokaryotes), and tend to be involved in gene-fusion events. The database STRING is a precomputed global resource for the exploration and analysis of these associations.\n[12519996:12519996_0] Functional links between proteins can often be inferred from genomic associations between the genes that encode them: groups of genes that are required for the same function tend to show similar species coverage, are often located in close proximity on the genome (in prokaryotes), and tend to be involved in gene-fusion events.\n[18546511:18546511_0] The detection of gene fusion events across genomes can be used for the prediction of functional associations of proteins, including physical interactions or complex formation.", "answer": "<think> Okay, let's tackle this question. The user is asking how we can infer functional associations from gene fusion events. Looking at the evidence provided, there are three references. First, reference [12519996:12519996_1] and [12519996:12519996_0] both mention that functional links can be inferred from genomic associations, including gene fusion events. They talk about genes required for the same function showing similar species coverage, proximity in the genome, and involvement in gene fusions. So that's one point. Then, reference [18546511:18546511_0] states that detecting gene", "citations": [{"doc_id": "12519996", "chunk_id": "12519996_1"}, {"doc_id": "12519996", "chunk_id": "12519996_0"}, {"doc_id": "18546511", "chunk_id": "18546511_0"}], "candidates": [{"answer": "<think> Okay, I need to generate a biomedical answer based on the given evidence. Let me start by understanding the question: How could we infer functional associations from gene fusion events? Looking at the evidence provided, there are three documents. The first two (12519996) mention that functional links can be inferred from genomic associations, including gene-fusion events. The third document (18546511) states that detecting gene fusion events across genomes can predict protein functional associations. So the answer should combine these points. The key idea is that gene fusions indicate that genes are physically linked, which might mean they function together. So, by analyzing these fusions, we can infer their functions. I need to make sure to cite the relevant documents", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. Let me start by understanding the question: How could we infer functional associations from gene fusion events? Looking at the evidence provided, there are three documents. The first two (12519996) mention that functional links can be inferred from genomic associations, including gene fusion events. The third document (18546511) says that detecting gene fusions across genomes can predict functional associations. So the answer should combine these points. The main idea is that gene fusion events are used to predict functional associations. The citations would be from the two documents that mention gene fusion, and the third one as well. But since the user wants one candidate answer, I need to pick the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know how we can infer functional associations from gene fusion events. Looking at the evidence provided, there are three documents. First, document 12519996 has two chunks. Both mention that functional links can be inferred from genomic associations, including gene fusion events. They talk about genes required for the same function showing similar species coverage, proximity in the genome, and being part of gene-fusion events. So that's a key point. Then there's document 18546511 which says that detecting gene fusion events across genomes can predict functional associations like physical interactions or complex formation. That's another point to consider. The answer needs to be concise with citations in the format [doc_id", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer based on the provided evidence. Let me start by understanding the question: How could we infer functional associations from gene fusion events? Looking at the evidence, there are three references. The first two (12519996) mention that functional links can be inferred from genomic associations, including gene-fusion events. The third (18546511) says that detecting gene fusions across genomes can predict protein functional associations. So the answer should tie together the idea that gene fusion events are part of the genomic associations that help infer functional links. The confidence level: since two of the three sources mention this, and the third supports it as well, I think a confidence of 0.8 is reasonable", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking how we can infer functional associations from gene fusion events. Looking at the evidence provided, there are three documents. First, document 12519996:12519996_1 mentions that functional links can be inferred from genomic associations, including gene-fusion events. It also talks about similar species coverage, proximity in the genome, and gene fusion. Then, the same doc again, 12519996:12519996_0 repeats the same points. The third document, 18546511:18546511_0 says that detecting gene fusions across genomes can predict", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer based on the given evidence. Let me start by understanding the question: How could we infer functional associations from gene fusion events? Looking at the evidence provided, there are three documents. The first two (12519996) mention that functional links can be inferred from genomic associations, including gene fusion events. They talk about genes required for the same function showing similar species coverage, proximity in the genome, and involvement in gene-fusion events. The third document (18546511) states that detecting gene fusion events across genomes can predict protein functional associations, like physical interactions or complex formation. So, the answer should tie together the idea that gene fusion events are a way to infer functional associations.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking how we can infer functional associations from gene fusion events. Looking at the evidence provided, there are three references. First, reference [12519996:12519996_1] and [12519996:12519996_0] both mention that functional links can be inferred from genomic associations, including gene fusion events. They talk about genes required for the same function showing similar species coverage, proximity in the genome, and involvement in gene fusions. So that's one point. Then, reference [18546511:18546511_0] states that detecting gene", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this query. The user is asking how to infer functional associations from gene fusion events. Looking at the evidence provided, there are three documents. First, document 12519996 has two chunks. Both mention that functional links can be inferred from genomic associations, including gene fusion events. They talk about genes required for the same function showing similar species coverage, proximity in the genome, and involvement in gene fusions. Also, STRING database is mentioned as a resource. Then there's document 18546511 which says that detecting gene fusion events across genomes can predict functional associations like physical interactions or complex formation. So, the answer should combine these points. The main idea is that gene fusion events are indicators of functional relationships", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["10573422", "11178267", "11438739", "11820254", "11864366", "12049665", "12095249", "12429059", "12429063", "12519996", "12952538", "14673105", "15128449", "15215406", "15701682", "15960802", "15980440", "16221304", "16381848", "16571130", "17597916", "17767732", "18025684", "18081932", "18546511", "18629289", "19582169", "20532224", "20851221", "21729286", "22161322", "22267904", "22925561", "23220349", "23365410"], "ideal_answer": "The detection of gene fusion events across genomes can be used for the prediction of functional associations of proteins, based on the observation that related proteins in one organism (including physically interacting proteins/members of complexes, proteins involved in the same pathway) tend to be found in other species as a fused composite gene encoding a single multifunctional protein. For this purpose, gene fusion events may be used as the sole evidence or as independent information combined with other 'genome-aware' or similarity-based methods, and functional association may be predicted at different levels. An advantage of this approach is that it is not necessary to know the function of the composite/components to infer association."}
{"question_id": "514241fcd24251bc05000006", "question": "The protein NONO forms heterodimers. With which proteins?", "retrieved_chunks": [{"doc_id": "22416126", "chunk_id": "22416126_0", "score": 5.8980278968811035, "text": "Structure of the heterodimer of human NONO and paraspeckle protein component 1"}, {"doc_id": "22101825", "chunk_id": "22101825_1", "score": 5.792722225189209, "text": "difficult heterodimeric complex of two human proteins, paraspeckle component 1 (PSPC1) and non-POU domain-containing octamer-binding protein (NONO), that are involved in gene regulation and the structural integrity of nuclear bodies termed paraspeckles is described."}, {"doc_id": "22102035", "chunk_id": "22102035_1", "score": 5.631742477416992, "text": "The paraspeckle component 1 (PSPC1) and non-POU-domain-containing octamer-binding protein (NONO) heterodimer is an essential structural component of paraspeckles,"}], "context": "[22416126:22416126_0] Structure of the heterodimer of human NONO and paraspeckle protein component 1\n[22101825:22101825_1] difficult heterodimeric complex of two human proteins, paraspeckle component 1 (PSPC1) and non-POU domain-containing octamer-binding protein (NONO), that are involved in gene regulation and the structural integrity of nuclear bodies termed paraspeckles is described.\n[22102035:22102035_1] The paraspeckle component 1 (PSPC1) and non-POU-domain-containing octamer-binding protein (NONO) heterodimer is an essential structural component of paraspeckles,", "answer": "<think> Okay, so the user is asking which proteins form heterodimers with NONO. Let me check the evidence provided. Looking at the evidence, there are three references. The first one mentions the heterodimer of human NONO and paraspeckle protein component 1. The second reference talks about a difficult heterodimeric complex between PSPC1 and NONO, involved in gene regulation. The third one again states that PSPC1 and NONO form a heterodimer as an essential part of paraspeckles. All three sources point to PSPC1 (paraspeckle component 1) as the protein that forms a heterodimer with NONO. The answer should be PSPC1, and the confidence is high since all three documents support", "citations": [], "candidates": [{"answer": "<think> Okay, so the user is asking which proteins form heterodimers with NONO. Let me check the evidence provided. Looking at the evidence, there are three references. The first one mentions the heterodimer of human NONO and paraspeckle protein component 1. The second reference talks about a difficult heterodimeric complex between PSPC1 and NONO, involved in gene regulation. The third one again states that PSPC1 and NONO form a heterodimer as an essential part of paraspeckles. All three sources point to PSPC1 (paraspeckle component 1) as the protein that forms a heterodimer with NONO. The answer should be PSPC1, and the confidence is high since all three documents support", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which proteins form heterodimers with NONO. The evidence provided has three entries. First, looking at the evidence documents. The first one mentions the heterodimer of human NONO and paraspeckle protein component 1. The second document refers to a complex involving PSPC1 and NONO, both involved in gene regulation and nuclear bodies called paraspeckles. The third document also states that PSPC1 and NONO form a heterodimer, essential for paraspeckles. So all three documents point to PSPC1 as the protein that forms a heterodimer with NONO. The answer should be PSPC1. Now, checking the citations: the first document is 224", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which proteins form heterodimers with NONO. The evidence provided has three chunks. First, looking at the evidence: Chunk 22416126 mentions the heterodimer of human NONO and paraspeckle protein component 1. So that's one protein: PSPC1. Then chunk 22101825 talks about a difficult complex of PSPC1 and NONO, again mentioning they form a heterodimer. This reinforces the same pair. Chunk 22102035 also states that PSPC1 and NONO form a heterodimer, essential for paraspeckles. So all three chunks point to PSPC1", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which proteins form heterodimers with NONO. The evidence provided has three references. First, looking at the evidence: - The first document (22416126) mentions the heterodimer of human NONO and paraspeckle protein component 1. So that's PSPC1. - The second document (22101825) talks about a complex between PSPC1 and NONO, again confirming they form a heterodimer. - The third document (22102035) also states the same thing about PSPC1 and NONO forming a heterodimer. All three sources point to PSPC1 as the protein that forms", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which proteins form heterodimers with NONO. The evidence provided has three chunks. First, looking at the evidence documents. The first one mentions a heterodimer of human NONO and paraspeckle protein component 1. The second document talks about a difficult heterodimeric complex between PSPC1 and NONO, involved in gene regulation and nuclear bodies called paraspeckles. The third document again states that PSPC1 and NONO form a heterodimer essential for paraspeckles. So, all three documents point to PSPC1 (also known as paraspeckle protein component 1) as the partner protein. The key is to confirm that all references agree on this. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which proteins form heterodimers with NONO. The evidence provided has three entries. First, looking at the evidence documents. The first one, 22416126:22416126_0, mentions the heterodimer of human NONO and paraspeckle protein component 1. So that's PSPC1. The second document, 22101825:22101825_1, talks about a difficult heterodimeric complex of PSPC1 and NONO. So again, same proteins. The third document, 22102035:22102", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which proteins form heterodimers with NONO. The evidence provided has three references. First, looking at the document IDs and chunk IDs. The first one, 22416126:22416126_0, mentions the heterodimer of human NONO and paraspeckle protein component 1. So that's PSPC1. The second document, 22101825:22101825_1, talks about a difficult heterodimeric complex of PSPC1 and NONO. Again, same proteins. The third one, 22102035:22", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking which proteins form heterodimers with NONO. Let me look at the evidence provided. First, the evidence mentions several documents. The first one, 22416126:22416126_0, talks about the heterodimer of human NONO and paraspeckle protein component 1. So that's a direct mention of PSPC1. Then, document 22101825:22101825_1 says it's a difficult heterodimeric complex of PSPC1 and NONO. That reinforces the same pair. The third document, 22102035:2210203", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["16148043", "18655028", "19423654", "20421735", "22101825", "22102035", "22416126"], "ideal_answer": "The protein NONO forms heterodimers with PSPC1, SFPQ."}
{"question_id": "5709ee36cf1c32585100001e", "question": "Which syndrome is associated with mutant DVL1?", "retrieved_chunks": [{"doc_id": "25817014", "chunk_id": "25817014_1", "score": 6.228790283203125, "text": "Mutations in DVL1 cause an osteosclerotic form of Robinow syndrome."}, {"doc_id": "25817016", "chunk_id": "25817016_0", "score": 5.217873573303223, "text": "DVL1 frameshift mutations clustering in the penultimate exon cause autosomal-dominant Robinow syndrome."}, {"doc_id": "25817014", "chunk_id": "25817014_0", "score": 2.777920722961426, "text": "Here, we identified de novo frameshift mutations in DVL1, a mediator of both canonical and non-canonical Wnt signaling, as the cause of RS-OS, an RS subtype involving osteosclerosis, in three unrelated individuals."}], "context": "[25817014:25817014_1] Mutations in DVL1 cause an osteosclerotic form of Robinow syndrome.\n[25817016:25817016_0] DVL1 frameshift mutations clustering in the penultimate exon cause autosomal-dominant Robinow syndrome.\n[25817014:25817014_0] Here, we identified de novo frameshift mutations in DVL1, a mediator of both canonical and non-canonical Wnt signaling, as the cause of RS-OS, an RS subtype involving osteosclerosis, in three unrelated individuals.", "answer": "<think> Okay, let's tackle this question. The user is asking which syndrome is associated with mutant DVL1. Looking at the evidence provided, there are a few documents mentioning DVL1 and Robinow syndrome. First, document [25817014:25817014_1] states that mutations in DVL1 cause an osteosclerotic form of Robinow syndrome. So that's a direct link between DVL1 mutations and Robinow syndrome, specifically the osteosclerotic type. Then document [25817016:25817016_0] mentions DVL1 frameshift mutations causing autosomal-dominant Robinow syndrome. This reinforces that Robinow syndrome", "citations": [{"doc_id": "25817014", "chunk_id": "25817014_1"}, {"doc_id": "25817016", "chunk_id": "25817016_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which syndrome is associated with mutant DVL1. Looking at the evidence provided, there are a few documents mentioning DVL1 and Robinow syndrome. First, document [25817014:25817014_1] states that mutations in DVL1 cause an osteosclerotic form of Robinow syndrome. So that's a direct link between DVL1 mutations and Robinow syndrome, specifically the osteosclerotic type. Then document [25817016:25817016_0] mentions DVL1 frameshift mutations causing autosomal-dominant Robinow syndrome. This reinforces that Robinow syndrome", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which syndrome is associated with mutant DVL1. The evidence provided has three chunks. First, I need to look at each chunk. The first one says mutations in DVL1 cause an osteosclerotic form of Robinow syndrome. The second mentions DVL1 frameshift mutations causing autosomal-dominant Robinow syndrome. The third talks about de novo frameshift mutations in DVL1 leading to RS-OS, which is a subtype of Robinow syndrome involving osteosclerosis. So all three chunks point to Robinow syndrome. The first and third mention \"RS-OS\" which is a subtype. The second just says \"Robinow syndrome\" without the subtype. The answer needs to be concise.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which syndrome is associated with mutant DVL1. The evidence provided has three chunks. First, I need to look at each chunk. The first one says mutations in DVL1 cause an osteosclerotic form of Robinow syndrome. The second mentions DVL1 frameshift mutations causing autosomal-dominant Robinow syndrome. The third chunk talks about de novo frameshift mutations in DVL1 leading to RS-OS, which is an RS subtype with osteosclerosis. So, all three chunks mention Robinow syndrome, but with different subtypes. The first and third refer to \"RS-OS\" which is an osteosclerotic form. The second mentions autosomal-dominant Robinow", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which syndrome is associated with mutant DVL1. The evidence provided has three chunks. First chunk: [25817014:25817014_1] says mutations in DVL1 cause an osteosclerotic form of Robinow syndrome. So that's a direct mention of Robinow syndrome with the osteosclerotic variant. Second chunk: [25817016:25817016_0] mentions DVL1 frameshift mutations causing autosomal-dominant Robinow syndrome. Again, same syndrome but different presentation. Third chunk: [25817014:2581", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's see. The user is asking which syndrome is associated with mutant DVL1. The evidence provided has three chunks. First chunk: 25817014:25817014_1 says mutations in DVL1 cause an osteosclerotic form of Robinow syndrome. So that's a direct link between DVL1 mutations and Robinow syndrome, specifically the osteosclerotic type. Second chunk: 25817016:25817016_0 mentions DVL1 frameshift mutations causing autosomal-dominant Robinow syndrome. This also points to Robinow syndrome again, but with a different mention of frameshift mutations and dominance pattern. Third", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which syndrome is associated with mutant DVL1. The evidence provided has three chunks. First, looking at the evidence: Chunk 25817014_1 says mutations in DVL1 cause an osteosclerotic form of Robinow syndrome. So that's a direct link between DVL1 mutations and Robinow syndrome, specifically the osteosclerotic type. Chunk 25817016_0 mentions DVL1 frameshift mutations causing autosomal-dominant Robinow syndrome. This reinforces that Robinow syndrome is the answer here, with different types (osteosclerotic vs. general). Chunk 25817014_", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which syndrome is associated with mutant DVL1. The evidence provided has three chunks. First, I need to look at each chunk and see what they say. The first chunk says mutations in DVL1 cause an osteosclerotic form of Robinow syndrome. The second mentions DVL1 frameshift mutations causing autosomal-dominant Robinow syndrome. The third chunk talks about de novo frameshift mutations in DVL1 causing RS-OS, which is a subtype of Robinow syndrome involving osteosclerosis. So all three chunks are pointing to Robinow syndrome, but with different subtypes. The first and third mention \"RS-OS\" which is an osteosclerotic form. The second mentions", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which syndrome is associated with mutant DVL1. The evidence provided has three chunks. First chunk: [25817014:25817014_1] says mutations in DVL1 cause an osteosclerotic form of Robinow syndrome. So that's a direct link between DVL1 and Robinow syndrome, specifically the osteosclerotic type. Second chunk: [25817016:25817016_0] mentions DVL1 frameshift mutations causing autosomal-dominant Robinow syndrome. Again, same syndrome but different mention of frameshift mutations and autosomal dominant inheritance. Third chunk:", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["25817014", "25817016"], "ideal_answer": "Mutations in DVL1 cause an osteosclerotic form of Robinow syndrome."}
{"question_id": "517179718ed59a060a00000e", "question": "Are proteasome inhibitors good candidates for treatment of leukemia and solid tumors?", "retrieved_chunks": [{"doc_id": "16258456", "chunk_id": "16258456_1", "score": 8.169944763183594, "text": "Preclinical evidence using bortezomib, the only proteasome inhibitor to enter clinical trials, suggests that proteasome inhibition may be effective in the treatment of hematologic and solid malignancies by promoting apoptosis, retarding angiogenesis, and inhibiting tumor cell adhesion and production of growth factors by acting on molecules such as nuclear factor-kappaB."}, {"doc_id": "22027222", "chunk_id": "22027222_0", "score": 8.061288833618164, "text": "The proteasome inhibitor bortezomib, registered for Multiple Myeloma treatment, is currently explored for activity in solid tumors including non-small cell lung cancer (NSCLC)."}, {"doc_id": "21634429", "chunk_id": "21634429_0", "score": 6.557025909423828, "text": "Bortezomib, a dipeptidyl boronic acid and potent inhibitor of the 26S proteasome, is remarkably effective against multiple myeloma (MM) but not against solid tumors."}], "context": "[16258456:16258456_1] Preclinical evidence using bortezomib, the only proteasome inhibitor to enter clinical trials, suggests that proteasome inhibition may be effective in the treatment of hematologic and solid malignancies by promoting apoptosis, retarding angiogenesis, and inhibiting tumor cell adhesion and production of growth factors by acting on molecules such as nuclear factor-kappaB.\n[22027222:22027222_0] The proteasome inhibitor bortezomib, registered for Multiple Myeloma treatment, is currently explored for activity in solid tumors including non-small cell lung cancer (NSCLC).\n[21634429:21634429_0] Bortezomib, a dipeptidyl boronic acid and potent inhibitor of the 26S proteasome, is remarkably effective against multiple myeloma (MM) but not against solid tumors.", "answer": "<think> Okay, let's tackle this question. The user is asking if proteasome inhibitors are good candidates for treating leukemia and solid tumors. The evidence provided has three chunks. First chunk [16258456:16258456_1] says that bortezomib, a proteasome inhibitor, shows promise in hematologic and solid malignancies by promoting apoptosis, retarding angiogenesis, etc. So this suggests they might be effective. Second chunk [22027222:22027222_0] mentions that bortezomib is used for multiple myeloma and being explored for solid tumors like NSCLC. This supports the idea of effectiveness in solid tumors.", "citations": [{"doc_id": "16258456", "chunk_id": "16258456_1"}, {"doc_id": "22027222", "chunk_id": "22027222_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants to know if proteasome inhibitors are good candidates for treating leukemia and solid tumors. The evidence provided has three chunks. First, chunk 16258456_1 says that bortezomib, a proteasome inhibitor, shows promise in hematologic and solid malignancies by inducing apoptosis, blocking angiogenesis, and inhibiting tumor cell adhesion. That's positive for both leukemia (hematologic) and solid tumors. Chunk 22027222_0 mentions that bortezomib is used for multiple myeloma and being explored in solid tumors like NSCLC. So that supports its use in solid tumors, but the question is about leukemia as well", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if proteasome inhibitors are good candidates for treating leukemia and solid tumors. The evidence provided has three chunks. First, chunk 16258456:16258456_1 says that bortezomib, a proteasome inhibitor, shows promise in both hematologic (like leukemia) and solid malignancies because it promotes apoptosis, stops angiogenesis, and inhibits tumor cell adhesion. That's positive for both leukemia and solid tumors. Then chunk 22027222:22027222_0 mentions that bortezomib is used for multiple myeloma (a type of leukemia?) and is being", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if proteasome inhibitors are good candidates for treating leukemia and solid tumors. The evidence provided has three chunks. First chunk [16258456:16258456_1] says that bortezomib, a proteasome inhibitor, shows promise in hematologic and solid malignancies by promoting apoptosis, retarding angiogenesis, etc. So this suggests they might be effective. Second chunk [22027222:22027222_0] mentions that bortezomib is used for multiple myeloma and being explored for solid tumors like NSCLC. This supports the idea of effectiveness in solid tumors.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if proteasome inhibitors are good candidates for treating leukemia and solid tumors. The evidence provided has three chunks. First chunk [16258456:16258456_1] says that preclinical studies with bortezomib show it might work on hematologic and solid malignancies by promoting apoptosis, retarding angiogenesis, etc. So that's positive for both leukemia (hematologic) and solid tumors. Second chunk [22027222:22027222_0] mentions that bortezomib is used for multiple myeloma and being explored for solid tumors like NSCLC. This supports", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if proteasome inhibitors are good candidates for treating leukemia and solid tumors. The evidence provided has three chunks. First, chunk 16258456_1 says that bortezomib, a proteasome inhibitor, shows effectiveness in hematologic and solid malignancies by promoting apoptosis, etc. So that's positive for both leukemia (hematologic) and solid tumors. Chunk 22027222_0 mentions that bortezomib is used for multiple myeloma and being explored for solid tumors like NSCLC. That supports the idea of solid tumors, but not sure about leukemia here. Chunk 21634429_0", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if proteasome inhibitors are good candidates for treating leukemia and solid tumors. The evidence provided has three chunks. First, chunk 16258456_1 says that bortezomib, a proteasome inhibitor, shows promise in hematologic (which includes leukemia) and solid malignancies because it promotes apoptosis, stops angiogenesis, and inhibits tumor cell adhesion. So that's positive for leukemia and solid tumors. Chunk 22027222_0 mentions that bortezomib is used for multiple myeloma (a type of leukemia?) and is being explored for solid tumors like NSCLC. So this supports the idea that it's being looked", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if proteasome inhibitors are good candidates for treating leukemia and solid tumors. The evidence provided has three chunks. First, chunk 16258456_1 says that bortezomib, a proteasome inhibitor, shows promise in hematologic and solid malignancies by inducing apoptosis, reducing angiogenesis, and inhibiting tumor cell adhesion. That's positive for both leukemia (hematologic) and solid tumors. Chunk 22027222_0 mentions that bortezomib is used for multiple myeloma and being explored in solid tumors like NSCLC. So that supports its use in solid tumors, but the original question also includes leukemia.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if proteasome inhibitors are good candidates for treating leukemia and solid tumors. The evidence given has three chunks. First, chunk 16258456:16258456_1 says that preclinical studies with bortezomib show it might work on hematologic and solid malignancies by causing apoptosis, stopping angiogenesis, and inhibiting tumor cell adhesion. That's positive for both leukemia (hematologic) and solid tumors. Then chunk 22027222:22027222_0 mentions that bortezomib is used for multiple myeloma and being studied in solid tumors like NSCLC", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["12171876", "15169797", "16135477", "17145882", "17431003", "19712963", "19821999", "20160034", "20219102", "22012631", "22057347", "22134540", "22353937", "22995770", "23181572", "23477519"], "ideal_answer": "Yes, several compounds that inhibit different members of the proteasome pathway (for example Bortezomib) are on trial for treatment of leukemia and solid tumors. It seems that a combination with other drugs may be a useful therapy for solid tumors."}
{"question_id": "553cae13f32186855800000e", "question": "Is there any link between CTF4 and CTF18 during sister chromatid cohesion?", "retrieved_chunks": [{"doc_id": "11287619", "chunk_id": "11287619_0", "score": 8.450674057006836, "text": "CTF4 and CTF18 are required for high-fidelity chromosome segregation. Both exhibit genetic and physical ties to replication fork constituents. We find that absence of either CTF4 or CTF18 causes sister chromatid cohesion failure and leads to a preanaphase accumulation of cells that depends on the spindle assembly checkpoint. The physical and genetic interactions between CTF4, CTF18, and core components of replication fork complexes observed in this study and others suggest that both gene products act in association with the replication fork to facilitate sister chromatid cohesion."}, {"doc_id": "11287619", "chunk_id": "11287619_4", "score": 8.312291145324707, "text": "The physical and genetic interactions between CTF4, CTF18, and core components of replication fork complexes observed in this study and others suggest that both gene products act in association with the replication fork to facilitate sister chromatid cohesion."}, {"doc_id": "11287619", "chunk_id": "11287619_3", "score": 7.9851484298706055, "text": "The physical and genetic interactions between CTF4, CTF18, and core components of replication fork complexes observed in this study and others suggest that both gene products act in association with the replication fork to facilitate sister chromatid cohesion"}], "context": "[11287619:11287619_0] CTF4 and CTF18 are required for high-fidelity chromosome segregation. Both exhibit genetic and physical ties to replication fork constituents. We find that absence of either CTF4 or CTF18 causes sister chromatid cohesion failure and leads to a preanaphase accumulation of cells that depends on the spindle assembly checkpoint. The physical and genetic interactions between CTF4, CTF18, and core components of replication fork complexes observed in this study and others suggest that both gene products act in association with the replication fork to facilitate sister chromatid cohesion.\n[11287619:11287619_4] The physical and genetic interactions between CTF4, CTF18, and core components of replication fork complexes observed in this study and others suggest that both gene products act in association with the replication fork to facilitate sister chromatid cohesion.\n[11287619:11287619_3] The physical and genetic interactions between CTF4, CTF18, and core components of replication fork complexes observed in this study and others suggest that both gene products act in association with the replication fork to facilitate sister chromatid cohesion", "answer": "<think> Okay, let's tackle this question. The user is asking if there's a link between CTF4 and CTF18 during sister chromatid cohesion. First, I need to look at the evidence provided. There are three chunks from the same source, all referencing a study (11287619). Let me read through them carefully. Chunk 1 mentions that both CTF4 and CTF18 are required for high-fidelity chromosome segregation and have genetic and physical ties to replication fork constituents. It states that when either is absent, sister chromatid cohesion fails, leading to preanaphase cell accumulation dependent on the spindle assembly checkpoint. This directly connects their roles in cohesion. Chunks 2 and 3 repeat the same point about physical and genetic", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if there's a link between CTF4 and CTF18 during sister chromatid cohesion. First, I need to look at the evidence provided. There are three chunks from the same source, all referencing a study (11287619). Let me read through them carefully. Chunk 1 mentions that both CTF4 and CTF18 are required for high-fidelity chromosome segregation and have genetic and physical ties to replication fork constituents. It states that when either is absent, sister chromatid cohesion fails, leading to preanaphase cell accumulation dependent on the spindle assembly checkpoint. This directly connects their roles in cohesion. Chunks 2 and 3 repeat the same point about physical and genetic", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there's a link between CTF4 and CTF18 during sister chromatid cohesion. First, I need to look at the evidence provided. There are three chunks from the same source, 11287619. Let me check each one. Chunk 11287619_0 says that both CTF4 and CTF18 are required for high-fidelity chromosome segregation and have genetic and physical ties to replication fork constituents. It mentions that absence of either leads to sister chromatid cohesion failure and preanaphase cell accumulation dependent on the spindle assembly checkpoint. So, this suggests they're involved in sister chromatid cohesion. Chunk 11287", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there's a link between CTF4 and CTF18 during sister chromatid cohesion. First, I need to look at the provided evidence. All three chunks from the same document (11287619) mention that CTF4 and CTF18 have physical and genetic interactions, and they both act with replication fork components to facilitate sister chromatid cohesion. The first chunk specifically says that their absence leads to cohesion failure. So, the answer should state that there is a link, citing the document. The confidence level is high because multiple chunks support this. I need to make sure the answer is concise and includes the correct citation. The base confidence can be 1.0 since", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there's a link between CTF4 and CTF18 during sister chromatid cohesion. The evidence provided has three chunks from the same document. Looking at chunk 11287619_0: It says that both CTF4 and CTF18 are required for high-fidelity chromosome segregation and have genetic and physical ties to replication fork constituents. The absence of either leads to sister chromatid cohesion failure and preanaphase accumulation dependent on the spindle assembly checkpoint. So this suggests they're involved in sister chromatid cohesion. Chunk 11287619_4 and 3 are similar, stating that their interactions with replication fork components suggest both act with the replication", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to answer whether there's a link between CTF4 and CTF18 during sister chromatid cohesion. Let me look at the evidence provided. The first document says that CTF4 and CTF18 are required for high-fidelity chromosome segregation and have genetic and physical ties to replication fork constituents. It also mentions that their absence leads to sister chromatid cohesion failure. So there's a direct link here. The other chunks repeat the same point about their interactions and association with replication forks to facilitate cohesion. So, the answer should state that there is a link, citing the documents. The confidence is high because multiple sources mention this. I'll make sure to reference the correct chunk IDs. The base confidence can be 1.0 since all evidence", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to answer whether there's a link between CTF4 and CTF18 during sister chromatid cohesion. Let me look at the evidence provided. The first document says that both CTF4 and CTF18 are required for high-fidelity chromosome segregation and have genetic and physical ties to replication fork constituents. It also mentions that their absence leads to sister chromatid cohesion failure. So there's a direct link here. The other chunks repeat the same points, emphasizing their interactions and role in facilitating cohesion through replication forks. So the answer should state that there is a link, citing the documents. The confidence is high because multiple sources support this. I'll make sure to mention the specific document IDs and chunk numbers as per the citations. </think> { \"", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to answer whether there's a link between CTF4 and CTF18 during sister chromatid cohesion. Let me look at the evidence provided. The first document says that both CTF4 and CTF18 are required for high-fidelity chromosome segregation and have genetic and physical ties to replication fork constituents. It also mentions that their absence causes sister chromatid cohesion failure. So there's a direct link here. The same point is repeated in documents 4 and 3, which talk about their interactions with replication fork components and their role in facilitating sister chromatid cohesion. So the answer should mention that there is a link, citing the documents. The confidence level would be high because multiple sources support this. I'll check if all the documents are from the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to answer whether there's a link between CTF4 and CTF18 during sister chromatid cohesion based on the provided evidence. Let me look at the evidence again. The first document says that both CTF4 and CTF18 are required for high-fidelity chromosome segregation and have genetic and physical ties to replication fork constituents. It also mentions that when either is absent, sister chromatid cohesion fails, leading to preanaphase cell accumulation dependent on the spindle assembly checkpoint. The other documents repeat that there are physical and genetic interactions between these genes and replication fork components, suggesting they act with the replication fork to facilitate sister chromatid cohesion. So, the key points here are that both genes are involved in sister chromatid cohesion, they interact genetically and", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["11287619", "14742714", "15226378", "16962805", "17483413", "19430531", "23036200", "23334284"], "ideal_answer": "Yes. CTF4 and CTF18 are required for high-fidelity chromosome segregation. Both exhibit genetic and physical ties to replication fork constituents. Absence of either CTF4 or CTF18 causes sister chromatid cohesion failure and leads to a preanaphase accumulation of cells that depends on the spindle assembly checkpoint. The physical and genetic interactions between CTF4, CTF18, and core components of replication fork complexes suggest that both gene products act in association with the replication fork to facilitate sister chromatid cohesion."}
{"question_id": "56a7d5afa17756b72f000002", "question": "What is the Genomic Regions Enrichment of Annotations Tool (GREAT)?", "retrieved_chunks": [{"doc_id": "20436461", "chunk_id": "20436461_4", "score": 9.439291000366211, "text": "We developed the Genomic Regions Enrichment of Annotations Tool (GREAT) to analyze the functional significance of cis-regulatory regions identified by localized measurements of DNA binding events across an entire genome. Whereas previous methods took into account only binding proximal to genes, GREAT is able to properly incorporate distal binding sites and control for false positives using a binomial test over the input genomic regions."}, {"doc_id": "20436461", "chunk_id": "20436461_3", "score": 9.350509643554688, "text": "We developed the Genomic Regions Enrichment of Annotations Tool (GREAT) to analyze the functional significance of cis-regulatory regions identified by localized measurements of DNA binding events across an entire genome. Whereas previous methods took into account only binding proximal to genes, GREAT is able to properly incorporate distal binding sites and control for false positives using a binomial test over the input genomic regions"}, {"doc_id": "20436461", "chunk_id": "20436461_2", "score": 8.946434020996094, "text": "We developed the Genomic Regions Enrichment of Annotations Tool (GREAT) to analyze the functional significance of cis-regulatory regions identified by localized measurements of DNA binding events across an entire genome."}], "context": "[20436461:20436461_4] We developed the Genomic Regions Enrichment of Annotations Tool (GREAT) to analyze the functional significance of cis-regulatory regions identified by localized measurements of DNA binding events across an entire genome. Whereas previous methods took into account only binding proximal to genes, GREAT is able to properly incorporate distal binding sites and control for false positives using a binomial test over the input genomic regions.\n[20436461:20436461_3] We developed the Genomic Regions Enrichment of Annotations Tool (GREAT) to analyze the functional significance of cis-regulatory regions identified by localized measurements of DNA binding events across an entire genome. Whereas previous methods took into account only binding proximal to genes, GREAT is able to properly incorporate distal binding sites and control for false positives using a binomial test over the input genomic regions\n[20436461:20436461_2] We developed the Genomic Regions Enrichment of Annotations Tool (GREAT) to analyze the functional significance of cis-regulatory regions identified by localized measurements of DNA binding events across an entire genome.", "answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. Let me start by understanding the question: What is the Genomic Regions Enrichment of Annotations Tool (GREAT)? Looking at the evidence provided, there are three chunks from the same document ID. All of them mention that GREAT was developed to analyze the functional significance of cis-regulatory regions identified through DNA binding events across the genome. The key points here are that it's for analyzing these regions, uses localized measurements of DNA binding, and differs from previous methods by incorporating distal binding sites and using a binomial test to control false positives. I need to make sure the answer is concise and includes citations. The chunks are all from the same document, so I can use one citation. The answer should state", "citations": [], "candidates": [{"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. Let me start by understanding the question: What is the Genomic Regions Enrichment of Annotations Tool (GREAT)? Looking at the evidence provided, there are three chunks from the same document ID. All of them mention that GREAT was developed to analyze the functional significance of cis-regulatory regions identified through DNA binding events across the genome. The key points here are that it's for analyzing these regions, uses localized measurements of DNA binding, and differs from previous methods by incorporating distal binding sites and using a binomial test to control false positives. I need to make sure the answer is concise and includes citations. The chunks are all from the same document, so I can use one citation. The answer should state", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence about the Genomic Regions Enrichment of Annotations Tool (GREAT). Let me start by understanding the question. The user is asking what GREAT is, so I need to extract the definition and key features from the provided evidence. Looking at the evidence, there are three chunks. All of them mention that GREAT was developed to analyze the functional significance of cis-regulatory regions identified through DNA binding events across the genome. The first two chunks also note that previous methods only considered proximal binding sites, whereas GREAT incorporates distal sites and uses a binomial test to control for false positives. So the answer should include the purpose of GREAT, its main advantage over previous methods (incorporating distal sites and controlling false", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer for the question about GREAT. Let me look at the evidence provided. The user provided three chunks from the same document ID, all talking about the development of GREAT. The first two chunks mention that GREAT is used to analyze the functional significance of cis-regulatory regions identified by DNA binding events across the genome. They also note that previous methods only considered proximal bindings, but GREAT incorporates distal sites and uses a binomial test for false positives. So the answer should be concise, mentioning that GREAT analyzes the functional significance of cis-regulatory regions using DNA binding data, incorporating both proximal and distal sites, and using a binomial test. The citation would be from the first chunk, which is [2043646", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The question is about what the Genomic Regions Enrichment of Annotations Tool (GREAT) is. Let me look at the evidence. The evidence has three chunks from the same document ID, 20436461. All three chunks mention that GREAT was developed to analyze the functional significance of cis-regulatory regions identified by DNA binding events across the genome. The first two chunks also note that previous methods only considered proximal bindings, but GREAT incorporates distal sites and uses a binomial test to control false positives. So the answer should be concise, mentioning that GREAT analyzes functional significance of cis-regulatory regions using DNA binding measurements. Also, include that it handles distal binding sites and", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer about what the Genomic Regions Enrichment of Annotations Tool (GREAT) is, based on the provided evidence. Let me start by reading through the evidence carefully. The user provided three chunks from the same document ID, all talking about GREAT. The first two chunks are slightly duplicated but mention that GREAT was developed to analyze the functional significance of cis-regulatory regions identified by localized DNA binding measurements across the entire genome. They also note that previous methods only considered binding proximal to genes, whereas GREAT incorporates distal binding sites and uses a binomial test to control for false positives. The third chunk is a bit shorter, just reiterating the development of GREAT for analyzing cis-regulatory regions from DNA binding events. So the answer should", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer about what the GREAT tool is based on the provided evidence. Let me look at the evidence first. The user provided three chunks from the same document ID, all talking about the development of GREAT. The main points are that GREAT analyzes the functional significance of cis-regulatory regions identified through DNA binding events across the genome. It mentions that previous methods only considered proximal binding sites, but GREAT incorporates distal ones and uses a binomial test to control false positives. So the answer should be concise, mentioning that GREAT is used to analyze the functional significance of cis-regulatory regions by considering both proximal and distal binding sites, and using a binomial test. The citation would be from the first chunk, which is [2043", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is about what the Genomic Regions Enrichment of Annotations Tool (GREAT) is. Let me look at the evidence provided. The evidence has three chunks, all from the same document ID 20436461. Each chunk starts with \"We developed...\" and explains that GREAT is used to analyze the functional significance of cis-regulatory regions identified by DNA binding events across the genome. The key points are that it's for analyzing functional significance, uses localized measurements of DNA binding, and that it incorporates distal binding sites while controlling for false positives with a binomial test. So the answer should be concise, mentioning that GREAT is developed to analyze the functional significance of cis-reg", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a JSON answer for the question about the GREAT tool. Let me start by understanding the user's query and the provided evidence. The question is asking what the Genomic Regions Enrichment of Annotations Tool (GREAT) is. The evidence given has three chunks, all from the same document ID, 20436461, but different chunk IDs. All three chunks mention that GREAT was developed to analyze the functional significance of cis-regulatory regions identified by DNA binding events across the genome. They also note that previous methods only considered proximal bindings, whereas GREAT incorporates distal sites and uses a binomial test to control false positives. So, I need to condense this information into a concise answer with citations. The answer should mention", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["20436461"], "ideal_answer": "Genomic Regions Enrichment of Annotations Tool (GREAT) is a tool to analyse the functional significance of cis-regulatory regions identified by localised measurements of DNA binding events across an entire genome. Whereas previous methods took into account only binding proximal to genes, GREAT is able to properly incorporate distal binding sites and control for false positives using a binomial test over the input genomic regions. GREAT incorporates annotations from 20 ontologies and is available as a web application. Applying GREAT to data sets from chromatin immunoprecipitation coupled with massively parallel sequencing (ChIP-seq) of multiple transcription-associated factors, including SRF, NRSF, GABP, Stat3 and p300 in different developmental contexts, many functions of these factors are recovered that are missed by existing gene-based tools, and testable hypotheses are generated. The utility of GREAT is not limited to ChIP-seq, as it could also be applied to open chromatin, localized epigenomic markers and similar functional data sets, as well as comparative genomics sets."}
{"question_id": "54d649843706e89528000009", "question": "What is the target of the drug Olaparib?", "retrieved_chunks": [{"doc_id": "27317574", "chunk_id": "27317574_0", "score": 3.4074201583862305, "text": "Of note is the recent U.S. Food and Drug Administration breakthrough therapy designation of olaparib for the treatment of BRCA1/2- or ATM-mutated metastatic castration-resistant prostate cancer."}, {"doc_id": "25302833", "chunk_id": "25302833_0", "score": 2.935744285583496, "text": "olaparib, a small molecule inhibitor of the repair enzymes PARP1/2."}, {"doc_id": "29327913", "chunk_id": "29327913_0", "score": 2.263927936553955, "text": "Indeed, three PARP1 inhibitors (Olaparib, Rucaparib, and Niraparib) have recently been approved by the Food and Drug Administration for the treatment of ovarian cancer."}], "context": "[27317574:27317574_0] Of note is the recent U.S. Food and Drug Administration breakthrough therapy designation of olaparib for the treatment of BRCA1/2- or ATM-mutated metastatic castration-resistant prostate cancer.\n[25302833:25302833_0] olaparib, a small molecule inhibitor of the repair enzymes PARP1/2.\n[29327913:29327913_0] Indeed, three PARP1 inhibitors (Olaparib, Rucaparib, and Niraparib) have recently been approved by the Food and Drug Administration for the treatment of ovarian cancer.", "answer": "<think> Okay, let's tackle this question. The user is asking about the target of the drug Olaparib. I need to look at the provided evidence to find the correct answer. First, looking at the evidence documents. The first one [27317574:27317574_0] mentions that olaparib is designated for BRCA1/2 or ATM-mutated prostate cancer, but that's about its indication, not the target. The second document [25302833:25302833_0] states that olaparib is a small molecule inhibitor of PARP1/2 repair enzymes. That seems directly relevant. The third document [29", "citations": [{"doc_id": "27317574", "chunk_id": "27317574_0"}, {"doc_id": "25302833", "chunk_id": "25302833_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the target of the drug Olaparib. I need to look at the provided evidence to find the correct answer. First, looking at the evidence documents. The first one [27317574:27317574_0] mentions that olaparib is designated for BRCA1/2 or ATM-mutated prostate cancer, but that's about its indication, not the target. The second document [25302833:25302833_0] states that olaparib is a small molecule inhibitor of PARP1/2 repair enzymes. That seems directly relevant. The third document [29", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the target of the drug Olaparib. I need to look at the provided evidence to find the correct answer. First, looking at the evidence snippets. The first one mentions that olaparib is a breakthrough therapy for BRCA1/2 or ATM-mutated prostate cancer, but that's about its indication, not the target. The second snippet says olaparib is a small molecule inhibitor of PARP1/2 repair enzymes. That seems directly relevant. The third snippet lists PARP1 inhibitors, including Olaparib, approved for ovarian cancer. So the key point here is that the target is PARP1/2. The second evidence document clearly states that. The confidence", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the target of the drug Olaparib. I need to look at the provided evidence to find the correct answer. First, looking at the evidence documents: The first document [27317574:27317574_0] mentions that olaparib is designated for BRCA1/2 or ATM-mutated prostate cancer, but that's about its indication, not the target. The second document [25302833:25302833_0] states that olaparib is a small molecule inhibitor of PARP1/2 repair enzymes. That seems directly relevant. The target here would be PAR", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the target of the drug Olaparib. I need to look at the provided evidence to find the answer. First, looking at the evidence snippets. The first one mentions olaparib being a breakthrough therapy for BRCA1/2 or ATM-mutated prostate cancer, but that's about its indication, not the target. The second snippet says olaparib is a small molecule inhibitor of PARP1/2 repair enzymes. That seems directly relevant. The third snippet lists PARP1 inhibitors, including Olaparib, approved for ovarian cancer. So the target here is PARP1/2. I need to confirm that the answer is PARP1/2. The second evidence document", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking about the target of the drug Olaparib. Let me look at the evidence provided. First, the evidence has three chunks. The first one mentions that olaparib is a PARP1/2 inhibitor. The second chunk says it's a small molecule inhibitor of repair enzymes PARP1/2. The third chunk lists Olaparib as a PARP1 inhibitor. Wait, all three chunks point to PARP1/2 as the target. The first chunk says \"PARP1/2\" and the others mention \"PARP1\". But the second chunk explicitly states \"repair enzymes PARP1/2\", so that's probably the key part here. The third chunk also confirms it as a PARP", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the user is asking about the target of the drug Olaparib. Let me look at the evidence provided. First, the evidence has three chunks. The first one mentions that olaparib is a PARP1/2 inhibitor. The second chunk says it's a small molecule inhibitor of repair enzymes PARP1/2. The third chunk lists it as a PARP1 inhibitor approved for ovarian cancer. Wait, all the chunks point to PARP1 and PARP2 as the targets. The first chunk says \"PARP1/2\" and the others mention \"PARP1\". But the second chunk explicitly states \"repair enzymes PARP1/2\", so that's a bit conflicting. However, the third chunk mentions PARP1", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the target of the drug Olaparib. I need to look at the evidence provided to find the correct answer. First, looking at the evidence documents. The first one mentions that olaparib is a PARP1/2 inhibitor. The second document says it's a small molecule inhibitor of the repair enzymes PARP1/2. The third one lists it as a PARP1 inhibitor. So all three sources point to PARP1 and PARP2 as the targets. The answer should be concise, citing the relevant documents. The base confidence is high since multiple sources agree. I should pick the most direct citation. The second document [25302833:253", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the target of the drug Olaparib. I need to look at the provided evidence to find the correct answer. First, looking at the evidence documents. The first one mentions that olaparib is a PARP1/2 inhibitor. The second document says it's a small molecule inhibitor of the repair enzymes PARP1/2. The third document also lists Olaparib as a PARP1 inhibitor. So all three sources point to PARP1/2 as the target. The answer should be concise, citing the relevant documents. The base confidence is high since all three pieces of evidence support the same conclusion. I'll check if there's any conflicting info, but everything here aligns.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["25120693", "25127709", "25128455", "25139258", "25144364", "25218906", "25221646", "25275045", "25302833", "25366685", "25374341", "25417706", "25481791", "25483710", "25526472", "25531448"], "ideal_answer": "The drug Olaparib target the protein poly(ADP-ribose) polymerase."}
{"question_id": "52f7c4bd2059c6d71c00002d", "question": "Are thyroid hormone receptor alpha1 mutations implicated in thyroid hormone resistance syndrome?", "retrieved_chunks": [{"doc_id": "23633213", "chunk_id": "23633213_0", "score": 5.744899272918701, "text": "Clinical phenotype of a new type of thyroid hormone resistance caused by a mutation of the TRα1 receptor"}, {"doc_id": "18334584", "chunk_id": "18334584_0", "score": 2.2735002040863037, "text": "When thyroid hormone production was reduced by PTU, high doses of LT(4) (3.7 microg/kg.d) were needed to normalize serum TSH, confirming that mutation of MCT8 is a cause of resistance to thyroid hormone"}, {"doc_id": "21468521", "chunk_id": "21468521_0", "score": 1.8230788707733154, "text": "Novel mutation in MCT8 gene in a Brazilian boy with thyroid hormone resistance and severe neurologic abnormalities."}], "context": "[23633213:23633213_0] Clinical phenotype of a new type of thyroid hormone resistance caused by a mutation of the TRα1 receptor\n[18334584:18334584_0] When thyroid hormone production was reduced by PTU, high doses of LT(4) (3.7 microg/kg.d) were needed to normalize serum TSH, confirming that mutation of MCT8 is a cause of resistance to thyroid hormone\n[21468521:21468521_0] Novel mutation in MCT8 gene in a Brazilian boy with thyroid hormone resistance and severe neurologic abnormalities.", "answer": "<think> Okay, I need to answer whether thyroid hormone receptor alpha1 mutations are implicated in thyroid hormone resistance syndrome based on the given evidence. Let's look at the evidence provided. First, the first document [23633213:23633213_0] mentions a new type of thyroid hormone resistance caused by a mutation of the TRα1 receptor. That directly links TRα1 mutations to thyroid hormone resistance. So that's a strong point. The second evidence [18334584:18334584_0] talks about PTU reducing thyroid hormone production and needing high doses of LT4 to normalize TSH, confirming that MCT8 mutation causes resistance. Wait, MCT8 is", "citations": [{"doc_id": "23633213", "chunk_id": "23633213_0"}, {"doc_id": "18334584", "chunk_id": "18334584_0"}], "candidates": [{"answer": "<think> Okay, I need to answer whether thyroid hormone receptor alpha1 mutations are implicated in thyroid hormone resistance syndrome based on the given evidence. Let's look at the evidence provided. First, the first document [23633213:23633213_0] mentions a new type of thyroid hormone resistance caused by a mutation of the TRα1 receptor. That directly links TRα1 mutations to thyroid hormone resistance. So that's a strong point. The second evidence [18334584:18334584_0] talks about PTU reducing thyroid hormone production and needing high doses of LT4 to normalize TSH, confirming that MCT8 mutation causes resistance. Wait, MCT8 is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to answer the question about whether thyroid hormone receptor alpha1 mutations are implicated in thyroid hormone resistance syndrome. Let me look at the evidence provided. First, the user provided three references. The first one is [23633213:23633213_0], which mentions a clinical phenotype of a new type of thyroid hormone resistance caused by a mutation of the TRα1 receptor. That seems directly relevant because TRα1 is the alpha1 thyroid hormone receptor. So this study suggests that mutations in TRα1 are involved in thyroid hormone resistance. The second evidence, [18334584:18334584_0], talks about when thyroid hormone production is reduced by PT", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking if thyroid hormone receptor alpha1 mutations are involved in thyroid hormone resistance syndrome. The evidence provided includes three chunks. First, I need to check each chunk for relevant information. The first one mentions a new type of thyroid hormone resistance caused by a mutation of the TRα1 receptor. That directly links the mutation to the condition. The second chunk talks about PTU reducing thyroid hormone production and needing high doses of LT4, which confirms that MCT8 mutations cause resistance. Wait, but the question is about TRα1, not MCT8. Hmm, maybe there's a connection here? Or perhaps the user is confused between TRα1 and MCT8? The third chunk mentions a novel mutation in the MCT", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if thyroid hormone receptor alpha1 mutations are implicated in thyroid hormone resistance syndrome. The evidence provided includes three references. First, I need to understand what each of these references says. The first one, 23633213:23633213_0, mentions a new type of thyroid hormone resistance caused by a mutation in the TRα1 receptor. That directly links TRα1 mutations to thyroid hormone resistance. The second reference, 18334584:18334584_0, talks about PTU reducing thyroid hormone production and needing high doses of LT4 to normalize TSH, confirming that MCT8 mutations cause resistance", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if thyroid hormone receptor alpha1 mutations are involved in thyroid hormone resistance syndrome. The evidence provided has three documents. First, looking at the first document: \"Clinical phenotype of a new type of thyroid hormone resistance caused by a mutation of the TRα1 receptor.\" This directly mentions TRα1 mutation leading to thyroid hormone resistance. So that's a strong point for the answer. The second document says that when thyroid hormone production is reduced, high doses of LT4 are needed, confirming that MCT8 mutations cause resistance. Wait, MCT8 is different from TRα1. The question is about TRα1, so this might be a separate cause. But maybe there's a connection? Or perhaps the user is confl", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if thyroid hormone receptor alpha1 mutations are involved in thyroid hormone resistance syndrome. The evidence provided has three references. First, I need to understand what each of these references says. The first one, 23633213:23633213_0, mentions a new type of thyroid hormone resistance caused by a TRα1 receptor mutation. That directly points to the alpha1 receptor. The second reference, 18334584:18334584_0, talks about PTU reducing thyroid hormone production and needing high doses of LT4 to normalize TSH, confirming that MCT8 mutations cause resistance. Wait, MCT8", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking if thyroid hormone receptor alpha1 mutations are involved in thyroid hormone resistance syndrome. The evidence provided has three documents. First, I need to check each document to see if they mention TRα1 mutations. The first document, 23633213:23633213_0, talks about a new type of thyroid hormone resistance caused by a mutation of the TRα1 receptor. That directly answers the question with a yes. The second document, 18334584:18334584_0, mentions that when thyroid hormone production is reduced, high doses of LT4 are needed, confirming that MCT8 mutations cause resistance", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, the user is asking if thyroid hormone receptor alpha1 mutations are involved in thyroid hormone resistance syndrome. Let me look at the evidence provided. First, the evidence includes three documents. The first one, 23633213:23633213_0, mentions a new type of thyroid hormone resistance caused by a mutation of the TRα1 receptor. That directly links TRα1 mutations to the syndrome. The second document, 18334584:18334584_0, talks about PTU reducing thyroid hormone production and needing high doses of LT4 to normalize TSH, confirming that MCT8 mutations cause resistance. Wait, MCT8 is a different gene,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["12356724", "12750454", "15860414", "15913586", "15988389", "17040361", "17906375", "23633213", "7711514", "7913092", "8068885", "8115332", "8384535", "8475937", "8594618", "8954015", "9092799", "9350446", "9685218"], "ideal_answer": "The lack of TR alpha1 exacerbates the manifestation of RTH in TR betaPV mice. Therefore, TR alpha1 could play a compensatory role in mediating the functions of T3 in heterozygous patients with RTH"}
{"question_id": "53188c12b166e2b80600001a", "question": "What is the role of RhoA in bladder cancer?", "retrieved_chunks": [{"doc_id": "21054792", "chunk_id": "21054792_0", "score": 7.008846759796143, "text": "Published reports suggest that elevated RhoA/Rho-kinase signaling plays a role in the development of benign prostatic hyperplasia, erectile dysfunction, kidney failure, ejaculation disorders, prostate and bladder cancer initiation, and eventual metastasis."}, {"doc_id": "19896475", "chunk_id": "19896475_0", "score": 4.328656196594238, "text": "Our results provide evidence that Ras-induced RhoA and NF-kappaB activation was involved in the invasion/migration of bladder cancer."}, {"doc_id": "22006759", "chunk_id": "22006759_0", "score": 3.896911144256592, "text": "Alterations in RhoA, RhoB, RhoC, Rac1 and Cdc42 expression play a significant role in the genesis and progression of UCC of the urinary bladder."}], "context": "[21054792:21054792_0] Published reports suggest that elevated RhoA/Rho-kinase signaling plays a role in the development of benign prostatic hyperplasia, erectile dysfunction, kidney failure, ejaculation disorders, prostate and bladder cancer initiation, and eventual metastasis.\n[19896475:19896475_0] Our results provide evidence that Ras-induced RhoA and NF-kappaB activation was involved in the invasion/migration of bladder cancer.\n[22006759:22006759_0] Alterations in RhoA, RhoB, RhoC, Rac1 and Cdc42 expression play a significant role in the genesis and progression of UCC of the urinary bladder.", "answer": "<think> Okay, so the user is asking about the role of RhoA in bladder cancer. Let me look at the evidence provided. First, document 21054792 mentions that elevated RhoA/Rho-kinase signaling is involved in the development and metastasis of bladder cancer. That's a direct mention. Then, document 19896475 talks about Ras-induced RhoA and NF-kappaB activation being involved in invasion and migration of bladder cancer cells. So RhoA is linked to those processes. The third document, 22006759, states that changes in RhoA, RhoB, etc., play a significant role in the genesis and progression of urinary tract cancers, including", "citations": [], "candidates": [{"answer": "<think> Okay, so the user is asking about the role of RhoA in bladder cancer. Let me look at the evidence provided. First, document 21054792 mentions that elevated RhoA/Rho-kinase signaling is involved in the development and metastasis of bladder cancer. That's a direct mention. Then, document 19896475 talks about Ras-induced RhoA and NF-kappaB activation being involved in invasion and migration of bladder cancer cells. So RhoA is linked to those processes. The third document, 22006759, states that changes in RhoA, RhoB, etc., play a significant role in the genesis and progression of urinary tract cancers, including", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about RhoA's role in bladder cancer. The user provided three evidence snippets, so I need to parse those. First, looking at the first evidence: it mentions that elevated RhoA/Rho-kinase signaling is involved in the development of prostate and bladder cancer initiation and metastasis. That directly connects RhoA to bladder cancer. The second snippet says Ras-induced RhoA and NF-kappaB activation are involved in invasion/migration of bladder cancer. So RhoA's role here is in the invasive and migratory aspects, which are important for cancer progression. Third evidence talks about alterations in RhoA, RhoB, etc., playing a significant role in the genesis and progression of urinary tract cancers, including", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about the role of RhoA in bladder cancer. The user provided three evidence snippets, so I need to parse each one and see how they relate to the question. First, looking at the first evidence: it mentions that elevated RhoA/Rho-kinase signaling is involved in the development of various conditions, including bladder cancer initiation and metastasis. That's a direct mention of RhoA's role in bladder cancer. The citation here is 21054792:21054792_0. Second evidence from 19896475: Ras-induced RhoA and NF-kappaB activation are involved in the invasion/migration of bladder cancer. This suggests that", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about RhoA's role in bladder cancer. The user provided three evidence snippets, so I need to parse those and find the relevant information. First, looking at the first evidence: it mentions that elevated RhoA/Rho-kinase signaling is involved in the development of bladder cancer and metastasis. That's a direct mention of RhoA's role. So that's a strong point. The second evidence says Ras-induced RhoA and NF-kappaB activation are involved in invasion/migration of bladder cancer. So here, RhoA is linked to invasion and migration, which are aspects of cancer progression. Third evidence talks about alterations in RhoA, RhoB, RhoC, Rac1, and Cdc", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so I need to figure out the role of RhoA in bladder cancer based on the given evidence. Let's look at the three references provided. The first one, 21054792:21054792_0, says that elevated RhoA/Rho-kinase signaling is involved in the development of various conditions including bladder cancer. That suggests RhoA might be promoting the growth or progression of bladder cancer. The second evidence, 19896475:19896475_0, mentions that Ras-induced RhoA and NF-kappaB activation are involved in the invasion and migration of bladder cancer cells. So RhoA is linked to how cancer spreads", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about RhoA's role in bladder cancer. The user provided three evidence snippets, so I need to parse each one and see what they say. First snippet (21054792): It mentions that elevated RhoA/Rho-kinase signaling is involved in the development of prostate cancer, bladder cancer initiation, and metastasis. So that's a direct link between RhoA and bladder cancer, specifically in terms of initiation and metastasis. Second snippet (19896475): This talks about Ras-induced RhoA and NF-kappaB activation being involved in the invasion and migration of bladder cancer cells. So here, RhoA is linked to the invasive properties of bladder cancer. Third", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to answer the question about the role of RhoA in bladder cancer based on the given evidence. Let me look at the evidence provided. First, document 21054792 mentions that elevated RhoA/Rho-kinase signaling is involved in the development and metastasis of bladder cancer. That's a direct mention of RhoA's role. Then, document 19896475 talks about Ras-induced RhoA and NF-kappaB activation being involved in the invasion and migration of bladder cancer cells. So RhoA is linked to those processes. The third document, 22006759, states that changes in RhoA, RhoB, etc., play a", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question about RhoA's role in bladder cancer. The user provided three evidence snippets, so I need to parse each one and see what they contribute. First, the first evidence (21054792) mentions that elevated RhoA/Rho-kinase signaling is involved in bladder cancer initiation and metastasis. That's a direct mention of RhoA's role in bladder cancer. The second snippet (19896475) talks about Ras-induced RhoA and NF-kappaB activation being involved in the invasion and migration of bladder cancer cells. So this connects RhoA to the invasive properties of bladder cancer. The third one (22006759) states that changes", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["12855641", "18190825", "19896475", "21054792", "22006759"], "ideal_answer": "In urinary bladder cancer, RhoA was more commonly found to be activated in the later stages of the disease. This activation was related to poor tumor differentiation, muscle invasion, lymph node metastasis, and shortened disease-free and overall survival."}
{"question_id": "56f802ea09dd18d46b000017", "question": "List human proteins that are subject to a dimer-to-tetramer transition.", "retrieved_chunks": [{"doc_id": "21987805", "chunk_id": "21987805_0", "score": 4.002292633056641, "text": "We conclude that the human Orai1 and Orai3 channels undergo a dimer-to-tetramer transition to form a Ca(2+)-selective pore during store-operated activation and that Orai3 forms a dimeric nonselective cation pore upon activation by 2-APB."}, {"doc_id": "25619277", "chunk_id": "25619277_0", "score": 1.8298176527023315, "text": "while SHMT2 undergoes a dimer-to-tetramer transition upon PLP binding."}, {"doc_id": "25548170", "chunk_id": "25548170_0", "score": 0.11977335810661316, "text": "the ability of GAC to undergo the dimer-to-tetramer transition necessary for enzyme activation."}], "context": "[21987805:21987805_0] We conclude that the human Orai1 and Orai3 channels undergo a dimer-to-tetramer transition to form a Ca(2+)-selective pore during store-operated activation and that Orai3 forms a dimeric nonselective cation pore upon activation by 2-APB.\n[25619277:25619277_0] while SHMT2 undergoes a dimer-to-tetramer transition upon PLP binding.\n[25548170:25548170_0] the ability of GAC to undergo the dimer-to-tetramer transition necessary for enzyme activation.", "answer": "<think> Okay, let's tackle this question. The user wants a list of human proteins that undergo a dimer-to-tetramer transition. Looking at the evidence provided, there are three references. First, the Orai1 and Orai3 channels from [21987805:21987805_0] are mentioned as undergoing this transition. Then, SHMT2 in [25619277:25619277_0] has a dimer-to-tetramer transition upon PLP binding. The third one is GAC from [25548170:25548170_0], which can undergo the transition necessary for enzyme activation.", "citations": [{"doc_id": "21987805", "chunk_id": "21987805_0"}, {"doc_id": "25619277", "chunk_id": "25619277_0"}, {"doc_id": "25548170", "chunk_id": "25548170_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this query. The user is asking for human proteins that undergo a dimer-to-tetramer transition. The evidence provided has three chunks. First chunk: Orai1 and Orai3 channels in humans have this transition during store-operated activation. That's definitely a candidate. The citation is 21987805:21987805_0. Second chunk mentions SHMT2 undergoing the transition upon PLP binding. But wait, SHMT2 is a human protein? The chunk doesn't specify, but the question is about human proteins. Need to check if SHMT2 is human. Since the evidence is from a study, maybe it's human. But I'm not 100% sure", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants a list of human proteins that undergo a dimer-to-tetramer transition. Looking at the evidence provided, there are three references. First, the reference 21987805 mentions Orai1 and Orai3 channels in humans. They undergo a dimer-to-tetramer transition during store-operated activation. That's definitely two proteins here. Next, reference 25619277 talks about SHMT2 undergoing a transition upon PLP binding. So SHMT2 is another one. Then, reference 25548170 mentions GAC having the ability to undergo this transition. But wait, GAC—what's that? I need to", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user wants a list of human proteins that undergo a dimer-to-tetramer transition. The evidence provided has three chunks. First chunk: Orai1 and Orai3 channels in humans have this transition during store-operated activation. That's two proteins. The citation is 21987805:21987805_0. Second chunk mentions SHMT2 undergoing the transition upon PLP binding. But wait, SHMT2 is a human protein? The citation is 25619277:25619277_0. Need to confirm if SHMT2 is indeed human. The question specifies \"human proteins,\" so assuming the evidence is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's see. The user is asking for human proteins that undergo a dimer-to-tetramer transition. I need to look at the evidence provided. First, the evidence has three entries. Let me check each one. The first one mentions Orai1 and Orai3 channels in humans. They talk about a dimer-to-tetramer transition during store-operated activation. So that's two proteins here. The citation is 21987805:21987805_0. The second entry is about SHMT2, which undergoes a transition upon PLP binding. The citation is 25619277:25619277_0. But wait,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants a list of human proteins that undergo a dimer-to-tetramer transition. Looking at the evidence provided, there are three references. First, the reference 21987805 mentions Orai1 and Orai3 channels in humans. They undergo a dimer-to-tetramer transition during store-operated activation. That's definitely two proteins here. Next, reference 25619277 talks about SHMT2 undergoing a transition upon PLP binding. SHMT2 is a human protein, so that's another one. Then, reference 25548170 mentions GAC being able to undergo the dimer-to-tetramer transition for enzyme activation. G", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants a list of human proteins that undergo a dimer-to-tetramer transition. Looking at the evidence provided, there are three references. First, the Orai1 and Orai3 channels from [21987805:21987805_0] are mentioned as undergoing this transition. Then, SHMT2 in [25619277:25619277_0] has a dimer-to-tetramer transition upon PLP binding. The third one is GAC from [25548170:25548170_0], which can undergo the transition necessary for enzyme activation.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user wants a list of human proteins that undergo a dimer-to-tetramer transition. Looking at the evidence provided, there are three references. First, the reference 21987805 mentions Orai1 and Orai3 channels in humans. They undergo a dimer-to-tetramer transition during store-operated activation. That's two proteins here. Then, reference 25619277 talks about SHMT2 undergoing a transition upon PLP binding. SHMT2 is a human protein, so that's another one. The third reference, 25548170, mentions GAC. But wait, GAC is a gene, right? The protein", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this query. The user wants a list of human proteins that undergo a dimer-to-tetramer transition. The evidence provided has three chunks. First chunk: Orai1 and Orai3 channels in humans have this transition during store-operated activation. That's two proteins. The citation is 21987805:21987805_0. Second chunk mentions SHMT2 undergoing a dimer-to-tetramer transition upon PLP binding. But wait, SHMT2 is a human protein? I need to check if that's correct. The chunk says \"while SHMT2...\" so maybe it's a human protein. But the citation is 25619277:2", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["21080238", "21987805", "23739980", "25548170", "25619277"], "ideal_answer": "GAC SHMT2 AMPAR Orai1 Orai3"}
{"question_id": "5335c7f2d6d3ac6a34000051", "question": "Inhibition of which transporter is the mechanism of action of drug Canagliflozin?", "retrieved_chunks": [{"doc_id": "24025022", "chunk_id": "24025022_0", "score": 4.4549360275268555, "text": "Sodium glucose co-transporter 2 (SGLT2) inhibition with canagliflozin in type 2 diabetes mellitus."}, {"doc_id": "23895803", "chunk_id": "23895803_0", "score": 3.698556423187256, "text": "The sodium glucose co-transporter 2 inhibitor canagliflozin lowered blood glucose, blood pressure, and body weight, with increased risk of urogenital infections in Phase 2 studies."}, {"doc_id": "24998153", "chunk_id": "24998153_1", "score": 3.3878092765808105, "text": "Inhibitors of the sodium-glucose co-transporter 2 (SGLT2) promote the excretion of glucose to reduce glycated hemoglobin (HbA1c) levels. Canagliflozin was the first SGLT2 inhibitor to be approved by the US FDA for use in the treatment of type 2 diabetes, and recently dapagliflozin has also been approved."}], "context": "[24025022:24025022_0] Sodium glucose co-transporter 2 (SGLT2) inhibition with canagliflozin in type 2 diabetes mellitus.\n[23895803:23895803_0] The sodium glucose co-transporter 2 inhibitor canagliflozin lowered blood glucose, blood pressure, and body weight, with increased risk of urogenital infections in Phase 2 studies.\n[24998153:24998153_1] Inhibitors of the sodium-glucose co-transporter 2 (SGLT2) promote the excretion of glucose to reduce glycated hemoglobin (HbA1c) levels. Canagliflozin was the first SGLT2 inhibitor to be approved by the US FDA for use in the treatment of type 2 diabetes, and recently dapagliflozin has also been approved.", "answer": "<think> Okay, so I need to figure out the answer to the question: \"Inhibition of which transporter is the mechanism of action of drug Canagliflozin?\" The user provided three evidence snippets. Let me go through each one. First evidence: [24025022:24025022_0] says that canagliflozin inhibits SGLT2, which is sodium glucose co-transporter 2. That seems directly relevant. The second snippet [23895803:23895803_0] mentions that it's an SGLT2 inhibitor and talks about its effects on blood glucose, pressure, etc. The third one [249", "citations": [{"doc_id": "24025022", "chunk_id": "24025022_0"}, {"doc_id": "23895803", "chunk_id": "23895803_0"}], "candidates": [{"answer": "<think> Okay, so I need to figure out the answer to the question about which transporter is inhibited by Canagliflozin. The user provided some evidence documents. Looking at the first document, it says that canagliflozin inhibits SGLT2. The second document mentions that it's an SGLT2 inhibitor. The third one also talks about SGLT2 inhibitors promoting glucose excretion. All three documents point to SGLT2 as the target. The answer should be concise, citing the document. The first document is 24025022:24025022_0, which directly states that it's an SGLT2 inhibitor. So the answer would be Sodium glucose co-transport", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the mechanism of action of Canagliflozin, specifically which transporter it inhibits. First, I need to look at the evidence provided. The first document (24025022:24025022_0) directly states that Canagliflozin is a sodium glucose co-transporter 2 (SGLT2) inhibitor. That's a clear citation. The second document (23895803:23895803_0) also mentions SGLT2 inhibition, talking about lowering blood glucose and other effects. The third document (24998153:249", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the mechanism of action of Canagliflozin, specifically which transporter it inhibits. First, I need to look at the provided evidence. The first document (24025022:24025022_0) mentions that Canagliflozin is a sodium glucose co-transporter 2 (SGLT2) inhibitor. That seems directly relevant. The second document (23895803:23895803_0) also talks about SGLT2 inhibition, noting that it lowers blood glucose, etc. The third document (24998153:2499", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the mechanism of action of Canagliflozin, specifically which transporter it inhibits. First, I need to look at the evidence provided. The first document mentions that Canagliflozin inhibits SGLT2. The second one also talks about it being an SGLT2 inhibitor. The third document confirms that SGLT2 inhibitors promote glucose excretion and that Canagliflozin is indeed an SGLT2 inhibitor. So all three sources point to SGLT2 as the transporter. The answer should be straightforward. The confidence level is high because all three documents consistently state this. I need to make sure the answer is concise and includes the correct citations. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so the question is asking which transporter's inhibition is the mechanism of action for Canagliflozin. Let me look at the evidence provided. First evidence document 24025022:24025022_0 says that Canagliflozin inhibits SGLT2, which is sodium glucose co-transporter 2. That seems directly relevant. The second document, 23895803:23895803_0, mentions that it's an SGLT2 inhibitor and talks about its effects on blood glucose, pressure, etc. The third document, 24998153:24998153_", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the mechanism of action of Canagliflozin, specifically which transporter it inhibits. First, I need to look at the evidence provided. The first document says that canagliflozin is a sodium glucose co-transporter 2 (SGLT2) inhibitor. That seems directly relevant. The second document mentions that it lowers blood glucose, etc., and the third confirms that SGLT2 inhibitors promote glucose excretion. So all three documents point to SGLT2 as the target. The first document explicitly states that Canagliflozin inhibits SGLT2. The other two support this by talking about the effects of SGLT2 inhibition. There's", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to figure out the answer to the question about which transporter is inhibited by Canagliflozin. Let me look at the evidence provided. The first evidence snippet says that Canagliflozin inhibits sodium glucose co-transporter 2 (SGLT2) in type 2 diabetes. The second snippet mentions that it's an SGLT2 inhibitor, which lowers blood glucose, etc. The third one also refers to SGLT2 inhibitors promoting glucose excretion and mentions Canagliflozin as the first SGLT2 inhibitor approved by the FDA. So all three sources point to SGLT2 as the transporter being inhibited. The answer should be SGLT2, and the citations would be from the first", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, so I need to figure out the answer to the question: \"Inhibition of which transporter is the mechanism of action of drug Canagliflozin?\" The user provided three evidence snippets. Let me go through each one. First evidence: [24025022:24025022_0] says that canagliflozin inhibits SGLT2, which is sodium glucose co-transporter 2. That seems directly relevant. The second snippet [23895803:23895803_0] mentions that it's an SGLT2 inhibitor and talks about its effects on blood glucose, pressure, etc. The third one [249", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["10481836", "21680987", "22547464", "22621689", "23042029", "23087012", "23326927", "23412078", "23563279", "23590413", "23729000", "23895803", "24025022", "24040872", "24257692"], "ideal_answer": "Inhibition of sodium glucose co-transporter 2 (SGLT2) is the major mechanism of action of canagliflozin. Canagliflozin is the first SGLT2 inhibitor to be approved in the USA for the treatment of type 2 diabetes and is under regulatory review in the EU. Other SGLT2 inhibitors include dapagliflozin and empagliflozin."}
{"question_id": "531b2fc3b166e2b80600003c", "question": "What is the prognostic role of thyroid hormone in patients with heart failure?", "retrieved_chunks": [{"doc_id": "17893267", "chunk_id": "17893267_0", "score": 4.069559097290039, "text": "changes in thyroid hormone were closely correlated to myocardial functional status in patients with heart failure."}, {"doc_id": "18031713", "chunk_id": "18031713_0", "score": 2.0082345008850098, "text": "These data reveal that in human heart failure the reduction of beta-adrenergic receptors is associated with reduced expression of both TRalpha1 and TRalpha2 isoforms of thyroid hormone receptors."}, {"doc_id": "18031713", "chunk_id": "18031713_1", "score": 1.321460485458374, "text": "hese data reveal that in human heart failure the reduction of beta-adrenergic receptors is associated with reduced expression of both TRalpha1 and TRalpha2 isoforms of thyroid hormone receptors."}], "context": "[17893267:17893267_0] changes in thyroid hormone were closely correlated to myocardial functional status in patients with heart failure.\n[18031713:18031713_0] These data reveal that in human heart failure the reduction of beta-adrenergic receptors is associated with reduced expression of both TRalpha1 and TRalpha2 isoforms of thyroid hormone receptors.\n[18031713:18031713_1] hese data reveal that in human heart failure the reduction of beta-adrenergic receptors is associated with reduced expression of both TRalpha1 and TRalpha2 isoforms of thyroid hormone receptors.", "answer": "<think> Okay, let's tackle this question. The user wants to know the prognostic role of thyroid hormone in heart failure patients. The evidence given has three chunks. First chunk [17893267:17893267_0] says that changes in thyroid hormone are closely correlated with myocardial functional status in heart failure. That seems directly related to the prognostic role because if thyroid hormone levels change, they might indicate how well the heart is functioning. So this chunk supports a connection between thyroid hormone and prognosis. The other two chunks [18031713:18031713_0] and [18031713:18031713", "citations": [{"doc_id": "17893267", "chunk_id": "17893267_0"}, {"doc_id": "18031713", "chunk_id": "18031713_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants to know the prognostic role of thyroid hormone in heart failure patients. The evidence given has three chunks. First chunk [17893267:17893267_0] says that changes in thyroid hormone are closely correlated with myocardial functional status in heart failure. That seems directly related to the prognostic role because if thyroid hormone levels change, they might indicate how well the heart is functioning. So this chunk supports a connection between thyroid hormone and prognosis. The other two chunks [18031713:18031713_0] and [18031713:18031713", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer based on the provided evidence. Let me start by understanding the question: What is the prognostic role of thyroid hormone in patients with heart failure? Looking at the evidence, there are three references. The first one says that changes in thyroid hormone are closely correlated with myocardial functional status in heart failure patients. That suggests that thyroid hormone levels might be an indicator of how well the heart is functioning, which would relate to prognosis. The other two references mention that reduced beta-adrenergic receptors in heart failure are linked to lower expression of TRalpha1 and TRalpha2 isoforms of thyroid hormone receptors. This implies that thyroid hormone receptors are involved in the pathophysiology of heart failure, possibly affecting the prognosis. If the receptors", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer based on the provided evidence. The question is about the prognostic role of thyroid hormone in heart failure patients. First, let me look at the evidence given. There are three references here. The first one (17893267:17893267_0) says that changes in thyroid hormone are closely correlated with myocardial functional status in heart failure patients. That seems directly relevant to the prognostic role because if thyroid hormone levels change, they might indicate how well the heart is functioning. The other two references (18031713:18031713_0 and 18031713:180", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know the prognostic role of thyroid hormone in heart failure patients. The evidence provided has three entries. First, I need to understand what each piece of evidence is saying. The first one says that changes in thyroid hormone are correlated with myocardial functional status in heart failure. That suggests thyroid hormone levels might be linked to how well the heart is functioning. So that's a direct link between thyroid hormone and prognosis. The other two entries mention reduced beta-adrenergic receptors and reduced expression of TRalpha1 and TRalpha2 in heart failure. This seems to connect thyroid hormone receptors (TR) with heart failure, implying that lower receptor levels might affect the body's response to thyroid hormones. But how does this relate to", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the prognostic role of thyroid hormone in heart failure patients. I need to look at the provided evidence to form an answer. First, evidence [17893267:17893267_0] says that changes in thyroid hormone are closely correlated with myocardial functional status in heart failure. That suggests thyroid hormone levels might be a prognostic indicator because they relate to how well the heart is functioning. So that's a key point. Then, the other two pieces of evidence [18031713:18031713_0 and 1] talk about reduced beta-adrenergic receptors in heart failure being linked", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer based on the provided evidence. The question is about the prognostic role of thyroid hormone in heart failure patients. First, let me look at the evidence given. There are three entries. The first one [17893267:17893267_0] says that changes in thyroid hormone are closely correlated with myocardial functional status in heart failure patients. That seems directly relevant to the prognostic role because if thyroid hormone levels change, they might indicate how well the heart is functioning. The other two entries [18031713:18031713_0] and [18031713:180", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer based on the given evidence. The question is about the prognostic role of thyroid hormone in heart failure patients. Looking at the evidence provided, there are three entries. The first one [17893267:17893267_0] says that changes in thyroid hormone are closely correlated with myocardial functional status in heart failure patients. That seems directly relevant to the prognostic role because if thyroid hormone levels change, they might indicate how well the heart is functioning. The other two entries [18031713:18031713_0] and [18031713:1803171", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user wants to know the prognostic role of thyroid hormone in heart failure patients. The evidence provided has three chunks. First chunk [17893267:17893267_0] says that changes in thyroid hormone are correlated with myocardial function in heart failure. That suggests thyroid hormone levels might indicate how well the heart is functioning, which is a prognostic factor. The other two chunks from [18031713] talk about reduced beta-adrenergic receptors and lower TRalpha1 and TRalpha2 isoforms in heart failure. This implies that thyroid hormone receptor expression is affected, which could mean that thyroid hormones might not be working properly in these patients", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["12165115", "12963854", "15259379", "15642542", "15694896", "16499159", "17315395", "17893267", "17923583", "17966446", "18221125", "19006851", "19110971", "19181292", "19917524", "20024637", "20978564", "2189307", "22870736", "23369135", "23435988", "23555069", "2358611", "8333797", "8960429", "9489964"], "ideal_answer": "Altered thyroid profile, particularly sick euthyroid syndrome, is an independent predictor of mortality in patients with chronic heart failure, adding prognostic information to conventional clinical and functional cardiac parameters."}
{"question_id": "531376c8e3eabad021000012", "question": "which mutations of phospholamban gene have been found to cause hypertrophic cardiomyopathy?", "retrieved_chunks": [{"doc_id": "12705874", "chunk_id": "12705874_0", "score": 6.816137790679932, "text": "Using neonatal rat cardiomyocytes, the mutation, -77A-->G, increased the phospholamban promoter activity. No nucleotide change in the phospholamban coding region was found in 99 patients with cardiomyopathy. We suspect that the mutation plays an important role in the development of hypertrophic cardiomyopathy."}, {"doc_id": "18285522", "chunk_id": "18285522_0", "score": 5.734952449798584, "text": "The cardiac troponin C (cTnC) mutation, L29Q, has been found in a patient with familial hypertrophic cardiomyopathy."}, {"doc_id": "15205937", "chunk_id": "15205937_1", "score": 5.487497806549072, "text": "Previous work has shown that mutations in muscle LIM protein (MLP) can cause hypertrophic cardiomyopathy (HCM). In order to gain an insight into the molecular basis of the disease phenotype, we analysed the binding characteristics of wild-type MLP and of the (C58G) mutant MLP that causes hypertrophic cardiomyopathy."}], "context": "[12705874:12705874_0] Using neonatal rat cardiomyocytes, the mutation, -77A-->G, increased the phospholamban promoter activity. No nucleotide change in the phospholamban coding region was found in 99 patients with cardiomyopathy. We suspect that the mutation plays an important role in the development of hypertrophic cardiomyopathy.\n[18285522:18285522_0] The cardiac troponin C (cTnC) mutation, L29Q, has been found in a patient with familial hypertrophic cardiomyopathy.\n[15205937:15205937_1] Previous work has shown that mutations in muscle LIM protein (MLP) can cause hypertrophic cardiomyopathy (HCM). In order to gain an insight into the molecular basis of the disease phenotype, we analysed the binding characteristics of wild-type MLP and of the (C58G) mutant MLP that causes hypertrophic cardiomyopathy.", "answer": "<think> Okay, let's tackle this question. The user is asking which mutations in the phospholamban gene cause hypertrophic cardiomyopathy. Looking at the evidence provided, I need to check each reference to see if they mention phospholamban mutations. First, evidence [12705874:12705874_0] talks about a mutation -77A-->G in the phospholamban promoter. The article says this mutation increases promoter activity and that no coding region changes were found in 99 patients. But it mentions that the mutation might be involved in HCM. So this is a possible answer. Next, [18285522:18285522_0", "citations": [{"doc_id": "12705874", "chunk_id": "12705874_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which mutations in the phospholamban gene cause hypertrophic cardiomyopathy. Looking at the evidence provided, I need to check each reference to see if they mention phospholamban mutations. First, evidence [12705874:12705874_0] talks about a mutation -77A-->G in the phospholamban promoter. The article says this mutation increases promoter activity and that no coding region changes were found in 99 patients. But it mentions that the mutation might be involved in HCM. So this is a possible answer. Next, [18285522:18285522_0", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's see. The user is asking which mutations in the phospholamban gene cause hypertrophic cardiomyopathy. I need to look at the evidence provided. First, evidence document [12705874:12705874_0] mentions a mutation -77A-->G in the phospholamban promoter, which increases promoter activity and is linked to HCM. But wait, the note says there's no nucleotide change in the coding region in 99 patients. So this mutation is in the promoter, not the coding region. However, the question is about mutations of the phospholamban gene. The promoter is part of the gene, so maybe this counts. Then, [182", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which mutations in the phospholamban gene cause hypertrophic cardiomyopathy. Looking at the evidence provided, I need to check each reference to see if they mention phospholamban mutations. First, reference [12705874:12705874_0] talks about a mutation -77A-->G in the phospholamban promoter. The context says this mutation increases promoter activity and that no coding region changes were found in 99 patients. But the conclusion is that this mutation might play a role in HCM. However, the question specifically asks for mutations in the phospholamban gene. The mention here is about the promoter, which is part", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which mutations in the phospholamban gene cause hypertrophic cardiomyopathy. Looking at the evidence provided, there are three references. First, reference [12705874:12705874_0] mentions a mutation -77A-->G in the phospholamban promoter region. It says this mutation increases promoter activity and that no coding region changes were found in 99 patients. The conclusion is that this mutation might be involved in HCM. Then, reference [18285522:18285522_0] talks about a cTnC mutation L29Q in a patient with familial H", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which mutations in the phospholamban gene cause hypertrophic cardiomyopathy. Looking at the evidence provided, I need to check each document to see if they mention phospholamban mutations. First, document [12705874:12705874_0] talks about a mutation -77A-->G in the phospholamban promoter. The context is neonatal rat cardiomyocytes, and it's mentioned that this mutation might play a role in HCM. However, the note says there were no nucleotide changes in the coding region of phospholamban in 99 patients. So this mutation is in the promoter, not the coding region.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which mutations in the phospholamban gene cause hypertrophic cardiomyopathy. Looking at the evidence provided, I need to check each document to see if they mention phospholamban mutations. First document: [12705874:12705874_0] talks about a mutation -77A-->G in the phospholamban promoter. It says this mutation increases promoter activity and that no coding region changes were found in 99 patients. The conclusion is that this mutation might play a role in HCM. So this seems relevant. Second document: [18285522:18285522_0]", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which mutations in the phospholamban gene cause hypertrophic cardiomyopathy. First, I need to look through the provided evidence to find any mentions of phospholamban gene mutations. Looking at the first evidence entry [12705874:12705874_0], it mentions a mutation -77A-->G in the phospholamban promoter. The text says this mutation increases promoter activity and that no coding region changes were found in 99 patients. However, they suspect this mutation plays a role in HCM. Wait, but the question is about mutations in the phospholamban gene. The entry mentions a promoter mutation, which is outside the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking which mutations in the phospholamban gene cause hypertrophic cardiomyopathy. Looking at the evidence provided, I need to check each reference to see if they mention phospholamban mutations. First, reference [12705874:12705874_0] talks about a mutation -77A-->G in the phospholamban promoter. The article says this mutation increases promoter activity and suspects it plays a role in HCM. So that's a possible answer. The other references, [18285522:18285522_0] mentions a cTnC mutation, which is not phospholamb", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}], "selected_score": 3.2700000000000005, "gold_docs": ["12705874", "16829191", "17655857", "21167350"], "ideal_answer": "The following mutations of the phospholamban gene have been found to be associated with hypertrophic cardiomyopathy: PLN L39X nonsense mutation; PLN Leu39Ter; PLN -42 C>G and PLN -77A-->G"}
{"question_id": "5545186cbf90a13052000002", "question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "retrieved_chunks": [{"doc_id": "17015469", "chunk_id": "17015469_1", "score": 8.785056114196777, "text": "The proficient repair of the nontranscribed strand cannot be explained by the dedicated subpathway of transcription-coupled repair (TCR), which is targeted to the transcribed strand in expressed genes."}, {"doc_id": "17015469", "chunk_id": "17015469_0", "score": 8.618755340576172, "text": "The proficient repair of the nontranscribed strand cannot be explained by the dedicated subpathway of transcription-coupled repair (TCR), which is targeted to the transcribed strand in expressed genes"}, {"doc_id": "20978633", "chunk_id": "20978633_0", "score": 8.365862846374512, "text": "transcription-coupled repair (TCR) since targets for DNA damage are situated on the transcribed or coding strand of DNA"}], "context": "[17015469:17015469_1] The proficient repair of the nontranscribed strand cannot be explained by the dedicated subpathway of transcription-coupled repair (TCR), which is targeted to the transcribed strand in expressed genes.\n[17015469:17015469_0] The proficient repair of the nontranscribed strand cannot be explained by the dedicated subpathway of transcription-coupled repair (TCR), which is targeted to the transcribed strand in expressed genes\n[20978633:20978633_0] transcription-coupled repair (TCR) since targets for DNA damage are situated on the transcribed or coding strand of DNA", "answer": "<think> Okay, let's tackle this question. The user is asking which gene strand is targeted by transcription-coupled repair (TCR). The evidence provided has three chunks. First, looking at chunk 17015469_1: It says that the proficient repair of the nontranscribed strand can't be explained by TCR, which is targeted to the transcribed strand. So here, TCR is targeting the transcribed strand. Chunk 17015469_0 is a duplicate of the first one, so same info. Then chunk 20978633_0 mentions that TCR targets DNA damage on the transcribed or coding strand. So combining these, the answer should be that TCR targets", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which gene strand is targeted by transcription-coupled repair (TCR). The evidence provided has three chunks. First, looking at chunk 17015469_1: It says that the proficient repair of the nontranscribed strand can't be explained by TCR, which is targeted to the transcribed strand. So here, TCR is targeting the transcribed strand. Chunk 17015469_0 is a duplicate of the first one, so same info. Then chunk 20978633_0 mentions that TCR targets DNA damage on the transcribed or coding strand. So combining these, the answer should be that TCR targets", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which gene strand is targeted by transcription-coupled repair (TCR). The evidence provided has three chunks. First, looking at chunk 17015469_1: It says that the proficient repair of the nontranscribed strand can't be explained by TCR, which is targeted to the transcribed strand in expressed genes. So here, TCR is targeting the transcribed strand. Chunk 17015469_0 is a duplicate of the first one, so same info. Then chunk 20978633_0 states that TCR targets DNA damage on the transcribed or coding strand. So both chunks confirm that TCR targets the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which gene strand is targeted by transcription-coupled repair (TCR). The evidence provided has three chunks. First, I need to understand what transcription-coupled repair does. From my knowledge, TCR is a mechanism that repairs DNA damage on the transcribed strand of actively transcribing genes. This is because when RNA polymerase transcribes a gene, it can cause damage to the DNA, and TCR specifically addresses this by repairing the damaged strand. Looking at the evidence: Chunk 17015469_1 says that TCR is targeted to the transcribed strand in expressed genes. Similarly, chunk 17015469_0 repeats the same point. Chunk", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which gene strand is targeted by transcription-coupled repair (TCR). The evidence provided has three chunks. First, I need to understand what transcription-coupled repair does. From what I remember, TCR is a mechanism that repairs DNA damage on the transcribed strand of genes. But let me check the evidence. Looking at chunk 17015469_1: It says that the proficient repair of the nontranscribed strand can't be explained by TCR, which is targeted to the transcribed strand in expressed genes. So this suggests that TCR targets the transcribed strand. Chunk 17015469_0 is a duplicate of the first one, so", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which gene strand is targeted by transcription-coupled repair (TCR). The evidence provided has three chunks. First, I need to understand what transcription-coupled repair does. From what I remember, TCR is a mechanism that repairs DNA damage on the transcribed strand of genes. But let me check the evidence. Looking at chunk 17015469_1: It says \"the proficient repair of the nontranscribed strand cannot be explained by TCR, which is targeted to the transcribed strand in expressed genes.\" So here, TCR is targeting the transcribed strand. Chunk 17015469_0 is a duplicate of the first one, so", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which gene strand is targeted by transcription-coupled repair (TCR). The evidence provided has three chunks. First, I need to understand what transcription-coupled repair does. From what I remember, TCR is a mechanism that repairs DNA damage on the transcribed strand of actively transcribed genes. This is because when RNA polymerase encounters a lesion on the transcribed strand, it stalls, and the cell uses this as a signal to repair the damaged DNA. Looking at the evidence: The first two chunks (17015469_1 and 17015469_0) both say that the proficient repair of the nontranscribed strand can't be explained by T", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which gene strand is targeted by transcription-coupled repair (TCR). The evidence provided has three chunks. First, I need to understand what transcription-coupled repair does. From what I remember, TCR is a mechanism that repairs DNA damage on the transcribed strand of genes. But let me check the evidence. Looking at chunk 17015469_1: It says \"the proficient repair of the nontranscribed strand cannot be explained by TCR, which is targeted to the transcribed strand in expressed genes.\" So here, TCR is targeting the transcribed strand. The same info is repeated in chunk 17015469_0. Then chunk", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which gene strand is targeted by transcription-coupled repair (TCR). The evidence provided has three chunks. First, I need to understand what transcription-coupled repair does. From what I remember, TCR is a mechanism that repairs DNA damage on the transcribed strand of actively transcribing genes. This is because during transcription, RNA polymerase can stall if there's a lesion on the DNA, so the cell needs to repair that specific strand. Looking at the evidence: The first two chunks (17015469_1 and 17015469_0) both say that TCR is targeted to the transcribed strand in expressed genes. The third chunk (", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.0700000000000003, "gold_docs": ["10637337", "11182543", "11452033", "11821423", "12142466", "12509290", "14599741", "14599769", "14734564", "15186415", "15249207", "15380101", "15913669", "16158195", "16394029", "16978026", "17015469", "17893751", "18291710", "18817898", "19381941", "20463888", "20978633", "21214942", "21466822", "22749141", "22902626", "7957102", "8807287", "8972850", "9065408", "9150262", "9288788", "9637246", "9934845"], "ideal_answer": "Nucleotide Excision Repair (NER) removes a variety of helix-distorting lesions from DNA. It has two sub-pathways, the global genome (gg) NER and the transcription-coupled repair (TCR). TCR is triggered when a RNA polymerase, translocating along the transcribed strand, is arrested at a lesion or unusual structure in the DNA. TCR is dedicated to target and repair the transcribed strand of an active gene."}
{"question_id": "5312280ce3eabad02100000a", "question": "Abnormalities in which chromosomes were linked to the Moyamoya disease?", "retrieved_chunks": [{"doc_id": "10754001", "chunk_id": "10754001_1", "score": 7.0889081954956055, "text": "Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25."}, {"doc_id": "10754001", "chunk_id": "10754001_2", "score": 6.575436115264893, "text": "The characteristic lesions of moyamoya disease are occasionally seen in neurofibromatosis type 1, of which the causative gene (NF1) has been assigned to chromosome 17q11.2."}, {"doc_id": "8898827", "chunk_id": "8898827_0", "score": 6.222747802734375, "text": "We postulate that a protein encoded on chromosome 21 may be related to the pathogenesis of moyamoya disease."}], "context": "[10754001:10754001_1] Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25.\n[10754001:10754001_2] The characteristic lesions of moyamoya disease are occasionally seen in neurofibromatosis type 1, of which the causative gene (NF1) has been assigned to chromosome 17q11.2.\n[8898827:8898827_0] We postulate that a protein encoded on chromosome 21 may be related to the pathogenesis of moyamoya disease.", "answer": "<think> Okay, let's tackle this question. The user is asking about which chromosomes are linked to Moyamoya disease based on the provided evidence. First, I need to look at the evidence given. There are three chunks here. Let me go through each one. The first chunk [10754001:10754001_1] says that familial moyamoya disease is linked to chromosome 17q25. That's a direct mention of chromosome 17. The second chunk [10754001:10754001_2] mentions neurofibromatosis type 1, which is associated with the NF1 gene on chromosome 17q11.2", "citations": [{"doc_id": "10754001", "chunk_id": "10754001_1"}, {"doc_id": "10754001", "chunk_id": "10754001_2"}], "candidates": [{"answer": "<think> Okay, so the user is asking about which chromosomes are linked to Moyamoya disease based on the provided evidence. Let me look at the evidence again. The first document says that familial Moyamoya disease is linked to chromosome 17q25. The second mentions neurofibromatosis type 1, which is associated with chromosome 17q11.2, but that's a different condition. The third document suggests chromosome 21 might be related. Wait, but the question is specifically about abnormalities in chromosomes linked to Moyamoya disease. So, the first evidence clearly states 17q25. The third one mentions 21, but it's a protein encoded there possibly related. However, the second document talks about neurofib", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about chromosomes linked to Moyamoya disease based on the provided evidence. First, I need to look at the evidence snippets. The first one says that familial Moyamoya disease is linked to chromosome 17q25. The second mentions neurofibromatosis type 1, which is on 17q11.2, but that's a different condition. The third snippet suggests chromosome 21 might be related. Wait, the question specifically asks about abnormalities in chromosomes linked to Moyamoya disease. So I need to check which of these are directly linked. The first evidence clearly states linkage to 17q25. The third mentions chromosome 21 possibly being related. But the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about which chromosomes are linked to Moyamoya disease based on the provided evidence. First, I need to look at the evidence given. There are three references here. Let me go through each one. The first one says that familial moyamoya disease is linked to chromosome 17q25. That's a direct mention of chromosome 17. The second reference mentions neurofibromatosis type 1, which is associated with the NF1 gene on chromosome 17q11.2. But the question is about Moyamaya disease itself, not neurofibromatosis. However, it does mention that the characteristic lesions are occasionally seen in neurofibromatosis type 1, which", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about which chromosomes are linked to Moyamoya disease based on the provided evidence. First, I need to look at the evidence given. There are three chunks here. Let me go through each one. The first chunk [10754001:10754001_1] says that familial moyamoya disease is linked to chromosome 17q25. That's a direct mention of chromosome 17. The second chunk [10754001:10754001_2] mentions neurofibromatosis type 1, which is associated with the NF1 gene on chromosome 17q11.2", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking about which chromosomes are linked to Moyamoya disease based on the provided evidence. First, I need to look at the evidence given. There are three references here. Let me go through each one. The first one says that familial Moyamoya disease is linked to chromosome 17q25. That's a direct mention. The second reference mentions neurofibromatosis type 1, which is associated with chromosome 17q11.2, but it's noted that this is occasionally seen in Moyamoya disease. However, the main link here is chromosome 17. The third piece of evidence suggests that a protein on chromosome 21 might be related, but it's a hypothesis,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about which chromosomes are linked to Moyamoya disease based on the provided evidence. First, I need to look at the evidence given. There are three references here. Let me go through each one. The first one says that familial moyamoya disease is linked to chromosome 17q25. That's a direct mention of chromosome 17. The second reference mentions neurofibromatosis type 1, which is associated with the NF1 gene on chromosome 17q11.2. But the question is about Moyamaya disease itself, not neurofibromatosis. However, it does note that the characteristic lesions are sometimes seen in neurofibromatosis type 1, which", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about which chromosomes are linked to Moyamoya disease based on the provided evidence. First, I need to look at the evidence given. There are three references here. Let me go through each one. The first one says that familial moyamoya disease is linked to chromosome 17q25. That's a direct mention of chromosome 17. The second reference mentions neurofibromatosis type 1, which is associated with the NF1 gene on chromosome 17q11.2. However, the question is about Moyamoya disease itself, not neurofibromatosis. But it's noted that the lesions can be seen in neurofibromatosis type 1, but that", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about chromosomes linked to Moyamoya disease based on the provided evidence. First, I need to look at the evidence given. There are three references here. The first one says that familial Moyamoya disease is linked to chromosome 17q25. The second mentions neurofibromatosis type 1, which is associated with chromosome 17q11.2, but that's a different condition. The third reference suggests chromosome 21 might be related. Wait, the question specifically asks about abnormalities in chromosomes linked to Moyamoya disease. So I need to focus on the direct links. The first evidence directly states linkage to 17q25. The third one mentions chromosome 2", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["10754001", "10757474", "11037190", "15340753", "15362573", "15675354", "15675355", "16164190", "16475235", "16723886", "17138018", "17431895", "18174554", "18463369", "18576213", "19335127", "19918425", "20635402", "20644152", "21048783", "21596366", "21631222", "21968521", "22426657", "22436252", "23077562", "23713105", "23966756", "24167642", "8898827", "8937199", "9128751", "9973290"], "ideal_answer": "chromosomes 3, 6, 8, 12, 15, 17, 21, X and Y were implicated in the Moyamoya disease."}
{"question_id": "5357a6d0f1005d6b58000004", "question": "Which is the branch site consensus sequence in U12-dependent introns?", "retrieved_chunks": [{"doc_id": "18824513", "chunk_id": "18824513_0", "score": 8.515624046325684, "text": "Highly conserved sequences at the 5' splice site and branch site of U12-dependent introns are important determinants for splicing by U12-dependent spliceosomes. This study investigates the in vivo splicing phenotypes of mutations in the branch site consensus sequence of the U12-dependent intron F from a human NOL1 (P120) minigene. Intron F contains a fully consensus branch site sequence (UUCCUUAAC)."}, {"doc_id": "18824513", "chunk_id": "18824513_2", "score": 6.467107772827148, "text": "Intron F contains a fully consensus branch site sequence (UUCCUUAAC)."}, {"doc_id": "18824513", "chunk_id": "18824513_1", "score": 6.313333511352539, "text": "Intron F contains a fully consensus branch site sequence (UUCCUUAAC)"}], "context": "[18824513:18824513_0] Highly conserved sequences at the 5' splice site and branch site of U12-dependent introns are important determinants for splicing by U12-dependent spliceosomes. This study investigates the in vivo splicing phenotypes of mutations in the branch site consensus sequence of the U12-dependent intron F from a human NOL1 (P120) minigene. Intron F contains a fully consensus branch site sequence (UUCCUUAAC).\n[18824513:18824513_2] Intron F contains a fully consensus branch site sequence (UUCCUUAAC).\n[18824513:18824513_1] Intron F contains a fully consensus branch site sequence (UUCCUUAAC)", "answer": "<think> Okay, let's tackle this question. The user is asking about the branch site consensus sequence in U12-dependent introns. The evidence provided has three chunks from the same document, all pointing to the sequence UUCCUUAAC in Intron F. First, I need to confirm if these chunks are citing the same source. All three are from [18824513:18824513_0], [18824513:18824513_2], and [18824513:18824513_1]. Wait, the first chunk is from 18824513_0, then the", "citations": [{"doc_id": "18824513", "chunk_id": "18824513_0"}, {"doc_id": "18824513", "chunk_id": "18824513_2"}, {"doc_id": "18824513", "chunk_id": "18824513_1"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the branch site consensus sequence in U12-dependent introns. The evidence provided has three chunks from the same document, all pointing to the sequence UUCCUUAAC in Intron F. First, I need to confirm if these chunks are citing the same source. All three are from [18824513:18824513_0], [18824513:18824513_2], and [18824513:18824513_1]. Wait, the first chunk is from 18824513_0, then the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.2700000000000005, "safe": false, "has_citation": 1}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the branch site consensus sequence in U12-dependent introns. The evidence provided has three chunks, all from the same document (18824513). Let me look at them. Chunk 1 says that Intron F has a fully consensus branch site sequence (UUCCUUAAC). Chunks 2 and 3 repeat the same information. So the answer should be UUCCUUAAC. The confidence is high because all three chunks mention this sequence. The document's focus is on the branch site in U12-dependent introns, so the citation is from that source. I need to make sure the answer is concise and includes the correct citation. Base confidence is 1", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the branch site consensus sequence in U12-dependent introns. I need to look at the provided evidence to find the answer. Looking at the evidence, there are three chunks from the same document (18824513). Each of them mentions that Intron F has a fully consensus branch site sequence (UUCCUUAAC). The first chunk also talks about the importance of these sequences for splicing, but the specific answer is in the second and third chunks. The question is asking for the consensus sequence, and the evidence directly states that the sequence is UUCCUUAAC. All three chunks point to this same sequence. So the answer should be that sequence with citations from the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the branch site consensus sequence in U12-dependent introns. The evidence provided has three chunks, all from the same document ID, 18824513. Looking at the evidence, each chunk mentions that Intron F has a fully consensus branch site sequence (UUCCUUAAC). The first chunk also talks about the importance of these sequences for splicing, but the answer specifically needs the consensus sequence. So, the answer should be UUCCUUAAC, as that's the sequence cited in all three chunks. The confidence is pretty high since multiple chunks mention the same sequence. The base_confidence can be 1.0 because all the evidence points to the same sequence", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the branch site consensus sequence in U12-dependent introns. The evidence provided has three chunks, all from the same document ID, 18824513. Looking at the evidence, each chunk mentions that Intron F has a fully consensus branch site sequence of \"UUCCUUAAC\". The first chunk also talks about the importance of these sequences for splicing, but the answer specifically needs the consensus sequence. I need to make sure that the answer is concise and cites the correct document chunk. Since all three chunks point to the same sequence, I can use one of them. The base confidence should be high because the evidence directly states it. The model is confident here since the information", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the branch site consensus sequence in U12-dependent introns. The evidence provided has three chunks from the same document, all pointing to the sequence UUCCUUAAC in Intron F. First, I need to make sure that the answer is directly taken from the evidence. All three chunks mention that Intron F has a fully consensus branch site sequence of UUCCUUAAC. The document ID is 18824513, and the chunk IDs are 0, 2, and 1. But since the question is about the consensus sequence itself, the answer should be the sequence provided. The confidence level is based on the fact that multiple chunks in the same document all", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the branch site consensus sequence in U12-dependent introns. I need to look at the provided evidence to find the answer. Looking at the evidence, there are three chunks from the same document (18824513). Each of them mentions that Intron F has a fully consensus branch site sequence (UUCCUUAAC). The first chunk also talks about mutations in this sequence affecting splicing, but the key point here is the sequence itself. The question is specifically about the consensus sequence. The evidence directly states that the branch site is UUCCUUAAC. All three chunks confirm this. So the answer should be that sequence. The confidence is high because multiple chunks from the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the branch site consensus sequence in U12-dependent introns. The evidence provided has three chunks, all pointing to the same sequence: UUCCUUAAC. First, I need to make sure that all the evidence supports this answer. Each of the three chunks (18824513_0, 18824513_1, and 18824513_2) mentions that Intron F has a fully consensus branch site sequence of UUCCUUAAC. The first chunk also talks about the importance of these sequences for splicing, which reinforces their significance. The answer should be concise and include citations. Since all the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 3.0700000000000003, "safe": false, "has_citation": 0}], "selected_score": 3.2700000000000005, "gold_docs": ["18824513"], "ideal_answer": "The branch site consensus sequence in U12-dependent introns is UUCCUUAAC."}
